(lp0
(dp1
S'line'
p2
VCharacterisation of most mutations found in CLCN2 in patients with CC2L leukodystrophy show that they cause a reduction in function of the chloride channel ClC-2.
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I139
sS'uniprot'
p8
VP51800
p9
sS'lengthInChars'
p10
I22
sS'name'
p11
Vchloride channel ClC-2
p12
sS'lengthInWords'
p13
I3
sasS'diseases'
p14
(lp15
(dp16
g7
I72
sS'cui'
p17
VC0023520
p18
sg10
I14
sg11
Vleukodystrophy
p19
sg13
I1
sasa(dp20
g2
VGlialCAM, a regulatory subunit of ClC-2 in glial cells and involved in the leukodystrophy megalencephalic leukoencephalopathy with subcortical cysts (MLC), increases the activity of a ClC-2 mutant by affecting ClC-2 gating and by stabilising the mutant at the plasma membrane.
p21
sg4
(lp22
(dp23
g7
I0
sg8
S''
p24
sg10
I8
sg11
VGlialCAM
p25
sg13
I1
sa(dp26
g7
I184
sg8
VP51788
p27
sg10
I12
sg11
VClC-2 mutant
p28
sg13
I2
sa(dp29
g7
I34
sg8
VP51788
p30
sg10
I5
sg11
VClC-2
p31
sg13
I1
sasg14
(lp32
(dp33
g7
I90
sg17
VC1858854
p34
sg10
I58
sg11
Vmegalencephalic leukoencephalopathy with subcortical cysts
p35
sg13
I5
sa(dp36
g7
I190
sg17
VC0596988
p37
sg10
I6
sg11
Vmutant
p38
sg13
I1
sa(dp39
g7
I75
sg17
VC0023520
p40
sg10
I14
sg11
Vleukodystrophy
p41
sg13
I1
sa(dp42
g7
I190
sg17
VC0596988
p43
sg10
I6
sg11
Vmutant
p44
sg13
I1
sa(dp45
g7
I150
sg17
VC1858854
p46
sg10
I3
sg11
VMLC
p47
sg13
I1
sasa(dp48
g2
VWe suggest that leukodystrophy-causing CLCN2 mutations reduce the functional expression of ClC-2, which is partly counteracted by GlialCAM/MLC1-mediated increase in the gating and stability of the channel.
p49
sg4
(lp50
(dp51
g7
I139
sg8
VP12829
p52
sg10
I4
sg11
VMLC1
p53
sg13
I1
sa(dp54
g7
I130
sg8
g24
sg10
I8
sg11
VGlialCAM
p55
sg13
I1
sa(dp56
g7
I91
sg8
VP51788
p57
sg10
I5
sg11
VClC-2
p58
sg13
I1
sa(dp59
g7
I39
sg8
VP51788
p60
sg10
I15
sg11
VCLCN2 mutations
p61
sg13
I2
sasg14
(lp62
(dp63
g7
I139
sg17
VC1858854
p64
sg10
I4
sg11
VMLC1
p65
sg13
I1
sa(dp66
g7
I16
sg17
VC0023520
p67
sg10
I14
sg11
Vleukodystrophy
p68
sg13
I1
sasa(dp69
g2
VThe review then discusses the diseases associated with ClC-2, including degeneration of the retina, Sjoegren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus.
p70
sg4
(lp71
(dp72
g7
I55
sg8
VP51788
p73
sg10
I5
sg11
VClC-2
p74
sg13
I1
sasg14
(lp75
(dp76
g7
I268
sg17
VC0010674
p77
sg10
I15
sg11
Vcystic fibrosis
p78
sg13
I2
sa(dp79
g7
I306
sg17
VC0014544
p80
sg10
I8
sg11
Vepilepsy
p81
sg13
I1
sa(dp82
g7
I285
sg17
VC0270612
p83
sg10
I19
sg11
Vleukoencephalopathy
p84
sg13
I1
sa(dp85
g7
I133
sg17
VC0521707
p86
sg10
I9
sg11
Vcataracts
p87
sg13
I1
sa(dp88
g7
I72
sg17
VC0011164
p89
sg10
I12
sg11
Vdegeneration
p90
sg13
I1
sa(dp91
g7
I185
sg17
VC0684249
p92
sg10
I11
sg11
Vlung cancer
p93
sg13
I2
sa(dp94
g7
I258
sg17
VC0023418
p95
sg10
I8
sg11
Vleukemia
p96
sg13
I1
sa(dp97
g7
I100
sg17
VC1527336
p98
sg10
I19
sg11
VSjoegren's syndrome
p99
sg13
I2
sa(dp100
g7
I222
sg17
VC0684336
p101
sg10
I8
sg11
Vimpaired
p102
sg13
I1
sa(dp103
g7
I72
sg17
VC0011164
p104
sg10
I12
sg11
Vdegeneration
p105
sg13
I1
sa(dp106
g7
I198
sg17
VC0009806
p107
sg10
I12
sg11
Vconstipation
p108
sg13
I1
sa(dp109
g7
I172
sg17
VC1321542
p110
sg10
I11
sg11
Vazoospermia
p111
sg13
I1
sa(dp112
g7
I319
sg17
VC0011849
p113
sg10
I17
sg11
Vdiabetes mellitus
p114
sg13
I2
sasa(dp115
g2
VA subset of these genes has been implicated in other neurobehavioral disorders including depression (SLIT3), epilepsy (CLCN2, PRICKLE1), intellectual disability (AP4M1), schizophrenia (WDR60), and Tourette syndrome (OFCC1).
p116
sg4
(lp117
(dp118
g7
I126
sg8
g24
sg10
I8
sg11
VPRICKLE1
p119
sg13
I1
sa(dp120
g7
I162
sg8
g24
sg10
I5
sg11
VAP4M1
p121
sg13
I1
sa(dp122
g7
I101
sg8
g24
sg10
I5
sg11
VSLIT3
p123
sg13
I1
sa(dp124
g7
I185
sg8
g24
sg10
I5
sg11
VWDR60
p125
sg13
I1
sa(dp126
g7
I109
sg8
VP10646
p127
sg10
I8
sg11
Vepilepsy
p128
sg13
I1
sa(dp129
g7
I119
sg8
VP51788
p130
sg10
I5
sg11
VCLCN2
p131
sg13
I1
sasg14
(lp132
(dp133
g7
I137
sg17
VC0025362
p134
sg10
I23
sg11
Vintellectual disability
p135
sg13
I2
sa(dp136
g7
I170
sg17
VC0036341
p137
sg10
I13
sg11
Vschizophrenia
p138
sg13
I1
sa(dp139
g7
I109
sg17
VC0014544
p140
sg10
I8
sg11
Vepilepsy
p141
sg13
I1
sa(dp142
g7
I89
sg17
VC0011581
p143
sg10
I10
sg11
Vdepression
p144
sg13
I1
sa(dp145
g7
I197
sg17
VC0040517
p146
sg10
I17
sg11
VTourette syndrome
p147
sg13
I2
sasa(dp148
g2
VEpilepsy with grand mal on awakening (EGMA) is a well-defined subtype of idiopathic generalized epilepsy.
p149
sg4
(lp150
sg14
(lp151
(dp152
g7
I73
sg17
VC0270850
p153
sg10
I31
sg11
Vidiopathic generalized epilepsy
p154
sg13
I3
sa(dp155
g7
I0
sg17
VC0014544
p156
sg10
I8
sg11
VEpilepsy
p157
sg13
I1
sa(dp158
g7
I14
sg17
VC0494475
p159
sg10
I9
sg11
Vgrand mal
p160
sg13
I2
sasa(dp161
g2
VAdditionally, using global gene expression analysis of partially reprogrammed cells, we identified SNAI3 as a novel invasion-related marker in human melanoma.
p162
sg4
(lp163
(dp164
g7
I99
sg8
g24
sg10
I5
sg11
VSNAI3
p165
sg13
I1
sasg14
(lp166
(dp167
g7
I149
sg17
VC0025202
p168
sg10
I8
sg11
Vmelanoma
p169
sg13
I1
sa(dp170
g7
I116
sg17
VC2699153
p171
sg10
I8
sg11
Vinvasion
p172
sg13
I1
sasa(dp173
g2
VSNAI3 expression correlates with tumor thickness in primary melanomas and thus, may be of prognostic value.
p174
sg4
(lp175
(dp176
g7
I0
sg8
g24
sg10
I5
sg11
VSNAI3
p177
sg13
I1
sasg14
(lp178
(dp179
g7
I60
sg17
VC0025202
p180
sg10
I9
sg11
Vmelanomas
p181
sg13
I1
sa(dp182
g7
I33
sg17
VC0027651
p183
sg10
I5
sg11
Vtumor
p184
sg13
I1
sasa(dp185
g2
VEffective silencing of Runx2 by short interfering RNA (siRNA) demonstrated downregulation of EMT-related molecules (SNAI2, SNAI3 and TWIST1), MMP2 and vasculogenic factors (VEGFA and VEGFC) in thyroid carcinoma cells.
p186
sg4
(lp187
(dp188
g7
I123
sg8
g24
sg10
I5
sg11
VSNAI3
p189
sg13
I1
sa(dp190
g7
I142
sg8
VP08253
p191
sg10
I4
sg11
VMMP2
p192
sg13
I1
sa(dp193
g7
I133
sg8
g24
sg10
I6
sg11
VTWIST1
p194
sg13
I1
sa(dp195
g7
I93
sg8
g24
sg10
I21
sg11
VEMT-related molecules
p196
sg13
I2
sa(dp197
g7
I23
sg8
g24
sg10
I5
sg11
VRunx2
p198
sg13
I1
sa(dp199
g7
I183
sg8
VP49767
p200
sg10
I5
sg11
VVEGFC
p201
sg13
I1
sa(dp202
g7
I116
sg8
g24
sg10
I5
sg11
VSNAI2
p203
sg13
I1
sa(dp204
g7
I151
sg8
VP19883
p205
sg10
I20
sg11
Vvasculogenic factors
p206
sg13
I2
sasg14
(lp207
(dp208
g7
I193
sg17
VC0549473
p209
sg10
I17
sg11
Vthyroid carcinoma
p210
sg13
I2
sasa(dp211
g2
VThyroid-stimulating hormone levels, goiter and thyroid dysfunction were higher in children who were anti-TPO1 than in diabetic children without thyroid autoimmunity.
p212
sg4
(lp213
(dp214
g7
I0
sg8
VP01222
p215
sg10
I27
sg11
VThyroid-stimulating hormone
p216
sg13
I2
sa(dp217
g7
I100
sg8
g24
sg10
I9
sg11
Vanti-TPO1
p218
sg13
I1
sasg14
(lp219
(dp220
g7
I36
sg17
VC0018021
p221
sg10
I6
sg11
Vgoiter
p222
sg13
I1
sa(dp223
g7
I152
sg17
VC0004368
p224
sg10
I12
sg11
Vautoimmunity
p225
sg13
I1
sa(dp226
g7
I47
sg17
VC0348024
p227
sg10
I19
sg11
Vthyroid dysfunction
p228
sg13
I2
sasa(dp229
g2
VMultiplex ligation-dependent probe amplification (MLPA) can be used to detect rearrangements that cause Alfa-thalassemia, particularly large deletions involving the whole Alfa cluster and/or deletions in the HS-40 region.
p230
sg4
(lp231
(dp232
g7
I208
sg8
g24
sg10
I12
sg11
VHS-40 region
p233
sg13
I2
sasg14
(lp234
(dp235
g7
I109
sg17
VC0039730
p236
sg10
I11
sg11
Vthalassemia
p237
sg13
I1
sa(dp238
g7
I35
sg17
VC1705759
p239
sg10
I13
sg11
Vamplification
p240
sg13
I1
sasa(dp241
g2
VIn addition to the -Alfa3.7 deletion identified in the patients with Hb H disease, four different Alfa0 deletions removing 15 to 225 kb DNA segments were found: two of them remove both the Alfa genes, one affects only the regulatory element (HS-40) region, and another one extends over the entire Alfa cluster and the HS-40 region.
p242
sg4
(lp243
(dp244
g7
I318
sg8
g24
sg10
I12
sg11
VHS-40 region
p245
sg13
I2
sasg14
(lp246
(dp247
g7
I72
sg17
VC0018609
p248
sg10
I9
sg11
VH disease
p249
sg13
I2
sasa(dp250
g2
VThe impact of urinary VDBP and KIM-1 on MARE was independent of known CIN risk factors such as anemia, preexisting renal failure, preexisting heart failure, and diabetes.
p251
sg4
(lp252
(dp253
g7
I40
sg8
g24
sg10
I4
sg11
VMARE
p254
sg13
I1
sa(dp255
g7
I31
sg8
g24
sg10
I5
sg11
VKIM-1
p256
sg13
I1
sa(dp257
g7
I22
sg8
VP02774
p258
sg10
I4
sg11
VVDBP
p259
sg13
I1
sasg14
(lp260
(dp261
g7
I95
sg17
VC0002871
p262
sg10
I6
sg11
Vanemia
p263
sg13
I1
sa(dp264
g7
I70
sg17
VC0206708
p265
sg10
I3
sg11
VCIN
p266
sg13
I1
sa(dp267
g7
I142
sg17
VC0018802
p268
sg10
I13
sg11
Vheart failure
p269
sg13
I2
sa(dp270
g7
I115
sg17
VC0035078
p271
sg10
I13
sg11
Vrenal failure
p272
sg13
I2
sa(dp273
g7
I161
sg17
VC0011849
p274
sg10
I8
sg11
Vdiabetes
p275
sg13
I1
sasa(dp276
g2
VThe data show that a tandem Maf recognition element (MARE) in locus control region (LCR) hypersensitive site 2 (HS2) reveals a remarkably high degree of occupancy during differentiation of mouse erythroleukemia cells.
p277
sg4
(lp278
(dp279
g7
I53
sg8
g24
sg10
I4
sg11
VMARE
p280
sg13
I1
sa(dp281
g7
I28
sg8
g24
sg10
I23
sg11
VMaf recognition element
p282
sg13
I3
sasg14
(lp283
(dp284
g7
I195
sg17
VC0023440
p285
sg10
I15
sg11
Verythroleukemia
p286
sg13
I1
sasa(dp287
g2
VTargeting of an artificial zinc finger DNA-binding domain (ZF-DBD) to the HS2 tandem MARE caused a reduction in the association of MARE-binding proteins and transcription complexes at LCR HS2 and the adult Betamajor-globin gene promoter but did not affect expression of the Betaminor-globin gene.
p288
sg4
(lp289
(dp290
g7
I27
sg8
g24
sg10
I30
sg11
Vzinc finger DNA-binding domain
p291
sg13
I4
sa(dp292
g7
I59
sg8
g24
sg10
I6
sg11
VZF-DBD
p293
sg13
I1
sa(dp294
g7
I131
sg8
g24
sg10
I21
sg11
VMARE-binding proteins
p295
sg13
I2
sasg14
(lp296
sa(dp297
g2
VThe data demonstrate that a stable MARE-associated footprint in LCR HS2 is important for the recruitment of transcription complexes to the adult Betamajor-globin gene promoter during erythroid cell differentiation.
p298
sg4
(lp299
sg14
(lp300
(dp301
g7
I93
sg17
VC0271510
p302
sg10
I11
sg11
Vrecruitment
p303
sg13
I1
sasa(dp304
g2
VNext, we demonstrate that CD172a(+)Slan DCs that produced IL-1Beta and TNF-Alfa accumulated in mLNs and colons of CD patients.
p305
sg4
(lp306
(dp307
g7
I71
sg8
VP01375
p308
sg10
I8
sg11
VTNF-Alfa
p309
sg13
I1
sa(dp310
g7
I58
sg8
VP01584
p311
sg10
I8
sg11
VIL-1Beta
p312
sg13
I1
sasg14
(lp313
(dp314
g7
I95
sg17
VC0026691
p315
sg10
I4
sg11
VmLNs
p316
sg13
I1
sa(dp317
g7
I40
sg17
VC0268238
p318
sg10
I3
sg11
VDCs
p319
sg13
I1
sasa(dp320
g2
VIn conclusion, we propose that proinflammatory CD14(bright)CD172a(+)Slan DCs are a distinguishing feature between CD and UC, as these cells accumulate uniquely in mLNs and colonic mucosa of CD patients.
p321
sg4
(lp322
(dp323
g7
I47
sg8
VP08571
p324
sg10
I29
sg11
VCD14(bright)CD172a(+)Slan DCs
p325
sg13
I2
sasg14
(lp326
(dp327
g7
I73
sg17
VC0268238
p328
sg10
I3
sg11
VDCs
p329
sg13
I1
sa(dp330
g7
I163
sg17
VC0026691
p331
sg10
I4
sg11
VmLNs
p332
sg13
I1
sasa(dp333
g2
VHere, we show that CD172a(+)CD11c(+) cells accumulate in the mesenteric lymph nodes (mLNs) and inflamed intestinal mucosa in patients with Crohn's disease (CD).
p334
sg4
(lp335
(dp336
g7
I19
sg8
VP20702
p337
sg10
I14
sg11
VCD172a(+)CD11c
p338
sg13
I1
sasg14
(lp339
(dp340
g7
I85
sg17
VC0026691
p341
sg10
I4
sg11
VmLNs
p342
sg13
I1
sa(dp343
g7
I139
sg17
VC0010346
p344
sg10
I15
sg11
VCrohn's disease
p345
sg13
I2
sa(dp346
g7
I61
sg17
VC0026691
p347
sg10
I22
sg11
Vmesenteric lymph nodes
p348
sg13
I3
sa(dp349
g7
I19
sg17
VC0010346
p350
sg10
I2
sg11
VCD
p351
sg13
I1
sasa(dp352
g2
VAn avidity-improved CD47 fusion protein (CD47-Var1) suppresses the release of a wide array of inflammatory cytokines by CD172a(+) cells, which may include HLA-DR(-)CD172a(+) neutrophils, in inflamed colonic explant cultures and impairs the ability of HLA-DR(+)CD172a(+) cells to activate memory Th17 but not Th1 responses in mLNs.
p353
sg4
(lp354
(dp355
g7
I41
sg8
g24
sg10
I9
sg11
VCD47-Var1
p356
sg13
I1
sa(dp357
g7
I251
sg8
VP30486
p358
sg10
I15
sg11
VHLA-DR(+)CD172a
p359
sg13
I1
sa(dp360
g7
I155
sg8
VP30486
p361
sg10
I15
sg11
VHLA-DR(-)CD172a
p362
sg13
I1
sa(dp363
g7
I20
sg8
g24
sg10
I19
sg11
VCD47 fusion protein
p364
sg13
I3
sasg14
(lp365
(dp366
g7
I325
sg17
VC0026691
p367
sg10
I4
sg11
VmLNs
p368
sg13
I1
sasa(dp369
g2
VWe first show that mucosal CD103(-) DCs selectively express SIRPalpha and that their frequency was augmented in the lamina propria and mLNs of mice that developed Th17-biased colitis in response to trinitrobenzene sulfonic acid.
p370
sg4
(lp371
(dp372
g7
I27
sg8
VP38570
p373
sg10
I12
sg11
VCD103(-) DCs
p374
sg13
I2
sasg14
(lp375
(dp376
g7
I135
sg17
VC0026691
p377
sg10
I4
sg11
VmLNs
p378
sg13
I1
sa(dp379
g7
I36
sg17
VC0268238
p380
sg10
I3
sg11
VDCs
p381
sg13
I1
sa(dp382
g7
I175
sg17
VC0009319
p383
sg10
I7
sg11
Vcolitis
p384
sg13
I1
sasa(dp385
g2
VCD47 expression was required on the SIRPalpha(+)CD103(-) DCs for efficient trafficking to mLNs in vivo, whereas it was dispensable on both DCs and T cells for Th17 polarization in vitro.
p386
sg4
(lp387
(dp388
g7
I36
sg8
VP38570
p389
sg10
I20
sg11
VSIRPalpha(+)CD103(-)
p390
sg13
I1
sa(dp391
g7
I0
sg8
g24
sg10
I4
sg11
VCD47
p392
sg13
I1
sasg14
(lp393
(dp394
g7
I57
sg17
VC0268238
p395
sg10
I3
sg11
VDCs
p396
sg13
I1
sa(dp397
g7
I57
sg17
VC0268238
p398
sg10
I3
sg11
VDCs
p399
sg13
I1
sa(dp400
g7
I90
sg17
VC0026691
p401
sg10
I4
sg11
VmLNs
p402
sg13
I1
sasa(dp403
g2
VEffects of Ca2+ and calmodulin on the adenylate cyclase activity of a prolactin and growth hormone-producing pituitary tumor cell strain (GH3) were examined.
p404
sg4
(lp405
(dp406
g7
I38
sg8
g24
sg10
I17
sg11
Vadenylate cyclase
p407
sg13
I2
sa(dp408
g7
I84
sg8
VP01242
p409
sg10
I14
sg11
Vgrowth hormone
p410
sg13
I2
sa(dp411
g7
I20
sg8
g24
sg10
I10
sg11
Vcalmodulin
p412
sg13
I1
sa(dp413
g7
I70
sg8
VP01236
p414
sg10
I9
sg11
Vprolactin
p415
sg13
I1
sasg14
(lp416
(dp417
g7
I84
sg17
VC0278864
p418
sg10
I40
sg11
Vgrowth hormone-producing pituitary tumor
p419
sg13
I4
sasa(dp420
g2
VThe control of PTG hyperplasia is most important in the management of secondary hyperparathyroidism (SHPT), because the advanced stage of hyperplasia is considered irreversible.
p421
sg4
(lp422
sg14
(lp423
(dp424
g7
I19
sg17
VC0020507
p425
sg10
I11
sg11
Vhyperplasia
p426
sg13
I1
sa(dp427
g7
I101
sg17
VC0020503
p428
sg10
I4
sg11
VSHPT
p429
sg13
I1
sa(dp430
g7
I19
sg17
VC0020507
p431
sg10
I11
sg11
Vhyperplasia
p432
sg13
I1
sa(dp433
g7
I70
sg17
VC0020503
p434
sg10
I29
sg11
Vsecondary hyperparathyroidism
p435
sg13
I2
sasa(dp436
g2
VControl of secondary hyperparathyroidism (SHPT) using active vitamin D analogues becomes difficult in advanced SHPT, because the enlarged parathyroid glands (PTGs) are resistant to medical therapy.
p437
sg4
(lp438
sg14
(lp439
(dp440
g7
I11
sg17
VC0020503
p441
sg10
I29
sg11
Vsecondary hyperparathyroidism
p442
sg13
I2
sa(dp443
g7
I42
sg17
VC0020503
p444
sg10
I4
sg11
VSHPT
p445
sg13
I1
sa(dp446
g7
I42
sg17
VC0020503
p447
sg10
I4
sg11
VSHPT
p448
sg13
I1
sasa(dp449
g2
VThe long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT).
p450
sg4
(lp451
sg14
(lp452
(dp453
g7
I193
sg17
VC0020503
p454
sg10
I4
sg11
VSHPT
p455
sg13
I1
sa(dp456
g7
I162
sg17
VC0020503
p457
sg10
I29
sg11
Vsecondary hyperparathyroidism
p458
sg13
I2
sasa(dp459
g2
VIt has been suggested that microRNA-9 (miR-9) is associated with the development of knee osteoarthritis (OA).
p460
sg4
(lp461
(dp462
g7
I27
sg8
g24
sg10
I10
sg11
VmicroRNA-9
p463
sg13
I1
sa(dp464
g7
I39
sg8
g24
sg10
I5
sg11
VmiR-9
p465
sg13
I1
sasg14
(lp466
(dp467
g7
I84
sg17
VC0409959
p468
sg10
I19
sg11
Vknee osteoarthritis
p469
sg13
I2
sasa(dp470
g2
VX-linked hypophosphatemia (XLH), autosomal dominant HR (ADHR), and autosomal recessive HR (ARHR) are examples of hereditary forms of HR, which are mainly caused by mutations in the phosphate regulating endopeptidase homolog, X-linked (PHEX), FGF23, and, dentin matrix protein-1 (DMP1) and ecto-nucleotide pyro phosphatase/phosphodiesterase 1 (ENPP1) genes, respectively.
p471
sg4
(lp472
(dp473
g7
I242
sg8
g24
sg10
I5
sg11
VFGF23
p474
sg13
I1
sa(dp475
g7
I202
sg8
g24
sg10
I31
sg11
Vendopeptidase homolog, X-linked
p476
sg13
I3
sa(dp477
g7
I33
sg8
VP56715
p478
sg10
I21
sg11
Vautosomal dominant HR
p479
sg13
I3
sa(dp480
g7
I254
sg8
g24
sg10
I23
sg11
Vdentin matrix protein-1
p481
sg13
I3
sa(dp482
g7
I56
sg8
VP30518
p483
sg10
I4
sg11
VADHR
p484
sg13
I1
sa(dp485
g7
I279
sg8
g24
sg10
I4
sg11
VDMP1
p486
sg13
I1
sa(dp487
g7
I343
sg8
VP22413
p488
sg10
I5
sg11
VENPP1
p489
sg13
I1
sa(dp490
g7
I235
sg8
VP78562
p491
sg10
I4
sg11
VPHEX
p492
sg13
I1
sa(dp493
g7
I289
sg8
VP22413
p494
sg10
I52
sg11
Vecto-nucleotide pyro phosphatase/phosphodiesterase 1
p495
sg13
I4
sasg14
(lp496
(dp497
g7
I0
sg17
VC0733682
p498
sg10
I25
sg11
VX-linked hypophosphatemia
p499
sg13
I2
sa(dp500
g7
I91
sg17
VC0342643
p501
sg10
I4
sg11
VARHR
p502
sg13
I1
sa(dp503
g7
I33
sg17
VC0342642
p504
sg10
I21
sg11
Vautosomal dominant HR
p505
sg13
I3
sa(dp506
g7
I56
sg17
VC0342642
p507
sg10
I4
sg11
VADHR
p508
sg13
I1
sa(dp509
g7
I27
sg17
VC0733682
p510
sg10
I3
sg11
VXLH
p511
sg13
I1
sa(dp512
g7
I67
sg17
VC0342643
p513
sg10
I22
sg11
Vautosomal recessive HR
p514
sg13
I3
sasa(dp515
g2
VHomozygous inactivating mutations in DMP1 (dentin matrix protein 1), the gene encoding a noncollagenous bone matrix protein expressed in osteoblasts and osteocytes, cause autosomal recessive hypophosphatemia (ARHP).
p516
sg4
(lp517
sg14
(lp518
(dp519
g7
I171
sg17
VC0342643
p520
sg10
I36
sg11
Vautosomal recessive hypophosphatemia
p521
sg13
I3
sa(dp522
g7
I209
sg17
VC0342643
p523
sg10
I4
sg11
VARHP
p524
sg13
I1
sasa(dp525
g2
VAn autosomal recessive form of hypophosphatemia (ARHP) was recently shown to be caused by homozygous mutations in DMP1, the gene encoding dentin matrix protein-1 (DMP-1), a non-collagenous bone matrix protein with an important role in the development and mineralization of bone and teeth.
p526
sg4
(lp527
(dp528
g7
I163
sg8
g24
sg10
I5
sg11
VDMP-1
p529
sg13
I1
sa(dp530
g7
I173
sg8
VP63145
p531
sg10
I35
sg11
Vnon-collagenous bone matrix protein
p532
sg13
I4
sa(dp533
g7
I124
sg8
g24
sg10
I37
sg11
Vgene encoding dentin matrix protein-1
p534
sg13
I5
sa(dp535
g7
I114
sg8
g24
sg10
I4
sg11
VDMP1
p536
sg13
I1
sasg14
(lp537
(dp538
g7
I49
sg17
VC0342643
p539
sg10
I4
sg11
VARHP
p540
sg13
I1
sa(dp541
g7
I3
sg17
VC0342643
p542
sg10
I44
sg11
Vautosomal recessive form of hypophosphatemia
p543
sg13
I5
sasa(dp544
g2
VAmong various causes of low serum phosphorous are inherited disorders associated with increased urinary excretion of phosphate, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemia (ARHP), and hereditary hypophosphatemic rickets with hypercalciuria (HHRH).
p545
sg4
(lp546
(dp547
g7
I183
sg8
VP30518
p548
sg10
I4
sg11
VADHR
p549
sg13
I1
sa(dp550
g7
I138
sg8
VP30518
p551
sg10
I43
sg11
Vautosomal dominant hypophosphatemic rickets
p552
sg13
I4
sasg14
(lp553
(dp554
g7
I261
sg17
VC0342643
p555
sg10
I4
sg11
VARHP
p556
sg13
I1
sa(dp557
g7
I138
sg17
VC0342642
p558
sg10
I43
sg11
Vautosomal dominant hypophosphatemic rickets
p559
sg13
I4
sa(dp560
g7
I283
sg17
VC0342645
p561
sg10
I44
sg11
Vhypophosphatemic rickets with hypercalciuria
p562
sg13
I4
sa(dp563
g7
I329
sg17
VC0342645
p564
sg10
I4
sg11
VHHRH
p565
sg13
I1
sa(dp566
g7
I217
sg17
VC0733682
p567
sg10
I3
sg11
VXLH
p568
sg13
I1
sa(dp569
g7
I223
sg17
VC0342643
p570
sg10
I36
sg11
Vautosomal recessive hypophosphatemia
p571
sg13
I3
sa(dp572
g7
I183
sg17
VC0342642
p573
sg10
I4
sg11
VADHR
p574
sg13
I1
sa(dp575
g7
I190
sg17
VC0733682
p576
sg10
I25
sg11
VX-linked hypophosphatemia
p577
sg13
I2
sasa(dp578
g2
VRecently, positional cloning approaches furthermore led to the identification of homozygous inactivating mutations in dentin matrix protein 1 (DMP1) as the cause of an autosomal recessive form of hypophosphatemia.
p579
sg4
(lp580
(dp581
g7
I118
sg8
VP14222
p582
sg10
I23
sg11
Vdentin matrix protein 1
p583
sg13
I4
sa(dp584
g7
I143
sg8
g24
sg10
I4
sg11
VDMP1
p585
sg13
I1
sasg14
(lp586
(dp587
g7
I196
sg17
VC0085682
p588
sg10
I16
sg11
Vhypophosphatemia
p589
sg13
I1
sasa(dp590
g2
VPharmacological treatment of SOD1(G37R) mice with minocycline, a compound that attenuates microgliosis and slows down disease, lessened the dysregulation of Cdk5/Cdk4 and the phosphorylation of Rb.
p591
sg4
(lp592
(dp593
g7
I29
sg8
VP00441
p594
sg10
I4
sg11
VSOD1
p595
sg13
I1
sa(dp596
g7
I157
sg8
g24
sg10
I4
sg11
VCdk5
p597
sg13
I1
sa(dp598
g7
I162
sg8
VP11802
p599
sg10
I4
sg11
VCdk4
p600
sg13
I1
sasg14
(lp601
sa(dp602
g2
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p603
sg4
(lp604
(dp605
g7
I57
sg8
VP35398
p606
sg10
I36
sg11
VT-cell-specific transcription factor
p607
sg13
I3
sa(dp608
g7
I276
sg8
VP11473
p609
sg10
I18
sg11
Vvitamin D receptor
p610
sg13
I3
sa(dp611
g7
I109
sg8
VP00519
p612
sg10
I39
sg11
V"proto-oncogene tyrosine-protein kinase
p613
sg13
I3
sa(dp614
g7
I399
sg8
g24
sg10
I31
sg11
VPR domain zinc finger protein 1
p615
sg13
I6
sa(dp616
g7
I322
sg8
VP29323
p617
sg10
I3
sg11
VERK
p618
sg13
I1
sa(dp619
g7
I362
sg8
VP20823
p620
sg10
I35
sg11
Vrunt-related transcription factor 1
p621
sg13
I4
sa(dp622
g7
I477
sg8
VP01584
p623
sg10
I13
sg11
Vinterleukin 1
p624
sg13
I2
sa(dp625
g7
I152
sg8
VP12931
p626
sg10
I8
sg11
Vsarcoma"
p627
sg13
I1
sa(dp628
g7
I163
sg8
VP10914
p629
sg10
I30
sg11
Vinterferon regulatory factor 1
p630
sg13
I4
sa(dp631
g7
I227
sg8
VP49336
p632
sg10
I31
sg11
Vcyclin-dependent kinase (CDK) 4
p633
sg13
I4
sa(dp634
g7
I296
sg8
VP56524
p635
sg10
I19
sg11
Vhistone deacetylase
p636
sg13
I2
sa(dp637
g7
I95
sg8
VP12931
p638
sg10
I3
sg11
VSrc
p639
sg13
I1
sa(dp640
g7
I217
sg8
VP14635
p641
sg10
I8
sg11
Vcyclin B
p642
sg13
I2
sa(dp643
g7
I334
sg8
VP10415
p644
sg10
I26
sg11
Vbcl-2-associated X protein
p645
sg13
I3
sa(dp646
g7
I317
sg8
VP53779
p647
sg10
I4
sg11
VMAPK
p648
sg13
I1
sa(dp649
g7
I432
sg8
VP09619
p650
sg10
I39
sg11
Vplatelet-derived growth factor receptor
p651
sg13
I4
sa(dp652
g7
I265
sg8
VP29466
p653
sg10
I9
sg11
Vcaspase-1
p654
sg13
I1
sa(dp655
g7
I195
sg8
VP04818
p656
sg10
I20
sg11
Vthymidylate synthase
p657
sg13
I2
sa(dp658
g7
I252
sg8
VP24941
p659
sg10
I3
sg11
VCDK
p660
sg13
I1
sasg14
(lp661
(dp662
g7
I152
sg17
VC1261473
p663
sg10
I7
sg11
Vsarcoma
p664
sg13
I1
sa(dp665
g7
I362
sg17
VC0013336
p666
sg10
I4
sg11
Vrunt
p667
sg13
I1
sasa(dp668
g2
VTherefore, targeting the caspase-1/PPARGamma/MCAD pathway might be a promising therapeutic approach to prevent tumor progression.Tumor associated macrophages (TAMs) promote cancer progression.
p669
sg4
(lp670
(dp671
g7
I45
sg8
VP11310
p672
sg10
I4
sg11
VMCAD
p673
sg13
I1
sa(dp674
g7
I25
sg8
VP29466
p675
sg10
I9
sg11
Vcaspase-1
p676
sg13
I1
sasg14
(lp677
(dp678
g7
I173
sg17
VC0178874
p679
sg10
I18
sg11
Vcancer progression
p680
sg13
I2
sa(dp681
g7
I45
sg17
VC0220710
p682
sg10
I4
sg11
VMCAD
p683
sg13
I1
sa(dp684
g7
I129
sg17
VC0027651
p685
sg10
I5
sg11
VTumor
p686
sg13
I1
sa(dp687
g7
I111
sg17
VC0178874
p688
sg10
I17
sg11
Vtumor progression
p689
sg13
I2
sasa(dp690
g2
VHere, the author show that caspase-1 promotes TAMs differentiation by attenuating medium-chain acyl-CoA dehydrogenase activity and that inhibition of this axis results in suppression of tumour growth in a transgenic mouse model of breast cancer.
p691
sg4
(lp692
(dp693
g7
I95
sg8
VP49366
p694
sg10
I22
sg11
Vacyl-CoA dehydrogenase
p695
sg13
I2
sa(dp696
g7
I27
sg8
VP29466
p697
sg10
I9
sg11
Vcaspase-1
p698
sg13
I1
sasg14
(lp699
(dp700
g7
I100
sg17
VC2678439
p701
sg10
I3
sg11
VCoA
p702
sg13
I1
sa(dp703
g7
I231
sg17
VC0678222
p704
sg10
I13
sg11
Vbreast cancer
p705
sg13
I2
sa(dp706
g7
I171
sg17
VC0221103
p707
sg10
I11
sg11
Vsuppression
p708
sg13
I1
sa(dp709
g7
I186
sg17
VC0027651
p710
sg10
I6
sg11
Vtumour
p711
sg13
I1
sasa(dp712
g2
VEnsuing western blotting or immunostaining results showed that Rictor/mTORC2 signaling was activated in kidney interstitial myofibroblasts from mice with unilateral ureteral obstruction.
p713
sg4
(lp714
(dp715
g7
I63
sg8
g24
sg10
I6
sg11
VRictor
p716
sg13
I1
sasg14
(lp717
(dp718
g7
I165
sg17
VC0041956
p719
sg10
I20
sg11
Vureteral obstruction
p720
sg13
I2
sasa(dp721
g2
VCompared with control littermates, the kidneys of Rictor knockout mice developed less interstitial extracellular matrix deposition and inflammatory cell infiltration at 1 or 2 weeks after ureteral obstruction.
p722
sg4
(lp723
sg14
(lp724
(dp725
g7
I188
sg17
VC0041956
p726
sg10
I20
sg11
Vureteral obstruction
p727
sg13
I2
sa(dp728
g7
I135
sg17
VC0302158
p729
sg10
I30
sg11
Vinflammatory cell infiltration
p730
sg13
I3
sasa(dp731
g2
VLess progression of Hoffa-synovitis and effusion-synovitis was observed in the TG-C group compared to placebo (9.6% vs. 21.1%, adjusted RR 0.5, 95%CI [0.2,1.2], p = 0.115).
p732
sg4
(lp733
sg14
(lp734
(dp735
g7
I40
sg17
VC0013687
p736
sg10
I8
sg11
Veffusion
p737
sg13
I1
sa(dp738
g7
I26
sg17
VC0039103
p739
sg10
I9
sg11
Vsynovitis
p740
sg13
I1
sa(dp741
g7
I26
sg17
VC0039103
p742
sg10
I9
sg11
Vsynovitis
p743
sg13
I1
sasa(dp744
g2
VIntraarticular treatment with TG-C showed fewer patients in the treated group with progression in structural OA features and other MRI-defined inflammatory markers such as Hoffa-synovitis and effusion-synovitis.
p745
sg4
(lp746
sg14
(lp747
(dp748
g7
I192
sg17
VC0013687
p749
sg10
I8
sg11
Veffusion
p750
sg13
I1
sa(dp751
g7
I178
sg17
VC0039103
p752
sg10
I9
sg11
Vsynovitis
p753
sg13
I1
sa(dp754
g7
I178
sg17
VC0039103
p755
sg10
I9
sg11
Vsynovitis
p756
sg13
I1
sasa(dp757
g2
VA total of 104 patients (89.4% females) fulfilling the 1990 ACR criteria for FMS and the Rome III criteria for IBS classification and 125 unrelated age- and sex-matched IBS patients without FMS underwent the following studies: haematological, coagulation and biochemistry tests, serological and genetic markers for CD (i.e., tissue transglutaminase 2 (tTG-2) and major histocompatibility complex HLA-DQ2/HLA-DQ8), multiple gastric and duodenal biopsies, FMS tender points (TPs), Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), 36-Item Short Form Health Survey (SF-36) and Visual Analogue Scales (VASs) for tiredness and gastrointestinal complaints.
p758
sg4
(lp759
(dp760
g7
I325
sg8
VP21980
p761
sg10
I25
sg11
Vtissue transglutaminase 2
p762
sg13
I3
sa(dp763
g7
I400
sg8
g24
sg10
I3
sg11
VDQ2
p764
sg13
I1
sa(dp765
g7
I363
sg8
VP18464
p766
sg10
I36
sg11
Vmajor histocompatibility complex HLA
p767
sg13
I4
sa(dp768
g7
I352
sg8
VP21980
p769
sg10
I5
sg11
VtTG-2
p770
sg13
I1
sa(dp771
g7
I404
sg8
VP30486
p772
sg10
I7
sg11
VHLA-DQ8
p773
sg13
I1
sasg14
(lp774
(dp775
g7
I111
sg17
VC0022104
p776
sg10
I3
sg11
VIBS
p777
sg13
I1
sa(dp778
g7
I77
sg17
VC0016053
p779
sg10
I3
sg11
VFMS
p780
sg13
I1
sa(dp781
g7
I638
sg17
VC0015672
p782
sg10
I9
sg11
Vtiredness
p783
sg13
I1
sa(dp784
g7
I479
sg17
VC0016053
p785
sg10
I12
sg11
VFibromyalgia
p786
sg13
I1
sa(dp787
g7
I77
sg17
VC0016053
p788
sg10
I3
sg11
VFMS
p789
sg13
I1
sa(dp790
g7
I77
sg17
VC0016053
p791
sg10
I3
sg11
VFMS
p792
sg13
I1
sa(dp793
g7
I111
sg17
VC0022104
p794
sg10
I3
sg11
VIBS
p795
sg13
I1
sasa(dp796
g2
VGFD effectiveness was assessed at baseline and after 1 year, examining the score changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and tiredness, drug prescriptions and tissue-Trans-Glutaminase (tTG) serum levels.
p797
sg4
(lp798
(dp799
g7
I367
sg8
VP21980
p800
sg10
I3
sg11
VtTG
p801
sg13
I1
sa(dp802
g7
I341
sg8
g24
sg10
I24
sg11
Vtissue-Trans-Glutaminase
p803
sg13
I1
sasg14
(lp804
(dp805
g7
I307
sg17
VC0015672
p806
sg10
I9
sg11
Vtiredness
p807
sg13
I1
sa(dp808
g7
I0
sg17
VC1851112
p809
sg10
I3
sg11
VGFD
p810
sg13
I1
sa(dp811
g7
I122
sg17
VC0016053
p812
sg10
I12
sg11
VFibromyalgia
p813
sg13
I1
sasa(dp814
g2
VNon-organ specific AAb (ANA, anti-Ro52, anti-Ro60, anti-La, anti-RNP) but not anti-thyroid peroxidase, anti-tissue transglutaminase or myositis-specific antibodies, were more frequent in s-IBM patients, and 14/51 (27%) had another autoimmune disease (Sjoegren's syndrome, thyroiditis, psoriasis, vitiligo).
p815
sg4
(lp816
(dp817
g7
I40
sg8
VP10155
p818
sg10
I9
sg11
Vanti-Ro60
p819
sg13
I1
sa(dp820
g7
I78
sg8
VP40225
p821
sg10
I23
sg11
Vanti-thyroid peroxidase
p822
sg13
I2
sa(dp823
g7
I60
sg8
g24
sg10
I8
sg11
Vanti-RNP
p824
sg13
I1
sa(dp825
g7
I135
sg8
VP04280
p826
sg10
I28
sg11
Vmyositis-specific antibodies
p827
sg13
I2
sa(dp828
g7
I24
sg8
g24
sg10
I3
sg11
VANA
p829
sg13
I1
sa(dp830
g7
I29
sg8
VP19474
p831
sg10
I9
sg11
Vanti-Ro52
p832
sg13
I1
sa(dp833
g7
I103
sg8
VP21980
p834
sg10
I28
sg11
Vanti-tissue transglutaminase
p835
sg13
I2
sasg14
(lp836
(dp837
g7
I189
sg17
VC0238190
p838
sg10
I3
sg11
VIBM
p839
sg13
I1
sa(dp840
g7
I251
sg17
VC1527336
p841
sg10
I19
sg11
VSjoegren's syndrome
p842
sg13
I2
sa(dp843
g7
I231
sg17
VC0004364
p844
sg10
I18
sg11
Vautoimmune disease
p845
sg13
I2
sa(dp846
g7
I296
sg17
VC0042900
p847
sg10
I8
sg11
Vvitiligo
p848
sg13
I1
sa(dp849
g7
I135
sg17
VC0027121
p850
sg10
I8
sg11
Vmyositis
p851
sg13
I1
sa(dp852
g7
I272
sg17
VC0040147
p853
sg10
I11
sg11
Vthyroiditis
p854
sg13
I1
sa(dp855
g7
I285
sg17
VC0033860
p856
sg10
I9
sg11
Vpsoriasis
p857
sg13
I1
sasa(dp858
g2
VBy applying CD146 and CD105 antibodies on human retinas from glaucomatous eyes, CD146-positive retinal ganglion cells (RGCs) were found, some being placed in perivascular positions; ongoing processes of neurites extension were related to these neurons.
p859
sg4
(lp860
(dp861
g7
I12
sg8
VP43121
p862
sg10
I5
sg11
VCD146
p863
sg13
I1
sa(dp864
g7
I12
sg8
VP43121
p865
sg10
I5
sg11
VCD146
p866
sg13
I1
sa(dp867
g7
I22
sg8
VP17813
p868
sg10
I5
sg11
VCD105
p869
sg13
I1
sasg14
(lp870
(dp871
g7
I103
sg17
VC1258666
p872
sg10
I8
sg11
Vganglion
p873
sg13
I1
sasa(dp874
g2
VThese results support the hypothesis that in glaucoma eyes the CD146-positive RGCs result from regenerative processes driven by stem cells in the retinal perivascular niches.
p875
sg4
(lp876
(dp877
g7
I63
sg8
VP43121
p878
sg10
I19
sg11
VCD146-positive RGCs
p879
sg13
I2
sasg14
(lp880
(dp881
g7
I45
sg17
VC0017601
p882
sg10
I8
sg11
Vglaucoma
p883
sg13
I1
sasa(dp884
g2
VCD146/MCAM and CD166/ALCAM, previously unreported in cells from fvERMs, were also expressed.
p885
sg4
(lp886
(dp887
g7
I15
sg8
g24
sg10
I5
sg11
VCD166
p888
sg13
I1
sa(dp889
g7
I21
sg8
g24
sg10
I5
sg11
VALCAM
p890
sg13
I1
sa(dp891
g7
I6
sg8
VP43121
p892
sg10
I4
sg11
VMCAM
p893
sg13
I1
sa(dp894
g7
I0
sg8
VP43121
p895
sg10
I5
sg11
VCD146
p896
sg13
I1
sasg14
(lp897
sa(dp898
g2
VTwo new and potentially promising melanocytic markers, microphthalmia transcription factor (MiTF) and melanoma cell adhesion molecule (Mel-CAM), have been shown to be sensitive markers of epithelioid melanoma, but have not been tested in desmoplastic/spindle cell melanoma or in other rare melanocytic neuroectodermal tumors such as clear cell sarcoma.
p899
sg4
(lp900
(dp901
g7
I55
sg8
VP35398
p902
sg10
I35
sg11
Vmicrophthalmia transcription factor
p903
sg13
I3
sa(dp904
g7
I135
sg8
VP61006
p905
sg10
I7
sg11
VMel-CAM
p906
sg13
I1
sa(dp907
g7
I92
sg8
g24
sg10
I4
sg11
VMiTF
p908
sg13
I1
sa(dp909
g7
I102
sg8
VP43121
p910
sg10
I31
sg11
Vmelanoma cell adhesion molecule
p911
sg13
I4
sasg14
(lp912
(dp913
g7
I238
sg17
VC1511789
p914
sg10
I12
sg11
Vdesmoplastic
p915
sg13
I1
sa(dp916
g7
I55
sg17
VC0026010
p917
sg10
I14
sg11
Vmicrophthalmia
p918
sg13
I1
sa(dp919
g7
I333
sg17
VC0206651
p920
sg10
I18
sg11
Vclear cell sarcoma
p921
sg13
I3
sa(dp922
g7
I139
sg17
VC1861821
p923
sg10
I3
sg11
VCAM
p924
sg13
I1
sa(dp925
g7
I135
sg17
VC3149631
p926
sg10
I3
sg11
VMel
p927
sg13
I1
sa(dp928
g7
I188
sg17
VC0334443
p929
sg10
I20
sg11
Vepithelioid melanoma
p930
sg13
I2
sa(dp931
g7
I302
sg17
VC0206093
p932
sg10
I22
sg11
Vneuroectodermal tumors
p933
sg13
I2
sa(dp934
g7
I102
sg17
VC0025202
p935
sg10
I8
sg11
Vmelanoma
p936
sg13
I1
sa(dp937
g7
I251
sg17
VC0334444
p938
sg10
I21
sg11
Vspindle cell melanoma
p939
sg13
I3
sa(dp940
g7
I116
sg17
VC0001511
p941
sg10
I8
sg11
Vadhesion
p942
sg13
I1
sasa(dp943
g2
VWe investigated the effect of carnosine as an adjuvant therapy on urinary albumin excretion (UAE), the tubular damage marker alpha 1-microglobulin (A1M), and oxidative stress in pediatric patients with type 1 diabetes and nephropathy.
p944
sg4
(lp945
(dp946
g7
I74
sg8
VP00441
p947
sg10
I7
sg11
Valbumin
p948
sg13
I1
sa(dp949
g7
I125
sg8
VP25100
p950
sg10
I21
sg11
Valpha 1-microglobulin
p951
sg13
I2
sa(dp952
g7
I148
sg8
VP02760
p953
sg10
I3
sg11
VA1M
p954
sg13
I1
sasg14
(lp955
(dp956
g7
I158
sg17
VC0242606
p957
sg10
I16
sg11
Voxidative stress
p958
sg13
I2
sa(dp959
g7
I202
sg17
VC0011854
p960
sg10
I15
sg11
Vtype 1 diabetes
p961
sg13
I3
sa(dp962
g7
I222
sg17
VC0022658
p963
sg10
I11
sg11
Vnephropathy
p964
sg13
I1
sasa(dp965
g2
VThe following parameters were measured in 377 patients with type 2 diabetes: HbA1c, serum concentrations of 1,5-AG, GA and creatinine, hemoglobin, urinary albumin/creatinine ratio, and urinary excretion of Alfa1 -microglobulin (A1M).
p966
sg4
(lp967
(dp968
g7
I206
sg8
VP02760
p969
sg10
I20
sg11
VAlfa1 -microglobulin
p970
sg13
I2
sa(dp971
g7
I135
sg8
g24
sg10
I10
sg11
Vhemoglobin
p972
sg13
I1
sa(dp973
g7
I155
sg8
VP00441
p974
sg10
I7
sg11
Valbumin
p975
sg13
I1
sa(dp976
g7
I228
sg8
VP02760
p977
sg10
I3
sg11
VA1M
p978
sg13
I1
sasg14
(lp979
(dp980
g7
I60
sg17
VC0011860
p981
sg10
I15
sg11
Vtype 2 diabetes
p982
sg13
I3
sasa(dp983
g2
VVonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs).
p984
sg4
(lp985
(dp986
g7
I21
sg8
VP50750
p987
sg10
I8
sg11
VTAK-438F
p988
sg13
I1
sasg14
(lp989
(dp990
g7
I117
sg17
VC0035222
p991
sg10
I21
sg11
Vacid-related diseases
p992
sg13
I2
sa(dp993
g7
I140
sg17
VC0035222
p994
sg10
I4
sg11
VARDs
p995
sg13
I1
sasa(dp996
g2
VIn many countries, the introduction of generic proton pump inhibitors (PPIs) onto the pharmaceutical market increased the phenomenon of therapeutic substitution in acid-related disorders (ARDs).
p997
sg4
(lp998
sg14
(lp999
(dp1000
g7
I164
sg17
VC0035222
p1001
sg10
I22
sg11
Vacid-related disorders
p1002
sg13
I2
sa(dp1003
g7
I188
sg17
VC0035222
p1004
sg10
I4
sg11
VARDs
p1005
sg13
I1
sasa(dp1006
g2
VWe present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.
p1007
sg4
(lp1008
(dp1009
g7
I120
sg8
g24
sg10
I5
sg11
VPRKRA
p1010
sg13
I1
sa(dp1011
g7
I135
sg8
g24
sg10
I4
sg11
VANO3
p1012
sg13
I1
sasg14
(lp1013
(dp1014
g7
I47
sg17
VC0393593
p1015
sg10
I8
sg11
Vdystonia
p1016
sg13
I1
sasa(dp1017
g2
VANO3 encodes anoctamin-3, a Ca+2-dependent phospholipid scramblase expressed in striatal-neurons, that has been implicated in autosomal dominant craniocervical dystonia (Dystonia-24, DYT24, MIM# 615034).
p1018
sg4
(lp1019
(dp1020
g7
I13
sg8
g24
sg10
I11
sg11
Vanoctamin-3
p1021
sg13
I1
sa(dp1022
g7
I0
sg8
g24
sg10
I4
sg11
VANO3
p1023
sg13
I1
sa(dp1024
g7
I28
sg8
VP19525
p1025
sg10
I38
sg11
VCa+2-dependent phospholipid scramblase
p1026
sg13
I3
sasg14
(lp1027
(dp1028
g7
I160
sg17
VC0393593
p1029
sg10
I8
sg11
Vdystonia
p1030
sg13
I1
sa(dp1031
g7
I170
sg17
VC0393593
p1032
sg10
I8
sg11
VDystonia
p1033
sg13
I1
sasa(dp1034
g2
VThree genes (GCH1, THAP1, TOR1A) were associated with isolated generalized dystonia, whereas 2 (ANO3, ADCY5) gave rise to combined dystonia-myoclonus phenotypes.
p1035
sg4
(lp1036
(dp1037
g7
I102
sg8
g24
sg10
I5
sg11
VADCY5
p1038
sg13
I1
sa(dp1039
g7
I13
sg8
VP30793
p1040
sg10
I4
sg11
VGCH1
p1041
sg13
I1
sa(dp1042
g7
I26
sg8
g24
sg10
I5
sg11
VTOR1A
p1043
sg13
I1
sa(dp1044
g7
I19
sg8
g24
sg10
I5
sg11
VTHAP1
p1045
sg13
I1
sa(dp1046
g7
I96
sg8
g24
sg10
I4
sg11
VANO3
p1047
sg13
I1
sasg14
(lp1048
(dp1049
g7
I75
sg17
VC0393593
p1050
sg10
I8
sg11
Vdystonia
p1051
sg13
I1
sa(dp1052
g7
I63
sg17
VC1848954
p1053
sg10
I20
sg11
Vgeneralized dystonia
p1054
sg13
I2
sa(dp1055
g7
I140
sg17
VC0027066
p1056
sg10
I9
sg11
Vmyoclonus
p1057
sg13
I1
sasa(dp1058
g2
VFurthermore, it provides confirmatory evidence for a dystonia-relevant role of ANO3 and ADCY5, both of which likely associate with a broader spectrum of dystonic expressions than previously thought.
p1059
sg4
(lp1060
(dp1061
g7
I88
sg8
g24
sg10
I5
sg11
VADCY5
p1062
sg13
I1
sa(dp1063
g7
I79
sg8
g24
sg10
I4
sg11
VANO3
p1064
sg13
I1
sasg14
(lp1065
(dp1066
g7
I53
sg17
VC0393593
p1067
sg10
I8
sg11
Vdystonia
p1068
sg13
I1
sasa(dp1069
g2
VIn the past 4 years, the definition and classification of dystonia have been revised, and new genes have been identified in patients with isolated hereditary dystonia (DYT23, DYT24, and DYT25).
p1070
sg4
(lp1071
sg14
(lp1072
(dp1073
g7
I58
sg17
VC0393593
p1074
sg10
I8
sg11
Vdystonia
p1075
sg13
I1
sa(dp1076
g7
I147
sg17
VC0752207
p1077
sg10
I19
sg11
Vhereditary dystonia
p1078
sg13
I2
sasa(dp1079
g2
VCompromised anoctamin function is causing a wide range of diseases, such as hearing loss (ANO2), bleeding disorder (ANO6), ataxia and dystonia (ANO3, 10), persistent borrelia and mycobacteria infection (ANO10), skeletal syndromes like gnathodiaphyseal dysplasia and limb girdle muscle dystrophy (ANO5), and cancer (ANO1, 6, 7).
p1080
sg4
(lp1081
(dp1082
g7
I266
sg8
g24
sg10
I35
sg11
Vlimb girdle muscle dystrophy (ANO5)
p1083
sg13
I5
sa(dp1084
g7
I203
sg8
g24
sg10
I5
sg11
VANO10
p1085
sg13
I1
sasg14
(lp1086
(dp1087
g7
I166
sg17
VC0024198
p1088
sg10
I8
sg11
Vborrelia
p1089
sg13
I1
sa(dp1090
g7
I97
sg17
VC0005779
p1091
sg10
I17
sg11
Vbleeding disorder
p1092
sg13
I2
sa(dp1093
g7
I192
sg17
VC0009450
p1094
sg10
I9
sg11
Vinfection
p1095
sg13
I1
sa(dp1096
g7
I134
sg17
VC0393593
p1097
sg10
I8
sg11
Vdystonia
p1098
sg13
I1
sa(dp1099
g7
I123
sg17
VC0004134
p1100
sg10
I6
sg11
Vataxia
p1101
sg13
I1
sa(dp1102
g7
I307
sg17
VC0006826
p1103
sg10
I6
sg11
Vcancer
p1104
sg13
I1
sa(dp1105
g7
I220
sg17
VC0039082
p1106
sg10
I9
sg11
Vsyndromes
p1107
sg13
I1
sa(dp1108
g7
I235
sg17
VC1833736
p1109
sg10
I26
sg11
Vgnathodiaphyseal dysplasia
p1110
sg13
I2
sa(dp1111
g7
I76
sg17
VC0011053
p1112
sg10
I12
sg11
Vhearing loss
p1113
sg13
I2
sa(dp1114
g7
I285
sg17
VC0333606
p1115
sg10
I9
sg11
Vdystrophy
p1116
sg13
I1
sasa(dp1117
g2
VSome genes, such as ANO3, GNAL and CIZ1, have been discovered for isolated dystonia, but they are probably not a common cause of classic cervical dystonia.
p1118
sg4
(lp1119
(dp1120
g7
I20
sg8
g24
sg10
I4
sg11
VANO3
p1121
sg13
I1
sa(dp1122
g7
I35
sg8
g24
sg10
I4
sg11
VCIZ1
p1123
sg13
I1
sa(dp1124
g7
I26
sg8
VP38405
p1125
sg10
I4
sg11
VGNAL
p1126
sg13
I1
sasg14
(lp1127
(dp1128
g7
I75
sg17
VC0393593
p1129
sg10
I8
sg11
Vdystonia
p1130
sg13
I1
sa(dp1131
g7
I137
sg17
VC0949445
p1132
sg10
I17
sg11
Vcervical dystonia
p1133
sg13
I2
sasa(dp1134
g2
VClinical and genetic heterogeneity also characterizes myoclonus-dystonia, which includes not only the classical phenotype associated with epsilon-sarcoglycan mutations but rarely also presentation of ANO3 gene mutations, TITF1 gene mutations typically underlying benign hereditary chorea, and some dopamine synthesis pathway conditions due to GCH1 and TH mutations.
p1135
sg4
(lp1136
(dp1137
g7
I221
sg8
VP43699
p1138
sg10
I10
sg11
VTITF1 gene
p1139
sg13
I2
sa(dp1140
g7
I200
sg8
g24
sg10
I9
sg11
VANO3 gene
p1141
sg13
I2
sa(dp1142
g7
I343
sg8
VP30793
p1143
sg10
I4
sg11
VGCH1
p1144
sg13
I1
sasg14
(lp1145
(dp1146
g7
I54
sg17
VC0027066
p1147
sg10
I9
sg11
Vmyoclonus
p1148
sg13
I1
sa(dp1149
g7
I64
sg17
VC0393593
p1150
sg10
I8
sg11
Vdystonia
p1151
sg13
I1
sa(dp1152
g7
I263
sg17
VC0393584
p1153
sg10
I24
sg11
Vbenign hereditary chorea
p1154
sg13
I3
sasa(dp1155
g2
VWhen 10 cases of M5 were subdivided by the differential level into undifferentiated (M5a) and differentiated monocytic leukemia (M5b), expression of CD45RA and CD45RO was strictly restricted to cases with M5a and M5b, respectively.
p1156
sg4
(lp1157
sg14
(lp1158
(dp1159
g7
I129
sg17
VC0598894
p1160
sg10
I3
sg11
VM5b
p1161
sg13
I1
sa(dp1162
g7
I109
sg17
VC0598894
p1163
sg10
I18
sg11
Vmonocytic leukemia
p1164
sg13
I2
sa(dp1165
g7
I129
sg17
VC0598894
p1166
sg10
I3
sg11
VM5b
p1167
sg13
I1
sasa(dp1168
g2
VIn this review, we describe the fusion genes recently reported in bone and soft-tissue tumors such as solitary fibrous tumor, aneurysmal bone cyst, nodular fasciitis, CIC-DUX4 fusion gene-positive small round cell tumors, or BCOR-CCNB3-positive sarcoma as well as other genetic aberrations in dedifferentiated liposarcoma, malignant rhabdoid tumor, cartilaginous tumor, Langerhans cell histiocytosis chondroblastoma, or giant cell tumor of the bone.
p1169
sg4
(lp1170
(dp1171
g7
I171
sg8
g24
sg10
I4
sg11
VDUX4
p1172
sg13
I1
sa(dp1173
g7
I225
sg8
g24
sg10
I10
sg11
VBCOR-CCNB3
p1174
sg13
I1
sa(dp1175
g7
I167
sg8
g24
sg10
I3
sg11
VCIC
p1176
sg13
I1
sasg14
(lp1177
(dp1178
g7
I245
sg17
VC1261473
p1179
sg10
I7
sg11
Vsarcoma
p1180
sg13
I1
sa(dp1181
g7
I87
sg17
VC0027651
p1182
sg10
I6
sg11
Vtumors
p1183
sg13
I1
sa(dp1184
g7
I420
sg17
VC0017547
p1185
sg10
I5
sg11
Vgiant
p1186
sg13
I1
sa(dp1187
g7
I349
sg17
VC0476147
p1188
sg10
I19
sg11
Vcartilaginous tumor
p1189
sg13
I2
sa(dp1190
g7
I148
sg17
VC0410005
p1191
sg10
I17
sg11
Vnodular fasciitis
p1192
sg13
I2
sa(dp1193
g7
I370
sg17
VC0019621
p1194
sg10
I29
sg11
VLangerhans cell histiocytosis
p1195
sg13
I3
sa(dp1196
g7
I87
sg17
VC0027651
p1197
sg10
I6
sg11
Vtumors
p1198
sg13
I1
sa(dp1199
g7
I293
sg17
VC0205824
p1200
sg10
I28
sg11
Vdedifferentiated liposarcoma
p1201
sg13
I2
sa(dp1202
g7
I400
sg17
VC0008441
p1203
sg10
I15
sg11
Vchondroblastoma
p1204
sg13
I1
sa(dp1205
g7
I323
sg17
VC0206743
p1206
sg10
I24
sg11
Vmalignant rhabdoid tumor
p1207
sg13
I3
sa(dp1208
g7
I102
sg17
VC1266119
p1209
sg10
I22
sg11
Vsolitary fibrous tumor
p1210
sg13
I3
sa(dp1211
g7
I431
sg17
VC0005967
p1212
sg10
I17
sg11
Vtumor of the bone
p1213
sg13
I4
sa(dp1214
g7
I126
sg17
VC0152244
p1215
sg10
I20
sg11
Vaneurysmal bone cyst
p1216
sg13
I3
sasa(dp1217
g2
VThe individual diagnostic marker positivity was 98% for GATA-binding protein 3, 95% for androgen receptor, 90% for progesterone receptor, 88% for deleted in pancreatic cancer 4, 75% for gross cystic disease fluid protein 15, 72% for cytokeratin 7, 55% for mammaglobin, and 15% for vimentin and Wilms tumor protein 1.
p1218
sg4
(lp1219
(dp1220
g7
I56
sg8
VP23771
p1221
sg10
I22
sg11
VGATA-binding protein 3
p1222
sg13
I3
sa(dp1223
g7
I256
sg8
g24
sg10
I11
sg11
Vmammaglobin
p1224
sg13
I1
sa(dp1225
g7
I115
sg8
VP06401
p1226
sg10
I21
sg11
Vprogesterone receptor
p1227
sg13
I2
sa(dp1228
g7
I88
sg8
VP10275
p1229
sg10
I17
sg11
Vandrogen receptor
p1230
sg13
I2
sa(dp1231
g7
I294
sg8
VP14222
p1232
sg10
I21
sg11
VWilms tumor protein 1
p1233
sg13
I4
sasg14
(lp1234
(dp1235
g7
I192
sg17
VC0334054
p1236
sg10
I14
sg11
Vcystic disease
p1237
sg13
I2
sa(dp1238
g7
I157
sg17
VC0235974
p1239
sg10
I17
sg11
Vpancreatic cancer
p1240
sg13
I2
sa(dp1241
g7
I294
sg17
VC0027708
p1242
sg10
I11
sg11
VWilms tumor
p1243
sg13
I2
sasa(dp1244
g2
VAstrocyte loss may be caused by cytotoxic T cells as seen in Rasmussen encephalitis, auto-antibodies such as in neuromyelitis optica (aquaporin-4 antibodies), or cytokines such as TNF-Alfa in major depressive disorder.
p1245
sg4
(lp1246
(dp1247
g7
I180
sg8
VP01375
p1248
sg10
I8
sg11
VTNF-Alfa
p1249
sg13
I1
sa(dp1250
g7
I134
sg8
VP55087
p1251
sg10
I22
sg11
Vaquaporin-4 antibodies
p1252
sg13
I2
sasg14
(lp1253
(dp1254
g7
I112
sg17
VC0027873
p1255
sg10
I20
sg11
Vneuromyelitis optica
p1256
sg13
I2
sa(dp1257
g7
I61
sg17
VC0393484
p1258
sg10
I22
sg11
VRasmussen encephalitis
p1259
sg13
I2
sa(dp1260
g7
I192
sg17
VC1269683
p1261
sg10
I25
sg11
Vmajor depressive disorder
p1262
sg13
I3
sasa(dp1263
g2
VMutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D are found in aldosterone producing adenoma (APA) and familial hyperaldosteronism (FH).
p1264
sg4
(lp1265
(dp1266
g7
I13
sg8
VP48544
p1267
sg10
I5
sg11
VKCNJ5
p1268
sg13
I1
sa(dp1269
g7
I39
sg8
g24
sg10
I7
sg11
VCACNA1D
p1270
sg13
I1
sa(dp1271
g7
I20
sg8
VP05023
p1272
sg10
I6
sg11
VATP1A1
p1273
sg13
I1
sa(dp1274
g7
I28
sg8
g24
sg10
I6
sg11
VATP2B3
p1275
sg13
I1
sasg14
(lp1276
(dp1277
g7
I82
sg17
VC0001430
p1278
sg10
I7
sg11
Vadenoma
p1279
sg13
I1
sa(dp1280
g7
I109
sg17
VC0020428
p1281
sg10
I18
sg11
Vhyperaldosteronism
p1282
sg13
I1
sasa(dp1283
g2
VOur results suggest that these mutations, in addition to mutations in the KCNJ5 gene and other genes such as ATP1A1, ATP2B3 and CACNA1D, may be responsible for the tumorigenesis of APAs and CPAs with subclinical Cushing's syndrome.
p1284
sg4
(lp1285
(dp1286
g7
I74
sg8
VP48544
p1287
sg10
I10
sg11
VKCNJ5 gene
p1288
sg13
I2
sa(dp1289
g7
I117
sg8
g24
sg10
I6
sg11
VATP2B3
p1290
sg13
I1
sa(dp1291
g7
I128
sg8
g24
sg10
I7
sg11
VCACNA1D
p1292
sg13
I1
sa(dp1293
g7
I109
sg8
VP05023
p1294
sg10
I6
sg11
VATP1A1
p1295
sg13
I1
sasg14
(lp1296
(dp1297
g7
I164
sg17
VC0007621
p1298
sg10
I13
sg11
Vtumorigenesis
p1299
sg13
I1
sa(dp1300
g7
I212
sg17
VC0010481
p1301
sg10
I18
sg11
VCushing's syndrome
p1302
sg13
I2
sasa(dp1303
g2
VScreening of SOX2 was completed in 89 patients with a variety of ocular anomalies, including 28 with A/M and 61 with normal eye size and anterior segment dysgenesis (28), cataract (14), isolated coloboma (5), or other eye disorders (14).
p1304
sg4
(lp1305
(dp1306
g7
I13
sg8
VP48431
p1307
sg10
I4
sg11
VSOX2
p1308
sg13
I1
sasg14
(lp1309
(dp1310
g7
I218
sg17
VC0015397
p1311
sg10
I13
sg11
Veye disorders
p1312
sg13
I2
sa(dp1313
g7
I195
sg17
VC0009363
p1314
sg10
I8
sg11
Vcoloboma
p1315
sg13
I1
sa(dp1316
g7
I137
sg17
VC0266525
p1317
sg10
I27
sg11
Vanterior segment dysgenesis
p1318
sg13
I3
sa(dp1319
g7
I171
sg17
VC0086543
p1320
sg10
I8
sg11
Vcataract
p1321
sg13
I1
sasa(dp1322
g2
VThe overexpression of Kir3.2, a subunit of the G protein-gated inwardly rectifying K(+) channel, is implicated in some of the neurological phenotypes of Down syndrome (DS).
p1323
sg4
(lp1324
(dp1325
g7
I47
sg8
g24
sg10
I9
sg11
VG protein
p1326
sg13
I2
sa(dp1327
g7
I22
sg8
VP48051
p1328
sg10
I6
sg11
VKir3.2
p1329
sg13
I1
sasg14
(lp1330
(dp1331
g7
I153
sg17
VC0013080
p1332
sg10
I13
sg11
VDown syndrome
p1333
sg13
I2
sa(dp1334
g7
I168
sg17
VC0013080
p1335
sg10
I2
sg11
VDS
p1336
sg13
I1
sasa(dp1337
g2
VKeppen-Lubinsky syndrome (KPLBS) is a rare disease mainly characterized by severe developmental delay and intellectual disability, microcephaly, large prominent eyes, a narrow nasal bridge, a tented upper lip, a high palate, an open mouth, tightly adherent skin, an aged appearance, and severe generalized lipodystrophy.
p1338
sg4
(lp1339
sg14
(lp1340
(dp1341
g7
I131
sg17
VC0025958
p1342
sg10
I12
sg11
Vmicrocephaly
p1343
sg13
I1
sa(dp1344
g7
I82
sg17
VC0424605
p1345
sg10
I19
sg11
Vdevelopmental delay
p1346
sg13
I2
sa(dp1347
g7
I0
sg17
VC3279800
p1348
sg10
I24
sg11
VKeppen-Lubinsky syndrome
p1349
sg13
I2
sa(dp1350
g7
I294
sg17
VC0221032
p1351
sg10
I25
sg11
Vgeneralized lipodystrophy
p1352
sg13
I2
sa(dp1353
g7
I212
sg17
VC1398297
p1354
sg10
I11
sg11
Vhigh palate
p1355
sg13
I2
sa(dp1356
g7
I38
sg17
VC0678236
p1357
sg10
I12
sg11
Vrare disease
p1358
sg13
I2
sa(dp1359
g7
I106
sg17
VC0025362
p1360
sg10
I23
sg11
Vintellectual disability
p1361
sg13
I2
sa(dp1362
g7
I26
sg17
VC3279800
p1363
sg10
I5
sg11
VKPLBS
p1364
sg13
I1
sa(dp1365
g7
I205
sg17
VC0264511
p1366
sg10
I3
sg11
Vlip
p1367
sg13
I1
sasa(dp1368
g2
VWe sequenced the exomes of three unrelated individuals affected by KPLBS and found de novo heterozygous mutations in KCNJ6 (GIRK2), which encodes an inwardly rectifying potassium channel and maps to the Down syndrome critical region between DIRK1A and DSCR4.
p1369
sg4
(lp1370
(dp1371
g7
I104
sg8
VP48051
p1372
sg10
I18
sg11
Vmutations in KCNJ6
p1373
sg13
I3
sa(dp1374
g7
I252
sg8
VP56555
p1375
sg10
I5
sg11
VDSCR4
p1376
sg13
I1
sa(dp1377
g7
I124
sg8
VP48051
p1378
sg10
I5
sg11
VGIRK2
p1379
sg13
I1
sasg14
(lp1380
(dp1381
g7
I67
sg17
VC3279800
p1382
sg10
I5
sg11
VKPLBS
p1383
sg13
I1
sa(dp1384
g7
I203
sg17
VC1860787
p1385
sg10
I29
sg11
VDown syndrome critical region
p1386
sg13
I4
sasa(dp1387
g2
VWe evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water.
p1388
sg4
(lp1389
(dp1390
g7
I27
sg8
g24
sg10
I41
sg11
Vglucose-lysine Maillard reaction products
p1391
sg13
I4
sa(dp1392
g7
I70
sg8
g24
sg10
I12
sg11
VGlc-Lys MRPs
p1393
sg13
I2
sasg14
(lp1394
(dp1395
g7
I139
sg17
VC0011195
p1396
sg10
I22
sg11
Vdextran sulfate sodium
p1397
sg13
I3
sa(dp1398
g7
I163
sg17
VC0011195
p1399
sg10
I3
sg11
VDSS
p1400
sg13
I1
sa(dp1401
g7
I87
sg17
VC0009319
p1402
sg10
I7
sg11
Vcolitis
p1403
sg13
I1
sasa(dp1404
g2
VGlc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels.
p1405
sg4
(lp1406
(dp1407
g7
I0
sg8
g24
sg10
I12
sg11
VGlc-Lys MRPs
p1408
sg13
I2
sa(dp1409
g7
I187
sg8
VP61626
p1410
sg10
I31
sg11
Vcolon length and serum lysozyme
p1411
sg13
I5
sasg14
(lp1412
(dp1413
g7
I24
sg17
VC0011195
p1414
sg10
I3
sg11
VDSS
p1415
sg13
I1
sa(dp1416
g7
I36
sg17
VC0009319
p1417
sg10
I7
sg11
Vcolitis
p1418
sg13
I1
sasa(dp1419
g2
VThis study was aimed at determining whether repeated low-level exposure to MRPs, generated via two different heat treatments, can contribute to the modulation of experimental colitis in mice.
p1420
sg4
(lp1421
sg14
(lp1422
(dp1423
g7
I175
sg17
VC0009319
p1424
sg10
I7
sg11
Vcolitis
p1425
sg13
I1
sasa(dp1426
g2
VFurthermore, we used a sandwich immunoassay to measure serum concentrations of MRPs in 62 patients were simultaneously assessed by the Crohn's disease activity index (CDAI) and the severity activity index of Goebell (SAI).
p1427
sg4
(lp1428
(dp1429
g7
I135
sg8
g24
sg10
I30
sg11
VCrohn's disease activity index
p1430
sg13
I4
sa(dp1431
g7
I167
sg8
g24
sg10
I4
sg11
VCDAI
p1432
sg13
I1
sasg14
(lp1433
(dp1434
g7
I135
sg17
VC0010346
p1435
sg10
I15
sg11
VCrohn's disease
p1436
sg13
I2
sasa(dp1437
g2
VIn the present study monospecific antibodies against MRPs were used to investigate immunohistochemically the distribution of these proteins in routinely processed bowel tissues from 23 patients with ulcerative colitis (UC).
p1438
sg4
(lp1439
sg14
(lp1440
(dp1441
g7
I219
sg17
VC0009324
p1442
sg10
I2
sg11
VUC
p1443
sg13
I1
sa(dp1444
g7
I199
sg17
VC0009324
p1445
sg10
I18
sg11
Vulcerative colitis
p1446
sg13
I2
sasa(dp1447
g2
VThe dimeric hybrid-IgG/IgA inhibited the binding of digoxigenin-conjugated Stx1B to natural ligands (CD77) displayed on Burkitt's lymphoma cell line Ramos.
p1448
sg4
(lp1449
(dp1450
g7
I75
sg8
VP61266
p1451
sg10
I5
sg11
VStx1B
p1452
sg13
I1
sa(dp1453
g7
I23
sg8
VP11912
p1454
sg10
I3
sg11
VIgA
p1455
sg13
I1
sasg14
(lp1456
(dp1457
g7
I120
sg17
VC0006413
p1458
sg10
I18
sg11
VBurkitt's lymphoma
p1459
sg13
I2
sasa(dp1460
g2
VFurthermore, the purified Stx1 B subunit was able to bind specifically to Gb3Cer expressed on Burkitt's lymphoma cells.
p1461
sg4
(lp1462
(dp1463
g7
I26
sg8
g24
sg10
I14
sg11
VStx1 B subunit
p1464
sg13
I3
sasg14
(lp1465
(dp1466
g7
I94
sg17
VC0006413
p1467
sg10
I18
sg11
VBurkitt's lymphoma
p1468
sg13
I2
sasa(dp1469
g2
VFurthermore, we found that Mcl-1 could be a potential therapeutic target of MECK-induced apoptosis and its stability is regulated by extracellular signal-regulated kinases 1/2 (ERK1/2) signaling MECK can be used as a safe and efficient therapeutic alternative for the treatment of salivary gland cancer.
p1470
sg4
(lp1471
(dp1472
g7
I177
sg8
VP27361
p1473
sg10
I6
sg11
VERK1/2
p1474
sg13
I1
sa(dp1475
g7
I133
sg8
g24
sg10
I42
sg11
Vextracellular signal-regulated kinases 1/2
p1476
sg13
I4
sa(dp1477
g7
I27
sg8
VP07954
p1478
sg10
I5
sg11
VMcl-1
p1479
sg13
I1
sasg14
(lp1480
(dp1481
g7
I281
sg17
VC0220636
p1482
sg10
I21
sg11
Vsalivary gland cancer
p1483
sg13
I3
sa(dp1484
g7
I27
sg17
VC1708350
p1485
sg10
I3
sg11
VMcl
p1486
sg13
I1
sasa(dp1487
g2
VAlthough NF-KB RelA (p65) is essential for the expression of many cytokines during pneumonia, its targeted mutation in the lung epithelium was inconsequential for pneumonia-driven LIF induction.
p1488
sg4
(lp1489
(dp1490
g7
I9
sg8
g24
sg10
I10
sg11
VNF-KB RelA
p1491
sg13
I2
sa(dp1492
g7
I21
sg8
VP21579
p1493
sg10
I3
sg11
Vp65
p1494
sg13
I1
sasg14
(lp1495
(dp1496
g7
I83
sg17
VC0032285
p1497
sg10
I9
sg11
Vpneumonia
p1498
sg13
I1
sa(dp1499
g7
I83
sg17
VC0032285
p1500
sg10
I9
sg11
Vpneumonia
p1501
sg13
I1
sasa(dp1502
g2
VOverall, our data suggest a signaling axis whereby activation of NF-KB RelA in myeloid cells promotes epithelial LIF induction during lung infections, representing a means through which these two cell types collaborate to improve tissue resilience during pneumonia.
p1503
sg4
(lp1504
(dp1505
g7
I102
sg8
VP15018
p1506
sg10
I14
sg11
Vepithelial LIF
p1507
sg13
I2
sa(dp1508
g7
I65
sg8
g24
sg10
I10
sg11
VNF-KB RelA
p1509
sg13
I2
sasg14
(lp1510
(dp1511
g7
I139
sg17
VC0021311
p1512
sg10
I10
sg11
Vinfections
p1513
sg13
I1
sa(dp1514
g7
I255
sg17
VC0032285
p1515
sg10
I9
sg11
Vpneumonia
p1516
sg13
I1
sasa(dp1517
g2
VSectm1 was induced during the early stages of pneumococcal pneumonia, and mutation of NF-KB RelA in epithelial cells did not diminish its expression.
p1518
sg4
(lp1519
(dp1520
g7
I86
sg8
g24
sg10
I10
sg11
VNF-KB RelA
p1521
sg13
I2
sa(dp1522
g7
I0
sg8
g24
sg10
I6
sg11
VSectm1
p1523
sg13
I1
sasg14
(lp1524
(dp1525
g7
I46
sg17
VC0155862
p1526
sg10
I22
sg11
Vpneumococcal pneumonia
p1527
sg13
I2
sasa(dp1528
g2
VTo determine the functional significance of the hepatic APR during pneumonia, we challenged APR-null mice lacking hepatocyte signal transducer and activator of transcription 3 (STAT3) and v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) with Escherichia coli in the airspaces.
p1529
sg4
(lp1530
(dp1531
g7
I114
sg8
VP40763
p1532
sg10
I61
sg11
Vhepatocyte signal transducer and activator of transcription 3
p1533
sg13
I8
sa(dp1534
g7
I188
sg8
g24
sg10
I58
sg11
Vv-rel avian reticuloendotheliosis viral oncogene homolog A
p1535
sg13
I7
sa(dp1536
g7
I248
sg8
g24
sg10
I4
sg11
VRelA
p1537
sg13
I1
sa(dp1538
g7
I177
sg8
VP40763
p1539
sg10
I5
sg11
VSTAT3
p1540
sg13
I1
sasg14
(lp1541
(dp1542
g7
I67
sg17
VC0032285
p1543
sg10
I9
sg11
Vpneumonia
p1544
sg13
I1
sa(dp1545
g7
I194
sg17
VC0276487
p1546
sg10
I27
sg11
Vavian reticuloendotheliosis
p1547
sg13
I2
sasa(dp1548
g2
VEpithelial cells expressed multiple neutrophil-stimulating cytokines during pneumonia, all of which depended on RelA.
p1549
sg4
(lp1550
(dp1551
g7
I112
sg8
g24
sg10
I4
sg11
VRelA
p1552
sg13
I1
sasg14
(lp1553
(dp1554
g7
I76
sg17
VC0032285
p1555
sg10
I9
sg11
Vpneumonia
p1556
sg13
I1
sasa(dp1557
g2
VEpithelial RelA mutation decreased whole lung levels of CXCL5 and GM-CSF during pneumococcal pneumonia, whereas lung levels of other neutrophil-recruiting factors were unaffected.
p1558
sg4
(lp1559
(dp1560
g7
I66
sg8
VP04141
p1561
sg10
I6
sg11
VGM-CSF
p1562
sg13
I1
sa(dp1563
g7
I56
sg8
VP42830
p1564
sg10
I5
sg11
VCXCL5
p1565
sg13
I1
sa(dp1566
g7
I11
sg8
g24
sg10
I4
sg11
VRelA
p1567
sg13
I1
sasg14
(lp1568
(dp1569
g7
I80
sg17
VC0155862
p1570
sg10
I22
sg11
Vpneumococcal pneumonia
p1571
sg13
I2
sasa(dp1572
g2
VWe demonstrate that RelA-P-Ser536 is a feature of human lung and skin fibroblasts, but not lung epithelial cells, in vitro and is present in sclerotic skin and diseased lungs of patients suffering from idiopathic pulmonary fibrosis.
p1573
sg4
(lp1574
(dp1575
g7
I20
sg8
g24
sg10
I6
sg11
VRelA-P
p1576
sg13
I1
sasg14
(lp1577
(dp1578
g7
I202
sg17
VC3161101
p1579
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p1580
sg13
I3
sa(dp1581
g7
I187
sg17
VC0683278
p1582
sg10
I9
sg11
Vsuffering
p1583
sg13
I1
sa(dp1584
g7
I141
sg17
VC0036429
p1585
sg10
I9
sg11
Vsclerotic
p1586
sg13
I1
sasa(dp1587
g2
VBecause innate immunity gene induction depends on NF-KB RelA (also known as p65) during pneumonia, we generated a murine model of RelA mutated throughout the alveolar epithelium.
p1588
sg4
(lp1589
(dp1590
g7
I76
sg8
VP21579
p1591
sg10
I3
sg11
Vp65
p1592
sg13
I1
sa(dp1593
g7
I56
sg8
g24
sg10
I4
sg11
VRelA
p1594
sg13
I1
sa(dp1595
g7
I50
sg8
g24
sg10
I10
sg11
VNF-KB RelA
p1596
sg13
I2
sasg14
(lp1597
(dp1598
g7
I88
sg17
VC0032285
p1599
sg10
I9
sg11
Vpneumonia
p1600
sg13
I1
sasa(dp1601
g2
VSorted cell populations from mouse lungs revealed that CXCL5 was induced during pneumonia in type I cells, which did not require RelA.
p1602
sg4
(lp1603
(dp1604
g7
I129
sg8
g24
sg10
I4
sg11
VRelA
p1605
sg13
I1
sa(dp1606
g7
I55
sg8
VP42830
p1607
sg10
I5
sg11
VCXCL5
p1608
sg13
I1
sasg14
(lp1609
(dp1610
g7
I80
sg17
VC0032285
p1611
sg10
I9
sg11
Vpneumonia
p1612
sg13
I1
sasa(dp1613
g2
VThese are also, to our knowledge, the first evidence for entirely RelA-independent pathways of innate immunity gene induction in any cell during pneumonia.
p1614
sg4
(lp1615
(dp1616
g7
I66
sg8
g24
sg10
I4
sg11
VRelA
p1617
sg13
I1
sasg14
(lp1618
(dp1619
g7
I145
sg17
VC0032285
p1620
sg10
I9
sg11
Vpneumonia
p1621
sg13
I1
sasa(dp1622
g2
VWe review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).
p1623
sg4
(lp1624
(dp1625
g7
I421
sg8
g24
sg10
I6
sg11
VRAB39B
p1626
sg13
I1
sa(dp1627
g7
I204
sg8
g24
sg10
I5
sg11
VPINK1
p1628
sg13
I1
sa(dp1629
g7
I440
sg8
g24
sg10
I4
sg11
VSCA2
p1630
sg13
I1
sa(dp1631
g7
I267
sg8
g24
sg10
I5
sg11
VLRRK2
p1632
sg13
I1
sa(dp1633
g7
I349
sg8
VP30793
p1634
sg10
I4
sg11
VGCH1
p1635
sg13
I1
sa(dp1636
g7
I414
sg8
g24
sg10
I5
sg11
VFBXO7
p1637
sg13
I1
sa(dp1638
g7
I355
sg8
g24
sg10
I7
sg11
VATP13A2
p1639
sg13
I1
sa(dp1640
g7
I364
sg8
g24
sg10
I6
sg11
VPLA2G6
p1641
sg13
I1
sa(dp1642
g7
I433
sg8
g24
sg10
I5
sg11
VATXN2
p1643
sg13
I1
sasg14
(lp1644
(dp1645
g7
I295
sg17
VC0017205
p1646
sg10
I15
sg11
VGaucher disease
p1647
sg13
I2
sa(dp1648
g7
I93
sg17
VC0242422
p1649
sg10
I12
sg11
Vparkinsonism
p1650
sg13
I1
sa(dp1651
g7
I461
sg17
VC0795880
p1652
sg10
I21
sg11
V22q deletion syndrome
p1653
sg13
I3
sa(dp1654
g7
I93
sg17
VC0242422
p1655
sg10
I12
sg11
Vparkinsonism
p1656
sg13
I1
sa(dp1657
g7
I440
sg17
VC0752121
p1658
sg10
I4
sg11
VSCA2
p1659
sg13
I1
sasa(dp1660
g2
VWe performed genetic testing consisting of C9orf72 hexanucleotide expansion, ATXN2 polyglutamine (polyQ) expansion, and targeted next generation sequencing using the ONDRISeq, a gene panel consisting of 80 genes known to be associated with neurodegenerative diseases such as ALS, FTD, Alzheimer's disease, Parkinson's disease, and vascular cognitive impairment.
p1661
sg4
(lp1662
(dp1663
g7
I77
sg8
g24
sg10
I5
sg11
VATXN2
p1664
sg13
I1
sasg14
(lp1665
(dp1666
g7
I340
sg17
VC0338656
p1667
sg10
I20
sg11
Vcognitive impairment
p1668
sg13
I2
sa(dp1669
g7
I306
sg17
VC0030567
p1670
sg10
I19
sg11
VParkinson's disease
p1671
sg13
I2
sa(dp1672
g7
I240
sg17
VC0524851
p1673
sg10
I26
sg11
Vneurodegenerative diseases
p1674
sg13
I2
sa(dp1675
g7
I285
sg17
VC1521724
p1676
sg10
I19
sg11
VAlzheimer's disease
p1677
sg13
I2
sa(dp1678
g7
I280
sg17
VC0338451
p1679
sg10
I3
sg11
VFTD
p1680
sg13
I1
sa(dp1681
g7
I275
sg17
VC0002736
p1682
sg10
I3
sg11
VALS
p1683
sg13
I1
sasa(dp1684
g2
VPathological developments leading to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are associated with misbehavior of several key proteins, such as SOD1 (superoxide dismutase 1), TARDBP/TDP-43, FUS, C9orf72, and dipeptide repeat proteins generated as a result of the translation of the intronic hexanucleotide expansions in the C9orf72 gene, PFN1 (profilin 1), GLE1 (GLE1, RNA export mediator), PURA (purine rich element binding protein A), FLCN (folliculin), RBM45 (RNA binding motif protein 45), SS18L1/CREST, HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1), HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1), ATXN2 (ataxin 2), MAPT (microtubule associated protein tau), and TIA1 (TIA1 cytotoxic granule associated RNA binding protein).
p1685
sg4
(lp1686
(dp1687
g7
I556
sg8
VP09651
p1688
sg10
I42
sg11
Vheterogeneous nuclear ribonucleoprotein A1
p1689
sg13
I4
sa(dp1690
g7
I684
sg8
g24
sg10
I34
sg11
Vmicrotubule associated protein tau
p1691
sg13
I4
sa(dp1692
g7
I396
sg8
g24
sg10
I4
sg11
VGLE1
p1693
sg13
I1
sa(dp1694
g7
I430
sg8
g24
sg10
I4
sg11
VPURA
p1695
sg13
I1
sa(dp1696
g7
I383
sg8
VP07737
p1697
sg10
I10
sg11
Vprofilin 1
p1698
sg13
I2
sa(dp1699
g7
I482
sg8
g24
sg10
I10
sg11
Vfolliculin
p1700
sg13
I1
sa(dp1701
g7
I436
sg8
g24
sg10
I37
sg11
Vpurine rich element binding protein A
p1702
sg13
I6
sa(dp1703
g7
I725
sg8
VP31483
p1704
sg10
I4
sg11
VTIA1
p1705
sg13
I1
sa(dp1706
g7
I183
sg8
VP00441
p1707
sg10
I4
sg11
VSOD1
p1708
sg13
I1
sa(dp1709
g7
I229
sg8
VP35637
p1710
sg10
I3
sg11
VFUS
p1711
sg13
I1
sa(dp1712
g7
I189
sg8
VP00441
p1713
sg10
I22
sg11
Vsuperoxide dismutase 1
p1714
sg13
I3
sa(dp1715
g7
I678
sg8
g24
sg10
I4
sg11
VMAPT
p1716
sg13
I1
sa(dp1717
g7
I396
sg8
g24
sg10
I4
sg11
VGLE1
p1718
sg13
I1
sa(dp1719
g7
I667
sg8
g24
sg10
I8
sg11
Vataxin 2
p1720
sg13
I2
sa(dp1721
g7
I612
sg8
VP22626
p1722
sg10
I45
sg11
Vheterogeneous nuclear ribonucleoprotein A2/B1
p1723
sg13
I4
sa(dp1724
g7
I234
sg8
g24
sg10
I7
sg11
VC9orf72
p1725
sg13
I1
sa(dp1726
g7
I214
sg8
g24
sg10
I13
sg11
VTARDBP/TDP-43
p1727
sg13
I1
sa(dp1728
g7
I731
sg8
VP00390
p1729
sg10
I53
sg11
VTIA1 cytotoxic granule associated RNA binding protein
p1730
sg13
I7
sa(dp1731
g7
I601
sg8
VP22626
p1732
sg10
I9
sg11
VHNRNPA2B1
p1733
sg13
I1
sa(dp1734
g7
I377
sg8
VP07737
p1735
sg10
I4
sg11
VPFN1
p1736
sg13
I1
sa(dp1737
g7
I363
sg8
g24
sg10
I12
sg11
VC9orf72 gene
p1738
sg13
I2
sa(dp1739
g7
I476
sg8
g24
sg10
I4
sg11
VFLCN
p1740
sg13
I1
sa(dp1741
g7
I660
sg8
g24
sg10
I5
sg11
VATXN2
p1742
sg13
I1
sa(dp1743
g7
I547
sg8
VP09651
p1744
sg10
I7
sg11
VHNRNPA1
p1745
sg13
I1
sasg14
(lp1746
(dp1747
g7
I68
sg17
VC0002736
p1748
sg10
I3
sg11
VALS
p1749
sg13
I1
sa(dp1750
g7
I77
sg17
VC0751072
p1751
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p1752
sg13
I3
sa(dp1753
g7
I540
sg17
VC0206138
p1754
sg10
I5
sg11
VCREST
p1755
sg13
I1
sa(dp1756
g7
I112
sg17
VC0751072
p1757
sg10
I4
sg11
VFTLD
p1758
sg13
I1
sa(dp1759
g7
I37
sg17
VC0002736
p1760
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p1761
sg13
I3
sasa(dp1762
g2
VSpinocerebellar ataxia type 2 (SCA2) is an autosomal dominant cerebellar ataxia that occurs as a consequence of abnormal CAG expansions in the ATXN2 gene.
p1763
sg4
(lp1764
(dp1765
g7
I143
sg8
g24
sg10
I10
sg11
VATXN2 gene
p1766
sg13
I2
sa(dp1767
g7
I0
sg8
g24
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p1768
sg13
I4
sa(dp1769
g7
I31
sg8
g24
sg10
I4
sg11
VSCA2
p1770
sg13
I1
sasg14
(lp1771
(dp1772
g7
I5
sg17
VC0007758
p1773
sg10
I17
sg11
Vcerebellar ataxia
p1774
sg13
I2
sa(dp1775
g7
I0
sg17
VC0752121
p1776
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p1777
sg13
I4
sa(dp1778
g7
I31
sg17
VC0752121
p1779
sg10
I4
sg11
VSCA2
p1780
sg13
I1
sasa(dp1781
g2
VRecent findings linking ataxin-2 intermediate expansions to other neurodegenerative diseases such as amyotrophic lateral sclerosis have provided insights into the ataxin-2-related toxicity mechanism in neurodegenerative diseases and have raised new ethical challenges to molecular predictive diagnosis of SCA2.
p1782
sg4
(lp1783
(dp1784
g7
I305
sg8
g24
sg10
I4
sg11
VSCA2
p1785
sg13
I1
sasg14
(lp1786
(dp1787
g7
I101
sg17
VC0002736
p1788
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p1789
sg13
I3
sa(dp1790
g7
I66
sg17
VC0524851
p1791
sg10
I26
sg11
Vneurodegenerative diseases
p1792
sg13
I2
sa(dp1793
g7
I66
sg17
VC0524851
p1794
sg10
I26
sg11
Vneurodegenerative diseases
p1795
sg13
I2
sa(dp1796
g7
I305
sg17
VC0752121
p1797
sg10
I4
sg11
VSCA2
p1798
sg13
I1
sasa(dp1799
g2
VSpinocerebellar ataxia type 2 (SCA2) is among the most common forms of autosomal dominant ataxias, accounting for 15% of the total families.
p1800
sg4
(lp1801
(dp1802
g7
I0
sg8
g24
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p1803
sg13
I4
sa(dp1804
g7
I31
sg8
g24
sg10
I4
sg11
VSCA2
p1805
sg13
I1
sasg14
(lp1806
(dp1807
g7
I90
sg17
VC0004134
p1808
sg10
I7
sg11
Vataxias
p1809
sg13
I1
sa(dp1810
g7
I0
sg17
VC0752121
p1811
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p1812
sg13
I4
sa(dp1813
g7
I31
sg17
VC0752121
p1814
sg10
I4
sg11
VSCA2
p1815
sg13
I1
sasa(dp1816
g2
VSpinocerebellar ataxia type 2 (SCA2) is due to a CAG expansion (CAGexp) at ATXN2.
p1817
sg4
(lp1818
(dp1819
g7
I75
sg8
g24
sg10
I5
sg11
VATXN2
p1820
sg13
I1
sa(dp1821
g7
I0
sg8
g24
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p1822
sg13
I4
sa(dp1823
g7
I31
sg8
g24
sg10
I4
sg11
VSCA2
p1824
sg13
I1
sasg14
(lp1825
(dp1826
g7
I0
sg17
VC0752121
p1827
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p1828
sg13
I4
sa(dp1829
g7
I31
sg17
VC0752121
p1830
sg10
I4
sg11
VSCA2
p1831
sg13
I1
sasa(dp1832
g2
VExpansion of polyglutamine trinucleotide (CAG) within ATXN2 gene with 35 or more repeats, results in spinocerebellar ataxia type-2.
p1833
sg4
(lp1834
(dp1835
g7
I54
sg8
g24
sg10
I10
sg11
VATXN2 gene
p1836
sg13
I2
sasg14
(lp1837
(dp1838
g7
I101
sg17
VC0087012
p1839
sg10
I22
sg11
Vspinocerebellar ataxia
p1840
sg13
I2
sasa(dp1841
g2
VRecent studies have identified the RNA-binding protein Ataxin-2 as a genetic determinant or risk factor for various diseases including spinocerebellar ataxia type II (SCA2) and amyotrophic lateral sclerosis (ALS), amongst others.
p1842
sg4
(lp1843
(dp1844
g7
I167
sg8
g24
sg10
I4
sg11
VSCA2
p1845
sg13
I1
sa(dp1846
g7
I55
sg8
g24
sg10
I8
sg11
VAtaxin-2
p1847
sg13
I1
sa(dp1848
g7
I151
sg8
VP27037
p1849
sg10
I14
sg11
Vataxia type II
p1850
sg13
I3
sasg14
(lp1851
(dp1852
g7
I167
sg17
VC0752121
p1853
sg10
I4
sg11
VSCA2
p1854
sg13
I1
sa(dp1855
g7
I177
sg17
VC0002736
p1856
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p1857
sg13
I3
sa(dp1858
g7
I208
sg17
VC0002736
p1859
sg10
I3
sg11
VALS
p1860
sg13
I1
sa(dp1861
g7
I135
sg17
VC0087012
p1862
sg10
I22
sg11
Vspinocerebellar ataxia
p1863
sg13
I2
sasa(dp1864
g2
VHere we show that synaptobrevin 2 sorting involves determinants within its SNARE motif that are recognized by the ANTH domains of the endocytic adaptors AP180 and clathrin assembly lymphoid myeloid leukemia (CALM).
p1865
sg4
(lp1866
(dp1867
g7
I18
sg8
VP63027
p1868
sg10
I15
sg11
Vsynaptobrevin 2
p1869
sg13
I2
sa(dp1870
g7
I153
sg8
g24
sg10
I5
sg11
VAP180
p1871
sg13
I1
sasg14
(lp1872
(dp1873
g7
I190
sg17
VC0023470
p1874
sg10
I16
sg11
Vmyeloid leukemia
p1875
sg13
I2
sasa(dp1876
g2
VSpecifically, fibroblast growth factor receptor 3 (FGFR3), desmoglein 2 (DSG2), E3 ubiquitin ligase c-CBL (casitas B-cell lymphoma), cancer/testis antigen NY-ESO-1 (CTAG1A/B), undifferentiated embryonic cell transcription factor 1 (UTF1) and synaptosomal-associated protein, 91 kDa homolog (SNAP91) were shown to represent specific biomarkers of human spermatogonia.
p1877
sg4
(lp1878
(dp1879
g7
I51
sg8
VP22607
p1880
sg10
I5
sg11
VFGFR3
p1881
sg13
I1
sa(dp1882
g7
I100
sg8
VP22681
p1883
sg10
I5
sg11
Vc-CBL
p1884
sg13
I1
sa(dp1885
g7
I59
sg8
g24
sg10
I12
sg11
Vdesmoglein 2
p1886
sg13
I2
sa(dp1887
g7
I155
sg8
VP78358
p1888
sg10
I8
sg11
VNY-ESO-1
p1889
sg13
I1
sa(dp1890
g7
I80
sg8
VP62979
p1891
sg10
I12
sg11
VE3 ubiquitin
p1892
sg13
I2
sa(dp1893
g7
I14
sg8
g24
sg10
I35
sg11
Vfibroblast growth factor receptor 3
p1894
sg13
I5
sa(dp1895
g7
I176
sg8
g24
sg10
I54
sg11
Vundifferentiated embryonic cell transcription factor 1
p1896
sg13
I6
sa(dp1897
g7
I291
sg8
g24
sg10
I6
sg11
VSNAP91
p1898
sg13
I1
sa(dp1899
g7
I73
sg8
g24
sg10
I4
sg11
VDSG2
p1900
sg13
I1
sa(dp1901
g7
I275
sg8
g24
sg10
I14
sg11
V91 kDa homolog
p1902
sg13
I3
sa(dp1903
g7
I165
sg8
VP78358
p1904
sg10
I8
sg11
VCTAG1A/B
p1905
sg13
I1
sa(dp1906
g7
I232
sg8
g24
sg10
I4
sg11
VUTF1
p1907
sg13
I1
sasg14
(lp1908
(dp1909
g7
I115
sg17
VC0079731
p1910
sg10
I15
sg11
VB-cell lymphoma
p1911
sg13
I2
sa(dp1912
g7
I133
sg17
VC0006826
p1913
sg10
I6
sg11
Vcancer
p1914
sg13
I1
sasa(dp1915
g2
VRecently, the gene encoding clathrin assembly protein of lymphoid myeloid leukemia (CALM), which is homologous to the AP180, was cloned from rat brain, and its expression differential to AP180 was reported (Kim and Lee, 1999).
p1916
sg4
(lp1917
(dp1918
g7
I118
sg8
g24
sg10
I5
sg11
VAP180
p1919
sg13
I1
sasg14
(lp1920
(dp1921
g7
I66
sg17
VC0023470
p1922
sg10
I16
sg11
Vmyeloid leukemia
p1923
sg13
I2
sasa(dp1924
g2
VThe clathrin assembly protein lymphoid myeloid leukemia (CALM) gene, encodes a homologoue of the neuronal clathrin assembly protein AP180.
p1925
sg4
(lp1926
sg14
(lp1927
(dp1928
g7
I39
sg17
VC0023470
p1929
sg10
I16
sg11
Vmyeloid leukemia
p1930
sg13
I2
sasa(dp1931
g2
VThe clathrin assembly lymphoid myeloid leukemia (CALM) gene encodes a putative homologue of the clathrin assembly synaptic protein AP180.
p1932
sg4
(lp1933
sg14
(lp1934
(dp1935
g7
I31
sg17
VC0023470
p1936
sg10
I16
sg11
Vmyeloid leukemia
p1937
sg13
I2
sasa(dp1938
g2
VThe expression level of ERp57 was also elevated in rat insulinoma INS-1 cells by inducible knock-down of the atg7-gene.
p1939
sg4
(lp1940
(dp1941
g7
I51
sg8
VP01308
p1942
sg10
I20
sg11
Vrat insulinoma INS-1
p1943
sg13
I3
sa(dp1944
g7
I109
sg8
g24
sg10
I9
sg11
Vatg7-gene
p1945
sg13
I1
sa(dp1946
g7
I24
sg8
VP30101
p1947
sg10
I5
sg11
VERp57
p1948
sg13
I1
sasg14
(lp1949
(dp1950
g7
I66
sg17
VC1533172
p1951
sg10
I3
sg11
VINS
p1952
sg13
I1
sa(dp1953
g7
I55
sg17
VC0021670
p1954
sg10
I10
sg11
Vinsulinoma
p1955
sg13
I1
sasa(dp1956
g2
VTissue specimens of nine dental follicles and 69 ameloblastomas were immunohistochemically examined with antibodies against ATG7, LC3, and p62.
p1957
sg4
(lp1958
(dp1959
g7
I130
sg8
g24
sg10
I3
sg11
VLC3
p1960
sg13
I1
sa(dp1961
g7
I139
sg8
VP37198
p1962
sg10
I3
sg11
Vp62
p1963
sg13
I1
sa(dp1964
g7
I124
sg8
g24
sg10
I4
sg11
VATG7
p1965
sg13
I1
sasg14
(lp1966
(dp1967
g7
I49
sg17
VC0002448
p1968
sg10
I14
sg11
Vameloblastomas
p1969
sg13
I1
sasa(dp1970
g2
VImmunohistochemical reactivity for ATG7, LC3, and p62 was detected in many odontogenic epithelial cells and several endothelial cells and fibroblasts in dental follicles and ameloblastomas.
p1971
sg4
(lp1972
(dp1973
g7
I35
sg8
g24
sg10
I4
sg11
VATG7
p1974
sg13
I1
sa(dp1975
g7
I41
sg8
g24
sg10
I3
sg11
VLC3
p1976
sg13
I1
sa(dp1977
g7
I50
sg8
VP37198
p1978
sg10
I3
sg11
Vp62
p1979
sg13
I1
sasg14
(lp1980
(dp1981
g7
I174
sg17
VC0002448
p1982
sg10
I14
sg11
Vameloblastomas
p1983
sg13
I1
sasa(dp1984
g2
VExpression of ATG7, LC3, and p62 was found markedly in neoplastic cells near the basement membrane rather than central polyhedral cells in ameloblastomas.
p1985
sg4
(lp1986
(dp1987
g7
I29
sg8
VP37198
p1988
sg10
I3
sg11
Vp62
p1989
sg13
I1
sa(dp1990
g7
I20
sg8
g24
sg10
I3
sg11
VLC3
p1991
sg13
I1
sa(dp1992
g7
I14
sg8
g24
sg10
I4
sg11
VATG7
p1993
sg13
I1
sasg14
(lp1994
(dp1995
g7
I139
sg17
VC0002448
p1996
sg10
I14
sg11
Vameloblastomas
p1997
sg13
I1
sasa(dp1998
g2
VExpression of ATG7, LC3, and p62 in dental follicles and ameloblastomas suggests that autophagy regulation might be affected by microenvironment alterations during tumorigenesis.
p1999
sg4
(lp2000
(dp2001
g7
I29
sg8
VP37198
p2002
sg10
I3
sg11
Vp62
p2003
sg13
I1
sa(dp2004
g7
I20
sg8
g24
sg10
I3
sg11
VLC3
p2005
sg13
I1
sa(dp2006
g7
I14
sg8
g24
sg10
I4
sg11
VATG7
p2007
sg13
I1
sasg14
(lp2008
(dp2009
g7
I164
sg17
VC0007621
p2010
sg10
I13
sg11
Vtumorigenesis
p2011
sg13
I1
sa(dp2012
g7
I57
sg17
VC0002448
p2013
sg10
I14
sg11
Vameloblastomas
p2014
sg13
I1
sasa(dp2015
g2
VAtg7 deficiency alters progression of Braf(V600E)-driven tumors from adenomas (Braf(V600E); atg7(-/-)) and adenocarcinomas (trp53(-/-); Braf(V600E); atg7(-/-)) to benign oncocytomas that accumulated morphologically and functionally defective mitochondria, suggesting that defects in mitochondrial metabolism may compromise continued tumor growth.
p2016
sg4
(lp2017
(dp2018
g7
I124
sg8
VP42771
p2019
sg10
I5
sg11
Vtrp53
p2020
sg13
I1
sa(dp2021
g7
I0
sg8
g24
sg10
I4
sg11
VAtg7
p2022
sg13
I1
sasg14
(lp2023
(dp2024
g7
I170
sg17
VC0949541
p2025
sg10
I11
sg11
Voncocytomas
p2026
sg13
I1
sa(dp2027
g7
I57
sg17
VC0027651
p2028
sg10
I6
sg11
Vtumors
p2029
sg13
I1
sa(dp2030
g7
I107
sg17
VC0001418
p2031
sg10
I15
sg11
Vadenocarcinomas
p2032
sg13
I1
sa(dp2033
g7
I69
sg17
VC0001430
p2034
sg10
I8
sg11
Vadenomas
p2035
sg13
I1
sa(dp2036
g7
I333
sg17
VC0598934
p2037
sg10
I12
sg11
Vtumor growth
p2038
sg13
I2
sasa(dp2039
g2
VAt later stages of tumorigenesis, Atg7 deficiency resulted in an accumulation of defective mitochondria, proliferative defects, reduced tumor burden, conversion of adenomas and adenocarcinomas to oncocytomas, and increased mouse life span.
p2040
sg4
(lp2041
(dp2042
g7
I34
sg8
g24
sg10
I4
sg11
VAtg7
p2043
sg13
I1
sasg14
(lp2044
(dp2045
g7
I19
sg17
VC0027651
p2046
sg10
I5
sg11
Vtumor
p2047
sg13
I1
sa(dp2048
g7
I196
sg17
VC0949541
p2049
sg10
I11
sg11
Voncocytomas
p2050
sg13
I1
sa(dp2051
g7
I177
sg17
VC0001418
p2052
sg10
I15
sg11
Vadenocarcinomas
p2053
sg13
I1
sa(dp2054
g7
I19
sg17
VC0007621
p2055
sg10
I13
sg11
Vtumorigenesis
p2056
sg13
I1
sa(dp2057
g7
I164
sg17
VC0001430
p2058
sg10
I8
sg11
Vadenomas
p2059
sg13
I1
sa(dp2060
g7
I105
sg17
VC0334094
p2061
sg10
I13
sg11
Vproliferative
p2062
sg13
I1
sasa(dp2063
g2
VUsing genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.
p2064
sg4
(lp2065
(dp2066
g7
I152
sg8
g24
sg10
I4
sg11
VAtg7
p2067
sg13
I1
sa(dp2068
g7
I161
sg8
VP01116
p2069
sg10
I4
sg11
VKRAS
p2070
sg13
I1
sasg14
(lp2071
(dp2072
g7
I194
sg17
VC0598934
p2073
sg10
I12
sg11
Vtumor growth
p2074
sg13
I2
sa(dp2075
g7
I88
sg17
VC0007131
p2076
sg10
I5
sg11
VNSCLC
p2077
sg13
I1
sa(dp2078
g7
I220
sg17
VC0001430
p2079
sg10
I8
sg11
Vadenomas
p2080
sg13
I1
sa(dp2081
g7
I259
sg17
VC0949541
p2082
sg10
I11
sg11
Voncocytomas
p2083
sg13
I1
sa(dp2084
g7
I88
sg17
VC0007131
p2085
sg10
I5
sg11
VNSCLC
p2086
sg13
I1
sa(dp2087
g7
I60
sg17
VC0007131
p2088
sg10
I26
sg11
Vnon-small-cell lung cancer
p2089
sg13
I3
sa(dp2090
g7
I233
sg17
VC0001418
p2091
sg10
I15
sg11
Vadenocarcinomas
p2092
sg13
I1
sasa(dp2093
g2
Vatg7 loss altered tumor fate from adenomas and carcinomas to oncocytomas-rare, predominantly benign tumors characterized by the accumulation of defective mitochondria.
p2094
sg4
(lp2095
(dp2096
g7
I0
sg8
g24
sg10
I4
sg11
Vatg7
p2097
sg13
I1
sasg14
(lp2098
(dp2099
g7
I18
sg17
VC0027651
p2100
sg10
I5
sg11
Vtumor
p2101
sg13
I1
sa(dp2102
g7
I61
sg17
VC0949541
p2103
sg10
I11
sg11
Voncocytomas
p2104
sg13
I1
sa(dp2105
g7
I34
sg17
VC0001430
p2106
sg10
I8
sg11
Vadenomas
p2107
sg13
I1
sa(dp2108
g7
I47
sg17
VC0007097
p2109
sg10
I10
sg11
Vcarcinomas
p2110
sg13
I1
sa(dp2111
g7
I93
sg17
VC0086692
p2112
sg10
I13
sg11
Vbenign tumors
p2113
sg13
I2
sasa(dp2114
g2
VSubsequent studies demonstrated that Atg5(-/-) and Atg7(-/-) livers give rise to adenomas, Atg4C(-/-) mice are susceptible to chemical carcinogenesis, and Bif1(-/-) mice are prone to spontaneous tumors, indicating that autophagy defects promote tumorigenesis.
p2115
sg4
(lp2116
(dp2117
g7
I91
sg8
g24
sg10
I5
sg11
VAtg4C
p2118
sg13
I1
sa(dp2119
g7
I155
sg8
g24
sg10
I4
sg11
VBif1
p2120
sg13
I1
sa(dp2121
g7
I37
sg8
g24
sg10
I4
sg11
VAtg5
p2122
sg13
I1
sa(dp2123
g7
I51
sg8
g24
sg10
I4
sg11
VAtg7
p2124
sg13
I1
sasg14
(lp2125
(dp2126
g7
I126
sg17
VC0596321
p2127
sg10
I23
sg11
Vchemical carcinogenesis
p2128
sg13
I2
sa(dp2129
g7
I245
sg17
VC0007621
p2130
sg10
I13
sg11
Vtumorigenesis
p2131
sg13
I1
sa(dp2132
g7
I81
sg17
VC0001430
p2133
sg10
I8
sg11
Vadenomas
p2134
sg13
I1
sa(dp2135
g7
I195
sg17
VC0027651
p2136
sg10
I6
sg11
Vtumors
p2137
sg13
I1
sasa(dp2138
g2
VScavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.
p2139
sg4
(lp2140
(dp2141
g7
I38
sg8
g24
sg10
I6
sg11
VSCARA3
p2142
sg13
I1
sa(dp2143
g7
I0
sg8
g24
sg10
I36
sg11
VScavenger receptor class A, member 3
p2144
sg13
I6
sasg14
(lp2145
(dp2146
g7
I150
sg17
VC0678222
p2147
sg10
I16
sg11
Vbreast carcinoma
p2148
sg13
I2
sa(dp2149
g7
I167
sg17
VC0013687
p2150
sg10
I9
sg11
Veffusions
p2151
sg13
I1
sa(dp2152
g7
I98
sg17
VC1514428
p2153
sg10
I28
sg11
Vprimary peritoneal carcinoma
p2154
sg13
I3
sasa(dp2155
g2
Vp15RS is a ubiquitously expressed nuclear protein that is positively regulated by p15 and, in turn, inhibits the expression of cyclin D and cyclin E. To determine whether p15RS has malignancy inhibitory functions in addition to its inhibitory effects on cell cycle entry, we ectopically expressed p15RS in metastatic melanoma A375 cells, in which p15 gene is deleted and p15RS expression is dramatically downregulated, and examined the effect on various malignant phenotypes.
p2156
sg4
(lp2157
(dp2158
g7
I0
sg8
g24
sg10
I5
sg11
Vp15RS
p2159
sg13
I1
sa(dp2160
g7
I0
sg8
g24
sg10
I5
sg11
Vp15RS
p2161
sg13
I1
sa(dp2162
g7
I0
sg8
g24
sg10
I5
sg11
Vp15RS
p2163
sg13
I1
sa(dp2164
g7
I0
sg8
g24
sg10
I5
sg11
Vp15RS
p2165
sg13
I1
sa(dp2166
g7
I347
sg8
VP53999
p2167
sg10
I8
sg11
Vp15 gene
p2168
sg13
I2
sa(dp2169
g7
I0
sg8
VP53999
p2170
sg10
I3
sg11
Vp15
p2171
sg13
I1
sa(dp2172
g7
I140
sg8
VP24864
p2173
sg10
I8
sg11
Vcyclin E
p2174
sg13
I2
sa(dp2175
g7
I127
sg8
VP24385
p2176
sg10
I8
sg11
Vcyclin D
p2177
sg13
I2
sasg14
(lp2178
(dp2179
g7
I181
sg17
VC0006826
p2180
sg10
I10
sg11
Vmalignancy
p2181
sg13
I1
sa(dp2182
g7
I306
sg17
VC0278883
p2183
sg10
I19
sg11
Vmetastatic melanoma
p2184
sg13
I2
sasa(dp2185
g2
VWilms' tumor 1-associating protein (WTAP) has been reported to be a ubiquitously expressed nuclear protein.
p2186
sg4
(lp2187
(dp2188
g7
I0
sg8
g24
sg10
I34
sg11
VWilms' tumor 1-associating protein
p2189
sg13
I4
sa(dp2190
g7
I36
sg8
g24
sg10
I4
sg11
VWTAP
p2191
sg13
I1
sasg14
(lp2192
(dp2193
g7
I0
sg17
VC0027708
p2194
sg10
I12
sg11
VWilms' tumor
p2195
sg13
I2
sasa(dp2196
g2
VThe results showed that TCF7L2 polymorphism was associated with breast cancer (Homogeneous model: OR=1.17, 95%CI=1.02-1.35, I (2) =21.8%, p for heterogeneity=0.276; Heterogeneous model: OR=1.11, 95%CI=1.03-1.20, I (2) =0.0%, p for heterogeneity=0.543), prostate cancer (Homogeneous model: OR=0.89, 95%CI=0.84-0.96, I (2) =0.0%, p for heterogeneity=0.640; Heterogeneous model: OR=0.89, 95%CI=0.84-0.95, I (2) =0.0%, p for heterogeneity=0.871), and colon cancer (Heterogeneous model: OR=1.15, 95%CI=1.01-1.31, I (2) =0.0%, p for heterogeneity=0.658), but not with colorectal cancer, lung cancer, and ovarian cancer.
p2197
sg4
(lp2198
sg14
(lp2199
(dp2200
g7
I598
sg17
VC1140680
p2201
sg10
I14
sg11
Vovarian cancer
p2202
sg13
I2
sa(dp2203
g7
I253
sg17
VC0600139
p2204
sg10
I15
sg11
Vprostate cancer
p2205
sg13
I2
sa(dp2206
g7
I64
sg17
VC0678222
p2207
sg10
I13
sg11
Vbreast cancer
p2208
sg13
I2
sa(dp2209
g7
I447
sg17
VC0699790
p2210
sg10
I12
sg11
Vcolon cancer
p2211
sg13
I2
sa(dp2212
g7
I562
sg17
VC1527249
p2213
sg10
I17
sg11
Vcolorectal cancer
p2214
sg13
I2
sa(dp2215
g7
I581
sg17
VC0684249
p2216
sg10
I11
sg11
Vlung cancer
p2217
sg13
I2
sasa(dp2218
g2
VThe present meta-analysis indicated that there were significantly associations between the TCF7L2 rs7903146 polymorphism and risk of breast, prostate and colon cancers, rather than colorectal cancer, lung cancer, and ovarian cancer.
p2219
sg4
(lp2220
sg14
(lp2221
(dp2222
g7
I200
sg17
VC0684249
p2223
sg10
I11
sg11
Vlung cancer
p2224
sg13
I2
sa(dp2225
g7
I154
sg17
VC0007102
p2226
sg10
I13
sg11
Vcolon cancers
p2227
sg13
I2
sa(dp2228
g7
I217
sg17
VC1140680
p2229
sg10
I14
sg11
Vovarian cancer
p2230
sg13
I2
sa(dp2231
g7
I181
sg17
VC1527249
p2232
sg10
I17
sg11
Vcolorectal cancer
p2233
sg13
I2
sasa(dp2234
g2
VMutations in the gene encoding comparative gene identification 58 (CGI-58), also known as Alfa Beta hydrolase domain-containing 5 (ABHD5), cause neutral lipid storage disorder with ichthyosis (NLSDI).
p2235
sg4
(lp2236
(dp2237
g7
I90
sg8
g24
sg10
I39
sg11
VAlfa Beta hydrolase domain-containing 5
p2238
sg13
I5
sa(dp2239
g7
I131
sg8
g24
sg10
I5
sg11
VABHD5
p2240
sg13
I1
sasg14
(lp2241
(dp2242
g7
I193
sg17
VC0268238
p2243
sg10
I5
sg11
VNLSDI
p2244
sg13
I1
sa(dp2245
g7
I145
sg17
VC0268238
p2246
sg10
I46
sg11
Vneutral lipid storage disorder with ichthyosis
p2247
sg13
I6
sasa(dp2248
g2
VIt has been elucidated that, of the ichthyosis-causative genes, ABCA12, ALOXE3, ALOX12B, CYP4F22, CERS3, ABHD5, PNPLA1 and ELOVL4 work in the formation of the corneocyte lipid envelope (CLE), a structure that is essential to sound skin barrier function.
p2249
sg4
(lp2250
(dp2251
g7
I72
sg8
g24
sg10
I6
sg11
VALOXE3
p2252
sg13
I1
sa(dp2253
g7
I89
sg8
g24
sg10
I7
sg11
VCYP4F22
p2254
sg13
I1
sa(dp2255
g7
I186
sg8
g24
sg10
I3
sg11
VCLE
p2256
sg13
I1
sa(dp2257
g7
I80
sg8
g24
sg10
I7
sg11
VALOX12B
p2258
sg13
I1
sa(dp2259
g7
I64
sg8
g24
sg10
I6
sg11
VABCA12
p2260
sg13
I1
sa(dp2261
g7
I105
sg8
g24
sg10
I5
sg11
VABHD5
p2262
sg13
I1
sa(dp2263
g7
I98
sg8
g24
sg10
I5
sg11
VCERS3
p2264
sg13
I1
sa(dp2265
g7
I123
sg8
g24
sg10
I6
sg11
VELOVL4
p2266
sg13
I1
sa(dp2267
g7
I159
sg8
g24
sg10
I25
sg11
Vcorneocyte lipid envelope
p2268
sg13
I3
sa(dp2269
g7
I112
sg8
g24
sg10
I6
sg11
VPNPLA1
p2270
sg13
I1
sasg14
(lp2271
(dp2272
g7
I159
sg17
VC2931489
p2273
sg10
I25
sg11
Vcorneocyte lipid envelope
p2274
sg13
I3
sa(dp2275
g7
I186
sg17
VC2931489
p2276
sg10
I3
sg11
VCLE
p2277
sg13
I1
sa(dp2278
g7
I36
sg17
VC0020758
p2279
sg10
I10
sg11
Vichthyosis
p2280
sg13
I1
sasa(dp2281
g2
VWe discuss known inborn errors of CTGM, including deficiencies of: AGPAT2 (a form of generalized lipodystrophy), LPIN1 (childhood rhabdomyolysis), LPIN2 (an inflammatory condition, Majeed syndrome, described elsewhere in this issue), DGAT1 (protein loosing enteropathy), perilipin 1 (partial lipodystrophy), CGI-58 (gene ABHD5, neutral lipid storage disease (NLSD) with ichthyosis and "Jordan's anomaly" of vacuolated polymorphonuclear leukocytes), adipose triglyceride lipase (ATGL, gene PNPLA2, NLSD with myopathy, cardiomyopathy and Jordan's anomaly), hormone-sensitive lipase (HSL, gene LIPE, hypertriglyceridemia, and insulin resistance).
p2282
sg4
(lp2283
(dp2284
g7
I623
sg8
VP01308
p2285
sg10
I7
sg11
Vinsulin
p2286
sg13
I1
sa(dp2287
g7
I586
sg8
g24
sg10
I9
sg11
Vgene LIPE
p2288
sg13
I2
sa(dp2289
g7
I478
sg8
g24
sg10
I4
sg11
VATGL
p2290
sg13
I1
sa(dp2291
g7
I581
sg8
g24
sg10
I3
sg11
VHSL
p2292
sg13
I1
sa(dp2293
g7
I484
sg8
g24
sg10
I11
sg11
Vgene PNPLA2
p2294
sg13
I2
sa(dp2295
g7
I555
sg8
g24
sg10
I24
sg11
Vhormone-sensitive lipase
p2296
sg13
I2
sa(dp2297
g7
I321
sg8
g24
sg10
I5
sg11
VABHD5
p2298
sg13
I1
sa(dp2299
g7
I271
sg8
g24
sg10
I11
sg11
Vperilipin 1
p2300
sg13
I2
sa(dp2301
g7
I234
sg8
g24
sg10
I5
sg11
VDGAT1
p2302
sg13
I1
sa(dp2303
g7
I67
sg8
g24
sg10
I6
sg11
VAGPAT2
p2304
sg13
I1
sa(dp2305
g7
I449
sg8
VP04118
p2306
sg10
I27
sg11
Vadipose triglyceride lipase
p2307
sg13
I3
sa(dp2308
g7
I113
sg8
g24
sg10
I5
sg11
VLPIN1
p2309
sg13
I1
sasg14
(lp2310
(dp2311
g7
I507
sg17
VC0026848
p2312
sg10
I8
sg11
Vmyopathy
p2313
sg13
I1
sa(dp2314
g7
I359
sg17
VC0268238
p2315
sg10
I4
sg11
VNLSD
p2316
sg13
I1
sa(dp2317
g7
I181
sg17
VC1864997
p2318
sg10
I15
sg11
VMajeed syndrome
p2319
sg13
I2
sa(dp2320
g7
I359
sg17
VC0268238
p2321
sg10
I4
sg11
VNLSD
p2322
sg13
I1
sa(dp2323
g7
I370
sg17
VC0020758
p2324
sg10
I10
sg11
Vichthyosis
p2325
sg13
I1
sa(dp2326
g7
I328
sg17
VC0268238
p2327
sg10
I29
sg11
Vneutral lipid storage disease
p2328
sg13
I4
sa(dp2329
g7
I517
sg17
VC0878544
p2330
sg10
I14
sg11
Vcardiomyopathy
p2331
sg13
I1
sa(dp2332
g7
I130
sg17
VC0035410
p2333
sg10
I14
sg11
Vrhabdomyolysis
p2334
sg13
I1
sa(dp2335
g7
I85
sg17
VC0221032
p2336
sg10
I25
sg11
Vgeneralized lipodystrophy
p2337
sg13
I2
sa(dp2338
g7
I257
sg17
VC0021831
p2339
sg10
I11
sg11
Venteropathy
p2340
sg13
I1
sa(dp2341
g7
I170
sg17
VC0012634
p2342
sg10
I9
sg11
Vcondition
p2343
sg13
I1
sa(dp2344
g7
I284
sg17
VC0220989
p2345
sg10
I21
sg11
Vpartial lipodystrophy
p2346
sg13
I2
sa(dp2347
g7
I623
sg17
VC0021655
p2348
sg10
I18
sg11
Vinsulin resistance
p2349
sg13
I2
sasa(dp2350
g2
VIn current study, we have discovered, using a comprehensive investigative regimen, a novel and tissue-specific role of claudin-3, a tight junction integral protein, in inhibiting colon cancer progression by serving as the common rheostat of Stat-3 and Wnt-signaling activation.
p2351
sg4
(lp2352
(dp2353
g7
I119
sg8
g24
sg10
I9
sg11
Vclaudin-3
p2354
sg13
I1
sa(dp2355
g7
I241
sg8
g24
sg10
I6
sg11
VStat-3
p2356
sg13
I1
sasg14
(lp2357
(dp2358
g7
I185
sg17
VC0178874
p2359
sg10
I18
sg11
Vcancer progression
p2360
sg13
I2
sasa(dp2361
g2
VClaudin-3-/- mice revealed dedifferentiated and leaky colonic epithelium, and developed invasive adenocarcinoma when subjected to colon cancer.
p2362
sg4
(lp2363
sg14
(lp2364
(dp2365
g7
I97
sg17
VC0001418
p2366
sg10
I14
sg11
Vadenocarcinoma
p2367
sg13
I1
sa(dp2368
g7
I130
sg17
VC0699790
p2369
sg10
I12
sg11
Vcolon cancer
p2370
sg13
I2
sasa(dp2371
g2
VWnt-signaling hyperactivation, albeit in GSK-3Beta independent manner, differentiated colon cancer in claudin-3-/- mice versus WT-mice.
p2372
sg4
(lp2373
(dp2374
g7
I41
sg8
VP49841
p2375
sg10
I9
sg11
VGSK-3Beta
p2376
sg13
I1
sasg14
(lp2377
(dp2378
g7
I86
sg17
VC0699790
p2379
sg10
I12
sg11
Vcolon cancer
p2380
sg13
I2
sasa(dp2381
g2
VGenetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/Beta-catenin activation, which is further exacerbated by Stat-3-activation and help promote colon cancer.
p2382
sg4
(lp2383
(dp2384
g7
I51
sg8
g24
sg10
I14
sg11
Vclaudin-3 loss
p2385
sg13
I2
sa(dp2386
g7
I135
sg8
g24
sg10
I6
sg11
VStat-3
p2387
sg13
I1
sa(dp2388
g7
I78
sg8
VP35222
p2389
sg10
I12
sg11
VBeta-catenin
p2390
sg13
I1
sasg14
(lp2391
(dp2392
g7
I170
sg17
VC0699790
p2393
sg10
I12
sg11
Vcolon cancer
p2394
sg13
I2
sasa(dp2395
g2
VAmong the paradoxical claudin reaction nuclear localization of marker was observed relatively rarely: claudin-3 in 2.5% cases of colon cancer; claudin-4 in 8.5% of colon polyps.
p2396
sg4
(lp2397
sg14
(lp2398
(dp2399
g7
I129
sg17
VC0699790
p2400
sg10
I12
sg11
Vcolon cancer
p2401
sg13
I2
sa(dp2402
g7
I164
sg17
VC0009376
p2403
sg10
I12
sg11
Vcolon polyps
p2404
sg13
I2
sasa(dp2405
g2
VMislocalization claudin-3 to nucleus in colon cancer and mislocalization claudin-4 to nucleus in adenomas of the colon were detected for the first time.
p2406
sg4
(lp2407
(dp2408
g7
I0
sg8
g24
sg10
I25
sg11
VMislocalization claudin-3
p2409
sg13
I2
sa(dp2410
g7
I73
sg8
g24
sg10
I9
sg11
Vclaudin-4
p2411
sg13
I1
sasg14
(lp2412
(dp2413
g7
I97
sg17
VC0001430
p2414
sg10
I8
sg11
Vadenomas
p2415
sg13
I1
sa(dp2416
g7
I40
sg17
VC0699790
p2417
sg10
I12
sg11
Vcolon cancer
p2418
sg13
I2
sasa(dp2419
g2
VOur approach aimed at evaluation of a selective and targeted cancer gene therapy of claudin-3- and/or claudin-4- expressing colon carcinoma in vitro and in vivo by using translation optimized CPE expressing vector.
p2420
sg4
(lp2421
sg14
(lp2422
(dp2423
g7
I124
sg17
VC0699790
p2424
sg10
I15
sg11
Vcolon carcinoma
p2425
sg13
I2
sa(dp2426
g7
I61
sg17
VC0006826
p2427
sg10
I6
sg11
Vcancer
p2428
sg13
I1
sasa(dp2429
g2
VIn this study the recombinant CPE and a translation optimized CPE expressing vector (optCPE) was used for targeted gene therapy of claudin-3 and/or -4 overexpressing colon cancer cell lines.
p2430
sg4
(lp2431
sg14
(lp2432
(dp2433
g7
I166
sg17
VC0699790
p2434
sg10
I12
sg11
Vcolon cancer
p2435
sg13
I2
sasa(dp2436
g2
VAll experiments were performed in the human SW480, SW620, HCT116, CaCo-2 and HT-29 colon cancer and the isogenic Sk-Mel5 and Sk-Mel5 Cldn-3-YFP melanoma cell lines.
p2437
sg4
(lp2438
sg14
(lp2439
(dp2440
g7
I83
sg17
VC0699790
p2441
sg10
I12
sg11
Vcolon cancer
p2442
sg13
I2
sa(dp2443
g7
I144
sg17
VC0025202
p2444
sg10
I8
sg11
Vmelanoma
p2445
sg13
I1
sasa(dp2446
g2
VClaudin-3 and -4 overexpressing colon carcinoma lines showed high sensitivity towards both recCPE application and optCPE gene transfer.
p2447
sg4
(lp2448
(dp2449
g7
I0
sg8
g24
sg10
I16
sg11
VClaudin-3 and -4
p2450
sg13
I3
sasg14
(lp2451
(dp2452
g7
I32
sg17
VC0699790
p2453
sg10
I15
sg11
Vcolon carcinoma
p2454
sg13
I2
sasa(dp2455
g2
VThis novel approach demonstrates that optCPE gene transfer represents a promising and efficient therapeutic option for a targeted suicide gene therapy of claudin-3 and/or claudin-4 overexpressing colon carcinomas, leading to rapid and effective tumor cell killing in vitro and in vivo.
p2456
sg4
(lp2457
(dp2458
g7
I171
sg8
g24
sg10
I9
sg11
Vclaudin-4
p2459
sg13
I1
sasg14
(lp2460
(dp2461
g7
I245
sg17
VC0027651
p2462
sg10
I5
sg11
Vtumor
p2463
sg13
I1
sa(dp2464
g7
I202
sg17
VC0007097
p2465
sg10
I10
sg11
Vcarcinomas
p2466
sg13
I1
sasa(dp2467
g2
VTo investigate the expression of claudin-3 in colorectal carcinoma and its association with the occurrence, progression and prognosis of colorectal cancer.
p2468
sg4
(lp2469
(dp2470
g7
I33
sg8
g24
sg10
I9
sg11
Vclaudin-3
p2471
sg13
I1
sasg14
(lp2472
(dp2473
g7
I46
sg17
VC0009402
p2474
sg10
I20
sg11
Vcolorectal carcinoma
p2475
sg13
I2
sa(dp2476
g7
I137
sg17
VC0009402
p2477
sg10
I17
sg11
Vcolorectal cancer
p2478
sg13
I2
sasa(dp2479
g2
VClaudin-3 is over-expressed in colorectal cancer tissues, and its high expression may promote the occurrence and progression of colorectal cancer.
p2480
sg4
(lp2481
(dp2482
g7
I0
sg8
g24
sg10
I9
sg11
VClaudin-3
p2483
sg13
I1
sasg14
(lp2484
(dp2485
g7
I31
sg17
VC1527249
p2486
sg10
I17
sg11
Vcolorectal cancer
p2487
sg13
I2
sa(dp2488
g7
I31
sg17
VC1527249
p2489
sg10
I17
sg11
Vcolorectal cancer
p2490
sg13
I2
sasa(dp2491
g2
VHere, we report that epidermal growth factor (EGF) increases the expression of claudin-3 in human colorectal adenocarcinoma HT-29 cells.
p2492
sg4
(lp2493
(dp2494
g7
I79
sg8
g24
sg10
I9
sg11
Vclaudin-3
p2495
sg13
I1
sa(dp2496
g7
I46
sg8
VP01133
p2497
sg10
I3
sg11
VEGF
p2498
sg13
I1
sa(dp2499
g7
I21
sg8
VP01133
p2500
sg10
I23
sg11
Vepidermal growth factor
p2501
sg13
I3
sasg14
(lp2502
(dp2503
g7
I98
sg17
VC1319315
p2504
sg10
I25
sg11
Vcolorectal adenocarcinoma
p2505
sg13
I2
sasa(dp2506
g2
VIn conclusion, our results show a novel role for claudin-3 overexpression in promoting the malignant potential of colorectal cancer cells, which is potentially regulated by the EGF-activated ERK1/2 and PI3K-Akt pathways.
p2507
sg4
(lp2508
(dp2509
g7
I49
sg8
g24
sg10
I9
sg11
Vclaudin-3
p2510
sg13
I1
sa(dp2511
g7
I177
sg8
VP01133
p2512
sg10
I3
sg11
VEGF
p2513
sg13
I1
sa(dp2514
g7
I202
sg8
VP42336
p2515
sg10
I4
sg11
VPI3K
p2516
sg13
I1
sa(dp2517
g7
I207
sg8
g24
sg10
I3
sg11
VAkt
p2518
sg13
I1
sa(dp2519
g7
I191
sg8
VP27361
p2520
sg10
I6
sg11
VERK1/2
p2521
sg13
I1
sasg14
(lp2522
(dp2523
g7
I114
sg17
VC1527249
p2524
sg10
I17
sg11
Vcolorectal cancer
p2525
sg13
I2
sasa(dp2526
g2
VPatients with essential thrombocythemia (ET) and polycythemia vera (PV), complicated by microvascular ischemic or thrombotic events, have shortened platelet survival, increased beta-thromboglobulin, platelet factor 4, and thrombomodulin levels, and increased urinary thromboxane B2 excretion.
p2527
sg4
(lp2528
(dp2529
g7
I177
sg8
VP02775
p2530
sg10
I20
sg11
Vbeta-thromboglobulin
p2531
sg13
I1
sa(dp2532
g7
I199
sg8
VP02776
p2533
sg10
I17
sg11
Vplatelet factor 4
p2534
sg13
I3
sa(dp2535
g7
I222
sg8
VP07204
p2536
sg10
I14
sg11
Vthrombomodulin
p2537
sg13
I1
sasg14
(lp2538
(dp2539
g7
I68
sg17
VC0032463
p2540
sg10
I2
sg11
VPV
p2541
sg13
I1
sa(dp2542
g7
I14
sg17
VC0040028
p2543
sg10
I25
sg11
Vessential thrombocythemia
p2544
sg13
I2
sa(dp2545
g7
I41
sg17
VC0040028
p2546
sg10
I2
sg11
VET
p2547
sg13
I1
sa(dp2548
g7
I49
sg17
VC0032463
p2549
sg10
I17
sg11
Vpolycythemia vera
p2550
sg13
I2
sasa(dp2551
g2
VOur results suggest that CEP68 gene variants may play an important role in MNSAID-UA susceptibility and, despite the different regulatory mechanisms involved depending on the specific affected organ, in the development of hypersensitivity reactions to NSAIDs.
p2552
sg4
(lp2553
(dp2554
g7
I25
sg8
g24
sg10
I19
sg11
VCEP68 gene variants
p2555
sg13
I3
sasg14
(lp2556
(dp2557
g7
I222
sg17
VC0020517
p2558
sg10
I26
sg11
Vhypersensitivity reactions
p2559
sg13
I2
sasa(dp2560
g2
VBaboon anti-pig antibody (Ab) was measured before CPB, before circulatory arrest, during AbA, at the end of CPB, and daily after HTx.
p2561
sg4
(lp2562
sg14
(lp2563
(dp2564
g7
I62
sg17
VC0444720
p2565
sg10
I18
sg11
Vcirculatory arrest
p2566
sg13
I2
sasa(dp2567
g2
VAt 4 dpi a severe fibrinosuppurative bronchopneumonia had developed.
p2568
sg4
(lp2569
sg14
(lp2570
(dp2571
g7
I37
sg17
VC0006285
p2572
sg10
I16
sg11
Vbronchopneumonia
p2573
sg13
I1
sasa(dp2574
g2
VHowever, the SrGAP3-deficient mice showed little to no interest in burying marbles; a behavior that is seen in some animal models related to autism, supporting the view that SrGAP3 plays a role in neurodevelopmental disorders.
p2575
sg4
(lp2576
(dp2577
g7
I13
sg8
g24
sg10
I6
sg11
VSrGAP3
p2578
sg13
I1
sa(dp2579
g7
I13
sg8
g24
sg10
I6
sg11
VSrGAP3
p2580
sg13
I1
sasg14
(lp2581
(dp2582
g7
I141
sg17
VC0004352
p2583
sg10
I6
sg11
Vautism
p2584
sg13
I1
sasa(dp2585
g2
VBA synthesis was directly quantified by measuring serum concentrations of 7alpha-hydroxycholest-4-en-3-one (C4), along with serum FGF19 and other parameters, in 44 patients with primary biliary cirrhosis (PBC) and 10 healthy subjects.
p2586
sg4
(lp2587
(dp2588
g7
I130
sg8
g24
sg10
I5
sg11
VFGF19
p2589
sg13
I1
sasg14
(lp2590
(dp2591
g7
I178
sg17
VC0008312
p2592
sg10
I25
sg11
Vprimary biliary cirrhosis
p2593
sg13
I3
sa(dp2594
g7
I205
sg17
VC0008312
p2595
sg10
I3
sg11
VPBC
p2596
sg13
I1
sasa(dp2597
g2
VWhether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are involved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.
p2598
sg4
(lp2599
(dp2600
g7
I8
sg8
g24
sg10
I27
sg11
Vfibroblast growth factor 19
p2601
sg13
I4
sa(dp2602
g7
I69
sg8
VP23945
p2603
sg10
I3
sg11
VFXR
p2604
sg13
I1
sa(dp2605
g7
I47
sg8
g24
sg10
I20
sg11
Vfarnesoid X receptor
p2606
sg13
I3
sa(dp2607
g7
I37
sg8
g24
sg10
I5
sg11
VFGF19
p2608
sg13
I1
sasg14
(lp2609
(dp2610
g7
I173
sg17
VC0008312
p2611
sg10
I3
sg11
VPBC
p2612
sg13
I1
sa(dp2613
g7
I146
sg17
VC0008312
p2614
sg10
I25
sg11
Vprimary biliary cirrhosis
p2615
sg13
I3
sasa(dp2616
g2
VOur results provide further insight into the specific relationship between histone H4 modification and gene expression during spermatogenesis, which could help to elucidate the epigenetic disorders underlying male infertility.
p2617
sg4
(lp2618
(dp2619
g7
I75
sg8
VP62805
p2620
sg10
I10
sg11
Vhistone H4
p2621
sg13
I2
sasg14
(lp2622
(dp2623
g7
I209
sg17
VC0021364
p2624
sg10
I16
sg11
Vmale infertility
p2625
sg13
I2
sasa(dp2626
g2
VPrevious studies have resulted in the isolation of the human HSST gene from within the Treacher Collins syndrome locus (TCOF1) critical region on 5q.
p2627
sg4
(lp2628
(dp2629
g7
I120
sg8
g24
sg10
I5
sg11
VTCOF1
p2630
sg13
I1
sa(dp2631
g7
I55
sg8
VP52848
p2632
sg10
I15
sg11
Vhuman HSST gene
p2633
sg13
I3
sasg14
(lp2634
(dp2635
g7
I87
sg17
VC0242387
p2636
sg10
I25
sg11
VTreacher Collins syndrome
p2637
sg13
I3
sasa(dp2638
g2
VAs a result of these studies, mutations within the coding sequence and adjacent splice junctions of HSST can be excluded from a causative role in the pathogenesis of Treacher Collins syndrome.
p2639
sg4
(lp2640
sg14
(lp2641
(dp2642
g7
I150
sg17
VC0699748
p2643
sg10
I12
sg11
Vpathogenesis
p2644
sg13
I1
sa(dp2645
g7
I166
sg17
VC0242387
p2646
sg10
I25
sg11
VTreacher Collins syndrome
p2647
sg13
I3
sasa(dp2648
g2
VIn univariate analyses, diabetes mellitus, chronic kidney disease, ischemic etiology of LBBB, dilated left atrium, reduced LVEF, dilated left ventricle, and impaired LV global strain (GLS &gt; -12.2%, global circumferential strain &gt; -11.8%, and twist &lt; 6.5) showed associations with the composite end point.
p2649
sg4
(lp2650
sg14
(lp2651
(dp2652
g7
I157
sg17
VC0684336
p2653
sg10
I8
sg11
Vimpaired
p2654
sg13
I1
sa(dp2655
g7
I24
sg17
VC0011849
p2656
sg10
I17
sg11
Vdiabetes mellitus
p2657
sg13
I2
sa(dp2658
g7
I129
sg17
VC0745674
p2659
sg10
I22
sg11
Vdilated left ventricle
p2660
sg13
I3
sa(dp2661
g7
I88
sg17
VC0023211
p2662
sg10
I4
sg11
VLBBB
p2663
sg13
I1
sa(dp2664
g7
I43
sg17
VC1561643
p2665
sg10
I22
sg11
Vchronic kidney disease
p2666
sg13
I3
sasa(dp2667
g2
VIndividuals with T1D had increased systolic torsion (P = 0.035), systolic torsion rate (P = 0.032), peak Ecl (P = 0.001), and rates of change of systolic (P = 0.007) and diastolic (P = 0.007) Ecl Individuals with T1D, with normal structure, LVEF, and strain, have increased extracellular volume and increased native T1 values with associated augmented torsion and Ecl These measures may be useful in detecting the early stages of diabetic cardiomyopathy and warrant larger prospective studies.NEW &amp; NOTEWORTHY Individuals with type 1 diabetes, with normal left ventricular structure and function (ejection fraction and strain), have signs of interstitial fibrosis, measured with MRI as increased extracellular volume fraction and increased native myocardial T1, which significantly correlated with a number of measures of augmented left ventricular twist function.
p2668
sg4
(lp2669
sg14
(lp2670
(dp2671
g7
I531
sg17
VC0011854
p2672
sg10
I15
sg11
Vtype 1 diabetes
p2673
sg13
I3
sa(dp2674
g7
I44
sg17
VC1265748
p2675
sg10
I7
sg11
Vtorsion
p2676
sg13
I1
sa(dp2677
g7
I646
sg17
VC0240035
p2678
sg10
I21
sg11
Vinterstitial fibrosis
p2679
sg13
I2
sa(dp2680
g7
I44
sg17
VC1265748
p2681
sg10
I7
sg11
Vtorsion
p2682
sg13
I1
sa(dp2683
g7
I430
sg17
VC0853897
p2684
sg10
I23
sg11
Vdiabetic cardiomyopathy
p2685
sg13
I2
sa(dp2686
g7
I44
sg17
VC1265748
p2687
sg10
I7
sg11
Vtorsion
p2688
sg13
I1
sasa(dp2689
g2
VIn this study, we show that hyperinsulinemia in the Rag/MKR mice increases the expression of mesenchymal transcription factors, TWIST1 and ZEB1, and increases the expression of the angiogenesis marker, vascular endothelial growth factor A (VEGFA).
p2690
sg4
(lp2691
(dp2692
g7
I240
sg8
g24
sg10
I5
sg11
VVEGFA
p2693
sg13
I1
sa(dp2694
g7
I52
sg8
VP52803
p2695
sg10
I3
sg11
VRag
p2696
sg13
I1
sa(dp2697
g7
I139
sg8
VP37275
p2698
sg10
I4
sg11
VZEB1
p2699
sg13
I1
sa(dp2700
g7
I56
sg8
VP33032
p2701
sg10
I3
sg11
VMKR
p2702
sg13
I1
sa(dp2703
g7
I128
sg8
g24
sg10
I6
sg11
VTWIST1
p2704
sg13
I1
sa(dp2705
g7
I202
sg8
g24
sg10
I36
sg11
Vvascular endothelial growth factor A
p2706
sg13
I5
sasg14
(lp2707
(dp2708
g7
I28
sg17
VC0020459
p2709
sg10
I16
sg11
Vhyperinsulinemia
p2710
sg13
I1
sasa(dp2711
g2
VAortic PWV correlated crudely with age (p &lt; 0.001), the presence of diabetes (p &lt; 0.001), hypertension (p &lt; 0.001), eGFR (p &lt; 0.001), LVMI (p = 0.01), e/e' (p &lt; 0.001) and LV twist (p = 0.003).
p2712
sg4
(lp2713
sg14
(lp2714
(dp2715
g7
I96
sg17
VC0020538
p2716
sg10
I12
sg11
Vhypertension
p2717
sg13
I1
sa(dp2718
g7
I71
sg17
VC0011849
p2719
sg10
I8
sg11
Vdiabetes
p2720
sg13
I1
sasa(dp2721
g2
VThere is limited information regarding the role of left ventricular (LV) twist and the effect of exercise in type 2 diabetes (T2D).
p2722
sg4
(lp2723
sg14
(lp2724
(dp2725
g7
I126
sg17
VC0011860
p2726
sg10
I3
sg11
VT2D
p2727
sg13
I1
sa(dp2728
g7
I109
sg17
VC0011860
p2729
sg10
I15
sg11
Vtype 2 diabetes
p2730
sg13
I3
sasa(dp2731
g2
VThese results demonstrated that quercetin ameliorates the EMT of HK-2 and NRK-52E cells induced by high glucose and renal fibrosis induced by diabetes, and these effects have been associated with the inhibition of the two transcriptional factors (snail and twist) and the activation of mTORC1/p70S6K.
p2732
sg4
(lp2733
(dp2734
g7
I74
sg8
g24
sg10
I7
sg11
VNRK-52E
p2735
sg13
I1
sasg14
(lp2736
(dp2737
g7
I142
sg17
VC0011849
p2738
sg10
I8
sg11
Vdiabetes
p2739
sg13
I1
sa(dp2740
g7
I116
sg17
VC0151650
p2741
sg10
I14
sg11
Vrenal fibrosis
p2742
sg13
I2
sasa(dp2743
g2
VActivin Receptor-Like Kinase 5 (ALK-5) is related to some types of cancer, such as breast, lung and pancreas.
p2744
sg4
(lp2745
(dp2746
g7
I0
sg8
VP36897
p2747
sg10
I30
sg11
VActivin Receptor-Like Kinase 5
p2748
sg13
I4
sa(dp2749
g7
I32
sg8
VP36897
p2750
sg10
I5
sg11
VALK-5
p2751
sg13
I1
sasg14
(lp2752
(dp2753
g7
I67
sg17
VC0006826
p2754
sg10
I6
sg11
Vcancer
p2755
sg13
I1
sasa(dp2756
g2
VOverall, we discussed about the main interactions between ALK-5 and six inhibitors that may be used as starting point for designing of new molecules to the cancer treatment.
p2757
sg4
(lp2758
(dp2759
g7
I58
sg8
VP36897
p2760
sg10
I5
sg11
VALK-5
p2761
sg13
I1
sasg14
(lp2762
(dp2763
g7
I156
sg17
VC0006826
p2764
sg10
I6
sg11
Vcancer
p2765
sg13
I1
sasa(dp2766
g2
VIn summary, the results suggest that eupatolide suppresses the migration and invasion of breast cancer cells by blocking the canonical ALK5-SMAD3 signaling pathway and the non-canonical ERK and AKT signaling pathways.
p2767
sg4
(lp2768
(dp2769
g7
I186
sg8
VP29323
p2770
sg10
I3
sg11
VERK
p2771
sg13
I1
sa(dp2772
g7
I135
sg8
VP36897
p2773
sg10
I4
sg11
VALK5
p2774
sg13
I1
sa(dp2775
g7
I194
sg8
g24
sg10
I3
sg11
VAKT
p2776
sg13
I1
sasg14
(lp2777
(dp2778
g7
I77
sg17
VC2699153
p2779
sg10
I8
sg11
Vinvasion
p2780
sg13
I1
sa(dp2781
g7
I112
sg17
VC0233660
p2782
sg10
I8
sg11
Vblocking
p2783
sg13
I1
sa(dp2784
g7
I89
sg17
VC0678222
p2785
sg10
I13
sg11
Vbreast cancer
p2786
sg13
I2
sasa(dp2787
g2
VExpression of a mutant TBetaRI that signals but does not interact with Smad7 prevented the CerS4-mediated inhibition of migration in various cancer cells.
p2788
sg4
(lp2789
(dp2790
g7
I71
sg8
g24
sg10
I5
sg11
VSmad7
p2791
sg13
I1
sa(dp2792
g7
I91
sg8
g24
sg10
I5
sg11
VCerS4
p2793
sg13
I1
sasg14
(lp2794
(dp2795
g7
I141
sg17
VC0006826
p2796
sg10
I6
sg11
Vcancer
p2797
sg13
I1
sa(dp2798
g7
I16
sg17
VC0596988
p2799
sg10
I6
sg11
Vmutant
p2800
sg13
I1
sasa(dp2801
g2
VTBetaRI-Smo cross-talk at the cilia in CerS4-deficient 4T1 mammary cancer cells induced liver metastasis from orthotopic allografts in both wild-type and CerS4-deficient mice, which was prevented by overexpression of Smad7 or knockdown of intraflagellar transport protein 88 (IFT88).
p2802
sg4
(lp2803
(dp2804
g7
I239
sg8
g24
sg10
I35
sg11
Vintraflagellar transport protein 88
p2805
sg13
I4
sa(dp2806
g7
I39
sg8
g24
sg10
I5
sg11
VCerS4
p2807
sg13
I1
sa(dp2808
g7
I8
sg8
g24
sg10
I3
sg11
VSmo
p2809
sg13
I1
sa(dp2810
g7
I276
sg8
g24
sg10
I5
sg11
VIFT88
p2811
sg13
I1
sa(dp2812
g7
I39
sg8
g24
sg10
I5
sg11
VCerS4
p2813
sg13
I1
sa(dp2814
g7
I217
sg8
g24
sg10
I5
sg11
VSmad7
p2815
sg13
I1
sasg14
(lp2816
(dp2817
g7
I67
sg17
VC0006826
p2818
sg10
I6
sg11
Vcancer
p2819
sg13
I1
sa(dp2820
g7
I88
sg17
VC0494165
p2821
sg10
I16
sg11
Vliver metastasis
p2822
sg13
I2
sasa(dp2823
g2
VTransforming growth factor type 1 receptor (ALK5) is kinase associated with a wide variety of pathological processes, and inhibition of ALK5 is a good strategy to treat many kinds of cancer and fibrotic diseases.
p2824
sg4
(lp2825
(dp2826
g7
I0
sg8
g24
sg10
I42
sg11
VTransforming growth factor type 1 receptor
p2827
sg13
I6
sa(dp2828
g7
I44
sg8
VP36897
p2829
sg10
I4
sg11
VALK5
p2830
sg13
I1
sa(dp2831
g7
I44
sg8
VP36897
p2832
sg10
I4
sg11
VALK5
p2833
sg13
I1
sasg14
(lp2834
(dp2835
g7
I94
sg17
VC0030660
p2836
sg10
I22
sg11
Vpathological processes
p2837
sg13
I2
sa(dp2838
g7
I183
sg17
VC0006826
p2839
sg10
I6
sg11
Vcancer
p2840
sg13
I1
sasa(dp2841
g2
VThe high mortality rates observed in patients with invasive aspergillosis caused by azole-resistant A. fumigatus (ARAF) isolates pose serious challenges to the clinical microbiologist for timely identification of resistance and appropriate therapeutic interventions.
p2842
sg4
(lp2843
sg14
(lp2844
(dp2845
g7
I51
sg17
VC0238013
p2846
sg10
I22
sg11
Vinvasive aspergillosis
p2847
sg13
I2
sasa(dp2848
g2
VMKL/myocardin-like 2 (MKL2) encodes myocardin-related transcription factor B in a megakaryoblastic leukemia gene family, and C11orf95 (chromosome 11 open reading frame 95) is a hypothetical protein.
p2849
sg4
(lp2850
(dp2851
g7
I0
sg8
g24
sg10
I20
sg11
VMKL/myocardin-like 2
p2852
sg13
I2
sa(dp2853
g7
I36
sg8
g24
sg10
I40
sg11
Vmyocardin-related transcription factor B
p2854
sg13
I4
sa(dp2855
g7
I22
sg8
g24
sg10
I4
sg11
VMKL2
p2856
sg13
I1
sasg14
(lp2857
(dp2858
g7
I82
sg17
VC0023462
p2859
sg10
I25
sg11
Vmegakaryoblastic leukemia
p2860
sg13
I2
sasa(dp2861
g2
VSerum levels of IL-16, IL-33 and the decoy receptor of IL-33, soluble ST2, are elevated in allergic rhinitis.
p2862
sg4
(lp2863
(dp2864
g7
I16
sg8
g24
sg10
I5
sg11
VIL-16
p2865
sg13
I1
sasg14
(lp2866
(dp2867
g7
I91
sg17
VC2607914
p2868
sg10
I17
sg11
Vallergic rhinitis
p2869
sg13
I2
sasa(dp2870
g2
VRecent studies show that IL-16, soluble ST2 or anti-IL-33 reduce type 2 cytokines (such as IL-5) and eosinophilia in murine models of allergic asthma or allergic rhinitis respectively.
p2871
sg4
(lp2872
(dp2873
g7
I65
sg8
VP01374
p2874
sg10
I16
sg11
Vtype 2 cytokines
p2875
sg13
I3
sa(dp2876
g7
I91
sg8
VP05113
p2877
sg10
I4
sg11
VIL-5
p2878
sg13
I1
sa(dp2879
g7
I25
sg8
g24
sg10
I18
sg11
VIL-16, soluble ST2
p2880
sg13
I3
sasg14
(lp2881
(dp2882
g7
I134
sg17
VC0155877
p2883
sg10
I15
sg11
Vallergic asthma
p2884
sg13
I2
sa(dp2885
g7
I153
sg17
VC2607914
p2886
sg10
I17
sg11
Vallergic rhinitis
p2887
sg13
I2
sa(dp2888
g7
I101
sg17
VC0014457
p2889
sg10
I12
sg11
Veosinophilia
p2890
sg13
I1
sasa(dp2891
g2
VIn this study, we studied the release of IL-5, IL-16, IL-33 and soluble ST2 in allergic rhinitis patients after nasal allergen challenge and natural pollen exposure.
p2892
sg4
(lp2893
(dp2894
g7
I47
sg8
g24
sg10
I5
sg11
VIL-16
p2895
sg13
I1
sa(dp2896
g7
I41
sg8
VP05113
p2897
sg10
I4
sg11
VIL-5
p2898
sg13
I1
sasg14
(lp2899
(dp2900
g7
I79
sg17
VC2607914
p2901
sg10
I17
sg11
Vallergic rhinitis
p2902
sg13
I2
sasa(dp2903
g2
VThe observed upregulation of soluble ST2 and IL-16 after nasal allergen challenge and during peak pollination season suggests potential regulatory roles of these cytokines in the inflammatory reaction in allergic rhinitis.
p2904
sg4
(lp2905
(dp2906
g7
I45
sg8
g24
sg10
I5
sg11
VIL-16
p2907
sg13
I1
sa(dp2908
g7
I37
sg8
VP10767
p2909
sg10
I3
sg11
VST2
p2910
sg13
I1
sasg14
(lp2911
(dp2912
g7
I204
sg17
VC2607914
p2913
sg10
I17
sg11
Vallergic rhinitis
p2914
sg13
I2
sa(dp2915
g7
I179
sg17
VC0021368
p2916
sg10
I21
sg11
Vinflammatory reaction
p2917
sg13
I2
sasa(dp2918
g2
VTo detect the expression and distribution of the lung surfactant protein D (surfactant protein D,SP-D ) and IL-16 in nasal mucosa of allergic rhinitis and nasal polyps, and then probe into their significance in the pathology of allergic rhinitis and nasal polyps.
p2919
sg4
(lp2920
(dp2921
g7
I97
sg8
VP35247
p2922
sg10
I4
sg11
VSP-D
p2923
sg13
I1
sa(dp2924
g7
I54
sg8
VP35247
p2925
sg10
I20
sg11
Vsurfactant protein D
p2926
sg13
I3
sa(dp2927
g7
I54
sg8
VP35247
p2928
sg10
I20
sg11
Vsurfactant protein D
p2929
sg13
I3
sa(dp2930
g7
I108
sg8
g24
sg10
I5
sg11
VIL-16
p2931
sg13
I1
sasg14
(lp2932
(dp2933
g7
I215
sg17
VC0677042
p2934
sg10
I9
sg11
Vpathology
p2935
sg13
I1
sa(dp2936
g7
I155
sg17
VC0027430
p2937
sg10
I12
sg11
Vnasal polyps
p2938
sg13
I2
sa(dp2939
g7
I133
sg17
VC2607914
p2940
sg10
I17
sg11
Vallergic rhinitis
p2941
sg13
I2
sa(dp2942
g7
I155
sg17
VC0027430
p2943
sg10
I12
sg11
Vnasal polyps
p2944
sg13
I2
sa(dp2945
g7
I133
sg17
VC2607914
p2946
sg10
I17
sg11
Vallergic rhinitis
p2947
sg13
I2
sasa(dp2948
g2
VFifteen cases of allergic rhinitis, fifteen cases of nasal polyps and fifteen cases of inferior turbinate mucosa were studied to detect the expression of SP-D and IL-16 by immunohistochemistry method.
p2949
sg4
(lp2950
(dp2951
g7
I154
sg8
VP35247
p2952
sg10
I4
sg11
VSP-D
p2953
sg13
I1
sa(dp2954
g7
I163
sg8
g24
sg10
I5
sg11
VIL-16
p2955
sg13
I1
sasg14
(lp2956
(dp2957
g7
I17
sg17
VC2607914
p2958
sg10
I17
sg11
Vallergic rhinitis
p2959
sg13
I2
sa(dp2960
g7
I53
sg17
VC0027430
p2961
sg10
I12
sg11
Vnasal polyps
p2962
sg13
I2
sasa(dp2963
g2
VThe expression of SP-D and IL-16 in allergic rhinitis and nasal polyps were dramatically higher in controls (P &lt; 0.01).
p2964
sg4
(lp2965
(dp2966
g7
I27
sg8
g24
sg10
I5
sg11
VIL-16
p2967
sg13
I1
sa(dp2968
g7
I18
sg8
VP35247
p2969
sg10
I4
sg11
VSP-D
p2970
sg13
I1
sasg14
(lp2971
(dp2972
g7
I36
sg17
VC2607914
p2973
sg10
I17
sg11
Vallergic rhinitis
p2974
sg13
I2
sa(dp2975
g7
I58
sg17
VC0027430
p2976
sg10
I12
sg11
Vnasal polyps
p2977
sg13
I2
sasa(dp2978
g2
VThere was no remarkable difference in the expression of SP-D and IL-16 between allergic rhinitis and nasal polyps (P &gt; 0.05).
p2979
sg4
(lp2980
(dp2981
g7
I65
sg8
g24
sg10
I5
sg11
VIL-16
p2982
sg13
I1
sa(dp2983
g7
I56
sg8
VP35247
p2984
sg10
I4
sg11
VSP-D
p2985
sg13
I1
sasg14
(lp2986
(dp2987
g7
I101
sg17
VC0027430
p2988
sg10
I12
sg11
Vnasal polyps
p2989
sg13
I2
sa(dp2990
g7
I79
sg17
VC2607914
p2991
sg10
I17
sg11
Vallergic rhinitis
p2992
sg13
I2
sasa(dp2993
g2
VIL-16 is an important eosinophil chemokine in the process of allergic rhinitis and nasal polyps,and it can also enhance the local role of eosinophils,thus it can involve in the process of allergic rhinitis and nasal polyps disease.
p2994
sg4
(lp2995
(dp2996
g7
I0
sg8
g24
sg10
I5
sg11
VIL-16
p2997
sg13
I1
sasg14
(lp2998
(dp2999
g7
I61
sg17
VC2607914
p3000
sg10
I17
sg11
Vallergic rhinitis
p3001
sg13
I2
sa(dp3002
g7
I61
sg17
VC2607914
p3003
sg10
I17
sg11
Vallergic rhinitis
p3004
sg13
I2
sa(dp3005
g7
I83
sg17
VC0027430
p3006
sg10
I12
sg11
Vnasal polyps
p3007
sg13
I2
sa(dp3008
g7
I83
sg17
VC0027430
p3009
sg10
I12
sg11
Vnasal polyps
p3010
sg13
I2
sasa(dp3011
g2
VThough a chemotactin for CD4(+) cells and eosinophils, IL-16 also modulates their production of factors that influence inflammatory lung diseases, e.g., asthma and allergic rhinitis.
p3012
sg4
(lp3013
(dp3014
g7
I55
sg8
g24
sg10
I5
sg11
VIL-16
p3015
sg13
I1
sa(dp3016
g7
I25
sg8
VP01730
p3017
sg10
I3
sg11
VCD4
p3018
sg13
I1
sasg14
(lp3019
(dp3020
g7
I153
sg17
VC0004096
p3021
sg10
I6
sg11
Vasthma
p3022
sg13
I1
sa(dp3023
g7
I132
sg17
VC0024115
p3024
sg10
I13
sg11
Vlung diseases
p3025
sg13
I2
sa(dp3026
g7
I164
sg17
VC2607914
p3027
sg10
I17
sg11
Vallergic rhinitis
p3028
sg13
I2
sasa(dp3029
g2
VInterleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis.
p3030
sg4
(lp3031
(dp3032
g7
I16
sg8
g24
sg10
I5
sg11
VIL-16
p3033
sg13
I1
sa(dp3034
g7
I0
sg8
g24
sg10
I14
sg11
VInterleukin-16
p3035
sg13
I1
sa(dp3036
g7
I73
sg8
VP01730
p3037
sg10
I4
sg11
VCD4+
p3038
sg13
I1
sasg14
(lp3039
(dp3040
g7
I136
sg17
VC2607914
p3041
sg10
I17
sg11
Vallergic rhinitis
p3042
sg13
I2
sasa(dp3043
g2
VWe evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model.
p3044
sg4
(lp3045
(dp3046
g7
I32
sg8
g24
sg10
I5
sg11
VIL-16
p3047
sg13
I1
sa(dp3048
g7
I32
sg8
g24
sg10
I5
sg11
VIL-16
p3049
sg13
I1
sasg14
(lp3050
(dp3051
g7
I195
sg17
VC2607914
p3052
sg10
I17
sg11
Vallergic rhinitis
p3053
sg13
I2
sasa(dp3054
g2
VThese results suggest that IL-16 was both systemically and locally upregulated in the murine allergic rhinitis model and that IL-16 changed in parallel to allergic state by treatment with the drugs.
p3055
sg4
(lp3056
(dp3057
g7
I27
sg8
g24
sg10
I5
sg11
VIL-16
p3058
sg13
I1
sa(dp3059
g7
I27
sg8
g24
sg10
I5
sg11
VIL-16
p3060
sg13
I1
sasg14
(lp3061
(dp3062
g7
I155
sg17
VC0020517
p3063
sg10
I14
sg11
Vallergic state
p3064
sg13
I2
sa(dp3065
g7
I93
sg17
VC2607914
p3066
sg10
I17
sg11
Vallergic rhinitis
p3067
sg13
I2
sasa(dp3068
g2
VThe results showed abnormally increased levels of IL-16 (294.4 +/- 15.24 pg/ml), serum eosinophils with absolute count (510.0 +/- 93.57, P&gt;0.05), and total serum IgE (287.9 +/- 61.22 IU/ml) using ELFA in patients of combined asthma and rhinitis, than in each of them alone.
p3069
sg4
(lp3070
(dp3071
g7
I159
sg8
VP01854
p3072
sg10
I9
sg11
Vserum IgE
p3073
sg13
I2
sa(dp3074
g7
I50
sg8
g24
sg10
I5
sg11
VIL-16
p3075
sg13
I1
sasg14
(lp3076
(dp3077
g7
I239
sg17
VC0035455
p3078
sg10
I8
sg11
Vrhinitis
p3079
sg13
I1
sa(dp3080
g7
I165
sg17
VC0270850
p3081
sg10
I3
sg11
VIgE
p3082
sg13
I1
sa(dp3083
g7
I228
sg17
VC0004096
p3084
sg10
I6
sg11
Vasthma
p3085
sg13
I1
sasa(dp3086
g2
VWe first examined the IL-16 expression of serum and mucosal tissue in patients with allergic rhinitis.
p3087
sg4
(lp3088
(dp3089
g7
I22
sg8
g24
sg10
I5
sg11
VIL-16
p3090
sg13
I1
sasg14
(lp3091
(dp3092
g7
I84
sg17
VC2607914
p3093
sg10
I17
sg11
Vallergic rhinitis
p3094
sg13
I2
sasa(dp3095
g2
VIL-16 levels were elevated in the serum of patients with allergic rhinitis compared with normal controls.
p3096
sg4
(lp3097
(dp3098
g7
I0
sg8
g24
sg10
I5
sg11
VIL-16
p3099
sg13
I1
sasg14
(lp3100
(dp3101
g7
I57
sg17
VC2607914
p3102
sg10
I17
sg11
Vallergic rhinitis
p3103
sg13
I2
sasa(dp3104
g2
VIL-16 was significantly correlated with eosinophils in the peripheral blood of allergic rhinitis patients.
p3105
sg4
(lp3106
(dp3107
g7
I0
sg8
g24
sg10
I5
sg11
VIL-16
p3108
sg13
I1
sasg14
(lp3109
(dp3110
g7
I79
sg17
VC2607914
p3111
sg10
I17
sg11
Vallergic rhinitis
p3112
sg13
I2
sasa(dp3113
g2
VThis IL-16 cytokine may be strongly associated with the developmental mechanism of allergic rhinitis.
p3114
sg4
(lp3115
(dp3116
g7
I5
sg8
g24
sg10
I14
sg11
VIL-16 cytokine
p3117
sg13
I2
sasg14
(lp3118
(dp3119
g7
I83
sg17
VC2607914
p3120
sg10
I17
sg11
Vallergic rhinitis
p3121
sg13
I2
sasa(dp3122
g2
VSpeech fluency was assessed in 35 patients with frontotemporal lobar degeneration (FTLD) who presented with progressive non-fluent aphasia (PNFA, n=11), semantic dementia (SemD, n=12), or a social and executive disorder without aphasia (SOC/EXEC, n=12).
p3123
sg4
(lp3124
(dp3125
g7
I172
sg8
g24
sg10
I4
sg11
VSemD
p3126
sg13
I1
sa(dp3127
g7
I153
sg8
g24
sg10
I17
sg11
Vsemantic dementia
p3128
sg13
I2
sasg14
(lp3129
(dp3130
g7
I48
sg17
VC0751072
p3131
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p3132
sg13
I3
sa(dp3133
g7
I153
sg17
VC0338462
p3134
sg10
I17
sg11
Vsemantic dementia
p3135
sg13
I2
sa(dp3136
g7
I172
sg17
VC0338462
p3137
sg10
I4
sg11
VSemD
p3138
sg13
I1
sa(dp3139
g7
I83
sg17
VC0751072
p3140
sg10
I4
sg11
VFTLD
p3141
sg13
I1
sa(dp3142
g7
I131
sg17
VC0003537
p3143
sg10
I7
sg11
Vaphasia
p3144
sg13
I1
sa(dp3145
g7
I120
sg17
VC0349390
p3146
sg10
I18
sg11
Vnon-fluent aphasia
p3147
sg13
I2
sasa(dp3148
g2
VTwo subtypes commonly present with a language disorder: semantic dementia (SemD) and progressive nonfluent aphasia (PNFA).
p3149
sg4
(lp3150
(dp3151
g7
I56
sg8
g24
sg10
I17
sg11
Vsemantic dementia
p3152
sg13
I2
sa(dp3153
g7
I75
sg8
g24
sg10
I4
sg11
VSemD
p3154
sg13
I1
sasg14
(lp3155
(dp3156
g7
I37
sg17
VC0023015
p3157
sg10
I17
sg11
Vlanguage disorder
p3158
sg13
I2
sa(dp3159
g7
I56
sg17
VC0338462
p3160
sg10
I17
sg11
Vsemantic dementia
p3161
sg13
I2
sa(dp3162
g7
I85
sg17
VC0751706
p3163
sg10
I29
sg11
Vprogressive nonfluent aphasia
p3164
sg13
I3
sa(dp3165
g7
I116
sg17
VC0751706
p3166
sg10
I4
sg11
VPNFA
p3167
sg13
I1
sa(dp3168
g7
I75
sg17
VC0338462
p3169
sg10
I4
sg11
VSemD
p3170
sg13
I1
sasa(dp3171
g2
VExpression of several genes associated with schizophrenia or autism including Sema3a, Trfr2 and Vldlr were found to be altered as were protein levels of Foxp2.
p3172
sg4
(lp3173
(dp3174
g7
I96
sg8
VP98155
p3175
sg10
I5
sg11
VVldlr
p3176
sg13
I1
sa(dp3177
g7
I78
sg8
g24
sg10
I6
sg11
VSema3a
p3178
sg13
I1
sasg14
(lp3179
(dp3180
g7
I44
sg17
VC0036341
p3181
sg10
I13
sg11
Vschizophrenia
p3182
sg13
I1
sa(dp3183
g7
I61
sg17
VC0004352
p3184
sg10
I6
sg11
Vautism
p3185
sg13
I1
sasa(dp3186
g2
VWe classified 67 patients with PPA into three clinical variants: semantic dementia (SEMD), progressive nonfluent aphasia (PNFA), and logopenic progressive aphasia (LPA), and we compared the severity of behavioral dysfunction, as measured by the Neuropsychiatric Inventory, in these groups and patients with frontotemporal dementia (FTD) and Alzheimer disease (AD).
p3187
sg4
(lp3188
sg14
(lp3189
(dp3190
g7
I65
sg17
VC0338462
p3191
sg10
I17
sg11
Vsemantic dementia
p3192
sg13
I2
sa(dp3193
g7
I332
sg17
VC0338451
p3194
sg10
I3
sg11
VFTD
p3195
sg13
I1
sa(dp3196
g7
I91
sg17
VC0751706
p3197
sg10
I29
sg11
Vprogressive nonfluent aphasia
p3198
sg13
I3
sa(dp3199
g7
I341
sg17
VC0002395
p3200
sg10
I17
sg11
VAlzheimer disease
p3201
sg13
I2
sa(dp3202
g7
I84
sg17
VC0338462
p3203
sg10
I4
sg11
VSEMD
p3204
sg13
I1
sa(dp3205
g7
I122
sg17
VC0751706
p3206
sg10
I4
sg11
VPNFA
p3207
sg13
I1
sa(dp3208
g7
I307
sg17
VC0338451
p3209
sg10
I23
sg11
Vfrontotemporal dementia
p3210
sg13
I2
sa(dp3211
g7
I143
sg17
VC0338457
p3212
sg10
I19
sg11
Vprogressive aphasia
p3213
sg13
I2
sa(dp3214
g7
I360
sg17
VC0002395
p3215
sg10
I2
sg11
VAD
p3216
sg13
I1
sa(dp3217
g7
I31
sg17
VC0282513
p3218
sg10
I3
sg11
VPPA
p3219
sg13
I1
sasa(dp3220
g2
VThe authors asked patients with progressive nonfluent aphasia (PNFA), patients with semantic dementia (SemD), and nonaphasic patients with a disorder of social comportment and executive functioning (SOC/EXEC) to narrate the story of a wordless children's picture book.
p3221
sg4
(lp3222
(dp3223
g7
I84
sg8
g24
sg10
I17
sg11
Vsemantic dementia
p3224
sg13
I2
sa(dp3225
g7
I199
sg8
g24
sg10
I3
sg11
VSOC
p3226
sg13
I1
sa(dp3227
g7
I103
sg8
g24
sg10
I4
sg11
VSemD
p3228
sg13
I1
sasg14
(lp3229
(dp3230
g7
I32
sg17
VC0751706
p3231
sg10
I29
sg11
Vprogressive nonfluent aphasia
p3232
sg13
I3
sa(dp3233
g7
I63
sg17
VC0751706
p3234
sg10
I4
sg11
VPNFA
p3235
sg13
I1
sa(dp3236
g7
I103
sg17
VC0338462
p3237
sg10
I4
sg11
VSemD
p3238
sg13
I1
sa(dp3239
g7
I84
sg17
VC0338462
p3240
sg10
I17
sg11
Vsemantic dementia
p3241
sg13
I2
sasa(dp3242
g2
VEach sequence is manually annotated with primary function, subfunction and subcellular location, and extensively annotated in an automated process with data extracted from external databases, including gene information from LocusLink and Ensembl; disease information from OMIM; protein-protein interaction data from MINT and DIP; functional domain information from Pfam; protein fingerprints from PRINTS; protein family and family-specific signatures from InterPro; structure data from PDB; mutation data from PMD; BLAST homology data from NCBI NR; and proteins found to be related based on LocusLink and SWISS-PROT references and sequence and taxonomy data.
p3243
sg4
(lp3244
sg14
(lp3245
(dp3246
g7
I510
sg17
VC1832661
p3247
sg10
I3
sg11
VPMD
p3248
sg13
I1
sa(dp3249
g7
I325
sg17
VC0238378
p3250
sg10
I3
sg11
VDIP
p3251
sg13
I1
sa(dp3252
g7
I486
sg17
VC0029401
p3253
sg10
I3
sg11
VPDB
p3254
sg13
I1
sasa(dp3255
g2
VAn increase in the ratio of Abeta(WT)/Abeta(MUT(Arctic)), therefore, may result in the accumulation of potential neurotoxic protofibrils and acceleration of disease progression in familial Alzheimer's disease mutation carriers.
p3256
sg4
(lp3257
(dp3258
g7
I44
sg8
VP22033
p3259
sg10
I3
sg11
VMUT
p3260
sg13
I1
sa(dp3261
g7
I28
sg8
g24
sg10
I5
sg11
VAbeta
p3262
sg13
I1
sa(dp3263
g7
I28
sg8
g24
sg10
I5
sg11
VAbeta
p3264
sg13
I1
sasg14
(lp3265
(dp3266
g7
I157
sg17
VC0242656
p3267
sg10
I19
sg11
Vdisease progression
p3268
sg13
I2
sa(dp3269
g7
I180
sg17
VC0276496
p3270
sg10
I28
sg11
Vfamilial Alzheimer's disease
p3271
sg13
I3
sasa(dp3272
g2
VTo gain insight into the pathogenesis of these tumors we have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, b-catenin, SMARCB1, synaptophysin, chromogranin A, and CD56) and mutational status (PTEN, KRAS, PIK3CA, TP53 and POLE) of 4 dedifferentiated endometrial carcinomas with strong and diffuse neuroendocrine expression.
p3273
sg4
(lp3274
(dp3275
g7
I140
sg8
g24
sg10
I7
sg11
VSMARCB1
p3276
sg13
I1
sa(dp3277
g7
I112
sg8
VP43246
p3278
sg10
I4
sg11
VMSH2
p3279
sg13
I1
sa(dp3280
g7
I164
sg8
VP10645
p3281
sg10
I14
sg11
Vchromogranin A
p3282
sg13
I2
sa(dp3283
g7
I149
sg8
VP08247
p3284
sg10
I13
sg11
Vsynaptophysin
p3285
sg13
I1
sa(dp3286
g7
I100
sg8
VP40692
p3287
sg10
I4
sg11
VMLH1
p3288
sg13
I1
sa(dp3289
g7
I124
sg8
VP42771
p3290
sg10
I3
sg11
Vp53
p3291
sg13
I1
sa(dp3292
g7
I225
sg8
VP42336
p3293
sg10
I6
sg11
VPIK3CA
p3294
sg13
I1
sa(dp3295
g7
I118
sg8
VP52701
p3296
sg10
I4
sg11
VMSH6
p3297
sg13
I1
sa(dp3298
g7
I106
sg8
VP25054
p3299
sg10
I4
sg11
VPMS2
p3300
sg13
I1
sa(dp3301
g7
I213
sg8
VP60484
p3302
sg10
I4
sg11
VPTEN
p3303
sg13
I1
sa(dp3304
g7
I219
sg8
VP01116
p3305
sg10
I4
sg11
VKRAS
p3306
sg13
I1
sa(dp3307
g7
I242
sg8
g24
sg10
I4
sg11
VPOLE
p3308
sg13
I1
sasg14
(lp3309
(dp3310
g7
I270
sg17
VC0476089
p3311
sg10
I22
sg11
Vendometrial carcinomas
p3312
sg13
I2
sa(dp3313
g7
I47
sg17
VC0027651
p3314
sg10
I6
sg11
Vtumors
p3315
sg13
I1
sa(dp3316
g7
I25
sg17
VC0699748
p3317
sg10
I12
sg11
Vpathogenesis
p3318
sg13
I1
sasa(dp3319
g2
VIn gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma.
p3320
sg4
(lp3321
sg14
(lp3322
(dp3323
g7
I76
sg17
VC0206681
p3324
sg10
I20
sg11
Vclear cell carcinoma
p3325
sg13
I3
sa(dp3326
g7
I17
sg17
VC0006826
p3327
sg10
I6
sg11
Vcancer
p3328
sg13
I1
sa(dp3329
g7
I108
sg17
VC0206687
p3330
sg10
I22
sg11
Vendometrioid carcinoma
p3331
sg13
I2
sasa(dp3332
g2
VWe recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma.
p3333
sg4
(lp3334
(dp3335
g7
I89
sg8
VP28370
p3336
sg10
I3
sg11
VSWI
p3337
sg13
I1
sa(dp3338
g7
I120
sg8
VP51532
p3339
sg10
I4
sg11
VBRG1
p3340
sg13
I1
sa(dp3341
g7
I139
sg8
g24
sg10
I4
sg11
VINI1
p3342
sg13
I1
sa(dp3343
g7
I167
sg8
g24
sg10
I6
sg11
VARID1B
p3344
sg13
I1
sa(dp3345
g7
I93
sg8
g24
sg10
I3
sg11
VSNF
p3346
sg13
I1
sasg14
(lp3347
(dp3348
g7
I106
sg17
VC0544461
p3349
sg10
I12
sg11
Vinactivation
p3350
sg13
I1
sa(dp3351
g7
I281
sg17
VC0476089
p3352
sg10
I21
sg11
Vendometrial carcinoma
p3353
sg13
I2
sa(dp3354
g7
I106
sg17
VC0544461
p3355
sg10
I12
sg11
Vinactivation
p3356
sg13
I1
sa(dp3357
g7
I227
sg17
VC0002793
p3358
sg10
I17
sg11
Vdedifferentiation
p3359
sg13
I1
sa(dp3360
g7
I106
sg17
VC0544461
p3361
sg10
I12
sg11
Vinactivation
p3362
sg13
I1
sa(dp3363
g7
I106
sg17
VC0544461
p3364
sg10
I12
sg11
Vinactivation
p3365
sg13
I1
sasa(dp3366
g2
VThe tumor suppressor gene, AT Rich Interactive Domain 1A (ARID1A) mutation has been reported in a variety of cancers, especially the endometrium-related gynecological cancers, including the ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma.
p3367
sg4
(lp3368
(dp3369
g7
I27
sg8
g24
sg10
I29
sg11
VAT Rich Interactive Domain 1A
p3370
sg13
I5
sa(dp3371
g7
I58
sg8
g24
sg10
I6
sg11
VARID1A
p3372
sg13
I1
sasg14
(lp3373
(dp3374
g7
I109
sg17
VC0006826
p3375
sg10
I7
sg11
Vcancers
p3376
sg13
I1
sa(dp3377
g7
I198
sg17
VC0206681
p3378
sg10
I20
sg11
Vclear cell carcinoma
p3379
sg13
I3
sa(dp3380
g7
I220
sg17
VC0346163
p3381
sg10
I30
sg11
Vovarian endometrioid carcinoma
p3382
sg13
I3
sa(dp3383
g7
I228
sg17
VC0206687
p3384
sg10
I22
sg11
Vendometrioid carcinoma
p3385
sg13
I2
sa(dp3386
g7
I109
sg17
VC0006826
p3387
sg10
I7
sg11
Vcancers
p3388
sg13
I1
sa(dp3389
g7
I4
sg17
VC0027651
p3390
sg10
I5
sg11
Vtumor
p3391
sg13
I1
sasa(dp3392
g2
VThe current study aimed to evaluate serum levels of MFAP4 in patients with pulmonary fibrosis in order to test its potential as biomarker in clinical practice.
p3393
sg4
(lp3394
(dp3395
g7
I52
sg8
VP55083
p3396
sg10
I5
sg11
VMFAP4
p3397
sg13
I1
sasg14
(lp3398
(dp3399
g7
I75
sg17
VC0034069
p3400
sg10
I18
sg11
Vpulmonary fibrosis
p3401
sg13
I2
sasa(dp3402
g2
VA further aim was to determine whether MFAP4 deficiency in mice affects the formation of pulmonary fibrosis in the bleomycin model of lung fibrosis.
p3403
sg4
(lp3404
(dp3405
g7
I39
sg8
VP55083
p3406
sg10
I5
sg11
VMFAP4
p3407
sg13
I1
sasg14
(lp3408
(dp3409
g7
I89
sg17
VC0034069
p3410
sg10
I18
sg11
Vpulmonary fibrosis
p3411
sg13
I2
sa(dp3412
g7
I134
sg17
VC0034069
p3413
sg10
I13
sg11
Vlung fibrosis
p3414
sg13
I2
sasa(dp3415
g2
VMFAP4 levels were increased in BAL of bleomycin treated mice with pulmonary fibrosis.
p3416
sg4
(lp3417
(dp3418
g7
I0
sg8
VP55083
p3419
sg10
I5
sg11
VMFAP4
p3420
sg13
I1
sasg14
(lp3421
(dp3422
g7
I66
sg17
VC0034069
p3423
sg10
I18
sg11
Vpulmonary fibrosis
p3424
sg13
I2
sasa(dp3425
g2
VMFAP4 is not elevated in sera of patients with pulmonary fibrosis or bleomycin treated mice with pulmonary fibrosis.
p3426
sg4
(lp3427
(dp3428
g7
I0
sg8
VP55083
p3429
sg10
I5
sg11
VMFAP4
p3430
sg13
I1
sasg14
(lp3431
(dp3432
g7
I47
sg17
VC0034069
p3433
sg10
I18
sg11
Vpulmonary fibrosis
p3434
sg13
I2
sa(dp3435
g7
I47
sg17
VC0034069
p3436
sg10
I18
sg11
Vpulmonary fibrosis
p3437
sg13
I2
sasa(dp3438
g2
VThe aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD).
p3439
sg4
(lp3440
(dp3441
g7
I61
sg8
VP55083
p3442
sg10
I5
sg11
VMFAP4
p3443
sg13
I1
sasg14
(lp3444
(dp3445
g7
I145
sg17
VC0024117
p3446
sg10
I4
sg11
VCOPD
p3447
sg13
I1
sa(dp3448
g7
I106
sg17
VC0024117
p3449
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p3450
sg13
I4
sasa(dp3451
g2
VMultiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p &lt; 0.0001) and BODE index (p = 0.04).
p3452
sg4
(lp3453
sg14
(lp3454
(dp3455
g7
I16
sg17
VC0684320
p3456
sg10
I11
sg11
Vregressions
p3457
sg13
I1
sa(dp3458
g7
I102
sg17
VC0600260
p3459
sg10
I24
sg11
VObstructive Lung Disease
p3460
sg13
I3
sasa(dp3461
g2
VFor essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3.
p3462
sg4
(lp3463
(dp3464
g7
I598
sg8
VP49715
p3465
sg10
I5
sg11
VCEBPA
p3466
sg13
I1
sa(dp3467
g7
I200
sg8
g24
sg10
I4
sg11
VEZH2
p3468
sg13
I1
sa(dp3469
g7
I362
sg8
VP48735
p3470
sg10
I4
sg11
VIDH2
p3471
sg13
I1
sa(dp3472
g7
I609
sg8
g24
sg10
I5
sg11
VSH2B3
p3473
sg13
I1
sasg14
(lp3474
(dp3475
g7
I265
sg17
VC0032463
p3476
sg10
I17
sg11
Vpolycythemia vera
p3477
sg13
I2
sa(dp3478
g7
I4
sg17
VC0040028
p3479
sg10
I25
sg11
Vessential thrombocythemia
p3480
sg13
I2
sa(dp3481
g7
I66
sg17
VC1510411
p3482
sg10
I14
sg11
Vtransformation
p3483
sg13
I1
sa(dp3484
g7
I135
sg17
VC0023518
p3485
sg10
I12
sg11
Vleukocytosis
p3486
sg13
I1
sa(dp3487
g7
I127
sg17
VC0002871
p3488
sg10
I6
sg11
Vanemia
p3489
sg13
I1
sa(dp3490
g7
I135
sg17
VC0023518
p3491
sg10
I12
sg11
Vleukocytosis
p3492
sg13
I1
sa(dp3493
g7
I111
sg17
VC0836924
p3494
sg10
I14
sg11
Vthrombocytosis
p3495
sg13
I1
sasa(dp3496
g2
VIn the present case, i(17q)/-17, der(12p), del(5q26), del(7q36), and del(20q11) indicate possible alterations in TP53, ETV6, IDH2, EZH2, and SRSF2 genes, which are responsible for pathomechanism, genetic instability, clonal evolution, and advancement of disease condition.
p3497
sg4
(lp3498
(dp3499
g7
I119
sg8
VP41212
p3500
sg10
I4
sg11
VETV6
p3501
sg13
I1
sa(dp3502
g7
I125
sg8
VP48735
p3503
sg10
I4
sg11
VIDH2
p3504
sg13
I1
sa(dp3505
g7
I141
sg8
VP01893
p3506
sg10
I11
sg11
VSRSF2 genes
p3507
sg13
I2
sa(dp3508
g7
I131
sg8
g24
sg10
I4
sg11
VEZH2
p3509
sg13
I1
sasg14
(lp3510
(dp3511
g7
I262
sg17
VC0012634
p3512
sg10
I9
sg11
Vcondition
p3513
sg13
I1
sa(dp3514
g7
I217
sg17
VC1516669
p3515
sg10
I16
sg11
Vclonal evolution
p3516
sg13
I2
sasa(dp3517
g2
VAccumulating evidence indicates that enhancer of zeste homolog 2 (EZH2) promotes the metastatic ability of solid tumors, but the role of EZH2 in extramedullary infiltration (EMI) in acute myeloid leukemia (AML) has not been thoroughly explored.
p3518
sg4
(lp3519
(dp3520
g7
I66
sg8
g24
sg10
I4
sg11
VEZH2
p3521
sg13
I1
sa(dp3522
g7
I37
sg8
g24
sg10
I27
sg11
Venhancer of zeste homolog 2
p3523
sg13
I5
sa(dp3524
g7
I66
sg8
g24
sg10
I4
sg11
VEZH2
p3525
sg13
I1
sasg14
(lp3526
(dp3527
g7
I182
sg17
VC0023467
p3528
sg10
I22
sg11
Vacute myeloid leukemia
p3529
sg13
I3
sa(dp3530
g7
I160
sg17
VC0332448
p3531
sg10
I12
sg11
Vinfiltration
p3532
sg13
I1
sa(dp3533
g7
I107
sg17
VC0280100
p3534
sg10
I12
sg11
Vsolid tumors
p3535
sg13
I2
sa(dp3536
g7
I206
sg17
VC0023467
p3537
sg10
I3
sg11
VAML
p3538
sg13
I1
sasa(dp3539
g2
VWe found that the messenger RNA (mRNA) and protein expression levels of EZH2 in AML patients were both significantly higher than in idiopathic thrombocytopenic purpura (ITP) patients.
p3540
sg4
(lp3541
(dp3542
g7
I72
sg8
g24
sg10
I4
sg11
VEZH2
p3543
sg13
I1
sasg14
(lp3544
(dp3545
g7
I80
sg17
VC0023467
p3546
sg10
I3
sg11
VAML
p3547
sg13
I1
sa(dp3548
g7
I169
sg17
VC0043117
p3549
sg10
I3
sg11
VITP
p3550
sg13
I1
sa(dp3551
g7
I132
sg17
VC0043117
p3552
sg10
I35
sg11
Vidiopathic thrombocytopenic purpura
p3553
sg13
I3
sasa(dp3554
g2
VHistopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative.
p3555
sg4
(lp3556
(dp3557
g7
I225
sg8
VP55786
p3558
sg10
I3
sg11
VPSA
p3559
sg13
I1
sa(dp3560
g7
I198
sg8
g24
sg10
I13
sg11
Vthyroglobulin
p3561
sg13
I1
sasg14
(lp3562
(dp3563
g7
I225
sg17
VC1519176
p3564
sg10
I3
sg11
VPSA
p3565
sg13
I1
sa(dp3566
g7
I135
sg17
VC0238463
p3567
sg10
I27
sg11
Vpapillary thyroid carcinoma
p3568
sg13
I3
sa(dp3569
g7
I82
sg17
VC0001430
p3570
sg10
I8
sg11
Vadenomas
p3571
sg13
I1
sasa(dp3572
g2
VUnivariate analysis showed that male gender, thyroglobulin concentrations &gt;=300 ng/ml and tumor diameter &gt;30 mm were significantly more frequent in patients with oxyphile carcinoma compared to patients with oxyphile adenoma, while coexisting Hashimoto thyreoiditis and positive AntiTPO antibodies appeared significantly less frequent in the carcinoma group.
p3573
sg4
(lp3574
(dp3575
g7
I45
sg8
g24
sg10
I13
sg11
Vthyroglobulin
p3576
sg13
I1
sasg14
(lp3577
(dp3578
g7
I93
sg17
VC0027651
p3579
sg10
I5
sg11
Vtumor
p3580
sg13
I1
sa(dp3581
g7
I177
sg17
VC0007097
p3582
sg10
I9
sg11
Vcarcinoma
p3583
sg13
I1
sa(dp3584
g7
I177
sg17
VC0007097
p3585
sg10
I9
sg11
Vcarcinoma
p3586
sg13
I1
sa(dp3587
g7
I222
sg17
VC0001430
p3588
sg10
I7
sg11
Vadenoma
p3589
sg13
I1
sasa(dp3590
g2
VThe histologic appearance together with the immune profile was diagnostic of WCCA, with diffuse positivity for GATA3, focal weak positivity for parathyroid hormone, and negativity for PAX8, thyroglobulin, TTF1, synaptophysin, chromogranin, and S100p.
p3591
sg4
(lp3592
(dp3593
g7
I205
sg8
VP43699
p3594
sg10
I4
sg11
VTTF1
p3595
sg13
I1
sa(dp3596
g7
I226
sg8
VP08311
p3597
sg10
I12
sg11
Vchromogranin
p3598
sg13
I1
sa(dp3599
g7
I190
sg8
g24
sg10
I13
sg11
Vthyroglobulin
p3600
sg13
I1
sa(dp3601
g7
I211
sg8
VP08247
p3602
sg10
I13
sg11
Vsynaptophysin
p3603
sg13
I1
sa(dp3604
g7
I184
sg8
g24
sg10
I4
sg11
VPAX8
p3605
sg13
I1
sa(dp3606
g7
I144
sg8
VP01270
p3607
sg10
I19
sg11
Vparathyroid hormone
p3608
sg13
I2
sa(dp3609
g7
I244
sg8
VP25815
p3610
sg10
I5
sg11
VS100p
p3611
sg13
I1
sa(dp3612
g7
I111
sg8
VP23771
p3613
sg10
I5
sg11
VGATA3
p3614
sg13
I1
sasg14
(lp3615
sa(dp3616
g2
VAfter immunohistochemical characterization using a panel of chromogranin A, thyroglobulin, and calcitonin, 7 of the former thyroid neoplasms were diagnosed as thyroid adenomas, 1 was diagnosed as a thyroid carcinoma, and 4 were diagnosed as parathyroid adenomas.
p3617
sg4
(lp3618
(dp3619
g7
I95
sg8
VP06881
p3620
sg10
I10
sg11
Vcalcitonin
p3621
sg13
I1
sa(dp3622
g7
I60
sg8
VP10645
p3623
sg10
I14
sg11
Vchromogranin A
p3624
sg13
I2
sa(dp3625
g7
I76
sg8
g24
sg10
I13
sg11
Vthyroglobulin
p3626
sg13
I1
sasg14
(lp3627
(dp3628
g7
I123
sg17
VC0040136
p3629
sg10
I17
sg11
Vthyroid neoplasms
p3630
sg13
I2
sa(dp3631
g7
I198
sg17
VC0549473
p3632
sg10
I17
sg11
Vthyroid carcinoma
p3633
sg13
I2
sa(dp3634
g7
I241
sg17
VC0262587
p3635
sg10
I20
sg11
Vparathyroid adenomas
p3636
sg13
I2
sa(dp3637
g7
I167
sg17
VC0001430
p3638
sg10
I8
sg11
Vadenomas
p3639
sg13
I1
sasa(dp3640
g2
VThe findings obtained using these cell lines derived from ovarian clear cell adenocarcinoma indicate that integrin alpha3 may associated with the acquisition of malignant potential by clear cell adenocarcinoma.
p3641
sg4
(lp3642
sg14
(lp3643
(dp3644
g7
I66
sg17
VC0206681
p3645
sg10
I25
sg11
Vclear cell adenocarcinoma
p3646
sg13
I3
sa(dp3647
g7
I58
sg17
VC1518693
p3648
sg10
I33
sg11
Vovarian clear cell adenocarcinoma
p3649
sg13
I4
sasa(dp3650
g2
VNo entanto, a existencia de uma patologia cronica pode determinar um elevado nivel de cuidados preventivos gerais, inclusivamente resultando numa melhoria global do seu nivel de saude oral, o que podera justificar os resultados obtidos.Conclusao: A presenca de diabetes mellitus tipo 1 em doentes tratados com bomba de insulina nao esta associada a um aumento da prevalencia de lesoes de carie dentaria.
p3651
sg4
(lp3652
sg14
(lp3653
(dp3654
g7
I261
sg17
VC0011849
p3655
sg10
I17
sg11
Vdiabetes mellitus
p3656
sg13
I2
sasa(dp3657
g2
VFew of the substrates of Tankyrases are Telomeric Repeat binding Factor protein (TRF1), Axis Inhibitory protein (AXIN 1&amp;amp;2), Insulin Responsive Amino Peptidase (IRAP), Nuclear Mitotic Apparatus protein (NuMa), that become aberrantly active due to the apparent overexpression of the enzyme during hyper proliferative disease conditions like cancer, fibrosis and metabolic disorders like diabetes.
p3658
sg4
(lp3659
(dp3660
g7
I168
sg8
g24
sg10
I4
sg11
VIRAP
p3661
sg13
I1
sa(dp3662
g7
I25
sg8
g24
sg10
I10
sg11
VTankyrases
p3663
sg13
I1
sa(dp3664
g7
I132
sg8
g24
sg10
I34
sg11
VInsulin Responsive Amino Peptidase
p3665
sg13
I4
sa(dp3666
g7
I40
sg8
VP54274
p3667
sg10
I39
sg11
VTelomeric Repeat binding Factor protein
p3668
sg13
I5
sa(dp3669
g7
I-1
sg8
g24
sg10
I8
sg11
VAXIN 1&2
p3670
sg13
I2
sa(dp3671
g7
I81
sg8
VP54274
p3672
sg10
I4
sg11
VTRF1
p3673
sg13
I1
sasg14
(lp3674
(dp3675
g7
I309
sg17
VC0334094
p3676
sg10
I13
sg11
Vproliferative
p3677
sg13
I1
sa(dp3678
g7
I368
sg17
VC0025517
p3679
sg10
I19
sg11
Vmetabolic disorders
p3680
sg13
I2
sa(dp3681
g7
I355
sg17
VC0016059
p3682
sg10
I8
sg11
Vfibrosis
p3683
sg13
I1
sa(dp3684
g7
I393
sg17
VC0011849
p3685
sg10
I8
sg11
Vdiabetes
p3686
sg13
I1
sa(dp3687
g7
I347
sg17
VC0006826
p3688
sg10
I6
sg11
Vcancer
p3689
sg13
I1
sasa(dp3690
g2
VO objetivo deste estudo foi avaliar a utilidade deste exame numa populacao de criancas e adolescentes obesos, maioritariamente de etnia caucasiana.Material e Metodos: Foram recrutados 226 doentes [indice de massa corporal z-score 3,35 A+/- 0,59, 90% caucasianos, 55% do sexo feminino, idade mediana de 12,3 (ambito: 8,9 a 17,6) anos] referenciados a consulta de obesidade pediatrica de um hospital terciario, com criterios para rastreio de diabetes mellitus tipo 2.
p3691
sg4
(lp3692
sg14
(lp3693
(dp3694
g7
I440
sg17
VC0011849
p3695
sg10
I17
sg11
Vdiabetes mellitus
p3696
sg13
I2
sasa(dp3697
g2
VFinally, we speculate on the potential benefits of the inhibition of Sin3B-containing complexes for the treatment of cancer.
p3698
sg4
(lp3699
(dp3700
g7
I69
sg8
g24
sg10
I5
sg11
VSin3B
p3701
sg13
I1
sasg14
(lp3702
(dp3703
g7
I117
sg17
VC0006826
p3704
sg10
I6
sg11
Vcancer
p3705
sg13
I1
sasa(dp3706
g2
VExpert opinion: Further identification and characterization of specific Sin3B-containing complexes provide a unique opportunity to prevent the pro-tumorigenic effects of the senescence-associated secretory phenotype, and to abrogate cancer stem cell quiescence and the associated resistance to therapy.
p3707
sg4
(lp3708
(dp3709
g7
I72
sg8
g24
sg10
I5
sg11
VSin3B
p3710
sg13
I1
sasg14
(lp3711
(dp3712
g7
I233
sg17
VC0006826
p3713
sg10
I6
sg11
Vcancer
p3714
sg13
I1
sasa(dp3715
g2
VSIN3B has been implicated in the initiation of senescence in vitro Here we show that in a mouse model of prostate cancer, SIN3B provides a barrier to malignant progression.
p3716
sg4
(lp3717
(dp3718
g7
I0
sg8
g24
sg10
I5
sg11
VSIN3B
p3719
sg13
I1
sa(dp3720
g7
I0
sg8
g24
sg10
I5
sg11
VSIN3B
p3721
sg13
I1
sasg14
(lp3722
(dp3723
g7
I105
sg17
VC0600139
p3724
sg10
I15
sg11
Vprostate cancer
p3725
sg13
I2
sasa(dp3726
g2
VSIN3B was required for PTEN-induced cellular senescence and prevented progression to invasive prostate adenocarcinoma.
p3727
sg4
(lp3728
(dp3729
g7
I0
sg8
g24
sg10
I5
sg11
VSIN3B
p3730
sg13
I1
sa(dp3731
g7
I23
sg8
VP60484
p3732
sg10
I4
sg11
VPTEN
p3733
sg13
I1
sasg14
(lp3734
(dp3735
g7
I94
sg17
VC0007112
p3736
sg10
I23
sg11
Vprostate adenocarcinoma
p3737
sg13
I2
sasa(dp3738
g2
VFurthermore, SIN3B was downregulated in human prostate adenocarcinoma correlating with upregulation of its target genes.
p3739
sg4
(lp3740
(dp3741
g7
I13
sg8
g24
sg10
I5
sg11
VSIN3B
p3742
sg13
I1
sasg14
(lp3743
(dp3744
g7
I46
sg17
VC0007112
p3745
sg10
I23
sg11
Vprostate adenocarcinoma
p3746
sg13
I2
sasa(dp3747
g2
VOur results suggest a tumor suppressor function for SIN3B that limits prostate adenocarcinoma progression, with potential implications for the use of SIN3B and its target genes as candidate diagnostic markers to distinguish indolent from aggressive disease.
p3748
sg4
(lp3749
(dp3750
g7
I52
sg8
g24
sg10
I5
sg11
VSIN3B
p3751
sg13
I1
sa(dp3752
g7
I52
sg8
g24
sg10
I5
sg11
VSIN3B
p3753
sg13
I1
sasg14
(lp3754
(dp3755
g7
I22
sg17
VC0027651
p3756
sg10
I5
sg11
Vtumor
p3757
sg13
I1
sa(dp3758
g7
I70
sg17
VC0007112
p3759
sg10
I23
sg11
Vprostate adenocarcinoma
p3760
sg13
I2
sa(dp3761
g7
I238
sg17
VC0001807
p3762
sg10
I10
sg11
Vaggressive
p3763
sg13
I1
sasa(dp3764
g2
VHowever, specific roles for SIN3A and SIN3B in breast cancer progression have not been characterized.
p3765
sg4
(lp3766
(dp3767
g7
I38
sg8
g24
sg10
I5
sg11
VSIN3B
p3768
sg13
I1
sa(dp3769
g7
I28
sg8
g24
sg10
I5
sg11
VSIN3A
p3770
sg13
I1
sasg14
(lp3771
(dp3772
g7
I54
sg17
VC0178874
p3773
sg10
I18
sg11
Vcancer progression
p3774
sg13
I2
sasa(dp3775
g2
VAdditionally, we analyzed microarray data sets to identify correlations of SIN3A and SIN3B expression with survival in patients with breast cancer.
p3776
sg4
(lp3777
(dp3778
g7
I85
sg8
g24
sg10
I5
sg11
VSIN3B
p3779
sg13
I1
sa(dp3780
g7
I75
sg8
g24
sg10
I5
sg11
VSIN3A
p3781
sg13
I1
sasg14
(lp3782
(dp3783
g7
I133
sg17
VC0678222
p3784
sg10
I13
sg11
Vbreast cancer
p3785
sg13
I2
sasa(dp3786
g2
VThese data sets indicated that high mRNA expression of SIN3A as well as low mRNA expression of SIN3B correlates with longer relapse free survival specifically in patients with triple negative breast cancer which corresponds with our in vitro and in vivo data.
p3787
sg4
(lp3788
(dp3789
g7
I95
sg8
g24
sg10
I5
sg11
VSIN3B
p3790
sg13
I1
sa(dp3791
g7
I55
sg8
g24
sg10
I5
sg11
VSIN3A
p3792
sg13
I1
sasg14
(lp3793
(dp3794
g7
I124
sg17
VC0277556
p3795
sg10
I7
sg11
Vrelapse
p3796
sg13
I1
sa(dp3797
g7
I192
sg17
VC0678222
p3798
sg10
I13
sg11
Vbreast cancer
p3799
sg13
I2
sasa(dp3800
g2
VThese results demonstrate key functional differences between SIN3 paralogs in regulating the process of breast cancer metastasis and suggest metastasis suppressive roles of SIN3A and metastasis promoting roles of SIN3B.
p3801
sg4
(lp3802
(dp3803
g7
I173
sg8
g24
sg10
I5
sg11
VSIN3A
p3804
sg13
I1
sa(dp3805
g7
I213
sg8
g24
sg10
I5
sg11
VSIN3B
p3806
sg13
I1
sa(dp3807
g7
I61
sg8
g24
sg10
I4
sg11
VSIN3
p3808
sg13
I1
sasg14
(lp3809
(dp3810
g7
I118
sg17
VC0027627
p3811
sg10
I10
sg11
Vmetastasis
p3812
sg13
I1
sa(dp3813
g7
I104
sg17
VC0678222
p3814
sg10
I13
sg11
Vbreast cancer
p3815
sg13
I2
sa(dp3816
g7
I118
sg17
VC0027627
p3817
sg10
I10
sg11
Vmetastasis
p3818
sg13
I1
sa(dp3819
g7
I118
sg17
VC0027627
p3820
sg10
I10
sg11
Vmetastasis
p3821
sg13
I1
sasa(dp3822
g2
VFinally, by immunohistochemical staining of primary breast tissue microarrays we find that EMSY/KDM5A/SIN3B complex subunits are frequently overexpressed in primary breast cancer cases in a correlative manner.
p3823
sg4
(lp3824
(dp3825
g7
I96
sg8
VP29375
p3826
sg10
I5
sg11
VKDM5A
p3827
sg13
I1
sa(dp3828
g7
I102
sg8
g24
sg10
I5
sg11
VSIN3B
p3829
sg13
I1
sa(dp3830
g7
I91
sg8
g24
sg10
I4
sg11
VEMSY
p3831
sg13
I1
sasg14
(lp3832
(dp3833
g7
I165
sg17
VC0678222
p3834
sg10
I13
sg11
Vbreast cancer
p3835
sg13
I2
sasa(dp3836
g2
VHere, using a mouse model of pancreatic cancer, we have demonstrated that SIN3B is required for activated KRAS-induced senescence in vivo.
p3837
sg4
(lp3838
(dp3839
g7
I106
sg8
VP01116
p3840
sg10
I4
sg11
VKRAS
p3841
sg13
I1
sa(dp3842
g7
I74
sg8
g24
sg10
I5
sg11
VSIN3B
p3843
sg13
I1
sasg14
(lp3844
(dp3845
g7
I29
sg17
VC0235974
p3846
sg10
I17
sg11
Vpancreatic cancer
p3847
sg13
I2
sasa(dp3848
g2
VFurthermore, evaluation of human pancreatic tissue and cancer cells revealed that Sin3B was decreased in control and PDAC samples, compared with samples from patients with pancreatic inflammation.
p3849
sg4
(lp3850
(dp3851
g7
I82
sg8
g24
sg10
I5
sg11
VSin3B
p3852
sg13
I1
sasg14
(lp3853
(dp3854
g7
I183
sg17
VC0021368
p3855
sg10
I12
sg11
Vinflammation
p3856
sg13
I1
sa(dp3857
g7
I55
sg17
VC0006826
p3858
sg10
I6
sg11
Vcancer
p3859
sg13
I1
sasa(dp3860
g2
VAmong proteins in the c-Myc/Max/Mad/Sin3 regulatory complex, Mad4 and Sin3B are routinely detected in human glioblastoma multiforme (GBM) cell lines.
p3861
sg4
(lp3862
(dp3863
g7
I36
sg8
g24
sg10
I4
sg11
VSin3
p3864
sg13
I1
sa(dp3865
g7
I61
sg8
g24
sg10
I4
sg11
VMad4
p3866
sg13
I1
sa(dp3867
g7
I22
sg8
VP12524
p3868
sg10
I5
sg11
Vc-Myc
p3869
sg13
I1
sa(dp3870
g7
I70
sg8
g24
sg10
I5
sg11
VSin3B
p3871
sg13
I1
sa(dp3872
g7
I32
sg8
VP23109
p3873
sg10
I3
sg11
VMad
p3874
sg13
I1
sasg14
(lp3875
(dp3876
g7
I133
sg17
VC1621958
p3877
sg10
I3
sg11
VGBM
p3878
sg13
I1
sa(dp3879
g7
I108
sg17
VC1621958
p3880
sg10
I23
sg11
Vglioblastoma multiforme
p3881
sg13
I2
sasa(dp3882
g2
VIn response to gamma radiation, the expression of Sin3B and Mad4 in GBM cells was upregulated in parallel over time, suggesting that Sin3B may play a role in the regulation of Mad4 stability.
p3883
sg4
(lp3884
(dp3885
g7
I50
sg8
g24
sg10
I5
sg11
VSin3B
p3886
sg13
I1
sa(dp3887
g7
I60
sg8
g24
sg10
I4
sg11
VMad4
p3888
sg13
I1
sa(dp3889
g7
I60
sg8
g24
sg10
I4
sg11
VMad4
p3890
sg13
I1
sa(dp3891
g7
I50
sg8
g24
sg10
I5
sg11
VSin3B
p3892
sg13
I1
sasg14
(lp3893
(dp3894
g7
I68
sg17
VC0017636
p3895
sg10
I3
sg11
VGBM
p3896
sg13
I1
sasa(dp3897
g2
VUsing the Drosophila heart as a platform for identifying novel gene interactions leading to heart disease, we found that the Rho-GTPase Cdc42 cooperates with the cardiac transcription factor Tinman/Nkx2-5.
p3898
sg4
(lp3899
(dp3900
g7
I198
sg8
VP52952
p3901
sg10
I6
sg11
VNkx2-5
p3902
sg13
I1
sa(dp3903
g7
I125
sg8
VP08100
p3904
sg10
I10
sg11
VRho-GTPase
p3905
sg13
I1
sa(dp3906
g7
I136
sg8
VP60953
p3907
sg10
I5
sg11
VCdc42
p3908
sg13
I1
sa(dp3909
g7
I162
sg8
VP35398
p3910
sg10
I28
sg11
Vcardiac transcription factor
p3911
sg13
I3
sasg14
(lp3912
(dp3913
g7
I92
sg17
VC0018799
p3914
sg10
I13
sg11
Vheart disease
p3915
sg13
I2
sasa(dp3916
g2
VWhat is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.
p3917
sg4
(lp3918
(dp3919
g7
I105
sg8
g24
sg10
I6
sg11
VSnapin
p3920
sg13
I1
sa(dp3921
g7
I59
sg8
g24
sg10
I6
sg11
VCav1.3
p3922
sg13
I1
sasg14
(lp3923
(dp3924
g7
I171
sg17
VC0004238
p3925
sg10
I2
sg11
VAF
p3926
sg13
I1
sa(dp3927
g7
I150
sg17
VC0004238
p3928
sg10
I19
sg11
Vatrial fibrillation
p3929
sg13
I2
sasa(dp3930
g2
VFurthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.
p3931
sg4
(lp3932
(dp3933
g7
I29
sg8
g24
sg10
I15
sg11
VCav1.3 channels
p3934
sg13
I2
sasg14
(lp3935
(dp3936
g7
I59
sg17
VC0155709
p3937
sg10
I31
sg11
Vatrial fibrillation and flutter
p3938
sg13
I4
sa(dp3939
g7
I13
sg17
VC0544461
p3940
sg10
I12
sg11
Vinactivation
p3941
sg13
I1
sasa(dp3942
g2
VThe significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.
p3943
sg4
(lp3944
(dp3945
g7
I139
sg8
g24
sg10
I6
sg11
VCav1.3
p3946
sg13
I1
sasg14
(lp3947
(dp3948
g7
I151
sg17
VC0596988
p3949
sg10
I6
sg11
Vmutant
p3950
sg13
I1
sa(dp3951
g7
I114
sg17
VC0004238
p3952
sg10
I19
sg11
Vatrial fibrillation
p3953
sg13
I2
sasa(dp3954
g2
VThe novel Cav1.3 (Alfa1D) L-type Ca^2+ channel plays a significant role in sinoatrial (SA) and atrioventricular (AV) nodes function and in atrial fibrillation.
p3955
sg4
(lp3956
(dp3957
g7
I10
sg8
g24
sg10
I6
sg11
VCav1.3
p3958
sg13
I1
sasg14
(lp3959
(dp3960
g7
I139
sg17
VC0004238
p3961
sg10
I19
sg11
Vatrial fibrillation
p3962
sg13
I2
sasa(dp3963
g2
VInterestingly, oncogenic CARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(Ub)n-Bcl10 production to extents that correlate with their abilities to activate NF-KB and with their enhanced abilities to bind HOIP and Bcl10.
p3964
sg4
(lp3965
(dp3966
g7
I15
sg8
g24
sg10
I25
sg11
Voncogenic CARD11 variants
p3967
sg13
I3
sa(dp3968
g7
I117
sg8
g24
sg10
I5
sg11
VBcl10
p3969
sg13
I1
sasg14
(lp3970
(dp3971
g7
I57
sg17
VC0079744
p3972
sg10
I29
sg11
Vdiffuse large B cell lymphoma
p3973
sg13
I5
sasa(dp3974
g2
VOur previous studies showed important regulatory functions of RNF31 in controlling important oncogenic pathways in breast cancer, such as ERAlfa and p53.
p3975
sg4
(lp3976
(dp3977
g7
I62
sg8
g24
sg10
I5
sg11
VRNF31
p3978
sg13
I1
sa(dp3979
g7
I149
sg8
VP42771
p3980
sg10
I3
sg11
Vp53
p3981
sg13
I1
sasg14
(lp3982
(dp3983
g7
I115
sg17
VC0678222
p3984
sg10
I13
sg11
Vbreast cancer
p3985
sg13
I2
sasa(dp3986
g2
VThis review highlights recent discoveries on RNF31 functions in nuclear factor modifications, breast cancer progression and possible therapeutic inhibitors targeting RNF31.
p3987
sg4
(lp3988
(dp3989
g7
I45
sg8
g24
sg10
I5
sg11
VRNF31
p3990
sg13
I1
sa(dp3991
g7
I45
sg8
g24
sg10
I5
sg11
VRNF31
p3992
sg13
I1
sasg14
(lp3993
(dp3994
g7
I101
sg17
VC0178874
p3995
sg10
I18
sg11
Vcancer progression
p3996
sg13
I2
sasa(dp3997
g2
VThe atypical E3 ubiquitin ligase RNF31 is highly expressed in human breast cancer, the most frequent neoplastic lethality among women.
p3998
sg4
(lp3999
(dp4000
g7
I13
sg8
VP62979
p4001
sg10
I12
sg11
VE3 ubiquitin
p4002
sg13
I2
sa(dp4003
g7
I33
sg8
g24
sg10
I5
sg11
VRNF31
p4004
sg13
I1
sasg14
(lp4005
(dp4006
g7
I68
sg17
VC0678222
p4007
sg10
I13
sg11
Vbreast cancer
p4008
sg13
I2
sasa(dp4009
g2
VHere, RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 (TP53) signaling as a potential RNF31 target.
p4010
sg4
(lp4011
(dp4012
g7
I107
sg8
VP42771
p4013
sg10
I3
sg11
Vp53
p4014
sg13
I1
sa(dp4015
g7
I6
sg8
g24
sg10
I5
sg11
VRNF31
p4016
sg13
I1
sa(dp4017
g7
I6
sg8
g24
sg10
I5
sg11
VRNF31
p4018
sg13
I1
sasg14
(lp4019
(dp4020
g7
I25
sg17
VC0678222
p4021
sg10
I13
sg11
Vbreast cancer
p4022
sg13
I2
sasa(dp4023
g2
VInterestingly, RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner.
p4024
sg4
(lp4025
(dp4026
g7
I15
sg8
g24
sg10
I5
sg11
VRNF31
p4027
sg13
I1
sa(dp4028
g7
I31
sg8
VP42771
p4029
sg10
I3
sg11
Vp53
p4030
sg13
I1
sa(dp4031
g7
I31
sg8
VP42771
p4032
sg10
I3
sg11
Vp53
p4033
sg13
I1
sa(dp4034
g7
I15
sg8
g24
sg10
I5
sg11
VRNF31
p4035
sg13
I1
sasg14
(lp4036
(dp4037
g7
I76
sg17
VC0678222
p4038
sg10
I13
sg11
Vbreast cancer
p4039
sg13
I2
sasa(dp4040
g2
VTogether, our findings suggest RNF31 as a potential therapeutic target to restore p53 function in breast cancer.
p4041
sg4
(lp4042
(dp4043
g7
I82
sg8
VP42771
p4044
sg10
I3
sg11
Vp53
p4045
sg13
I1
sa(dp4046
g7
I31
sg8
g24
sg10
I5
sg11
VRNF31
p4047
sg13
I1
sasg14
(lp4048
(dp4049
g7
I98
sg17
VC0678222
p4050
sg10
I13
sg11
Vbreast cancer
p4051
sg13
I2
sasa(dp4052
g2
VBy examining the kinetics of pathway activation in TRAIL-sensitive lymphoma cells wild-type or deficient for RIP1, TRAF2, cIAP1/2 or HOIP, we report here that TRAIL induces two phases of JNK and NF-KB activation.
p4053
sg4
(lp4054
(dp4055
g7
I115
sg8
g24
sg10
I5
sg11
VTRAF2
p4056
sg13
I1
sa(dp4057
g7
I109
sg8
VP47985
p4058
sg10
I4
sg11
VRIP1
p4059
sg13
I1
sa(dp4060
g7
I122
sg8
g24
sg10
I7
sg11
VcIAP1/2
p4061
sg13
I1
sa(dp4062
g7
I187
sg8
VP53779
p4063
sg10
I3
sg11
VJNK
p4064
sg13
I1
sa(dp4065
g7
I51
sg8
VP50591
p4066
sg10
I5
sg11
VTRAIL
p4067
sg13
I1
sasg14
(lp4068
(dp4069
g7
I67
sg17
VC0024299
p4070
sg10
I8
sg11
Vlymphoma
p4071
sg13
I1
sasa(dp4072
g2
VLiterature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. 2012).
p4073
sg4
(lp4074
(dp4075
g7
I102
sg8
VP23975
p4076
sg10
I26
sg11
Vnorepinephrine transporter
p4077
sg13
I2
sasg14
(lp4078
(dp4079
g7
I170
sg17
VC0332875
p4080
sg10
I3
sg11
VWeb
p4081
sg13
I1
sa(dp4082
g7
I86
sg17
VC0344307
p4083
sg10
I9
sg11
Vanalgesia
p4084
sg13
I1
sasa(dp4085
g2
VNorepinephrine transporter blockade seems to be essential for analgesia, but optimal concentrations are unknown.
p4086
sg4
(lp4087
sg14
(lp4088
(dp4089
g7
I62
sg17
VC0344307
p4090
sg10
I9
sg11
Vanalgesia
p4091
sg13
I1
sasa(dp4092
g2
VThe third type is the secondary PHA1, which is strongly associated with urinary tract infections and/or urinary tract malformations.
p4093
sg4
(lp4094
sg14
(lp4095
(dp4096
g7
I118
sg17
VC0000768
p4097
sg10
I13
sg11
Vmalformations
p4098
sg13
I1
sa(dp4099
g7
I72
sg17
VC0042029
p4100
sg10
I24
sg11
Vurinary tract infections
p4101
sg13
I3
sasa(dp4102
g2
VTo identify mutation in SCNN1B and SCNN1G genes in an adolescent with suspicious Liddle syndrome and his family members and to explore the screening target subjects of Liddle syndrome.
p4103
sg4
(lp4104
(dp4105
g7
I24
sg8
VP51168
p4106
sg10
I6
sg11
VSCNN1B
p4107
sg13
I1
sa(dp4108
g7
I35
sg8
VP51168
p4109
sg10
I12
sg11
VSCNN1G genes
p4110
sg13
I2
sasg14
(lp4111
(dp4112
g7
I81
sg17
VC0221043
p4113
sg10
I15
sg11
VLiddle syndrome
p4114
sg13
I2
sa(dp4115
g7
I81
sg17
VC0221043
p4116
sg10
I15
sg11
VLiddle syndrome
p4117
sg13
I2
sasa(dp4118
g2
VGenetic analysis of the C-terminus of SCNN1B and SCNN1G genes was conducted in an adolescent, with treatment-resistant hypertension and hypokalemia, who was suspected of having Liddle syndrome, and his family members.
p4119
sg4
(lp4120
(dp4121
g7
I38
sg8
VP51168
p4122
sg10
I6
sg11
VSCNN1B
p4123
sg13
I1
sa(dp4124
g7
I49
sg8
VP51168
p4125
sg10
I12
sg11
VSCNN1G genes
p4126
sg13
I2
sasg14
(lp4127
(dp4128
g7
I119
sg17
VC0020538
p4129
sg10
I12
sg11
Vhypertension
p4130
sg13
I1
sa(dp4131
g7
I177
sg17
VC0221043
p4132
sg10
I15
sg11
VLiddle syndrome
p4133
sg13
I2
sasa(dp4134
g2
VIn adulthood, an induced nephron-specific deficiency of AlfaENaC (Scnn1a) resulted in pseudohypoaldosteronism type 1 (PHA-1) with sodium loss, hyperkalemia, and metabolic acidosis that is rescued through high-sodium/low-potassium (HNa+/LK+) diet.
p4135
sg4
(lp4136
(dp4137
g7
I86
sg8
VP37088
p4138
sg10
I30
sg11
Vpseudohypoaldosteronism type 1
p4139
sg13
I3
sa(dp4140
g7
I66
sg8
VP37088
p4141
sg10
I6
sg11
VScnn1a
p4142
sg13
I1
sa(dp4143
g7
I118
sg8
g24
sg10
I5
sg11
VPHA-1
p4144
sg13
I1
sasg14
(lp4145
(dp4146
g7
I86
sg17
VC0268436
p4147
sg10
I30
sg11
Vpseudohypoaldosteronism type 1
p4148
sg13
I3
sa(dp4149
g7
I118
sg17
VC0268436
p4150
sg10
I5
sg11
VPHA-1
p4151
sg13
I1
sa(dp4152
g7
I161
sg17
VC0220981
p4153
sg10
I18
sg11
Vmetabolic acidosis
p4154
sg13
I2
sasa(dp4155
g2
VLiddle syndrome is an autosomal dominant genetic condition that causes hypertension and hypokalemia due to a gain-of-function mutation in the SCNN1B or SCNN1G genes which code for the epithelial sodium channel in the kidney.
p4156
sg4
(lp4157
(dp4158
g7
I142
sg8
VP51168
p4159
sg10
I6
sg11
VSCNN1B
p4160
sg13
I1
sa(dp4161
g7
I152
sg8
VP51168
p4162
sg10
I12
sg11
VSCNN1G genes
p4163
sg13
I2
sasg14
(lp4164
(dp4165
g7
I41
sg17
VC0019247
p4166
sg10
I17
sg11
Vgenetic condition
p4167
sg13
I2
sa(dp4168
g7
I0
sg17
VC0221043
p4169
sg10
I15
sg11
VLiddle syndrome
p4170
sg13
I2
sa(dp4171
g7
I71
sg17
VC0020538
p4172
sg10
I12
sg11
Vhypertension
p4173
sg13
I1
sasa(dp4174
g2
VLoss-of-function mutations of the MR are responsible for renal pseudohypoaldosteronism type 1 (PHA1), a rare disease of mineralocorticoid resistance presenting in the newborn with weight loss, failure to thrive, vomiting and dehydration, associated with hyperkalemia and metabolic acidosis, despite extremely elevated levels of plasma renin and aldosterone.
p4175
sg4
(lp4176
(dp4177
g7
I57
sg8
VP37088
p4178
sg10
I36
sg11
Vrenal pseudohypoaldosteronism type 1
p4179
sg13
I4
sa(dp4180
g7
I328
sg8
VP00797
p4181
sg10
I12
sg11
Vplasma renin
p4182
sg13
I2
sa(dp4183
g7
I95
sg8
VP37088
p4184
sg10
I4
sg11
VPHA1
p4185
sg13
I1
sasg14
(lp4186
(dp4187
g7
I212
sg17
VC0042963
p4188
sg10
I8
sg11
Vvomiting
p4189
sg13
I1
sa(dp4190
g7
I104
sg17
VC0678236
p4191
sg10
I12
sg11
Vrare disease
p4192
sg13
I2
sa(dp4193
g7
I271
sg17
VC0220981
p4194
sg10
I18
sg11
Vmetabolic acidosis
p4195
sg13
I2
sa(dp4196
g7
I193
sg17
VC0015544
p4197
sg10
I17
sg11
Vfailure to thrive
p4198
sg13
I3
sa(dp4199
g7
I95
sg17
VC0268436
p4200
sg10
I4
sg11
VPHA1
p4201
sg13
I1
sa(dp4202
g7
I63
sg17
VC0268436
p4203
sg10
I30
sg11
Vpseudohypoaldosteronism type 1
p4204
sg13
I3
sa(dp4205
g7
I225
sg17
VC0011175
p4206
sg10
I11
sg11
Vdehydration
p4207
sg13
I1
sasa(dp4208
g2
VIn the presence of pyelonephritis, the same biochemical picture can occur with transient type 1 pseudohypoaldosteronism (PHA-1) also termed type 4 renal tubular acidosis.
p4209
sg4
(lp4210
(dp4211
g7
I121
sg8
g24
sg10
I5
sg11
VPHA-1
p4212
sg13
I1
sa(dp4213
g7
I56
sg8
g24
sg10
I63
sg11
Vpicture can occur with transient type 1 pseudohypoaldosteronism
p4214
sg13
I8
sasg14
(lp4215
(dp4216
g7
I147
sg17
VC0001126
p4217
sg10
I22
sg11
Vrenal tubular acidosis
p4218
sg13
I3
sa(dp4219
g7
I96
sg17
VC0033805
p4220
sg10
I23
sg11
Vpseudohypoaldosteronism
p4221
sg13
I1
sa(dp4222
g7
I121
sg17
VC0030779
p4223
sg10
I3
sg11
VPHA
p4224
sg13
I1
sa(dp4225
g7
I19
sg17
VC0034186
p4226
sg10
I14
sg11
Vpyelonephritis
p4227
sg13
I1
sasa(dp4228
g2
VPseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease characterized by resistance to aldosterone, and the renal form of PHA1 is associated with heterozygous inactivating mutations in NR3C2, which encodes mineralocorticoid receptor (MR).
p4229
sg4
(lp4230
(dp4231
g7
I32
sg8
VP37088
p4232
sg10
I4
sg11
VPHA1
p4233
sg13
I1
sa(dp4234
g7
I32
sg8
VP37088
p4235
sg10
I4
sg11
VPHA1
p4236
sg13
I1
sa(dp4237
g7
I193
sg8
VP08235
p4238
sg10
I5
sg11
VNR3C2
p4239
sg13
I1
sa(dp4240
g7
I0
sg8
VP37088
p4241
sg10
I30
sg11
VPseudohypoaldosteronism type 1
p4242
sg13
I3
sasg14
(lp4243
(dp4244
g7
I32
sg17
VC0268436
p4245
sg10
I4
sg11
VPHA1
p4246
sg13
I1
sa(dp4247
g7
I32
sg17
VC0268436
p4248
sg10
I4
sg11
VPHA1
p4249
sg13
I1
sa(dp4250
g7
I0
sg17
VC0268436
p4251
sg10
I30
sg11
VPseudohypoaldosteronism type 1
p4252
sg13
I3
sa(dp4253
g7
I48
sg17
VC0019247
p4254
sg10
I15
sg11
Vgenetic disease
p4255
sg13
I2
sasa(dp4256
g2
VRecent work has identified cancer-associated U2AF35 missense mutations in two zinc-finger (ZnF) domains, but little is known about Q157R/P substitutions within the second ZnF.
p4257
sg4
(lp4258
(dp4259
g7
I45
sg8
g24
sg10
I6
sg11
VU2AF35
p4260
sg13
I1
sasg14
(lp4261
(dp4262
g7
I27
sg17
VC0006826
p4263
sg10
I6
sg11
Vcancer
p4264
sg13
I1
sasa(dp4265
g2
VZinc finger (ZNF) proteins, a diverse family of proteins, have multiple biological functions in cancer.
p4266
sg4
(lp4267
(dp4268
g7
I0
sg8
g24
sg10
I26
sg11
VZinc finger (ZNF) proteins
p4269
sg13
I4
sasg14
(lp4270
(dp4271
g7
I96
sg17
VC0006826
p4272
sg10
I6
sg11
Vcancer
p4273
sg13
I1
sasa(dp4274
g2
VHowever, the function and underlying mechanisms of ZNF185 in the tumorigenesis of lung adenocarcinoma (LAC) remain unclear.
p4275
sg4
(lp4276
(dp4277
g7
I51
sg8
g24
sg10
I6
sg11
VZNF185
p4278
sg13
I1
sasg14
(lp4279
(dp4280
g7
I103
sg17
VC0152013
p4281
sg10
I3
sg11
VLAC
p4282
sg13
I1
sa(dp4283
g7
I82
sg17
VC0152013
p4284
sg10
I19
sg11
Vlung adenocarcinoma
p4285
sg13
I2
sa(dp4286
g7
I65
sg17
VC0007621
p4287
sg10
I13
sg11
Vtumorigenesis
p4288
sg13
I1
sasa(dp4289
g2
VWe found that the protein expression of ZNF185 was significantly downregulated in LAC tissues compared with the adjacent non-cancerous tissues (ANCT) (37.10% vs 58.06%, P=0.015), and was negatively correlated with the lymph node metastasis of the LAC patients (P=0.005).
p4290
sg4
(lp4291
(dp4292
g7
I40
sg8
g24
sg10
I6
sg11
VZNF185
p4293
sg13
I1
sasg14
(lp4294
(dp4295
g7
I218
sg17
VC0686619
p4296
sg10
I21
sg11
Vlymph node metastasis
p4297
sg13
I3
sasa(dp4298
g2
VIn view of the exploitation of tetraspanins by organisms for survival, these proteins could be targeted using specific antibodies, recombinant large extracellular loop (LEL) domains, small-molecule mimetics and siRNAs as potential novel and efficacious putative targets to combat African trypanosomiasis by killing the tsetse fly vector.
p4299
sg4
(lp4300
sg14
(lp4301
(dp4302
g7
I280
sg17
VC0041228
p4303
sg10
I23
sg11
VAfrican trypanosomiasis
p4304
sg13
I2
sa(dp4305
g7
I143
sg17
VC1846721
p4306
sg10
I24
sg11
Vlarge extracellular loop
p4307
sg13
I3
sa(dp4308
g7
I169
sg17
VC1846721
p4309
sg10
I3
sg11
VLEL
p4310
sg13
I1
sasa(dp4311
g2
VInfection of hepatocytic cells by two major pathogens, the hepatitis C virus and the malaria parasite, also requires the tetraspanin CD81.
p4312
sg4
(lp4313
(dp4314
g7
I121
sg8
g24
sg10
I16
sg11
Vtetraspanin CD81
p4315
sg13
I2
sasg14
(lp4316
(dp4317
g7
I0
sg17
VC0009450
p4318
sg10
I9
sg11
VInfection
p4319
sg13
I1
sa(dp4320
g7
I59
sg17
VC0019196
p4321
sg10
I11
sg11
Vhepatitis C
p4322
sg13
I2
sa(dp4323
g7
I85
sg17
VC0024530
p4324
sg10
I7
sg11
Vmalaria
p4325
sg13
I1
sasa(dp4326
g2
VOur results unravel a functional link between CD81 and cholesterol during infection by malaria parasites, and illustrate that tetraspanin microdomains constitute a novel type of membrane microdomains that could be used by pathogens for infection.
p4327
sg4
(lp4328
(dp4329
g7
I46
sg8
VP60033
p4330
sg10
I4
sg11
VCD81
p4331
sg13
I1
sa(dp4332
g7
I126
sg8
g24
sg10
I24
sg11
Vtetraspanin microdomains
p4333
sg13
I2
sasg14
(lp4334
(dp4335
g7
I87
sg17
VC0024530
p4336
sg10
I7
sg11
Vmalaria
p4337
sg13
I1
sa(dp4338
g7
I74
sg17
VC0009450
p4339
sg10
I9
sg11
Vinfection
p4340
sg13
I1
sa(dp4341
g7
I74
sg17
VC0009450
p4342
sg10
I9
sg11
Vinfection
p4343
sg13
I1
sasa(dp4344
g2
VThe CXCL11 gene may also play a role in BK polyomavirus-associated nephropathy.
p4345
sg4
(lp4346
(dp4347
g7
I4
sg8
g24
sg10
I11
sg11
VCXCL11 gene
p4348
sg13
I2
sasg14
(lp4349
(dp4350
g7
I43
sg17
VC1696946
p4351
sg10
I35
sg11
Vpolyomavirus-associated nephropathy
p4352
sg13
I2
sasa(dp4353
g2
VOur aim was to compare expression levels of CXCL11 in BK polyomavirus-infected versus noninfected kidney transplant patients with nephropathy and healthy controls.
p4354
sg4
(lp4355
(dp4356
g7
I44
sg8
g24
sg10
I6
sg11
VCXCL11
p4357
sg13
I1
sasg14
(lp4358
(dp4359
g7
I130
sg17
VC0022658
p4360
sg10
I11
sg11
Vnephropathy
p4361
sg13
I1
sasa(dp4362
g2
VTaken together, the results indicated that sorafenib had protective effects against renal fibrosis; its mechanism of action was associated with inhibition of macrophage infiltration via the CXCR3/CXCL11 pathway.
p4363
sg4
(lp4364
(dp4365
g7
I190
sg8
VP49682
p4366
sg10
I5
sg11
VCXCR3
p4367
sg13
I1
sa(dp4368
g7
I196
sg8
g24
sg10
I6
sg11
VCXCL11
p4369
sg13
I1
sasg14
(lp4370
(dp4371
g7
I169
sg17
VC0332448
p4372
sg10
I12
sg11
Vinfiltration
p4373
sg13
I1
sa(dp4374
g7
I84
sg17
VC0151650
p4375
sg10
I14
sg11
Vrenal fibrosis
p4376
sg13
I2
sasa(dp4377
g2
VUrinary mRNA levels of CXCL10 and CXCL11 are decreased, and those of collagen I A1 chain and fibronectin are increased in diabetic nephropathy.
p4378
sg4
(lp4379
(dp4380
g7
I23
sg8
VP02778
p4381
sg10
I6
sg11
VCXCL10
p4382
sg13
I1
sa(dp4383
g7
I34
sg8
g24
sg10
I6
sg11
VCXCL11
p4384
sg13
I1
sasg14
(lp4385
(dp4386
g7
I122
sg17
VC0011881
p4387
sg10
I20
sg11
Vdiabetic nephropathy
p4388
sg13
I2
sasa(dp4389
g2
VFor this purpose, serum concentration of interleukin 2 (IL2), interleukin 10 (IL10), interferon-gamma (IFNG), Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9) were measured in blood samples obtained from F(2) piglets (n = 334) of a Duroc x Pietrain resource population (DUPI) after Mycoplasma hypopneumoniae (Mh), tetanus toxoid (TT) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccination at 6, 9 and 15 weeks of age.
p4390
sg4
(lp4391
(dp4392
g7
I78
sg8
VP22301
p4393
sg10
I4
sg11
VIL10
p4394
sg13
I1
sa(dp4395
g7
I164
sg8
g24
sg10
I4
sg11
VTLR9
p4396
sg13
I1
sa(dp4397
g7
I56
sg8
VP60568
p4398
sg10
I3
sg11
VIL2
p4399
sg13
I1
sa(dp4400
g7
I142
sg8
g24
sg10
I20
sg11
VToll-like receptor 9
p4401
sg13
I3
sa(dp4402
g7
I41
sg8
VP60568
p4403
sg10
I13
sg11
Vinterleukin 2
p4404
sg13
I2
sa(dp4405
g7
I110
sg8
g24
sg10
I20
sg11
VToll-like receptor 2
p4406
sg13
I3
sa(dp4407
g7
I132
sg8
g24
sg10
I4
sg11
VTLR2
p4408
sg13
I1
sa(dp4409
g7
I85
sg8
VP01579
p4410
sg10
I16
sg11
Vinterferon-gamma
p4411
sg13
I1
sa(dp4412
g7
I103
sg8
VP01579
p4413
sg10
I4
sg11
VIFNG
p4414
sg13
I1
sa(dp4415
g7
I62
sg8
VP22301
p4416
sg10
I14
sg11
Vinterleukin 10
p4417
sg13
I2
sasg14
(lp4418
(dp4419
g7
I325
sg17
VC0039614
p4420
sg10
I7
sg11
Vtetanus
p4421
sg13
I1
sa(dp4422
g7
I349
sg17
VC0376538
p4423
sg10
I45
sg11
VPorcine Reproductive and Respiratory Syndrome
p4424
sg13
I5
sa(dp4425
g7
I293
sg17
VC0026936
p4426
sg10
I10
sg11
VMycoplasma
p4427
sg13
I1
sasa(dp4428
g2
VNot only TLR-2 gene polymorphisms but also immunoglobulins (IgG, IgM, IgA), IgG subsets (G1, G2, G3), and specific antibody levels (anti-tetanus and anti-hemophilus influenza) were determined to exclude humoral immunodeficiencies.
p4429
sg4
(lp4430
(dp4431
g7
I65
sg8
VP29965
p4432
sg10
I3
sg11
VIgM
p4433
sg13
I1
sa(dp4434
g7
I9
sg8
g24
sg10
I10
sg11
VTLR-2 gene
p4435
sg13
I2
sa(dp4436
g7
I70
sg8
VP11912
p4437
sg10
I3
sg11
VIgA
p4438
sg13
I1
sa(dp4439
g7
I43
sg8
g24
sg10
I15
sg11
Vimmunoglobulins
p4440
sg13
I1
sasg14
(lp4441
(dp4442
g7
I165
sg17
VC0021400
p4443
sg10
I9
sg11
Vinfluenza
p4444
sg13
I1
sa(dp4445
g7
I211
sg17
VC0021051
p4446
sg10
I18
sg11
Vimmunodeficiencies
p4447
sg13
I1
sa(dp4448
g7
I137
sg17
VC0039614
p4449
sg10
I7
sg11
Vtetanus
p4450
sg13
I1
sasa(dp4451
g2
VWhile glutamate is not a known OAT4 or OATP2B1 substrate, we propose that its high intracellular concentration has the potential to drive accumulation of substrates from the fetal circulation.
p4452
sg4
(lp4453
(dp4454
g7
I39
sg8
g24
sg10
I7
sg11
VOATP2B1
p4455
sg13
I1
sa(dp4456
g7
I31
sg8
g24
sg10
I4
sg11
VOAT4
p4457
sg13
I1
sasg14
(lp4458
sa(dp4459
g2
VCycling of glutamate across the placenta involving efflux via OAT4 and OATP2B1 and subsequent reuptake will drive placental uptake of organic anions from the fetal circulation.
p4460
sg4
(lp4461
(dp4462
g7
I71
sg8
g24
sg10
I7
sg11
VOATP2B1
p4463
sg13
I1
sa(dp4464
g7
I62
sg8
g24
sg10
I4
sg11
VOAT4
p4465
sg13
I1
sasg14
(lp4466
sa(dp4467
g2
VEfflux transport of olmesartan via OAT4 from syncytiotrophoblasts to the fetal circulation might be facilitated in the presence of an inwardly directed physiological chloride gradient and extracellular DHEAS.
p4468
sg4
(lp4469
(dp4470
g7
I35
sg8
g24
sg10
I4
sg11
VOAT4
p4471
sg13
I1
sasg14
(lp4472
sa(dp4473
g2
VThis is probably the first case report of cobalamin intracellular metabolism defect (CblC/CblD/CblF/CblJ or ABCD4) presenting as diabetic ketoacidosis.
p4474
sg4
(lp4475
(dp4476
g7
I85
sg8
g24
sg10
I4
sg11
VCblC
p4477
sg13
I1
sa(dp4478
g7
I108
sg8
g24
sg10
I5
sg11
VABCD4
p4479
sg13
I1
sa(dp4480
g7
I90
sg8
g24
sg10
I4
sg11
VCblD
p4481
sg13
I1
sa(dp4482
g7
I95
sg8
g24
sg10
I4
sg11
VCblF
p4483
sg13
I1
sasg14
(lp4484
(dp4485
g7
I129
sg17
VC0011880
p4486
sg10
I21
sg11
Vdiabetic ketoacidosis
p4487
sg13
I2
sa(dp4488
g7
I95
sg17
VC1848578
p4489
sg10
I4
sg11
VCblF
p4490
sg13
I1
sasa(dp4491
g2
VModerate to severe sensorineural hearing loss and progressive RP characterizes Usher syndrome type IIa (USH2A), which maps to the long arm of chromosome 1q41.
p4492
sg4
(lp4493
(dp4494
g7
I104
sg8
g24
sg10
I5
sg11
VUSH2A
p4495
sg13
I1
sasg14
(lp4496
(dp4497
g7
I104
sg17
VC1848634
p4498
sg10
I5
sg11
VUSH2A
p4499
sg13
I1
sa(dp4500
g7
I79
sg17
VC0271097
p4501
sg10
I14
sg11
VUsher syndrome
p4502
sg13
I2
sa(dp4503
g7
I19
sg17
VC0018784
p4504
sg10
I26
sg11
Vsensorineural hearing loss
p4505
sg13
I3
sasa(dp4506
g2
VUsher syndrome type IIa (OMIM 276901), an autosomal recessive disorder characterized by moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, maps to the long arm of human chromosome 1q41 between markers AFM268ZD1 and AFM144XF2.
p4507
sg4
(lp4508
sg14
(lp4509
(dp4510
g7
I150
sg17
VC0035334
p4511
sg10
I20
sg11
Vretinitis pigmentosa
p4512
sg13
I2
sa(dp4513
g7
I0
sg17
VC0271097
p4514
sg10
I14
sg11
VUsher syndrome
p4515
sg13
I2
sa(dp4516
g7
I107
sg17
VC0018784
p4517
sg10
I26
sg11
Vsensorineural hearing loss
p4518
sg13
I3
sasa(dp4519
g2
VModerate to severe non-progressive high frequency hearing loss with RP and normal vestibular function describes Usher syndrome type IIa, which has been localized to 1q41.
p4520
sg4
(lp4521
sg14
(lp4522
(dp4523
g7
I35
sg17
VC0018780
p4524
sg10
I27
sg11
Vhigh frequency hearing loss
p4525
sg13
I4
sa(dp4526
g7
I112
sg17
VC0271097
p4527
sg10
I14
sg11
VUsher syndrome
p4528
sg13
I2
sasa(dp4529
g2
VAs one subtype of the class IIa HDACs, HDAC9 is capable to repress/de-repress their target genes in tumor, inflammation, atherosclerosis and metabolic diseases.
p4530
sg4
(lp4531
(dp4532
g7
I22
sg8
g24
sg10
I15
sg11
Vclass IIa HDACs
p4533
sg13
I3
sa(dp4534
g7
I39
sg8
g24
sg10
I5
sg11
VHDAC9
p4535
sg13
I1
sasg14
(lp4536
(dp4537
g7
I100
sg17
VC0027651
p4538
sg10
I5
sg11
Vtumor
p4539
sg13
I1
sa(dp4540
g7
I107
sg17
VC0021368
p4541
sg10
I12
sg11
Vinflammation
p4542
sg13
I1
sa(dp4543
g7
I141
sg17
VC0025517
p4544
sg10
I18
sg11
Vmetabolic diseases
p4545
sg13
I2
sa(dp4546
g7
I121
sg17
VC0004153
p4547
sg10
I15
sg11
Vatherosclerosis
p4548
sg13
I1
sasa(dp4549
g2
VTaken together, our data suggest that SNP rs2107595 may contribute to coronary atherosclerosis and CAD risk through a possible mechanism of regulating HDAC9 expression and gene-environment interactions.
p4550
sg4
(lp4551
(dp4552
g7
I151
sg8
g24
sg10
I5
sg11
VHDAC9
p4553
sg13
I1
sasg14
(lp4554
(dp4555
g7
I99
sg17
VC0010054
p4556
sg10
I3
sg11
VCAD
p4557
sg13
I1
sa(dp4558
g7
I70
sg17
VC0010054
p4559
sg10
I24
sg11
Vcoronary atherosclerosis
p4560
sg13
I2
sasa(dp4561
g2
VThese results suggest that HDAC9 may participate in ox-LDL-induced endothelial damage and inflammation during atherosclerosis development.
p4562
sg4
(lp4563
(dp4564
g7
I27
sg8
g24
sg10
I5
sg11
VHDAC9
p4565
sg13
I1
sasg14
(lp4566
(dp4567
g7
I90
sg17
VC0021368
p4568
sg10
I12
sg11
Vinflammation
p4569
sg13
I1
sa(dp4570
g7
I110
sg17
VC0004153
p4571
sg10
I15
sg11
Vatherosclerosis
p4572
sg13
I1
sasa(dp4573
g2
VOur results also supported robust associations with ischaemic stroke for four other loci that have been reported in previous studies, including PITX2 (first stage OR 1*39, 1*29-1*49, p=3*26 x 10-19; joint OR 1*37, 1*30-1*45, p=2*79 x 10-32) and ZFHX3 (first stage OR 1*19, 1*11-1*27, p=2*93 x 10-7; joint OR 1*17, 1*11-1*23, p=2*29 x 10-10) for cardioembolic stroke, and HDAC9 (first stage OR 1*29, 1*18-1*42, p=3*50 x 10-8; joint OR 1*24, 1*15-1*33, p=4*52 x 10-9) for large artery atherosclerosis stroke.
p4574
sg4
(lp4575
(dp4576
g7
I144
sg8
g24
sg10
I5
sg11
VPITX2
p4577
sg13
I1
sa(dp4578
g7
I371
sg8
g24
sg10
I5
sg11
VHDAC9
p4579
sg13
I1
sa(dp4580
g7
I245
sg8
g24
sg10
I5
sg11
VZFHX3
p4581
sg13
I1
sasg14
(lp4582
(dp4583
g7
I62
sg17
VC0038454
p4584
sg10
I6
sg11
Vstroke
p4585
sg13
I1
sa(dp4586
g7
I52
sg17
VC0948008
p4587
sg10
I16
sg11
Vischaemic stroke
p4588
sg13
I2
sa(dp4589
g7
I483
sg17
VC0004153
p4590
sg10
I15
sg11
Vatherosclerosis
p4591
sg13
I1
sa(dp4592
g7
I345
sg17
VC1531624
p4593
sg10
I20
sg11
Vcardioembolic stroke
p4594
sg13
I2
sasa(dp4595
g2
VIn this study, we investigated the candidacy and directionality of HDAC9 in atherosclerosis and analyzed associations between risk alleles at 7p21.1 and plaque characteristics.
p4596
sg4
(lp4597
(dp4598
g7
I67
sg8
g24
sg10
I5
sg11
VHDAC9
p4599
sg13
I1
sasg14
(lp4600
(dp4601
g7
I76
sg17
VC0004153
p4602
sg10
I15
sg11
Vatherosclerosis
p4603
sg13
I1
sa(dp4604
g7
I153
sg17
VC0011389
p4605
sg10
I6
sg11
Vplaque
p4606
sg13
I1
sasa(dp4607
g2
VTargeted inhibition of HDAC9 might be a viable strategy to prevent atherosclerosis.
p4608
sg4
(lp4609
(dp4610
g7
I23
sg8
g24
sg10
I5
sg11
VHDAC9
p4611
sg13
I1
sasg14
(lp4612
(dp4613
g7
I67
sg17
VC0004153
p4614
sg10
I15
sg11
Vatherosclerosis
p4615
sg13
I1
sasa(dp4616
g2
VThe ability of a pulsed oxygen delivery system (Puritan-Bennett Companion Oxygen Saver (COS-5) to track respiratory rate during exercise and the oxygenation achieved during the exercise while oxygen was being delivered by this system was compared to that attained while oxygen was delivered continuously in six patients with chronic obstructive pulmonary disease (COPD) and six patients with idiopathic pulmonary fibrosis (IPF).
p4617
sg4
(lp4618
sg14
(lp4619
(dp4620
g7
I325
sg17
VC0024117
p4621
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p4622
sg13
I4
sa(dp4623
g7
I392
sg17
VC3161101
p4624
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p4625
sg13
I3
sa(dp4626
g7
I423
sg17
VC3161101
p4627
sg10
I3
sg11
VIPF
p4628
sg13
I1
sa(dp4629
g7
I364
sg17
VC0024117
p4630
sg10
I4
sg11
VCOPD
p4631
sg13
I1
sasa(dp4632
g2
VPeripheral blood monocyte surface marker (CD14, CD16, CD163, CSF1R, CCR2, CCR4, CCR5, CXCR3, CXCR4, CX3CR1, HLA-DR, CD62L, SIGLEC-1) expression and capacity for phagocytosis, oxidative burst and LPS-stimulated TNF production were assessed in patients with hepatitis C (HCV) (n = 39) or non-alcoholic fatty liver disease (NAFLD) (n = 34) (classified as non-advanced disease, compensated cirrhosis and decompensated cirrhosis) and healthy controls (n = 11) by flow cytometry.
p4633
sg4
(lp4634
(dp4635
g7
I48
sg8
VP08637
p4636
sg10
I4
sg11
VCD16
p4637
sg13
I1
sa(dp4638
g7
I100
sg8
VP78423
p4639
sg10
I6
sg11
VCX3CR1
p4640
sg13
I1
sa(dp4641
g7
I80
sg8
VP32302
p4642
sg10
I4
sg11
VCCR5
p4643
sg13
I1
sa(dp4644
g7
I74
sg8
VP51679
p4645
sg10
I4
sg11
VCCR4
p4646
sg13
I1
sa(dp4647
g7
I86
sg8
VP49682
p4648
sg10
I5
sg11
VCXCR3
p4649
sg13
I1
sa(dp4650
g7
I54
sg8
g24
sg10
I5
sg11
VCD163
p4651
sg13
I1
sa(dp4652
g7
I210
sg8
VP01375
p4653
sg10
I3
sg11
VTNF
p4654
sg13
I1
sa(dp4655
g7
I61
sg8
VP09619
p4656
sg10
I5
sg11
VCSF1R
p4657
sg13
I1
sa(dp4658
g7
I108
sg8
VP30486
p4659
sg10
I6
sg11
VHLA-DR
p4660
sg13
I1
sa(dp4661
g7
I93
sg8
VP61073
p4662
sg10
I5
sg11
VCXCR4
p4663
sg13
I1
sa(dp4664
g7
I123
sg8
g24
sg10
I8
sg11
VSIGLEC-1
p4665
sg13
I1
sa(dp4666
g7
I116
sg8
VP14151
p4667
sg10
I5
sg11
VCD62L
p4668
sg13
I1
sa(dp4669
g7
I68
sg8
VP41597
p4670
sg10
I4
sg11
VCCR2
p4671
sg13
I1
sa(dp4672
g7
I42
sg8
VP08571
p4673
sg10
I4
sg11
VCD14
p4674
sg13
I1
sasg14
(lp4675
(dp4676
g7
I374
sg17
VC1608426
p4677
sg10
I21
sg11
Vcompensated cirrhosis
p4678
sg13
I2
sa(dp4679
g7
I400
sg17
VC1619727
p4680
sg10
I23
sg11
Vdecompensated cirrhosis
p4681
sg13
I2
sa(dp4682
g7
I321
sg17
VC0400966
p4683
sg10
I5
sg11
VNAFLD
p4684
sg13
I1
sa(dp4685
g7
I195
sg17
VC0175697
p4686
sg10
I3
sg11
VLPS
p4687
sg13
I1
sa(dp4688
g7
I256
sg17
VC0019196
p4689
sg10
I11
sg11
Vhepatitis C
p4690
sg13
I2
sa(dp4691
g7
I286
sg17
VC0400966
p4692
sg10
I33
sg11
Vnon-alcoholic fatty liver disease
p4693
sg13
I4
sasa(dp4694
g2
VSoluble CD163 (sCD163), a marker of Kupffer cell activation detectable in serum, correlates with inflammation and fibrosis in chronic viral hepatitis, but its role in nonalcoholic fatty liver disease is unknown.
p4695
sg4
(lp4696
(dp4697
g7
I15
sg8
g24
sg10
I6
sg11
VsCD163
p4698
sg13
I1
sa(dp4699
g7
I0
sg8
g24
sg10
I13
sg11
VSoluble CD163
p4700
sg13
I2
sasg14
(lp4701
(dp4702
g7
I126
sg17
VC0276623
p4703
sg10
I23
sg11
Vchronic viral hepatitis
p4704
sg13
I3
sa(dp4705
g7
I114
sg17
VC0016059
p4706
sg10
I8
sg11
Vfibrosis
p4707
sg13
I1
sa(dp4708
g7
I97
sg17
VC0021368
p4709
sg10
I12
sg11
Vinflammation
p4710
sg13
I1
sa(dp4711
g7
I167
sg17
VC0400966
p4712
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p4713
sg13
I4
sasa(dp4714
g2
VWe hypothesized that sCD163 would correlate with nonalcoholic fatty liver disease activity and fibrosis.
p4715
sg4
(lp4716
(dp4717
g7
I21
sg8
g24
sg10
I6
sg11
VsCD163
p4718
sg13
I1
sasg14
(lp4719
(dp4720
g7
I49
sg17
VC0400966
p4721
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p4722
sg13
I4
sa(dp4723
g7
I95
sg17
VC0016059
p4724
sg10
I8
sg11
Vfibrosis
p4725
sg13
I1
sasa(dp4726
g2
Vdermatoses presenting with erythematous-desquamative patches/plaques (plaque psoriasis, eczematous dermatitis, pityriasis rosea, mycosis fungoides and subacute cutaneous lupus erythematosus), papulosquamous/papulokeratotic dermatoses (lichen planus, pityriasis rosea, papulosquamous sarcoidosis, guttate psoriasis, pityriasis lichenoides chronica, classical pityriasis rubra pilaris, porokeratosis, lymphomatoid papulosis, papulosquamous chronic GVHD, parakeratosis variegata, Grover disease, Darier disease and BRAF-inhibitor-induced acantholytic dyskeratosis), facial inflammatory skin diseases (rosacea, seborrheic dermatitis, discoid lupus erythematosus, sarcoidosis, cutaneous leishmaniasis, lupus vulgaris, granuloma faciale and demodicidosis), acquired keratodermas (chronic hand eczema, palmar psoriasis, keratoderma due to mycosis fungoides, keratoderma resulting from pityriasis rubra pilaris, tinea manuum, palmar lichen planus and aquagenic palmar keratoderma), sclero-atrophic dermatoses (necrobiosis lipoidica, morphea and cutaneous lichen sclerosus), hypopigmented macular diseases (extragenital guttate lichen sclerosus, achromic pityriasis versicolor, guttate vitiligo, idiopathic guttate hypomelanosis, progressive macular hypomelanosis and postinflammatory hypopigmentations), hyperpigmented maculopapular diseases (pityriasis versicolor, lichen planus pigmentosus, Gougerot-Carteaud syndrome, Dowling-Degos disease, erythema ab igne, macular amyloidosis, lichen amyloidosus, friction melanosis, terra firma-forme dermatosis, urticaria pigmentosa and telangiectasia macularis eruptiva perstans), itchy papulonodular dermatoses (hypertrophic lichen planus, prurigo nodularis, nodular scabies and acquired perforating dermatosis), erythrodermas (due to psoriasis, atopic dermatitis, mycosis fungoides, pityriasis rubra pilaris and scabies), noninfectious balanitis (Zoon's plasma cell balanitis, psoriatic balanitis, seborrheic dermatitis and non-specific balanitis) and erythroplasia of Queyrat, inflammatory cicatricial alopecias (scalp discoid lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia and folliculitis decalvans), nonscarring alopecias (alopecia areata, trichotillomania, androgenetic alopecia and telogen effluvium) and scaling disorders of the scalp (tinea capitis, scalp psoriasis, seborrheic dermatitis and pityriasis amiantacea).
p4727
sg4
(lp4728
sg14
(lp4729
(dp4730
g7
I77
sg17
VC0033860
p4731
sg10
I9
sg11
Vpsoriasis
p4732
sg13
I1
sa(dp4733
g7
I88
sg17
VC0013595
p4734
sg10
I21
sg11
Veczematous dermatitis
p4735
sg13
I2
sa(dp4736
g7
I607
sg17
VC0036508
p4737
sg10
I21
sg11
Vseborrheic dermatitis
p4738
sg13
I2
sa(dp4739
g7
I2316
sg17
VC0406326
p4740
sg10
I15
sg11
Vscalp psoriasis
p4741
sg13
I2
sa(dp4742
g7
I129
sg17
VC0026948
p4743
sg10
I17
sg11
Vmycosis fungoides
p4744
sg13
I2
sa(dp4745
g7
I358
sg17
VC0032027
p4746
sg10
I24
sg11
Vpityriasis rubra pilaris
p4747
sg13
I3
sa(dp4748
g7
I1413
sg17
VC0406811
p4749
sg10
I21
sg11
VDowling-Degos disease
p4750
sg13
I2
sa(dp4751
g7
I235
sg17
VC0023646
p4752
sg10
I13
sg11
Vlichen planus
p4753
sg13
I2
sa(dp4754
g7
I1111
sg17
VC0406644
p4755
sg10
I24
sg11
Vguttate lichen sclerosus
p4756
sg13
I3
sa(dp4757
g7
I1694
sg17
VC0344064
p4758
sg10
I15
sg11
Vnodular scabies
p4759
sg13
I2
sa(dp4760
g7
I1177
sg17
VC0042900
p4761
sg10
I8
sg11
Vvitiligo
p4762
sg13
I1
sa(dp4763
g7
I1723
sg17
VC1304435
p4764
sg10
I22
sg11
Vperforating dermatosis
p4765
sg13
I2
sa(dp4766
g7
I283
sg17
VC0036202
p4767
sg10
I11
sg11
Vsarcoidosis
p4768
sg13
I1
sa(dp4769
g7
I1025
sg17
VC0036420
p4770
sg10
I7
sg11
Vmorphea
p4771
sg13
I1
sa(dp4772
g7
I0
sg17
VC0037274
p4773
sg10
I10
sg11
Vdermatoses
p4774
sg13
I1
sa(dp4775
g7
I2301
sg17
VC0040250
p4776
sg10
I13
sg11
Vtinea capitis
p4777
sg13
I2
sa(dp4778
g7
I1146
sg17
VC0040262
p4779
sg10
I21
sg11
Vpityriasis versicolor
p4780
sg13
I2
sa(dp4781
g7
I981
sg17
VC0333641
p4782
sg10
I8
sg11
Vatrophic
p4783
sg13
I1
sa(dp4784
g7
I2185
sg17
VC0002171
p4785
sg10
I15
sg11
Valopecia areata
p4786
sg13
I2
sa(dp4787
g7
I1475
sg17
VC0268397
p4788
sg10
I18
sg11
Vlichen amyloidosus
p4789
sg13
I2
sa(dp4790
g7
I630
sg17
VC0024138
p4791
sg10
I27
sg11
Vdiscoid lupus erythematosus
p4792
sg13
I3
sa(dp4793
g7
I774
sg17
VC1276092
p4794
sg10
I19
sg11
Vchronic hand eczema
p4795
sg13
I3
sa(dp4796
g7
I2106
sg17
VC1274700
p4797
sg10
I26
sg11
Vfrontal fibrosing alopecia
p4798
sg13
I3
sa(dp4799
g7
I1462
sg17
VC0002726
p4800
sg10
I11
sg11
Vamyloidosis
p4801
sg13
I1
sa(dp4802
g7
I1146
sg17
VC0040262
p4803
sg10
I21
sg11
Vpityriasis versicolor
p4804
sg13
I2
sa(dp4805
g7
I713
sg17
VC0239495
p4806
sg10
I17
sg11
Vgranuloma faciale
p4807
sg13
I2
sa(dp4808
g7
I1988
sg17
VC0154089
p4809
sg10
I24
sg11
Verythroplasia of Queyrat
p4810
sg13
I3
sa(dp4811
g7
I672
sg17
VC0023283
p4812
sg10
I23
sg11
Vcutaneous leishmaniasis
p4813
sg13
I2
sa(dp4814
g7
I0
sg17
VC0037274
p4815
sg10
I10
sg11
Vdermatoses
p4816
sg13
I1
sa(dp4817
g7
I151
sg17
VC0024140
p4818
sg10
I38
sg11
Vsubacute cutaneous lupus erythematosus
p4819
sg13
I4
sa(dp4820
g7
I1570
sg17
VC0263402
p4821
sg10
I42
sg11
Vtelangiectasia macularis eruptiva perstans
p4822
sg13
I4
sa(dp4823
g7
I0
sg17
VC0037274
p4824
sg10
I10
sg11
Vdermatoses
p4825
sg13
I1
sa(dp4826
g7
I607
sg17
VC0036508
p4827
sg10
I21
sg11
Vseborrheic dermatitis
p4828
sg13
I2
sa(dp4829
g7
I1436
sg17
VC0494853
p4830
sg10
I16
sg11
Verythema ab igne
p4831
sg13
I3
sa(dp4832
g7
I77
sg17
VC0033860
p4833
sg10
I9
sg11
Vpsoriasis
p4834
sg13
I1
sa(dp4835
g7
I1702
sg17
VC0036262
p4836
sg10
I7
sg11
Vscabies
p4837
sg13
I1
sa(dp4838
g7
I358
sg17
VC0032027
p4839
sg10
I24
sg11
Vpityriasis rubra pilaris
p4840
sg13
I3
sa(dp4841
g7
I399
sg17
VC0206182
p4842
sg10
I22
sg11
Vlymphomatoid papulosis
p4843
sg13
I2
sa(dp4844
g7
I0
sg17
VC0037274
p4845
sg10
I10
sg11
Vdermatoses
p4846
sg13
I1
sa(dp4847
g7
I1206
sg17
VC0162835
p4848
sg10
I13
sg11
Vhypomelanosis
p4849
sg13
I1
sa(dp4850
g7
I607
sg17
VC0036508
p4851
sg10
I21
sg11
Vseborrheic dermatitis
p4852
sg13
I2
sa(dp4853
g7
I760
sg17
VC0022579
p4854
sg10
I11
sg11
Vkeratoderma
p4855
sg13
I1
sa(dp4856
g7
I1187
sg17
VC0263583
p4857
sg10
I32
sg11
Vidiopathic guttate hypomelanosis
p4858
sg13
I3
sa(dp4859
g7
I1647
sg17
VC0023649
p4860
sg10
I26
sg11
Vhypertrophic lichen planus
p4861
sg13
I3
sa(dp4862
g7
I1358
sg17
VC0406366
p4863
sg10
I25
sg11
Vlichen planus pigmentosus
p4864
sg13
I3
sa(dp4865
g7
I598
sg17
VC0035854
p4866
sg10
I7
sg11
Vrosacea
p4867
sg13
I1
sa(dp4868
g7
I1002
sg17
VC0027538
p4869
sg10
I21
sg11
Vnecrobiosis lipoidica
p4870
sg13
I2
sa(dp4871
g7
I1047
sg17
VC0023652
p4872
sg10
I16
sg11
Vlichen sclerosus
p4873
sg13
I2
sa(dp4874
g7
I2202
sg17
VC0040953
p4875
sg10
I16
sg11
Vtrichotillomania
p4876
sg13
I1
sa(dp4877
g7
I2246
sg17
VC0263518
p4878
sg10
I17
sg11
Vtelogen effluvium
p4879
sg13
I2
sa(dp4880
g7
I111
sg17
VC0032026
p4881
sg10
I16
sg11
Vpityriasis rosea
p4882
sg13
I2
sa(dp4883
g7
I1872
sg17
VC0004690
p4884
sg10
I9
sg11
Vbalanitis
p4885
sg13
I1
sa(dp4886
g7
I760
sg17
VC0022579
p4887
sg10
I11
sg11
Vkeratoderma
p4888
sg13
I1
sa(dp4889
g7
I2085
sg17
VC0023645
p4890
sg10
I19
sg11
Vlichen planopilaris
p4891
sg13
I2
sa(dp4892
g7
I315
sg17
VC0162851
p4893
sg10
I31
sg11
Vpityriasis lichenoides chronica
p4894
sg13
I3
sa(dp4895
g7
I452
sg17
VC0030437
p4896
sg10
I23
sg11
Vparakeratosis variegata
p4897
sg13
I2
sa(dp4898
g7
I2137
sg17
VC0263503
p4899
sg10
I22
sg11
Vfolliculitis decalvans
p4900
sg13
I2
sa(dp4901
g7
I1615
sg17
VC0033774
p4902
sg10
I5
sg11
Vitchy
p4903
sg13
I1
sa(dp4904
g7
I235
sg17
VC0023646
p4905
sg10
I13
sg11
Vlichen planus
p4906
sg13
I2
sa(dp4907
g7
I129
sg17
VC0026948
p4908
sg10
I17
sg11
Vmycosis fungoides
p4909
sg13
I2
sa(dp4910
g7
I548
sg17
VC0334061
p4911
sg10
I12
sg11
Vdyskeratosis
p4912
sg13
I1
sa(dp4913
g7
I358
sg17
VC0032027
p4914
sg10
I24
sg11
Vpityriasis rubra pilaris
p4915
sg13
I3
sa(dp4916
g7
I1385
sg17
VC0263385
p4917
sg10
I26
sg11
VGougerot-Carteaud syndrome
p4918
sg13
I2
sa(dp4919
g7
I2220
sg17
VC0162311
p4920
sg10
I21
sg11
Vandrogenetic alopecia
p4921
sg13
I2
sa(dp4922
g7
I484
sg17
VC0022595
p4923
sg10
I15
sg11
Vdisease, Darier
p4924
sg13
I2
sa(dp4925
g7
I1545
sg17
VC0042111
p4926
sg10
I20
sg11
Vurticaria pigmentosa
p4927
sg13
I2
sa(dp4928
g7
I1872
sg17
VC0004690
p4929
sg10
I9
sg11
Vbalanitis
p4930
sg13
I1
sa(dp4931
g7
I438
sg17
VC0867389
p4932
sg10
I12
sg11
Vchronic GVHD
p4933
sg13
I2
sa(dp4934
g7
I697
sg17
VC0024131
p4935
sg10
I14
sg11
Vlupus vulgaris
p4936
sg13
I2
sa(dp4937
g7
I384
sg17
VC0162839
p4938
sg10
I13
sg11
Vporokeratosis
p4939
sg13
I1
sa(dp4940
g7
I904
sg17
VC0153246
p4941
sg10
I12
sg11
Vtinea manuum
p4942
sg13
I2
sa(dp4943
g7
I70
sg17
VC0406317
p4944
sg10
I16
sg11
Vplaque psoriasis
p4945
sg13
I2
sa(dp4946
g7
I1675
sg17
VC0263353
p4947
sg10
I17
sg11
Vprurigo nodularis
p4948
sg13
I2
sa(dp4949
g7
I1781
sg17
VC0011615
p4950
sg10
I17
sg11
Vatopic dermatitis
p4951
sg13
I2
sa(dp4952
g7
I1748
sg17
VC0011606
p4953
sg10
I13
sg11
Verythrodermas
p4954
sg13
I1
sa(dp4955
g7
I583
sg17
VC0037274
p4956
sg10
I13
sg11
Vskin diseases
p4957
sg13
I2
sa(dp4958
g7
I2359
sg17
VC0343100
p4959
sg10
I21
sg11
Vpityriasis amiantacea
p4960
sg13
I2
sa(dp4961
g7
I283
sg17
VC0036202
p4962
sg10
I11
sg11
Vsarcoidosis
p4963
sg13
I1
sa(dp4964
g7
I1515
sg17
VC2721650
p4965
sg10
I28
sg11
Vterra firma-forme dermatosis
p4966
sg13
I3
sa(dp4967
g7
I111
sg17
VC0032026
p4968
sg10
I16
sg11
Vpityriasis rosea
p4969
sg13
I2
sa(dp4970
g7
I630
sg17
VC0024138
p4971
sg10
I27
sg11
Vdiscoid lupus erythematosus
p4972
sg13
I3
sa(dp4973
g7
I1210
sg17
VC0221391
p4974
sg10
I9
sg11
Vmelanosis
p4975
sg13
I1
sa(dp4976
g7
I61
sg17
VC0333463
p4977
sg10
I7
sg11
Vplaques
p4978
sg13
I1
sa(dp4979
g7
I129
sg17
VC0026948
p4980
sg10
I17
sg11
Vmycosis fungoides
p4981
sg13
I2
sa(dp4982
g7
I1890
sg17
VC0403761
p4983
sg10
I21
sg11
Vplasma cell balanitis
p4984
sg13
I3
sa(dp4985
g7
I296
sg17
VC0343052
p4986
sg10
I17
sg11
Vguttate psoriasis
p4987
sg13
I2
sa(dp4988
g7
I760
sg17
VC0022579
p4989
sg10
I11
sg11
Vkeratoderma
p4990
sg13
I1
sa(dp4991
g7
I1872
sg17
VC0004690
p4992
sg10
I9
sg11
Vbalanitis
p4993
sg13
I1
sa(dp4994
g7
I760
sg17
VC0022579
p4995
sg10
I12
sg11
Vkeratodermas
p4996
sg13
I1
sasa(dp4997
g2
VKaposi varicelliform eruption or eczema herpeticum is well known to be associated with several chronic dermatoses, including atopic dermatitis, foliaceus pemphigus, seborrheic dermatitis, Darier disease, and congenital ichthyosiform erythroderma.
p4998
sg4
(lp4999
sg14
(lp5000
(dp5001
g7
I208
sg17
VC0079583
p5002
sg10
I37
sg11
Vcongenital ichthyosiform erythroderma
p5003
sg13
I3
sa(dp5004
g7
I0
sg17
VC0022504
p5005
sg10
I29
sg11
VKaposi varicelliform eruption
p5006
sg13
I3
sa(dp5007
g7
I165
sg17
VC0036508
p5008
sg10
I21
sg11
Vseborrheic dermatitis
p5009
sg13
I2
sa(dp5010
g7
I188
sg17
VC0022595
p5011
sg10
I14
sg11
VDarier disease
p5012
sg13
I2
sa(dp5013
g7
I154
sg17
VC0030807
p5014
sg10
I9
sg11
Vpemphigus
p5015
sg13
I1
sa(dp5016
g7
I103
sg17
VC0037274
p5017
sg10
I10
sg11
Vdermatoses
p5018
sg13
I1
sa(dp5019
g7
I33
sg17
VC0936250
p5020
sg10
I17
sg11
Veczema herpeticum
p5021
sg13
I2
sa(dp5022
g7
I125
sg17
VC0011615
p5023
sg10
I17
sg11
Vatopic dermatitis
p5024
sg13
I2
sasa(dp5025
g2
VMCI-186, a dose that prevents ischemic brain edema, had no significant effect on brain concentrations of dopamine, norepinephrine, 5-hydroxytryptamine, or their metabolites.
p5026
sg4
(lp5027
sg14
(lp5028
(dp5029
g7
I39
sg17
VC1527311
p5030
sg10
I11
sg11
Vbrain edema
p5031
sg13
I2
sa(dp5032
g7
I0
sg17
VC1270972
p5033
sg10
I3
sg11
VMCI
p5034
sg13
I1
sasa(dp5035
g2
VPretreatments with dexamethasone, parachlorophenylalanine (an inhibitor of 5-hydroxytryptamine synthesis), mepyramine and metiamide (H1 and H2 histamine receptor antagonists) or aminophylline did not influence significantly the development of brain edema evaluated 24 h after embolization.
p5036
sg4
(lp5037
(dp5038
g7
I140
sg8
g24
sg10
I21
sg11
VH2 histamine receptor
p5039
sg13
I3
sasg14
(lp5040
(dp5041
g7
I243
sg17
VC1527311
p5042
sg10
I11
sg11
Vbrain edema
p5043
sg13
I2
sasa(dp5044
g2
VTo study the effect of B lymphocyte-induced mature protein-1(Blimp1) expression in bone marrow mononuclear cells on the prognosis of patients with multiple myeloma.
p5045
sg4
(lp5046
(dp5047
g7
I61
sg8
g24
sg10
I6
sg11
VBlimp1
p5048
sg13
I1
sa(dp5049
g7
I44
sg8
VP17980
p5050
sg10
I16
sg11
Vmature protein-1
p5051
sg13
I2
sasg14
(lp5052
(dp5053
g7
I147
sg17
VC0026764
p5054
sg10
I16
sg11
Vmultiple myeloma
p5055
sg13
I2
sasa(dp5056
g2
VHere we further dissect the anti-myeloma mechanisms mediated by EZH2 inhibition and show that pharmacological inhibition of EZH2 reduces the expression of MM-associated oncogenes; IRF-4, XBP-1, PRDM1/BLIMP-1 and c-MYC.
p5057
sg4
(lp5058
(dp5059
g7
I64
sg8
g24
sg10
I4
sg11
VEZH2
p5060
sg13
I1
sa(dp5061
g7
I187
sg8
VP17861
p5062
sg10
I5
sg11
VXBP-1
p5063
sg13
I1
sa(dp5064
g7
I64
sg8
g24
sg10
I4
sg11
VEZH2
p5065
sg13
I1
sa(dp5066
g7
I194
sg8
g24
sg10
I5
sg11
VPRDM1
p5067
sg13
I1
sa(dp5068
g7
I212
sg8
VP12524
p5069
sg10
I5
sg11
Vc-MYC
p5070
sg13
I1
sa(dp5071
g7
I200
sg8
g24
sg10
I7
sg11
VBLIMP-1
p5072
sg13
I1
sa(dp5073
g7
I180
sg8
g24
sg10
I5
sg11
VIRF-4
p5074
sg13
I1
sasg14
(lp5075
(dp5076
g7
I33
sg17
VC0026764
p5077
sg10
I7
sg11
Vmyeloma
p5078
sg13
I1
sasa(dp5079
g2
VTo investigate the expression level of B lymphocyte-induced maturation protein-1(Blimp-1) mRNA in bone marrow mononuclear cells(BMMNC) of multiple myeloma(MM) patients and its clinical significance.
p5080
sg4
(lp5081
(dp5082
g7
I60
sg8
VP17980
p5083
sg10
I20
sg11
Vmaturation protein-1
p5084
sg13
I2
sasg14
(lp5085
(dp5086
g7
I138
sg17
VC0026764
p5087
sg10
I16
sg11
Vmultiple myeloma
p5088
sg13
I2
sasa(dp5089
g2
VMeanwhile, plasma could promote myeloma differentiation by up-regulating Blimp-1 and XBP-1 expression.
p5090
sg4
(lp5091
(dp5092
g7
I85
sg8
VP17861
p5093
sg10
I5
sg11
VXBP-1
p5094
sg13
I1
sa(dp5095
g7
I73
sg8
g24
sg10
I7
sg11
VBlimp-1
p5096
sg13
I1
sasg14
(lp5097
(dp5098
g7
I32
sg17
VC0026764
p5099
sg10
I7
sg11
Vmyeloma
p5100
sg13
I1
sasa(dp5101
g2
VHowever, how Blimp-1 ensures the survival of plasma cell malignancy, multiple myeloma (MM), has remained elusive.
p5102
sg4
(lp5103
sg14
(lp5104
(dp5105
g7
I57
sg17
VC0006826
p5106
sg10
I10
sg11
Vmalignancy
p5107
sg13
I1
sa(dp5108
g7
I69
sg17
VC0026764
p5109
sg10
I16
sg11
Vmultiple myeloma
p5110
sg13
I2
sasa(dp5111
g2
VThe finding that Blimp-1/PRDM1 enhances transcription of CS1 gene in multiple myeloma cells may help in developing novel strategies for therapeutic intervention in multiple myeloma.
p5112
sg4
(lp5113
(dp5114
g7
I57
sg8
g24
sg10
I8
sg11
VCS1 gene
p5115
sg13
I2
sa(dp5116
g7
I17
sg8
g24
sg10
I7
sg11
VBlimp-1
p5117
sg13
I1
sa(dp5118
g7
I25
sg8
g24
sg10
I5
sg11
VPRDM1
p5119
sg13
I1
sasg14
(lp5120
(dp5121
g7
I69
sg17
VC0026764
p5122
sg10
I16
sg11
Vmultiple myeloma
p5123
sg13
I2
sa(dp5124
g7
I69
sg17
VC0026764
p5125
sg10
I16
sg11
Vmultiple myeloma
p5126
sg13
I2
sasa(dp5127
g2
VLhx9 is an LIM (named for the first three proteins in which the domain was found, Lin-11, Isl1 and Mec-3) homeodomain protein involved in development and differentiation of the gonad.
p5128
sg4
(lp5129
(dp5130
g7
I106
sg8
g24
sg10
I11
sg11
Vhomeodomain
p5131
sg13
I1
sa(dp5132
g7
I99
sg8
g24
sg10
I5
sg11
VMec-3
p5133
sg13
I1
sa(dp5134
g7
I11
sg8
g24
sg10
I3
sg11
VLIM
p5135
sg13
I1
sa(dp5136
g7
I90
sg8
VP61371
p5137
sg10
I4
sg11
VIsl1
p5138
sg13
I1
sa(dp5139
g7
I0
sg8
g24
sg10
I4
sg11
VLhx9
p5140
sg13
I1
sasg14
(lp5141
sa(dp5142
g2
VWe report that CCRL2-deficient mice have a defect in neutrophil recruitment and are protected in 2 models of inflammatory arthritis.
p5143
sg4
(lp5144
(dp5145
g7
I15
sg8
g24
sg10
I5
sg11
VCCRL2
p5146
sg13
I1
sasg14
(lp5147
(dp5148
g7
I64
sg17
VC0271510
p5149
sg10
I11
sg11
Vrecruitment
p5150
sg13
I1
sa(dp5151
g7
I109
sg17
VC0003864
p5152
sg10
I22
sg11
Vinflammatory arthritis
p5153
sg13
I2
sasa(dp5154
g2
VThe concurrence of PJS and feminizing SCTs of the testes is an increasingly recognized cause of prepubertal gynecomastia.
p5155
sg4
(lp5156
(dp5157
g7
I19
sg8
g24
sg10
I23
sg11
VPJS and feminizing SCTs
p5158
sg13
I4
sasg14
(lp5159
(dp5160
g7
I38
sg17
VC0796149
p5161
sg10
I4
sg11
VSCTs
p5162
sg13
I1
sa(dp5163
g7
I108
sg17
VC0018418
p5164
sg10
I12
sg11
Vgynecomastia
p5165
sg13
I1
sa(dp5166
g7
I19
sg17
VC0031269
p5167
sg10
I3
sg11
VPJS
p5168
sg13
I1
sasa(dp5169
g2
VMost IgAD and CVID patients in our clinic population in the Southeastern United States have inherited part or all of two extended MHC haplotypes, referred to as haplotype 1 (HLA-DQB1 0201, HLA-DR3, C4B-Sf, C4A-0, G1-15, Bf-0.4, C2-a, HSP-7.5, TNF alpha-5, HLA-B8, HLA-A1) and haplotype 2 (HLA-DQB1 0201, HLA-DR-7, C4B-S, C4A-L, G11-4.5, Bf-0.6, C2-b, HSP-9, TNF alpha-9, HLA-B44, HLA-A29).
p5170
sg4
(lp5171
(dp5172
g7
I371
sg8
VP30486
p5173
sg10
I7
sg11
VHLA-B44
p5174
sg13
I1
sa(dp5175
g7
I243
sg8
VP01375
p5176
sg10
I11
sg11
VTNF alpha-5
p5177
sg13
I2
sa(dp5178
g7
I351
sg8
g24
sg10
I5
sg11
VHSP-9
p5179
sg13
I1
sa(dp5180
g7
I358
sg8
VP01375
p5181
sg10
I11
sg11
VTNF alpha-9
p5182
sg13
I2
sa(dp5183
g7
I174
sg8
VP09471
p5184
sg10
I13
sg11
VHLA-DQB1 0201
p5185
sg13
I2
sa(dp5186
g7
I380
sg8
VP30486
p5187
sg10
I7
sg11
VHLA-A29
p5188
sg13
I1
sa(dp5189
g7
I130
sg8
VP13747
p5190
sg10
I14
sg11
VMHC haplotypes
p5191
sg13
I2
sa(dp5192
g7
I198
sg8
VP04003
p5193
sg10
I3
sg11
VC4B
p5194
sg13
I1
sa(dp5195
g7
I189
sg8
VP30486
p5196
sg10
I7
sg11
VHLA-DR3
p5197
sg13
I1
sa(dp5198
g7
I198
sg8
VP04003
p5199
sg10
I5
sg11
VC4B-S
p5200
sg13
I1
sa(dp5201
g7
I234
sg8
g24
sg10
I7
sg11
VHSP-7.5
p5202
sg13
I1
sa(dp5203
g7
I304
sg8
VP30486
p5204
sg10
I8
sg11
VHLA-DR-7
p5205
sg13
I1
sa(dp5206
g7
I256
sg8
VP30486
p5207
sg10
I6
sg11
VHLA-B8
p5208
sg13
I1
sa(dp5209
g7
I174
sg8
VP09471
p5210
sg10
I13
sg11
VHLA-DQB1 0201
p5211
sg13
I2
sa(dp5212
g7
I328
sg8
VP56715
p5213
sg10
I7
sg11
VG11-4.5
p5214
sg13
I1
sasg14
(lp5215
(dp5216
g7
I234
sg17
VC0034152
p5217
sg10
I3
sg11
VHSP
p5218
sg13
I1
sa(dp5219
g7
I234
sg17
VC0034152
p5220
sg10
I3
sg11
VHSP
p5221
sg13
I1
sa(dp5222
g7
I14
sg17
VC0009447
p5223
sg10
I4
sg11
VCVID
p5224
sg13
I1
sasa(dp5225
g2
VIn search of a genetic linkage between the two immunodeficiencies, we examined the major histocompatibility complex (MHC) class III genes encoding complement components C2, C4A, and C4B and steroid 21-hydroxylase in addition to the HLA serotypes in individuals with either common variable immunodeficiency or IgA deficiency.
p5226
sg4
(lp5227
(dp5228
g7
I232
sg8
VP30486
p5229
sg10
I3
sg11
VHLA
p5230
sg13
I1
sa(dp5231
g7
I309
sg8
VP11912
p5232
sg10
I3
sg11
VIgA
p5233
sg13
I1
sa(dp5234
g7
I182
sg8
VP04003
p5235
sg10
I3
sg11
VC4B
p5236
sg13
I1
sa(dp5237
g7
I190
sg8
VP08686
p5238
sg10
I22
sg11
Vsteroid 21-hydroxylase
p5239
sg13
I2
sa(dp5240
g7
I83
sg8
g24
sg10
I74
sg11
Vmajor histocompatibility complex (MHC) class III genes encoding complement
p5241
sg13
I9
sasg14
(lp5242
(dp5243
g7
I47
sg17
VC0021051
p5244
sg10
I18
sg11
Vimmunodeficiencies
p5245
sg13
I1
sa(dp5246
g7
I273
sg17
VC0009447
p5247
sg10
I32
sg11
Vcommon variable immunodeficiency
p5248
sg13
I3
sa(dp5249
g7
I309
sg17
VC0162538
p5250
sg10
I14
sg11
VIgA deficiency
p5251
sg13
I2
sasa(dp5252
g2
VTwelve of 19 patients with common variable immunodeficiency (63%, P less than 0.001) and 9 of 16 patients with IgA deficiency (56%, P less than 0.01) had rare C2 alleles and/or C4A and 21-hydroxylase A deletions, whereas these gene features were seen in only 5 of 34 healthy individuals (15%) in the control group.
p5253
sg4
(lp5254
(dp5255
g7
I185
sg8
VP08686
p5256
sg10
I16
sg11
V21-hydroxylase A
p5257
sg13
I2
sa(dp5258
g7
I111
sg8
VP11912
p5259
sg10
I3
sg11
VIgA
p5260
sg13
I1
sasg14
(lp5261
(dp5262
g7
I27
sg17
VC0009447
p5263
sg10
I32
sg11
Vcommon variable immunodeficiency
p5264
sg13
I3
sa(dp5265
g7
I111
sg17
VC0162538
p5266
sg10
I14
sg11
VIgA deficiency
p5267
sg13
I2
sasa(dp5268
g2
VTotally implantable venous access port (TIVAP)-related infections (RIs) remain a serious health problem in cancer patients receiving an intravenous (i.v.)
p5269
sg4
(lp5270
sg14
(lp5271
(dp5272
g7
I107
sg17
VC0006826
p5273
sg10
I6
sg11
Vcancer
p5274
sg13
I1
sa(dp5275
g7
I55
sg17
VC0021311
p5276
sg10
I10
sg11
Vinfections
p5277
sg13
I1
sasa(dp5278
g2
VFurthermore, we provided a RIs-based algorithm for biomarker discovery and validation to screen for diseases such as cancer.
p5279
sg4
(lp5280
sg14
(lp5281
(dp5282
g7
I117
sg17
VC0006826
p5283
sg10
I6
sg11
Vcancer
p5284
sg13
I1
sasa(dp5285
g2
VThe first survey, sent to 94 cancer control and supportive care responsible individuals (CCL RIs) at 94 COG institutions, asked if the institution had a standardized approach to practice and focused on antiemetic agent choice.
p5286
sg4
(lp5287
sg14
(lp5288
(dp5289
g7
I29
sg17
VC0006826
p5290
sg10
I6
sg11
Vcancer
p5291
sg13
I1
sa(dp5292
g7
I89
sg17
VC1852438
p5293
sg10
I3
sg11
VCCL
p5294
sg13
I1
sasa(dp5295
g2
VLiver sections from patients with biliary atresia were evaluated to detect antigen for the BECs marker 4 and cytokeratin-7 (CK-7), proteins (fibroblast-specific protein 1, also known S100A4; the collagen chaperone heat shock protein 47, HSP47) characteristically expressed by cells undergoing EMT, as well as myofibroblasts marker a-smooth muscle actin (a-SMA).
p5296
sg4
(lp5297
(dp5298
g7
I124
sg8
VP14222
p5299
sg10
I46
sg11
VCK-7), proteins (fibroblast-specific protein 1
p5300
sg13
I5
sa(dp5301
g7
I109
sg8
VP08729
p5302
sg10
I13
sg11
Vcytokeratin-7
p5303
sg13
I1
sa(dp5304
g7
I237
sg8
VP50454
p5305
sg10
I5
sg11
VHSP47
p5306
sg13
I1
sa(dp5307
g7
I195
sg8
VP34931
p5308
sg10
I40
sg11
Vcollagen chaperone heat shock protein 47
p5309
sg13
I6
sa(dp5310
g7
I183
sg8
VP26447
p5311
sg10
I6
sg11
VS100A4
p5312
sg13
I1
sa(dp5313
g7
I354
sg8
g24
sg10
I5
sg11
Va-SMA
p5314
sg13
I1
sa(dp5315
g7
I331
sg8
g24
sg10
I21
sg11
Va-smooth muscle actin
p5316
sg13
I3
sasg14
(lp5317
(dp5318
g7
I34
sg17
VC0005411
p5319
sg10
I15
sg11
Vbiliary atresia
p5320
sg13
I2
sa(dp5321
g7
I356
sg17
VC0026847
p5322
sg10
I3
sg11
VSMA
p5323
sg13
I1
sasa(dp5324
g2
VHowever, BECs from biliary atresia resulted in increased expression of a-SMA, S100A4, with concurrent transition to a fibroblast-like morphology and decreased expression of AK-7.
p5325
sg4
(lp5326
(dp5327
g7
I173
sg8
VP55263
p5328
sg10
I4
sg11
VAK-7
p5329
sg13
I1
sa(dp5330
g7
I78
sg8
VP26447
p5331
sg10
I6
sg11
VS100A4
p5332
sg13
I1
sa(dp5333
g7
I73
sg8
g24
sg10
I3
sg11
VSMA
p5334
sg13
I1
sasg14
(lp5335
(dp5336
g7
I102
sg17
VC0599156
p5337
sg10
I10
sg11
Vtransition
p5338
sg13
I1
sa(dp5339
g7
I19
sg17
VC0005411
p5340
sg10
I15
sg11
Vbiliary atresia
p5341
sg13
I2
sa(dp5342
g7
I73
sg17
VC0026847
p5343
sg10
I3
sg11
VSMA
p5344
sg13
I1
sasa(dp5345
g2
VConsequently, there has been considerable interest in the pharmaceutical industry to develop selective TPL-2 inhibitors as drugs for the treatment of TNF-dependent inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
p5346
sg4
(lp5347
(dp5348
g7
I150
sg8
VP01375
p5349
sg10
I3
sg11
VTNF
p5350
sg13
I1
sa(dp5351
g7
I103
sg8
VP41279
p5352
sg10
I5
sg11
VTPL-2
p5353
sg13
I1
sasg14
(lp5354
(dp5355
g7
I220
sg17
VC0021390
p5356
sg10
I26
sg11
Vinflammatory bowel disease
p5357
sg13
I3
sa(dp5358
g7
I195
sg17
VC0003873
p5359
sg10
I20
sg11
Vrheumatoid arthritis
p5360
sg13
I2
sasa(dp5361
g2
VThus, pharmacologic inhibition of Tpl2 should be a valid approach to therapeutic intervention in the pathogenesis of rheumatoid arthritis and other inflammatory diseases in humans.
p5362
sg4
(lp5363
(dp5364
g7
I34
sg8
VP41279
p5365
sg10
I4
sg11
VTpl2
p5366
sg13
I1
sasg14
(lp5367
(dp5368
g7
I117
sg17
VC0003873
p5369
sg10
I20
sg11
Vrheumatoid arthritis
p5370
sg13
I2
sa(dp5371
g7
I101
sg17
VC0699748
p5372
sg10
I12
sg11
Vpathogenesis
p5373
sg13
I1
sasa(dp5374
g2
VTaken together, our results show that inhibition of Tpl2 in primary human cell types can decrease the production of TNFalpha and other pro-inflammatory mediators during inflammatory events, and they further support the notion that Tpl2 is an appropriate therapeutic target for rheumatoid arthritis and other human inflammatory diseases.
p5375
sg4
(lp5376
(dp5377
g7
I116
sg8
VP01375
p5378
sg10
I8
sg11
VTNFalpha
p5379
sg13
I1
sa(dp5380
g7
I52
sg8
VP41279
p5381
sg10
I4
sg11
VTpl2
p5382
sg13
I1
sa(dp5383
g7
I52
sg8
VP41279
p5384
sg10
I4
sg11
VTpl2
p5385
sg13
I1
sasg14
(lp5386
(dp5387
g7
I277
sg17
VC0003873
p5388
sg10
I20
sg11
Vrheumatoid arthritis
p5389
sg13
I2
sasa(dp5390
g2
VRecent studies using Tpl2 knockout mice have indicated an important role for Tpl2 in the lipopolysaccharide (LPS) induced production of tumor necrosis factor alpha (TNF-alpha) and other proinflammatory cytokines involved in diseases such as rheumatoid arthritis.
p5391
sg4
(lp5392
(dp5393
g7
I136
sg8
VP01375
p5394
sg10
I27
sg11
Vtumor necrosis factor alpha
p5395
sg13
I4
sa(dp5396
g7
I21
sg8
VP41279
p5397
sg10
I4
sg11
VTpl2
p5398
sg13
I1
sa(dp5399
g7
I21
sg8
VP41279
p5400
sg10
I4
sg11
VTpl2
p5401
sg13
I1
sa(dp5402
g7
I165
sg8
VP01375
p5403
sg10
I9
sg11
VTNF-alpha
p5404
sg13
I1
sasg14
(lp5405
(dp5406
g7
I136
sg17
VC0333516
p5407
sg10
I14
sg11
Vtumor necrosis
p5408
sg13
I2
sa(dp5409
g7
I89
sg17
VC0175697
p5410
sg10
I18
sg11
Vlipopolysaccharide
p5411
sg13
I1
sa(dp5412
g7
I109
sg17
VC0175697
p5413
sg10
I3
sg11
VLPS
p5414
sg13
I1
sa(dp5415
g7
I241
sg17
VC0003873
p5416
sg10
I20
sg11
Vrheumatoid arthritis
p5417
sg13
I2
sasa(dp5418
g2
VIn all, 78.08% had stage 1 HTN while 22% had stage 2 HTN.
p5419
sg4
(lp5420
sg14
(lp5421
(dp5422
g7
I27
sg17
VC0020538
p5423
sg10
I3
sg11
VHTN
p5424
sg13
I1
sa(dp5425
g7
I27
sg17
VC0020538
p5426
sg10
I3
sg11
VHTN
p5427
sg13
I1
sasa(dp5428
g2
VMoreover, ba-PWV showed a significant increase with increasing plasma tHcy level in subjects with both high normal BP and grade 1 HTN (p &lt; 0.05).
p5429
sg4
(lp5430
sg14
(lp5431
(dp5432
g7
I130
sg17
VC0020538
p5433
sg10
I3
sg11
VHTN
p5434
sg13
I1
sasa(dp5435
g2
VCompared with optimal BP stage, ba-PWV was significantly associated with high normal BP stage (Beta = 193, p &lt; 0.001) and grade 1 HTN (Beta = 413, p &lt; 0.001).There was a statistical interaction effect between high normal BP stage and optimal BP stage (p = 0.045).
p5436
sg4
(lp5437
sg14
(lp5438
(dp5439
g7
I133
sg17
VC0020538
p5440
sg10
I3
sg11
VHTN
p5441
sg13
I1
sasa(dp5442
g2
VThe similar result was found between subjects with optimal BP and those with grade 1 HTN (p = 0.037).
p5443
sg4
(lp5444
sg14
(lp5445
(dp5446
g7
I85
sg17
VC0020538
p5447
sg10
I3
sg11
VHTN
p5448
sg13
I1
sasa(dp5449
g2
VIn conclusion, tHcy was independently correlated with ba-PWV in subjects with high normal BP and grade 1 HTN.
p5450
sg4
(lp5451
sg14
(lp5452
(dp5453
g7
I105
sg17
VC0020538
p5454
sg10
I3
sg11
VHTN
p5455
sg13
I1
sasa(dp5456
g2
VHigh normal BP and grade 1 HTN may worsen the impact of tHcy on arterial stiffness in a Chinese rural community population.
p5457
sg4
(lp5458
sg14
(lp5459
(dp5460
g7
I73
sg17
VC0427008
p5461
sg10
I9
sg11
Vstiffness
p5462
sg13
I1
sa(dp5463
g7
I27
sg17
VC0020538
p5464
sg10
I3
sg11
VHTN
p5465
sg13
I1
sasa(dp5466
g2
VNpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA, ocTpoN oKKnh3NeN BHyTpeHHeN coHHoN apTepNN.
p5467
sg4
(lp5468
(dp5469
g7
I0
sg8
VP05452
p5470
sg10
I149
sg11
VNpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA
p5471
sg13
I17
sasg14
(lp5472
sa(dp5473
g2
VThe upper bound of a 95% confidence interval for the difference in prevalence of Stage 1 and 2 HTN between study arms indicates that discontinuation of study medication is unlikely to be associated with an increase in Stage 1 HTN of &gt;4.8 percentage points and in Stage 2 HTN of no &gt;5.8 percentage points.
p5474
sg4
(lp5475
sg14
(lp5476
(dp5477
g7
I95
sg17
VC0020538
p5478
sg10
I3
sg11
VHTN
p5479
sg13
I1
sa(dp5480
g7
I113
sg17
VC0206655
p5481
sg10
I4
sg11
Varms
p5482
sg13
I1
sa(dp5483
g7
I95
sg17
VC0020538
p5484
sg10
I3
sg11
VHTN
p5485
sg13
I1
sa(dp5486
g7
I95
sg17
VC0020538
p5487
sg10
I3
sg11
VHTN
p5488
sg13
I1
sasa(dp5489
g2
VTarget genes (e.g., cyclin-dependent kinase 6) of hsa-miR-942-5p were mainly enriched in cancer-related pathways, whereas target genes (e.g., CRK-Like Proto-Oncogene, Adaptor Protein) of hsa-miR-940 were enriched in the ErbB signaling pathway.
p5490
sg4
(lp5491
(dp5492
g7
I142
sg8
VP46108
p5493
sg10
I40
sg11
VCRK-Like Proto-Oncogene, Adaptor Protein
p5494
sg13
I4
sa(dp5495
g7
I187
sg8
g24
sg10
I11
sg11
Vhsa-miR-940
p5496
sg13
I1
sa(dp5497
g7
I50
sg8
g24
sg10
I14
sg11
Vhsa-miR-942-5p
p5498
sg13
I1
sa(dp5499
g7
I220
sg8
g24
sg10
I4
sg11
VErbB
p5500
sg13
I1
sa(dp5501
g7
I20
sg8
g24
sg10
I25
sg11
Vcyclin-dependent kinase 6
p5502
sg13
I3
sasg14
(lp5503
(dp5504
g7
I89
sg17
VC0006826
p5505
sg10
I6
sg11
Vcancer
p5506
sg13
I1
sa(dp5507
g7
I50
sg17
VC0393754
p5508
sg10
I3
sg11
Vhsa
p5509
sg13
I1
sa(dp5510
g7
I50
sg17
VC0393754
p5511
sg10
I3
sg11
Vhsa
p5512
sg13
I1
sasa(dp5513
g2
VHerein, we demonstrated that hypoxia induces the high expression of microRNA-940 (miR-940) in exosomes derived from epithelial ovarian cancer (EOC).
p5514
sg4
(lp5515
sg14
(lp5516
(dp5517
g7
I143
sg17
VC0677886
p5518
sg10
I3
sg11
VEOC
p5519
sg13
I1
sa(dp5520
g7
I29
sg17
VC0242184
p5521
sg10
I7
sg11
Vhypoxia
p5522
sg13
I1
sa(dp5523
g7
I116
sg17
VC0677886
p5524
sg10
I25
sg11
Vepithelial ovarian cancer
p5525
sg13
I3
sasa(dp5526
g2
VResults: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).
p5527
sg4
(lp5528
(dp5529
g7
I24
sg8
g24
sg10
I3
sg11
Vhsa
p5530
sg13
I1
sa(dp5531
g7
I38
sg8
g24
sg10
I11
sg11
Vhsa-mir-149
p5532
sg13
I1
sa(dp5533
g7
I51
sg8
g24
sg10
I11
sg11
Vhsa-mir-744
p5534
sg13
I1
sa(dp5535
g7
I24
sg8
g24
sg10
I12
sg11
Vhsa-mir-1180
p5536
sg13
I1
sasg14
(lp5537
(dp5538
g7
I24
sg17
VC0393754
p5539
sg10
I3
sg11
Vhsa
p5540
sg13
I1
sa(dp5541
g7
I24
sg17
VC0393754
p5542
sg10
I3
sg11
Vhsa
p5543
sg13
I1
sa(dp5544
g7
I24
sg17
VC0393754
p5545
sg10
I3
sg11
Vhsa
p5546
sg13
I1
sa(dp5547
g7
I24
sg17
VC0393754
p5548
sg10
I3
sg11
Vhsa
p5549
sg13
I1
sa(dp5550
g7
I109
sg17
VC2699153
p5551
sg10
I8
sg11
Vinvasion
p5552
sg13
I1
sa(dp5553
g7
I190
sg17
VC1512411
p5554
sg10
I24
sg11
Vhepatocellular carcinoma
p5555
sg13
I2
sa(dp5556
g7
I109
sg17
VC2699153
p5557
sg10
I8
sg11
Vinvasion
p5558
sg13
I1
sasa(dp5559
g2
VResults from the Survival analysis showed that hsa-mir-1180 (HR=1.623, 95% CI: 1.114-2.365, P=0.012), hsa-mir-149 (HR=2.400, 95% CI: 1.639-3.514) and hsa-mir-940 (HR=1.704, 95%CI: 1.188-2.443, P=0.004) were independent risk factors on the prognosis of patients with hepatocellular carcinoma (P&lt;0.05).
p5560
sg4
(lp5561
(dp5562
g7
I47
sg8
g24
sg10
I3
sg11
Vhsa
p5563
sg13
I1
sa(dp5564
g7
I47
sg8
g24
sg10
I3
sg11
Vhsa
p5565
sg13
I1
sa(dp5566
g7
I47
sg8
g24
sg10
I3
sg11
Vhsa
p5567
sg13
I1
sasg14
(lp5568
(dp5569
g7
I47
sg17
VC0393754
p5570
sg10
I3
sg11
Vhsa
p5571
sg13
I1
sa(dp5572
g7
I47
sg17
VC0393754
p5573
sg10
I3
sg11
Vhsa
p5574
sg13
I1
sa(dp5575
g7
I266
sg17
VC1512411
p5576
sg10
I24
sg11
Vhepatocellular carcinoma
p5577
sg13
I2
sa(dp5578
g7
I47
sg17
VC0393754
p5579
sg10
I3
sg11
Vhsa
p5580
sg13
I1
sasa(dp5581
g2
VConclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.
p5582
sg4
(lp5583
(dp5584
g7
I57
sg8
g24
sg10
I12
sg11
Vhsa-mir-1180
p5585
sg13
I1
sa(dp5586
g7
I71
sg8
g24
sg10
I11
sg11
Vhsa-mir-149
p5587
sg13
I1
sa(dp5588
g7
I84
sg8
g24
sg10
I11
sg11
Vhsa-mir-744
p5589
sg13
I1
sa(dp5590
g7
I57
sg8
g24
sg10
I3
sg11
Vhsa
p5591
sg13
I1
sasg14
(lp5592
(dp5593
g7
I57
sg17
VC0393754
p5594
sg10
I3
sg11
Vhsa
p5595
sg13
I1
sa(dp5596
g7
I156
sg17
VC1512411
p5597
sg10
I24
sg11
Vhepatocellular carcinoma
p5598
sg13
I2
sa(dp5599
g7
I156
sg17
VC1512411
p5600
sg10
I24
sg11
Vhepatocellular carcinoma
p5601
sg13
I2
sa(dp5602
g7
I57
sg17
VC0393754
p5603
sg10
I3
sg11
Vhsa
p5604
sg13
I1
sa(dp5605
g7
I57
sg17
VC0393754
p5606
sg10
I3
sg11
Vhsa
p5607
sg13
I1
sa(dp5608
g7
I57
sg17
VC0393754
p5609
sg10
I3
sg11
Vhsa
p5610
sg13
I1
sasa(dp5611
g2
V#\u76ee#\u7684#\uff1a #\u901a#\u8fc7#\u5bf9GEO (Gene Expression Omnibus) #\u4e0eTCGA (The Cancer Genome Atlas) #\u6570#\u636e#\u5e93#\u5206#\u6790, #\u6316#\u6398#\u809d#\u764c#\u8840#\u7ba1#\u4fb5#\u88ad#\u76f8#\u5173#\u7684microRNA, #\u5e76#\u5206#\u6790#\u5176#\u9884#\u540e#\u548c#\u53ef#\u80fd#\u673a#\u5236#\u3002 #\u65b9#\u6cd5#\uff1a #\u5229#\u7528GEO#\u6570#\u636e#\u5e93#\u83b7#\u5f97#\u809d#\u764c#\u8840#\u7ba1#\u4fb5#\u88admicroRNA#\u82af#\u7247#\u6570#\u636e (GSE67140) , #\u5bf95#\u79cd#\u4fb5#\u88ad#\u80fd#\u529b#\u4e0d#\u540c#\u7684#\u7ec6#\u80de#\u7cfb (SNU423#\u3001SNU449#\u3001HepG2#\u3001Hep3B#\u3001SNU398) #\u8868#\u8fbe#\u8c31#\u8fdb#\u884c#\u5dee#\u5f02#\u5206#\u6790, #\u5e76#\u572881#\u4efd#\u8840#\u7ba1#\u4fb5#\u88ad#\u9633#\u6027#\u7ec4#\u7ec7#\u6837#\u672c#\u4e0e91#\u4efd#\u8840#\u7ba1#\u4fb5#\u88ad#\u9634#\u6027#\u7ec4#\u7ec7#\u6837#\u672c#\u4e2d#\u9a8c#\u8bc1#\u5dee#\u5f02#\u5206#\u6790#\u7ed3#\u679c#\u3002#\u7ed3#\u5408TCGA#\u6570#\u636e#\u5e93#\u4e2d362#\u4f8b#\u809d#\u764c#\u75c5#\u4f8b#\u6570#\u636e#\u5206#\u6790#\u5176#\u9884#\u540e, #\u5e76#\u5bf9microRNA#\u6240#\u8c03#\u63a7#\u7684#\u57fa#\u56e0#\u8fdb#\u884cGO#\u4e0eKEGG#\u5206#\u6790#\u3002 #\u7ed3#\u679c#\uff1a hsa-mir-1180#\u3001hsa-mir-149#\u3001hsa-mir-744#\u3001hsa-mir-940#\u5728#\u4fb5#\u88ad#\u80fd#\u529b#\u5f3a#\u7684#\u809d#\u764c#\u7ec6#\u80de#\u548c#\u6709#\u8840#\u7ba1#\u4fb5#\u88ad#\u7684#\u809d#\u764c#\u7ec4#\u7ec7#\u4e2d#\u8868#\u8fbe#\u4e0a#\u8c03 (logFC&gt;1, P&lt;0.05) #\u3002#\u751f#\u5b58#\u5206#\u6790#\u663e#\u793a, hsa-mir-1180 (HR=1.623, 95%CI#\uff1a1.114~2.365, P=0.012) #\u3001hsa-mir-149 (HR=2.400, 95% CI#\uff1a1.639~3.514, P&lt;0.001) #\u3001hsa-mir-744 (HR=1.679, 95%CI#\uff1a1.161~2.427, P=0.006) #\u3001hsa-mir-940 (HR=1.704, 95%CI#\uff1a1.188~2.443, P=0.004) #\u662f#\u809d#\u764c#\u75c5#\u4f8b#\u9884#\u540e#\u72ec#\u7acb#\u5371#\u9669#\u56e0#\u7d20, #\u9ad8#\u8868#\u8fbe#\u4e0e#\u60a3#\u8005#\u751f#\u5b58#\u671f#\u7f29#\u77ed#\u663e#\u8457#\u76f8#\u5173 (P&lt;0.05) #\u3002GO#\u4e0eKEGG#\u5206#\u6790#\u5176#\u673a#\u5236#\u53ef#\u80fd#\u4e0e#\u514d#\u75ab#\u53cd#\u5e94#\u3001#\u7ec6#\u80de#\u9ecf#\u9644#\u3001#\u7d27#\u5bc6#\u8fde#\u63a5#\u7b49#\u4fe1#\u53f7#\u901a#\u8def#\u6709#\u5173#\u3002 #\u7ed3#\u8bba#\uff1a #\u901a#\u8fc7#\u5bf9TCGA#\u4e0eGEO#\u6570#\u636e#\u5e93#\u7684#\u6316#\u6398, #\u521d#\u6b65#\u53d1#\u73b0hsa-mir-1180#\u3001hsa-mir-149#\u3001hsa-mir-744#\u3001hsa-mir-940#\u5bf9#\u809d#\u764c#\u7684#\u9884#\u540e#\u6709#\u5f71#\u54cd, #\u53ef#\u4f5c#\u4e3a#\u809d#\u764c#\u9884#\u540e#\u7684#\u751f#\u7269#\u6807#\u5fd7#\u7269#\u3002.
p5612
sg4
(lp5613
sg14
(lp5614
(dp5615
g7
I465
sg17
VC0393754
p5616
sg10
I3
sg11
Vhsa
p5617
sg13
I1
sa(dp5618
g7
I478
sg17
VC0393754
p5619
sg10
I4
sg11
V\u3001hsa
p5620
sg13
I1
sa(dp5621
g7
I478
sg17
VC0393754
p5622
sg10
I4
sg11
V\u3001hsa
p5623
sg13
I1
sa(dp5624
g7
I478
sg17
VC0393754
p5625
sg10
I4
sg11
V\u3001hsa
p5626
sg13
I1
sa(dp5627
g7
I478
sg17
VC0393754
p5628
sg10
I4
sg11
V\u3001hsa
p5629
sg13
I1
sa(dp5630
g7
I465
sg17
VC0393754
p5631
sg10
I3
sg11
Vhsa
p5632
sg13
I1
sa(dp5633
g7
I478
sg17
VC0393754
p5634
sg10
I4
sg11
V\u3001hsa
p5635
sg13
I1
sa(dp5636
g7
I478
sg17
VC0393754
p5637
sg10
I4
sg11
V\u3001hsa
p5638
sg13
I1
sa(dp5639
g7
I478
sg17
VC0393754
p5640
sg10
I4
sg11
V\u3001hsa
p5641
sg13
I1
sa(dp5642
g7
I478
sg17
VC0393754
p5643
sg10
I4
sg11
V\u3001hsa
p5644
sg13
I1
sa(dp5645
g7
I478
sg17
VC0393754
p5646
sg10
I4
sg11
V\u3001hsa
p5647
sg13
I1
sa(dp5648
g7
I55
sg17
VC0006826
p5649
sg10
I6
sg11
VCancer
p5650
sg13
I1
sasa(dp5651
g2
VThe high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma.
p5652
sg4
(lp5653
(dp5654
g7
I23
sg8
g24
sg10
I7
sg11
VmiR-940
p5655
sg13
I1
sasg14
(lp5656
(dp5657
g7
I83
sg17
VC0279663
p5658
sg10
I33
sg11
Vovarian serous cystadenocarcinoma
p5659
sg13
I3
sasa(dp5660
g2
VIn our study, real-time (RT) quantitative PCR indicated that miR-940 levels were upregulated in human cervical cancer tissue samples and cell lines.
p5661
sg4
(lp5662
sg14
(lp5663
(dp5664
g7
I102
sg17
VC0302592
p5665
sg10
I15
sg11
Vcervical cancer
p5666
sg13
I2
sasa(dp5667
g2
VEctopic miR-940 accelerated cervical cancer cell growth, proliferation and cell cycle arrest in vitro as well as tumor formation in vivo.
p5668
sg4
(lp5669
sg14
(lp5670
(dp5671
g7
I37
sg17
VC1516170
p5672
sg10
I18
sg11
Vcancer cell growth
p5673
sg13
I3
sa(dp5674
g7
I113
sg17
VC0027651
p5675
sg10
I5
sg11
Vtumor
p5676
sg13
I1
sa(dp5677
g7
I57
sg17
VC0334094
p5678
sg10
I13
sg11
Vproliferation
p5679
sg13
I1
sasa(dp5680
g2
Vp27 and PTEN were evidenced as direct targets for miR-940 and inhibition of p27 and PTEN recovered the suppressive function of miR-940-silenced cell towards to proliferation and tumorigenicity in cervical cancer cells.
p5681
sg4
(lp5682
(dp5683
g7
I0
sg8
VP40305
p5684
sg10
I3
sg11
Vp27
p5685
sg13
I1
sa(dp5686
g7
I8
sg8
VP60484
p5687
sg10
I4
sg11
VPTEN
p5688
sg13
I1
sa(dp5689
g7
I0
sg8
VP40305
p5690
sg10
I3
sg11
Vp27
p5691
sg13
I1
sa(dp5692
g7
I8
sg8
VP60484
p5693
sg10
I4
sg11
VPTEN
p5694
sg13
I1
sasg14
(lp5695
(dp5696
g7
I196
sg17
VC0302592
p5697
sg10
I15
sg11
Vcervical cancer
p5698
sg13
I2
sa(dp5699
g7
I160
sg17
VC0334094
p5700
sg10
I13
sg11
Vproliferation
p5701
sg13
I1
sa(dp5702
g7
I178
sg17
VC1519697
p5703
sg10
I14
sg11
Vtumorigenicity
p5704
sg13
I1
sasa(dp5705
g2
VIn addition, miR-940 expression was inversely associated with p27 and PTEN expression levels and actively with cyclin D1 in cervical cancer specimens.
p5706
sg4
(lp5707
(dp5708
g7
I111
sg8
VP24385
p5709
sg10
I9
sg11
Vcyclin D1
p5710
sg13
I2
sa(dp5711
g7
I62
sg8
VP40305
p5712
sg10
I3
sg11
Vp27
p5713
sg13
I1
sa(dp5714
g7
I70
sg8
VP60484
p5715
sg10
I4
sg11
VPTEN
p5716
sg13
I1
sasg14
(lp5717
(dp5718
g7
I124
sg17
VC0302592
p5719
sg10
I15
sg11
Vcervical cancer
p5720
sg13
I2
sasa(dp5721
g2
VThe results from our study demonstrated that miR-940 regulated p27 and PTEN post-transcriptionally and might play a significant role in cervical cancer development and progression.
p5722
sg4
(lp5723
(dp5724
g7
I45
sg8
g24
sg10
I7
sg11
VmiR-940
p5725
sg13
I1
sa(dp5726
g7
I71
sg8
VP60484
p5727
sg10
I4
sg11
VPTEN
p5728
sg13
I1
sa(dp5729
g7
I63
sg8
VP40305
p5730
sg10
I3
sg11
Vp27
p5731
sg13
I1
sasg14
(lp5732
(dp5733
g7
I136
sg17
VC0302592
p5734
sg10
I15
sg11
Vcervical cancer
p5735
sg13
I2
sasa(dp5736
g2
VThus, miR-940 might provide a potential value as therapeutic target for cervical cancer treatment in future.
p5737
sg4
(lp5738
(dp5739
g7
I6
sg8
g24
sg10
I7
sg11
VmiR-940
p5740
sg13
I1
sasg14
(lp5741
(dp5742
g7
I72
sg17
VC0302592
p5743
sg10
I15
sg11
Vcervical cancer
p5744
sg13
I2
sasa(dp5745
g2
VWe aimed to explore the roles and regulatory mechanism of microRNA-940 (miR-940) in bladder cancer development.
p5746
sg4
(lp5747
sg14
(lp5748
(dp5749
g7
I84
sg17
VC0699885
p5750
sg10
I14
sg11
Vbladder cancer
p5751
sg13
I2
sasa(dp5752
g2
VThe expressions of miR-940 in bladder cancer tissues and cells were measured.
p5753
sg4
(lp5754
sg14
(lp5755
(dp5756
g7
I30
sg17
VC0699885
p5757
sg10
I14
sg11
Vbladder cancer
p5758
sg13
I2
sasa(dp5759
g2
VmiR-940 was up-regulated in bladder cancer tissues and cells.
p5760
sg4
(lp5761
sg14
(lp5762
(dp5763
g7
I28
sg17
VC0699885
p5764
sg10
I14
sg11
Vbladder cancer
p5765
sg13
I2
sasa(dp5766
g2
VOverexpression of miR-940 significantly increased bladder cancer cell proliferation, promoted migration and invasion, and inhibited cell apoptosis.
p5767
sg4
(lp5768
sg14
(lp5769
(dp5770
g7
I108
sg17
VC2699153
p5771
sg10
I8
sg11
Vinvasion
p5772
sg13
I1
sa(dp5773
g7
I50
sg17
VC0699885
p5774
sg10
I14
sg11
Vbladder cancer
p5775
sg13
I2
sa(dp5776
g7
I70
sg17
VC0334094
p5777
sg10
I13
sg11
Vproliferation
p5778
sg13
I1
sasa(dp5779
g2
VINPP4A and GSK3Beta were the direct targets of miR-940, and knockdown of INPP4A or GSK3Beta significantly increased cancer cell proliferation, migration and invasion, and inhibited cell apoptosis.
p5780
sg4
(lp5781
(dp5782
g7
I0
sg8
g24
sg10
I6
sg11
VINPP4A
p5783
sg13
I1
sa(dp5784
g7
I0
sg8
g24
sg10
I6
sg11
VINPP4A
p5785
sg13
I1
sasg14
(lp5786
(dp5787
g7
I128
sg17
VC0334094
p5788
sg10
I13
sg11
Vproliferation
p5789
sg13
I1
sa(dp5790
g7
I157
sg17
VC2699153
p5791
sg10
I8
sg11
Vinvasion
p5792
sg13
I1
sa(dp5793
g7
I116
sg17
VC0006826
p5794
sg10
I6
sg11
Vcancer
p5795
sg13
I1
sasa(dp5796
g2
VOur results indicate that overexpression of miR-940 may promote bladder cancer cell proliferation, migration and invasion, and inhibited cell apoptosis via targeting INPP4A or GSK3Beta and activating Wnt/Beta-catenin pathway.
p5797
sg4
(lp5798
(dp5799
g7
I44
sg8
g24
sg10
I7
sg11
VmiR-940
p5800
sg13
I1
sa(dp5801
g7
I166
sg8
g24
sg10
I6
sg11
VINPP4A
p5802
sg13
I1
sasg14
(lp5803
(dp5804
g7
I113
sg17
VC2699153
p5805
sg10
I8
sg11
Vinvasion
p5806
sg13
I1
sa(dp5807
g7
I64
sg17
VC0699885
p5808
sg10
I14
sg11
Vbladder cancer
p5809
sg13
I2
sa(dp5810
g7
I84
sg17
VC0334094
p5811
sg10
I13
sg11
Vproliferation
p5812
sg13
I1
sasa(dp5813
g2
VExpressions of miR-940, miR-15a, miR-16 and IL-23 in PTC tissues might be useful biomarkers and promising targets in the diagnosis of papillary thyroid carcinoma.
p5814
sg4
(lp5815
(dp5816
g7
I24
sg8
g24
sg10
I7
sg11
VmiR-15a
p5817
sg13
I1
sa(dp5818
g7
I44
sg8
g24
sg10
I5
sg11
VIL-23
p5819
sg13
I1
sa(dp5820
g7
I15
sg8
g24
sg10
I7
sg11
VmiR-940
p5821
sg13
I1
sa(dp5822
g7
I33
sg8
g24
sg10
I6
sg11
VmiR-16
p5823
sg13
I1
sa(dp5824
g7
I53
sg8
g24
sg10
I3
sg11
VPTC
p5825
sg13
I1
sasg14
(lp5826
(dp5827
g7
I134
sg17
VC0238463
p5828
sg10
I27
sg11
Vpapillary thyroid carcinoma
p5829
sg13
I3
sa(dp5830
g7
I53
sg17
VC0238463
p5831
sg10
I3
sg11
VPTC
p5832
sg13
I1
sasa(dp5833
g2
VThis study investigated the pivotal role of miR-940 in the progression of ovarian cancer and to reveal the possible molecular mechanism of its action.
p5834
sg4
(lp5835
sg14
(lp5836
(dp5837
g7
I74
sg17
VC1140680
p5838
sg10
I14
sg11
Vovarian cancer
p5839
sg13
I2
sasa(dp5840
g2
VOvarian cancer OVCAR3 cells were transfected with the miR-940 vector, miR-940 inhibitor, and/or small interfering RNA (siRNA) targeting PKC-Delta (si-PKC-Delta), respectively.
p5841
sg4
(lp5842
(dp5843
g7
I147
sg8
VP17252
p5844
sg10
I12
sg11
Vsi-PKC-Delta
p5845
sg13
I1
sa(dp5846
g7
I136
sg8
VP17252
p5847
sg10
I9
sg11
VPKC-Delta
p5848
sg13
I1
sasg14
(lp5849
(dp5850
g7
I0
sg17
VC1140680
p5851
sg10
I14
sg11
VOvarian cancer
p5852
sg13
I2
sa(dp5853
g7
I136
sg17
VC1868682
p5854
sg10
I3
sg11
VPKC
p5855
sg13
I1
sa(dp5856
g7
I136
sg17
VC1868682
p5857
sg10
I3
sg11
VPKC
p5858
sg13
I1
sasa(dp5859
g2
VTaken together, the results of our study suggest that upregulation of miR-940 may function as a suppressor in the progression of ovarian cancer by inhibiting cell proliferation and inducing apoptosis by targeting PKC-Delta.
p5860
sg4
(lp5861
(dp5862
g7
I213
sg8
VP17252
p5863
sg10
I9
sg11
VPKC-Delta
p5864
sg13
I1
sa(dp5865
g7
I70
sg8
g24
sg10
I7
sg11
VmiR-940
p5866
sg13
I1
sasg14
(lp5867
(dp5868
g7
I129
sg17
VC1140680
p5869
sg10
I14
sg11
Vovarian cancer
p5870
sg13
I2
sa(dp5871
g7
I213
sg17
VC1868682
p5872
sg10
I3
sg11
VPKC
p5873
sg13
I1
sa(dp5874
g7
I163
sg17
VC0334094
p5875
sg10
I13
sg11
Vproliferation
p5876
sg13
I1
sasa(dp5877
g2
VThis study may provide a basis for the possible application of miR-940 in illustrating the molecular pathogenic mechanism of ovarian cancer.
p5878
sg4
(lp5879
sg14
(lp5880
(dp5881
g7
I125
sg17
VC1140680
p5882
sg10
I14
sg11
Vovarian cancer
p5883
sg13
I2
sasa(dp5884
g2
VTo investigate the expression of miR-940 in the hepatocellular carcinoma (HCC) and its impact on function and biological mechanism in the HCC cells.
p5885
sg4
(lp5886
sg14
(lp5887
(dp5888
g7
I74
sg17
VC2239176
p5889
sg10
I3
sg11
VHCC
p5890
sg13
I1
sa(dp5891
g7
I74
sg17
VC2239176
p5892
sg10
I3
sg11
VHCC
p5893
sg13
I1
sa(dp5894
g7
I48
sg17
VC2239176
p5895
sg10
I24
sg11
Vhepatocellular carcinoma
p5896
sg13
I2
sasa(dp5897
g2
VGene variants known to contribute to Autoimmune Addison's disease (AAD) susceptibility include those at the MHC, MICA, CIITA, CTLA4, PTPN22, CYP27B1, NLRP-1 and CD274 loci.
p5898
sg4
(lp5899
(dp5900
g7
I108
sg8
VP13747
p5901
sg10
I3
sg11
VMHC
p5902
sg13
I1
sa(dp5903
g7
I161
sg8
g24
sg10
I10
sg11
VCD274 loci
p5904
sg13
I2
sa(dp5905
g7
I126
sg8
VP16410
p5906
sg10
I5
sg11
VCTLA4
p5907
sg13
I1
sa(dp5908
g7
I141
sg8
g24
sg10
I7
sg11
VCYP27B1
p5909
sg13
I1
sa(dp5910
g7
I150
sg8
g24
sg10
I6
sg11
VNLRP-1
p5911
sg13
I1
sa(dp5912
g7
I119
sg8
VP33076
p5913
sg10
I5
sg11
VCIITA
p5914
sg13
I1
sa(dp5915
g7
I133
sg8
g24
sg10
I6
sg11
VPTPN22
p5916
sg13
I1
sasg14
(lp5917
(dp5918
g7
I67
sg17
VC0271737
p5919
sg10
I3
sg11
VAAD
p5920
sg13
I1
sa(dp5921
g7
I37
sg17
VC0271737
p5922
sg10
I28
sg11
VAutoimmune Addison's disease
p5923
sg13
I3
sa(dp5924
g7
I113
sg17
VC0700319
p5925
sg10
I4
sg11
VMICA
p5926
sg13
I1
sasa(dp5927
g2
VNLRP1 is genetically associated with risk of several autoimmune diseases including generalized vitiligo, Addison disease, type 1 diabetes, rheumatoid arthritis, and others.
p5928
sg4
(lp5929
(dp5930
g7
I0
sg8
g24
sg10
I5
sg11
VNLRP1
p5931
sg13
I1
sasg14
(lp5932
(dp5933
g7
I83
sg17
VC1304470
p5934
sg10
I20
sg11
Vgeneralized vitiligo
p5935
sg13
I2
sa(dp5936
g7
I122
sg17
VC0011854
p5937
sg10
I15
sg11
Vtype 1 diabetes
p5938
sg13
I3
sa(dp5939
g7
I53
sg17
VC0004364
p5940
sg10
I19
sg11
Vautoimmune diseases
p5941
sg13
I2
sa(dp5942
g7
I105
sg17
VC0266273
p5943
sg10
I15
sg11
VAddison disease
p5944
sg13
I2
sa(dp5945
g7
I139
sg17
VC0003873
p5946
sg10
I20
sg11
Vrheumatoid arthritis
p5947
sg13
I2
sasa(dp5948
g2
VInvestigating large patient cohorts from six different autoimmune diseases, that is autoimmune Addison's disease (n=333), type 1 diabetes (n=1086), multiple sclerosis (n=502), rheumatoid arthritis (n=945), systemic lupus erythematosus (n=156) and juvenile idiopathic arthritis (n=505), against 3273 healthy controls, we analyzed four single nucleotide polymorphisms (SNPs) in NALP1.
p5949
sg4
(lp5950
(dp5951
g7
I376
sg8
g24
sg10
I5
sg11
VNALP1
p5952
sg13
I1
sasg14
(lp5953
(dp5954
g7
I122
sg17
VC0011854
p5955
sg10
I15
sg11
Vtype 1 diabetes
p5956
sg13
I3
sa(dp5957
g7
I148
sg17
VC0026769
p5958
sg10
I18
sg11
Vmultiple sclerosis
p5959
sg13
I2
sa(dp5960
g7
I176
sg17
VC0003873
p5961
sg10
I20
sg11
Vrheumatoid arthritis
p5962
sg13
I2
sa(dp5963
g7
I206
sg17
VC0024141
p5964
sg10
I28
sg11
Vsystemic lupus erythematosus
p5965
sg13
I3
sa(dp5966
g7
I55
sg17
VC0004364
p5967
sg10
I19
sg11
Vautoimmune diseases
p5968
sg13
I2
sa(dp5969
g7
I247
sg17
VC0553662
p5970
sg10
I29
sg11
Vjuvenile idiopathic arthritis
p5971
sg13
I3
sa(dp5972
g7
I84
sg17
VC0271737
p5973
sg10
I28
sg11
Vautoimmune Addison's disease
p5974
sg13
I3
sasa(dp5975
g2
VForty-four formalin-fixed, paraffin-embedded MRCL samples and 60 control cases (atypical/well-differentiated liposarcoma, pleomorphic liposarcoma, low-grade myofibrosarcoma, etc.)
p5976
sg4
(lp5977
sg14
(lp5978
(dp5979
g7
I109
sg17
VC0205825
p5980
sg10
I24
sg11
Vliposarcoma, pleomorphic
p5981
sg13
I2
sa(dp5982
g7
I109
sg17
VC0023827
p5983
sg10
I11
sg11
Vliposarcoma
p5984
sg13
I1
sa(dp5985
g7
I157
sg17
VC1708751
p5986
sg10
I15
sg11
Vmyofibrosarcoma
p5987
sg13
I1
sasa(dp5988
g2
VThe most frequent acupoints of acupuncture for PCOS were Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongji (CV 3) and Qihai (CV 6).
p5989
sg4
(lp5990
(dp5991
g7
I101
sg8
VP00915
p5992
sg10
I7
sg11
VEX-CA 1
p5993
sg13
I2
sasg14
(lp5994
(dp5995
g7
I47
sg17
VC0032460
p5996
sg10
I4
sg11
VPCOS
p5997
sg13
I1
sasa(dp5998
g2
VIn the modern treatment of acupuncture for PCOS, Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongii (CV 3) and Qihai (CV 6) are most used.
p5999
sg4
(lp6000
(dp6001
g7
I93
sg8
VP00915
p6002
sg10
I7
sg11
VEX-CA 1
p6003
sg13
I2
sasg14
(lp6004
(dp6005
g7
I43
sg17
VC0032460
p6006
sg10
I4
sg11
VPCOS
p6007
sg13
I1
sasa(dp6008
g2
VCarbonic anhydrase II (CA II) has an important role in thyroid hormone synthesis via regulating iodide (I-) transport across thyroidal cell membranes and the existence of autoantibodies against CA I and/or CA II have been shown in sera from patient with various autoimmune diseases such as Sjoegren's Syndrome, Systemic Lupus Erythmatosus, type 1 diabetes, primary biliary cirrhosis and ulcerative colitis.
p6009
sg4
(lp6010
(dp6011
g7
I23
sg8
VP00915
p6012
sg10
I4
sg11
VCA I
p6013
sg13
I2
sa(dp6014
g7
I0
sg8
VP00918
p6015
sg10
I21
sg11
VCarbonic anhydrase II
p6016
sg13
I3
sa(dp6017
g7
I23
sg8
VP00918
p6018
sg10
I5
sg11
VCA II
p6019
sg13
I2
sa(dp6020
g7
I23
sg8
VP00918
p6021
sg10
I5
sg11
VCA II
p6022
sg13
I2
sasg14
(lp6023
(dp6024
g7
I340
sg17
VC0011854
p6025
sg10
I15
sg11
Vtype 1 diabetes
p6026
sg13
I3
sa(dp6027
g7
I387
sg17
VC0009324
p6028
sg10
I18
sg11
Vulcerative colitis
p6029
sg13
I2
sa(dp6030
g7
I320
sg17
VC0024131
p6031
sg10
I5
sg11
VLupus
p6032
sg13
I1
sa(dp6033
g7
I290
sg17
VC1527336
p6034
sg10
I19
sg11
VSjoegren's Syndrome
p6035
sg13
I2
sa(dp6036
g7
I262
sg17
VC0004364
p6037
sg10
I19
sg11
Vautoimmune diseases
p6038
sg13
I2
sa(dp6039
g7
I357
sg17
VC0008312
p6040
sg10
I25
sg11
Vprimary biliary cirrhosis
p6041
sg13
I3
sasa(dp6042
g2
VEfforts to inhibit the chemokine receptor CCR9 using the agent CCX282-B in Crohn's disease were not successful.
p6043
sg4
(lp6044
(dp6045
g7
I23
sg8
VP51686
p6046
sg10
I23
sg11
Vchemokine receptor CCR9
p6047
sg13
I3
sasg14
(lp6048
(dp6049
g7
I75
sg17
VC0010346
p6050
sg10
I15
sg11
VCrohn's disease
p6051
sg13
I2
sasa(dp6052
g2
VOther therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.
p6053
sg4
(lp6054
(dp6055
g7
I112
sg8
g24
sg10
I32
sg11
Vaddressin cell adhesion molecule
p6056
sg13
I4
sa(dp6057
g7
I213
sg8
VP51686
p6058
sg10
I4
sg11
VCCR9
p6059
sg13
I1
sa(dp6060
g7
I269
sg8
g24
sg10
I31
sg11
VSMAD7 antisense oligonucleotide
p6061
sg13
I3
sasg14
(lp6062
(dp6063
g7
I127
sg17
VC0001511
p6064
sg10
I8
sg11
Vadhesion
p6065
sg13
I1
sa(dp6066
g7
I333
sg17
VC0010346
p6067
sg10
I15
sg11
VCrohn's disease
p6068
sg13
I2
sasa(dp6069
g2
VThe chemokine CCL25, and its receptor CCR9, constitute a unique chemokine/receptor pair, which regulates trafficking of T lymphocytes to the small intestine under physiological conditions and is an attractive target for small bowel Crohn's disease drug development.
p6070
sg4
(lp6071
(dp6072
g7
I14
sg8
g24
sg10
I5
sg11
VCCL25
p6073
sg13
I1
sa(dp6074
g7
I38
sg8
VP51686
p6075
sg10
I4
sg11
VCCR9
p6076
sg13
I1
sasg14
(lp6077
(dp6078
g7
I232
sg17
VC0010346
p6079
sg10
I15
sg11
VCrohn's disease
p6080
sg13
I2
sasa(dp6081
g2
VVercirnon is a CCR9 chemokine receptor antagonist being developed for the treatment of Crohn's disease.
p6082
sg4
(lp6083
(dp6084
g7
I15
sg8
VP51686
p6085
sg10
I23
sg11
VCCR9 chemokine receptor
p6086
sg13
I3
sasg14
(lp6087
(dp6088
g7
I87
sg17
VC0010346
p6089
sg10
I15
sg11
VCrohn's disease
p6090
sg13
I2
sasa(dp6091
g2
VIt is well established that the passive trans-placental passage of anti-Ro/SSA antibodies from mother to foetus is associated with the risk to develop an uncommon syndrome named neonatal lupus (NLE), where the congenital heart block represents the most severe clinical feature.
p6092
sg4
(lp6093
(dp6094
g7
I67
sg8
VP19474
p6095
sg10
I22
sg11
Vanti-Ro/SSA antibodies
p6096
sg13
I2
sasg14
(lp6097
(dp6098
g7
I178
sg17
VC0409979
p6099
sg10
I14
sg11
Vneonatal lupus
p6100
sg13
I2
sa(dp6101
g7
I210
sg17
VC0149530
p6102
sg10
I22
sg11
Vcongenital heart block
p6103
sg13
I3
sa(dp6104
g7
I163
sg17
VC0039082
p6105
sg10
I8
sg11
Vsyndrome
p6106
sg13
I1
sasa(dp6107
g2
VThe characteristics of NLE that were studied included congenital complete heart block (CCHB), second degree heart block, and hepatic fibrosis.
p6108
sg4
(lp6109
sg14
(lp6110
(dp6111
g7
I54
sg17
VC0340496
p6112
sg10
I31
sg11
Vcongenital complete heart block
p6113
sg13
I4
sa(dp6114
g7
I94
sg17
VC0264906
p6115
sg10
I25
sg11
Vsecond degree heart block
p6116
sg13
I4
sa(dp6117
g7
I87
sg17
VC0340496
p6118
sg10
I4
sg11
VCCHB
p6119
sg13
I1
sa(dp6120
g7
I125
sg17
VC0239946
p6121
sg10
I16
sg11
Vhepatic fibrosis
p6122
sg13
I2
sasa(dp6123
g2
VSera from patients known to frequently produce precipitating anti-SS-A/Ro antibody (subacute cutaneous lupus erythematosus [SCLE], 56 patients; Sjoegren's syndrome [SS], 41 patients; mothers of infants with neonatal LE [NLE], 10 individuals; infants with congenital heart block [CHB], 5 patients) were tested for reactivity to RoSP7-24 in ELISA.
p6124
sg4
(lp6125
(dp6126
g7
I61
sg8
VP37268
p6127
sg10
I21
sg11
Vanti-SS-A/Ro antibody
p6128
sg13
I2
sasg14
(lp6129
(dp6130
g7
I279
sg17
VC0151517
p6131
sg10
I3
sg11
VCHB
p6132
sg13
I1
sa(dp6133
g7
I144
sg17
VC1527336
p6134
sg10
I19
sg11
VSjoegren's syndrome
p6135
sg13
I2
sa(dp6136
g7
I255
sg17
VC0149530
p6137
sg10
I22
sg11
Vcongenital heart block
p6138
sg13
I3
sa(dp6139
g7
I84
sg17
VC0024140
p6140
sg10
I38
sg11
Vsubacute cutaneous lupus erythematosus
p6141
sg13
I4
sasa(dp6142
g2
VNLE is manifested most typically as transient subacute cutaneous lupus lesions or isolated complete congenital heart block.
p6143
sg4
(lp6144
(dp6145
g7
I0
sg8
g24
sg10
I3
sg11
VNLE
p6146
sg13
I1
sasg14
(lp6147
(dp6148
g7
I46
sg17
VC2362320
p6149
sg10
I24
sg11
Vsubacute cutaneous lupus
p6150
sg13
I3
sa(dp6151
g7
I100
sg17
VC0149530
p6152
sg10
I22
sg11
Vcongenital heart block
p6153
sg13
I3
sasa(dp6154
g2
VOur findings also suggested that the inhibitory effects of AC-93253 iodide on lung cancer progression may be attributable to its ability to modulate multiple proteins, including Src, PI3K, JNK, Paxillin, p130cas, MEK, ERK, and EGFR.
p6155
sg4
(lp6156
(dp6157
g7
I178
sg8
VP12931
p6158
sg10
I3
sg11
VSrc
p6159
sg13
I1
sa(dp6160
g7
I204
sg8
VP56945
p6161
sg10
I7
sg11
Vp130cas
p6162
sg13
I1
sa(dp6163
g7
I183
sg8
VP42336
p6164
sg10
I4
sg11
VPI3K
p6165
sg13
I1
sa(dp6166
g7
I189
sg8
VP53779
p6167
sg10
I3
sg11
VJNK
p6168
sg13
I1
sa(dp6169
g7
I218
sg8
VP29323
p6170
sg10
I3
sg11
VERK
p6171
sg13
I1
sa(dp6172
g7
I194
sg8
VP49023
p6173
sg10
I8
sg11
VPaxillin
p6174
sg13
I1
sa(dp6175
g7
I213
sg8
VP45985
p6176
sg10
I3
sg11
VMEK
p6177
sg13
I1
sasg14
(lp6178
(dp6179
g7
I83
sg17
VC0178874
p6180
sg10
I18
sg11
Vcancer progression
p6181
sg13
I2
sasa(dp6182
g2
VPaxillin and FAK activity are reduced in lung cancer cell lines following wiskostatin and nWASP knockdown as shown by immunofluorescence and western blot.
p6183
sg4
(lp6184
(dp6185
g7
I13
sg8
g24
sg10
I3
sg11
VFAK
p6186
sg13
I1
sa(dp6187
g7
I90
sg8
g24
sg10
I5
sg11
VnWASP
p6188
sg13
I1
sa(dp6189
g7
I0
sg8
VP49023
p6190
sg10
I8
sg11
VPaxillin
p6191
sg13
I1
sasg14
(lp6192
(dp6193
g7
I41
sg17
VC0684249
p6194
sg10
I11
sg11
Vlung cancer
p6195
sg13
I2
sasa(dp6196
g2
VTaken together, these results suggested that treatment with DBL may act as a potential candidate to inhibit lung cancer metastasis by inhibiting MMP-2 and -9 via affecting PI3K/AKT, MAPKs, FAK/paxillin, EMT/Snail and Slug, Nrf2/antioxidant enzymes, and NFKB signaling pathways.
p6197
sg4
(lp6198
(dp6199
g7
I189
sg8
g24
sg10
I3
sg11
VFAK
p6200
sg13
I1
sa(dp6201
g7
I145
sg8
VP08253
p6202
sg10
I5
sg11
VMMP-2
p6203
sg13
I1
sa(dp6204
g7
I217
sg8
g24
sg10
I4
sg11
VSlug
p6205
sg13
I1
sa(dp6206
g7
I177
sg8
g24
sg10
I3
sg11
VAKT
p6207
sg13
I1
sa(dp6208
g7
I203
sg8
g24
sg10
I3
sg11
VEMT
p6209
sg13
I1
sa(dp6210
g7
I172
sg8
VP42336
p6211
sg10
I4
sg11
VPI3K
p6212
sg13
I1
sa(dp6213
g7
I223
sg8
g24
sg10
I4
sg11
VNrf2
p6214
sg13
I1
sa(dp6215
g7
I253
sg8
g24
sg10
I4
sg11
VNFKB
p6216
sg13
I1
sa(dp6217
g7
I182
sg8
g24
sg10
I5
sg11
VMAPKs
p6218
sg13
I1
sa(dp6219
g7
I207
sg8
g24
sg10
I5
sg11
VSnail
p6220
sg13
I1
sa(dp6221
g7
I193
sg8
VP49023
p6222
sg10
I8
sg11
Vpaxillin
p6223
sg13
I1
sasg14
(lp6224
(dp6225
g7
I108
sg17
VC0684249
p6226
sg10
I11
sg11
Vlung cancer
p6227
sg13
I2
sa(dp6228
g7
I120
sg17
VC0027627
p6229
sg10
I10
sg11
Vmetastasis
p6230
sg13
I1
sasa(dp6231
g2
VEL decreased phosphorylation of FAK and its downstream targets, Src, paxillin, and decreased mRNA expression of cell motility-related genes, RhoA, Rac1, and Cdc42 in lung cancer cells.
p6232
sg4
(lp6233
(dp6234
g7
I147
sg8
VP63000
p6235
sg10
I4
sg11
VRac1
p6236
sg13
I1
sa(dp6237
g7
I141
sg8
VP61586
p6238
sg10
I4
sg11
VRhoA
p6239
sg13
I1
sa(dp6240
g7
I32
sg8
g24
sg10
I3
sg11
VFAK
p6241
sg13
I1
sa(dp6242
g7
I64
sg8
VP12931
p6243
sg10
I3
sg11
VSrc
p6244
sg13
I1
sa(dp6245
g7
I157
sg8
VP60953
p6246
sg10
I5
sg11
VCdc42
p6247
sg13
I1
sa(dp6248
g7
I69
sg8
VP49023
p6249
sg10
I8
sg11
Vpaxillin
p6250
sg13
I1
sasg14
(lp6251
(dp6252
g7
I166
sg17
VC0684249
p6253
sg10
I11
sg11
Vlung cancer
p6254
sg13
I2
sasa(dp6255
g2
VIt efficiently inhibits metastasis on NSCLC by reducing vascularization, and eliciting depression of the PI3K-AKT and FAK-Paxillin signaling pathways.
p6256
sg4
(lp6257
(dp6258
g7
I122
sg8
VP49023
p6259
sg10
I8
sg11
VPaxillin
p6260
sg13
I1
sa(dp6261
g7
I110
sg8
g24
sg10
I3
sg11
VAKT
p6262
sg13
I1
sa(dp6263
g7
I105
sg8
VP42336
p6264
sg10
I4
sg11
VPI3K
p6265
sg13
I1
sa(dp6266
g7
I118
sg8
g24
sg10
I3
sg11
VFAK
p6267
sg13
I1
sasg14
(lp6268
(dp6269
g7
I38
sg17
VC0007131
p6270
sg10
I5
sg11
VNSCLC
p6271
sg13
I1
sa(dp6272
g7
I24
sg17
VC0027627
p6273
sg10
I10
sg11
Vmetastasis
p6274
sg13
I1
sa(dp6275
g7
I87
sg17
VC0011581
p6276
sg10
I10
sg11
Vdepression
p6277
sg13
I1
sa(dp6278
g7
I56
sg17
VC0027686
p6279
sg10
I15
sg11
Vvascularization
p6280
sg13
I1
sasa(dp6281
g2
VHere, we assessed the impact of CD101 on the course of inflammatory bowel disease (IBD).
p6282
sg4
(lp6283
(dp6284
g7
I32
sg8
g24
sg10
I5
sg11
VCD101
p6285
sg13
I1
sasg14
(lp6286
(dp6287
g7
I83
sg17
VC0021390
p6288
sg10
I3
sg11
VIBD
p6289
sg13
I1
sa(dp6290
g7
I55
sg17
VC0021390
p6291
sg10
I26
sg11
Vinflammatory bowel disease
p6292
sg13
I3
sasa(dp6293
g2
VUsing a T-cell transfer model of chronic colitis, we found that in recipients of naive T cells from CD101(+/+) donors up to 30% of the recovered lymphocytes expressed CD101, correlating with an increased interleukin (IL)-2-mediated FoxP3 expression.
p6294
sg4
(lp6295
(dp6296
g7
I204
sg8
VP60568
p6297
sg10
I18
sg11
Vinterleukin (IL)-2
p6298
sg13
I2
sa(dp6299
g7
I232
sg8
g24
sg10
I5
sg11
VFoxP3
p6300
sg13
I1
sa(dp6301
g7
I100
sg8
g24
sg10
I5
sg11
VCD101
p6302
sg13
I1
sasg14
(lp6303
(dp6304
g7
I33
sg17
VC0267375
p6305
sg10
I15
sg11
Vchronic colitis
p6306
sg13
I2
sasa(dp6307
g2
VTransfer of CD101(-/-) T cells caused more severe colitis and was associated with an expansion of IL-17-producing T cells and an enhanced expression of IL-2RAlfa/Beta independently of FoxP3.
p6308
sg4
(lp6309
(dp6310
g7
I184
sg8
g24
sg10
I5
sg11
VFoxP3
p6311
sg13
I1
sasg14
(lp6312
(dp6313
g7
I50
sg17
VC0009319
p6314
sg10
I7
sg11
Vcolitis
p6315
sg13
I1
sasa(dp6316
g2
VThe co-transfer of naive and regulatory T cells (Treg) protected most effectively from colitis, when both donor and recipient mice expressed CD101.
p6317
sg4
(lp6318
(dp6319
g7
I141
sg8
g24
sg10
I5
sg11
VCD101
p6320
sg13
I1
sasg14
(lp6321
(dp6322
g7
I87
sg17
VC0009319
p6323
sg10
I7
sg11
Vcolitis
p6324
sg13
I1
sasa(dp6325
g2
VThus, CD101 deficiency is a novel marker for progressive colitis and potential target for therapeutic intervention.
p6326
sg4
(lp6327
(dp6328
g7
I6
sg8
g24
sg10
I5
sg11
VCD101
p6329
sg13
I1
sasg14
(lp6330
(dp6331
g7
I57
sg17
VC0009319
p6332
sg10
I7
sg11
Vcolitis
p6333
sg13
I1
sasa(dp6334
g2
VSubgroups of T cells (Th : CD4(+) or Tc : CD8(+) ); naive (CD27(+) CD28(+) CD45RA(+) CCR7(+) ), central memory (CD27(+) CD28(+) CD45RA(-) CCR7(+) ), effector memory (early differentiated; CD27(+) CD28(+) CD45RA(-) CCR7(-) and late differentiated; CD27(-) CD28(-) CD45RA(-) CCR7(-) ), terminally differentiated effector cells (TEMRA; CD27(-) CD28(-) CD45RA(+) CCR7(-) ) and Treg (CD4(+) CD25(+) FOXP3(+) CD127(-) ) cells, and their expression of CD39, CD45RA, CD101 and CD129, were studied by flow cytometry in T1D and/or coeliac disease children or without any of these diseases (reference group).
p6335
sg4
(lp6336
(dp6337
g7
I247
sg8
VP26842
p6338
sg10
I7
sg11
VCD27(-)
p6339
sg13
I1
sa(dp6340
g7
I445
sg8
VP49961
p6341
sg10
I4
sg11
VCD39
p6342
sg13
I1
sa(dp6343
g7
I255
sg8
VP33681
p6344
sg10
I22
sg11
VCD28(-) CD45RA(-) CCR7
p6345
sg13
I3
sa(dp6346
g7
I27
sg8
VP01730
p6347
sg10
I3
sg11
VCD4
p6348
sg13
I1
sa(dp6349
g7
I341
sg8
VP33681
p6350
sg10
I22
sg11
VCD28(-) CD45RA(+) CCR7
p6351
sg13
I3
sa(dp6352
g7
I247
sg8
VP26842
p6353
sg10
I7
sg11
VCD27(-)
p6354
sg13
I1
sa(dp6355
g7
I112
sg8
VP26842
p6356
sg10
I30
sg11
VCD27(+) CD28(+) CD45RA(-) CCR7
p6357
sg13
I4
sa(dp6358
g7
I42
sg8
VP01732
p6359
sg10
I3
sg11
VCD8
p6360
sg13
I1
sa(dp6361
g7
I59
sg8
VP26842
p6362
sg10
I30
sg11
VCD27(+) CD28(+) CD45RA(+) CCR7
p6363
sg13
I4
sa(dp6364
g7
I188
sg8
VP26842
p6365
sg10
I33
sg11
VCD27(+) CD28(+) CD45RA(-) CCR7(-)
p6366
sg13
I4
sa(dp6367
g7
I459
sg8
g24
sg10
I5
sg11
VCD101
p6368
sg13
I1
sa(dp6369
g7
I469
sg8
g24
sg10
I5
sg11
VCD129
p6370
sg13
I1
sa(dp6371
g7
I379
sg8
VP01730
p6372
sg10
I29
sg11
VCD4(+) CD25(+) FOXP3(+) CD127
p6373
sg13
I4
sasg14
(lp6374
(dp6375
g7
I521
sg17
VC0007570
p6376
sg10
I15
sg11
Vcoeliac disease
p6377
sg13
I2
sasa(dp6378
g2
VChildren with exclusively coeliac disease had a higher MFI of CD101 (P &lt; 0*01), as well as a higher percentage of CD129(+) (P &lt; 0*05), in the CD4(+) CD25(hi) lymphocyte population, compared to references.
p6379
sg4
(lp6380
(dp6381
g7
I62
sg8
g24
sg10
I5
sg11
VCD101
p6382
sg13
I1
sa(dp6383
g7
I148
sg8
VP01730
p6384
sg10
I11
sg11
VCD4(+) CD25
p6385
sg13
I2
sasg14
(lp6386
(dp6387
g7
I26
sg17
VC0007570
p6388
sg10
I15
sg11
Vcoeliac disease
p6389
sg13
I2
sasa(dp6390
g2
VConversely, children with coeliac disease show signs of CD101(+) /CD129(+) Treg cells that may indicate suppressor activity.
p6391
sg4
(lp6392
(dp6393
g7
I66
sg8
g24
sg10
I5
sg11
VCD129
p6394
sg13
I1
sasg14
(lp6395
(dp6396
g7
I26
sg17
VC0007570
p6397
sg10
I15
sg11
Vcoeliac disease
p6398
sg13
I2
sasa(dp6399
g2
VFurther, to define the mechanism of action that explains the differential ability of C57BL/6 Treg versus dnTGF-BetaRII Treg on the ability to down-regulate autoimmune cholangitis, we noted significant differential expression of glycoprotein A repetitions predominant (GARP), CD73, CD101 and CD103 and a functionally significant increase in interleukin (IL)-10 in Treg from C57BL/6 compared to dnTGF-BetaRII mice.
p6400
sg4
(lp6401
(dp6402
g7
I340
sg8
VP60568
p6403
sg10
I19
sg11
Vinterleukin (IL)-10
p6404
sg13
I2
sa(dp6405
g7
I275
sg8
VP21589
p6406
sg10
I4
sg11
VCD73
p6407
sg13
I1
sa(dp6408
g7
I291
sg8
VP38570
p6409
sg10
I5
sg11
VCD103
p6410
sg13
I1
sa(dp6411
g7
I281
sg8
g24
sg10
I5
sg11
VCD101
p6412
sg13
I1
sa(dp6413
g7
I228
sg8
VP55822
p6414
sg10
I38
sg11
Vglycoprotein A repetitions predominant
p6415
sg13
I4
sa(dp6416
g7
I268
sg8
VP55822
p6417
sg10
I4
sg11
VGARP
p6418
sg13
I1
sasg14
(lp6419
(dp6420
g7
I167
sg17
VC0008311
p6421
sg10
I11
sg11
Vcholangitis
p6422
sg13
I1
sa(dp6423
g7
I156
sg17
VC0443146
p6424
sg10
I10
sg11
Vautoimmune
p6425
sg13
I1
sasa(dp6426
g2
VCD101-knockout mice generated on the B6 background also exhibit substantially more severe N. aromaticivorans-induced liver disease correlating with increased IFN-Gamma and IL-17 responses compared with wild-type mice.
p6427
sg4
(lp6428
(dp6429
g7
I0
sg8
g24
sg10
I5
sg11
VCD101
p6430
sg13
I1
sa(dp6431
g7
I158
sg8
VP01579
p6432
sg10
I9
sg11
VIFN-Gamma
p6433
sg13
I1
sasg14
(lp6434
(dp6435
g7
I117
sg17
VC0023895
p6436
sg10
I13
sg11
Vliver disease
p6437
sg13
I2
sasa(dp6438
g2
VGastric juice from 15 normals, 20 patients with gastric ulcer and 14 patients with erosive haemorrhagic gastroduodenitis was investigated in respect of its activity on unheated and heated fibrin plates and its content of FDP and plasminogen or plasmin with immunochemical methods.
p6439
sg4
(lp6440
(dp6441
g7
I188
sg8
VP22087
p6442
sg10
I6
sg11
Vfibrin
p6443
sg13
I1
sa(dp6444
g7
I221
sg8
g24
sg10
I3
sg11
VFDP
p6445
sg13
I1
sa(dp6446
g7
I229
sg8
VP00747
p6447
sg10
I11
sg11
Vplasminogen
p6448
sg13
I1
sa(dp6449
g7
I229
sg8
VP00747
p6450
sg10
I7
sg11
Vplasmin
p6451
sg13
I1
sasg14
(lp6452
(dp6453
g7
I48
sg17
VC0038358
p6454
sg10
I13
sg11
Vgastric ulcer
p6455
sg13
I2
sa(dp6456
g7
I104
sg17
VC0267166
p6457
sg10
I16
sg11
Vgastroduodenitis
p6458
sg13
I1
sasa(dp6459
g2
VThe patients with erosive haemorrhagic gastroduodenitis showed no increase in fibrinolysis in the blood, but low values for plasminogen and alpha2-M, and the serum contained FDP.
p6460
sg4
(lp6461
(dp6462
g7
I174
sg8
g24
sg10
I3
sg11
VFDP
p6463
sg13
I1
sa(dp6464
g7
I124
sg8
VP00747
p6465
sg10
I11
sg11
Vplasminogen
p6466
sg13
I1
sasg14
(lp6467
(dp6468
g7
I39
sg17
VC0267166
p6469
sg10
I16
sg11
Vgastroduodenitis
p6470
sg13
I1
sasa(dp6471
g2
VIn the patient's lymphocytes, mRNA expression of TGFBeta2 was lower than control, and might cause DORV as it does in TGFBeta2-deficient mice.
p6472
sg4
(lp6473
sg14
(lp6474
(dp6475
g7
I98
sg17
VC0013069
p6476
sg10
I4
sg11
VDORV
p6477
sg13
I1
sasa(dp6478
g2
VActivin BA, follistatin, and activin receptor type IIA proteins were observed in normal and cleft palate tissues throughout pregnancy (gestational weeks 11 to 40).
p6479
sg4
(lp6480
(dp6481
g7
I0
sg8
VP58166
p6482
sg10
I7
sg11
VActivin
p6483
sg13
I1
sa(dp6484
g7
I29
sg8
VP27037
p6485
sg10
I34
sg11
Vactivin receptor type IIA proteins
p6486
sg13
I5
sasg14
(lp6487
(dp6488
g7
I92
sg17
VC0008925
p6489
sg10
I12
sg11
Vcleft palate
p6490
sg13
I2
sasa(dp6491
g2
VWe have previously shown that follistatin-deficient mice have numerous embryonic defects including shiny, taut skin, growth retardation, and cleft palate leading to death within hours of birth.
p6492
sg4
(lp6493
(dp6494
g7
I30
sg8
VP19883
p6495
sg10
I11
sg11
Vfollistatin
p6496
sg13
I1
sasg14
(lp6497
(dp6498
g7
I117
sg17
VC0151686
p6499
sg10
I18
sg11
Vgrowth retardation
p6500
sg13
I2
sa(dp6501
g7
I141
sg17
VC0008925
p6502
sg10
I12
sg11
Vcleft palate
p6503
sg13
I2
sasa(dp6504
g2
VTwo rheumatic disease patients had a relatively high titer of IgG(2)anti-p80-coilin antibodies.
p6505
sg4
(lp6506
(dp6507
g7
I62
sg8
VP38432
p6508
sg10
I32
sg11
VIgG(2)anti-p80-coilin antibodies
p6509
sg13
I2
sasg14
(lp6510
(dp6511
g7
I4
sg17
VC0035435
p6512
sg10
I17
sg11
Vrheumatic disease
p6513
sg13
I2
sasa(dp6514
g2
VThe IgG(2)subclass of anti-p80-coilin antibodies may be a specific marker for systemic autoimmune disease.
p6515
sg4
(lp6516
(dp6517
g7
I22
sg8
VP38432
p6518
sg10
I26
sg11
Vanti-p80-coilin antibodies
p6519
sg13
I2
sasg14
(lp6520
(dp6521
g7
I78
sg17
VC2895206
p6522
sg10
I27
sg11
Vsystemic autoimmune disease
p6523
sg13
I3
sasa(dp6524
g2
VThe patients with localized scleroderma who were positive for anti-p80-coilin antibody had all been classified as having linear scleroderma.
p6525
sg4
(lp6526
(dp6527
g7
I62
sg8
VP38432
p6528
sg10
I24
sg11
Vanti-p80-coilin antibody
p6529
sg13
I2
sasg14
(lp6530
(dp6531
g7
I18
sg17
VC0036420
p6532
sg10
I21
sg11
Vlocalized scleroderma
p6533
sg13
I2
sa(dp6534
g7
I121
sg17
VC0263409
p6535
sg10
I18
sg11
Vlinear scleroderma
p6536
sg13
I2
sasa(dp6537
g2
VOur data indicate that anti-p80-coilin antibody is uncommon in skin diseases: however, this antibody is present in patients with a milder form of linear scleroderma, although the incidence of positivity may not be high.
p6538
sg4
(lp6539
(dp6540
g7
I23
sg8
VP38432
p6541
sg10
I24
sg11
Vanti-p80-coilin antibody
p6542
sg13
I2
sasg14
(lp6543
(dp6544
g7
I63
sg17
VC0037274
p6545
sg10
I13
sg11
Vskin diseases
p6546
sg13
I2
sa(dp6547
g7
I146
sg17
VC0263409
p6548
sg10
I18
sg11
Vlinear scleroderma
p6549
sg13
I2
sasa(dp6550
g2
VWe also discuss several of the antigen-autoantibody systems found in systemic lupus erythematosus (Smith antigen, U1-nuclear ribonucleoprotein, SS-A/Ro, SS-B/La, proliferating cell nuclear antigen ribosomal ribonucleoprotein, double-strand DNA, histones, antiphospholipids, Ku, Ki/SL), systemic sclerosis (centromere, topo I, RNA polymerases, fibrillarin, polymyositis-Scl, Th/To), polymyositis/dermatomyositis (transferRNA synthetases, signal recognition particle, and others), and SS (SS-A/Ro, SS-B/La, nucleolar organizing region-90, p80-coilin), addressing their clinical significance, common detection methods, immunogenetic associations, and the molecular and cellular biology of the cognate antigens.
p6551
sg4
(lp6552
(dp6553
g7
I162
sg8
VP12004
p6554
sg10
I62
sg11
Vproliferating cell nuclear antigen ribosomal ribonucleoprotein
p6555
sg13
I6
sa(dp6556
g7
I144
sg8
VP37268
p6557
sg10
I4
sg11
VSS-A
p6558
sg13
I1
sa(dp6559
g7
I326
sg8
g24
sg10
I15
sg11
VRNA polymerases
p6560
sg13
I2
sa(dp6561
g7
I343
sg8
VP22087
p6562
sg10
I11
sg11
Vfibrillarin
p6563
sg13
I1
sa(dp6564
g7
I537
sg8
VP20333
p6565
sg10
I3
sg11
Vp80
p6566
sg13
I1
sa(dp6567
g7
I153
sg8
VP37268
p6568
sg10
I4
sg11
VSS-B
p6569
sg13
I1
sa(dp6570
g7
I114
sg8
VP26599
p6571
sg10
I28
sg11
VU1-nuclear ribonucleoprotein
p6572
sg13
I2
sa(dp6573
g7
I541
sg8
VP38432
p6574
sg10
I6
sg11
Vcoilin
p6575
sg13
I1
sa(dp6576
g7
I99
sg8
VP14209
p6577
sg10
I13
sg11
VSmith antigen
p6578
sg13
I2
sa(dp6579
g7
I153
sg8
VP37268
p6580
sg10
I4
sg11
VSS-B
p6581
sg13
I1
sasg14
(lp6582
(dp6583
g7
I286
sg17
VC0036421
p6584
sg10
I18
sg11
Vsystemic sclerosis
p6585
sg13
I2
sa(dp6586
g7
I356
sg17
VC0085655
p6587
sg10
I12
sg11
Vpolymyositis
p6588
sg13
I1
sa(dp6589
g7
I69
sg17
VC0024141
p6590
sg10
I28
sg11
Vsystemic lupus erythematosus
p6591
sg13
I3
sa(dp6592
g7
I356
sg17
VC0085655
p6593
sg10
I12
sg11
Vpolymyositis
p6594
sg13
I1
sa(dp6595
g7
I395
sg17
VC0221056
p6596
sg10
I15
sg11
Vdermatomyositis
p6597
sg13
I1
sasa(dp6598
g2
VHowever, IL-17 deficiency did not affect the development of dermatitis at all, in clear contrast to that of arthritis and aortitis.
p6599
sg4
(lp6600
sg14
(lp6601
(dp6602
g7
I108
sg17
VC0003864
p6603
sg10
I9
sg11
Varthritis
p6604
sg13
I1
sa(dp6605
g7
I122
sg17
VC0003509
p6606
sg10
I8
sg11
Vaortitis
p6607
sg13
I1
sa(dp6608
g7
I60
sg17
VC0011603
p6609
sg10
I10
sg11
Vdermatitis
p6610
sg13
I1
sasa(dp6611
g2
VThe development of arthritis and aortitis was significantly suppressed by the deficiency of TNFalpha or IL-17.
p6612
sg4
(lp6613
(dp6614
g7
I92
sg8
VP01375
p6615
sg10
I8
sg11
VTNFalpha
p6616
sg13
I1
sasg14
(lp6617
(dp6618
g7
I19
sg17
VC0003864
p6619
sg10
I9
sg11
Varthritis
p6620
sg13
I1
sa(dp6621
g7
I33
sg17
VC0003509
p6622
sg10
I8
sg11
Vaortitis
p6623
sg13
I1
sasa(dp6624
g2
VApolipoprotein E (ApoE) has been extensively studied in Alzheimer's disease (AD), but little is known of apolipoprotein A-I (ApoA-I) in cerebrospinal fluid (CSF).
p6625
sg4
(lp6626
(dp6627
g7
I105
sg8
VP02647
p6628
sg10
I18
sg11
Vapolipoprotein A-I
p6629
sg13
I2
sa(dp6630
g7
I18
sg8
VP02649
p6631
sg10
I4
sg11
VApoE
p6632
sg13
I1
sa(dp6633
g7
I0
sg8
VP02649
p6634
sg10
I16
sg11
VApolipoprotein E
p6635
sg13
I2
sa(dp6636
g7
I125
sg8
VP02647
p6637
sg10
I6
sg11
VApoA-I
p6638
sg13
I1
sasg14
(lp6639
(dp6640
g7
I56
sg17
VC1521724
p6641
sg10
I19
sg11
VAlzheimer's disease
p6642
sg13
I2
sa(dp6643
g7
I77
sg17
VC1521724
p6644
sg10
I2
sg11
VAD
p6645
sg13
I1
sasa(dp6646
g2
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p6647
sg4
(lp6648
(dp6649
g7
I2137
sg8
VP21579
p6650
sg10
I4
sg11
VSyt1
p6651
sg13
I1
sa(dp6652
g7
I1886
sg8
VP02647
p6653
sg10
I5
sg11
VApoA1
p6654
sg13
I1
sa(dp6655
g7
I1065
sg8
VP00390
p6656
sg10
I10
sg11
VLZ-H group
p6657
sg13
I2
sa(dp6658
g7
I2142
sg8
VP02649
p6659
sg10
I4
sg11
VApoE
p6660
sg13
I1
sa(dp6661
g7
I145
sg8
VP48651
p6662
sg10
I8
sg11
VAPP/PS-1
p6663
sg13
I1
sa(dp6664
g7
I2142
sg8
VP02649
p6665
sg10
I4
sg11
VApoE
p6666
sg13
I1
sa(dp6667
g7
I2603
sg8
g24
sg10
I16
sg11
VABeta-40 protein
p6668
sg13
I2
sa(dp6669
g7
I1886
sg8
VP02647
p6670
sg10
I5
sg11
VApoA1
p6671
sg13
I1
sa(dp6672
g7
I2021
sg8
g24
sg10
I8
sg11
VABeta-40
p6673
sg13
I1
sa(dp6674
g7
I1065
sg8
VP00390
p6675
sg10
I10
sg11
VLZ-H group
p6676
sg13
I2
sa(dp6677
g7
I145
sg8
g24
sg10
I3
sg11
VAPP
p6678
sg13
I1
sa(dp6679
g7
I1065
sg8
VP00390
p6680
sg10
I10
sg11
VLZ-H group
p6681
sg13
I2
sa(dp6682
g7
I149
sg8
VP48651
p6683
sg10
I4
sg11
VPS-1
p6684
sg13
I1
sa(dp6685
g7
I2137
sg8
VP21579
p6686
sg10
I4
sg11
VSyt1
p6687
sg13
I1
sasg14
(lp6688
(dp6689
g7
I102
sg17
VC0004368
p6690
sg10
I12
sg11
Vautoimmunity
p6691
sg13
I1
sa(dp6692
g7
I172
sg17
VC1521724
p6693
sg10
I19
sg11
VAlzheimer's disease
p6694
sg13
I2
sa(dp6695
g7
I2494
sg17
VC0004930
p6696
sg10
I18
sg11
Vbehavior disorders
p6697
sg13
I2
sa(dp6698
g7
I653
sg17
VC0443146
p6699
sg10
I10
sg11
Vautoimmune
p6700
sg13
I1
sa(dp6701
g7
I653
sg17
VC0443146
p6702
sg10
I10
sg11
Vautoimmune
p6703
sg13
I1
sasa(dp6704
g2
VWe aimed to explore the correlations between eukaryotic translation initiation factor 3, subunit A (eIF3a) polymorphisms and susceptibility to and chemoradiotherapy efficacy in cervical carcinoma.
p6705
sg4
(lp6706
(dp6707
g7
I100
sg8
g24
sg10
I5
sg11
VeIF3a
p6708
sg13
I1
sasg14
(lp6709
(dp6710
g7
I177
sg17
VC0302592
p6711
sg10
I18
sg11
Vcervical carcinoma
p6712
sg13
I2
sasa(dp6713
g2
VCompared with carriers of the CC genotype, carriers of the T genotype of the eIF3a Arg803Lys C&gt;T polymorphism had a higher risk of cervical carcinoma.
p6714
sg4
(lp6715
(dp6716
g7
I77
sg8
g24
sg10
I17
sg11
VeIF3a Arg803Lys C
p6717
sg13
I3
sasg14
(lp6718
(dp6719
g7
I134
sg17
VC0302592
p6720
sg10
I18
sg11
Vcervical carcinoma
p6721
sg13
I2
sasa(dp6722
g2
VUnivariate analysis revealed that age, eIF3a Arg803Lys C&gt;T polymorphism, differentiation degree, FIGO stage, and LNM were prognostic factors of cervical carcinoma, and multivariate analysis showed that age &gt;= 60 years, higher FIGO stage, and LNM, as well as the CT and TT genotypes of the eIF3a Arg803Lys C&gt;T polymorphism, were risk factors related to the prognosis of cervical carcinoma.
p6723
sg4
(lp6724
(dp6725
g7
I39
sg8
g24
sg10
I17
sg11
VeIF3a Arg803Lys C
p6726
sg13
I3
sa(dp6727
g7
I39
sg8
g24
sg10
I17
sg11
VeIF3a Arg803Lys C
p6728
sg13
I3
sasg14
(lp6729
(dp6730
g7
I147
sg17
VC0302592
p6731
sg10
I18
sg11
Vcervical carcinoma
p6732
sg13
I2
sa(dp6733
g7
I147
sg17
VC0302592
p6734
sg10
I18
sg11
Vcervical carcinoma
p6735
sg13
I2
sasa(dp6736
g2
VThe eIF3a Arg803Lys C&gt;T polymorphism is connected with a higher susceptibility to cervical carcinoma and may affect chemoradiotherapy efficacy in and prognosis of cervical carcinoma.
p6737
sg4
(lp6738
(dp6739
g7
I4
sg8
g24
sg10
I17
sg11
VeIF3a Arg803Lys C
p6740
sg13
I3
sasg14
(lp6741
(dp6742
g7
I85
sg17
VC0302592
p6743
sg10
I18
sg11
Vcervical carcinoma
p6744
sg13
I2
sa(dp6745
g7
I85
sg17
VC0302592
p6746
sg10
I18
sg11
Vcervical carcinoma
p6747
sg13
I2
sasa(dp6748
g2
VThese findings suggest that the p185 neu may be a prognostic indicator not only for breast adenocarcinomas but also for lymphoproliferative disorders, and that the transforming p185 protein may be involved in the mechanisms of aggressive expansion of lymphoid neoplasias.
p6749
sg4
(lp6750
(dp6751
g7
I37
sg8
VP04626
p6752
sg10
I3
sg11
Vneu
p6753
sg13
I1
sa(dp6754
g7
I32
sg8
g24
sg10
I4
sg11
Vp185
p6755
sg13
I1
sa(dp6756
g7
I177
sg8
g24
sg10
I12
sg11
Vp185 protein
p6757
sg13
I2
sasg14
(lp6758
(dp6759
g7
I227
sg17
VC0001807
p6760
sg10
I10
sg11
Vaggressive
p6761
sg13
I1
sa(dp6762
g7
I91
sg17
VC0001418
p6763
sg10
I15
sg11
Vadenocarcinomas
p6764
sg13
I1
sa(dp6765
g7
I120
sg17
VC0024314
p6766
sg10
I29
sg11
Vlymphoproliferative disorders
p6767
sg13
I2
sa(dp6768
g7
I260
sg17
VC0027651
p6769
sg10
I10
sg11
Vneoplasias
p6770
sg13
I1
sasa(dp6771
g2
VThe authors investigated the correlation between clinicopathologic factors and the overexpression of the p185(HER2) in Korean gastric adenocarcinoma patients, and determined whether the antiproliferative effects of anti- p185(HER2) antibody can also be observed on gastric cancer cell lines that overexpress this growth factor receptor.
p6772
sg4
(lp6773
(dp6774
g7
I215
sg8
g24
sg10
I10
sg11
Vanti- p185
p6775
sg13
I2
sa(dp6776
g7
I110
sg8
VP04626
p6777
sg10
I4
sg11
VHER2
p6778
sg13
I1
sa(dp6779
g7
I105
sg8
g24
sg10
I4
sg11
Vp185
p6780
sg13
I1
sa(dp6781
g7
I313
sg8
g24
sg10
I22
sg11
Vgrowth factor receptor
p6782
sg13
I3
sa(dp6783
g7
I110
sg8
VP04626
p6784
sg10
I4
sg11
VHER2
p6785
sg13
I1
sasg14
(lp6786
(dp6787
g7
I265
sg17
VC0024623
p6788
sg10
I14
sg11
Vgastric cancer
p6789
sg13
I2
sa(dp6790
g7
I126
sg17
VC0278701
p6791
sg10
I22
sg11
Vgastric adenocarcinoma
p6792
sg13
I2
sasa(dp6793
g2
VWe evaluated the relationship between p185(HER2) overexpression and clinicopathological features in 94 (M: F=52: 42) gastric adenocarcinoma patients (median age 59 years).
p6794
sg4
(lp6795
(dp6796
g7
I43
sg8
VP04626
p6797
sg10
I4
sg11
VHER2
p6798
sg13
I1
sa(dp6799
g7
I38
sg8
g24
sg10
I4
sg11
Vp185
p6800
sg13
I1
sasg14
(lp6801
(dp6802
g7
I117
sg17
VC0278701
p6803
sg10
I22
sg11
Vgastric adenocarcinoma
p6804
sg13
I2
sasa(dp6805
g2
VTo explore the role of humanized anti-p185(HER2) monoclonal antibody trastuzumab (Herceptin ) in vitro, the growth curve of Korean gastric cancer cells that overexpress the p185(HER2) protein was studied and a cell cycle analysis was performed.
p6806
sg4
(lp6807
(dp6808
g7
I43
sg8
VP04626
p6809
sg10
I4
sg11
VHER2
p6810
sg13
I1
sa(dp6811
g7
I23
sg8
g24
sg10
I19
sg11
Vhumanized anti-p185
p6812
sg13
I2
sa(dp6813
g7
I43
sg8
VP04626
p6814
sg10
I4
sg11
VHER2
p6815
sg13
I1
sa(dp6816
g7
I38
sg8
g24
sg10
I4
sg11
Vp185
p6817
sg13
I1
sasg14
(lp6818
(dp6819
g7
I131
sg17
VC0024623
p6820
sg10
I14
sg11
Vgastric cancer
p6821
sg13
I2
sasa(dp6822
g2
Vp185(HER2) overexpression was found to be more frequent in advanced gastric cancer than early gastric cancer (54.1% vs 24.2%, p=0.008).
p6823
sg4
(lp6824
(dp6825
g7
I5
sg8
VP04626
p6826
sg10
I4
sg11
VHER2
p6827
sg13
I1
sa(dp6828
g7
I0
sg8
g24
sg10
I4
sg11
Vp185
p6829
sg13
I1
sasg14
(lp6830
(dp6831
g7
I88
sg17
VC0349530
p6832
sg10
I20
sg11
Vearly gastric cancer
p6833
sg13
I3
sa(dp6834
g7
I68
sg17
VC0024623
p6835
sg10
I14
sg11
Vgastric cancer
p6836
sg13
I2
sasa(dp6837
g2
VAmong several Korean gastric cancer cell lines, SNU-1, SNU-5, and SNU-620 overexpress p185(HER2).
p6838
sg4
(lp6839
(dp6840
g7
I86
sg8
g24
sg10
I4
sg11
Vp185
p6841
sg13
I1
sa(dp6842
g7
I91
sg8
VP04626
p6843
sg10
I4
sg11
VHER2
p6844
sg13
I1
sasg14
(lp6845
(dp6846
g7
I21
sg17
VC0024623
p6847
sg10
I14
sg11
Vgastric cancer
p6848
sg13
I2
sasa(dp6849
g2
VTrastuzumab inhibited the proliferation of p185(HER2) overexpressed Korean gastric cancer cell line by 21% with down-regulation of p185(HER2) protein expression.
p6850
sg4
(lp6851
(dp6852
g7
I43
sg8
g24
sg10
I4
sg11
Vp185
p6853
sg13
I1
sa(dp6854
g7
I48
sg8
VP04626
p6855
sg10
I4
sg11
VHER2
p6856
sg13
I1
sa(dp6857
g7
I48
sg8
VP04626
p6858
sg10
I4
sg11
VHER2
p6859
sg13
I1
sa(dp6860
g7
I43
sg8
g24
sg10
I4
sg11
Vp185
p6861
sg13
I1
sasg14
(lp6862
(dp6863
g7
I75
sg17
VC0024623
p6864
sg10
I14
sg11
Vgastric cancer
p6865
sg13
I2
sa(dp6866
g7
I26
sg17
VC0334094
p6867
sg10
I13
sg11
Vproliferation
p6868
sg13
I1
sasa(dp6869
g2
VS: Taken together, our observations suggest the potential prognostic significance of p185(HER2) overexpression in Korean gastric adenocarcinoma patients and point to the need for further research on this mechanism.
p6870
sg4
(lp6871
(dp6872
g7
I85
sg8
g24
sg10
I4
sg11
Vp185
p6873
sg13
I1
sa(dp6874
g7
I90
sg8
VP04626
p6875
sg10
I4
sg11
VHER2
p6876
sg13
I1
sasg14
(lp6877
(dp6878
g7
I121
sg17
VC0278701
p6879
sg10
I22
sg11
Vgastric adenocarcinoma
p6880
sg13
I2
sasa(dp6881
g2
VThis suggests the possible use of p185(HER2) as a therapeutic target in gastric cancer.
p6882
sg4
(lp6883
(dp6884
g7
I39
sg8
VP04626
p6885
sg10
I4
sg11
VHER2
p6886
sg13
I1
sa(dp6887
g7
I34
sg8
g24
sg10
I4
sg11
Vp185
p6888
sg13
I1
sasg14
(lp6889
(dp6890
g7
I72
sg17
VC0024623
p6891
sg10
I14
sg11
Vgastric cancer
p6892
sg13
I2
sasa(dp6893
g2
VAdministration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER2, p185), has improved outcomes for patients with HER2-positive gastric cancer (GC), but some relevant issues remain to be investigated and will emerge with new anti-GC drugs.
p6894
sg4
(lp6895
(dp6896
g7
I85
sg8
VP01133
p6897
sg10
I40
sg11
Vhuman epidermal growth factor receptor 2
p6898
sg13
I6
sa(dp6899
g7
I127
sg8
VP04626
p6900
sg10
I4
sg11
VHER2
p6901
sg13
I1
sa(dp6902
g7
I133
sg8
g24
sg10
I4
sg11
Vp185
p6903
sg13
I1
sa(dp6904
g7
I127
sg8
VP04626
p6905
sg10
I4
sg11
VHER2
p6906
sg13
I1
sasg14
(lp6907
(dp6908
g7
I194
sg17
VC0024623
p6909
sg10
I14
sg11
Vgastric cancer
p6910
sg13
I2
sa(dp6911
g7
I210
sg17
VC0024623
p6912
sg10
I2
sg11
VGC
p6913
sg13
I1
sa(dp6914
g7
I210
sg17
VC0024623
p6915
sg10
I2
sg11
VGC
p6916
sg13
I1
sasa(dp6917
g2
VEukaryotic translation initiation factor 3 subunit A (eIF3a) plays critical roles in regulating the initiation of protein translation, and eIF3a is highly expressed in lung cancer.
p6918
sg4
(lp6919
(dp6920
g7
I54
sg8
g24
sg10
I5
sg11
VeIF3a
p6921
sg13
I1
sa(dp6922
g7
I54
sg8
g24
sg10
I5
sg11
VeIF3a
p6923
sg13
I1
sa(dp6924
g7
I0
sg8
g24
sg10
I52
sg11
VEukaryotic translation initiation factor 3 subunit A
p6925
sg13
I7
sasg14
(lp6926
(dp6927
g7
I168
sg17
VC0684249
p6928
sg10
I11
sg11
Vlung cancer
p6929
sg13
I2
sasa(dp6930
g2
VIn this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC).
p6931
sg4
(lp6932
(dp6933
g7
I82
sg8
g24
sg10
I5
sg11
VeIF3a
p6934
sg13
I1
sasg14
(lp6935
(dp6936
g7
I206
sg17
VC0007131
p6937
sg10
I5
sg11
VNSCLC
p6938
sg13
I1
sa(dp6939
g7
I178
sg17
VC0007131
p6940
sg10
I26
sg11
Vnon-small cell lung cancer
p6941
sg13
I4
sasa(dp6942
g2
VThe positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients.
p6943
sg4
(lp6944
(dp6945
g7
I32
sg8
g24
sg10
I5
sg11
VeIF3a
p6946
sg13
I1
sasg14
(lp6947
(dp6948
g7
I122
sg17
VC0007131
p6949
sg10
I5
sg11
VNSCLC
p6950
sg13
I1
sasa(dp6951
g2
VTo investigate the correlation between eukaryotic translation initiation factor 3, subunit A (eIF3a) and human epididymis protein 4 (HE4) expression and ovarian cancer.
p6952
sg4
(lp6953
(dp6954
g7
I133
sg8
VP01031
p6955
sg10
I3
sg11
VHE4
p6956
sg13
I1
sa(dp6957
g7
I105
sg8
VP01031
p6958
sg10
I26
sg11
Vhuman epididymis protein 4
p6959
sg13
I4
sa(dp6960
g7
I94
sg8
g24
sg10
I5
sg11
VeIF3a
p6961
sg13
I1
sasg14
(lp6962
(dp6963
g7
I153
sg17
VC1140680
p6964
sg10
I14
sg11
Vovarian cancer
p6965
sg13
I2
sasa(dp6966
g2
VRT-PCR or immunohistochemistry was used to examine eIF3a and HE4 mRNA or protein expression in ovarian tissues from patients with ovarian cancer (n=181) or benign ovarian tumors, or from the healthy women.
p6967
sg4
(lp6968
(dp6969
g7
I51
sg8
g24
sg10
I5
sg11
VeIF3a
p6970
sg13
I1
sasg14
(lp6971
(dp6972
g7
I130
sg17
VC1140680
p6973
sg10
I14
sg11
Vovarian cancer
p6974
sg13
I2
sa(dp6975
g7
I156
sg17
VC0004997
p6976
sg10
I21
sg11
Vbenign ovarian tumors
p6977
sg13
I3
sasa(dp6978
g2
VThere were significant differences in mRNA and protein expression of eIF3a and HE4 among normal ovarian tissues, benign ovarian tumor tissues, and ovarian cancer tissues (P&lt; 0.05).
p6979
sg4
(lp6980
(dp6981
g7
I69
sg8
g24
sg10
I5
sg11
VeIF3a
p6982
sg13
I1
sasg14
(lp6983
(dp6984
g7
I147
sg17
VC1140680
p6985
sg10
I14
sg11
Vovarian cancer
p6986
sg13
I2
sa(dp6987
g7
I113
sg17
VC0004997
p6988
sg10
I20
sg11
Vbenign ovarian tumor
p6989
sg13
I3
sasa(dp6990
g2
VThere were significant differences in mRNA expression of eIF3a and HE4 between the normal tissues and the ovarian cancer tissues, or between the benign ovarian tumor tissues and the normal tissues (P&lt; 0.001).
p6991
sg4
(lp6992
(dp6993
g7
I57
sg8
g24
sg10
I5
sg11
VeIF3a
p6994
sg13
I1
sasg14
(lp6995
(dp6996
g7
I145
sg17
VC0004997
p6997
sg10
I20
sg11
Vbenign ovarian tumor
p6998
sg13
I3
sa(dp6999
g7
I106
sg17
VC1140680
p7000
sg10
I14
sg11
Vovarian cancer
p7001
sg13
I2
sasa(dp7002
g2
VThe mRNA expression of eIF3a in the normal ovarian tissues was significantly higher than that in the benign ovarian tumor tissues or that in the ovarian cancer tissues.
p7003
sg4
(lp7004
(dp7005
g7
I23
sg8
g24
sg10
I5
sg11
VeIF3a
p7006
sg13
I1
sasg14
(lp7007
(dp7008
g7
I101
sg17
VC0004997
p7009
sg10
I20
sg11
Vbenign ovarian tumor
p7010
sg13
I3
sa(dp7011
g7
I145
sg17
VC1140680
p7012
sg10
I14
sg11
Vovarian cancer
p7013
sg13
I2
sasa(dp7014
g2
VPositive expression rates for eIF3a or HE4 protein in normal, benign tumor, and cancer tissues were 0, 66.7%, and 81.0% or 0, 27.8%, and 56.2%, respectively.
p7015
sg4
(lp7016
(dp7017
g7
I30
sg8
g24
sg10
I5
sg11
VeIF3a
p7018
sg13
I1
sasg14
(lp7019
(dp7020
g7
I62
sg17
VC0086692
p7021
sg10
I12
sg11
Vbenign tumor
p7022
sg13
I2
sa(dp7023
g7
I80
sg17
VC0006826
p7024
sg10
I6
sg11
Vcancer
p7025
sg13
I1
sasa(dp7026
g2
VThere were significant differences in positive expression rates of eIF3a protein and HE4 protein between the ovarian tumor tissues and benign ovarian tumor tissues, between the ovarian cancer tissues and the normal ovarian tissues, or between the benign ovarian tumor tissues and the normal ovarian tissues (P&lt; 0.001).
p7027
sg4
(lp7028
(dp7029
g7
I67
sg8
g24
sg10
I13
sg11
VeIF3a protein
p7030
sg13
I2
sasg14
(lp7031
(dp7032
g7
I135
sg17
VC0004997
p7033
sg10
I20
sg11
Vbenign ovarian tumor
p7034
sg13
I3
sa(dp7035
g7
I109
sg17
VC0919267
p7036
sg10
I13
sg11
Vovarian tumor
p7037
sg13
I2
sa(dp7038
g7
I135
sg17
VC0004997
p7039
sg10
I20
sg11
Vbenign ovarian tumor
p7040
sg13
I3
sa(dp7041
g7
I177
sg17
VC1140680
p7042
sg10
I14
sg11
Vovarian cancer
p7043
sg13
I2
sasa(dp7044
g2
VThe expressions of eIF3a and HE4 are associated with ovarian cancer, and extracellular regulated protein kinases may play a role in the interaction between eIF3a and HE4.
p7045
sg4
(lp7046
(dp7047
g7
I19
sg8
g24
sg10
I5
sg11
VeIF3a
p7048
sg13
I1
sa(dp7049
g7
I73
sg8
VP10398
p7050
sg10
I39
sg11
Vextracellular regulated protein kinases
p7051
sg13
I4
sa(dp7052
g7
I19
sg8
g24
sg10
I5
sg11
VeIF3a
p7053
sg13
I1
sasg14
(lp7054
(dp7055
g7
I53
sg17
VC1140680
p7056
sg10
I14
sg11
Vovarian cancer
p7057
sg13
I2
sasa(dp7058
g2
VWe describe an ultrasensitive electrochemical nucleic acid assay amplified by carbon nanotubes (CNTs)-based labels for the detection of human acute lymphocytic leukemia (ALL)-related p185 BCR-ABL fusion transcript.
p7059
sg4
(lp7060
(dp7061
g7
I192
sg8
VP55157
p7062
sg10
I3
sg11
VABL
p7063
sg13
I1
sa(dp7064
g7
I183
sg8
g24
sg10
I4
sg11
Vp185
p7065
sg13
I1
sa(dp7066
g7
I188
sg8
VP11274
p7067
sg10
I3
sg11
VBCR
p7068
sg13
I1
sasg14
(lp7069
(dp7070
g7
I192
sg17
VC0000744
p7071
sg10
I3
sg11
VABL
p7072
sg13
I1
sa(dp7073
g7
I142
sg17
VC1961102
p7074
sg10
I26
sg11
Vacute lymphocytic leukemia
p7075
sg13
I3
sa(dp7076
g7
I170
sg17
VC1961102
p7077
sg10
I3
sg11
VALL
p7078
sg13
I1
sasa(dp7079
g2
VPlasma levels of annexin V-MP, endothelial-derived MP, platelet-derived MP (CD61+ and P-Selectin+), leukocyte-derived MP, tissue factor-bearing (TF+) and CD36+MP were prospectively measured in 20 patients with III degree obesity (BMI &gt;= 40 kg/m(2)) before (T0) and 3 (T3) and 12 (T12) months after sleeve gastrectomy (SLG).
p7080
sg4
(lp7081
(dp7082
g7
I100
sg8
VP13726
p7083
sg10
I49
sg11
Vleukocyte-derived MP, tissue factor-bearing (TF+)
p7084
sg13
I5
sa(dp7085
g7
I17
sg8
VP08758
p7086
sg10
I57
sg11
Vannexin V-MP, endothelial-derived MP, platelet-derived MP
p7087
sg13
I6
sa(dp7088
g7
I76
sg8
VP05106
p7089
sg10
I5
sg11
VCD61+
p7090
sg13
I1
sasg14
(lp7091
(dp7092
g7
I221
sg17
VC0028754
p7093
sg10
I7
sg11
Vobesity
p7094
sg13
I1
sasa(dp7095
g2
VKey messages Bilirubin levels are inversely related to cardiovascular disease, and overexpression of heme oxygenase-1 (the enzyme that determines bilirubin production) has prevented post-infarction ventricular remodeling in experimental animals, but the association between bilirubin levels and the progression of ventricular volumes and function in patients with acute myocardial infarction remained unexplored.
p7096
sg4
(lp7097
(dp7098
g7
I101
sg8
VP09601
p7099
sg10
I16
sg11
Vheme oxygenase-1
p7100
sg13
I2
sasg14
(lp7101
(dp7102
g7
I187
sg17
VC0021308
p7103
sg10
I10
sg11
Vinfarction
p7104
sg13
I1
sa(dp7105
g7
I55
sg17
VC0007222
p7106
sg10
I22
sg11
Vcardiovascular disease
p7107
sg13
I2
sa(dp7108
g7
I364
sg17
VC0155626
p7109
sg10
I27
sg11
Vacute myocardial infarction
p7110
sg13
I3
sasa(dp7111
g2
VHO-1 is known to be protective in the setting of acute myocardial infarction.
p7112
sg4
(lp7113
(dp7114
g7
I0
sg8
VP09601
p7115
sg10
I4
sg11
VHO-1
p7116
sg13
I1
sasg14
(lp7117
(dp7118
g7
I49
sg17
VC0155626
p7119
sg10
I27
sg11
Vacute myocardial infarction
p7120
sg13
I3
sasa(dp7121
g2
VIn vitro experiments revealed enteropeptidase as a putative substrate for Bace1 suggesting a role in acute pancreatitis.
p7122
sg4
(lp7123
(dp7124
g7
I74
sg8
VP56817
p7125
sg10
I5
sg11
VBace1
p7126
sg13
I1
sa(dp7127
g7
I30
sg8
VP98073
p7128
sg10
I15
sg11
Venteropeptidase
p7129
sg13
I1
sasg14
(lp7130
(dp7131
g7
I101
sg17
VC0001339
p7132
sg10
I18
sg11
Vacute pancreatitis
p7133
sg13
I2
sasa(dp7134
g2
Vacute necrotizing pancreatitis was induced in anesthetized pigs by the retrograde infusion of 1 ml/kg of 5% sodium taurocholate and 8 U/kg enterokinase in the pancreatic duct.
p7135
sg4
(lp7136
(dp7137
g7
I134
sg8
VP98073
p7138
sg10
I17
sg11
VU/kg enterokinase
p7139
sg13
I2
sasg14
(lp7140
(dp7141
g7
I0
sg17
VC0267941
p7142
sg10
I30
sg11
Vacute necrotizing pancreatitis
p7143
sg13
I3
sasa(dp7144
g2
VConversely, duodenopancreatic reflux of proteolytically active enteropeptidase may cause acute and chronic pancreatitis.
p7145
sg4
(lp7146
(dp7147
g7
I63
sg8
VP98073
p7148
sg10
I15
sg11
Venteropeptidase
p7149
sg13
I1
sasg14
(lp7150
(dp7151
g7
I99
sg17
VC0149521
p7152
sg10
I20
sg11
Vchronic pancreatitis
p7153
sg13
I2
sa(dp7154
g7
I30
sg17
VC0017168
p7155
sg10
I6
sg11
Vreflux
p7156
sg13
I1
sasa(dp7157
g2
VA noninvasive model of necrohemorrhagic pancreatitis induced by simultaneous intravenous cerulein/enterokinase (EK) infusion has recently been established in rats.
p7158
sg4
(lp7159
(dp7160
g7
I112
sg8
VP98073
p7161
sg10
I2
sg11
VEK
p7162
sg13
I1
sa(dp7163
g7
I89
sg8
VP98073
p7164
sg10
I21
sg11
Vcerulein/enterokinase
p7165
sg13
I1
sasg14
(lp7166
(dp7167
g7
I40
sg17
VC0030305
p7168
sg10
I12
sg11
Vpancreatitis
p7169
sg13
I1
sasa(dp7170
g2
VStudy hemodynamic pattern and lipoperoxidation during methylene blue (MB) treatment on taurocholate - enterokinase induced acute pancreatitis (AP).
p7171
sg4
(lp7172
(dp7173
g7
I87
sg8
VP98073
p7174
sg10
I27
sg11
Vtaurocholate - enterokinase
p7175
sg13
I3
sasg14
(lp7176
(dp7177
g7
I123
sg17
VC0001339
p7178
sg10
I18
sg11
Vacute pancreatitis
p7179
sg13
I2
sa(dp7180
g7
I143
sg17
VC0001339
p7181
sg10
I2
sg11
VAP
p7182
sg13
I1
sasa(dp7183
g2
VThe HLA-B47,DR7 haplotype in congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency contains a deletion of most of the active CYP21 gene and the entire adjacent C4B gene.
p7184
sg4
(lp7185
(dp7186
g7
I141
sg8
VP08686
p7187
sg10
I10
sg11
VCYP21 gene
p7188
sg13
I2
sa(dp7189
g7
I176
sg8
VP04003
p7190
sg10
I8
sg11
VC4B gene
p7191
sg13
I2
sa(dp7192
g7
I12
sg8
VP13761
p7193
sg10
I13
sg11
VDR7 haplotype
p7194
sg13
I2
sa(dp7195
g7
I4
sg8
VP30486
p7196
sg10
I7
sg11
VHLA-B47
p7197
sg13
I1
sa(dp7198
g7
I73
sg8
VP08686
p7199
sg10
I14
sg11
V21-hydroxylase
p7200
sg13
I1
sasg14
(lp7201
(dp7202
g7
I61
sg17
VC0520463
p7203
sg10
I3
sg11
VCAH
p7204
sg13
I1
sa(dp7205
g7
I29
sg17
VC0001627
p7206
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p7207
sg13
I3
sa(dp7208
g7
I73
sg17
VC0852654
p7209
sg10
I25
sg11
V21-hydroxylase deficiency
p7210
sg13
I2
sasa(dp7211
g2
VThe HLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7 is associated with congenital adrenal hyperplasia (CAH), since it only carries the dysfunctional steroid 21-hydroxylase A pseudogene as well as the 5' adjacent complement C4A gene.
p7212
sg4
(lp7213
(dp7214
g7
I4
sg8
VP30486
p7215
sg10
I38
sg11
VHLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7
p7216
sg13
I3
sa(dp7217
g7
I140
sg8
VP08686
p7218
sg10
I35
sg11
Vsteroid 21-hydroxylase A pseudogene
p7219
sg13
I4
sa(dp7220
g7
I191
sg8
g24
sg10
I31
sg11
V5' adjacent complement C4A gene
p7221
sg13
I5
sasg14
(lp7222
(dp7223
g7
I62
sg17
VC0001627
p7224
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p7225
sg13
I3
sa(dp7226
g7
I94
sg17
VC0520463
p7227
sg10
I3
sg11
VCAH
p7228
sg13
I1
sasa(dp7229
g2
VThe mutation of vesicle-associated membrane protein-associated protein B (VAPB) was proved to cause family amyotrophic lateral sclerosis (FALS).
p7230
sg4
(lp7231
(dp7232
g7
I16
sg8
g24
sg10
I56
sg11
Vvesicle-associated membrane protein-associated protein B
p7233
sg13
I5
sa(dp7234
g7
I74
sg8
g24
sg10
I4
sg11
VVAPB
p7235
sg13
I1
sasg14
(lp7236
(dp7237
g7
I138
sg17
VC1862939
p7238
sg10
I4
sg11
VFALS
p7239
sg13
I1
sa(dp7240
g7
I100
sg17
VC1862939
p7241
sg10
I36
sg11
Vfamily amyotrophic lateral sclerosis
p7242
sg13
I4
sa(dp7243
g7
I16
sg17
VC0333262
p7244
sg10
I7
sg11
Vvesicle
p7245
sg13
I1
sasa(dp7246
g2
VALS8 is a late-onset familial autosomal dominant form of Amyotrophic Lateral Sclerosis (ALS) caused by a point mutation (P56S) in the VAPB gene (VAMP associated protein isoform B).
p7247
sg4
(lp7248
(dp7249
g7
I0
sg8
g24
sg10
I4
sg11
VALS8
p7250
sg13
I1
sa(dp7251
g7
I134
sg8
g24
sg10
I9
sg11
VVAPB gene
p7252
sg13
I2
sa(dp7253
g7
I145
sg8
g24
sg10
I33
sg11
VVAMP associated protein isoform B
p7254
sg13
I5
sasg14
(lp7255
(dp7256
g7
I0
sg17
VC1837728
p7257
sg10
I4
sg11
VALS8
p7258
sg13
I1
sa(dp7259
g7
I0
sg17
VC0002736
p7260
sg10
I3
sg11
VALS
p7261
sg13
I1
sa(dp7262
g7
I57
sg17
VC0002736
p7263
sg10
I29
sg11
VAmyotrophic Lateral Sclerosis
p7264
sg13
I3
sasa(dp7265
g2
VThis supports the loss of VAPB function in ALS8 pathogenesis and suggests that reducing intracellular PtdIns4P might be an effective therapeutic strategy in delaying progressive loss of motor neurons.
p7266
sg4
(lp7267
(dp7268
g7
I43
sg8
g24
sg10
I4
sg11
VALS8
p7269
sg13
I1
sa(dp7270
g7
I26
sg8
g24
sg10
I4
sg11
VVAPB
p7271
sg13
I1
sa(dp7272
g7
I79
sg8
g24
sg10
I31
sg11
Vreducing intracellular PtdIns4P
p7273
sg13
I3
sasg14
(lp7274
(dp7275
g7
I48
sg17
VC0699748
p7276
sg10
I12
sg11
Vpathogenesis
p7277
sg13
I1
sa(dp7278
g7
I43
sg17
VC1837728
p7279
sg10
I4
sg11
VALS8
p7280
sg13
I1
sasa(dp7281
g2
VMutations in VAP-B that have been identified in familial forms of amyotrophic lateral sclerosis (ALS or Lou-Gehrig's disease) cause aggregation of the VAP-B protein, which then impairs its binding to several proteins, including Nir2.
p7282
sg4
(lp7283
(dp7284
g7
I228
sg8
g24
sg10
I4
sg11
VNir2
p7285
sg13
I1
sa(dp7286
g7
I13
sg8
g24
sg10
I5
sg11
VVAP-B
p7287
sg13
I1
sa(dp7288
g7
I151
sg8
g24
sg10
I13
sg11
VVAP-B protein
p7289
sg13
I2
sasg14
(lp7290
(dp7291
g7
I97
sg17
VC0002736
p7292
sg10
I3
sg11
VALS
p7293
sg13
I1
sa(dp7294
g7
I66
sg17
VC0002736
p7295
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p7296
sg13
I3
sa(dp7297
g7
I108
sg17
VC0002736
p7298
sg10
I16
sg11
VGehrig's disease
p7299
sg13
I2
sasa(dp7300
g2
VA mutation in VAPB causes a familial form of Amyotrophic Lateral Sclerosis.
p7301
sg4
(lp7302
(dp7303
g7
I14
sg8
g24
sg10
I4
sg11
VVAPB
p7304
sg13
I1
sasg14
(lp7305
(dp7306
g7
I45
sg17
VC0002736
p7307
sg10
I29
sg11
VAmyotrophic Lateral Sclerosis
p7308
sg13
I3
sasa(dp7309
g2
VWe present two cases of Peters anomaly (Peters plus syndrome and a maximum manifestation variant) with abnormally thickened cornea and corneal staphyloma.
p7310
sg4
(lp7311
sg14
(lp7312
(dp7313
g7
I24
sg17
VC0344559
p7314
sg10
I14
sg11
VPeters anomaly
p7315
sg13
I2
sa(dp7316
g7
I135
sg17
VC0152440
p7317
sg10
I18
sg11
Vcorneal staphyloma
p7318
sg13
I2
sa(dp7319
g7
I40
sg17
VC0796012
p7320
sg10
I20
sg11
VPeters plus syndrome
p7321
sg13
I3
sasa(dp7322
g2
VWnt3a and Wnt5a are ligands orchestrating the canonical and non-canonical pathways, respectively, with involvement in hepatocellular carcinoma (HCC).
p7323
sg4
(lp7324
(dp7325
g7
I10
sg8
VP41221
p7326
sg10
I5
sg11
VWnt5a
p7327
sg13
I1
sa(dp7328
g7
I0
sg8
VP56704
p7329
sg10
I5
sg11
VWnt3a
p7330
sg13
I1
sasg14
(lp7331
(dp7332
g7
I144
sg17
VC2239176
p7333
sg10
I3
sg11
VHCC
p7334
sg13
I1
sa(dp7335
g7
I118
sg17
VC2239176
p7336
sg10
I24
sg11
Vhepatocellular carcinoma
p7337
sg13
I2
sasa(dp7338
g2
VTo investigate member 3a of Wingless-type MMTV integration site family (Wnt3a) expression in cancerous and surrounding tissues and the relationship between clinicopathologic features of hepatocellular carcinoma (HCC) and Wnt3a expression.
p7339
sg4
(lp7340
(dp7341
g7
I15
sg8
VP61587
p7342
sg10
I9
sg11
Vmember 3a
p7343
sg13
I2
sa(dp7344
g7
I72
sg8
VP56704
p7345
sg10
I5
sg11
VWnt3a
p7346
sg13
I1
sa(dp7347
g7
I28
sg8
g24
sg10
I42
sg11
VWingless-type MMTV integration site family
p7348
sg13
I5
sa(dp7349
g7
I72
sg8
VP56704
p7350
sg10
I5
sg11
VWnt3a
p7351
sg13
I1
sasg14
(lp7352
(dp7353
g7
I212
sg17
VC2239176
p7354
sg10
I3
sg11
VHCC
p7355
sg13
I1
sa(dp7356
g7
I186
sg17
VC2239176
p7357
sg10
I24
sg11
Vhepatocellular carcinoma
p7358
sg13
I2
sasa(dp7359
g2
VWe then use a realistic GENESIS model to test two hypothesis about interneuron hypofunction and conclude that a reduction in GAD67 is the most likely candidate as the cause for hypofrontality as observed in Schizophrenia.
p7360
sg4
(lp7361
(dp7362
g7
I125
sg8
VP49419
p7363
sg10
I5
sg11
VGAD67
p7364
sg13
I1
sasg14
(lp7365
(dp7366
g7
I79
sg17
VC0679221
p7367
sg10
I12
sg11
Vhypofunction
p7368
sg13
I1
sa(dp7369
g7
I207
sg17
VC0036341
p7370
sg10
I13
sg11
VSchizophrenia
p7371
sg13
I1
sasa(dp7372
g2
VThe objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients.
p7373
sg4
(lp7374
(dp7375
g7
I74
sg8
g24
sg10
I41
sg11
VATP binding cassette subfamily B member 1
p7376
sg13
I7
sa(dp7377
g7
I117
sg8
VP08183
p7378
sg10
I5
sg11
VABCB1
p7379
sg13
I1
sa(dp7380
g7
I63
sg8
VP20815
p7381
sg10
I6
sg11
VCYP3A5
p7382
sg13
I1
sasg14
(lp7383
(dp7384
g7
I271
sg17
VC0278678
p7385
sg10
I31
sg11
Vmetastatic renal cell carcinoma
p7386
sg13
I4
sasa(dp7387
g2
VPolymorphisms in VEGFR3 and CYP3A5*1 might be able to define a subset of patients with renal-cell carcinoma with decreased sunitinib response and tolerability.
p7388
sg4
(lp7389
(dp7390
g7
I28
sg8
VP20815
p7391
sg10
I8
sg11
VCYP3A5*1
p7392
sg13
I1
sa(dp7393
g7
I17
sg8
VP35916
p7394
sg10
I6
sg11
VVEGFR3
p7395
sg13
I1
sasg14
(lp7396
(dp7397
g7
I98
sg17
VC0007097
p7398
sg10
I9
sg11
Vcarcinoma
p7399
sg13
I1
sasa(dp7400
g2
VTo examine whether common genetic variation at the SLC10A1 locus is associated with risk of persistent HBV infection, haplotype-tagging and imputed single nucleotide polymorphisms (SNPs) were assessed in two case-control sample sets, totally including 2,550 cases (persistently HBV infected subjects, PIs) and 2,124 controls (spontaneously recovered subjects, SRs) of Southern Chinese ancestry.
p7401
sg4
(lp7402
(dp7403
g7
I360
sg8
VP35270
p7404
sg10
I3
sg11
VSRs
p7405
sg13
I1
sa(dp7406
g7
I51
sg8
g24
sg10
I13
sg11
VSLC10A1 locus
p7407
sg13
I2
sasg14
(lp7408
(dp7409
g7
I107
sg17
VC0009450
p7410
sg10
I9
sg11
Vinfection
p7411
sg13
I1
sa(dp7412
g7
I103
sg17
VC0019163
p7413
sg10
I3
sg11
VHBV
p7414
sg13
I1
sa(dp7415
g7
I103
sg17
VC0019163
p7416
sg10
I3
sg11
VHBV
p7417
sg13
I1
sa(dp7418
g7
I360
sg17
VC0175693
p7419
sg10
I3
sg11
VSRs
p7420
sg13
I1
sasa(dp7421
g2
VThe effectiveness of topical terbinafine (TBF) to tinea pedis was evaluated an animal model in which guinea pigs were experimentally infected through their planta pedis with Trichophyton mentagrophytes, then a 1% TBF or butenafine (BTF) cream was administered topically once daily for 4 consecutive weeks.
p7422
sg4
(lp7423
sg14
(lp7424
(dp7425
g7
I50
sg17
VC0040259
p7426
sg10
I11
sg11
Vtinea pedis
p7427
sg13
I2
sasa(dp7428
g2
VHowever, mutations in RecQL4 result in three human disorders: (I) Rothmund-Thomson syndrome (RTS), (II) RAPADILINO and (III) Baller-Gerold syndrome (BGS).
p7429
sg4
(lp7430
(dp7431
g7
I22
sg8
g24
sg10
I6
sg11
VRecQL4
p7432
sg13
I1
sasg14
(lp7433
(dp7434
g7
I66
sg17
VC0032339
p7435
sg10
I25
sg11
VRothmund-Thomson syndrome
p7436
sg13
I2
sa(dp7437
g7
I149
sg17
VC0265308
p7438
sg10
I3
sg11
VBGS
p7439
sg13
I1
sa(dp7440
g7
I93
sg17
VC0032339
p7441
sg10
I3
sg11
VRTS
p7442
sg13
I1
sa(dp7443
g7
I125
sg17
VC0265308
p7444
sg10
I22
sg11
VBaller-Gerold syndrome
p7445
sg13
I2
sasa(dp7446
g2
VThis is in accordance with clinical and epidemiological findings demonstrating that defects in three RecQL helicases, i.e., WRN, BLM, RECQL4, are related to human progeroid and cancer predisposition syndromes, i.e., Werner, Bloom, and Rothmund Thomson syndrome, respectively.
p7447
sg4
(lp7448
(dp7449
g7
I101
sg8
VP46063
p7450
sg10
I15
sg11
VRecQL helicases
p7451
sg13
I2
sa(dp7452
g7
I129
sg8
VP54132
p7453
sg10
I3
sg11
VBLM
p7454
sg13
I1
sa(dp7455
g7
I134
sg8
g24
sg10
I6
sg11
VRECQL4
p7456
sg13
I1
sasg14
(lp7457
(dp7458
g7
I235
sg17
VC0032339
p7459
sg10
I25
sg11
VRothmund Thomson syndrome
p7460
sg13
I3
sa(dp7461
g7
I199
sg17
VC0039082
p7462
sg10
I9
sg11
Vsyndromes
p7463
sg13
I1
sa(dp7464
g7
I124
sg17
VC0043119
p7465
sg10
I3
sg11
VWRN
p7466
sg13
I1
sa(dp7467
g7
I177
sg17
VC0006826
p7468
sg10
I6
sg11
Vcancer
p7469
sg13
I1
sa(dp7470
g7
I129
sg17
VC0005859
p7471
sg10
I3
sg11
VBLM
p7472
sg13
I1
sasa(dp7473
g2
VHuman RecQ homologs include RECQ1, BLM, WRN, RECQ4, and RECQ5Beta, three of which have been linked to diseases with elevated risk of cancer and growth defects (Bloom Syndrome and Rothmund-Thomson Syndrome) or premature aging (Werner Syndrome).
p7474
sg4
(lp7475
(dp7476
g7
I45
sg8
g24
sg10
I5
sg11
VRECQ4
p7477
sg13
I1
sa(dp7478
g7
I40
sg8
VP02545
p7479
sg10
I3
sg11
VWRN
p7480
sg13
I1
sa(dp7481
g7
I0
sg8
g24
sg10
I19
sg11
VHuman RecQ homologs
p7482
sg13
I3
sa(dp7483
g7
I28
sg8
VP46063
p7484
sg10
I5
sg11
VRECQ1
p7485
sg13
I1
sa(dp7486
g7
I35
sg8
VP54132
p7487
sg10
I3
sg11
VBLM
p7488
sg13
I1
sasg14
(lp7489
(dp7490
g7
I226
sg17
VC0043119
p7491
sg10
I15
sg11
VWerner Syndrome
p7492
sg13
I2
sa(dp7493
g7
I209
sg17
VC0231341
p7494
sg10
I15
sg11
Vpremature aging
p7495
sg13
I2
sa(dp7496
g7
I35
sg17
VC0005859
p7497
sg10
I3
sg11
VBLM
p7498
sg13
I1
sa(dp7499
g7
I133
sg17
VC0006826
p7500
sg10
I6
sg11
Vcancer
p7501
sg13
I1
sa(dp7502
g7
I160
sg17
VC0005859
p7503
sg10
I14
sg11
VBloom Syndrome
p7504
sg13
I2
sa(dp7505
g7
I179
sg17
VC0032339
p7506
sg10
I25
sg11
VRothmund-Thomson Syndrome
p7507
sg13
I2
sa(dp7508
g7
I40
sg17
VC0043119
p7509
sg10
I3
sg11
VWRN
p7510
sg13
I1
sasa(dp7511
g2
VDepletion of PAICS largely cancelled breast cancer expansion, exemplifying a prognostic gene with breast cancer activity.
p7512
sg4
(lp7513
sg14
(lp7514
(dp7515
g7
I37
sg17
VC0678222
p7516
sg10
I13
sg11
Vbreast cancer
p7517
sg13
I2
sa(dp7518
g7
I37
sg17
VC0678222
p7519
sg10
I13
sg11
Vbreast cancer
p7520
sg13
I2
sasa(dp7521
g2
VWe propose that pharmacological inhibition of components within this network, such as PAICS, may be used in conjunction with the Fra-1 prognostic classifier towards personalized management of poor prognosis breast cancer.
p7522
sg4
(lp7523
(dp7524
g7
I129
sg8
VP15407
p7525
sg10
I5
sg11
VFra-1
p7526
sg13
I1
sa(dp7527
g7
I86
sg8
VP22234
p7528
sg10
I5
sg11
VPAICS
p7529
sg13
I1
sasg14
(lp7530
(dp7531
g7
I207
sg17
VC0678222
p7532
sg10
I13
sg11
Vbreast cancer
p7533
sg13
I2
sa(dp7534
g7
I129
sg17
VC1858361
p7535
sg10
I3
sg11
VFra
p7536
sg13
I1
sasa(dp7537
g2
VOur goal was to investigate de novo purine biosynthetic gene PAICS expression and evaluate its role in prostate cancer progression.
p7538
sg4
(lp7539
sg14
(lp7540
(dp7541
g7
I112
sg17
VC0178874
p7542
sg10
I18
sg11
Vcancer progression
p7543
sg13
I2
sasa(dp7544
g2
VNext-generation sequencing, qRTPCR and immunoblot analysis revealed an elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a progressive manner in prostate cancer.
p7545
sg4
(lp7546
(dp7547
g7
I130
sg8
VP22234
p7548
sg10
I40
sg11
VPhosphoribosylaminoimidazole Carboxylase
p7549
sg13
I2
sa(dp7550
g7
I232
sg8
VP22234
p7551
sg10
I5
sg11
VPAICS
p7552
sg13
I1
sa(dp7553
g7
I172
sg8
VP22234
p7554
sg10
I58
sg11
VPhosphoribosylaminoimidazole Succinocarboxamide Synthetase
p7555
sg13
I3
sasg14
(lp7556
(dp7557
g7
I266
sg17
VC0600139
p7558
sg10
I15
sg11
Vprostate cancer
p7559
sg13
I2
sasa(dp7560
g2
VThrough several in vitro and in vivo functional studies, we show that PAICS is necessary for proliferation and invasion in prostate cancer cells.
p7561
sg4
(lp7562
(dp7563
g7
I70
sg8
VP22234
p7564
sg10
I5
sg11
VPAICS
p7565
sg13
I1
sasg14
(lp7566
(dp7567
g7
I93
sg17
VC0334094
p7568
sg10
I13
sg11
Vproliferation
p7569
sg13
I1
sa(dp7570
g7
I123
sg17
VC0600139
p7571
sg10
I15
sg11
Vprostate cancer
p7572
sg13
I2
sa(dp7573
g7
I111
sg17
VC2699153
p7574
sg10
I8
sg11
Vinvasion
p7575
sg13
I1
sasa(dp7576
g2
VWe identified JQ1, a BET bromodomain inhibitor previously implicated in regulating MYC expression and demonstrated role in prostate cancer, abrogates PAICS expression in several prostate cancer cells.
p7577
sg4
(lp7578
(dp7579
g7
I83
sg8
VP12524
p7580
sg10
I3
sg11
VMYC
p7581
sg13
I1
sa(dp7582
g7
I150
sg8
VP22234
p7583
sg10
I5
sg11
VPAICS
p7584
sg13
I1
sasg14
(lp7585
(dp7586
g7
I123
sg17
VC0600139
p7587
sg10
I15
sg11
Vprostate cancer
p7588
sg13
I2
sa(dp7589
g7
I123
sg17
VC0600139
p7590
sg10
I15
sg11
Vprostate cancer
p7591
sg13
I2
sasa(dp7592
g2
VHere, we report that evaluation of PAICS in prostate cancer progression and its role in prostate cancer cell proliferation and invasion and suggest it as a valid therapeutic target.
p7593
sg4
(lp7594
sg14
(lp7595
(dp7596
g7
I127
sg17
VC2699153
p7597
sg10
I8
sg11
Vinvasion
p7598
sg13
I1
sa(dp7599
g7
I53
sg17
VC0178874
p7600
sg10
I18
sg11
Vcancer progression
p7601
sg13
I2
sa(dp7602
g7
I109
sg17
VC0334094
p7603
sg10
I13
sg11
Vproliferation
p7604
sg13
I1
sa(dp7605
g7
I44
sg17
VC0600139
p7606
sg10
I15
sg11
Vprostate cancer
p7607
sg13
I2
sasa(dp7608
g2
VWe suggest JQ1, a BET-domain inhibitor, as possible therapeutic option in targeting PAICS in prostate cancer.
p7609
sg4
(lp7610
sg14
(lp7611
(dp7612
g7
I93
sg17
VC0600139
p7613
sg10
I15
sg11
Vprostate cancer
p7614
sg13
I2
sasa(dp7615
g2
VWe discovered increased expression of phosphoribosyl amidotransferase (PPAT) and phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzymes of de novo purine biosynthetic pathway in lung adenocarcinomas.
p7616
sg4
(lp7617
(dp7618
g7
I71
sg8
g24
sg10
I4
sg11
VPPAT
p7619
sg13
I1
sa(dp7620
g7
I183
sg8
VP22234
p7621
sg10
I5
sg11
VPAICS
p7622
sg13
I1
sa(dp7623
g7
I38
sg8
g24
sg10
I31
sg11
Vphosphoribosyl amidotransferase
p7624
sg13
I2
sa(dp7625
g7
I81
sg8
VP22234
p7626
sg10
I100
sg11
Vphosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase
p7627
sg13
I5
sasg14
(lp7628
(dp7629
g7
I245
sg17
VC0001418
p7630
sg10
I15
sg11
Vadenocarcinomas
p7631
sg13
I1
sasa(dp7632
g2
VTranscript analyses from next-generation RNA sequencing and gene expression profiling studies suggested that PPAT and PAICS can serve as prognostic biomarkers for aggressive lung adenocarcinoma.
p7633
sg4
(lp7634
(dp7635
g7
I109
sg8
g24
sg10
I4
sg11
VPPAT
p7636
sg13
I1
sa(dp7637
g7
I118
sg8
VP22234
p7638
sg10
I5
sg11
VPAICS
p7639
sg13
I1
sasg14
(lp7640
(dp7641
g7
I174
sg17
VC0152013
p7642
sg10
I19
sg11
Vlung adenocarcinoma
p7643
sg13
I2
sa(dp7644
g7
I163
sg17
VC0001807
p7645
sg10
I10
sg11
Vaggressive
p7646
sg13
I1
sasa(dp7647
g2
VFurthermore we identified genomic amplification and aneuploidy of the divergently transcribed PPAT-PAICS genomic region in a subset of lung cancers.
p7648
sg4
(lp7649
(dp7650
g7
I99
sg8
VP22234
p7651
sg10
I5
sg11
VPAICS
p7652
sg13
I1
sa(dp7653
g7
I94
sg8
g24
sg10
I4
sg11
VPPAT
p7654
sg13
I1
sasg14
(lp7655
(dp7656
g7
I135
sg17
VC0242379
p7657
sg10
I12
sg11
Vlung cancers
p7658
sg13
I2
sa(dp7659
g7
I52
sg17
VC0002938
p7660
sg10
I10
sg11
Vaneuploidy
p7661
sg13
I1
sa(dp7662
g7
I34
sg17
VC1705759
p7663
sg10
I13
sg11
Vamplification
p7664
sg13
I1
sasa(dp7665
g2
VIn summary, this study reveals the regulatory mechanisms by which purine biosynthetic pathway enzymes PPAT and PAICS, and pyruvate kinase activity is increased and exposes an existing metabolic vulnerability in lung cancer cells that can be explored for pharmacological intervention.
p7666
sg4
(lp7667
(dp7668
g7
I102
sg8
g24
sg10
I4
sg11
VPPAT
p7669
sg13
I1
sa(dp7670
g7
I122
sg8
VP30613
p7671
sg10
I15
sg11
Vpyruvate kinase
p7672
sg13
I2
sa(dp7673
g7
I111
sg8
VP22234
p7674
sg10
I5
sg11
VPAICS
p7675
sg13
I1
sasg14
(lp7676
(dp7677
g7
I211
sg17
VC0684249
p7678
sg10
I11
sg11
Vlung cancer
p7679
sg13
I2
sasa(dp7680
g2
VWe also identified mutations in four genes (MUC19, PAICS, RBMXL1, KIF23) never reported in melanoma, which might deserve further investigations.
p7681
sg4
(lp7682
(dp7683
g7
I58
sg8
g24
sg10
I6
sg11
VRBMXL1
p7684
sg13
I1
sa(dp7685
g7
I44
sg8
g24
sg10
I5
sg11
VMUC19
p7686
sg13
I1
sa(dp7687
g7
I51
sg8
VP22234
p7688
sg10
I5
sg11
VPAICS
p7689
sg13
I1
sa(dp7690
g7
I66
sg8
g24
sg10
I5
sg11
VKIF23
p7691
sg13
I1
sasg14
(lp7692
(dp7693
g7
I91
sg17
VC0025202
p7694
sg10
I8
sg11
Vmelanoma
p7695
sg13
I1
sasa(dp7696
g2
VAlterations in PAICS expression in humans have been associated with various types of cancer.
p7697
sg4
(lp7698
(dp7699
g7
I15
sg8
VP22234
p7700
sg10
I5
sg11
VPAICS
p7701
sg13
I1
sasg14
(lp7702
(dp7703
g7
I85
sg17
VC0006826
p7704
sg10
I6
sg11
Vcancer
p7705
sg13
I1
sasa(dp7706
g2
VAn IST1 clone, detected for the first time in 2000, was the most prevalent and responsible for the shigellosis epidemic in 2001 to 2003.
p7707
sg4
(lp7708
(dp7709
g7
I3
sg8
VP53990
p7710
sg10
I4
sg11
VIST1
p7711
sg13
I1
sasg14
(lp7712
(dp7713
g7
I99
sg17
VC0013371
p7714
sg10
I11
sg11
Vshigellosis
p7715
sg13
I1
sasa(dp7716
g2
VIn this observational, cross-sectional study, circulating levels of sclerostin and other laboratory parameters of mineral and bone disease, including intact parathyroid hormone (PTH), calcium, phosphate, magnesium, 25(OH) D-vitamin, 1,25 (OH)2 D-vitamin, and bone specific alkaline phosphatase (BALP) were assessed in 100 patients with end-stage renal disease recruited from an ongoing longitudinal cohort study in Stockholm, Sweden.
p7717
sg4
(lp7718
(dp7719
g7
I259
sg8
VP10696
p7720
sg10
I34
sg11
Vbone specific alkaline phosphatase
p7721
sg13
I4
sa(dp7722
g7
I178
sg8
VP01270
p7723
sg10
I3
sg11
VPTH
p7724
sg13
I1
sa(dp7725
g7
I150
sg8
VP01270
p7726
sg10
I26
sg11
Vintact parathyroid hormone
p7727
sg13
I3
sa(dp7728
g7
I295
sg8
VP10696
p7729
sg10
I4
sg11
VBALP
p7730
sg13
I1
sasg14
(lp7731
(dp7732
g7
I336
sg17
VC0022661
p7733
sg10
I23
sg11
Vend-stage renal disease
p7734
sg13
I3
sa(dp7735
g7
I126
sg17
VC0005940
p7736
sg10
I12
sg11
Vbone disease
p7737
sg13
I2
sasa(dp7738
g2
VFindings from research into mineral bone disorder associated with CKD (CKD-MBD) could help the medical community to better understand the vascular actions of certain molecules, such as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their relevance to the management of different pathologies in the general population.
p7739
sg4
(lp7740
(dp7741
g7
I197
sg8
g24
sg10
I27
sg11
Vfibroblast growth factor 23
p7742
sg13
I4
sa(dp7743
g7
I226
sg8
VP01270
p7744
sg10
I19
sg11
Vparathyroid hormone
p7745
sg13
I2
sasg14
(lp7746
(dp7747
g7
I36
sg17
VC0005940
p7748
sg10
I13
sg11
Vbone disorder
p7749
sg13
I2
sasa(dp7750
g2
VIn chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis.
p7751
sg4
(lp7752
(dp7753
g7
I33
sg8
g24
sg10
I10
sg11
Vsclerostin
p7754
sg13
I1
sasg14
(lp7755
(dp7756
g7
I3
sg17
VC1561643
p7757
sg10
I22
sg11
Vchronic kidney disease
p7758
sg13
I3
sa(dp7759
g7
I27
sg17
VC1561643
p7760
sg10
I3
sg11
VCKD
p7761
sg13
I1
sasa(dp7762
g2
VClinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.
p7763
sg4
(lp7764
sg14
(lp7765
sa(dp7766
g2
V(3) Compared with the control group, the expression of CD63 in basophils increased in anaphylactic shock lung tissue.
p7767
sg4
(lp7768
(dp7769
g7
I55
sg8
VP08962
p7770
sg10
I4
sg11
VCD63
p7771
sg13
I1
sasg14
(lp7772
(dp7773
g7
I86
sg17
VC0002792
p7774
sg10
I18
sg11
Vanaphylactic shock
p7775
sg13
I2
sa(dp7776
g7
I99
sg17
VC0035222
p7777
sg10
I10
sg11
Vshock lung
p7778
sg13
I2
sasa(dp7779
g2
VTo elucidate a potential mechanism involving BM88/Cend1, RanBPM and Dyrk1B in cell cycle progression/exit, we transiently co-expressed these proteins in mouse neuroblastoma Neuro 2a cells.
p7780
sg4
(lp7781
(dp7782
g7
I68
sg8
g24
sg10
I6
sg11
VDyrk1B
p7783
sg13
I1
sa(dp7784
g7
I50
sg8
g24
sg10
I5
sg11
VCend1
p7785
sg13
I1
sa(dp7786
g7
I45
sg8
g24
sg10
I4
sg11
VBM88
p7787
sg13
I1
sa(dp7788
g7
I57
sg8
g24
sg10
I6
sg11
VRanBPM
p7789
sg13
I1
sasg14
(lp7790
(dp7791
g7
I153
sg17
VC1524043
p7792
sg10
I19
sg11
Vmouse neuroblastoma
p7793
sg13
I2
sasa(dp7794
g2
VCalcium imaging experiments revealed that P2Y-induced calcium mobilization is diminished in mouse neuroblastoma Neuro 2a cells stably transfected with BM88 (N2A-BM88 cells) as compared with N2A cells or N2A cells differentiated with retinoic acid.
p7795
sg4
(lp7796
sg14
(lp7797
(dp7798
g7
I92
sg17
VC1524043
p7799
sg10
I19
sg11
Vmouse neuroblastoma
p7800
sg13
I2
sasa(dp7801
g2
VWe report here that trichostatin-A (TSA) specifically induces the transcription of Cend1, a neuronal-lineage specific regulator of cell cycle exit and differentiation, in neuroblastoma Neuro2A cells, but not in non-neuronal cells.
p7802
sg4
(lp7803
(dp7804
g7
I36
sg8
VP32119
p7805
sg10
I3
sg11
VTSA
p7806
sg13
I1
sa(dp7807
g7
I83
sg8
g24
sg10
I5
sg11
VCend1
p7808
sg13
I1
sa(dp7809
g7
I20
sg8
VP32119
p7810
sg10
I14
sg11
Vtrichostatin-A
p7811
sg13
I1
sasg14
(lp7812
(dp7813
g7
I171
sg17
VC0027819
p7814
sg10
I13
sg11
Vneuroblastoma
p7815
sg13
I1
sasa(dp7816
g2
VHere we have used mouse neuroblastoma Neuro 2a cells as an in vitro model of neuronal differentiation to dissect the functional properties of BM88 by implementing gain- and loss-of-function approaches.
p7817
sg4
(lp7818
sg14
(lp7819
(dp7820
g7
I18
sg17
VC1524043
p7821
sg10
I19
sg11
Vmouse neuroblastoma
p7822
sg13
I2
sasa(dp7823
g2
VBM88 overexpression also results in increased levels of the cell cycle regulatory protein p53, and accumulation of the hypophosphorylated form of the retinoblastoma protein leading to cell cycle arrest, with concomitant decreased levels and, in many cells, cytoplasmic localization of cyclin D1.
p7824
sg4
(lp7825
(dp7826
g7
I0
sg8
g24
sg10
I4
sg11
VBM88
p7827
sg13
I1
sa(dp7828
g7
I285
sg8
VP24385
p7829
sg10
I9
sg11
Vcyclin D1
p7830
sg13
I2
sa(dp7831
g7
I150
sg8
g24
sg10
I22
sg11
Vretinoblastoma protein
p7832
sg13
I2
sa(dp7833
g7
I82
sg8
VP42771
p7834
sg10
I11
sg11
Vprotein p53
p7835
sg13
I2
sasg14
(lp7836
(dp7837
g7
I150
sg17
VC0035335
p7838
sg10
I14
sg11
Vretinoblastoma
p7839
sg13
I1
sasa(dp7840
g2
VPrevious studies have shown that the BM88 antigen, a neuron-specific molecule, promotes the differentiation of mouse neuroblastoma cells [23] (Mamalaki A., Boutou E., Hurel C., Patsavoudi E., Tzartos S. and Matsas R. (1995) The BM88 antigen, a novel neuron-specific molecule, enhances the differentiation of mouse neuroblastoma cells.
p7841
sg4
(lp7842
(dp7843
g7
I37
sg8
g24
sg10
I12
sg11
VBM88 antigen
p7844
sg13
I2
sa(dp7845
g7
I37
sg8
g24
sg10
I12
sg11
VBM88 antigen
p7846
sg13
I2
sasg14
(lp7847
(dp7848
g7
I111
sg17
VC1524043
p7849
sg10
I19
sg11
Vmouse neuroblastoma
p7850
sg13
I2
sa(dp7851
g7
I111
sg17
VC1524043
p7852
sg10
I19
sg11
Vmouse neuroblastoma
p7853
sg13
I2
sasa(dp7854
g2
VMoreover, they respond differentially to growth factors [10] (Gomez J., Boutou E., Hurel C., Mamalaki A., Kentroti S. , Vernadakis A. and Matsas R. (1998) Overexpression of the neuron-specific molecule BM88 in mouse neuroblastoma cells: Altered responsiveness to growth factors.
p7855
sg4
(lp7856
sg14
(lp7857
(dp7858
g7
I210
sg17
VC1524043
p7859
sg10
I19
sg11
Vmouse neuroblastoma
p7860
sg13
I2
sasa(dp7861
g2
VPrevious studies have shown that the BM88 antigen, a novel neuron-specific molecule, promotes the differentiation of mouse neuroblastoma (Neuro 2a) cells.
p7862
sg4
(lp7863
(dp7864
g7
I37
sg8
g24
sg10
I12
sg11
VBM88 antigen
p7865
sg13
I2
sasg14
(lp7866
(dp7867
g7
I117
sg17
VC1524043
p7868
sg10
I19
sg11
Vmouse neuroblastoma
p7869
sg13
I2
sasa(dp7870
g2
VIn conclusion, our findings show that overexpression of the neuron-specific antigen BM88 in neuroblastoma cells modifies their properties with respect to growth factor sensitivity, and, hence, the Neuro 2a and Neuro 2a-BM88 are suitable cell models to examine the role of growth factors in neuronal differentiation.
p7871
sg4
(lp7872
(dp7873
g7
I60
sg8
VP14209
p7874
sg10
I28
sg11
Vneuron-specific antigen BM88
p7875
sg13
I3
sa(dp7876
g7
I210
sg8
g24
sg10
I13
sg11
VNeuro 2a-BM88
p7877
sg13
I2
sasg14
(lp7878
(dp7879
g7
I92
sg17
VC0027819
p7880
sg10
I13
sg11
Vneuroblastoma
p7881
sg13
I1
sasa(dp7882
g2
VHere, we investigated the expression stabilities of ten previously recommended reference genes (ABCT, CYP, EF1A, FBOX, GPDH, RPL30, TUA4, TUB4, TUA5, and UNK2) in soybean under biotic stress from Bean pod mottle virus (BPMV), powdery mildew (PMD), soybean aphid (SBA), and two-spotted spider mite (TSSM).
p7883
sg4
(lp7884
(dp7885
g7
I102
sg8
g24
sg10
I3
sg11
VCYP
p7886
sg13
I1
sa(dp7887
g7
I125
sg8
VP62888
p7888
sg10
I5
sg11
VRPL30
p7889
sg13
I1
sa(dp7890
g7
I107
sg8
VP68104
p7891
sg10
I4
sg11
VEF1A
p7892
sg13
I1
sasg14
(lp7893
(dp7894
g7
I242
sg17
VC1832661
p7895
sg10
I3
sg11
VPMD
p7896
sg13
I1
sa(dp7897
g7
I226
sg17
VC1832661
p7898
sg10
I14
sg11
Vpowdery mildew
p7899
sg13
I2
sasa(dp7900
g2
VIn conclusion, the anti-B7-1 antibody approach may provide a novel therapy for allergic asthma.
p7901
sg4
(lp7902
sg14
(lp7903
(dp7904
g7
I79
sg17
VC0155877
p7905
sg10
I15
sg11
Vallergic asthma
p7906
sg13
I2
sasa(dp7907
g2
VTo investigate whether there is altered expression and the clinical significance of soluble co-stimulatory molecules in asthmatic patients, plasma concentrations of sCTLA-4, sCD28, sCD80 and sCD86 in 51 adult allergic asthmatic adults with or without steroid treatment, and 35 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay (ELISA).
p7908
sg4
(lp7909
sg14
(lp7910
(dp7911
g7
I120
sg17
VC0004096
p7912
sg10
I9
sg11
Vasthmatic
p7913
sg13
I1
sa(dp7914
g7
I120
sg17
VC0004096
p7915
sg10
I9
sg11
Vasthmatic
p7916
sg13
I1
sasa(dp7917
g2
VThe surface expression of T cell costimulatory molecules CTLA-4 and CD28 and their counter-ligands, B7 molecules (CD80, CD86), is differentially induced for T cell activation and expansion in allergic asthma.
p7918
sg4
(lp7919
(dp7920
g7
I68
sg8
VP33681
p7921
sg10
I4
sg11
VCD28
p7922
sg13
I1
sa(dp7923
g7
I120
sg8
VP42081
p7924
sg10
I4
sg11
VCD86
p7925
sg13
I1
sa(dp7926
g7
I26
sg8
VP16410
p7927
sg10
I37
sg11
VT cell costimulatory molecules CTLA-4
p7928
sg13
I5
sa(dp7929
g7
I114
sg8
VP33681
p7930
sg10
I4
sg11
VCD80
p7931
sg13
I1
sasg14
(lp7932
(dp7933
g7
I192
sg17
VC0155877
p7934
sg10
I15
sg11
Vallergic asthma
p7935
sg13
I2
sasa(dp7936
g2
VPlasma concentrations of soluble CTLA-4 (sCTLA-4), CD28, CD80 and CD86 in 51 children with chronic allergic asthma with or without inhaled corticosteroid treatment, and 22 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay.
p7937
sg4
(lp7938
(dp7939
g7
I57
sg8
VP33681
p7940
sg10
I4
sg11
VCD80
p7941
sg13
I1
sa(dp7942
g7
I66
sg8
VP42081
p7943
sg10
I4
sg11
VCD86
p7944
sg13
I1
sa(dp7945
g7
I51
sg8
VP33681
p7946
sg10
I4
sg11
VCD28
p7947
sg13
I1
sa(dp7948
g7
I33
sg8
VP16410
p7949
sg10
I6
sg11
VCTLA-4
p7950
sg13
I1
sasg14
(lp7951
(dp7952
g7
I99
sg17
VC0155877
p7953
sg10
I15
sg11
Vallergic asthma
p7954
sg13
I2
sasa(dp7955
g2
VPlasma sCTLA-4, sCD28 and sCD80 concentrations are elevated in allergic asthma.
p7956
sg4
(lp7957
sg14
(lp7958
(dp7959
g7
I63
sg17
VC0155877
p7960
sg10
I15
sg11
Vallergic asthma
p7961
sg13
I2
sasa(dp7962
g2
VThe percentage of myoglobin denaturation (PMD) of the CA groups was also increased according to the level of CA during storage.
p7963
sg4
(lp7964
(dp7965
g7
I18
sg8
VP02144
p7966
sg10
I9
sg11
Vmyoglobin
p7967
sg13
I1
sasg14
(lp7968
(dp7969
g7
I42
sg17
VC1832661
p7970
sg10
I3
sg11
VPMD
p7971
sg13
I1
sa(dp7972
g7
I4
sg17
VC1832661
p7973
sg10
I36
sg11
Vpercentage of myoglobin denaturation
p7974
sg13
I4
sasa(dp7975
g2
VLow expression of (or IHC-negative) COX2, miR-200c, ERCC1 and TS, or high expression of (or IHC-positive) CDC25B and p16 are potential biomarkers for predicting the response of esophageal cancer patients treated with chemo(radio)therapy.
p7976
sg4
(lp7977
(dp7978
g7
I36
sg8
VP35354
p7979
sg10
I4
sg11
VCOX2
p7980
sg13
I1
sa(dp7981
g7
I117
sg8
VP42771
p7982
sg10
I3
sg11
Vp16
p7983
sg13
I1
sa(dp7984
g7
I42
sg8
g24
sg10
I8
sg11
VmiR-200c
p7985
sg13
I1
sa(dp7986
g7
I106
sg8
VP30305
p7987
sg10
I6
sg11
VCDC25B
p7988
sg13
I1
sa(dp7989
g7
I52
sg8
VP07992
p7990
sg10
I5
sg11
VERCC1
p7991
sg13
I1
sasg14
(lp7992
(dp7993
g7
I177
sg17
VC0014859
p7994
sg10
I17
sg11
Vesophageal cancer
p7995
sg13
I2
sasa(dp7996
g2
VERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.
p7997
sg4
(lp7998
(dp7999
g7
I6
sg8
g24
sg10
I3
sg11
VSNP
p8000
sg13
I1
sa(dp8001
g7
I0
sg8
VP07992
p8002
sg10
I5
sg11
VERCC1
p8003
sg13
I1
sa(dp8004
g7
I52
sg8
VP04626
p8005
sg10
I5
sg11
VERBB2
p8006
sg13
I1
sa(dp8007
g7
I0
sg8
VP07992
p8008
sg10
I5
sg11
VERCC1
p8009
sg13
I1
sasg14
(lp8010
(dp8011
g7
I194
sg17
VC0014859
p8012
sg10
I17
sg11
Vesophageal cancer
p8013
sg13
I2
sasa(dp8014
g2
VERCC1 C118T could be a predictive factor for the response to radiotherapy and chemotherapy, but not a prognostic factor for OS in esophageal cancer patients after surgery.
p8015
sg4
(lp8016
(dp8017
g7
I0
sg8
VP07992
p8018
sg10
I5
sg11
VERCC1
p8019
sg13
I1
sasg14
(lp8020
(dp8021
g7
I130
sg17
VC0014859
p8022
sg10
I17
sg11
Vesophageal cancer
p8023
sg13
I2
sasa(dp8024
g2
VIn the present meta-analysis, we demonstrated that the ERCC1 rs3212986 polymorphism was significantly correlated with the response rate of esophageal cancer patients to neoadjuvant therapy (OR =  .49, 95% CI = 0.31-0.76, heterogeneity P = 0.480).
p8025
sg4
(lp8026
(dp8027
g7
I55
sg8
VP07992
p8028
sg10
I15
sg11
VERCC1 rs3212986
p8029
sg13
I2
sasg14
(lp8030
(dp8031
g7
I139
sg17
VC0014859
p8032
sg10
I17
sg11
Vesophageal cancer
p8033
sg13
I2
sasa(dp8034
g2
VFurthermore, a considerable correlation was observed between ERCC1 rs11615 and the response rate of esophageal cancer patients to neoadjuvant therapy (OR = 0.228, 95% CI = 0.125-0.418, heterogeneity P = 0.291).
p8035
sg4
(lp8036
(dp8037
g7
I61
sg8
VP07992
p8038
sg10
I5
sg11
VERCC1
p8039
sg13
I1
sasg14
(lp8040
(dp8041
g7
I100
sg17
VC0014859
p8042
sg10
I17
sg11
Vesophageal cancer
p8043
sg13
I2
sasa(dp8044
g2
VThese findings indicate that the ERCC1 rs11615 and ERCC1 rs312986 polymorphisms may be candidate pharmacogenomic factors capable of predicting the response rate of esophageal cancer patients who accept neoadjuvant therapy.
p8045
sg4
(lp8046
(dp8047
g7
I33
sg8
VP07992
p8048
sg10
I13
sg11
VERCC1 rs11615
p8049
sg13
I2
sa(dp8050
g7
I33
sg8
VP07992
p8051
sg10
I5
sg11
VERCC1
p8052
sg13
I1
sasg14
(lp8053
(dp8054
g7
I164
sg17
VC0014859
p8055
sg10
I17
sg11
Vesophageal cancer
p8056
sg13
I2
sasa(dp8057
g2
VIn patients with colon cancer, the expression of TSP50, MAGE-A(1-6), and SSX1,2,4 genes was associated with a poor prognosis, that of MAGE-C1 and XAGE1 was related to a favorable prognosis.
p8058
sg4
(lp8059
(dp8060
g7
I73
sg8
g24
sg10
I14
sg11
VSSX1,2,4 genes
p8061
sg13
I2
sa(dp8062
g7
I49
sg8
g24
sg10
I5
sg11
VTSP50
p8063
sg13
I1
sa(dp8064
g7
I146
sg8
g24
sg10
I5
sg11
VXAGE1
p8065
sg13
I1
sa(dp8066
g7
I56
sg8
VP43355
p8067
sg10
I4
sg11
VMAGE
p8068
sg13
I1
sasg14
(lp8069
(dp8070
g7
I17
sg17
VC0699790
p8071
sg10
I12
sg11
Vcolon cancer
p8072
sg13
I2
sasa(dp8073
g2
VConsequently, the expression of CT antigens MAGE-A1, MAGE-A4, CT7/MAGE-C1, NY-ESO-1, and GAGE was analyzed in a series of pediatric melanomas.
p8074
sg4
(lp8075
(dp8076
g7
I32
sg8
VP43355
p8077
sg10
I19
sg11
VCT antigens MAGE-A1
p8078
sg13
I3
sa(dp8079
g7
I44
sg8
VP43355
p8080
sg10
I4
sg11
VMAGE
p8081
sg13
I1
sa(dp8082
g7
I62
sg8
g24
sg10
I3
sg11
VCT7
p8083
sg13
I1
sa(dp8084
g7
I75
sg8
VP78358
p8085
sg10
I8
sg11
VNY-ESO-1
p8086
sg13
I1
sa(dp8087
g7
I53
sg8
VP43355
p8088
sg10
I7
sg11
VMAGE-A4
p8089
sg13
I1
sasg14
(lp8090
(dp8091
g7
I132
sg17
VC0025202
p8092
sg10
I9
sg11
Vmelanomas
p8093
sg13
I1
sasa(dp8094
g2
VIn this study, we show that the dying myeloma cells treated with chaetocin resulted in the induction of heat shock protein (HSP) 90, which was inhibited by antioxidant N-acetyl cysteine, and showed an increase in the expression of MAGE-A3 and MAGE-C1/CT7.
p8095
sg4
(lp8096
(dp8097
g7
I104
sg8
VP34931
p8098
sg10
I27
sg11
Vheat shock protein (HSP) 90
p8099
sg13
I5
sa(dp8100
g7
I251
sg8
g24
sg10
I3
sg11
VCT7
p8101
sg13
I1
sa(dp8102
g7
I231
sg8
VP43355
p8103
sg10
I4
sg11
VMAGE
p8104
sg13
I1
sa(dp8105
g7
I231
sg8
VP43355
p8106
sg10
I7
sg11
VMAGE-A3
p8107
sg13
I1
sasg14
(lp8108
(dp8109
g7
I124
sg17
VC0034152
p8110
sg10
I3
sg11
VHSP
p8111
sg13
I1
sa(dp8112
g7
I38
sg17
VC0026764
p8113
sg10
I7
sg11
Vmyeloma
p8114
sg13
I1
sa(dp8115
g7
I104
sg17
VC0034152
p8116
sg10
I18
sg11
Vheat shock protein
p8117
sg13
I3
sasa(dp8118
g2
VWe used immunohistochemistry to examine the expression of four CTAs (MAGE-A, NY-ESO-1, CT7, and GAGE7) in various types of salivary gland carcinoma (n = 95).
p8119
sg4
(lp8120
(dp8121
g7
I77
sg8
VP78358
p8122
sg10
I8
sg11
VNY-ESO-1
p8123
sg13
I1
sa(dp8124
g7
I96
sg8
g24
sg10
I5
sg11
VGAGE7
p8125
sg13
I1
sa(dp8126
g7
I87
sg8
g24
sg10
I3
sg11
VCT7
p8127
sg13
I1
sa(dp8128
g7
I69
sg8
VP43355
p8129
sg10
I6
sg11
VMAGE-A
p8130
sg13
I1
sasg14
(lp8131
(dp8132
g7
I123
sg17
VC0948750
p8133
sg10
I24
sg11
Vsalivary gland carcinoma
p8134
sg13
I3
sasa(dp8135
g2
VWhen carcinoma cases were divided into low-grade and intermediate/high-grade types, NY-ESO-1 and CT7 were expressed more frequently in intermediate/high-grade carcinomas.
p8136
sg4
(lp8137
(dp8138
g7
I84
sg8
VP78358
p8139
sg10
I8
sg11
VNY-ESO-1
p8140
sg13
I1
sa(dp8141
g7
I97
sg8
g24
sg10
I3
sg11
VCT7
p8142
sg13
I1
sasg14
(lp8143
(dp8144
g7
I159
sg17
VC0007097
p8145
sg10
I10
sg11
Vcarcinomas
p8146
sg13
I1
sa(dp8147
g7
I5
sg17
VC0007097
p8148
sg10
I9
sg11
Vcarcinoma
p8149
sg13
I1
sasa(dp8150
g2
VThe expression of cancer testis antigen MAGE C1 has been linked to the malignant stem cell in this disease, and thus, we investigated the use of both flow cytometric and qRTPCR approaches to monitor its expression as an alternative monitoring methodology in this pilot study.
p8151
sg4
(lp8152
(dp8153
g7
I25
sg8
VP15735
p8154
sg10
I22
sg11
Vtestis antigen MAGE C1
p8155
sg13
I4
sasg14
(lp8156
(dp8157
g7
I18
sg17
VC0153594
p8158
sg10
I13
sg11
Vcancer testis
p8159
sg13
I2
sasa(dp8160
g2
VThese variants were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related signaling pathways (THSD1, MORN2, PTCRA).
p8161
sg4
(lp8162
(dp8163
g7
I152
sg8
g24
sg10
I5
sg11
VMORN2
p8164
sg13
I1
sa(dp8165
g7
I84
sg8
g24
sg10
I4
sg11
VTOX3
p8166
sg13
I1
sa(dp8167
g7
I69
sg8
g24
sg10
I5
sg11
VDNAH9
p8168
sg13
I1
sa(dp8169
g7
I145
sg8
g24
sg10
I5
sg11
VTHSD1
p8170
sg13
I1
sa(dp8171
g7
I76
sg8
g24
sg10
I6
sg11
VMAGEC1
p8172
sg13
I1
sa(dp8173
g7
I159
sg8
g24
sg10
I5
sg11
VPTCRA
p8174
sg13
I1
sa(dp8175
g7
I60
sg8
g24
sg10
I7
sg11
VANKRD35
p8176
sg13
I1
sasg14
(lp8177
(dp8178
g7
I51
sg17
VC0006826
p8179
sg10
I6
sg11
Vcancer
p8180
sg13
I1
sa(dp8181
g7
I51
sg17
VC0006826
p8182
sg10
I7
sg11
Vcancers
p8183
sg13
I1
sasa(dp8184
g2
VOur study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer.
p8185
sg4
(lp8186
(dp8187
g7
I132
sg8
g24
sg10
I7
sg11
VMAGE-C2
p8188
sg13
I1
sa(dp8189
g7
I120
sg8
VP43355
p8190
sg10
I4
sg11
VMAGE
p8191
sg13
I1
sasg14
(lp8192
(dp8193
g7
I92
sg17
VC0025202
p8194
sg10
I8
sg11
Vmelanoma
p8195
sg13
I1
sa(dp8196
g7
I143
sg17
VC0678222
p8197
sg10
I13
sg11
Vbreast cancer
p8198
sg13
I2
sasa(dp8199
g2
VReverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to investigate the expressions of MAGE-C1 and MAGE-C2 in breast benign disease specimens, tumor-free breast specimens, and breast cancer specimens; their correlation with clinicopathologic parameters and recurrence-free survival was elucidated.
p8200
sg4
(lp8201
(dp8202
g7
I126
sg8
VP43355
p8203
sg10
I4
sg11
VMAGE
p8204
sg13
I1
sa(dp8205
g7
I126
sg8
VP43355
p8206
sg10
I4
sg11
VMAGE
p8207
sg13
I1
sasg14
(lp8208
(dp8209
g7
I215
sg17
VC0678222
p8210
sg10
I13
sg11
Vbreast cancer
p8211
sg13
I2
sa(dp8212
g7
I182
sg17
VC0027651
p8213
sg10
I5
sg11
Vtumor
p8214
sg13
I1
sa(dp8215
g7
I296
sg17
VC1458156
p8216
sg10
I10
sg11
Vrecurrence
p8217
sg13
I1
sasa(dp8218
g2
VWe examined the influence of DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) together with histone deacetylase inhibitor trichostatin A on the expression of MAGE-C1 and MAGE-C2 in breast cancer cell lines.
p8219
sg4
(lp8220
(dp8221
g7
I122
sg8
VP32119
p8222
sg10
I24
sg11
Vinhibitor trichostatin A
p8223
sg13
I3
sa(dp8224
g7
I168
sg8
VP43355
p8225
sg10
I4
sg11
VMAGE
p8226
sg13
I1
sa(dp8227
g7
I102
sg8
VP56524
p8228
sg10
I19
sg11
Vhistone deacetylase
p8229
sg13
I2
sa(dp8230
g7
I180
sg8
g24
sg10
I7
sg11
VMAGE-C2
p8231
sg13
I1
sasg14
(lp8232
(dp8233
g7
I191
sg17
VC0678222
p8234
sg10
I13
sg11
Vbreast cancer
p8235
sg13
I2
sasa(dp8236
g2
VProteins for MAGE-C1 and MAGE-C2 expressions were 38.3% and 58.3% in breast cancer specimens, messenger RNA for MAGE-C1 and MAGE-C2 expressions were 43.3% and 61.7%, respectively.
p8237
sg4
(lp8238
(dp8239
g7
I13
sg8
VP43355
p8240
sg10
I4
sg11
VMAGE
p8241
sg13
I1
sa(dp8242
g7
I13
sg8
VP43355
p8243
sg10
I4
sg11
VMAGE
p8244
sg13
I1
sa(dp8245
g7
I13
sg8
VP43355
p8246
sg10
I4
sg11
VMAGE
p8247
sg13
I1
sa(dp8248
g7
I13
sg8
VP43355
p8249
sg10
I4
sg11
VMAGE
p8250
sg13
I1
sasg14
(lp8251
(dp8252
g7
I69
sg17
VC0678222
p8253
sg10
I13
sg11
Vbreast cancer
p8254
sg13
I2
sasa(dp8255
g2
VMAGE-C1 and MAGE-C2 maybe potential targets for tumor immunotherapy, and their expressions are associated with advanced breast cancer and poor outcome.
p8256
sg4
(lp8257
(dp8258
g7
I0
sg8
VP43355
p8259
sg10
I4
sg11
VMAGE
p8260
sg13
I1
sa(dp8261
g7
I0
sg8
VP43355
p8262
sg10
I4
sg11
VMAGE
p8263
sg13
I1
sasg14
(lp8264
(dp8265
g7
I120
sg17
VC0678222
p8266
sg10
I13
sg11
Vbreast cancer
p8267
sg13
I2
sa(dp8268
g7
I48
sg17
VC0027651
p8269
sg10
I5
sg11
Vtumor
p8270
sg13
I1
sasa(dp8271
g2
VAs CT7 and CT10 are highly expressed in cutaneous melanoma and are immunogenic in this disease, we analysed their expression throughout the different subtypes of mucosal melanoma and tumor development.
p8272
sg4
(lp8273
(dp8274
g7
I3
sg8
g24
sg10
I3
sg11
VCT7
p8275
sg13
I1
sa(dp8276
g7
I11
sg8
g24
sg10
I4
sg11
VCT10
p8277
sg13
I1
sasg14
(lp8278
(dp8279
g7
I50
sg17
VC0025202
p8280
sg10
I8
sg11
Vmelanoma
p8281
sg13
I1
sa(dp8282
g7
I183
sg17
VC0027651
p8283
sg10
I5
sg11
Vtumor
p8284
sg13
I1
sa(dp8285
g7
I40
sg17
VC0025202
p8286
sg10
I18
sg11
Vcutaneous melanoma
p8287
sg13
I2
sasa(dp8288
g2
VIn the present study, we investigated expression patterns of nanog in the rat heart after acute myocardial infarction by semi-quantitative RT-PCR, immunohistochemistry and Western blot analyses.
p8289
sg4
(lp8290
sg14
(lp8291
(dp8292
g7
I90
sg17
VC0155626
p8293
sg10
I27
sg11
Vacute myocardial infarction
p8294
sg13
I3
sasa(dp8295
g2
VMRI represents the gold standard tool for differential diagnosis (with schwannoma, paraganglioma and haemangioma) and correct staging, while immunohistochemical and cytomorphologic analysis (bcl-2 and CD34 positivity in 90% of cases) is needed for definitive diagnosis.
p8296
sg4
(lp8297
(dp8298
g7
I191
sg8
VP10415
p8299
sg10
I5
sg11
Vbcl-2
p8300
sg13
I1
sa(dp8301
g7
I201
sg8
VP28906
p8302
sg10
I4
sg11
VCD34
p8303
sg13
I1
sasg14
(lp8304
(dp8305
g7
I101
sg17
VC0018916
p8306
sg10
I11
sg11
Vhaemangioma
p8307
sg13
I1
sa(dp8308
g7
I71
sg17
VC0027809
p8309
sg10
I10
sg11
Vschwannoma
p8310
sg13
I1
sa(dp8311
g7
I83
sg17
VC0030421
p8312
sg10
I13
sg11
Vparaganglioma
p8313
sg13
I1
sasa(dp8314
g2
VL'RMN rappresenta l'esame principale per escludere altre diagnosi (schwannoma, paragangliome ed emangioma) e per una corretta stadiazione mentre l'immunoistochimica e l'analisi citomorfologica (bcl-2 e CD34 positiva nel 90% dei casi) e la base per una diagnosi definitiva.
p8315
sg4
(lp8316
(dp8317
g7
I202
sg8
VP28906
p8318
sg10
I4
sg11
VCD34
p8319
sg13
I1
sa(dp8320
g7
I194
sg8
VP10415
p8321
sg10
I5
sg11
Vbcl-2
p8322
sg13
I1
sasg14
(lp8323
(dp8324
g7
I67
sg17
VC0027809
p8325
sg10
I10
sg11
Vschwannoma
p8326
sg13
I1
sasa(dp8327
g2
VDisease-specific iPS cells were generated from skin fibroblasts obtained from the indicated PMD patient and two other PMD patients having a 637-kb chromosomal duplication including entire PLP1 and a novel missense mutation (W212C) of PLP1, by transfections of OCT3/4, C-MYC, KLF4 and SOX2 using retro-virus vectors.
p8328
sg4
(lp8329
(dp8330
g7
I188
sg8
VP60201
p8331
sg10
I4
sg11
VPLP1
p8332
sg13
I1
sa(dp8333
g7
I188
sg8
VP60201
p8334
sg10
I4
sg11
VPLP1
p8335
sg13
I1
sa(dp8336
g7
I275
sg8
g24
sg10
I4
sg11
VKLF4
p8337
sg13
I1
sa(dp8338
g7
I268
sg8
VP12524
p8339
sg10
I5
sg11
VC-MYC
p8340
sg13
I1
sa(dp8341
g7
I284
sg8
VP48431
p8342
sg10
I4
sg11
VSOX2
p8343
sg13
I1
sa(dp8344
g7
I260
sg8
g24
sg10
I6
sg11
VOCT3/4
p8345
sg13
I1
sasg14
(lp8346
(dp8347
g7
I147
sg17
VC1516516
p8348
sg10
I23
sg11
Vchromosomal duplication
p8349
sg13
I2
sa(dp8350
g7
I17
sg17
VC1837610
p8351
sg10
I3
sg11
ViPS
p8352
sg13
I1
sa(dp8353
g7
I92
sg17
VC1832661
p8354
sg10
I3
sg11
VPMD
p8355
sg13
I1
sa(dp8356
g7
I92
sg17
VC1832661
p8357
sg10
I3
sg11
VPMD
p8358
sg13
I1
sasa(dp8359
g2
VMice with increased KLF4 in NSCs and NSCs-derived ependymal cells developed hydrocephalus-like characteristics, including enlarged ventricles, thinned cortex, agenesis of the corpus callosum, and significantly reduced subcommissural organ.
p8360
sg4
(lp8361
(dp8362
g7
I20
sg8
g24
sg10
I4
sg11
VKLF4
p8363
sg13
I1
sasg14
(lp8364
(dp8365
g7
I76
sg17
VC0020255
p8366
sg10
I13
sg11
Vhydrocephalus
p8367
sg13
I1
sa(dp8368
g7
I159
sg17
VC0175754
p8369
sg10
I31
sg11
Vagenesis of the corpus callosum
p8370
sg13
I5
sasa(dp8371
g2
VThese results indicate that down-regulation of KLF4 is critical for neural development and its dysregulation may lead to hydrocephalus.
p8372
sg4
(lp8373
(dp8374
g7
I47
sg8
g24
sg10
I4
sg11
VKLF4
p8375
sg13
I1
sasg14
(lp8376
(dp8377
g7
I121
sg17
VC0020255
p8378
sg10
I13
sg11
Vhydrocephalus
p8379
sg13
I1
sasa(dp8380
g2
VOur findings further reveal that activated Akt and STAT3 pathways induce the upregulation of HIF1Alfa and its downstream targets (LDHA and PDK1), leading to increased glycolysis in myeloma cells.
p8381
sg4
(lp8382
(dp8383
g7
I43
sg8
g24
sg10
I3
sg11
VAkt
p8384
sg13
I1
sa(dp8385
g7
I139
sg8
g24
sg10
I4
sg11
VPDK1
p8386
sg13
I1
sa(dp8387
g7
I130
sg8
VP00338
p8388
sg10
I4
sg11
VLDHA
p8389
sg13
I1
sa(dp8390
g7
I51
sg8
VP40763
p8391
sg10
I5
sg11
VSTAT3
p8392
sg13
I1
sasg14
(lp8393
(dp8394
g7
I181
sg17
VC0026764
p8395
sg10
I7
sg11
Vmyeloma
p8396
sg13
I1
sasa(dp8397
g2
VWe show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism.
p8398
sg4
(lp8399
(dp8400
g7
I94
sg8
VP00338
p8401
sg10
I4
sg11
VLDHA
p8402
sg13
I1
sa(dp8403
g7
I103
sg8
g24
sg10
I5
sg11
VHIF1A
p8404
sg13
I1
sa(dp8405
g7
I103
sg8
g24
sg10
I5
sg11
VHIF1A
p8406
sg13
I1
sa(dp8407
g7
I94
sg8
VP00338
p8408
sg10
I4
sg11
VLDHA
p8409
sg13
I1
sasg14
(lp8410
(dp8411
g7
I263
sg17
VC0598934
p8412
sg10
I12
sg11
Vtumor growth
p8413
sg13
I2
sa(dp8414
g7
I112
sg17
VC0026764
p8415
sg10
I16
sg11
Vmultiple myeloma
p8416
sg13
I2
sasa(dp8417
g2
VNovel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.
p8418
sg4
(lp8419
(dp8420
g7
I89
sg8
VP00338
p8421
sg10
I4
sg11
VLDHA
p8422
sg13
I1
sasg14
(lp8423
(dp8424
g7
I48
sg17
VC0026764
p8425
sg10
I16
sg11
Vmultiple myeloma
p8426
sg13
I2
sa(dp8427
g7
I124
sg17
VC0598934
p8428
sg10
I12
sg11
Vtumor growth
p8429
sg13
I2
sasa(dp8430
g2
VA 36,000-Mr protein purified from mouse myeloma on the basis of selective binding to a single-stranded DNA (ssDNA)-cellulose column has been identified as the lactate dehydrogenase A (LDH-A) subunit.
p8431
sg4
(lp8432
(dp8433
g7
I184
sg8
VP00338
p8434
sg10
I5
sg11
VLDH-A
p8435
sg13
I1
sa(dp8436
g7
I159
sg8
VP49366
p8437
sg10
I23
sg11
Vlactate dehydrogenase A
p8438
sg13
I3
sasg14
(lp8439
(dp8440
g7
I40
sg17
VC0026764
p8441
sg10
I7
sg11
Vmyeloma
p8442
sg13
I1
sasa(dp8443
g2
VA homogeneous preparation of this mouse myeloma ssDNA-binding protein, termed the 'low-salt-eluting protein', was found to possess LDH activity, and rabbit antiserum prepared against this protein was shown to cross-react with purified 36,000-Mr LDH-A subunits from mouse and bovine sources.
p8444
sg4
(lp8445
(dp8446
g7
I131
sg8
g24
sg10
I3
sg11
VLDH
p8447
sg13
I1
sa(dp8448
g7
I245
sg8
VP00338
p8449
sg10
I14
sg11
VLDH-A subunits
p8450
sg13
I2
sa(dp8451
g7
I34
sg8
g24
sg10
I35
sg11
Vmouse myeloma ssDNA-binding protein
p8452
sg13
I4
sasg14
(lp8453
(dp8454
g7
I40
sg17
VC0026764
p8455
sg10
I7
sg11
Vmyeloma
p8456
sg13
I1
sa(dp8457
g7
I123
sg17
VC0850310
p8458
sg10
I7
sg11
Vpossess
p8459
sg13
I1
sasa(dp8460
g2
VThese enzymic and immunological identities with LDH-A were not observed with purified helix-destabilizing protein 1 from mouse myeloma.
p8461
sg4
(lp8462
(dp8463
g7
I48
sg8
VP00338
p8464
sg10
I5
sg11
VLDH-A
p8465
sg13
I1
sasg14
(lp8466
(dp8467
g7
I127
sg17
VC0026764
p8468
sg10
I7
sg11
Vmyeloma
p8469
sg13
I1
sasa(dp8470
g2
VConcentrations of total lactate dehydrogenase (LDH; EC 1.1.1.27) and LDH isoenzyme patterns were studied in serum of 19 patients with multiple myeloma and in 19 healthy controls.
p8471
sg4
(lp8472
(dp8473
g7
I24
sg8
VP49366
p8474
sg10
I21
sg11
Vlactate dehydrogenase
p8475
sg13
I2
sa(dp8476
g7
I47
sg8
g24
sg10
I3
sg11
VLDH
p8477
sg13
I1
sa(dp8478
g7
I69
sg8
g24
sg10
I13
sg11
VLDH isoenzyme
p8479
sg13
I2
sasg14
(lp8480
(dp8481
g7
I134
sg17
VC0026764
p8482
sg10
I16
sg11
Vmultiple myeloma
p8483
sg13
I2
sasa(dp8484
g2
VDefective DNA repair is tightly correlated with worse neurological outcomes after stroke, whereas upregulation of DNA repair enzymes, such as APE1, OGG1, and XRCC1, improves long-term functional recovery following stroke.
p8485
sg4
(lp8486
(dp8487
g7
I158
sg8
VP18887
p8488
sg10
I5
sg11
VXRCC1
p8489
sg13
I1
sa(dp8490
g7
I142
sg8
VP27695
p8491
sg10
I4
sg11
VAPE1
p8492
sg13
I1
sasg14
(lp8493
(dp8494
g7
I184
sg17
VC0599766
p8495
sg10
I19
sg11
Vfunctional recovery
p8496
sg13
I2
sa(dp8497
g7
I82
sg17
VC0038454
p8498
sg10
I6
sg11
Vstroke
p8499
sg13
I1
sa(dp8500
g7
I82
sg17
VC0038454
p8501
sg10
I6
sg11
Vstroke
p8502
sg13
I1
sasa(dp8503
g2
VOur data showed that OGG1 Ser326Cys and XRCC1 Arg399Gln gene polymorphisms had impacts on the development of stroke.
p8504
sg4
(lp8505
(dp8506
g7
I40
sg8
VP18887
p8507
sg10
I20
sg11
VXRCC1 Arg399Gln gene
p8508
sg13
I3
sasg14
(lp8509
(dp8510
g7
I109
sg17
VC0038454
p8511
sg10
I6
sg11
Vstroke
p8512
sg13
I1
sasa(dp8513
g2
VPreviously, our laboratory showed that mice lacking the BER glycosylases 8-oxoguanine glycosylase 1 (Ogg1) or nei endonuclease VIII-like 1 (Neil1) recover more poorly from focal ischemic stroke than wild-type mice.
p8514
sg4
(lp8515
(dp8516
g7
I140
sg8
g24
sg10
I5
sg11
VNeil1
p8517
sg13
I1
sa(dp8518
g7
I110
sg8
g24
sg10
I28
sg11
Vnei endonuclease VIII-like 1
p8519
sg13
I4
sasg14
(lp8520
(dp8521
g7
I178
sg17
VC3272363
p8522
sg10
I15
sg11
Vischemic stroke
p8523
sg13
I2
sasa(dp8524
g2
VGenotyping of polymorphisms of the OGG1 (Ser326Cys), XRCC1 (Arg399Gln), ERCC2 (Lys751Gln), and ERCC5 (Asp1104His) genes was performed and used to evaluate LAA stroke susceptibility.
p8525
sg4
(lp8526
(dp8527
g7
I95
sg8
VP28715
p8528
sg10
I24
sg11
VERCC5 (Asp1104His) genes
p8529
sg13
I3
sa(dp8530
g7
I72
sg8
VP18074
p8531
sg10
I5
sg11
VERCC2
p8532
sg13
I1
sa(dp8533
g7
I53
sg8
VP18887
p8534
sg10
I5
sg11
VXRCC1
p8535
sg13
I1
sasg14
(lp8536
(dp8537
g7
I159
sg17
VC0038454
p8538
sg10
I6
sg11
Vstroke
p8539
sg13
I1
sasa(dp8540
g2
VA joint effect on risk elevation of LAA stroke was seen in those patients with OGG1 and ERCC2 polymorphisms (OR: 2.75, 95%CI: 1.26-6.00).
p8541
sg4
(lp8542
(dp8543
g7
I88
sg8
VP18074
p8544
sg10
I5
sg11
VERCC2
p8545
sg13
I1
sasg14
(lp8546
(dp8547
g7
I40
sg17
VC0038454
p8548
sg10
I6
sg11
Vstroke
p8549
sg13
I1
sasa(dp8550
g2
VMoreover, among smokers carrying the OGG1 Ser326Cys polymorphism, there was a tendency toward an increased risk of LAA stroke in those patients who had a greater number of high-risk genotypes of XRCC1, ERCC2, and ERCC5 polymorphisms (p(trend)=0.010).
p8551
sg4
(lp8552
(dp8553
g7
I202
sg8
VP18074
p8554
sg10
I5
sg11
VERCC2
p8555
sg13
I1
sa(dp8556
g7
I213
sg8
VP28715
p8557
sg10
I5
sg11
VERCC5
p8558
sg13
I1
sa(dp8559
g7
I195
sg8
VP18887
p8560
sg10
I5
sg11
VXRCC1
p8561
sg13
I1
sasg14
(lp8562
(dp8563
g7
I119
sg17
VC0038454
p8564
sg10
I6
sg11
Vstroke
p8565
sg13
I1
sasa(dp8566
g2
VAmong 22 patients who underwent LP shunt placement for IIH, 16 (72.8%) patients had severe and fulminant opening CSF pressures with values of more than 400 mmH(2)O.
p8567
sg4
(lp8568
sg14
(lp8569
sa(dp8570
g2
VThis study implicates increased I(NaL) in excessive atrial APD prolongation and arrhythmic EAD occurrence in a congenital LQTS3 mouse model.
p8571
sg4
(lp8572
sg14
(lp8573
(dp8574
g7
I91
sg17
VC1864233
p8575
sg10
I3
sg11
VEAD
p8576
sg13
I1
sasa(dp8577
g2
V(1) To report the different patterns of NAL and discuss the mechanisms encountered; (2) to determine the relationship between a given type of lymphoma and a specific type of neuropathy; and (3) to assess the prognosis of NAL.
p8578
sg4
(lp8579
sg14
(lp8580
(dp8581
g7
I142
sg17
VC0024299
p8582
sg10
I8
sg11
Vlymphoma
p8583
sg13
I1
sa(dp8584
g7
I174
sg17
VC0442874
p8585
sg10
I10
sg11
Vneuropathy
p8586
sg13
I1
sasa(dp8587
g2
VTwo thousand four hundred ninety-three consecutive dermatitis patients in 9 dermatology clinics were patch tested with a TDM 6.6%, consisting of Disperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1 and 17, all 1.0% each, and D Blue 106 and D Blue 124, each 0.3%.
p8588
sg4
(lp8589
(dp8590
g7
I145
sg8
VP16435
p8591
sg10
I59
sg11
VDisperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1
p8592
sg13
I15
sasg14
(lp8593
(dp8594
g7
I51
sg17
VC0011603
p8595
sg10
I10
sg11
Vdermatitis
p8596
sg13
I1
sasa(dp8597
g2
VThe name hydrolethalus refers to the main findings, namely polyhydramnios, hydrocephalus and lethality.
p8598
sg4
(lp8599
sg14
(lp8600
(dp8601
g7
I75
sg17
VC0020255
p8602
sg10
I13
sg11
Vhydrocephalus
p8603
sg13
I1
sa(dp8604
g7
I59
sg17
VC0020224
p8605
sg10
I14
sg11
Vpolyhydramnios
p8606
sg13
I1
sasa(dp8607
g2
VVACTERL with hydrocephalus appears distinct from hydrolethalus and similar conditions but is itself heterogeneous.
p8608
sg4
(lp8609
sg14
(lp8610
(dp8611
g7
I13
sg17
VC0020255
p8612
sg10
I13
sg11
Vhydrocephalus
p8613
sg13
I1
sasa(dp8614
g2
VIn this study, we evaluated the feasibility of combining p53-DC vaccine and rAd-p53 gene therapy, using the p53-overexpressing and non-expressing prostate cancer cells in vitro.
p8615
sg4
(lp8616
(dp8617
g7
I57
sg8
VP42771
p8618
sg10
I6
sg11
Vp53-DC
p8619
sg13
I1
sa(dp8620
g7
I57
sg8
VP42771
p8621
sg10
I4
sg11
Vp53-
p8622
sg13
I1
sa(dp8623
g7
I57
sg8
VP42771
p8624
sg10
I3
sg11
Vp53
p8625
sg13
I1
sa(dp8626
g7
I76
sg8
VP55042
p8627
sg10
I3
sg11
VrAd
p8628
sg13
I1
sasg14
(lp8629
(dp8630
g7
I146
sg17
VC0600139
p8631
sg10
I15
sg11
Vprostate cancer
p8632
sg13
I2
sasa(dp8633
g2
VIn addition, rAd-p53 infection can induce overexpression of p53 and thus the cytotoxicity of CTLs differentiated by the p53-DC vaccine in p53 non-expressing prostate cancer cells.
p8634
sg4
(lp8635
(dp8636
g7
I17
sg8
VP42771
p8637
sg10
I3
sg11
Vp53
p8638
sg13
I1
sa(dp8639
g7
I120
sg8
VP42771
p8640
sg10
I6
sg11
Vp53-DC
p8641
sg13
I1
sa(dp8642
g7
I13
sg8
VP55042
p8643
sg10
I7
sg11
VrAd-p53
p8644
sg13
I1
sa(dp8645
g7
I17
sg8
VP42771
p8646
sg10
I3
sg11
Vp53
p8647
sg13
I1
sasg14
(lp8648
(dp8649
g7
I77
sg17
VC0596402
p8650
sg10
I12
sg11
Vcytotoxicity
p8651
sg13
I1
sa(dp8652
g7
I21
sg17
VC0009450
p8653
sg10
I9
sg11
Vinfection
p8654
sg13
I1
sa(dp8655
g7
I157
sg17
VC0600139
p8656
sg10
I15
sg11
Vprostate cancer
p8657
sg13
I2
sasa(dp8658
g2
VThis study detected the migration of MSCs to high metastasis liver carcinoma cells MHCC-97H in vitro, investigated the inhibitory effect of rAd-NK4-MSCs on the growth and metastasis of MHCC-97H cells, further explored the inhibitory mechanism of rAd-NK4-MSCs to MHCC-97H cell metastasis, and examined the inhibitory effect of rAd-NK4-MSCs on the migration of human umbilical vein endothelial cells (HUVECs) in vitro.
p8659
sg4
(lp8660
(dp8661
g7
I140
sg8
VP55042
p8662
sg10
I12
sg11
VrAd-NK4-MSCs
p8663
sg13
I1
sa(dp8664
g7
I140
sg8
VP55042
p8665
sg10
I3
sg11
VrAd
p8666
sg13
I1
sa(dp8667
g7
I140
sg8
VP55042
p8668
sg10
I12
sg11
VrAd-NK4-MSCs
p8669
sg13
I1
sa(dp8670
g7
I144
sg8
VP24001
p8671
sg10
I3
sg11
VNK4
p8672
sg13
I1
sasg14
(lp8673
(dp8674
g7
I50
sg17
VC0027627
p8675
sg10
I10
sg11
Vmetastasis
p8676
sg13
I1
sa(dp8677
g7
I50
sg17
VC0027627
p8678
sg10
I10
sg11
Vmetastasis
p8679
sg13
I1
sa(dp8680
g7
I61
sg17
VC2239176
p8681
sg10
I15
sg11
Vliver carcinoma
p8682
sg13
I2
sa(dp8683
g7
I50
sg17
VC0027627
p8684
sg10
I10
sg11
Vmetastasis
p8685
sg13
I1
sasa(dp8686
g2
VThe present study was conducted to identify the anti-tumor effects of rAd/p53, which is a recombinant human serotype 5 adenovirus, in cutaneous squamous cell carcinoma (cSCC).
p8687
sg4
(lp8688
(dp8689
g7
I70
sg8
VP55042
p8690
sg10
I3
sg11
VrAd
p8691
sg13
I1
sa(dp8692
g7
I74
sg8
VP42771
p8693
sg10
I3
sg11
Vp53
p8694
sg13
I1
sasg14
(lp8695
(dp8696
g7
I134
sg17
VC0553723
p8697
sg10
I33
sg11
Vcutaneous squamous cell carcinoma
p8698
sg13
I4
sa(dp8699
g7
I119
sg17
VC0001486
p8700
sg10
I10
sg11
Vadenovirus
p8701
sg13
I1
sa(dp8702
g7
I169
sg17
VC0553723
p8703
sg10
I4
sg11
VcSCC
p8704
sg13
I1
sa(dp8705
g7
I53
sg17
VC0027651
p8706
sg10
I5
sg11
Vtumor
p8707
sg13
I1
sasa(dp8708
g2
VFinally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells.
p8709
sg4
(lp8710
(dp8711
g7
I79
sg8
g24
sg10
I48
sg11
VHistone demethylase Lysine specific demethylase1
p8712
sg13
I5
sa(dp8713
g7
I165
sg8
g24
sg10
I24
sg11
VLarge tumor suppressor 2
p8714
sg13
I4
sa(dp8715
g7
I191
sg8
g24
sg10
I5
sg11
VLATS2
p8716
sg13
I1
sa(dp8717
g7
I202
sg8
VP01116
p8718
sg10
I3
sg11
VRas
p8719
sg13
I1
sasg14
(lp8720
(dp8721
g7
I147
sg17
VC0027651
p8722
sg10
I5
sg11
Vtumor
p8723
sg13
I1
sa(dp8724
g7
I230
sg17
VC0011849
p8725
sg10
I8
sg11
Vdiabetes
p8726
sg13
I1
sa(dp8727
g7
I147
sg17
VC0027651
p8728
sg10
I5
sg11
Vtumor
p8729
sg13
I1
sa(dp8730
g7
I263
sg17
VC0007131
p8731
sg10
I5
sg11
VNSCLC
p8732
sg13
I1
sasa(dp8733
g2
VTo compare clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal carcinoma (NPC).
p8734
sg4
(lp8735
(dp8736
g7
I97
sg8
VP55042
p8737
sg10
I7
sg11
VrAd-p53
p8738
sg13
I1
sa(dp8739
g7
I146
sg8
VP27797
p8740
sg10
I3
sg11
VCRT
p8741
sg13
I1
sa(dp8742
g7
I53
sg8
VP55042
p8743
sg10
I42
sg11
Vrecombinant human adenovirus-p53 injection
p8744
sg13
I4
sa(dp8745
g7
I127
sg8
VP27797
p8746
sg10
I17
sg11
Vchemoradiotherapy
p8747
sg13
I1
sasg14
(lp8748
(dp8749
g7
I71
sg17
VC0001486
p8750
sg10
I10
sg11
Vadenovirus
p8751
sg13
I1
sa(dp8752
g7
I210
sg17
VC2931822
p8753
sg10
I24
sg11
Vnasopharyngeal carcinoma
p8754
sg13
I2
sa(dp8755
g7
I236
sg17
VC2931822
p8756
sg10
I3
sg11
VNPC
p8757
sg13
I1
sasa(dp8758
g2
VWe used data generated from a haploid hydatidiform mole genome (CHM1) and a diploid human genome (NA12878) to test our approach.
p8759
sg4
(lp8760
(dp8761
g7
I64
sg8
g24
sg10
I4
sg11
VCHM1
p8762
sg13
I1
sasg14
(lp8763
(dp8764
g7
I38
sg17
VC0020217
p8765
sg10
I17
sg11
Vhydatidiform mole
p8766
sg13
I2
sasa(dp8767
g2
VOur results show the recovery of an allele of the non-coding minisatellite MS1 (located on chromosome 1 at 1p33-35) at greater than 97% identity to reference (GRCh38) from the unprocessed sequence data of a haploid complete hydatidiform mole (CHM1) cell line.
p8768
sg4
(lp8769
sg14
(lp8770
(dp8771
g7
I215
sg17
VC0678213
p8772
sg10
I26
sg11
Vcomplete hydatidiform mole
p8773
sg13
I3
sasa(dp8774
g2
VWe demonstrate the utility of Alpha-CENTAURI in characterizing repeat structure for alpha satellite containing reads in the hydatidiform mole (CHM1, haploid-like) genome.
p8775
sg4
(lp8776
(dp8777
g7
I143
sg8
g24
sg10
I4
sg11
VCHM1
p8778
sg13
I1
sasg14
(lp8779
(dp8780
g7
I124
sg17
VC0020217
p8781
sg10
I17
sg11
Vhydatidiform mole
p8782
sg13
I2
sasa(dp8783
g2
VIn order to overcome the issue of allelic diversity, we used genomic DNA from an essentially haploid hydatidiform mole, CHM1.
p8784
sg4
(lp8785
(dp8786
g7
I120
sg8
g24
sg10
I4
sg11
VCHM1
p8787
sg13
I1
sasg14
(lp8788
(dp8789
g7
I101
sg17
VC0020217
p8790
sg10
I17
sg11
Vhydatidiform mole
p8791
sg13
I2
sasa(dp8792
g2
VConsistent with these findings, we observed that in an IL-33-administered asthmatic airway inflammation model, IL-13 levels were markedly increased in bronchoalveolar lavage fluid, but its levels were markedly suppressed by treatment with inhibitors of 5-LO, 12-LO or BLT2, further suggesting roles of 5-/12-LO in IL-33-induced IL-13 production.
p8793
sg4
(lp8794
(dp8795
g7
I268
sg8
g24
sg10
I4
sg11
VBLT2
p8796
sg13
I1
sa(dp8797
g7
I111
sg8
VP35225
p8798
sg10
I5
sg11
VIL-13
p8799
sg13
I1
sa(dp8800
g7
I111
sg8
VP35225
p8801
sg10
I5
sg11
VIL-13
p8802
sg13
I1
sasg14
(lp8803
(dp8804
g7
I91
sg17
VC0021368
p8805
sg10
I12
sg11
Vinflammation
p8806
sg13
I1
sa(dp8807
g7
I74
sg17
VC0004096
p8808
sg10
I9
sg11
Vasthmatic
p8809
sg13
I1
sasa(dp8810
g2
VOur results suggest that "MyD88-5-/12-LO-BLT2-NF-KB" cascade significantly contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus potentially contributing to asthmatic development and exacerbation.
p8811
sg4
(lp8812
(dp8813
g7
I41
sg8
g24
sg10
I4
sg11
VBLT2
p8814
sg13
I1
sa(dp8815
g7
I26
sg8
g24
sg10
I5
sg11
VMyD88
p8816
sg13
I1
sa(dp8817
g7
I121
sg8
VP35225
p8818
sg10
I5
sg11
VIL-13
p8819
sg13
I1
sasg14
(lp8820
(dp8821
g7
I175
sg17
VC0004096
p8822
sg10
I9
sg11
Vasthmatic
p8823
sg13
I1
sasa(dp8824
g2
VDNA methylation changes at a number of these genes have been linked to various forms of human disease, including cancers, such as asthma and acute myeloid leukemia (ALOX12), gastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia (KCNK15), Wilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L), suggesting a potential etiologic role for MEs in tumorigenesis and underscoring the possible developmental origins of these malignancies.
p8825
sg4
(lp8826
(dp8827
g7
I174
sg8
VP12830
p8828
sg10
I85
sg11
Vgastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia
p8829
sg13
I12
sa(dp8830
g7
I270
sg8
g24
sg10
I80
sg11
VWilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L)
p8831
sg13
I10
sa(dp8832
g7
I261
sg8
g24
sg10
I6
sg11
VKCNK15
p8833
sg13
I1
sasg14
(lp8834
(dp8835
g7
I197
sg17
VC0678222
p8836
sg10
I13
sg11
Vbreast cancer
p8837
sg13
I2
sa(dp8838
g7
I401
sg17
VC0007621
p8839
sg10
I13
sg11
Vtumorigenesis
p8840
sg13
I1
sa(dp8841
g7
I174
sg17
VC0024623
p8842
sg10
I14
sg11
Vgastric cancer
p8843
sg13
I2
sa(dp8844
g7
I141
sg17
VC0023467
p8845
sg10
I22
sg11
Vacute myeloid leukemia
p8846
sg13
I3
sa(dp8847
g7
I236
sg17
VC1961102
p8848
sg10
I23
sg11
Vacute lymphoid leukemia
p8849
sg13
I3
sa(dp8850
g7
I219
sg17
VC0699790
p8851
sg10
I12
sg11
Vcolon cancer
p8852
sg13
I2
sa(dp8853
g7
I130
sg17
VC0004096
p8854
sg10
I6
sg11
Vasthma
p8855
sg13
I1
sa(dp8856
g7
I476
sg17
VC0006826
p8857
sg10
I12
sg11
Vmalignancies
p8858
sg13
I1
sa(dp8859
g7
I323
sg17
VC1527249
p8860
sg10
I17
sg11
Vcolorectal cancer
p8861
sg13
I2
sa(dp8862
g7
I394
sg17
VC0265215
p8863
sg10
I3
sg11
VMEs
p8864
sg13
I1
sa(dp8865
g7
I113
sg17
VC0006826
p8866
sg10
I7
sg11
Vcancers
p8867
sg13
I1
sa(dp8868
g7
I270
sg17
VC0027708
p8869
sg10
I11
sg11
VWilms tumor
p8870
sg13
I2
sasa(dp8871
g2
VDNA methylation of ALOX12 may be an epigenetic biomarker for the risk of asthma-related phenotypes.
p8872
sg4
(lp8873
(dp8874
g7
I19
sg8
VP18054
p8875
sg10
I6
sg11
VALOX12
p8876
sg13
I1
sasg14
(lp8877
(dp8878
g7
I73
sg17
VC0004096
p8879
sg10
I6
sg11
Vasthma
p8880
sg13
I1
sasa(dp8881
g2
VWe provide evidence that MJD in five pedigrees of Azorean descent is also linked to chromosome 14q in an 18-cM region between the markers D14S67 and AACT (multipoint lod score +7.00 near D14S81).
p8882
sg4
(lp8883
(dp8884
g7
I149
sg8
VP05154
p8885
sg10
I4
sg11
VAACT
p8886
sg13
I1
sasg14
(lp8887
(dp8888
g7
I25
sg17
VC0024408
p8889
sg10
I3
sg11
VMJD
p8890
sg13
I1
sasa(dp8891
g2
VHere we report linkage disequilibrium of rs2288904 with rs3087969 and the association of these SLC44A2 SNPs with Meniere's disease severity.
p8892
sg4
(lp8893
(dp8894
g7
I95
sg8
g24
sg10
I12
sg11
VSLC44A2 SNPs
p8895
sg13
I2
sasg14
(lp8896
(dp8897
g7
I23
sg17
VC0394006
p8898
sg10
I14
sg11
Vdisequilibrium
p8899
sg13
I1
sa(dp8900
g7
I113
sg17
VC0025281
p8901
sg10
I17
sg11
VMeniere's disease
p8902
sg13
I2
sasa(dp8903
g2
VThe association of SLC44A2 SNPs with VTE suggests that thrombi affecting cochlear vessels could be a factor in Meniere's disease.
p8904
sg4
(lp8905
(dp8906
g7
I19
sg8
g24
sg10
I12
sg11
VSLC44A2 SNPs
p8907
sg13
I2
sasg14
(lp8908
(dp8909
g7
I55
sg17
VC0087086
p8910
sg10
I7
sg11
Vthrombi
p8911
sg13
I1
sa(dp8912
g7
I111
sg17
VC0025281
p8913
sg10
I17
sg11
VMeniere's disease
p8914
sg13
I2
sasa(dp8915
g2
VThe present study deals with CTLA-4 gene selected polymorphisms (rs11571317 C/T and rs3087243G/A) to explore their relation with breast cancer susceptibility and progression in BC patients.
p8916
sg4
(lp8917
(dp8918
g7
I29
sg8
VP16410
p8919
sg10
I11
sg11
VCTLA-4 gene
p8920
sg13
I2
sasg14
(lp8921
(dp8922
g7
I129
sg17
VC0678222
p8923
sg10
I13
sg11
Vbreast cancer
p8924
sg13
I2
sasa(dp8925
g2
VClinical experience with checkpoint inhibitors in hepatocellular carcinoma includes early trials with the anti-CTLA-4 agent tremelimumab, and a large phase 2 trial with the anti-PD-1 agent nivolumab.
p8926
sg4
(lp8927
(dp8928
g7
I106
sg8
VP16410
p8929
sg10
I11
sg11
Vanti-CTLA-4
p8930
sg13
I1
sasg14
(lp8931
(dp8932
g7
I50
sg17
VC1512411
p8933
sg10
I24
sg11
Vhepatocellular carcinoma
p8934
sg13
I2
sasa(dp8935
g2
VSeveral immune checkpoint inhibitors that target programmed cell death protein 1 (PD1), its ligand PDL1, and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have already been approved for use in bladder cancer, representing the most important change to the urological oncologist's tool-kit in over a decade.
p8936
sg4
(lp8937
(dp8938
g7
I154
sg8
VP16410
p8939
sg10
I5
sg11
VCTLA4
p8940
sg13
I1
sa(dp8941
g7
I99
sg8
g24
sg10
I4
sg11
VPDL1
p8942
sg13
I1
sa(dp8943
g7
I82
sg8
VP37840
p8944
sg10
I3
sg11
VPD1
p8945
sg13
I1
sa(dp8946
g7
I109
sg8
VP16410
p8947
sg10
I43
sg11
Vcytotoxic T lymphocyte-associated protein 4
p8948
sg13
I5
sa(dp8949
g7
I49
sg8
VP37840
p8950
sg10
I31
sg11
Vprogrammed cell death protein 1
p8951
sg13
I5
sasg14
(lp8952
(dp8953
g7
I199
sg17
VC0699885
p8954
sg10
I14
sg11
Vbladder cancer
p8955
sg13
I2
sasa(dp8956
g2
VOur model predicts survival in anti-CTLA-4-treated patients with melanoma and anti-PD-1-treated patients with lung cancer.
p8957
sg4
(lp8958
(dp8959
g7
I31
sg8
VP16410
p8960
sg10
I11
sg11
Vanti-CTLA-4
p8961
sg13
I1
sa(dp8962
g7
I78
sg8
VP18621
p8963
sg10
I9
sg11
Vanti-PD-1
p8964
sg13
I1
sasg14
(lp8965
(dp8966
g7
I65
sg17
VC0025202
p8967
sg10
I8
sg11
Vmelanoma
p8968
sg13
I1
sa(dp8969
g7
I110
sg17
VC0684249
p8970
sg10
I11
sg11
Vlung cancer
p8971
sg13
I2
sasa(dp8972
g2
VSmall animal PET/CT studies showed that 89Zr-C4 detected antigen levels on a patient derived xenograft (PDX) established from a non-small-cell lung cancer (NSCLC) patient before an 8-month response to anti-PD-1 and anti-CTLA4 therapy.
p8973
sg4
(lp8974
(dp8975
g7
I201
sg8
VP18621
p8976
sg10
I9
sg11
Vanti-PD-1
p8977
sg13
I1
sa(dp8978
g7
I215
sg8
VP16410
p8979
sg10
I10
sg11
Vanti-CTLA4
p8980
sg13
I1
sasg14
(lp8981
(dp8982
g7
I128
sg17
VC0007131
p8983
sg10
I26
sg11
Vnon-small-cell lung cancer
p8984
sg13
I3
sa(dp8985
g7
I156
sg17
VC0007131
p8986
sg10
I5
sg11
VNSCLC
p8987
sg13
I1
sasa(dp8988
g2
VAutosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identified in patients with POF.
p8989
sg4
(lp8990
(dp8991
g7
I124
sg8
VP15291
p8992
sg10
I4
sg11
VGALT
p8993
sg13
I1
sa(dp8994
g7
I154
sg8
VP23945
p8995
sg10
I4
sg11
VFSHR
p8996
sg13
I1
sa(dp8997
g7
I140
sg8
VP23945
p8998
sg10
I12
sg11
VFSH receptor
p8999
sg13
I2
sa(dp9000
g7
I67
sg8
g24
sg10
I4
sg11
VPMM2
p9001
sg13
I1
sa(dp9002
g7
I83
sg8
g24
sg10
I39
sg11
Vgalactose-1-phosphate uridyltransferase
p9003
sg13
I2
sa(dp9004
g7
I45
sg8
g24
sg10
I20
sg11
Vphosphomannomutase 2
p9005
sg13
I2
sasg14
(lp9006
(dp9007
g7
I294
sg17
VC0006840
p9008
sg10
I11
sg11
Vcandidiasis
p9009
sg13
I1
sa(dp9010
g7
I317
sg17
VC0333606
p9011
sg10
I9
sg11
Vdystrophy
p9012
sg13
I1
sa(dp9013
g7
I195
sg17
VC0005744
p9014
sg10
I16
sg11
VBlepharophimosis
p9015
sg13
I1
sa(dp9016
g7
I225
sg17
VC0443146
p9017
sg10
I10
sg11
Vautoimmune
p9018
sg13
I1
sa(dp9019
g7
I366
sg17
VC0085215
p9020
sg10
I3
sg11
VPOF
p9021
sg13
I1
sasa(dp9022
g2
VOsteoclast-specific genes such as Trap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7 (Clcn7), cathepsin K (Ctsk) as well as osteoclast-specific transcription factor and microphthalmia transcription factor (MITF) were up-regulated in the treated cells, whilst the messenger RNA (mRNA) levels of Dspp, Dmp1 and Opg were reduced in the induced cells.
p9023
sg4
(lp9024
(dp9025
g7
I332
sg8
g24
sg10
I4
sg11
VDmp1
p9026
sg13
I1
sa(dp9027
g7
I126
sg8
VP43235
p9028
sg10
I11
sg11
Vcathepsin K
p9029
sg13
I2
sa(dp9030
g7
I118
sg8
VP51798
p9031
sg10
I5
sg11
VClcn7
p9032
sg13
I1
sa(dp9033
g7
I201
sg8
VP35398
p9034
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9035
sg13
I3
sa(dp9036
g7
I326
sg8
g24
sg10
I4
sg11
VDspp
p9037
sg13
I1
sa(dp9038
g7
I139
sg8
VP43235
p9039
sg10
I4
sg11
VCtsk
p9040
sg13
I1
sa(dp9041
g7
I238
sg8
g24
sg10
I4
sg11
VMITF
p9042
sg13
I1
sa(dp9043
g7
I34
sg8
g24
sg10
I82
sg11
VTrap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7
p9044
sg13
I9
sa(dp9045
g7
I341
sg8
g24
sg10
I3
sg11
VOpg
p9046
sg13
I1
sasg14
(lp9047
(dp9048
g7
I40
sg17
VC0029454
p9049
sg10
I13
sg11
Vosteopetrosis
p9050
sg13
I1
sa(dp9051
g7
I201
sg17
VC0026010
p9052
sg10
I14
sg11
Vmicrophthalmia
p9053
sg13
I1
sasa(dp9054
g2
VCathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts.
p9055
sg4
(lp9056
(dp9057
g7
I0
sg8
VP43235
p9058
sg10
I11
sg11
VCathepsin K
p9059
sg13
I2
sa(dp9060
g7
I56
sg8
VP35398
p9061
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9062
sg13
I3
sa(dp9063
g7
I93
sg8
g24
sg10
I4
sg11
VMITF
p9064
sg13
I1
sasg14
(lp9065
(dp9066
g7
I56
sg17
VC0026010
p9067
sg10
I14
sg11
Vmicrophthalmia
p9068
sg13
I1
sasa(dp9069
g2
VAmong cell species that infiltrated in perichondral granulation, LCA, CD68 (monocytes/macrophages), and CD4 cells were dominant in number; MMP-8, MMP-9, and elastase were expressed only in the perichondral granulation; whereas MMP-3 and cathepsin K and L were detected in both chondrocytes and granulations.
p9070
sg4
(lp9071
(dp9072
g7
I146
sg8
VP14780
p9073
sg10
I5
sg11
VMMP-9
p9074
sg13
I1
sa(dp9075
g7
I139
sg8
VP22894
p9076
sg10
I5
sg11
VMMP-8
p9077
sg13
I1
sa(dp9078
g7
I237
sg8
VP43235
p9079
sg10
I17
sg11
Vcathepsin K and L
p9080
sg13
I4
sa(dp9081
g7
I104
sg8
VP01730
p9082
sg10
I3
sg11
VCD4
p9083
sg13
I1
sa(dp9084
g7
I157
sg8
VP30740
p9085
sg10
I8
sg11
Velastase
p9086
sg13
I1
sa(dp9087
g7
I227
sg8
VP08254
p9088
sg10
I5
sg11
VMMP-3
p9089
sg13
I1
sa(dp9090
g7
I65
sg8
VP09496
p9091
sg10
I3
sg11
VLCA
p9092
sg13
I1
sa(dp9093
g7
I70
sg8
VP34810
p9094
sg10
I4
sg11
VCD68
p9095
sg13
I1
sasg14
(lp9096
(dp9097
g7
I24
sg17
VC0332448
p9098
sg10
I11
sg11
Vinfiltrated
p9099
sg13
I1
sa(dp9100
g7
I65
sg17
VC0339527
p9101
sg10
I3
sg11
VLCA
p9102
sg13
I1
sasa(dp9103
g2
VOverexpression of microphthalmia transcription factor has been shown to mediate the expression of cathepsin-K in osteoclasts.
p9104
sg4
(lp9105
(dp9106
g7
I18
sg8
VP35398
p9107
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9108
sg13
I3
sa(dp9109
g7
I98
sg8
VP43235
p9110
sg10
I11
sg11
Vcathepsin-K
p9111
sg13
I1
sasg14
(lp9112
(dp9113
g7
I18
sg17
VC0026010
p9114
sg10
I14
sg11
Vmicrophthalmia
p9115
sg13
I1
sasa(dp9116
g2
VWe studied cathepsin-K in 17 cytogenetically confirmed microphthalmia transcription factor/TFE-family translocation renal cell carcinomas.
p9117
sg4
(lp9118
(dp9119
g7
I55
sg8
VP35398
p9120
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9121
sg13
I3
sasg14
(lp9122
(dp9123
g7
I116
sg17
VC0007134
p9124
sg10
I21
sg11
Vrenal cell carcinomas
p9125
sg13
I3
sa(dp9126
g7
I55
sg17
VC0026010
p9127
sg10
I14
sg11
Vmicrophthalmia
p9128
sg13
I1
sa(dp9129
g7
I102
sg17
VC0040715
p9130
sg10
I13
sg11
Vtranslocation
p9131
sg13
I1
sasa(dp9132
g2
VRadiographs of the hands of 60 patients with cartilage hair hypoplasia (CHH), 69 with trichorhinophalangeal syndrome I (TRP I) and 11 with TRP II were examined, including 26 longitudinal observations.
p9133
sg4
(lp9134
(dp9135
g7
I139
sg8
VP13686
p9136
sg10
I6
sg11
VTRP II
p9137
sg13
I2
sasg14
(lp9138
(dp9139
g7
I120
sg17
VC0432233
p9140
sg10
I5
sg11
VTRP I
p9141
sg13
I2
sa(dp9142
g7
I45
sg17
VC0220748
p9143
sg10
I25
sg11
Vcartilage hair hypoplasia
p9144
sg13
I3
sa(dp9145
g7
I72
sg17
VC0220748
p9146
sg10
I3
sg11
VCHH
p9147
sg13
I1
sa(dp9148
g7
I86
sg17
VC0432233
p9149
sg10
I32
sg11
Vtrichorhinophalangeal syndrome I
p9150
sg13
I3
sasa(dp9151
g2
VWe report here the new approach of fusing putidaredoxin reductase (PdR) to the carboxy-terminus of CYP101A1 (P450cam) via a linker peptide and reconstituting camphor hydroxylase activity with free putidaredoxin (Pdx).
p9152
sg4
(lp9153
(dp9154
g7
I42
sg8
g24
sg10
I23
sg11
Vputidaredoxin reductase
p9155
sg13
I2
sa(dp9156
g7
I67
sg8
g24
sg10
I3
sg11
VPdR
p9157
sg13
I1
sasg14
(lp9158
(dp9159
g7
I42
sg17
VC1845050
p9160
sg10
I23
sg11
Vputidaredoxin reductase
p9161
sg13
I2
sa(dp9162
g7
I67
sg17
VC1845050
p9163
sg10
I3
sg11
VPdR
p9164
sg13
I1
sasa(dp9165
g2
VFor other diseases, a well-established example relates to CYP1B1 where homozygosity for rare mutations occurs in primary congenital glaucoma.
p9166
sg4
(lp9167
(dp9168
g7
I58
sg8
g24
sg10
I6
sg11
VCYP1B1
p9169
sg13
I1
sasg14
(lp9170
(dp9171
g7
I113
sg17
VC1533041
p9172
sg10
I27
sg11
Vprimary congenital glaucoma
p9173
sg13
I3
sasa(dp9174
g2
VRare CYP1B1 mutations and possibly polymorphisms may also contribute to risk for more common forms of glaucoma.
p9175
sg4
(lp9176
(dp9177
g7
I0
sg8
g24
sg10
I11
sg11
VRare CYP1B1
p9178
sg13
I2
sasg14
(lp9179
(dp9180
g7
I102
sg17
VC0017601
p9181
sg10
I8
sg11
Vglaucoma
p9182
sg13
I1
sasa(dp9183
g2
VHowever, the effects of the potential herb-drug interactions (HDIs) between LCA and therapeutic drugs on the inhibition of human cytochrome P450 (CYP) enzymes remain unclear.
p9184
sg4
(lp9185
(dp9186
g7
I146
sg8
g24
sg10
I3
sg11
VCYP
p9187
sg13
I1
sa(dp9188
g7
I123
sg8
VP20853
p9189
sg10
I21
sg11
Vhuman cytochrome P450
p9190
sg13
I3
sasg14
(lp9191
(dp9192
g7
I76
sg17
VC0339527
p9193
sg10
I3
sg11
VLCA
p9194
sg13
I1
sasa(dp9195
g2
VIn the present study, the inhibitory effects of LCA on seven major human CYP isoforms, including CYP1A2, 2D6, 2E1, 2C19, 2C8, 2C9 and 3A4, were investigated in human liver microsomes (HLMs).
p9196
sg4
(lp9197
(dp9198
g7
I61
sg8
g24
sg10
I24
sg11
Vmajor human CYP isoforms
p9199
sg13
I4
sa(dp9200
g7
I97
sg8
VP05177
p9201
sg10
I6
sg11
VCYP1A2
p9202
sg13
I1
sasg14
(lp9203
(dp9204
g7
I48
sg17
VC0339527
p9205
sg10
I3
sg11
VLCA
p9206
sg13
I1
sasa(dp9207
g2
VThe results demonstrated that LCA significantly inhibited the activities of CYP1A2, 2C19, 2C8, 2C9 and 3A4 and exhibited weak inhibitory effects on CYP2E1 and CYP2D6.
p9208
sg4
(lp9209
(dp9210
g7
I76
sg8
VP05177
p9211
sg10
I6
sg11
VCYP1A2
p9212
sg13
I1
sa(dp9213
g7
I148
sg8
VP05181
p9214
sg10
I6
sg11
VCYP2E1
p9215
sg13
I1
sa(dp9216
g7
I159
sg8
VP10635
p9217
sg10
I6
sg11
VCYP2D6
p9218
sg13
I1
sasg14
(lp9219
(dp9220
g7
I30
sg17
VC0339527
p9221
sg10
I3
sg11
VLCA
p9222
sg13
I1
sasa(dp9223
g2
VDixon and Lineweaver-Burk plots revealed that the inhibition types of LCA against CYP1A2, 2C9, 2C19 and 2C8 were best fit as mixed-type inhibitions, while LCA was a competitive inhibitor towards CYP3A4.
p9224
sg4
(lp9225
(dp9226
g7
I195
sg8
VP08684
p9227
sg10
I6
sg11
VCYP3A4
p9228
sg13
I1
sa(dp9229
g7
I82
sg8
VP05177
p9230
sg10
I6
sg11
VCYP1A2
p9231
sg13
I1
sasg14
(lp9232
(dp9233
g7
I70
sg17
VC0339527
p9234
sg10
I3
sg11
VLCA
p9235
sg13
I1
sa(dp9236
g7
I70
sg17
VC0339527
p9237
sg10
I3
sg11
VLCA
p9238
sg13
I1
sa(dp9239
g7
I118
sg17
VC0036572
p9240
sg10
I3
sg11
Vfit
p9241
sg13
I1
sasa(dp9242
g2
VFurthermore, the areas under the plasma concentration-time curves (AUCs) of several drugs that are primarily metabolized by CYPs were estimated to increase by 2-398% in the presence of LCA, which suggested that LCA exhibited high HDI potentials via CYP inhibition.
p9243
sg4
(lp9244
sg14
(lp9245
(dp9246
g7
I185
sg17
VC0339527
p9247
sg10
I3
sg11
VLCA
p9248
sg13
I1
sa(dp9249
g7
I185
sg17
VC0339527
p9250
sg10
I3
sg11
VLCA
p9251
sg13
I1
sasa(dp9252
g2
VTo evaluate safety and efficacy of intravenous pulse cyclophosphamide (CyP) in acute macular serpiginous choroiditis (SC).
p9253
sg4
(lp9254
sg14
(lp9255
(dp9256
g7
I118
sg17
VC0729842
p9257
sg10
I2
sg11
VSC
p9258
sg13
I1
sa(dp9259
g7
I93
sg17
VC0729842
p9260
sg10
I23
sg11
Vserpiginous choroiditis
p9261
sg13
I2
sasa(dp9262
g2
VDiabetes significantly changed the kidney expression of Rage, Sod2, Tgfb1 and Ctgf, Pdp2, nephrin, and Lias.
p9263
sg4
(lp9264
(dp9265
g7
I68
sg8
VP01137
p9266
sg10
I5
sg11
VTgfb1
p9267
sg13
I1
sa(dp9268
g7
I103
sg8
g24
sg10
I4
sg11
VLias
p9269
sg13
I1
sa(dp9270
g7
I56
sg8
g24
sg10
I4
sg11
VRage
p9271
sg13
I1
sa(dp9272
g7
I62
sg8
VP04179
p9273
sg10
I4
sg11
VSod2
p9274
sg13
I1
sa(dp9275
g7
I84
sg8
g24
sg10
I4
sg11
VPdp2
p9276
sg13
I1
sa(dp9277
g7
I78
sg8
VP29279
p9278
sg10
I4
sg11
VCtgf
p9279
sg13
I1
sa(dp9280
g7
I90
sg8
g24
sg10
I7
sg11
Vnephrin
p9281
sg13
I1
sasg14
(lp9282
(dp9283
g7
I0
sg17
VC0011849
p9284
sg10
I8
sg11
VDiabetes
p9285
sg13
I1
sasa(dp9286
g2
VThe main findings were 1) obesity resulted in a 46% decrease in PDP activity expressed per milligram extracted mitochondrial protein only in RG, while PDP isoform content was unchanged; 2) 8 wk of endurance training led to a significant 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; 3) 8 wk of endurance training led to a trending 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; and 4) PDP2 protein content was not affected by obesity or training.
p9287
sg4
(lp9288
(dp9289
g7
I64
sg8
g24
sg10
I3
sg11
VPDP
p9290
sg13
I1
sa(dp9291
g7
I347
sg8
g24
sg10
I12
sg11
VPDP1 protein
p9292
sg13
I2
sa(dp9293
g7
I347
sg8
g24
sg10
I12
sg11
VPDP1 protein
p9294
sg13
I2
sa(dp9295
g7
I602
sg8
g24
sg10
I4
sg11
VPDP2
p9296
sg13
I1
sasg14
(lp9297
(dp9298
g7
I303
sg17
VC0028754
p9299
sg10
I5
sg11
Vobese
p9300
sg13
I1
sa(dp9301
g7
I303
sg17
VC0028754
p9302
sg10
I5
sg11
Vobese
p9303
sg13
I1
sa(dp9304
g7
I26
sg17
VC0028754
p9305
sg10
I7
sg11
Vobesity
p9306
sg13
I1
sa(dp9307
g7
I26
sg17
VC0028754
p9308
sg10
I7
sg11
Vobesity
p9309
sg13
I1
sasa(dp9310
g2
VStarvation and streptozotocin-induced diabetes cause decreases in PDP2 mRNA abundance, PDP2 protein amount, and PDP activity in rat heart and kidney.
p9311
sg4
(lp9312
(dp9313
g7
I66
sg8
g24
sg10
I9
sg11
VPDP2 mRNA
p9314
sg13
I2
sa(dp9315
g7
I87
sg8
g24
sg10
I12
sg11
VPDP2 protein
p9316
sg13
I2
sa(dp9317
g7
I66
sg8
g24
sg10
I3
sg11
VPDP
p9318
sg13
I1
sasg14
(lp9319
(dp9320
g7
I38
sg17
VC0011849
p9321
sg10
I8
sg11
Vdiabetes
p9322
sg13
I1
sasa(dp9323
g2
VThis study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013).
p9324
sg4
(lp9325
(dp9326
g7
I73
sg8
VP42771
p9327
sg10
I6
sg11
VCDKN2A
p9328
sg13
I1
sa(dp9329
g7
I81
sg8
g24
sg10
I5
sg11
VSMAD4
p9330
sg13
I1
sa(dp9331
g7
I67
sg8
VP01116
p9332
sg10
I4
sg11
VKRAS
p9333
sg13
I1
sa(dp9334
g7
I92
sg8
VP01893
p9335
sg10
I10
sg11
VTP53 genes
p9336
sg13
I2
sasg14
(lp9337
(dp9338
g7
I195
sg17
VC0027651
p9339
sg10
I6
sg11
Vtumors
p9340
sg13
I1
sa(dp9341
g7
I232
sg17
VC0281361
p9342
sg10
I25
sg11
Vpancreatic adenocarcinoma
p9343
sg13
I2
sa(dp9344
g7
I314
sg17
VC0006826
p9345
sg10
I6
sg11
VCancer
p9346
sg13
I1
sa(dp9347
g7
I314
sg17
VC0006826
p9348
sg10
I6
sg11
VCancer
p9349
sg13
I1
sasa(dp9350
g2
VWe established a genetic diagnosis in six families with autosomal recessive HSP (SPG11 in three families and TFG/SPG57, SACS and ALS2 in one family each).
p9351
sg4
(lp9352
(dp9353
g7
I109
sg8
g24
sg10
I3
sg11
VTFG
p9354
sg13
I1
sa(dp9355
g7
I129
sg8
g24
sg10
I4
sg11
VALS2
p9356
sg13
I1
sa(dp9357
g7
I120
sg8
g24
sg10
I4
sg11
VSACS
p9358
sg13
I1
sa(dp9359
g7
I76
sg8
g24
sg10
I3
sg11
VHSP
p9360
sg13
I1
sasg14
(lp9361
(dp9362
g7
I129
sg17
VC1859807
p9363
sg10
I4
sg11
VALS2
p9364
sg13
I1
sa(dp9365
g7
I120
sg17
VC1849140
p9366
sg10
I4
sg11
VSACS
p9367
sg13
I1
sa(dp9368
g7
I76
sg17
VC0034152
p9369
sg10
I3
sg11
VHSP
p9370
sg13
I1
sa(dp9371
g7
I81
sg17
VC1858479
p9372
sg10
I5
sg11
VSPG11
p9373
sg13
I1
sasa(dp9374
g2
VWe are now performing molecular testing of the HSP patients using Sanger sequencing (SPG4, SPG11, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 20, 21, 31, 33, 39, 42, ABCD1, alsin, and ARSACS), and resequencing microarray (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 17, 20, 21, 31, 33, and ABCD1).
p9375
sg4
(lp9376
(dp9377
g7
I237
sg8
VP33897
p9378
sg10
I5
sg11
VABCD1
p9379
sg13
I1
sa(dp9380
g7
I244
sg8
g24
sg10
I5
sg11
Valsin
p9381
sg13
I1
sa(dp9382
g7
I98
sg8
g24
sg10
I5
sg11
VSPG31
p9383
sg13
I1
sa(dp9384
g7
I85
sg8
g24
sg10
I4
sg11
VSPG4
p9385
sg13
I1
sa(dp9386
g7
I237
sg8
VP33897
p9387
sg10
I5
sg11
VABCD1
p9388
sg13
I1
sasg14
(lp9389
(dp9390
g7
I118
sg17
VC1855900
p9391
sg10
I33
sg11
Vcomparative genomic hybridization
p9392
sg13
I3
sa(dp9393
g7
I98
sg17
VC1853247
p9394
sg10
I5
sg11
VSPG31
p9395
sg13
I1
sa(dp9396
g7
I153
sg17
VC1855900
p9397
sg10
I3
sg11
VCGH
p9398
sg13
I1
sa(dp9399
g7
I109
sg17
VC1849140
p9400
sg10
I6
sg11
VARSACS
p9401
sg13
I1
sa(dp9402
g7
I91
sg17
VC0795953
p9403
sg10
I4
sg11
VSPG1
p9404
sg13
I1
sa(dp9405
g7
I85
sg17
VC1866855
p9406
sg10
I4
sg11
VSPG4
p9407
sg13
I1
sa(dp9408
g7
I91
sg17
VC0795953
p9409
sg10
I4
sg11
VSPG1
p9410
sg13
I1
sa(dp9411
g7
I91
sg17
VC1858479
p9412
sg10
I5
sg11
VSPG11
p9413
sg13
I1
sa(dp9414
g7
I109
sg17
VC1849140
p9415
sg10
I6
sg11
VARSACS
p9416
sg13
I1
sa(dp9417
g7
I47
sg17
VC0034152
p9418
sg10
I3
sg11
VHSP
p9419
sg13
I1
sasa(dp9420
g2
VMeanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.
p9421
sg4
(lp9422
sg14
(lp9423
(dp9424
g7
I40
sg17
VC1858479
p9425
sg10
I5
sg11
VSPG11
p9426
sg13
I1
sa(dp9427
g7
I50
sg17
VC1849140
p9428
sg10
I6
sg11
VARSACS
p9429
sg13
I1
sasa(dp9430
g2
VWe are now performing molecular testing for the HSP patients using direct sequencing (SPG4, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1/2/3A/4/5/6/7/8/10/11/13/15/17/20/21/31/33/39/42/ABCD1/alsin/SACS), and resequencing microarray (SPG1/2/3A/4/5/6/7/8/10/11/13/17/20/21/31/33/ABCD1).
p9431
sg4
(lp9432
(dp9433
g7
I92
sg8
g24
sg10
I5
sg11
VSPG31
p9434
sg13
I1
sa(dp9435
g7
I212
sg8
VP33897
p9436
sg10
I5
sg11
VABCD1
p9437
sg13
I1
sa(dp9438
g7
I212
sg8
VP33897
p9439
sg10
I5
sg11
VABCD1
p9440
sg13
I1
sa(dp9441
g7
I86
sg8
g24
sg10
I4
sg11
VSPG4
p9442
sg13
I1
sa(dp9443
g7
I105
sg8
g24
sg10
I4
sg11
VSACS
p9444
sg13
I1
sa(dp9445
g7
I218
sg8
g24
sg10
I5
sg11
Valsin
p9446
sg13
I1
sasg14
(lp9447
(dp9448
g7
I92
sg17
VC1853247
p9449
sg10
I5
sg11
VSPG31
p9450
sg13
I1
sa(dp9451
g7
I103
sg17
VC1849140
p9452
sg10
I6
sg11
VARSACS
p9453
sg13
I1
sa(dp9454
g7
I112
sg17
VC1855900
p9455
sg10
I33
sg11
Vcomparative genomic hybridization
p9456
sg13
I3
sa(dp9457
g7
I147
sg17
VC1855900
p9458
sg10
I3
sg11
VCGH
p9459
sg13
I1
sa(dp9460
g7
I48
sg17
VC0034152
p9461
sg10
I3
sg11
VHSP
p9462
sg13
I1
sa(dp9463
g7
I159
sg17
VC0795953
p9464
sg10
I4
sg11
VSPG1
p9465
sg13
I1
sa(dp9466
g7
I159
sg17
VC0795953
p9467
sg10
I4
sg11
VSPG1
p9468
sg13
I1
sa(dp9469
g7
I105
sg17
VC1849140
p9470
sg10
I4
sg11
VSACS
p9471
sg13
I1
sa(dp9472
g7
I86
sg17
VC1866855
p9473
sg10
I4
sg11
VSPG4
p9474
sg13
I1
sasa(dp9475
g2
VMeanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.
p9476
sg4
(lp9477
sg14
(lp9478
(dp9479
g7
I40
sg17
VC1858479
p9480
sg10
I5
sg11
VSPG11
p9481
sg13
I1
sa(dp9482
g7
I50
sg17
VC1849140
p9483
sg10
I6
sg11
VARSACS
p9484
sg13
I1
sasa(dp9485
g2
VAutosomal recessive spastic ataxia of Charlevoix-Saguenay is an early onset form of hereditary spastic paraplegia with a peculiar clinical presentation.
p9486
sg4
(lp9487
sg14
(lp9488
(dp9489
g7
I0
sg17
VC1849140
p9490
sg10
I57
sg11
VAutosomal recessive spastic ataxia of Charlevoix-Saguenay
p9491
sg13
I6
sa(dp9492
g7
I84
sg17
VC0037773
p9493
sg10
I29
sg11
Vhereditary spastic paraplegia
p9494
sg13
I3
sasa(dp9495
g2
VOn the basis of our data, we therefore suggest that social avoidance (expressed as social phobia or avoidant personality disorder) has been underestimated in previous studies of carriers with the FMR-1 full mutation or premutation.
p9496
sg4
(lp9497
(dp9498
g7
I196
sg8
g24
sg10
I5
sg11
VFMR-1
p9499
sg13
I1
sasg14
(lp9500
(dp9501
g7
I83
sg17
VC0031572
p9502
sg10
I13
sg11
Vsocial phobia
p9503
sg13
I2
sa(dp9504
g7
I100
sg17
VC0004444
p9505
sg10
I29
sg11
Vavoidant personality disorder
p9506
sg13
I3
sasa(dp9507
g2
VAnalysis of GenBank-derived clones on the Y chromosome revealed the presence of two full-length copies in azoospermia factor region b (AZFb) (PRY1 and PRY2) and two shorter versions of the PRY gene containing exons 3, 4 and 5 in AZFc (PRY3 and PRY4).
p9508
sg4
(lp9509
(dp9510
g7
I151
sg8
g24
sg10
I4
sg11
VPRY2
p9511
sg13
I1
sa(dp9512
g7
I106
sg8
g24
sg10
I27
sg11
Vazoospermia factor region b
p9513
sg13
I4
sa(dp9514
g7
I135
sg8
g24
sg10
I4
sg11
VAZFb
p9515
sg13
I1
sa(dp9516
g7
I189
sg8
g24
sg10
I8
sg11
VPRY gene
p9517
sg13
I2
sa(dp9518
g7
I142
sg8
g24
sg10
I4
sg11
VPRY1
p9519
sg13
I1
sasg14
(lp9520
(dp9521
g7
I106
sg17
VC1384583
p9522
sg10
I18
sg11
Vazoospermia factor
p9523
sg13
I2
sasa(dp9524
g2
VPRY1 and PRY2, two gene copies that are located in AZFb, a region often deleted in patients with severe male infertility, were shown to be expressed in the testis.
p9525
sg4
(lp9526
(dp9527
g7
I9
sg8
g24
sg10
I4
sg11
VPRY2
p9528
sg13
I1
sa(dp9529
g7
I0
sg8
g24
sg10
I4
sg11
VPRY1
p9530
sg13
I1
sasg14
(lp9531
(dp9532
g7
I104
sg17
VC0021364
p9533
sg10
I16
sg11
Vmale infertility
p9534
sg13
I2
sasa(dp9535
g2
VExpression of KIR3DL2 on NK and T cells was quantified in peripheral blood (PB) from 35 patients with SpA and 5 patients with juvenile enthesitis-related arthritis (juvenile ERA); samples were compared with samples from healthy and rheumatoid arthritis (RA) controls.
p9536
sg4
(lp9537
(dp9538
g7
I14
sg8
VP43630
p9539
sg10
I7
sg11
VKIR3DL2
p9540
sg13
I1
sasg14
(lp9541
(dp9542
g7
I175
sg17
VC0003873
p9543
sg10
I2
sg11
VRA
p9544
sg13
I1
sa(dp9545
g7
I135
sg17
VC1282952
p9546
sg10
I10
sg11
Venthesitis
p9547
sg13
I1
sa(dp9548
g7
I232
sg17
VC0003873
p9549
sg10
I20
sg11
Vrheumatoid arthritis
p9550
sg13
I2
sa(dp9551
g7
I154
sg17
VC0003864
p9552
sg10
I9
sg11
Varthritis
p9553
sg13
I1
sasa(dp9554
g2
VNKB1 inhibits cytoxic activity of T lymphocytes mediated by superantigens, which is one of the contributing factors in the pathogenesis of rheumatoid arthritis (RA).
p9555
sg4
(lp9556
(dp9557
g7
I0
sg8
VP43629
p9558
sg10
I4
sg11
VNKB1
p9559
sg13
I1
sasg14
(lp9560
(dp9561
g7
I139
sg17
VC0003873
p9562
sg10
I20
sg11
Vrheumatoid arthritis
p9563
sg13
I2
sa(dp9564
g7
I123
sg17
VC0699748
p9565
sg10
I12
sg11
Vpathogenesis
p9566
sg13
I1
sa(dp9567
g7
I161
sg17
VC0003873
p9568
sg10
I2
sg11
VRA
p9569
sg13
I1
sasa(dp9570
g2
VKiller Ig-like receptors (KIRs) are expressed on CD4(+)CD28(null) T cells, a highly oligoclonal subset of T cells that is expanded in patients with rheumatoid arthritis.
p9571
sg4
(lp9572
(dp9573
g7
I0
sg8
g24
sg10
I24
sg11
VKiller Ig-like receptors
p9574
sg13
I3
sa(dp9575
g7
I26
sg8
VP55040
p9576
sg10
I4
sg11
VKIRs
p9577
sg13
I1
sa(dp9578
g7
I55
sg8
VP33681
p9579
sg10
I4
sg11
VCD28
p9580
sg13
I1
sa(dp9581
g7
I49
sg8
VP01730
p9582
sg10
I3
sg11
VCD4
p9583
sg13
I1
sasg14
(lp9584
(dp9585
g7
I148
sg17
VC0003873
p9586
sg10
I20
sg11
Vrheumatoid arthritis
p9587
sg13
I2
sasa(dp9588
g2
VFunctional involvement of NKAIN2 in miR-181d-regulated pancreatic cancer development was tested by small interfering RNA-mediated NKAIN2 knockdown in miR-181d-downregulated PANC-1 and AsPC-1 cells.
p9589
sg4
(lp9590
(dp9591
g7
I26
sg8
g24
sg10
I6
sg11
VNKAIN2
p9592
sg13
I1
sa(dp9593
g7
I36
sg8
g24
sg10
I8
sg11
VmiR-181d
p9594
sg13
I1
sa(dp9595
g7
I36
sg8
g24
sg10
I8
sg11
VmiR-181d
p9596
sg13
I1
sasg14
(lp9597
(dp9598
g7
I55
sg17
VC0235974
p9599
sg10
I17
sg11
Vpancreatic cancer
p9600
sg13
I2
sasa(dp9601
g2
VNKAIN2 was directly targeted by miR-181d in pancreatic cancer.
p9602
sg4
(lp9603
(dp9604
g7
I32
sg8
g24
sg10
I8
sg11
VmiR-181d
p9605
sg13
I1
sa(dp9606
g7
I0
sg8
g24
sg10
I6
sg11
VNKAIN2
p9607
sg13
I1
sasg14
(lp9608
(dp9609
g7
I44
sg17
VC0235974
p9610
sg10
I17
sg11
Vpancreatic cancer
p9611
sg13
I2
sasa(dp9612
g2
VSmall interfering RNA-mediated NKAIN2 knockdown reversed the inhibition of miR-181d downregulation on pancreatic cancer development.
p9613
sg4
(lp9614
(dp9615
g7
I75
sg8
g24
sg10
I8
sg11
VmiR-181d
p9616
sg13
I1
sa(dp9617
g7
I31
sg8
g24
sg10
I6
sg11
VNKAIN2
p9618
sg13
I1
sasg14
(lp9619
(dp9620
g7
I102
sg17
VC0235974
p9621
sg10
I17
sg11
Vpancreatic cancer
p9622
sg13
I2
sasa(dp9623
g2
VInhibiting miR-181d may suppress pancreatic cancer development, possibly through the inverse regulation on NKAIN2.
p9624
sg4
(lp9625
(dp9626
g7
I107
sg8
g24
sg10
I6
sg11
VNKAIN2
p9627
sg13
I1
sa(dp9628
g7
I11
sg8
g24
sg10
I8
sg11
VmiR-181d
p9629
sg13
I1
sasg14
(lp9630
(dp9631
g7
I33
sg17
VC0235974
p9632
sg10
I17
sg11
Vpancreatic cancer
p9633
sg13
I2
sasa(dp9634
g2
VRecurrent chromosome breakpoints at 6q22.31, leading to truncation and potential loss-of-function of the NKAIN2 gene, in Chinese prostate cancer patients were previously identified.
p9635
sg4
(lp9636
(dp9637
g7
I105
sg8
g24
sg10
I11
sg11
VNKAIN2 gene
p9638
sg13
I2
sasg14
(lp9639
(dp9640
g7
I129
sg17
VC0600139
p9641
sg10
I15
sg11
Vprostate cancer
p9642
sg13
I2
sa(dp9643
g7
I56
sg17
VC1706395
p9644
sg10
I10
sg11
Vtruncation
p9645
sg13
I1
sasa(dp9646
g2
VIn this study we investigated genomic, methylation and expression changes of NKAIN2 in a large number of prostate cancer samples and determined its functional role in prostate cancer cells.
p9647
sg4
(lp9648
(dp9649
g7
I77
sg8
g24
sg10
I6
sg11
VNKAIN2
p9650
sg13
I1
sasg14
(lp9651
(dp9652
g7
I105
sg17
VC0600139
p9653
sg10
I15
sg11
Vprostate cancer
p9654
sg13
I2
sa(dp9655
g7
I105
sg17
VC0600139
p9656
sg10
I15
sg11
Vprostate cancer
p9657
sg13
I2
sasa(dp9658
g2
VFluorescence in situ hybridization analysis confirmed that NKAIN2 truncation is specific to Chinese while deletion of the gene is frequent in both Chinese and UK prostate cancers.
p9659
sg4
(lp9660
(dp9661
g7
I59
sg8
g24
sg10
I6
sg11
VNKAIN2
p9662
sg13
I1
sasg14
(lp9663
(dp9664
g7
I162
sg17
VC0376358
p9665
sg10
I16
sg11
Vprostate cancers
p9666
sg13
I2
sa(dp9667
g7
I66
sg17
VC1706395
p9668
sg10
I10
sg11
Vtruncation
p9669
sg13
I1
sasa(dp9670
g2
VSomatic mutations of NKAIN2 in prostate cancer samples exist but at very low frequency, suggesting that it is a putative tumor suppressor gene (TSG) with haploid insufficiency.
p9671
sg4
(lp9672
(dp9673
g7
I21
sg8
g24
sg10
I6
sg11
VNKAIN2
p9674
sg13
I1
sasg14
(lp9675
(dp9676
g7
I31
sg17
VC0600139
p9677
sg10
I15
sg11
Vprostate cancer
p9678
sg13
I2
sa(dp9679
g7
I0
sg17
VC0544886
p9680
sg10
I17
sg11
VSomatic mutations
p9681
sg13
I2
sa(dp9682
g7
I121
sg17
VC0027651
p9683
sg10
I5
sg11
Vtumor
p9684
sg13
I1
sasa(dp9685
g2
VOur functional studies showed that overexpression of NKAIN2 in prostate cancer cells inhibits cellular growth by promoting cell apoptosis, and decreasing cell migration and invasion.
p9686
sg4
(lp9687
(dp9688
g7
I53
sg8
g24
sg10
I6
sg11
VNKAIN2
p9689
sg13
I1
sasg14
(lp9690
(dp9691
g7
I63
sg17
VC0600139
p9692
sg10
I15
sg11
Vprostate cancer
p9693
sg13
I2
sa(dp9694
g7
I173
sg17
VC2699153
p9695
sg10
I8
sg11
Vinvasion
p9696
sg13
I1
sasa(dp9697
g2
VConversely, knockdown of NKAIN2 promotes prostate cancer cell growth by inhibiting cell apoptosis, and increasing cell migration and invasion.
p9698
sg4
(lp9699
(dp9700
g7
I25
sg8
g24
sg10
I6
sg11
VNKAIN2
p9701
sg13
I1
sasg14
(lp9702
(dp9703
g7
I133
sg17
VC2699153
p9704
sg10
I8
sg11
Vinvasion
p9705
sg13
I1
sa(dp9706
g7
I50
sg17
VC1516170
p9707
sg10
I18
sg11
Vcancer cell growth
p9708
sg13
I3
sasa(dp9709
g2
VThese data imply that NKAIN2 is a novel TSG whose activity is commonly reduced in prostate cancer.
p9710
sg4
(lp9711
(dp9712
g7
I40
sg8
g24
sg10
I3
sg11
VTSG
p9713
sg13
I1
sa(dp9714
g7
I22
sg8
g24
sg10
I6
sg11
VNKAIN2
p9715
sg13
I1
sasg14
(lp9716
(dp9717
g7
I82
sg17
VC0600139
p9718
sg10
I15
sg11
Vprostate cancer
p9719
sg13
I2
sasa(dp9720
g2
VOur recent work detected recurrent chromosomal truncation at the Na(+)/K(+) transporting ATPase interacting 2 (NKAIN2) gene in prostate cancer, which was also found to be truncated in leukemia and lymphoma, suggesting that NKAIN2 is potentially one of the TSGs located in the 6q commonly deleted region in human cancers.
p9721
sg4
(lp9722
(dp9723
g7
I65
sg8
g24
sg10
I44
sg11
VNa(+)/K(+) transporting ATPase interacting 2
p9724
sg13
I5
sa(dp9725
g7
I111
sg8
g24
sg10
I6
sg11
VNKAIN2
p9726
sg13
I1
sa(dp9727
g7
I108
sg8
g24
sg10
I15
sg11
V2 (NKAIN2) gene
p9728
sg13
I3
sasg14
(lp9729
(dp9730
g7
I184
sg17
VC0023418
p9731
sg10
I8
sg11
Vleukemia
p9732
sg13
I1
sa(dp9733
g7
I197
sg17
VC0024299
p9734
sg10
I8
sg11
Vlymphoma
p9735
sg13
I1
sa(dp9736
g7
I47
sg17
VC1706395
p9737
sg10
I10
sg11
Vtruncation
p9738
sg13
I1
sa(dp9739
g7
I312
sg17
VC0006826
p9740
sg10
I7
sg11
Vcancers
p9741
sg13
I1
sa(dp9742
g7
I127
sg17
VC0600139
p9743
sg10
I15
sg11
Vprostate cancer
p9744
sg13
I2
sasa(dp9745
g2
VFluorescent in situ hybridisation with BAC/PAC clones and long range polymerase chain reaction products assessed in the human genome sequence localised the chromosome 1 breakpoint to a 9.8 kb segment within a hypothetical gene, LOC388735, and the chromosome 6 breakpoint to a 12.8 kb segment in intron 4 of the T-cell lymphoma breakpoint-associated target 1 (TCBA1) gene.
p9746
sg4
(lp9747
(dp9748
g7
I359
sg8
g24
sg10
I5
sg11
VTCBA1
p9749
sg13
I1
sa(dp9750
g7
I311
sg8
g24
sg10
I46
sg11
VT-cell lymphoma breakpoint-associated target 1
p9751
sg13
I5
sasg14
(lp9752
(dp9753
g7
I311
sg17
VC0079772
p9754
sg10
I15
sg11
VT-cell lymphoma
p9755
sg13
I2
sa(dp9756
g7
I43
sg17
VC0033036
p9757
sg10
I3
sg11
VPAC
p9758
sg13
I1
sasa(dp9759
g2
VDisruption and/or formation of TCBA1 fusion genes in T cell lymphoma and leukaemia cell lines suggests a role for this gene in tumorigenesis.
p9760
sg4
(lp9761
(dp9762
g7
I31
sg8
g24
sg10
I18
sg11
VTCBA1 fusion genes
p9763
sg13
I3
sasg14
(lp9764
(dp9765
g7
I73
sg17
VC0023418
p9766
sg10
I9
sg11
Vleukaemia
p9767
sg13
I1
sa(dp9768
g7
I127
sg17
VC0007621
p9769
sg10
I13
sg11
Vtumorigenesis
p9770
sg13
I1
sa(dp9771
g7
I53
sg17
VC0079772
p9772
sg10
I15
sg11
VT cell lymphoma
p9773
sg13
I3
sasa(dp9774
g2
VWe identified two T-cell lymphoma/leukemia cell lines with different differentiation stages that had breakpoints within the same novel gene, TCBA1 (T-cell lymphoma breakpoint associated target 1).
p9775
sg4
(lp9776
(dp9777
g7
I18
sg8
g24
sg10
I15
sg11
VT-cell lymphoma
p9778
sg13
I2
sa(dp9779
g7
I148
sg8
g24
sg10
I46
sg11
VT-cell lymphoma breakpoint associated target 1
p9780
sg13
I6
sa(dp9781
g7
I141
sg8
g24
sg10
I5
sg11
VTCBA1
p9782
sg13
I1
sasg14
(lp9783
(dp9784
g7
I18
sg17
VC0079772
p9785
sg10
I15
sg11
VT-cell lymphoma
p9786
sg13
I2
sa(dp9787
g7
I18
sg17
VC0079772
p9788
sg10
I15
sg11
VT-cell lymphoma
p9789
sg13
I2
sa(dp9790
g7
I34
sg17
VC0023418
p9791
sg10
I8
sg11
Vleukemia
p9792
sg13
I1
sasa(dp9793
g2
VIn a T-cell lymphoblastic lymphoma cell line, HT-1, the TCBA1 fused to SUSP1 (SUMO-1-specific protease), creating a SUSP1-TCBA1 chimeric gene.
p9794
sg4
(lp9795
(dp9796
g7
I56
sg8
g24
sg10
I5
sg11
VTCBA1
p9797
sg13
I1
sa(dp9798
g7
I56
sg8
g24
sg10
I5
sg11
VTCBA1
p9799
sg13
I1
sa(dp9800
g7
I71
sg8
g24
sg10
I5
sg11
VSUSP1
p9801
sg13
I1
sa(dp9802
g7
I71
sg8
g24
sg10
I5
sg11
VSUSP1
p9803
sg13
I1
sasg14
(lp9804
(dp9805
g7
I12
sg17
VC0079748
p9806
sg10
I22
sg11
Vlymphoblastic lymphoma
p9807
sg13
I2
sasa(dp9808
g2
VHowever, in an adult T-cell leukemia cell line, ATN-1, no chimeric gene was detected, although aberrant TCBA1 transcripts were produced.
p9809
sg4
(lp9810
(dp9811
g7
I104
sg8
g24
sg10
I17
sg11
VTCBA1 transcripts
p9812
sg13
I2
sasg14
(lp9813
(dp9814
g7
I15
sg17
VC0023492
p9815
sg10
I21
sg11
Vadult T-cell leukemia
p9816
sg13
I3
sa(dp9817
g7
I48
sg17
VC0268494
p9818
sg10
I3
sg11
VATN
p9819
sg13
I1
sasa(dp9820
g2
VThe expression levels of TUG1 were determined using Real-Time qPCR in a total of 44 patients with bladder urothelial carcinomas.
p9821
sg4
(lp9822
sg14
(lp9823
(dp9824
g7
I117
sg17
VC0007097
p9825
sg10
I10
sg11
Vcarcinomas
p9826
sg13
I1
sasa(dp9827
g2
VBladder urothelial carcinoma T24 and 5637 cells were transfected with TUG1 siRNA or negative control siRNA.
p9828
sg4
(lp9829
sg14
(lp9830
(dp9831
g7
I0
sg17
VC0279680
p9832
sg10
I28
sg11
VBladder urothelial carcinoma
p9833
sg13
I3
sasa(dp9834
g2
VTUG1 was up-regulated in bladder urothelial carcinoma compared to paired normal urothelium.
p9835
sg4
(lp9836
sg14
(lp9837
(dp9838
g7
I25
sg17
VC0279680
p9839
sg10
I28
sg11
Vbladder urothelial carcinoma
p9840
sg13
I3
sasa(dp9841
g2
VCell proliferation inhibition and apoptosis induction were observed in TUG1 siRNA-transfected bladder urothelial carcinoma T24 and 5637 cells.
p9842
sg4
(lp9843
sg14
(lp9844
(dp9845
g7
I5
sg17
VC0334094
p9846
sg10
I13
sg11
Vproliferation
p9847
sg13
I1
sa(dp9848
g7
I94
sg17
VC0279680
p9849
sg10
I28
sg11
Vbladder urothelial carcinoma
p9850
sg13
I3
sasa(dp9851
g2
VOur data suggest that lincRNA TUG1 is emerging as a novel player in the disease state of bladder urothelial carcinoma.
p9852
sg4
(lp9853
sg14
(lp9854
(dp9855
g7
I89
sg17
VC0279680
p9856
sg10
I28
sg11
Vbladder urothelial carcinoma
p9857
sg13
I3
sasa(dp9858
g2
VTUG1 may have potential roles as a biomarker and/or a therapeutic target in bladder urothelial carcinoma.
p9859
sg4
(lp9860
sg14
(lp9861
(dp9862
g7
I76
sg17
VC0279680
p9863
sg10
I28
sg11
Vbladder urothelial carcinoma
p9864
sg13
I3
sasa(dp9865
g2
VSerial samples of serum Cystatin C and urine NGAL were collected from 139 consecutive patients with congenital heart defects aged 3 days to 30 years after admission to the intensive care unit, 2 and 6 hours after the end of cardiopulmonary bypass.
p9866
sg4
(lp9867
(dp9868
g7
I39
sg8
VP80188
p9869
sg10
I10
sg11
Vurine NGAL
p9870
sg13
I2
sa(dp9871
g7
I24
sg8
VP01034
p9872
sg10
I10
sg11
VCystatin C
p9873
sg13
I2
sasg14
(lp9874
(dp9875
g7
I100
sg17
VC0018798
p9876
sg10
I24
sg11
Vcongenital heart defects
p9877
sg13
I3
sasa(dp9878
g2
VHyper-IgE syndrome (HIES) is a very rare primary immune deficiency characterized by elevated serum IgE levels, recurrent bacterial infections, chronic dermatitis, and connective tissue abnormalities.
p9879
sg4
(lp9880
(dp9881
g7
I0
sg8
VP01854
p9882
sg10
I9
sg11
VHyper-IgE
p9883
sg13
I1
sa(dp9884
g7
I93
sg8
VP01854
p9885
sg10
I9
sg11
Vserum IgE
p9886
sg13
I2
sasg14
(lp9887
(dp9888
g7
I6
sg17
VC0270850
p9889
sg10
I3
sg11
VIgE
p9890
sg13
I1
sa(dp9891
g7
I0
sg17
VC0022398
p9892
sg10
I18
sg11
VHyper-IgE syndrome
p9893
sg13
I2
sa(dp9894
g7
I20
sg17
VC0022398
p9895
sg10
I4
sg11
VHIES
p9896
sg13
I1
sa(dp9897
g7
I143
sg17
VC0262975
p9898
sg10
I18
sg11
Vchronic dermatitis
p9899
sg13
I2
sa(dp9900
g7
I49
sg17
VC0850497
p9901
sg10
I17
sg11
Vimmune deficiency
p9902
sg13
I2
sa(dp9903
g7
I111
sg17
VC1844383
p9904
sg10
I30
sg11
Vrecurrent bacterial infections
p9905
sg13
I3
sasa(dp9906
g2
VWe describe the clinical course of a 2-month-old infant who was evaluated for autosomal dominant Hyper IgE Syndrome based on eczema, periorbital cellulitis, skin abscesses, increased total IgE levels and blood eosinophilia.
p9907
sg4
(lp9908
(dp9909
g7
I103
sg8
VP01854
p9910
sg10
I3
sg11
VIgE
p9911
sg13
I1
sa(dp9912
g7
I88
sg8
VP01854
p9913
sg10
I18
sg11
Vdominant Hyper IgE
p9914
sg13
I3
sasg14
(lp9915
(dp9916
g7
I97
sg17
VC0022398
p9917
sg10
I18
sg11
VHyper IgE Syndrome
p9918
sg13
I3
sa(dp9919
g7
I125
sg17
VC0013595
p9920
sg10
I6
sg11
Veczema
p9921
sg13
I1
sa(dp9922
g7
I210
sg17
VC0014457
p9923
sg10
I12
sg11
Veosinophilia
p9924
sg13
I1
sa(dp9925
g7
I157
sg17
VC0149777
p9926
sg10
I14
sg11
Vskin abscesses
p9927
sg13
I2
sa(dp9928
g7
I103
sg17
VC0270850
p9929
sg10
I3
sg11
VIgE
p9930
sg13
I1
sa(dp9931
g7
I133
sg17
VC0149754
p9932
sg10
I22
sg11
Vperiorbital cellulitis
p9933
sg13
I2
sasa(dp9934
g2
VIL-22 induces STAT3 phosphorylation and mediates psoriasis-related gene expression.
p9935
sg4
(lp9936
(dp9937
g7
I14
sg8
VP40763
p9938
sg10
I5
sg11
VSTAT3
p9939
sg13
I1
sa(dp9940
g7
I0
sg8
g24
sg10
I5
sg11
VIL-22
p9941
sg13
I1
sasg14
(lp9942
(dp9943
g7
I49
sg17
VC0033860
p9944
sg10
I9
sg11
Vpsoriasis
p9945
sg13
I1
sasa(dp9946
g2
VThe IL-22-STAT3-Bcl-3 pathway may be important in the pathogenesis of psoriasis.
p9947
sg4
(lp9948
(dp9949
g7
I4
sg8
g24
sg10
I17
sg11
VIL-22-STAT3-Bcl-3
p9950
sg13
I1
sasg14
(lp9951
(dp9952
g7
I54
sg17
VC0699748
p9953
sg10
I12
sg11
Vpathogenesis
p9954
sg13
I1
sa(dp9955
g7
I70
sg17
VC0033860
p9956
sg10
I9
sg11
Vpsoriasis
p9957
sg13
I1
sasa(dp9958
g2
VBy using quantitative real-time polymerase chain reaction, we identified significant upregulation of PMEPA1 gene expression in malignant tissues of patients with gastric adenocarcinoma.
p9959
sg4
(lp9960
(dp9961
g7
I101
sg8
g24
sg10
I11
sg11
VPMEPA1 gene
p9962
sg13
I2
sasg14
(lp9963
(dp9964
g7
I162
sg17
VC0278701
p9965
sg10
I22
sg11
Vgastric adenocarcinoma
p9966
sg13
I2
sasa(dp9967
g2
VBy using developed antibodies, we observed pronounced expression of TMEPAI in normal gastric epithelial cells while tumor cells from gastric adenomas, and adenocarcinoma samples were mostly negative for target protein expression.
p9968
sg4
(lp9969
sg14
(lp9970
(dp9971
g7
I141
sg17
VC0001430
p9972
sg10
I8
sg11
Vadenomas
p9973
sg13
I1
sa(dp9974
g7
I116
sg17
VC0027651
p9975
sg10
I5
sg11
Vtumor
p9976
sg13
I1
sa(dp9977
g7
I155
sg17
VC0001418
p9978
sg10
I14
sg11
Vadenocarcinoma
p9979
sg13
I1
sasa(dp9980
g2
VAnalysis of expressed sequence tag databases showed that STAG1/PMEPA1 also was expressed in pancreatic, endometrial, and prostatic adenocarcinomas.
p9981
sg4
(lp9982
(dp9983
g7
I57
sg8
g24
sg10
I5
sg11
VSTAG1
p9984
sg13
I1
sa(dp9985
g7
I63
sg8
g24
sg10
I6
sg11
VPMEPA1
p9986
sg13
I1
sasg14
(lp9987
(dp9988
g7
I31
sg17
VC0037293
p9989
sg10
I3
sg11
Vtag
p9990
sg13
I1
sa(dp9991
g7
I131
sg17
VC0001418
p9992
sg10
I15
sg11
Vadenocarcinomas
p9993
sg13
I1
sasa(dp9994
g2
VIt is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.
p9995
sg4
(lp9996
(dp9997
g7
I115
sg8
g24
sg10
I5
sg11
VTRPV1
p9998
sg13
I1
sasg14
(lp9999
(dp10000
g7
I85
sg17
VC0242606
p10001
sg10
I16
sg11
Voxidative stress
p10002
sg13
I2
sa(dp10003
g7
I61
sg17
VC0155877
p10004
sg10
I15
sg11
Vallergic asthma
p10005
sg13
I2
sasa(dp10006
g2
VOur data suggests the involvement of TRPV1 in allergic asthma and thus we feel this target merits further investigation.
p10007
sg4
(lp10008
(dp10009
g7
I37
sg8
g24
sg10
I5
sg11
VTRPV1
p10010
sg13
I1
sasg14
(lp10011
(dp10012
g7
I46
sg17
VC0155877
p10013
sg10
I15
sg11
Vallergic asthma
p10014
sg13
I2
sasa(dp10015
g2
VTNFAlfa, a proinflammatory cytokine known to be involved in the pathogenesis of allergic asthma, has been shown to induce hyperalgesia in somatic tissue via a sensitizing effect on dorsal root ganglion neurons expressing transient receptor potential vanilloid type 1 receptor (TRPV1).
p10016
sg4
(lp10017
(dp10018
g7
I277
sg8
g24
sg10
I5
sg11
VTRPV1
p10019
sg13
I1
sa(dp10020
g7
I221
sg8
g24
sg10
I54
sg11
Vtransient receptor potential vanilloid type 1 receptor
p10021
sg13
I7
sasg14
(lp10022
(dp10023
g7
I193
sg17
VC1258666
p10024
sg10
I8
sg11
Vganglion
p10025
sg13
I1
sa(dp10026
g7
I64
sg17
VC0699748
p10027
sg10
I12
sg11
Vpathogenesis
p10028
sg13
I1
sa(dp10029
g7
I122
sg17
VC0020429
p10030
sg10
I12
sg11
Vhyperalgesia
p10031
sg13
I1
sa(dp10032
g7
I80
sg17
VC0155877
p10033
sg10
I15
sg11
Vallergic asthma
p10034
sg13
I2
sasa(dp10035
g2
VSequencing of genes known to be causative for WS [microphthalmia transcription factor (MITF), Pax3, Sox10, SNAI2 ] failed to show any candidate mutations to explain this complex cutaneous depigmentation phenotype.
p10036
sg4
(lp10037
(dp10038
g7
I87
sg8
g24
sg10
I4
sg11
VMITF
p10039
sg13
I1
sa(dp10040
g7
I100
sg8
VP56693
p10041
sg10
I5
sg11
VSox10
p10042
sg13
I1
sa(dp10043
g7
I49
sg8
g24
sg10
I36
sg11
V[microphthalmia transcription factor
p10044
sg13
I3
sa(dp10045
g7
I107
sg8
g24
sg10
I5
sg11
VSNAI2
p10046
sg13
I1
sa(dp10047
g7
I94
sg8
VP23760
p10048
sg10
I4
sg11
VPax3
p10049
sg13
I1
sasg14
(lp10050
(dp10051
g7
I50
sg17
VC0026010
p10052
sg10
I14
sg11
Vmicrophthalmia
p10053
sg13
I1
sa(dp10054
g7
I188
sg17
VC0162835
p10055
sg10
I14
sg11
Vdepigmentation
p10056
sg13
I1
sasa(dp10057
g2
VThe mice include splotch (Sp), microphthalmia (mi), Slugh-/-, WS4, JF1, lethal-spotting (ls), and Dominant megacolon (Dom).
p10058
sg4
(lp10059
(dp10060
g7
I62
sg8
VP56693
p10061
sg10
I3
sg11
VWS4
p10062
sg13
I1
sasg14
(lp10063
(dp10064
g7
I4
sg17
VC0026010
p10065
sg10
I2
sg11
Vmi
p10066
sg13
I1
sa(dp10067
g7
I62
sg17
VC1848519
p10068
sg10
I3
sg11
VWS4
p10069
sg13
I1
sa(dp10070
g7
I79
sg17
VC0025874
p10071
sg10
I8
sg11
Vspotting
p10072
sg13
I1
sa(dp10073
g7
I107
sg17
VC0235904
p10074
sg10
I9
sg11
Vmegacolon
p10075
sg13
I1
sa(dp10076
g7
I31
sg17
VC0026010
p10077
sg10
I14
sg11
Vmicrophthalmia
p10078
sg13
I1
sasa(dp10079
g2
VThe effect of ELL3 depletion on cell morphology, latent Epstein Barr Virus (EBV) lytic replication and differentiation markers in a Burkitt's lymphoma (BL) cell line cells are presented.
p10080
sg4
(lp10081
(dp10082
g7
I14
sg8
g24
sg10
I4
sg11
VELL3
p10083
sg13
I1
sasg14
(lp10084
(dp10085
g7
I132
sg17
VC0006413
p10086
sg10
I18
sg11
VBurkitt's lymphoma
p10087
sg13
I2
sa(dp10088
g7
I152
sg17
VC0006413
p10089
sg10
I2
sg11
VBL
p10090
sg13
I1
sa(dp10091
g7
I81
sg17
VC0024348
p10092
sg10
I5
sg11
Vlytic
p10093
sg13
I1
sasa(dp10094
g2
VBurkitt's lymphoma and a sub-set of Diffuse Large B cell lymphoma cell lines abundantly express ELL3.
p10095
sg4
(lp10096
(dp10097
g7
I96
sg8
g24
sg10
I4
sg11
VELL3
p10098
sg13
I1
sasg14
(lp10099
(dp10100
g7
I0
sg17
VC0006413
p10101
sg10
I18
sg11
VBurkitt's lymphoma
p10102
sg13
I2
sa(dp10103
g7
I36
sg17
VC0079744
p10104
sg10
I29
sg11
VDiffuse Large B cell lymphoma
p10105
sg13
I5
sasa(dp10106
g2
VThis article provides a comprehensive review of the syndromes and disorders associated with NTDs, including Pallister-Hall syndrome, Walker-Warburg syndrome and Fukuyama congenital muscular dystrophy, MURCS association, Roberts syndrome, cerebro-costo-mandibular syndrome, laterality sequences, hydrolethalus syndrome, Knobloch syndrome, oculoauriculovertebral spectrum (hemifacial microsomia), cervico-oculo-acoustic syndrome, Fanconi anemia, Miller-Dieker lissencephaly syndrome, Fraser syndrome, frontonasal dysplasia, Adams-Oliver syndrome, CHILD syndrome, dyssegmental dysplasia, and monozygotic twinning.
p10107
sg4
(lp10108
sg14
(lp10109
(dp10110
g7
I328
sg17
VC0220681
p10111
sg10
I32
sg11
Vsyndrome, oculoauriculovertebral
p10112
sg13
I2
sa(dp10113
g7
I52
sg17
VC0039082
p10114
sg10
I9
sg11
Vsyndromes
p10115
sg13
I1
sa(dp10116
g7
I238
sg17
VC0265342
p10117
sg10
I33
sg11
Vcerebro-costo-mandibular syndrome
p10118
sg13
I2
sa(dp10119
g7
I511
sg17
VC0334044
p10120
sg10
I9
sg11
Vdysplasia
p10121
sg13
I1
sa(dp10122
g7
I499
sg17
VC1876203
p10123
sg10
I21
sg11
Vfrontonasal dysplasia
p10124
sg13
I2
sa(dp10125
g7
I201
sg17
VC1832817
p10126
sg10
I17
sg11
VMURCS association
p10127
sg13
I2
sa(dp10128
g7
I52
sg17
VC0039082
p10129
sg10
I8
sg11
Vsyndrome
p10130
sg13
I1
sa(dp10131
g7
I522
sg17
VC0265268
p10132
sg10
I21
sg11
VAdams-Oliver syndrome
p10133
sg13
I2
sa(dp10134
g7
I395
sg17
VC0265239
p10135
sg10
I31
sg11
Vcervico-oculo-acoustic syndrome
p10136
sg13
I2
sa(dp10137
g7
I108
sg17
VC0265220
p10138
sg10
I23
sg11
VPallister-Hall syndrome
p10139
sg13
I2
sa(dp10140
g7
I371
sg17
VC1306710
p10141
sg10
I21
sg11
Vhemifacial microsomia
p10142
sg13
I2
sa(dp10143
g7
I295
sg17
VC2931104
p10144
sg10
I22
sg11
Vhydrolethalus syndrome
p10145
sg13
I2
sa(dp10146
g7
I123
sg17
VC0265221
p10147
sg10
I24
sg11
Vsyndrome, Walker-Warburg
p10148
sg13
I2
sa(dp10149
g7
I161
sg17
VC0410174
p10150
sg10
I38
sg11
VFukuyama congenital muscular dystrophy
p10151
sg13
I4
sa(dp10152
g7
I482
sg17
VC0265233
p10153
sg10
I15
sg11
VFraser syndrome
p10154
sg13
I2
sa(dp10155
g7
I220
sg17
VC0392475
p10156
sg10
I16
sg11
VRoberts syndrome
p10157
sg13
I2
sa(dp10158
g7
I545
sg17
VC0265267
p10159
sg10
I14
sg11
VCHILD syndrome
p10160
sg13
I2
sa(dp10161
g7
I472
sg17
VC0265233
p10162
sg10
I16
sg11
Vsyndrome, Fraser
p10163
sg13
I2
sa(dp10164
g7
I428
sg17
VC3469521
p10165
sg10
I14
sg11
VFanconi anemia
p10166
sg13
I2
sa(dp10167
g7
I444
sg17
VC0265219
p10168
sg10
I36
sg11
VMiller-Dieker lissencephaly syndrome
p10169
sg13
I3
sasa(dp10170
g2
VMoreover, the Etv5 mutation resulted in several developmental abnormalities including an increased incidence of embryonic and perinatal lethality, postnatal growth restriction, polydactyly and renal asymmetry.
p10171
sg4
(lp10172
(dp10173
g7
I14
sg8
VP41161
p10174
sg10
I13
sg11
VEtv5 mutation
p10175
sg13
I2
sasg14
(lp10176
(dp10177
g7
I177
sg17
VC0152427
p10178
sg10
I11
sg11
Vpolydactyly
p10179
sg13
I1
sasa(dp10180
g2
VHere, we show that conditional knockout of the FGF-activated transcription factor genes Etv4 and Etv5 in mouse led to ectopic Shh expression in the anterior limb bud and a preaxial polydactyly (PPD) skeletal phenotype.
p10181
sg4
(lp10182
(dp10183
g7
I126
sg8
g24
sg10
I3
sg11
VShh
p10184
sg13
I1
sa(dp10185
g7
I172
sg8
VP32754
p10186
sg10
I20
sg11
Vpreaxial polydactyly
p10187
sg13
I2
sa(dp10188
g7
I194
sg8
VP32754
p10189
sg10
I3
sg11
VPPD
p10190
sg13
I1
sa(dp10191
g7
I47
sg8
VP35398
p10192
sg10
I45
sg11
VFGF-activated transcription factor genes Etv4
p10193
sg13
I5
sa(dp10194
g7
I97
sg8
VP41161
p10195
sg10
I4
sg11
VEtv5
p10196
sg13
I1
sasg14
(lp10197
(dp10198
g7
I172
sg17
VC0345354
p10199
sg10
I20
sg11
Vpreaxial polydactyly
p10200
sg13
I2
sa(dp10201
g7
I194
sg17
VC0432215
p10202
sg10
I3
sg11
VPPD
p10203
sg13
I1
sasa(dp10204
g2
VMechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly.
p10205
sg4
(lp10206
(dp10207
g7
I182
sg8
VP00390
p10208
sg10
I4
sg11
VDARC
p10209
sg13
I1
sa(dp10210
g7
I152
sg8
VP00390
p10211
sg10
I28
sg11
VDuffy antigen receptor group
p10212
sg13
I4
sa(dp10213
g7
I121
sg8
VP42857
p10214
sg10
I3
sg11
Vp21
p10215
sg13
I1
sa(dp10216
g7
I56
sg8
VP27701
p10217
sg10
I4
sg11
VCD82
p10218
sg13
I1
sa(dp10219
g7
I237
sg8
g24
sg10
I48
sg11
VIL-8-mediated vascular endothelial (VE)-cadherin
p10220
sg13
I4
sasg14
(lp10221
(dp10222
g7
I198
sg17
VC0027651
p10223
sg10
I5
sg11
Vtumor
p10224
sg13
I1
sa(dp10225
g7
I71
sg17
VC0278883
p10226
sg10
I19
sg11
Vmetastatic melanoma
p10227
sg13
I2
sasa(dp10228
g2
VOur oneway ANOVA analysis results showed that in all cases from benign diseases to invasive carcinoma, the concentration of CXCL8, CXCR4 and CXCL12 was significantly different; in benign subgroups (benign change, benign change with proliferation, atypia), the concentration of CCL2 and CCR5 was significantly different; in invasive carcinoma cases, DARC concentration was significantly correlated with the relapse risk of patients.
p10229
sg4
(lp10230
(dp10231
g7
I286
sg8
VP32302
p10232
sg10
I4
sg11
VCCR5
p10233
sg13
I1
sa(dp10234
g7
I131
sg8
VP61073
p10235
sg10
I5
sg11
VCXCR4
p10236
sg13
I1
sa(dp10237
g7
I277
sg8
VP13500
p10238
sg10
I4
sg11
VCCL2
p10239
sg13
I1
sa(dp10240
g7
I141
sg8
VP48061
p10241
sg10
I6
sg11
VCXCL12
p10242
sg13
I1
sasg14
(lp10243
(dp10244
g7
I83
sg17
VC1334274
p10245
sg10
I18
sg11
Vinvasive carcinoma
p10246
sg13
I2
sa(dp10247
g7
I83
sg17
VC1334274
p10248
sg10
I18
sg11
Vinvasive carcinoma
p10249
sg13
I2
sa(dp10250
g7
I232
sg17
VC0334094
p10251
sg10
I13
sg11
Vproliferation
p10252
sg13
I1
sa(dp10253
g7
I406
sg17
VC0277556
p10254
sg10
I7
sg11
Vrelapse
p10255
sg13
I1
sasa(dp10256
g2
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p10257
sg4
(lp10258
(dp10259
g7
I1876
sg8
VP49366
p10260
sg10
I49
sg11
Vsuccinate dehydrogenase complex assembly factor 2
p10261
sg13
I6
sa(dp10262
g7
I1927
sg8
VP21912
p10263
sg10
I4
sg11
VSDHB
p10264
sg13
I1
sa(dp10265
g7
I1771
sg8
g24
sg10
I3
sg11
VSDH
p10266
sg13
I1
sa(dp10267
g7
I2023
sg8
VP61278
p10268
sg10
I30
sg11
VSSTRs = somatostatin receptors
p10269
sg13
I4
sa(dp10270
g7
I438
sg8
g24
sg10
I5
sg11
VEGLN2
p10271
sg13
I1
sa(dp10272
g7
I2266
sg8
VP40337
p10273
sg10
I3
sg11
VVHL
p10274
sg13
I1
sa(dp10275
g7
I1802
sg8
VP31040
p10276
sg10
I4
sg11
VSDHA
p10277
sg13
I1
sa(dp10278
g7
I1760
sg8
VP33981
p10279
sg10
I9
sg11
VS6 kinase
p10280
sg13
I2
sa(dp10281
g7
I578
sg8
g24
sg10
I5
sg11
VEPAS1
p10282
sg13
I1
sa(dp10283
g7
I1434
sg8
VP13674
p10284
sg10
I33
sg11
Vprolyl hydroxylase domain protein
p10285
sg13
I4
sa(dp10286
g7
I2303
sg8
VP49366
p10287
sg10
I33
sg11
Valpha-ketoglutarate dehydrogenase
p10288
sg13
I2
sa(dp10289
g7
I464
sg8
g24
sg10
I26
sg11
Vhypoxia inducible factor 2
p10290
sg13
I4
sa(dp10291
g7
I1140
sg8
VP42345
p10292
sg10
I4
sg11
VmTOR
p10293
sg13
I1
sa(dp10294
g7
I1754
sg8
VP62753
p10295
sg10
I3
sg11
VS6K
p10296
sg13
I1
sa(dp10297
g7
I592
sg8
g24
sg10
I32
sg11
Vendothelial PAS domain protein 2
p10298
sg13
I5
sa(dp10299
g7
I492
sg8
g24
sg10
I3
sg11
VelF
p10300
sg13
I1
sa(dp10301
g7
I584
sg8
g24
sg10
I5
sg11
VHIF2A
p10302
sg13
I1
sa(dp10303
g7
I2063
sg8
g24
sg10
I21
sg11
Vsuccinyl-CoA synthase
p10304
sg13
I2
sa(dp10305
g7
I231
sg8
VP31947
p10306
sg10
I20
sg11
VO-methyl transferase
p10307
sg13
I2
sa(dp10308
g7
I958
sg8
g24
sg10
I33
sg11
VIGF-1R = growth factor 1 receptor
p10309
sg13
I6
sa(dp10310
g7
I1777
sg8
VP49366
p10311
sg10
I23
sg11
Vsuccinate dehydrogenase
p10312
sg13
I2
sa(dp10313
g7
I926
sg8
VP48735
p10314
sg10
I30
sg11
VIDH = isocitrate dehydrogenase
p10315
sg13
I4
sa(dp10316
g7
I748
sg8
VP84243
p10317
sg10
I5
sg11
VH3F3A
p10318
sg13
I1
sa(dp10319
g7
I900
sg8
VP01116
p10320
sg10
I3
sg11
VRAS
p10321
sg13
I1
sa(dp10322
g7
I1058
sg8
VP49366
p10323
sg10
I27
sg11
VMDH2 = malate dehydrogenase
p10324
sg13
I4
sa(dp10325
g7
I385
sg8
g24
sg10
I7
sg11
VEGLN1/2
p10326
sg13
I1
sa(dp10327
g7
I253
sg8
VP16870
p10328
sg10
I24
sg11
VCPE = carboxypeptidase E
p10329
sg13
I4
sa(dp10330
g7
I1001
sg8
g24
sg10
I7
sg11
Vkinesin
p10331
sg13
I1
sa(dp10332
g7
I756
sg8
VP62805
p10333
sg10
I25
sg11
Vhistone 3.3 encoding gene
p10334
sg13
I4
sa(dp10335
g7
I625
sg8
g24
sg10
I30
sg11
Vhypoxia-inducible factor 2Alfa
p10336
sg13
I3
sa(dp10337
g7
I1648
sg8
VP35125
p10338
sg10
I20
sg11
Vrat sarcoma oncogene
p10339
sg13
I3
sa(dp10340
g7
I1670
sg8
VP07949
p10341
sg10
I3
sg11
VRET
p10342
sg13
I1
sa(dp10343
g7
I657
sg8
VP29323
p10344
sg10
I3
sg11
VERK
p10345
sg13
I1
sa(dp10346
g7
I1027
sg8
VP61244
p10347
sg10
I29
sg11
VMAX = myc-associated factor X
p10348
sg13
I5
sa(dp10349
g7
I408
sg8
g24
sg10
I28
sg11
Vhypoxia inducible factor 1/2
p10350
sg13
I4
sa(dp10351
g7
I2230
sg8
g24
sg10
I34
sg11
Vvascular endothelial growth factor
p10352
sg13
I4
sa(dp10353
g7
I444
sg8
g24
sg10
I4
sg11
VPHD1
p10354
sg13
I1
sasg14
(lp10355
(dp10356
g7
I1771
sg17
VC0018946
p10357
sg10
I3
sg11
VSDH
p10358
sg13
I1
sa(dp10359
g7
I1261
sg17
VC0206754
p10360
sg10
I21
sg11
Vneuroendocrine tumors
p10361
sg13
I2
sa(dp10362
g7
I1477
sg17
VC0031511
p10363
sg10
I16
sg11
VPheochromocytoma
p10364
sg13
I1
sa(dp10365
g7
I1648
sg17
VC1882848
p10366
sg10
I11
sg11
Vrat sarcoma
p10367
sg13
I2
sa(dp10368
g7
I408
sg17
VC0242184
p10369
sg10
I7
sg11
Vhypoxia
p10370
sg13
I1
sa(dp10371
g7
I790
sg17
VC0242184
p10372
sg10
I7
sg11
VHypoxia
p10373
sg13
I1
sa(dp10374
g7
I1213
sg17
VC1850380
p10375
sg10
I3
sg11
VNAd
p10376
sg13
I1
sa(dp10377
g7
I94
sg17
VC1845055
p10378
sg10
I4
sg11
VATRX
p10379
sg13
I1
sa(dp10380
g7
I197
sg17
VC2678439
p10381
sg10
I3
sg11
VCoA
p10382
sg13
I1
sa(dp10383
g7
I1498
sg17
VC0030421
p10384
sg10
I14
sg11
VParagangliomas
p10385
sg13
I1
sa(dp10386
g7
I883
sg17
VC0030421
p10387
sg10
I14
sg11
Vparagangliomas
p10388
sg13
I1
sa(dp10389
g7
I408
sg17
VC0242184
p10390
sg10
I7
sg11
Vhypoxia
p10391
sg13
I1
sa(dp10392
g7
I1284
sg17
VC0027831
p10393
sg10
I3
sg11
VNF1
p10394
sg13
I1
sa(dp10395
g7
I408
sg17
VC0242184
p10396
sg10
I7
sg11
Vhypoxia
p10397
sg13
I1
sa(dp10398
g7
I2266
sg17
VC0019562
p10399
sg10
I3
sg11
VVHL
p10400
sg13
I1
sa(dp10401
g7
I729
sg17
VC1260386
p10402
sg10
I3
sg11
VGSH
p10403
sg13
I1
sa(dp10404
g7
I135
sg17
VC0279702
p10405
sg10
I31
sg11
Vclear cell renal cell carcinoma
p10406
sg13
I5
sa(dp10407
g7
I566
sg17
VC0599156
p10408
sg10
I10
sg11
Vtransition
p10409
sg13
I1
sa(dp10410
g7
I94
sg17
VC1845055
p10411
sg10
I4
sg11
VATRX
p10412
sg13
I1
sa(dp10413
g7
I2144
sg17
VC0040715
p10414
sg10
I13
sg11
Vtranslocation
p10415
sg13
I1
sa(dp10416
g7
I197
sg17
VC2678439
p10417
sg10
I3
sg11
VCoA
p10418
sg13
I1
sa(dp10419
g7
I408
sg17
VC0242184
p10420
sg10
I7
sg11
Vhypoxia
p10421
sg13
I1
sasa(dp10422
g2
VImmunohistochemistry for phosphorylated-S6, phosphorylated-mTOR, mTOR, phosphorylated-AKT, hypoxia inducible factor-1Alfa, Raptor, phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinase (PI3K), and phosphorylated 4E-binding protein-1 was performed on tissue microarray constructs of patients treated for nonmetastatic kidney cancer from 1997 to 2010.
p10423
sg4
(lp10424
(dp10425
g7
I86
sg8
g24
sg10
I3
sg11
VAKT
p10426
sg13
I1
sa(dp10427
g7
I163
sg8
VP60484
p10428
sg10
I4
sg11
VPTEN
p10429
sg13
I1
sa(dp10430
g7
I59
sg8
VP42345
p10431
sg10
I4
sg11
VmTOR
p10432
sg13
I1
sa(dp10433
g7
I197
sg8
VP42336
p10434
sg10
I4
sg11
VPI3K
p10435
sg13
I1
sa(dp10436
g7
I123
sg8
g24
sg10
I19
sg11
VRaptor, phosphatase
p10437
sg13
I2
sa(dp10438
g7
I131
sg8
VP60484
p10439
sg10
I30
sg11
Vphosphatase and tensin homolog
p10440
sg13
I4
sa(dp10441
g7
I59
sg8
VP42345
p10442
sg10
I4
sg11
VmTOR
p10443
sg13
I1
sa(dp10444
g7
I91
sg8
g24
sg10
I30
sg11
Vhypoxia inducible factor-1Alfa
p10445
sg13
I3
sa(dp10446
g7
I208
sg8
g24
sg10
I35
sg11
Vphosphorylated 4E-binding protein-1
p10447
sg13
I3
sa(dp10448
g7
I170
sg8
g24
sg10
I25
sg11
Vphosphoinositide 3-kinase
p10449
sg13
I2
sasg14
(lp10450
(dp10451
g7
I91
sg17
VC0242184
p10452
sg10
I7
sg11
Vhypoxia
p10453
sg13
I1
sa(dp10454
g7
I328
sg17
VC0740457
p10455
sg10
I13
sg11
Vkidney cancer
p10456
sg13
I2
sasa(dp10457
g2
VCholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA).
p10458
sg4
(lp10459
sg14
(lp10460
(dp10461
g7
I211
sg17
VC1865926
p10462
sg10
I4
sg11
ViCCA
p10463
sg13
I1
sa(dp10464
g7
I0
sg17
VC0206698
p10465
sg10
I18
sg11
VCholangiocarcinoma
p10466
sg13
I1
sa(dp10467
g7
I229
sg17
VC3151140
p10468
sg10
I4
sg11
VpCCA
p10469
sg13
I1
sa(dp10470
g7
I69
sg17
VC0027651
p10471
sg10
I7
sg11
Vtumours
p10472
sg13
I1
sa(dp10473
g7
I125
sg17
VC0206698
p10474
sg10
I19
sg11
Vcholangiocarcinomas
p10475
sg13
I1
sasa(dp10476
g2
VCholangiocarcinoma (CCA) represents a diverse group of epithelial cancers associated with the biliary tract, and can best be stratified anatomically into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) subsets.
p10477
sg4
(lp10478
sg14
(lp10479
(dp10480
g7
I0
sg17
VC0206698
p10481
sg10
I18
sg11
VCholangiocarcinoma
p10482
sg13
I1
sa(dp10483
g7
I168
sg17
VC1865926
p10484
sg10
I4
sg11
ViCCA
p10485
sg13
I1
sa(dp10486
g7
I186
sg17
VC3151140
p10487
sg10
I4
sg11
VpCCA
p10488
sg13
I1
sa(dp10489
g7
I20
sg17
VC0220668
p10490
sg10
I3
sg11
VCCA
p10491
sg13
I1
sa(dp10492
g7
I66
sg17
VC0006826
p10493
sg10
I7
sg11
Vcancers
p10494
sg13
I1
sasa(dp10495
g2
VPreoperative evaluation of vasculobiliary anatomy in the umbilical fissure (U-point) is pivotal for perihilar cholangiocarcinoma (PCCA) applied to right-sided hepatectomy.
p10496
sg4
(lp10497
sg14
(lp10498
(dp10499
g7
I100
sg17
VC3151140
p10500
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p10501
sg13
I2
sa(dp10502
g7
I130
sg17
VC3151140
p10503
sg10
I4
sg11
VPCCA
p10504
sg13
I1
sasa(dp10505
g2
VThis study sought to define the role of adjuvant radiation therapy (RT) for patients with curative intent resection of perihilar cholangiocarcinoma (pCCA).
p10506
sg4
(lp10507
sg14
(lp10508
(dp10509
g7
I119
sg17
VC3151140
p10510
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p10511
sg13
I2
sa(dp10512
g7
I149
sg17
VC3151140
p10513
sg10
I4
sg11
VpCCA
p10514
sg13
I1
sasa(dp10515
g2
VOur goal was to characterize PD-L1 expression in intra-hepatic (iCCA) and perihilar (pCCA) cholangiocarcinomas, and to correlate our results with clinicopathological features, density of tumor-infiltrating lymphocytes (TILs) and PD-1 expression.A series of 58 iCCAs and 41 pCCAs was included in the study.
p10516
sg4
(lp10517
(dp10518
g7
I229
sg8
VP18621
p10519
sg10
I4
sg11
VPD-1
p10520
sg13
I1
sasg14
(lp10521
(dp10522
g7
I91
sg17
VC0206698
p10523
sg10
I19
sg11
Vcholangiocarcinomas
p10524
sg13
I1
sa(dp10525
g7
I193
sg17
VC0332448
p10526
sg10
I12
sg11
Vinfiltrating
p10527
sg13
I1
sa(dp10528
g7
I85
sg17
VC3151140
p10529
sg10
I4
sg11
VpCCA
p10530
sg13
I1
sa(dp10531
g7
I64
sg17
VC1865926
p10532
sg10
I4
sg11
ViCCA
p10533
sg13
I1
sa(dp10534
g7
I187
sg17
VC0027651
p10535
sg10
I5
sg11
Vtumor
p10536
sg13
I1
sasa(dp10537
g2
VLiver transplantation (LT) provides a good chance of cure for selected patients with hepatocellular carcinoma (HCC) and perihilar cholangiocarcinoma (pCCA).
p10538
sg4
(lp10539
sg14
(lp10540
(dp10541
g7
I150
sg17
VC3151140
p10542
sg10
I4
sg11
VpCCA
p10543
sg13
I1
sa(dp10544
g7
I111
sg17
VC2239176
p10545
sg10
I3
sg11
VHCC
p10546
sg13
I1
sa(dp10547
g7
I120
sg17
VC3151140
p10548
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p10549
sg13
I2
sa(dp10550
g7
I85
sg17
VC2239176
p10551
sg10
I24
sg11
Vhepatocellular carcinoma
p10552
sg13
I2
sasa(dp10553
g2
VBTC are sub-classified as intrahepatic cholangiocarcinoma (iCCA), perhilar/hilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA), and gallbladder carcinoma.
p10554
sg4
(lp10555
(dp10556
g7
I0
sg8
VP35070
p10557
sg10
I3
sg11
VBTC
p10558
sg13
I1
sasg14
(lp10559
(dp10560
g7
I39
sg17
VC0206698
p10561
sg10
I18
sg11
Vcholangiocarcinoma
p10562
sg13
I1
sa(dp10563
g7
I66
sg17
VC3151140
p10564
sg10
I33
sg11
Vperhilar/hilar cholangiocarcinoma
p10565
sg13
I2
sa(dp10566
g7
I146
sg17
VC0235782
p10567
sg10
I21
sg11
Vgallbladder carcinoma
p10568
sg13
I2
sa(dp10569
g7
I26
sg17
VC0345905
p10570
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p10571
sg13
I2
sa(dp10572
g7
I101
sg17
VC3151140
p10573
sg10
I4
sg11
VpCCA
p10574
sg13
I1
sa(dp10575
g7
I59
sg17
VC1865926
p10576
sg10
I4
sg11
ViCCA
p10577
sg13
I1
sasa(dp10578
g2
VTo evaluate prognostic factors for stent patency and survival in patients with perihilar cholangiocarcinoma (pCCA) who underwent percutaneous biliary stent placement.
p10579
sg4
(lp10580
sg14
(lp10581
(dp10582
g7
I109
sg17
VC3151140
p10583
sg10
I4
sg11
VpCCA
p10584
sg13
I1
sa(dp10585
g7
I79
sg17
VC3151140
p10586
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p10587
sg13
I2
sasa(dp10588
g2
VClinical data were collected and analyzed from 71 cases of primary nephrotic syndrome with glucocorticoid-induced ocular hypertension, glaucoma or cataract from Jun.
p10589
sg4
(lp10590
(dp10591
g7
I161
sg8
VP05412
p10592
sg10
I3
sg11
VJun
p10593
sg13
I1
sasg14
(lp10594
(dp10595
g7
I147
sg17
VC0086543
p10596
sg10
I8
sg11
Vcataract
p10597
sg13
I1
sa(dp10598
g7
I135
sg17
VC0017601
p10599
sg10
I8
sg11
Vglaucoma
p10600
sg13
I1
sa(dp10601
g7
I67
sg17
VC0027726
p10602
sg10
I18
sg11
Vnephrotic syndrome
p10603
sg13
I2
sa(dp10604
g7
I114
sg17
VC0028840
p10605
sg10
I19
sg11
Vocular hypertension
p10606
sg13
I2
sasa(dp10607
g2
Vc-Jun, c-Jun N-terminal kinase(JNK) and endothelin B (ETB) receptor have been shown to contribute to the pathogenesis of glaucoma.
p10608
sg4
(lp10609
(dp10610
g7
I0
sg8
VP05412
p10611
sg10
I5
sg11
Vc-Jun
p10612
sg13
I1
sa(dp10613
g7
I31
sg8
VP53779
p10614
sg10
I3
sg11
VJNK
p10615
sg13
I1
sa(dp10616
g7
I40
sg8
g24
sg10
I27
sg11
Vendothelin B (ETB) receptor
p10617
sg13
I4
sa(dp10618
g7
I7
sg8
VP53779
p10619
sg10
I23
sg11
Vc-Jun N-terminal kinase
p10620
sg13
I3
sasg14
(lp10621
(dp10622
g7
I105
sg17
VC0699748
p10623
sg10
I12
sg11
Vpathogenesis
p10624
sg13
I1
sa(dp10625
g7
I121
sg17
VC0017601
p10626
sg10
I8
sg11
Vglaucoma
p10627
sg13
I1
sasa(dp10628
g2
VOcular hypertension also caused upregulations in the iron-regulating protein ceruloplasmin, the anaerobic glycolytic enzyme lactate dehydrogenase, and the transcription factors cFos and p-cJun.
p10629
sg4
(lp10630
(dp10631
g7
I53
sg8
VP00450
p10632
sg10
I37
sg11
Viron-regulating protein ceruloplasmin
p10633
sg13
I3
sa(dp10634
g7
I124
sg8
VP49366
p10635
sg10
I21
sg11
Vlactate dehydrogenase
p10636
sg13
I2
sa(dp10637
g7
I177
sg8
VP01100
p10638
sg10
I4
sg11
VcFos
p10639
sg13
I1
sasg14
(lp10640
(dp10641
g7
I0
sg17
VC0028840
p10642
sg10
I19
sg11
VOcular hypertension
p10643
sg13
I2
sasa(dp10644
g2
VJUN is expressed after glaucoma-relevant injuries and Jun deficiency protects RGCs after mechanical injury to the optic nerve.
p10645
sg4
(lp10646
(dp10647
g7
I54
sg8
VP05412
p10648
sg10
I3
sg11
VJun
p10649
sg13
I1
sa(dp10650
g7
I0
sg8
VP05412
p10651
sg10
I3
sg11
VJUN
p10652
sg13
I1
sasg14
(lp10653
(dp10654
g7
I23
sg17
VC0017601
p10655
sg10
I8
sg11
Vglaucoma
p10656
sg13
I1
sasa(dp10657
g2
VHere, we tested the importance of JNK-JUN signaling for RGC death after ocular hypertensive axonal injury in an age-related, mouse model of ocular hypertension.
p10658
sg4
(lp10659
(dp10660
g7
I38
sg8
VP05412
p10661
sg10
I3
sg11
VJUN
p10662
sg13
I1
sa(dp10663
g7
I34
sg8
VP53779
p10664
sg10
I3
sg11
VJNK
p10665
sg13
I1
sasg14
(lp10666
(dp10667
g7
I140
sg17
VC0028840
p10668
sg10
I19
sg11
Vocular hypertension
p10669
sg13
I2
sasa(dp10670
g2
VJUN was expressed in a temporal and spatial pattern consistent with a role in glaucomatous injury.
p10671
sg4
(lp10672
(dp10673
g7
I0
sg8
VP05412
p10674
sg10
I3
sg11
VJUN
p10675
sg13
I1
sasg14
(lp10676
sa(dp10677
g2
VTo determine the importance of JUN in ocular hypertension-induced RGC death, a floxed allele of Jun and a retinal expressed cre recombinase (Six3-cre) were backcrossed onto the DBA/2J background.
p10678
sg4
(lp10679
(dp10680
g7
I124
sg8
g24
sg10
I15
sg11
Vcre recombinase
p10681
sg13
I2
sa(dp10682
g7
I141
sg8
g24
sg10
I8
sg11
VSix3-cre
p10683
sg13
I1
sa(dp10684
g7
I96
sg8
VP05412
p10685
sg10
I3
sg11
VJun
p10686
sg13
I1
sasg14
(lp10687
(dp10688
g7
I177
sg17
VC0398550
p10689
sg10
I3
sg11
VDBA
p10690
sg13
I1
sa(dp10691
g7
I38
sg17
VC0028840
p10692
sg10
I19
sg11
Vocular hypertension
p10693
sg13
I2
sasa(dp10694
g2
VJun deficiency protected RGC somas from ocular hypertensive injury, but did not protect RGC axons from glaucomatous neurodegeneration.
p10695
sg4
(lp10696
(dp10697
g7
I0
sg8
VP05412
p10698
sg10
I3
sg11
VJun
p10699
sg13
I1
sasg14
(lp10700
(dp10701
g7
I116
sg17
VC0027746
p10702
sg10
I17
sg11
Vneurodegeneration
p10703
sg13
I1
sasa(dp10704
g2
VJun is a major regulator of RGC somal degeneration after glaucomatous ocular hypertensive injury.
p10705
sg4
(lp10706
(dp10707
g7
I0
sg8
VP05412
p10708
sg10
I3
sg11
VJun
p10709
sg13
I1
sasg14
(lp10710
(dp10711
g7
I38
sg17
VC0011164
p10712
sg10
I12
sg11
Vdegeneration
p10713
sg13
I1
sasa(dp10714
g2
VThese results suggest in glaucomatous neurodegeneration, JNK-JUN signaling has a major role as a pro-death signaling pathway between axonal injury and somal degeneration.
p10715
sg4
(lp10716
(dp10717
g7
I61
sg8
VP05412
p10718
sg10
I3
sg11
VJUN
p10719
sg13
I1
sa(dp10720
g7
I57
sg8
VP53779
p10721
sg10
I3
sg11
VJNK
p10722
sg13
I1
sasg14
(lp10723
(dp10724
g7
I43
sg17
VC0011164
p10725
sg10
I12
sg11
Vdegeneration
p10726
sg13
I1
sa(dp10727
g7
I38
sg17
VC0027746
p10728
sg10
I17
sg11
Vneurodegeneration
p10729
sg13
I1
sasa(dp10730
g2
VTo our knowledge the co-existence of Pompe disease and thymic neuroendocrine tumor in the same patient has not been previously reported.
p10731
sg4
(lp10732
sg14
(lp10733
(dp10734
g7
I62
sg17
VC0206754
p10735
sg10
I20
sg11
Vneuroendocrine tumor
p10736
sg13
I2
sa(dp10737
g7
I37
sg17
VC0017921
p10738
sg10
I13
sg11
VPompe disease
p10739
sg13
I2
sasa(dp10740
g2
VSignificantly more A-C (block 2: rs230528-rs230521) haplotypes (P = 0.0003 after Bonferroni's corrections) and G-A-A (block 4: rs4648068-rs3774964-rs3774968) haplotypes (P = 0.021) were found in the patients with ovarian cancer.
p10741
sg4
(lp10742
sg14
(lp10743
(dp10744
g7
I213
sg17
VC1140680
p10745
sg10
I14
sg11
Vovarian cancer
p10746
sg13
I2
sasa(dp10747
g2
VThe thyroid conditions for which surgery was indicated were: diffuse toxic goiter in 8 patients; multinodular toxic and nontoxic goiter in 30 patients; autonomous nodule in 2 patients; 2 patients with benign nodules at fine needle aspiration biopsy (FNAB); 4 patients with nodules positive for carcinoma at FNAB, among them 2 with unilateral cervical lymph nodes enlargement; 4 patients with highly suspect nodule on FNAB.
p10748
sg4
(lp10749
sg14
(lp10750
(dp10751
g7
I61
sg17
VC0342122
p10752
sg10
I20
sg11
Vdiffuse toxic goiter
p10753
sg13
I3
sa(dp10754
g7
I163
sg17
VC0028259
p10755
sg10
I6
sg11
Vnodule
p10756
sg13
I1
sa(dp10757
g7
I120
sg17
VC0221777
p10758
sg10
I15
sg11
Vnontoxic goiter
p10759
sg13
I2
sa(dp10760
g7
I163
sg17
VC0028259
p10761
sg10
I6
sg11
Vnodule
p10762
sg13
I1
sa(dp10763
g7
I208
sg17
VC0028259
p10764
sg10
I7
sg11
Vnodules
p10765
sg13
I1
sa(dp10766
g7
I208
sg17
VC0028259
p10767
sg10
I7
sg11
Vnodules
p10768
sg13
I1
sa(dp10769
g7
I363
sg17
VC2711450
p10770
sg10
I11
sg11
Venlargement
p10771
sg13
I1
sa(dp10772
g7
I294
sg17
VC0007097
p10773
sg10
I9
sg11
Vcarcinoma
p10774
sg13
I1
sa(dp10775
g7
I231
sg17
VC0700198
p10776
sg10
I10
sg11
Vaspiration
p10777
sg13
I1
sasa(dp10778
g2
VThe aim of the present study was to comparatively investigate the effects of piroxicam, a selective COX-I inhibitor, and celecoxib, a selective COX-II inhibitor, on cognitive functions in an AlCl3-induced neurotoxicity mouse model to understand the specific role of each COX enzyme in the hippocampus and cortex.
p10779
sg4
(lp10780
(dp10781
g7
I100
sg8
VP00395
p10782
sg10
I5
sg11
VCOX-I
p10783
sg13
I1
sa(dp10784
g7
I144
sg8
VP00403
p10785
sg10
I6
sg11
VCOX-II
p10786
sg13
I1
sasg14
(lp10787
sa(dp10788
g2
VOf these differentially expressed genes, we elected to further examine the increase in COX1 expression, because of data implicating energy utilization in METH neurotoxicity and the known role of COX1 in energy metabolism.
p10789
sg4
(lp10790
(dp10791
g7
I87
sg8
VP00395
p10792
sg10
I4
sg11
VCOX1
p10793
sg13
I1
sa(dp10794
g7
I87
sg8
VP00395
p10795
sg10
I4
sg11
VCOX1
p10796
sg13
I1
sasg14
(lp10797
sa(dp10798
g2
VThe precise role of COX1 and other genes in METH neurotoxicity remains to be elucidated.
p10799
sg4
(lp10800
(dp10801
g7
I20
sg8
VP00395
p10802
sg10
I4
sg11
VCOX1
p10803
sg13
I1
sasg14
(lp10804
sa(dp10805
g2
VVarious genes involved in the control of cell proliferation and invasion (p16INK4A, RASSF1A, PTEN, Rap1GAP, TIMP3, DAPK, RARBeta2, E-cadherin, and CITED1) as well as genes specific of thyroid differentiation (Na+/I- symport, TSH receptor, pendrin, SL5A8, and TTF-1) present aberrant methylation in thyroid cancer.
p10806
sg4
(lp10807
(dp10808
g7
I93
sg8
VP60484
p10809
sg10
I4
sg11
VPTEN
p10810
sg13
I1
sa(dp10811
g7
I115
sg8
VP53355
p10812
sg10
I4
sg11
VDAPK
p10813
sg13
I1
sa(dp10814
g7
I225
sg8
VP16473
p10815
sg10
I12
sg11
VTSH receptor
p10816
sg13
I2
sa(dp10817
g7
I74
sg8
VP42771
p10818
sg10
I8
sg11
Vp16INK4A
p10819
sg13
I1
sa(dp10820
g7
I108
sg8
VP35625
p10821
sg10
I5
sg11
VTIMP3
p10822
sg13
I1
sa(dp10823
g7
I147
sg8
g24
sg10
I6
sg11
VCITED1
p10824
sg13
I1
sa(dp10825
g7
I99
sg8
VP47736
p10826
sg10
I7
sg11
VRap1GAP
p10827
sg13
I1
sa(dp10828
g7
I259
sg8
VP43699
p10829
sg10
I5
sg11
VTTF-1
p10830
sg13
I1
sa(dp10831
g7
I131
sg8
VP12830
p10832
sg10
I10
sg11
VE-cadherin
p10833
sg13
I1
sa(dp10834
g7
I239
sg8
g24
sg10
I7
sg11
Vpendrin
p10835
sg13
I1
sasg14
(lp10836
(dp10837
g7
I298
sg17
VC0007115
p10838
sg10
I14
sg11
Vthyroid cancer
p10839
sg13
I2
sa(dp10840
g7
I46
sg17
VC0334094
p10841
sg10
I13
sg11
Vproliferation
p10842
sg13
I1
sa(dp10843
g7
I64
sg17
VC2699153
p10844
sg10
I8
sg11
Vinvasion
p10845
sg13
I1
sasa(dp10846
g2
VImmunohistochemistry was performed using primary antibodies to cytokeratin 19, HBME1, and CITED1 that have been found to be useful in the diagnosis of thyroid carcinoma.
p10847
sg4
(lp10848
(dp10849
g7
I90
sg8
g24
sg10
I6
sg11
VCITED1
p10850
sg13
I1
sa(dp10851
g7
I63
sg8
g24
sg10
I14
sg11
Vcytokeratin 19
p10852
sg13
I2
sasg14
(lp10853
(dp10854
g7
I151
sg17
VC0549473
p10855
sg10
I17
sg11
Vthyroid carcinoma
p10856
sg13
I2
sasa(dp10857
g2
VMarkers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary thyroid carcinomas from follicular adenomas.
p10858
sg4
(lp10859
(dp10860
g7
I27
sg8
g24
sg10
I6
sg11
VCITED1
p10861
sg13
I1
sasg14
(lp10862
(dp10863
g7
I124
sg17
VC0007097
p10864
sg10
I10
sg11
Vcarcinomas
p10865
sg13
I1
sa(dp10866
g7
I140
sg17
VC0205647
p10867
sg10
I19
sg11
Vfollicular adenomas
p10868
sg13
I2
sasa(dp10869
g2
VThese analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p &lt; 0.0001).
p10870
sg4
(lp10871
(dp10872
g7
I178
sg8
VP17931
p10873
sg10
I26
sg11
Vgalectin-3, cytokeratin 19
p10874
sg13
I3
sa(dp10875
g7
I210
sg8
VP26447
p10876
sg10
I6
sg11
VS100A4
p10877
sg13
I1
sa(dp10878
g7
I170
sg8
g24
sg10
I6
sg11
VCITED1
p10879
sg13
I1
sasg14
(lp10880
(dp10881
g7
I76
sg17
VC0205647
p10882
sg10
I19
sg11
Vfollicular adenomas
p10883
sg13
I2
sa(dp10884
g7
I141
sg17
VC0007097
p10885
sg10
I10
sg11
Vcarcinomas
p10886
sg13
I1
sasa(dp10887
g2
VA combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma.
p10888
sg4
(lp10889
(dp10890
g7
I58
sg8
VP17931
p10891
sg10
I10
sg11
Vgalectin-3
p10892
sg13
I1
sa(dp10893
g7
I101
sg8
g24
sg10
I6
sg11
VCITED1
p10894
sg13
I1
sa(dp10895
g7
I58
sg8
VP17931
p10896
sg10
I10
sg11
Vgalectin-3
p10897
sg13
I1
sasg14
(lp10898
(dp10899
g7
I215
sg17
VC0238463
p10900
sg10
I27
sg11
Vpapillary thyroid carcinoma
p10901
sg13
I3
sa(dp10902
g7
I169
sg17
VC0205647
p10903
sg10
I18
sg11
Vfollicular adenoma
p10904
sg13
I2
sasa(dp10905
g2
VWe examined acetylcholinesterase, plasma neuronal proteins, secreted beta-amyloid precursor protein (APP), and amyloid-beta 40 and amyloid-beta 42 peptides in children with and without autism.
p10906
sg4
(lp10907
(dp10908
g7
I101
sg8
g24
sg10
I3
sg11
VAPP
p10909
sg13
I1
sa(dp10910
g7
I12
sg8
VP12821
p10911
sg10
I20
sg11
Vacetylcholinesterase
p10912
sg13
I1
sa(dp10913
g7
I34
sg8
VP29475
p10914
sg10
I65
sg11
Vplasma neuronal proteins, secreted beta-amyloid precursor protein
p10915
sg13
I7
sa(dp10916
g7
I111
sg8
g24
sg10
I44
sg11
Vamyloid-beta 40 and amyloid-beta 42 peptides
p10917
sg13
I6
sasg14
(lp10918
(dp10919
g7
I185
sg17
VC0004352
p10920
sg10
I6
sg11
Vautism
p10921
sg13
I1
sa(dp10922
g7
I74
sg17
VC0011560
p10923
sg10
I7
sg11
Vamyloid
p10924
sg13
I1
sa(dp10925
g7
I74
sg17
VC0011560
p10926
sg10
I7
sg11
Vamyloid
p10927
sg13
I1
sa(dp10928
g7
I74
sg17
VC0011560
p10929
sg10
I7
sg11
Vamyloid
p10930
sg13
I1
sasa(dp10931
g2
VThe growth associated protein 43-positive fibres also seemed to be less in six samples of club foot.
p10932
sg4
(lp10933
sg14
(lp10934
(dp10935
g7
I90
sg17
VC0009081
p10936
sg10
I9
sg11
Vclub foot
p10937
sg13
I2
sasa(dp10938
g2
VHere we showed that miR-342-5p and miR-608 suppressed the tumorigenesis of colon cancer cells in vitro and in vivo by targeting NAA10 mRNA for degradation.
p10939
sg4
(lp10940
(dp10941
g7
I20
sg8
g24
sg10
I10
sg11
VmiR-342-5p
p10942
sg13
I1
sa(dp10943
g7
I128
sg8
VP41227
p10944
sg10
I10
sg11
VNAA10 mRNA
p10945
sg13
I2
sasg14
(lp10946
(dp10947
g7
I75
sg17
VC0699790
p10948
sg10
I12
sg11
Vcolon cancer
p10949
sg13
I2
sa(dp10950
g7
I58
sg17
VC0007621
p10951
sg10
I13
sg11
Vtumorigenesis
p10952
sg13
I1
sasa(dp10953
g2
VOur results implicate miR-342-5p and miR-608 in colon cancer development and unveil the underlying mechanism of this phenomenon, which involves NAA10.
p10954
sg4
(lp10955
(dp10956
g7
I22
sg8
g24
sg10
I10
sg11
VmiR-342-5p
p10957
sg13
I1
sa(dp10958
g7
I144
sg8
VP41227
p10959
sg10
I5
sg11
VNAA10
p10960
sg13
I1
sa(dp10961
g7
I37
sg8
g24
sg10
I7
sg11
VmiR-608
p10962
sg13
I1
sasg14
(lp10963
(dp10964
g7
I48
sg17
VC0699790
p10965
sg10
I12
sg11
Vcolon cancer
p10966
sg13
I2
sasa(dp10967
g2
VWe demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases).
p10968
sg4
(lp10969
(dp10970
g7
I127
sg8
VP04626
p10971
sg10
I4
sg11
VHER2
p10972
sg13
I1
sa(dp10973
g7
I83
sg8
g24
sg10
I8
sg11
VmiR-744*
p10974
sg13
I1
sa(dp10975
g7
I127
sg8
VP04626
p10976
sg10
I4
sg11
VHER2
p10977
sg13
I1
sa(dp10978
g7
I68
sg8
g24
sg10
I10
sg11
VmiR-342-5p
p10979
sg13
I1
sasg14
(lp10980
(dp10981
g7
I211
sg17
VC0678222
p10982
sg10
I13
sg11
Vbreast cancer
p10983
sg13
I2
sa(dp10984
g7
I141
sg17
VC1458155
p10985
sg10
I13
sg11
Vbreast tumors
p10986
sg13
I2
sa(dp10987
g7
I148
sg17
VC0027651
p10988
sg10
I6
sg11
Vtumors
p10989
sg13
I1
sasa(dp10990
g2
VFurthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts.
p10991
sg4
(lp10992
(dp10993
g7
I34
sg8
g24
sg10
I10
sg11
VmiR-342-5p
p10994
sg13
I1
sasg14
(lp10995
(dp10996
g7
I89
sg17
VC0678222
p10997
sg10
I13
sg11
Vbreast cancer
p10998
sg13
I2
sasa(dp10999
g2
VCompromised CN function is a significant cause of erectile dysfunction development following prostatectomy and serves as the primary target for potential neuroprotective or regenerative strategies utilizing NGFs such as BDNF, GDF-5, and NTN, and/or targeted novel therapeutics modulating signaling pathways.
p11000
sg4
(lp11001
(dp11002
g7
I226
sg8
VP43026
p11003
sg10
I5
sg11
VGDF-5
p11004
sg13
I1
sasg14
(lp11005
(dp11006
g7
I50
sg17
VC0242350
p11007
sg10
I20
sg11
Verectile dysfunction
p11008
sg13
I2
sasa(dp11009
g2
VThe manifestation of LHON was associated with increased mortality and increased incidence of several disorders including stroke, demyelinating disorder, dementia, and epilepsy.
p11010
sg4
(lp11011
sg14
(lp11012
(dp11013
g7
I121
sg17
VC0038454
p11014
sg10
I6
sg11
Vstroke
p11015
sg13
I1
sa(dp11016
g7
I153
sg17
VC0497327
p11017
sg10
I8
sg11
Vdementia
p11018
sg13
I1
sa(dp11019
g7
I21
sg17
VC0917796
p11020
sg10
I4
sg11
VLHON
p11021
sg13
I1
sa(dp11022
g7
I129
sg17
VC0011303
p11023
sg10
I22
sg11
Vdemyelinating disorder
p11024
sg13
I2
sa(dp11025
g7
I167
sg17
VC0014544
p11026
sg10
I8
sg11
Vepilepsy
p11027
sg13
I1
sasa(dp11028
g2
VLeber's Hereditary Optic Neuropathy (LHON) shares features with Multiple Sclerosis (MS).
p11029
sg4
(lp11030
sg14
(lp11031
(dp11032
g7
I0
sg17
VC0917796
p11033
sg10
I35
sg11
VLeber's Hereditary Optic Neuropathy
p11034
sg13
I4
sa(dp11035
g7
I37
sg17
VC0917796
p11036
sg10
I4
sg11
VLHON
p11037
sg13
I1
sa(dp11038
g7
I64
sg17
VC0026769
p11039
sg10
I18
sg11
VMultiple Sclerosis
p11040
sg13
I2
sa(dp11041
g7
I84
sg17
VC0026769
p11042
sg10
I2
sg11
VMS
p11043
sg13
I1
sasa(dp11044
g2
VLeber's hereditary optic neuropathy (LHON) is a mitochondrial DNA (mtDNA) associated neurodegenerative disorder of retinal ganglion cells.
p11045
sg4
(lp11046
sg14
(lp11047
(dp11048
g7
I0
sg17
VC0917796
p11049
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p11050
sg13
I4
sa(dp11051
g7
I37
sg17
VC0917796
p11052
sg10
I4
sg11
VLHON
p11053
sg13
I1
sa(dp11054
g7
I85
sg17
VC0524851
p11055
sg10
I26
sg11
Vneurodegenerative disorder
p11056
sg13
I2
sa(dp11057
g7
I123
sg17
VC1258666
p11058
sg10
I8
sg11
Vganglion
p11059
sg13
I1
sasa(dp11060
g2
VMT-ND4: mitochondrially encoded NADH dehydrogenase 4; MT-TL1: mitochondrially encoded tRNA leucine 1 (UUA/G); PCR: polymerase chain reaction; OXPHOS: mitochondrial oxidative phosphorylation; ATP: adenosine triphosphate; mtDNA: mitochondrial DNA; SNPs: single nucleotide substitutions; AD: alzheimer's disease; PD: parkinson's disease; MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; ROS: reactive oxygen species.
p11061
sg4
(lp11062
(dp11063
g7
I54
sg8
g24
sg10
I6
sg11
VMT-TL1
p11064
sg13
I1
sa(dp11065
g7
I62
sg8
VP30740
p11066
sg10
I38
sg11
Vmitochondrially encoded tRNA leucine 1
p11067
sg13
I5
sa(dp11068
g7
I8
sg8
VP49366
p11069
sg10
I44
sg11
Vmitochondrially encoded NADH dehydrogenase 4
p11070
sg13
I5
sa(dp11071
g7
I0
sg8
VP03905
p11072
sg10
I6
sg11
VMT-ND4
p11073
sg13
I1
sasg14
(lp11074
(dp11075
g7
I314
sg17
VC0030567
p11076
sg10
I19
sg11
Vparkinson's disease
p11077
sg13
I2
sa(dp11078
g7
I342
sg17
VC1964017
p11079
sg10
I77
sg11
Vmitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
p11080
sg13
I8
sa(dp11081
g7
I335
sg17
VC0162671
p11082
sg10
I5
sg11
VMELAS
p11083
sg13
I1
sa(dp11084
g7
I289
sg17
VC1521724
p11085
sg10
I19
sg11
Valzheimer's disease
p11086
sg13
I2
sasa(dp11087
g2
VLeber's hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding's disease.
p11088
sg4
(lp11089
sg14
(lp11090
(dp11091
g7
I0
sg17
VC0917796
p11092
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p11093
sg13
I4
sa(dp11094
g7
I37
sg17
VC0917796
p11095
sg10
I4
sg11
VLHON
p11096
sg13
I1
sa(dp11097
g7
I37
sg17
VC0917796
p11098
sg10
I4
sg11
VLHON
p11099
sg13
I1
sa(dp11100
g7
I60
sg17
VC0026769
p11101
sg10
I18
sg11
Vmultiple sclerosis
p11102
sg13
I2
sasa(dp11103
g2
VThe role of oxidative stress in the five most common inherited mitochondrial diseases, Friedreich ataxia, LHON, MELAS, MERRF, and Leigh syndrome (LS), is discussed.
p11104
sg4
(lp11105
(dp11106
g7
I112
sg8
VP03886
p11107
sg10
I5
sg11
VMELAS
p11108
sg13
I1
sa(dp11109
g7
I119
sg8
VP03915
p11110
sg10
I5
sg11
VMERRF
p11111
sg13
I1
sasg14
(lp11112
(dp11113
g7
I63
sg17
VC0751651
p11114
sg10
I22
sg11
Vmitochondrial diseases
p11115
sg13
I2
sa(dp11116
g7
I112
sg17
VC0162671
p11117
sg10
I5
sg11
VMELAS
p11118
sg13
I1
sa(dp11119
g7
I130
sg17
VC0023264
p11120
sg10
I14
sg11
VLeigh syndrome
p11121
sg13
I2
sa(dp11122
g7
I12
sg17
VC0242606
p11123
sg10
I16
sg11
Voxidative stress
p11124
sg13
I2
sa(dp11125
g7
I146
sg17
VC0023264
p11126
sg10
I2
sg11
VLS
p11127
sg13
I1
sa(dp11128
g7
I87
sg17
VC0016719
p11129
sg10
I17
sg11
VFriedreich ataxia
p11130
sg13
I2
sa(dp11131
g7
I106
sg17
VC0917796
p11132
sg10
I4
sg11
VLHON
p11133
sg13
I1
sa(dp11134
g7
I119
sg17
VC0162672
p11135
sg10
I5
sg11
VMERRF
p11136
sg13
I1
sasa(dp11137
g2
VOf the five most common mitochondrial diseases, the strongest support for oxidative stress is for Friedreich ataxia (6.42%), followed by LHON (2.45%), MELAS (2.18%), MERRF (1.71%), and LS (1.03%).
p11138
sg4
(lp11139
sg14
(lp11140
(dp11141
g7
I137
sg17
VC0917796
p11142
sg10
I4
sg11
VLHON
p11143
sg13
I1
sa(dp11144
g7
I166
sg17
VC0162672
p11145
sg10
I5
sg11
VMERRF
p11146
sg13
I1
sa(dp11147
g7
I24
sg17
VC0751651
p11148
sg10
I22
sg11
Vmitochondrial diseases
p11149
sg13
I2
sa(dp11150
g7
I151
sg17
VC0162671
p11151
sg10
I5
sg11
VMELAS
p11152
sg13
I1
sa(dp11153
g7
I98
sg17
VC0016719
p11154
sg10
I17
sg11
VFriedreich ataxia
p11155
sg13
I2
sa(dp11156
g7
I74
sg17
VC0242606
p11157
sg10
I16
sg11
Voxidative stress
p11158
sg13
I2
sasa(dp11159
g2
VLeber's hereditary optic neuropathy (LHON) and a multiple sclerosis (MS)-like illness appear to coexist 50 times more frequently than would be expected by chance.
p11160
sg4
(lp11161
sg14
(lp11162
(dp11163
g7
I0
sg17
VC0917796
p11164
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p11165
sg13
I4
sa(dp11166
g7
I37
sg17
VC0917796
p11167
sg10
I4
sg11
VLHON
p11168
sg13
I1
sa(dp11169
g7
I69
sg17
VC0026769
p11170
sg10
I2
sg11
VMS
p11171
sg13
I1
sa(dp11172
g7
I49
sg17
VC0026769
p11173
sg10
I18
sg11
Vmultiple sclerosis
p11174
sg13
I2
sasa(dp11175
g2
VMutations in the retinitis pigmentosa 1 (RP1) gene are a common cause of retinitis pigmentosa (RP).
p11176
sg4
(lp11177
(dp11178
g7
I17
sg8
VP56715
p11179
sg10
I22
sg11
Vretinitis pigmentosa 1
p11180
sg13
I3
sa(dp11181
g7
I41
sg8
VP56715
p11182
sg10
I3
sg11
VRP1
p11183
sg13
I1
sasg14
(lp11184
(dp11185
g7
I17
sg17
VC0220701
p11186
sg10
I22
sg11
Vretinitis pigmentosa 1
p11187
sg13
I3
sa(dp11188
g7
I41
sg17
VC0035334
p11189
sg10
I2
sg11
VRP
p11190
sg13
I1
sa(dp11191
g7
I17
sg17
VC0035334
p11192
sg10
I20
sg11
Vretinitis pigmentosa
p11193
sg13
I2
sa(dp11194
g7
I41
sg17
VC0220701
p11195
sg10
I3
sg11
VRP1
p11196
sg13
I1
sasa(dp11197
g2
VFurthermore, these findings indicate that the RP1 form of inherited retinal degeneration is part of the larger class of neurodegenerative diseases caused by MAP dysfunction.
p11198
sg4
(lp11199
(dp11200
g7
I46
sg8
VP56715
p11201
sg10
I3
sg11
VRP1
p11202
sg13
I1
sasg14
(lp11203
(dp11204
g7
I46
sg17
VC0220701
p11205
sg10
I3
sg11
VRP1
p11206
sg13
I1
sa(dp11207
g7
I120
sg17
VC0524851
p11208
sg10
I26
sg11
Vneurodegenerative diseases
p11209
sg13
I2
sa(dp11210
g7
I68
sg17
VC0035304
p11211
sg10
I20
sg11
Vretinal degeneration
p11212
sg13
I2
sasa(dp11213
g2
VOur objective was to determine the ethical options of Paediatric Intensive Care Unit (PICU) paediatricians as regards a child with SMA-1 and respiratory failure.
p11214
sg4
(lp11215
(dp11216
g7
I131
sg8
g24
sg10
I5
sg11
VSMA-1
p11217
sg13
I1
sasg14
(lp11218
(dp11219
g7
I141
sg17
VC1145670
p11220
sg10
I19
sg11
Vrespiratory failure
p11221
sg13
I2
sa(dp11222
g7
I131
sg17
VC0026847
p11223
sg10
I3
sg11
VSMA
p11224
sg13
I1
sasa(dp11225
g2
VFaced with child with SMA-1 and respiratory failure, most paediatricians are in favour of initiating NIV and LET when such support is insufficient, but they would accept the family's decision, even in case of disagreement.
p11226
sg4
(lp11227
(dp11228
g7
I22
sg8
g24
sg10
I5
sg11
VSMA-1
p11229
sg13
I1
sasg14
(lp11230
(dp11231
g7
I22
sg17
VC0026847
p11232
sg10
I3
sg11
VSMA
p11233
sg13
I1
sa(dp11234
g7
I32
sg17
VC1145670
p11235
sg10
I19
sg11
Vrespiratory failure
p11236
sg13
I2
sasa(dp11237
g2
VA scenario of acute respiratory failure in an infant with SMA-1 has been included in a training program using advanced simulation for Primary Care pediatricians (PCP).
p11238
sg4
(lp11239
(dp11240
g7
I58
sg8
g24
sg10
I5
sg11
VSMA-1
p11241
sg13
I1
sasg14
(lp11242
(dp11243
g7
I58
sg17
VC0026847
p11244
sg10
I3
sg11
VSMA
p11245
sg13
I1
sa(dp11246
g7
I134
sg17
VC2919094
p11247
sg10
I26
sg11
VPrimary Care pediatricians
p11248
sg13
I3
sa(dp11249
g7
I162
sg17
VC2919094
p11250
sg10
I3
sg11
VPCP
p11251
sg13
I1
sa(dp11252
g7
I14
sg17
VC0264490
p11253
sg10
I25
sg11
Vacute respiratory failure
p11254
sg13
I3
sasa(dp11255
g2
VWhen faced with a simulated SMA-1 infant with respiratory failure, PCP have difficulties in interacting with the family, and to involve it in the decision making process.
p11256
sg4
(lp11257
sg14
(lp11258
(dp11259
g7
I67
sg17
VC2919094
p11260
sg10
I3
sg11
VPCP
p11261
sg13
I1
sa(dp11262
g7
I46
sg17
VC1145670
p11263
sg10
I19
sg11
Vrespiratory failure
p11264
sg13
I2
sa(dp11265
g7
I28
sg17
VC0026847
p11266
sg10
I3
sg11
VSMA
p11267
sg13
I1
sasa(dp11268
g2
VTREX1 acts in concert with the SET complex in granzyme A-mediated apoptosis, and mutations in TREX1 cause Aicardi-Goutieres syndrome and familial chilblain lupus.
p11269
sg4
(lp11270
(dp11271
g7
I0
sg8
g24
sg10
I5
sg11
VTREX1
p11272
sg13
I1
sa(dp11273
g7
I0
sg8
g24
sg10
I5
sg11
VTREX1
p11274
sg13
I1
sasg14
(lp11275
(dp11276
g7
I146
sg17
VC0024145
p11277
sg10
I15
sg11
Vchilblain lupus
p11278
sg13
I2
sa(dp11279
g7
I106
sg17
VC0796126
p11280
sg10
I26
sg11
VAicardi-Goutieres syndrome
p11281
sg13
I2
sasa(dp11282
g2
VLymphoblastoid cells carrying the D18N mutation are significantly less sensitive to granzyme A-mediated cell death, suggesting a novel role for this caspase-independent form of apoptosis in the pathogenesis of familial chilblain lupus.
p11283
sg4
(lp11284
(dp11285
g7
I149
sg8
VP39880
p11286
sg10
I7
sg11
Vcaspase
p11287
sg13
I1
sasg14
(lp11288
(dp11289
g7
I194
sg17
VC0699748
p11290
sg10
I12
sg11
Vpathogenesis
p11291
sg13
I1
sa(dp11292
g7
I219
sg17
VC0024145
p11293
sg10
I15
sg11
Vchilblain lupus
p11294
sg13
I2
sasa(dp11295
g2
VA recent article explored protective modifiers, including plastin 3 (PLS3) and coronin 1C (CORO1C), in spinal muscular atrophy (SMA).
p11296
sg4
(lp11297
(dp11298
g7
I58
sg8
VP13797
p11299
sg10
I9
sg11
Vplastin 3
p11300
sg13
I2
sa(dp11301
g7
I69
sg8
VP13797
p11302
sg10
I4
sg11
VPLS3
p11303
sg13
I1
sa(dp11304
g7
I79
sg8
g24
sg10
I10
sg11
Vcoronin 1C
p11305
sg13
I2
sa(dp11306
g7
I91
sg8
g24
sg10
I6
sg11
VCORO1C
p11307
sg13
I1
sasg14
(lp11308
(dp11309
g7
I103
sg17
VC0026847
p11310
sg10
I23
sg11
Vspinal muscular atrophy
p11311
sg13
I3
sa(dp11312
g7
I128
sg17
VC0026847
p11313
sg10
I3
sg11
VSMA
p11314
sg13
I1
sasa(dp11315
g2
VHowever, the expression of CYP26C1, another CYP26 family member, in primary breast carcinoma remains to be clarified.
p11316
sg4
(lp11317
(dp11318
g7
I44
sg8
g24
sg10
I19
sg11
VCYP26 family member
p11319
sg13
I3
sa(dp11320
g7
I27
sg8
g24
sg10
I7
sg11
VCYP26C1
p11321
sg13
I1
sasg14
(lp11322
(dp11323
g7
I76
sg17
VC0678222
p11324
sg10
I16
sg11
Vbreast carcinoma
p11325
sg13
I2
sasa(dp11326
g2
VIn the present study, we examined the expression of CYP26C1 by immunohistochemistry, using three different types of microarray, and observed strong cytoplasmic staining of CYP26C1 in 73 of the 219 (33.3 %) breast carcinomas.
p11327
sg4
(lp11328
(dp11329
g7
I52
sg8
g24
sg10
I7
sg11
VCYP26C1
p11330
sg13
I1
sa(dp11331
g7
I52
sg8
g24
sg10
I7
sg11
VCYP26C1
p11332
sg13
I1
sasg14
(lp11333
(dp11334
g7
I206
sg17
VC0678222
p11335
sg10
I17
sg11
Vbreast carcinomas
p11336
sg13
I2
sasa(dp11337
g2
VIn addition, CYP26C1 positivity was independent of the expression status of the hormone receptors and immunohistochemical surrogates for the intrinsic subtypes of breast cancer.
p11338
sg4
(lp11339
(dp11340
g7
I13
sg8
g24
sg10
I7
sg11
VCYP26C1
p11341
sg13
I1
sasg14
(lp11342
(dp11343
g7
I163
sg17
VC0678222
p11344
sg10
I13
sg11
Vbreast cancer
p11345
sg13
I2
sasa(dp11346
g2
VThis report is the first to demonstrate elevated expression of CYP26C1 in primary breast carcinomas.
p11347
sg4
(lp11348
(dp11349
g7
I63
sg8
g24
sg10
I7
sg11
VCYP26C1
p11350
sg13
I1
sasg14
(lp11351
(dp11352
g7
I82
sg17
VC0678222
p11353
sg10
I17
sg11
Vbreast carcinomas
p11354
sg13
I2
sasa(dp11355
g2
VIn the present study we chose to investigate 7 genes involved in the synthesis, degradation and transportation of RA, ALDH1A1, ALDH1A2, ALDH1A3, CYP26A1, CYP26B1, CYP26C1 and Transthyretin (TTR), for their roles in the development of schizophrenia.
p11356
sg4
(lp11357
(dp11358
g7
I136
sg8
VP47895
p11359
sg10
I7
sg11
VALDH1A3
p11360
sg13
I1
sa(dp11361
g7
I190
sg8
VP02766
p11362
sg10
I3
sg11
VTTR
p11363
sg13
I1
sa(dp11364
g7
I175
sg8
VP02766
p11365
sg10
I13
sg11
VTransthyretin
p11366
sg13
I1
sa(dp11367
g7
I163
sg8
g24
sg10
I7
sg11
VCYP26C1
p11368
sg13
I1
sa(dp11369
g7
I154
sg8
g24
sg10
I7
sg11
VCYP26B1
p11370
sg13
I1
sa(dp11371
g7
I145
sg8
g24
sg10
I7
sg11
VCYP26A1
p11372
sg13
I1
sa(dp11373
g7
I127
sg8
g24
sg10
I7
sg11
VALDH1A2
p11374
sg13
I1
sa(dp11375
g7
I118
sg8
VP00352
p11376
sg10
I7
sg11
VALDH1A1
p11377
sg13
I1
sasg14
(lp11378
(dp11379
g7
I234
sg17
VC0036341
p11380
sg10
I13
sg11
Vschizophrenia
p11381
sg13
I1
sasa(dp11382
g2
VThe index of low SIRT1 and high MMP2 respectively correlated with patients history of MI (p=0.3, p=0.01) and marginally with presence or history of atrial fibrillation (AF) (p=0.213, p=0.076).
p11383
sg4
(lp11384
(dp11385
g7
I17
sg8
g24
sg10
I5
sg11
VSIRT1
p11386
sg13
I1
sasg14
(lp11387
(dp11388
g7
I148
sg17
VC0004238
p11389
sg10
I19
sg11
Vatrial fibrillation
p11390
sg13
I2
sa(dp11391
g7
I169
sg17
VC0004238
p11392
sg10
I2
sg11
VAF
p11393
sg13
I1
sasa(dp11394
g2
VBACKGROUND To examine changes of mRNA and protein expressions of MMP-2, Bcl-2, and BAX in atrial fibrillation (AF) patients, and investigate the correlations among these 3 biomarkers.
p11395
sg4
(lp11396
(dp11397
g7
I65
sg8
VP08253
p11398
sg10
I5
sg11
VMMP-2
p11399
sg13
I1
sa(dp11400
g7
I72
sg8
VP10415
p11401
sg10
I5
sg11
VBcl-2
p11402
sg13
I1
sasg14
(lp11403
(dp11404
g7
I90
sg17
VC0004238
p11405
sg10
I19
sg11
Vatrial fibrillation
p11406
sg13
I2
sa(dp11407
g7
I111
sg17
VC0004238
p11408
sg10
I2
sg11
VAF
p11409
sg13
I1
sasa(dp11410
g2
VIn conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.
p11411
sg4
(lp11412
(dp11413
g7
I29
sg8
g24
sg10
I6
sg11
VKcnj16
p11414
sg13
I1
sasg14
(lp11415
(dp11416
g7
I147
sg17
VC2748572
p11417
sg10
I13
sg11
VEAST syndrome
p11418
sg13
I2
sasa(dp11419
g2
VWe investigated the localization of KCNJ10 and the homologous KCNJ16 in kidney and the functional consequences of KCNJ10 mutations found in our patients with EAST syndrome.
p11420
sg4
(lp11421
(dp11422
g7
I62
sg8
g24
sg10
I6
sg11
VKCNJ16
p11423
sg13
I1
sa(dp11424
g7
I36
sg8
VP78508
p11425
sg10
I6
sg11
VKCNJ10
p11426
sg13
I1
sa(dp11427
g7
I114
sg8
VP78508
p11428
sg10
I16
sg11
VKCNJ10 mutations
p11429
sg13
I2
sasg14
(lp11430
(dp11431
g7
I158
sg17
VC2748572
p11432
sg10
I13
sg11
VEAST syndrome
p11433
sg13
I2
sasa(dp11434
g2
VToxin C13S1C1 was also cytotoxic against breast adenocarcinoma MDA-MB-231 cells (LC50 = 62+/-2myg/ml) and colorectal adenocarcinoma HT-29 cells (LC50 = 110+/-4myg/ml).
p11435
sg4
(lp11436
(dp11437
g7
I0
sg8
g24
sg10
I5
sg11
VToxin
p11438
sg13
I1
sasg14
(lp11439
(dp11440
g7
I106
sg17
VC1319315
p11441
sg10
I25
sg11
Vcolorectal adenocarcinoma
p11442
sg13
I2
sa(dp11443
g7
I41
sg17
VC0858252
p11444
sg10
I21
sg11
Vbreast adenocarcinoma
p11445
sg13
I2
sasa(dp11446
g2
VWe report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.
p11447
sg4
(lp11448
(dp11449
g7
I248
sg8
VP06401
p11450
sg10
I22
sg11
Vprogesterone receptors
p11451
sg13
I2
sa(dp11452
g7
I280
sg8
VP04626
p11453
sg10
I3
sg11
Vneu
p11454
sg13
I1
sa(dp11455
g7
I275
sg8
VP04626
p11456
sg10
I4
sg11
VHer2
p11457
sg13
I1
sasg14
(lp11458
(dp11459
g7
I38
sg17
VC1335320
p11460
sg10
I33
sg11
Vpapillary carcinoma of the breast
p11461
sg13
I5
sa(dp11462
g7
I188
sg17
VC0332448
p11463
sg10
I10
sg11
Vinfiltrate
p11464
sg13
I1
sasa(dp11465
g2
VMoreover, Sec24bY613 genetically interacts with a loss-of-function Vangl2 allele (Vangl2LP), causing a marked increase in the prevalence of spina bifida.
p11466
sg4
(lp11467
(dp11468
g7
I67
sg8
g24
sg10
I13
sg11
VVangl2 allele
p11469
sg13
I2
sasg14
(lp11470
(dp11471
g7
I140
sg17
VC0080178
p11472
sg10
I12
sg11
Vspina bifida
p11473
sg13
I2
sasa(dp11474
g2
VThe overall goal of TASK2 of the AES/ILAE Translational Task Force is to organize and coordinate systematic reviews on selected topics regarding animal research in epilepsy.
p11475
sg4
(lp11476
(dp11477
g7
I20
sg8
g24
sg10
I5
sg11
VTASK2
p11478
sg13
I1
sasg14
(lp11479
(dp11480
g7
I164
sg17
VC0014544
p11481
sg10
I8
sg11
Vepilepsy
p11482
sg13
I1
sasa(dp11483
g2
VK2P 5.1 channels (also called TASK-2 or Kcnk5) have already been shown to be relevant in the pathophysiology of autoimmune disease because they are known to be upregulated on peripheral and central T lymphocytes of multiple sclerosis (MS) patients.
p11484
sg4
(lp11485
(dp11486
g7
I0
sg8
g24
sg10
I16
sg11
VK2P 5.1 channels
p11487
sg13
I3
sa(dp11488
g7
I40
sg8
g24
sg10
I5
sg11
VKcnk5
p11489
sg13
I1
sa(dp11490
g7
I30
sg8
g24
sg10
I6
sg11
VTASK-2
p11491
sg13
I1
sasg14
(lp11492
(dp11493
g7
I235
sg17
VC0026769
p11494
sg10
I2
sg11
VMS
p11495
sg13
I1
sa(dp11496
g7
I112
sg17
VC0004364
p11497
sg10
I18
sg11
Vautoimmune disease
p11498
sg13
I2
sa(dp11499
g7
I215
sg17
VC0026769
p11500
sg10
I18
sg11
Vmultiple sclerosis
p11501
sg13
I2
sasa(dp11502
g2
VRecent studies have indicated the impact of K2P5.1 upregulation in T lymphocytes on the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
p11503
sg4
(lp11504
(dp11505
g7
I44
sg8
g24
sg10
I6
sg11
VK2P5.1
p11506
sg13
I1
sasg14
(lp11507
(dp11508
g7
I157
sg17
VC0026769
p11509
sg10
I18
sg11
Vmultiple sclerosis
p11510
sg13
I2
sa(dp11511
g7
I132
sg17
VC0003873
p11512
sg10
I20
sg11
Vrheumatoid arthritis
p11513
sg13
I2
sa(dp11514
g7
I88
sg17
VC0699748
p11515
sg10
I12
sg11
Vpathogenesis
p11516
sg13
I1
sa(dp11517
g7
I104
sg17
VC0004364
p11518
sg10
I19
sg11
Vautoimmune diseases
p11519
sg13
I2
sasa(dp11520
g2
VSo far KCNK5 has been described to be up-regulated in T cells in multiple sclerosis patients and to be implicated in the volume regulatory mechanism regulatory volume decrease (RVD) in T cells.
p11521
sg4
(lp11522
(dp11523
g7
I7
sg8
g24
sg10
I5
sg11
VKCNK5
p11524
sg13
I1
sasg14
(lp11525
(dp11526
g7
I65
sg17
VC0026769
p11527
sg10
I18
sg11
Vmultiple sclerosis
p11528
sg13
I2
sasa(dp11529
g2
VRecent studies highlighted the potential role of the K2P5.1 K(+) channel in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
p11530
sg4
(lp11531
(dp11532
g7
I53
sg8
g24
sg10
I8
sg11
VK2P5.1 K
p11533
sg13
I2
sasg14
(lp11534
(dp11535
g7
I96
sg17
VC0004364
p11536
sg10
I19
sg11
Vautoimmune diseases
p11537
sg13
I2
sa(dp11538
g7
I149
sg17
VC0026769
p11539
sg10
I18
sg11
Vmultiple sclerosis
p11540
sg13
I2
sa(dp11541
g7
I80
sg17
VC0699748
p11542
sg10
I12
sg11
Vpathogenesis
p11543
sg13
I1
sa(dp11544
g7
I124
sg17
VC0003873
p11545
sg10
I20
sg11
Vrheumatoid arthritis
p11546
sg13
I2
sasa(dp11547
g2
VExpression levels of K2P5.1 (TASK2; KCNK5) channels belonging to the family of two-pore domain potassium channels have previously been correlated to the activity of autoreactive T lymphocytes in patients with multiple sclerosis and rheumatoid arthritis.
p11548
sg4
(lp11549
(dp11550
g7
I21
sg8
g24
sg10
I6
sg11
VK2P5.1
p11551
sg13
I1
sa(dp11552
g7
I29
sg8
g24
sg10
I5
sg11
VTASK2
p11553
sg13
I1
sa(dp11554
g7
I36
sg8
g24
sg10
I5
sg11
VKCNK5
p11555
sg13
I1
sasg14
(lp11556
(dp11557
g7
I209
sg17
VC0026769
p11558
sg10
I18
sg11
Vmultiple sclerosis
p11559
sg13
I2
sa(dp11560
g7
I232
sg17
VC0003873
p11561
sg10
I20
sg11
Vrheumatoid arthritis
p11562
sg13
I2
sasa(dp11563
g2
VThus, we evaluated the effect of serum availability on the expression of commonly used HKG (ACTB, B2M, GAPDH, GUSB, HPRT1, IPO8, MRPL19, PGK1, PPIA, RPLP0, RPS23, SDHA, TBP, UBC, and YWHAZ) in seven colon adenocarcinoma cell lines (Caco-2, DLD-1, HCT116, HT29, Lovo, SW480, and SW620).
p11564
sg4
(lp11565
(dp11566
g7
I110
sg8
VP08236
p11567
sg10
I4
sg11
VGUSB
p11568
sg13
I1
sa(dp11569
g7
I98
sg8
VP61769
p11570
sg10
I3
sg11
VB2M
p11571
sg13
I1
sa(dp11572
g7
I123
sg8
g24
sg10
I4
sg11
VIPO8
p11573
sg13
I1
sa(dp11574
g7
I169
sg8
VP20226
p11575
sg10
I3
sg11
VTBP
p11576
sg13
I1
sa(dp11577
g7
I240
sg8
VP98173
p11578
sg10
I5
sg11
VDLD-1
p11579
sg13
I1
sa(dp11580
g7
I137
sg8
VP00558
p11581
sg10
I4
sg11
VPGK1
p11582
sg13
I1
sa(dp11583
g7
I103
sg8
VP04406
p11584
sg10
I5
sg11
VGAPDH
p11585
sg13
I1
sa(dp11586
g7
I156
sg8
VP62266
p11587
sg10
I5
sg11
VRPS23
p11588
sg13
I1
sa(dp11589
g7
I92
sg8
VP63261
p11590
sg10
I4
sg11
VACTB
p11591
sg13
I1
sa(dp11592
g7
I149
sg8
VP05388
p11593
sg10
I5
sg11
VRPLP0
p11594
sg13
I1
sa(dp11595
g7
I143
sg8
VP62937
p11596
sg10
I4
sg11
VPPIA
p11597
sg13
I1
sa(dp11598
g7
I116
sg8
VP55884
p11599
sg10
I5
sg11
VHPRT1
p11600
sg13
I1
sa(dp11601
g7
I129
sg8
VP49406
p11602
sg10
I6
sg11
VMRPL19
p11603
sg13
I1
sa(dp11604
g7
I163
sg8
VP31040
p11605
sg10
I4
sg11
VSDHA
p11606
sg13
I1
sa(dp11607
g7
I174
sg8
g24
sg10
I3
sg11
VUBC
p11608
sg13
I1
sasg14
(lp11609
(dp11610
g7
I199
sg17
VC0338106
p11611
sg10
I20
sg11
Vcolon adenocarcinoma
p11612
sg13
I2
sasa(dp11613
g2
VWe investigated whether the expression of PGK1 varies between metastatic and non-metastatic colon cancer.
p11614
sg4
(lp11615
(dp11616
g7
I42
sg8
VP00558
p11617
sg10
I4
sg11
VPGK1
p11618
sg13
I1
sasg14
(lp11619
(dp11620
g7
I81
sg17
VC0278484
p11621
sg10
I23
sg11
Vmetastatic colon cancer
p11622
sg13
I3
sasa(dp11623
g2
VWe compared PGK1 expression in colon cancer patients either with or without metastasis via polymerase chain reaction (PCR) and immunohistochemistry.
p11624
sg4
(lp11625
(dp11626
g7
I12
sg8
VP00558
p11627
sg10
I4
sg11
VPGK1
p11628
sg13
I1
sasg14
(lp11629
(dp11630
g7
I31
sg17
VC0699790
p11631
sg10
I12
sg11
Vcolon cancer
p11632
sg13
I2
sa(dp11633
g7
I76
sg17
VC0027627
p11634
sg10
I10
sg11
Vmetastasis
p11635
sg13
I1
sasa(dp11636
g2
VPCR results showed an increased expression of PGK1 in colon cancer tissue from metastatic patients in comparison to patients with no metastasis (fold change 2.6, p&lt;0.001).
p11637
sg4
(lp11638
(dp11639
g7
I46
sg8
VP00558
p11640
sg10
I4
sg11
VPGK1
p11641
sg13
I1
sasg14
(lp11642
(dp11643
g7
I133
sg17
VC0027627
p11644
sg10
I10
sg11
Vmetastasis
p11645
sg13
I1
sa(dp11646
g7
I54
sg17
VC0699790
p11647
sg10
I12
sg11
Vcolon cancer
p11648
sg13
I2
sasa(dp11649
g2
VThe results indicate that increased expression of PGK1 in colon cancer tissue is associated with metastasis.
p11650
sg4
(lp11651
(dp11652
g7
I50
sg8
VP00558
p11653
sg10
I4
sg11
VPGK1
p11654
sg13
I1
sasg14
(lp11655
(dp11656
g7
I58
sg17
VC0699790
p11657
sg10
I12
sg11
Vcolon cancer
p11658
sg13
I2
sa(dp11659
g7
I97
sg17
VC0027627
p11660
sg10
I10
sg11
Vmetastasis
p11661
sg13
I1
sasa(dp11662
g2
VTYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
p11663
sg4
(lp11664
(dp11665
g7
I9
sg8
VP00558
p11666
sg10
I4
sg11
VPGK1
p11667
sg13
I1
sa(dp11668
g7
I9
sg8
VP00558
p11669
sg10
I4
sg11
VPGK1
p11670
sg13
I1
sa(dp11671
g7
I0
sg8
VP04818
p11672
sg10
I4
sg11
VTYMS
p11673
sg13
I1
sa(dp11674
g7
I118
sg8
VP30486
p11675
sg10
I9
sg11
VHLA-A2(+)
p11676
sg13
I1
sa(dp11677
g7
I0
sg8
VP04818
p11678
sg10
I4
sg11
VTYMS
p11679
sg13
I1
sasg14
(lp11680
(dp11681
g7
I128
sg17
VC0699790
p11682
sg10
I12
sg11
Vcolon cancer
p11683
sg13
I2
sa(dp11684
g7
I252
sg17
VC0027651
p11685
sg10
I5
sg11
Vtumor
p11686
sg13
I1
sasa(dp11687
g2
VIn one sample we sequenced 7231 contiguous base pairs that covered completely the region from the 5'end of the 16S rRNA gene to the 5'end of the 23S rRNA gene comprising the whole 16S rRNA (rrs), and the following genes: Ala tRNA (alaT), Ile tRNA (ileT), adenylosuccinate lyase (purB), adenylosuccinate synthetase (purA), methylpurine-DNA glycosylase (mag), hypoxanthine-guanine phosphoribosyltransferase (hpt), an hydrolase (HAD superfamily) and a 135 bp 5' fragment of the 23S rRNA (rrlA) genes.
p11688
sg4
(lp11689
(dp11690
g7
I315
sg8
g24
sg10
I4
sg11
VpurA
p11691
sg13
I1
sa(dp11692
g7
I352
sg8
VP20916
p11693
sg10
I3
sg11
Vmag
p11694
sg13
I1
sa(dp11695
g7
I279
sg8
g24
sg10
I4
sg11
VpurB
p11696
sg13
I1
sa(dp11697
g7
I322
sg8
g24
sg10
I28
sg11
Vmethylpurine-DNA glycosylase
p11698
sg13
I2
sa(dp11699
g7
I255
sg8
VP30566
p11700
sg10
I22
sg11
Vadenylosuccinate lyase
p11701
sg13
I2
sa(dp11702
g7
I406
sg8
VP00738
p11703
sg10
I3
sg11
Vhpt
p11704
sg13
I1
sa(dp11705
g7
I221
sg8
VP00709
p11706
sg10
I25
sg11
VAla tRNA (alaT), Ile tRNA
p11707
sg13
I5
sa(dp11708
g7
I190
sg8
VP49788
p11709
sg10
I3
sg11
Vrrs
p11710
sg13
I1
sa(dp11711
g7
I475
sg8
VP01893
p11712
sg10
I21
sg11
V23S rRNA (rrlA) genes
p11713
sg13
I4
sa(dp11714
g7
I286
sg8
VP30520
p11715
sg10
I27
sg11
Vadenylosuccinate synthetase
p11716
sg13
I2
sa(dp11717
g7
I358
sg8
VP00492
p11718
sg10
I46
sg11
Vhypoxanthine-guanine phosphoribosyltransferase
p11719
sg13
I2
sasg14
(lp11720
(dp11721
g7
I190
sg17
VC1849334
p11722
sg10
I3
sg11
Vrrs
p11723
sg13
I1
sasa(dp11724
g2
VAdditionally, NOLC1 expression was decreased in human hepatocellular carcinoma (HCC) tissue, and the ectopic expression of NOLC1 repressed the proliferation of HCC cells and tumor growth in a HCC xenograft model.
p11725
sg4
(lp11726
(dp11727
g7
I14
sg8
g24
sg10
I5
sg11
VNOLC1
p11728
sg13
I1
sa(dp11729
g7
I14
sg8
g24
sg10
I5
sg11
VNOLC1
p11730
sg13
I1
sasg14
(lp11731
(dp11732
g7
I174
sg17
VC0598934
p11733
sg10
I12
sg11
Vtumor growth
p11734
sg13
I2
sa(dp11735
g7
I80
sg17
VC2239176
p11736
sg10
I3
sg11
VHCC
p11737
sg13
I1
sa(dp11738
g7
I143
sg17
VC0334094
p11739
sg10
I13
sg11
Vproliferation
p11740
sg13
I1
sa(dp11741
g7
I80
sg17
VC2239176
p11742
sg10
I3
sg11
VHCC
p11743
sg13
I1
sa(dp11744
g7
I80
sg17
VC2239176
p11745
sg10
I3
sg11
VHCC
p11746
sg13
I1
sa(dp11747
g7
I54
sg17
VC2239176
p11748
sg10
I24
sg11
Vhepatocellular carcinoma
p11749
sg13
I2
sasa(dp11750
g2
VCUL3(KBTBD8) monoubiquitylates NOLC1 and its paralogue TCOF1, the mutation of which underlies the neurocristopathy Treacher Collins syndrome.
p11751
sg4
(lp11752
(dp11753
g7
I5
sg8
g24
sg10
I6
sg11
VKBTBD8
p11754
sg13
I1
sa(dp11755
g7
I0
sg8
g24
sg10
I4
sg11
VCUL3
p11756
sg13
I1
sa(dp11757
g7
I55
sg8
g24
sg10
I5
sg11
VTCOF1
p11758
sg13
I1
sa(dp11759
g7
I31
sg8
g24
sg10
I5
sg11
VNOLC1
p11760
sg13
I1
sasg14
(lp11761
(dp11762
g7
I115
sg17
VC0242387
p11763
sg10
I25
sg11
VTreacher Collins syndrome
p11764
sg13
I3
sasa(dp11765
g2
VTreacher Collins syndrome (TCS), a representative human ribosomopathy with craniofacial abnormalities, is attributed to mutations in the tcof1 gene that has a homologous gene called nopp140.
p11766
sg4
(lp11767
(dp11768
g7
I137
sg8
g24
sg10
I10
sg11
Vtcof1 gene
p11769
sg13
I2
sa(dp11770
g7
I182
sg8
g24
sg10
I7
sg11
Vnopp140
p11771
sg13
I1
sasg14
(lp11772
(dp11773
g7
I27
sg17
VC0242387
p11774
sg10
I3
sg11
VTCS
p11775
sg13
I1
sa(dp11776
g7
I0
sg17
VC0242387
p11777
sg10
I25
sg11
VTreacher Collins syndrome
p11778
sg13
I3
sa(dp11779
g7
I75
sg17
VC0376634
p11780
sg10
I26
sg11
Vcraniofacial abnormalities
p11781
sg13
I2
sasa(dp11782
g2
VPrevious studies suggest that NOLC1 is crucial for normal cell growth, and plays a role in the regulation of tumorigenesis of nasopharyngeal carcinoma (NPC) and demonstrate that both NOLC1 and tumor protein 53 work synergistically to activate the MDM2 promoter in NPC cells.
p11783
sg4
(lp11784
(dp11785
g7
I30
sg8
g24
sg10
I5
sg11
VNOLC1
p11786
sg13
I1
sa(dp11787
g7
I30
sg8
g24
sg10
I5
sg11
VNOLC1
p11788
sg13
I1
sasg14
(lp11789
(dp11790
g7
I109
sg17
VC0007621
p11791
sg10
I13
sg11
Vtumorigenesis
p11792
sg13
I1
sa(dp11793
g7
I126
sg17
VC2931822
p11794
sg10
I24
sg11
Vnasopharyngeal carcinoma
p11795
sg13
I2
sa(dp11796
g7
I152
sg17
VC2931822
p11797
sg10
I3
sg11
VNPC
p11798
sg13
I1
sa(dp11799
g7
I152
sg17
VC2931822
p11800
sg10
I3
sg11
VNPC
p11801
sg13
I1
sa(dp11802
g7
I109
sg17
VC0027651
p11803
sg10
I5
sg11
Vtumor
p11804
sg13
I1
sasa(dp11805
g2
VYet, the functioning of NOLC1 in liver cancer remains unknown.
p11806
sg4
(lp11807
(dp11808
g7
I24
sg8
g24
sg10
I5
sg11
VNOLC1
p11809
sg13
I1
sasg14
(lp11810
(dp11811
g7
I33
sg17
VC0345904
p11812
sg10
I12
sg11
Vliver cancer
p11813
sg13
I2
sasa(dp11814
g2
VIn this study, we showed that NOLC1 was silenced or downregulated in liver tumor tissues when compared with that in the matched non-cancer tissues.
p11815
sg4
(lp11816
(dp11817
g7
I30
sg8
g24
sg10
I5
sg11
VNOLC1
p11818
sg13
I1
sasg14
(lp11819
(dp11820
g7
I69
sg17
VC0023903
p11821
sg10
I11
sg11
Vliver tumor
p11822
sg13
I2
sa(dp11823
g7
I132
sg17
VC0006826
p11824
sg10
I6
sg11
Vcancer
p11825
sg13
I1
sasa(dp11826
g2
VLow expression of NOLC1 in hepatoma cell lines and liver cancer tissues was associated with cyclin D3.
p11827
sg4
(lp11828
(dp11829
g7
I92
sg8
VP30281
p11830
sg10
I9
sg11
Vcyclin D3
p11831
sg13
I2
sa(dp11832
g7
I18
sg8
g24
sg10
I5
sg11
VNOLC1
p11833
sg13
I1
sasg14
(lp11834
(dp11835
g7
I27
sg17
VC0023903
p11836
sg10
I8
sg11
Vhepatoma
p11837
sg13
I1
sa(dp11838
g7
I51
sg17
VC0345904
p11839
sg10
I12
sg11
Vliver cancer
p11840
sg13
I2
sasa(dp11841
g2
VIn conclusion, our study demonstrated that DNA methylation is a key mechanism of silenced NOLC1 expression in human hepatocellular carcinoma cells, and NOLC1 gene hypermethylation of the four CpG dinucleotides is a potential biomarker for hepatocellular carcinoma.
p11842
sg4
(lp11843
(dp11844
g7
I152
sg8
g24
sg10
I10
sg11
VNOLC1 gene
p11845
sg13
I2
sa(dp11846
g7
I90
sg8
g24
sg10
I5
sg11
VNOLC1
p11847
sg13
I1
sasg14
(lp11848
(dp11849
g7
I116
sg17
VC1512411
p11850
sg10
I24
sg11
Vhepatocellular carcinoma
p11851
sg13
I2
sa(dp11852
g7
I116
sg17
VC1512411
p11853
sg10
I24
sg11
Vhepatocellular carcinoma
p11854
sg13
I2
sasa(dp11855
g2
VSevere combined immunodeficiency mice bearing NPC xenografts derived from NOLC1-short hairpin-RNA-transfected animals were found to have 82% lower levels of tumor growth than control mice as well as marked tumor cell apoptosis.
p11856
sg4
(lp11857
(dp11858
g7
I74
sg8
g24
sg10
I5
sg11
VNOLC1
p11859
sg13
I1
sasg14
(lp11860
(dp11861
g7
I157
sg17
VC0598934
p11862
sg10
I12
sg11
Vtumor growth
p11863
sg13
I2
sa(dp11864
g7
I0
sg17
VC0085110
p11865
sg10
I32
sg11
VSevere combined immunodeficiency
p11866
sg13
I3
sa(dp11867
g7
I157
sg17
VC0027651
p11868
sg10
I5
sg11
Vtumor
p11869
sg13
I1
sa(dp11870
g7
I46
sg17
VC2931822
p11871
sg10
I3
sg11
VNPC
p11872
sg13
I1
sasa(dp11873
g2
VThe aim of the study was to examine the effects of endurance exercise on circulating vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p11874
sg4
(lp11875
(dp11876
g7
I133
sg8
VP05362
p11877
sg10
I33
sg11
Vintercellular adhesion molecule-1
p11878
sg13
I3
sa(dp11879
g7
I85
sg8
VP19320
p11880
sg10
I33
sg11
Vvascular cell adhesion molecule-1
p11881
sg13
I4
sasg14
(lp11882
(dp11883
g7
I180
sg17
VC0037054
p11884
sg10
I17
sg11
Vsickle cell trait
p11885
sg13
I3
sa(dp11886
g7
I199
sg17
VC1848934
p11887
sg10
I3
sg11
VSCT
p11888
sg13
I1
sa(dp11889
g7
I99
sg17
VC0001511
p11890
sg10
I8
sg11
Vadhesion
p11891
sg13
I1
sa(dp11892
g7
I99
sg17
VC0001511
p11893
sg10
I8
sg11
Vadhesion
p11894
sg13
I1
sa(dp11895
g7
I229
sg17
VC0002312
p11896
sg10
I17
sg11
Valpha-thalassemia
p11897
sg13
I1
sasa(dp11898
g2
VThe aim of the study was to examine the effects of exercise on soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p11899
sg4
(lp11900
(dp11901
g7
I119
sg8
VP05362
p11902
sg10
I33
sg11
Vintercellular adhesion molecule-1
p11903
sg13
I3
sa(dp11904
g7
I71
sg8
VP19320
p11905
sg10
I33
sg11
Vvascular cell adhesion molecule-1
p11906
sg13
I4
sasg14
(lp11907
(dp11908
g7
I85
sg17
VC0001511
p11909
sg10
I8
sg11
Vadhesion
p11910
sg13
I1
sa(dp11911
g7
I85
sg17
VC0001511
p11912
sg10
I8
sg11
Vadhesion
p11913
sg13
I1
sa(dp11914
g7
I215
sg17
VC0002312
p11915
sg10
I17
sg11
Valpha-thalassemia
p11916
sg13
I1
sa(dp11917
g7
I166
sg17
VC0037054
p11918
sg10
I17
sg11
Vsickle cell trait
p11919
sg13
I3
sa(dp11920
g7
I185
sg17
VC1848934
p11921
sg10
I3
sg11
VSCT
p11922
sg13
I1
sasa(dp11923
g2
VAs compared to normal, increased sICAM-1 was found in beta-thal/HbE patients with non-splenectomy; BE-NS (p = 0.002), increased ELAM-1 in beta-thal/HbE patients with splenectomy; BE-S (p = 0.01) and HbH with Hb Constant Spring; HbH/CS (p = 0.001), and increased sVCAM-1 in BE-NS; (p = &lt; 0.0001) and BE-S (p = 0.002).
p11924
sg4
(lp11925
(dp11926
g7
I64
sg8
VP02100
p11927
sg10
I3
sg11
VHbE
p11928
sg13
I1
sa(dp11929
g7
I128
sg8
VP16581
p11930
sg10
I6
sg11
VELAM-1
p11931
sg13
I1
sa(dp11932
g7
I208
sg8
g24
sg10
I18
sg11
VHb Constant Spring
p11933
sg13
I3
sasg14
(lp11934
(dp11935
g7
I199
sg17
VC3161174
p11936
sg10
I3
sg11
VHbH
p11937
sg13
I1
sa(dp11938
g7
I199
sg17
VC3161174
p11939
sg10
I3
sg11
VHbH
p11940
sg13
I1
sasa(dp11941
g2
VFurthermore, treatment with AST or DEX significantly suppressed the mRNA and protein expression levels of the transcription factor GATA-3 and retinoic acid receptor-related orphan nuclear receptor (ROR)Gammat in tissue samples isolated from the spleen and nasal mucosa of mice with allergic rhinitis.
p11942
sg4
(lp11943
(dp11944
g7
I173
sg8
VP51843
p11945
sg10
I23
sg11
Vorphan nuclear receptor
p11946
sg13
I3
sa(dp11947
g7
I110
sg8
VP23771
p11948
sg10
I27
sg11
Vtranscription factor GATA-3
p11949
sg13
I3
sa(dp11950
g7
I142
sg8
VP10826
p11951
sg10
I22
sg11
Vretinoic acid receptor
p11952
sg13
I3
sasg14
(lp11953
(dp11954
g7
I282
sg17
VC2607914
p11955
sg10
I17
sg11
Vallergic rhinitis
p11956
sg13
I2
sasa(dp11957
g2
VThe present results suggested that treatment with AST may attenuate OVA-induced allergic rhinitis via regulating the expression of the transcription factors GATA-3, RORGammat, T-bet and Foxp3, which commit T helper cells to the Th1 phenotype.
p11958
sg4
(lp11959
(dp11960
g7
I50
sg8
VP51689
p11961
sg10
I3
sg11
VAST
p11962
sg13
I1
sa(dp11963
g7
I135
sg8
VP19883
p11964
sg10
I28
sg11
Vtranscription factors GATA-3
p11965
sg13
I3
sa(dp11966
g7
I176
sg8
g24
sg10
I5
sg11
VT-bet
p11967
sg13
I1
sa(dp11968
g7
I186
sg8
g24
sg10
I5
sg11
VFoxp3
p11969
sg13
I1
sasg14
(lp11970
(dp11971
g7
I80
sg17
VC2607914
p11972
sg10
I17
sg11
Vallergic rhinitis
p11973
sg13
I2
sasa(dp11974
g2
VCanagliflozin was associated with a low incidence of hypoglycemia when used with background AHAs that are not associated with hypoglycemia; the incidence was higher among patients on background AHAs associated with hypoglycemia (i.e.
p11975
sg4
(lp11976
sg14
(lp11977
(dp11978
g7
I53
sg17
VC0020615
p11979
sg10
I12
sg11
Vhypoglycemia
p11980
sg13
I1
sa(dp11981
g7
I53
sg17
VC0020615
p11982
sg10
I12
sg11
Vhypoglycemia
p11983
sg13
I1
sa(dp11984
g7
I53
sg17
VC0020615
p11985
sg10
I12
sg11
Vhypoglycemia
p11986
sg13
I1
sasa(dp11987
g2
VCanagliflozin was associated with a low incidence of hypoglycemia when not used in conjunction with AHAs associated with hypoglycemia (i.e., insulin or sulfonylurea).
p11988
sg4
(lp11989
(dp11990
g7
I141
sg8
VP01308
p11991
sg10
I7
sg11
Vinsulin
p11992
sg13
I1
sasg14
(lp11993
(dp11994
g7
I53
sg17
VC0020615
p11995
sg10
I12
sg11
Vhypoglycemia
p11996
sg13
I1
sa(dp11997
g7
I53
sg17
VC0020615
p11998
sg10
I12
sg11
Vhypoglycemia
p11999
sg13
I1
sasa(dp12000
g2
VAdding different AHAs to metformin was associated with varying effects on HbA1c, BW, SBP, hypoglycemia, UTI and GTI which should impact clinician choice when selecting adjunctive therapy.
p12001
sg4
(lp12002
sg14
(lp12003
(dp12004
g7
I90
sg17
VC0020615
p12005
sg10
I12
sg11
Vhypoglycemia
p12006
sg13
I1
sa(dp12007
g7
I104
sg17
VC0042029
p12008
sg10
I3
sg11
VUTI
p12009
sg13
I1
sasa(dp12010
g2
VIt has been shown at least four mutations of mitochondrial genome, namely, A1555G in MT-RNR1 gene, C3256T in MT-TL1 gene, G12315A in MT-TL2 gene, and G15059A in MT-CYB gene have significantly higher prevalence and mean value in lipofibrous plaques as compared to non-atherosclerotic intima, and therefore are associated with atherosclerosis.
p12011
sg4
(lp12012
(dp12013
g7
I85
sg8
VP43354
p12014
sg10
I12
sg11
VMT-RNR1 gene
p12015
sg13
I2
sa(dp12016
g7
I133
sg8
VP50591
p12017
sg10
I11
sg11
VMT-TL2 gene
p12018
sg13
I2
sa(dp12019
g7
I109
sg8
g24
sg10
I11
sg11
VMT-TL1 gene
p12020
sg13
I2
sa(dp12021
g7
I161
sg8
g24
sg10
I11
sg11
VMT-CYB gene
p12022
sg13
I2
sasg14
(lp12023
(dp12024
g7
I240
sg17
VC0333463
p12025
sg10
I7
sg11
Vplaques
p12026
sg13
I1
sa(dp12027
g7
I325
sg17
VC0004153
p12028
sg10
I15
sg11
Vatherosclerosis
p12029
sg13
I1
sasa(dp12030
g2
VTen mitochondrial mutations belonging to mitochondrial genes MT-RNR1 (rRNA 12S); MT-TL1 (tRNA-Leu, recognizes UUR); MT-TL2 (tRNA-Leu, recognizes CUN); MT-ND1, MT-ND2, MT-ND5, and MT-ND6 (subunits 1, 2, 5, and 6, respectively, of NADH dehydrogenase); and MT-CYB (cytochrome b) were potentially associated with atherosclerosis.
p12031
sg4
(lp12032
(dp12033
g7
I81
sg8
g24
sg10
I6
sg11
VMT-TL1
p12034
sg13
I1
sa(dp12035
g7
I116
sg8
VP50591
p12036
sg10
I6
sg11
VMT-TL2
p12037
sg13
I1
sa(dp12038
g7
I254
sg8
g24
sg10
I6
sg11
VMT-CYB
p12039
sg13
I1
sa(dp12040
g7
I167
sg8
VP03915
p12041
sg10
I6
sg11
VMT-ND5
p12042
sg13
I1
sa(dp12043
g7
I159
sg8
VP03891
p12044
sg10
I6
sg11
VMT-ND2
p12045
sg13
I1
sa(dp12046
g7
I229
sg8
VP49366
p12047
sg10
I18
sg11
VNADH dehydrogenase
p12048
sg13
I2
sa(dp12049
g7
I61
sg8
VP43354
p12050
sg10
I7
sg11
VMT-RNR1
p12051
sg13
I1
sa(dp12052
g7
I124
sg8
VP30740
p12053
sg10
I24
sg11
VtRNA-Leu, recognizes CUN
p12054
sg13
I3
sa(dp12055
g7
I89
sg8
VP30740
p12056
sg10
I24
sg11
VtRNA-Leu, recognizes UUR
p12057
sg13
I3
sa(dp12058
g7
I151
sg8
VP03886
p12059
sg10
I6
sg11
VMT-ND1
p12060
sg13
I1
sasg14
(lp12061
(dp12062
g7
I309
sg17
VC0004153
p12063
sg10
I15
sg11
Vatherosclerosis
p12064
sg13
I1
sasa(dp12065
g2
VThe vectors of chikungunya and dengue virus, Aedes aegypti and Aedes albopictus, the vector of lymphatic filariasis, Culex quinquefasciatus, and that of Japanese encephalitis, Culex tritaeniorhynchus, were found from 70 to 2,000 m asl in eastern Nepal.
p12066
sg4
(lp12067
sg14
(lp12068
(dp12069
g7
I153
sg17
VC0014057
p12070
sg10
I21
sg11
VJapanese encephalitis
p12071
sg13
I2
sa(dp12072
g7
I95
sg17
VC0013884
p12073
sg10
I20
sg11
Vlymphatic filariasis
p12074
sg13
I2
sa(dp12075
g7
I15
sg17
VC0008055
p12076
sg10
I11
sg11
Vchikungunya
p12077
sg13
I1
sa(dp12078
g7
I31
sg17
VC0011311
p12079
sg10
I6
sg11
Vdengue
p12080
sg13
I1
sasa(dp12081
g2
VThe results of an examination of a paraffin block histopathology specimen by fluorescence in-situ hybridization (FISH) showed no mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) (18q21.1), B-cell lymphoma 2 (BCL2) (18q21.3), or BCL6 (3q27) split signals in either the uterus or the greater omentum, however, trisomy 18 was detected in approximately 50%-70% of the tumor cells in both the uterus and the greater omentum.
p12082
sg4
(lp12083
(dp12084
g7
I251
sg8
VP41182
p12085
sg10
I4
sg11
VBCL6
p12086
sg13
I1
sa(dp12087
g7
I231
sg8
VP10415
p12088
sg10
I4
sg11
VBCL2
p12089
sg13
I1
sa(dp12090
g7
I212
sg8
VP10415
p12091
sg10
I17
sg11
VB-cell lymphoma 2
p12092
sg13
I3
sasg14
(lp12093
(dp12094
g7
I172
sg17
VC0040715
p12095
sg10
I13
sg11
Vtranslocation
p12096
sg13
I1
sa(dp12097
g7
I387
sg17
VC0027651
p12098
sg10
I5
sg11
Vtumor
p12099
sg13
I1
sa(dp12100
g7
I129
sg17
VC0242647
p12101
sg10
I42
sg11
Vmucosa associated lymphoid tissue lymphoma
p12102
sg13
I5
sa(dp12103
g7
I212
sg17
VC0079731
p12104
sg10
I15
sg11
VB-cell lymphoma
p12105
sg13
I2
sa(dp12106
g7
I331
sg17
VC0152096
p12107
sg10
I10
sg11
Vtrisomy 18
p12108
sg13
I2
sasa(dp12109
g2
VThe following abnormalities were most frequently observed: rearrangements involving 14q32, 19q13, 19p13, 1p, 3q27, and 8q24; del(6q); dup(1q); and trisomy 18.
p12110
sg4
(lp12111
sg14
(lp12112
(dp12113
g7
I147
sg17
VC0152096
p12114
sg10
I10
sg11
Vtrisomy 18
p12115
sg13
I2
sasa(dp12116
g2
VPassive avoidance test showed four Group rats shuttle times were 6.8+/-0.6, 1.2+/-0.2, 5.4+/-0.5, 3.6+/-0.3, incubation period were 26.1+/-3.9, 152.2+/-12.9, 65.8+/-7.0, 91.2+/-9.1, and water maze test had the same trend, with values in epilepsy groups significantly lower than the normal group of rats, which meant cognitive dysfunction.The above results also showed Baclofen further inhibited the learning and memory ability of the rats and CGP35348 promoted the learning and memory ability.The results of the Arc/Arg3.1 and GB1, GB2 level detection showed that epilepsy groups had significantly higher expression levels of Arc/Arg3.1 and GB1, GB2 than the normal group.Comparison among epilepsy groups showed that Baclofen group expressed lower levels of Arc/Arg3.1 and expressed higher levels of GB1, GB2, however CGP35348 group expressed higher levels of Arc/Arg3.1 and expressed lower levels of GB1, GB2.
p12117
sg4
(lp12118
(dp12119
g7
I516
sg8
g24
sg10
I6
sg11
VArg3.1
p12120
sg13
I1
sa(dp12121
g7
I532
sg8
g24
sg10
I3
sg11
VGB2
p12122
sg13
I1
sa(dp12123
g7
I527
sg8
VP62873
p12124
sg10
I3
sg11
VGB1
p12125
sg13
I1
sa(dp12126
g7
I516
sg8
g24
sg10
I6
sg11
VArg3.1
p12127
sg13
I1
sa(dp12128
g7
I532
sg8
g24
sg10
I3
sg11
VGB2
p12129
sg13
I1
sa(dp12130
g7
I532
sg8
g24
sg10
I3
sg11
VGB2
p12131
sg13
I1
sa(dp12132
g7
I512
sg8
g24
sg10
I3
sg11
VArc
p12133
sg13
I1
sa(dp12134
g7
I516
sg8
g24
sg10
I6
sg11
VArg3.1
p12135
sg13
I1
sa(dp12136
g7
I512
sg8
g24
sg10
I3
sg11
VArc
p12137
sg13
I1
sa(dp12138
g7
I512
sg8
g24
sg10
I3
sg11
VArc
p12139
sg13
I1
sa(dp12140
g7
I527
sg8
VP62873
p12141
sg10
I3
sg11
VGB1
p12142
sg13
I1
sa(dp12143
g7
I527
sg8
VP62873
p12144
sg10
I3
sg11
VGB1
p12145
sg13
I1
sa(dp12146
g7
I532
sg8
g24
sg10
I3
sg11
VGB2
p12147
sg13
I1
sa(dp12148
g7
I818
sg8
VP00390
p12149
sg10
I14
sg11
VCGP35348 group
p12150
sg13
I2
sa(dp12151
g7
I512
sg8
g24
sg10
I3
sg11
VArc
p12152
sg13
I1
sa(dp12153
g7
I516
sg8
g24
sg10
I6
sg11
VArg3.1
p12154
sg13
I1
sa(dp12155
g7
I527
sg8
VP62873
p12156
sg10
I3
sg11
VGB1
p12157
sg13
I1
sasg14
(lp12158
(dp12159
g7
I237
sg17
VC0014544
p12160
sg10
I8
sg11
Vepilepsy
p12161
sg13
I1
sa(dp12162
g7
I512
sg17
VC0001857
p12163
sg10
I3
sg11
VArc
p12164
sg13
I1
sa(dp12165
g7
I237
sg17
VC0014544
p12166
sg10
I8
sg11
Vepilepsy
p12167
sg13
I1
sa(dp12168
g7
I512
sg17
VC0001857
p12169
sg10
I3
sg11
VArc
p12170
sg13
I1
sa(dp12171
g7
I512
sg17
VC0001857
p12172
sg10
I3
sg11
VArc
p12173
sg13
I1
sa(dp12174
g7
I316
sg17
VC0338656
p12175
sg10
I21
sg11
Vcognitive dysfunction
p12176
sg13
I2
sa(dp12177
g7
I237
sg17
VC0014544
p12178
sg10
I8
sg11
Vepilepsy
p12179
sg13
I1
sa(dp12180
g7
I512
sg17
VC0001857
p12181
sg10
I3
sg11
VArc
p12182
sg13
I1
sasa(dp12183
g2
VTo search for the mechanism causing clinically silent corticotroph adenoma, we immunohistochemically examined the expression of prohormone convertase 1/3 (PC1/3) in this type of adenoma and compared our results with those obtained for Cushing's disease.
p12184
sg4
(lp12185
(dp12186
g7
I155
sg8
VP29120
p12187
sg10
I5
sg11
VPC1/3
p12188
sg13
I1
sa(dp12189
g7
I128
sg8
VP29120
p12190
sg10
I25
sg11
Vprohormone convertase 1/3
p12191
sg13
I3
sasg14
(lp12192
(dp12193
g7
I67
sg17
VC0001430
p12194
sg10
I7
sg11
Vadenoma
p12195
sg13
I1
sa(dp12196
g7
I54
sg17
VC1306214
p12197
sg10
I20
sg11
Vcorticotroph adenoma
p12198
sg13
I2
sa(dp12199
g7
I235
sg17
VC0221406
p12200
sg10
I17
sg11
VCushing's disease
p12201
sg13
I2
sa(dp12202
g7
I155
sg17
VC1706595
p12203
sg10
I3
sg11
VPC1
p12204
sg13
I1
sasa(dp12205
g2
VIn the present study, we tested the therapeutic and immunomodulatory effects of FTS and its derivative 5-fluoro-FTS (F-FTS) in the rat adjuvant-induced arthritis model (AIA).
p12206
sg4
(lp12207
(dp12208
g7
I117
sg8
g24
sg10
I5
sg11
VF-FTS
p12209
sg13
I1
sa(dp12210
g7
I103
sg8
g24
sg10
I12
sg11
V5-fluoro-FTS
p12211
sg13
I1
sasg14
(lp12212
(dp12213
g7
I152
sg17
VC0003864
p12214
sg10
I9
sg11
Varthritis
p12215
sg13
I1
sasa(dp12216
g2
VMR features were scored (0-3) following the Oslo hand OA score: BMLs, synovitis, cysts, flexor tenosynovitis (FTS).
p12217
sg4
(lp12218
sg14
(lp12219
(dp12220
g7
I110
sg17
VC0744058
p12221
sg10
I3
sg11
VFTS
p12222
sg13
I1
sa(dp12223
g7
I81
sg17
VC0010709
p12224
sg10
I5
sg11
Vcysts
p12225
sg13
I1
sa(dp12226
g7
I70
sg17
VC0039103
p12227
sg10
I9
sg11
Vsynovitis
p12228
sg13
I1
sa(dp12229
g7
I88
sg17
VC0744058
p12230
sg10
I20
sg11
Vflexor tenosynovitis
p12231
sg13
I2
sasa(dp12232
g2
VBMLs, synovitis, cysts, FTS and ETI were demonstrated in 56%, 90%, 22%, 16% and 30% of patients, respectively.
p12233
sg4
(lp12234
sg14
(lp12235
(dp12236
g7
I17
sg17
VC0010709
p12237
sg10
I5
sg11
Vcysts
p12238
sg13
I1
sa(dp12239
g7
I6
sg17
VC0039103
p12240
sg10
I9
sg11
Vsynovitis
p12241
sg13
I1
sasa(dp12242
g2
VBMLs (grade 2/3 vs 0: 3.5 (1.6-7.7)) and synovitis (3 vs 0: OR 3.6 (95% CI 1.9-6.6)) were severity-dependent associated with joint pain, but FTS and ETI were not.
p12243
sg4
(lp12244
sg14
(lp12245
(dp12246
g7
I125
sg17
VC0003862
p12247
sg10
I10
sg11
Vjoint pain
p12248
sg13
I2
sa(dp12249
g7
I41
sg17
VC0039103
p12250
sg10
I9
sg11
Vsynovitis
p12251
sg13
I1
sasa(dp12252
g2
VInfectious flexor tenosynovitis (FTS) is a serious infection of the hand and wrist that can lead to necrosis and amputation without prompt diagnosis and surgical debridement.
p12253
sg4
(lp12254
sg14
(lp12255
(dp12256
g7
I33
sg17
VC0744058
p12257
sg10
I3
sg11
VFTS
p12258
sg13
I1
sa(dp12259
g7
I11
sg17
VC0744058
p12260
sg10
I20
sg11
Vflexor tenosynovitis
p12261
sg13
I2
sa(dp12262
g7
I51
sg17
VC0009450
p12263
sg10
I9
sg11
Vinfection
p12264
sg13
I1
sa(dp12265
g7
I0
sg17
VC0009450
p12266
sg10
I10
sg11
VInfectious
p12267
sg13
I1
sasa(dp12268
g2
VOur objective in this work was to investigate the anti-inflammatory effects of the Ras inhibitor farnesylthiosalicylic acid (FTS) on adjuvant-induced arthritis (AIA) in rats, an experimental model for RA.
p12269
sg4
(lp12270
(dp12271
g7
I83
sg8
VP01116
p12272
sg10
I3
sg11
VRas
p12273
sg13
I1
sasg14
(lp12274
(dp12275
g7
I150
sg17
VC0003864
p12276
sg10
I9
sg11
Varthritis
p12277
sg13
I1
sasa(dp12278
g2
VDiabetic patients are susceptible to stenosing flexor tenosynovitis (FTS) and may have a diminished response to treatment.
p12279
sg4
(lp12280
sg14
(lp12281
(dp12282
g7
I47
sg17
VC0744058
p12283
sg10
I20
sg11
Vflexor tenosynovitis
p12284
sg13
I2
sa(dp12285
g7
I69
sg17
VC0744058
p12286
sg10
I3
sg11
VFTS
p12287
sg13
I1
sasa(dp12288
g2
VWith the rising participation of women in sports events, the prevalence of eating disorders and the female athlete triad (FTS), a syndrome of disordered eating, amenorrhea, and osteoporosis, have also increased in recent years.
p12289
sg4
(lp12290
sg14
(lp12291
(dp12292
g7
I161
sg17
VC0002453
p12293
sg10
I10
sg11
Vamenorrhea
p12294
sg13
I1
sa(dp12295
g7
I100
sg17
VC1721053
p12296
sg10
I20
sg11
Vfemale athlete triad
p12297
sg13
I3
sa(dp12298
g7
I75
sg17
VC0013473
p12299
sg10
I16
sg11
Veating disorders
p12300
sg13
I2
sa(dp12301
g7
I130
sg17
VC0039082
p12302
sg10
I8
sg11
Vsyndrome
p12303
sg13
I1
sa(dp12304
g7
I177
sg17
VC0029456
p12305
sg10
I12
sg11
Vosteoporosis
p12306
sg13
I1
sasa(dp12307
g2
VDupuytren's contracture (DC) (42 vs. 29.3%, respectively; P=0.01), limited joint mobility (LJM) (39 vs. 28.5%, respectively; P=0.01) and carpal tunnel syndrome (CTS) (5.3 vs. 1%, respectively; P=0.01) were significantly higher in T2DM patients than in the controls, but not stenosing flexor tenosynovitis (FTS, 'trigger finger').
p12308
sg4
(lp12309
sg14
(lp12310
(dp12311
g7
I161
sg17
VC0007286
p12312
sg10
I3
sg11
VCTS
p12313
sg13
I1
sa(dp12314
g7
I137
sg17
VC0007286
p12315
sg10
I22
sg11
Vcarpal tunnel syndrome
p12316
sg13
I3
sa(dp12317
g7
I311
sg17
VC0158328
p12318
sg10
I15
sg11
V'trigger finger
p12319
sg13
I2
sa(dp12320
g7
I25
sg17
VC0013312
p12321
sg10
I2
sg11
VDC
p12322
sg13
I1
sa(dp12323
g7
I0
sg17
VC0013312
p12324
sg10
I23
sg11
VDupuytren's contracture
p12325
sg13
I2
sa(dp12326
g7
I284
sg17
VC0744058
p12327
sg10
I20
sg11
Vflexor tenosynovitis
p12328
sg13
I2
sa(dp12329
g7
I306
sg17
VC0744058
p12330
sg10
I3
sg11
VFTS
p12331
sg13
I1
sasa(dp12332
g2
VData from several studies suggest that the gastrin family of growth factors potentiates colorectal cancer tumourigenesis.
p12333
sg4
(lp12334
(dp12335
g7
I43
sg8
VP01350
p12336
sg10
I14
sg11
Vgastrin family
p12337
sg13
I2
sa(dp12338
g7
I61
sg8
VP19883
p12339
sg10
I14
sg11
Vgrowth factors
p12340
sg13
I2
sasg14
(lp12341
(dp12342
g7
I88
sg17
VC1527249
p12343
sg10
I17
sg11
Vcolorectal cancer
p12344
sg13
I2
sasa(dp12345
g2
VThe aim of this study was to investigate whether progastrin expression may predict clinical outcome in colorectal cancer.
p12346
sg4
(lp12347
sg14
(lp12348
(dp12349
g7
I103
sg17
VC1527249
p12350
sg10
I17
sg11
Vcolorectal cancer
p12351
sg13
I2
sasa(dp12352
g2
VThis is the first study to show that progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer and supports its clinical relevance and potential use as a biomarker.
p12353
sg4
(lp12354
sg14
(lp12355
(dp12356
g7
I80
sg17
VC0001807
p12357
sg10
I10
sg11
Vaggressive
p12358
sg13
I1
sa(dp12359
g7
I91
sg17
VC0027651
p12360
sg10
I6
sg11
Vtumour
p12361
sg13
I1
sa(dp12362
g7
I125
sg17
VC1527249
p12363
sg10
I17
sg11
Vcolorectal cancer
p12364
sg13
I2
sasa(dp12365
g2
VThe aim of this study was to analyze plasma concentrations of enterohormones (motilin, ghrelin, gastrin and pancreatic polypeptide) and to verify if their abnormal levels may contribute to the severity of dyspeptic symptoms in colorectal cancer patients.
p12366
sg4
(lp12367
(dp12368
g7
I87
sg8
g24
sg10
I7
sg11
Vghrelin
p12369
sg13
I1
sa(dp12370
g7
I96
sg8
VP01350
p12371
sg10
I7
sg11
Vgastrin
p12372
sg13
I1
sa(dp12373
g7
I78
sg8
VP12872
p12374
sg10
I7
sg11
Vmotilin
p12375
sg13
I1
sasg14
(lp12376
(dp12377
g7
I227
sg17
VC1527249
p12378
sg10
I17
sg11
Vcolorectal cancer
p12379
sg13
I2
sasa(dp12380
g2
VThis study examined the expression level, subcellular localization, and binding activity of CacyBP/SIP in human colon cancer cells in the presence and absence of the hormone gastrin.
p12381
sg4
(lp12382
(dp12383
g7
I99
sg8
g24
sg10
I3
sg11
VSIP
p12384
sg13
I1
sa(dp12385
g7
I92
sg8
g24
sg10
I6
sg11
VCacyBP
p12386
sg13
I1
sa(dp12387
g7
I174
sg8
VP01350
p12388
sg10
I7
sg11
Vgastrin
p12389
sg13
I1
sasg14
(lp12390
(dp12391
g7
I112
sg17
VC0699790
p12392
sg10
I12
sg11
Vcolon cancer
p12393
sg13
I2
sasa(dp12394
g2
VCacyBP/SIP promoted the cell proliferation of colon cancer cells under both basal and gastrin stimulated conditions as shown by knockdown studies.
p12395
sg4
(lp12396
(dp12397
g7
I86
sg8
VP01350
p12398
sg10
I7
sg11
Vgastrin
p12399
sg13
I1
sa(dp12400
g7
I0
sg8
g24
sg10
I6
sg11
VCacyBP
p12401
sg13
I1
sa(dp12402
g7
I7
sg8
g24
sg10
I3
sg11
VSIP
p12403
sg13
I1
sasg14
(lp12404
(dp12405
g7
I46
sg17
VC0699790
p12406
sg10
I12
sg11
Vcolon cancer
p12407
sg13
I2
sa(dp12408
g7
I29
sg17
VC0334094
p12409
sg10
I13
sg11
Vproliferation
p12410
sg13
I1
sasa(dp12411
g2
VAs treatment with proton pump inhibitors (PPIs) increases the biosynthesis and secretion of gastrin, it has been postulated that treatment with PPIs could increase the risk of cancer, especially in Barrett's esophagus, gastric carcinoids, and colorectal cancer (CRC).
p12412
sg4
(lp12413
(dp12414
g7
I92
sg8
VP01350
p12415
sg10
I7
sg11
Vgastrin
p12416
sg13
I1
sasg14
(lp12417
(dp12418
g7
I198
sg17
VC0004763
p12419
sg10
I19
sg11
VBarrett's esophagus
p12420
sg13
I2
sa(dp12421
g7
I243
sg17
VC1527249
p12422
sg10
I17
sg11
Vcolorectal cancer
p12423
sg13
I2
sa(dp12424
g7
I227
sg17
VC0007095
p12425
sg10
I10
sg11
Vcarcinoids
p12426
sg13
I1
sa(dp12427
g7
I262
sg17
VC1527249
p12428
sg10
I3
sg11
VCRC
p12429
sg13
I1
sa(dp12430
g7
I176
sg17
VC0006826
p12431
sg10
I6
sg11
Vcancer
p12432
sg13
I1
sasa(dp12433
g2
VPathological studies showed lymph nodes metastasis in 2 patients with pancreatic gastrinomas, and in one patient with duodenal gastrinoma.
p12434
sg4
(lp12435
sg14
(lp12436
(dp12437
g7
I81
sg17
VC0017150
p12438
sg10
I11
sg11
Vgastrinomas
p12439
sg13
I1
sa(dp12440
g7
I118
sg17
VC1333321
p12441
sg10
I19
sg11
Vduodenal gastrinoma
p12442
sg13
I2
sa(dp12443
g7
I40
sg17
VC0027627
p12444
sg10
I10
sg11
Vmetastasis
p12445
sg13
I1
sasa(dp12446
g2
VA progressive increase in the expression of PD-1 and B7-H1/B7-DC on T cells and APC, respectively, was observed in the pancreatic lymph nodes of female non-obese diabetic (NOD) mice as they developed diabetes.
p12447
sg4
(lp12448
(dp12449
g7
I53
sg8
g24
sg10
I5
sg11
VB7-H1
p12450
sg13
I1
sa(dp12451
g7
I80
sg8
VP25054
p12452
sg10
I3
sg11
VAPC
p12453
sg13
I1
sa(dp12454
g7
I44
sg8
VP18621
p12455
sg10
I4
sg11
VPD-1
p12456
sg13
I1
sa(dp12457
g7
I59
sg8
g24
sg10
I5
sg11
VB7-DC
p12458
sg13
I1
sasg14
(lp12459
(dp12460
g7
I172
sg17
VC0751781
p12461
sg10
I3
sg11
VNOD
p12462
sg13
I1
sa(dp12463
g7
I80
sg17
VC0033036
p12464
sg10
I3
sg11
VAPC
p12465
sg13
I1
sa(dp12466
g7
I200
sg17
VC0011849
p12467
sg10
I8
sg11
Vdiabetes
p12468
sg13
I1
sa(dp12469
g7
I152
sg17
VC0751781
p12470
sg10
I18
sg11
Vnon-obese diabetic
p12471
sg13
I2
sasa(dp12472
g2
VB7-H1 and B7-DC have negative regulatory effects upon binding PD-1 on activated T cells and B7-H1 deficiency increases severity of both diabetes and EAE.
p12473
sg4
(lp12474
(dp12475
g7
I10
sg8
g24
sg10
I5
sg11
VB7-DC
p12476
sg13
I1
sa(dp12477
g7
I0
sg8
g24
sg10
I5
sg11
VB7-H1
p12478
sg13
I1
sa(dp12479
g7
I62
sg8
VP18621
p12480
sg10
I4
sg11
VPD-1
p12481
sg13
I1
sa(dp12482
g7
I0
sg8
g24
sg10
I5
sg11
VB7-H1
p12483
sg13
I1
sasg14
(lp12484
(dp12485
g7
I136
sg17
VC0011849
p12486
sg10
I8
sg11
Vdiabetes
p12487
sg13
I1
sasa(dp12488
g2
VThese characteristics have implicated KIR3DL2 in several pathologies: ankylosing spondylitis and cutaneous T-cell lymphomas such as Sezary syndrome, CD30+ cutaneous lymphoma, and transformed mycosis fungoides.
p12489
sg4
(lp12490
(dp12491
g7
I38
sg8
VP43630
p12492
sg10
I7
sg11
VKIR3DL2
p12493
sg13
I1
sasg14
(lp12494
(dp12495
g7
I132
sg17
VC0036920
p12496
sg10
I15
sg11
VSezary syndrome
p12497
sg13
I2
sa(dp12498
g7
I97
sg17
VC0079773
p12499
sg10
I26
sg11
Vcutaneous T-cell lymphomas
p12500
sg13
I3
sa(dp12501
g7
I70
sg17
VC0038013
p12502
sg10
I22
sg11
Vankylosing spondylitis
p12503
sg13
I2
sa(dp12504
g7
I155
sg17
VC1276146
p12505
sg10
I18
sg11
Vcutaneous lymphoma
p12506
sg13
I2
sa(dp12507
g7
I191
sg17
VC0026948
p12508
sg10
I17
sg11
Vmycosis fungoides
p12509
sg13
I2
sasa(dp12510
g2
VKIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sezary syndrome.
p12511
sg4
(lp12512
(dp12513
g7
I0
sg8
VP43630
p12514
sg10
I7
sg11
VKIR3DL2
p12515
sg13
I1
sa(dp12516
g7
I89
sg8
VP01732
p12517
sg10
I3
sg11
VCD8
p12518
sg13
I1
sasg14
(lp12519
(dp12520
g7
I164
sg17
VC0862196
p12521
sg10
I37
sg11
Vmycosis fungoides and Sezary syndrome
p12522
sg13
I5
sasa(dp12523
g2
VNot only we confirmed the expression of this marker in the blood and/or skin of mycosis fungoides patients but we also show for the first time CD158k expression (often associated with CD160) on cutaneous CD4+ T cells from healthy individuals (25.3 +/- 15%).
p12524
sg4
(lp12525
(dp12526
g7
I184
sg8
g24
sg10
I5
sg11
VCD160
p12527
sg13
I1
sa(dp12528
g7
I143
sg8
VP43627
p12529
sg10
I6
sg11
VCD158k
p12530
sg13
I1
sasg14
(lp12531
(dp12532
g7
I80
sg17
VC0026948
p12533
sg10
I17
sg11
Vmycosis fungoides
p12534
sg13
I2
sasa(dp12535
g2
VTherefore, CD4+ CD160+ T cells expressing CD158k might represent specialized cutaneous lymphocytes devoted to immune surveillance, from which could originate cutaneous T-cell lymphomas such as mycosis fungoides.
p12536
sg4
(lp12537
(dp12538
g7
I11
sg8
VP01730
p12539
sg10
I4
sg11
VCD4+
p12540
sg13
I1
sa(dp12541
g7
I42
sg8
VP43627
p12542
sg10
I6
sg11
VCD158k
p12543
sg13
I1
sasg14
(lp12544
(dp12545
g7
I158
sg17
VC0079773
p12546
sg10
I26
sg11
Vcutaneous T-cell lymphomas
p12547
sg13
I3
sa(dp12548
g7
I193
sg17
VC0026948
p12549
sg10
I17
sg11
Vmycosis fungoides
p12550
sg13
I2
sasa(dp12551
g2
Vp140/KIR3DL2 has been identified in malignant cell lines isolated from the skin and blood of patients with transformed mycosis fungoides (MF) and Sezary's syndrome (SS).
p12552
sg4
(lp12553
(dp12554
g7
I5
sg8
VP43630
p12555
sg10
I7
sg11
VKIR3DL2
p12556
sg13
I1
sa(dp12557
g7
I0
sg8
VP43630
p12558
sg10
I4
sg11
Vp140
p12559
sg13
I1
sasg14
(lp12560
(dp12561
g7
I146
sg17
VC0036920
p12562
sg10
I17
sg11
VSezary's syndrome
p12563
sg13
I2
sa(dp12564
g7
I119
sg17
VC0026948
p12565
sg10
I17
sg11
Vmycosis fungoides
p12566
sg13
I2
sasa(dp12567
g2
VChromosomal aberration (DS especially) are among the most frequent prenatally diagnosed birth defects, further being heart defects, neural tube defects (anencephaly, encephalocele, spina bifida), hydrocephalus, congenital skeletal system defects, abdominal wall defects (omphalocele, gastroschisis) and renal defects.
p12568
sg4
(lp12569
sg14
(lp12570
(dp12571
g7
I153
sg17
VC0002902
p12572
sg10
I11
sg11
Vanencephaly
p12573
sg13
I1
sa(dp12574
g7
I196
sg17
VC0020256
p12575
sg10
I25
sg11
Vhydrocephalus, congenital
p12576
sg13
I2
sa(dp12577
g7
I166
sg17
VC0014065
p12578
sg10
I13
sg11
Vencephalocele
p12579
sg13
I1
sa(dp12580
g7
I181
sg17
VC0080178
p12581
sg10
I12
sg11
Vspina bifida
p12582
sg13
I2
sa(dp12583
g7
I0
sg17
VC0008625
p12584
sg10
I22
sg11
VChromosomal aberration
p12585
sg13
I2
sa(dp12586
g7
I271
sg17
VC0795690
p12587
sg10
I11
sg11
Vomphalocele
p12588
sg13
I1
sa(dp12589
g7
I284
sg17
VC0265706
p12590
sg10
I13
sg11
Vgastroschisis
p12591
sg13
I1
sa(dp12592
g7
I117
sg17
VC0018798
p12593
sg10
I13
sg11
Vheart defects
p12594
sg13
I2
sa(dp12595
g7
I88
sg17
VC0000768
p12596
sg10
I13
sg11
Vbirth defects
p12597
sg13
I2
sasa(dp12598
g2
VIn some defects, prenatal diagnostics has also significantly influenced their incidence in births (anencephaly, gastroschisis and DS e.g.
p12599
sg4
(lp12600
sg14
(lp12601
(dp12602
g7
I99
sg17
VC0002902
p12603
sg10
I11
sg11
Vanencephaly
p12604
sg13
I1
sa(dp12605
g7
I112
sg17
VC0265706
p12606
sg10
I13
sg11
Vgastroschisis
p12607
sg13
I1
sasa(dp12608
g2
VThe Fxn KO/Mck model reproduces some key features of patients with Friedreich ataxia and provides an opportunity of ameliorating their symptoms with experimental therapies.
p12609
sg4
(lp12610
(dp12611
g7
I4
sg8
VP51587
p12612
sg10
I6
sg11
VFxn KO
p12613
sg13
I2
sasg14
(lp12614
(dp12615
g7
I67
sg17
VC0016719
p12616
sg10
I17
sg11
VFriedreich ataxia
p12617
sg13
I2
sasa(dp12618
g2
VFurther confirmation is obtained with identification of two mutations in the ARSB gene for MPS VI or mutations in the GALNS gene for MPS IVA.We report slowly progressing patients, one with MPS VI and two with MPS IVA, who presented with skeletal changes and hip findings resembling Legg-Calve-Perthes disease or spondyloepiphyseal dysplasia and normal/near normal urine GAG levels.
p12619
sg4
(lp12620
(dp12621
g7
I118
sg8
VP34059
p12622
sg10
I10
sg11
VGALNS gene
p12623
sg13
I2
sa(dp12624
g7
I133
sg8
VP05164
p12625
sg10
I7
sg11
VMPS IVA
p12626
sg13
I2
sa(dp12627
g7
I91
sg8
VP05164
p12628
sg10
I6
sg11
VMPS VI
p12629
sg13
I2
sasg14
(lp12630
(dp12631
g7
I133
sg17
VC0086651
p12632
sg10
I7
sg11
VMPS IVA
p12633
sg13
I2
sa(dp12634
g7
I91
sg17
VC0026709
p12635
sg10
I6
sg11
VMPS VI
p12636
sg13
I2
sa(dp12637
g7
I312
sg17
VC2745959
p12638
sg10
I28
sg11
Vspondyloepiphyseal dysplasia
p12639
sg13
I2
sa(dp12640
g7
I282
sg17
VC0023234
p12641
sg10
I26
sg11
VLegg-Calve-Perthes disease
p12642
sg13
I2
sa(dp12643
g7
I133
sg17
VC0086651
p12644
sg10
I7
sg11
VMPS IVA
p12645
sg13
I2
sa(dp12646
g7
I91
sg17
VC0026709
p12647
sg10
I6
sg11
VMPS VI
p12648
sg13
I2
sasa(dp12649
g2
VWe identified genes that might be truly causative, but GWAS might have failed to identify for 148 out of the GWAS-identified SNPs; for example, TUFM (P = 3.3E-48) was identified for inflammatory bowel disease (early onset); ZFP90 (P = 4.4E-34) for ulcerative colitis; and IDUA (P = 2.2E-11) for Parkinson's disease.
p12650
sg4
(lp12651
(dp12652
g7
I224
sg8
g24
sg10
I5
sg11
VZFP90
p12653
sg13
I1
sasg14
(lp12654
(dp12655
g7
I248
sg17
VC0009324
p12656
sg10
I18
sg11
Vulcerative colitis
p12657
sg13
I2
sa(dp12658
g7
I295
sg17
VC0030567
p12659
sg10
I19
sg11
VParkinson's disease
p12660
sg13
I2
sa(dp12661
g7
I182
sg17
VC0021390
p12662
sg10
I26
sg11
Vinflammatory bowel disease
p12663
sg13
I3
sasa(dp12664
g2
VApart from allergic bronchopulmonary aspergillosis (ABPA) and mould-caused mycoses, only sufficient evidence for an association between moisture/mould damage and the following health effects has been established: allergic respiratory disease, asthma (manifestation, progression and exacerbation), allergic rhinitis, hypersensitivity pneumonitis (extrinsic allergic alveolitis), and increased likelihood of respiratory infections/bronchitis.
p12665
sg4
(lp12666
sg14
(lp12667
(dp12668
g7
I346
sg17
VC0002390
p12669
sg10
I29
sg11
Vextrinsic allergic alveolitis
p12670
sg13
I3
sa(dp12671
g7
I429
sg17
VC0006277
p12672
sg10
I10
sg11
Vbronchitis
p12673
sg13
I1
sa(dp12674
g7
I11
sg17
VC0004031
p12675
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p12676
sg13
I3
sa(dp12677
g7
I316
sg17
VC0002390
p12678
sg10
I28
sg11
Vhypersensitivity pneumonitis
p12679
sg13
I2
sa(dp12680
g7
I52
sg17
VC0004031
p12681
sg10
I4
sg11
VABPA
p12682
sg13
I1
sa(dp12683
g7
I75
sg17
VC0026946
p12684
sg10
I7
sg11
Vmycoses
p12685
sg13
I1
sa(dp12686
g7
I213
sg17
VC1504369
p12687
sg10
I28
sg11
Vallergic respiratory disease
p12688
sg13
I3
sa(dp12689
g7
I243
sg17
VC0004096
p12690
sg10
I6
sg11
Vasthma
p12691
sg13
I1
sa(dp12692
g7
I406
sg17
VC0035243
p12693
sg10
I22
sg11
Vrespiratory infections
p12694
sg13
I2
sa(dp12695
g7
I297
sg17
VC2607914
p12696
sg10
I17
sg11
Vallergic rhinitis
p12697
sg13
I2
sasa(dp12698
g2
VWe studied the relationship between GORD and allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), or Aspergillus bronchitis.
p12699
sg4
(lp12700
sg14
(lp12701
(dp12702
g7
I61
sg17
VC2350529
p12703
sg10
I23
sg11
Vpulmonary aspergillosis
p12704
sg13
I2
sa(dp12705
g7
I45
sg17
VC0004031
p12706
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p12707
sg13
I3
sa(dp12708
g7
I135
sg17
VC2919277
p12709
sg10
I22
sg11
VAspergillus bronchitis
p12710
sg13
I2
sa(dp12711
g7
I86
sg17
VC0004031
p12712
sg10
I4
sg11
VABPA
p12713
sg13
I1
sasa(dp12714
g2
VWe reviewed four patients referred with elevated Aspergillus serology markers and marked pulmonary symptoms for ABPA, CPA, and Aspergillus bronchitis, and discussed the underlying pathophysiological relationship with GORD.
p12715
sg4
(lp12716
sg14
(lp12717
(dp12718
g7
I112
sg17
VC0004031
p12719
sg10
I4
sg11
VABPA
p12720
sg13
I1
sa(dp12721
g7
I127
sg17
VC2919277
p12722
sg10
I22
sg11
VAspergillus bronchitis
p12723
sg13
I2
sasa(dp12724
g2
VData were collected retrospectively from medical records included age, gender, predisposing factors for ABPA, chronic pulmonary aspergillosis, or Aspergillus bronchitis; presence of nocturnal reflux, nausea, epigastric pain, Medical Research Council dyspnea scale score, pH manometry data, endoscopic results (ulcers, Barrett's esophagus), treatment of GORD [proton-pump inhibitors (PPIs), surgical operation]; history of smoking, alcohol consumption; concomitant COPD; serological markers (anti-Aspergillus IgG, anti-Aspergillus IgE), and antifungal treatment.
p12725
sg4
(lp12726
(dp12727
g7
I513
sg8
VP01854
p12728
sg10
I20
sg11
Vanti-Aspergillus IgE
p12729
sg13
I2
sasg14
(lp12730
(dp12731
g7
I310
sg17
VC0041582
p12732
sg10
I6
sg11
Vulcers
p12733
sg13
I1
sa(dp12734
g7
I200
sg17
VC0027497
p12735
sg10
I6
sg11
Vnausea
p12736
sg13
I1
sa(dp12737
g7
I208
sg17
VC0232493
p12738
sg10
I15
sg11
Vepigastric pain
p12739
sg13
I2
sa(dp12740
g7
I192
sg17
VC0017168
p12741
sg10
I6
sg11
Vreflux
p12742
sg13
I1
sa(dp12743
g7
I530
sg17
VC0270850
p12744
sg10
I3
sg11
VIgE
p12745
sg13
I1
sa(dp12746
g7
I250
sg17
VC0013404
p12747
sg10
I7
sg11
Vdyspnea
p12748
sg13
I1
sa(dp12749
g7
I118
sg17
VC2350529
p12750
sg10
I23
sg11
Vpulmonary aspergillosis
p12751
sg13
I2
sa(dp12752
g7
I464
sg17
VC0024117
p12753
sg10
I4
sg11
VCOPD
p12754
sg13
I1
sa(dp12755
g7
I146
sg17
VC2919277
p12756
sg10
I22
sg11
VAspergillus bronchitis
p12757
sg13
I2
sa(dp12758
g7
I318
sg17
VC0004763
p12759
sg10
I19
sg11
VBarrett's esophagus
p12760
sg13
I2
sa(dp12761
g7
I104
sg17
VC0004031
p12762
sg10
I4
sg11
VABPA
p12763
sg13
I1
sasa(dp12764
g2
VOne had ABPA, one CPA, and two had Aspergillus bronchitis; median age was 57 years [range 39-71]; males-to-females ratio was 1:3.
p12765
sg4
(lp12766
sg14
(lp12767
(dp12768
g7
I8
sg17
VC0004031
p12769
sg10
I4
sg11
VABPA
p12770
sg13
I1
sa(dp12771
g7
I35
sg17
VC2919277
p12772
sg10
I22
sg11
VAspergillus bronchitis
p12773
sg13
I2
sasa(dp12774
g2
VApart from the allergic bronchopulmonary aspergillosis (ABPA) and the mycoses caused by mold, there is only sufficient evidence for the following associations between moisture/mold damages and different health effects: Allergic respiratory diseases, asthma (manifestation, progression, exacerbation), allergic rhinitis, exogenous allergic alveolitis and respiratory tract infections/bronchitis.
p12775
sg4
(lp12776
sg14
(lp12777
(dp12778
g7
I383
sg17
VC0006277
p12779
sg10
I10
sg11
Vbronchitis
p12780
sg13
I1
sa(dp12781
g7
I228
sg17
VC0035204
p12782
sg10
I20
sg11
Vrespiratory diseases
p12783
sg13
I2
sa(dp12784
g7
I56
sg17
VC0004031
p12785
sg10
I4
sg11
VABPA
p12786
sg13
I1
sa(dp12787
g7
I301
sg17
VC2607914
p12788
sg10
I17
sg11
Vallergic rhinitis
p12789
sg13
I2
sa(dp12790
g7
I354
sg17
VC0035243
p12791
sg10
I28
sg11
Vrespiratory tract infections
p12792
sg13
I3
sa(dp12793
g7
I15
sg17
VC0004031
p12794
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p12795
sg13
I3
sa(dp12796
g7
I250
sg17
VC0004096
p12797
sg10
I6
sg11
Vasthma
p12798
sg13
I1
sa(dp12799
g7
I70
sg17
VC0026946
p12800
sg10
I7
sg11
Vmycoses
p12801
sg13
I1
sa(dp12802
g7
I330
sg17
VC0002390
p12803
sg10
I19
sg11
Vallergic alveolitis
p12804
sg13
I2
sasa(dp12805
g2
Vcan lead to allergic bronchopulmonary aspergillosis (ABPA), Aspergillus sensitisation and Aspergillus bronchitis in CF.
p12806
sg4
(lp12807
sg14
(lp12808
(dp12809
g7
I12
sg17
VC0004031
p12810
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p12811
sg13
I3
sa(dp12812
g7
I90
sg17
VC2919277
p12813
sg10
I22
sg11
VAspergillus bronchitis
p12814
sg13
I2
sa(dp12815
g7
I53
sg17
VC0004031
p12816
sg10
I4
sg11
VABPA
p12817
sg13
I1
sasa(dp12818
g2
VPublished proportions of ABPA (17.7%), Aspergillus sensitisation (14.6%) and Aspergillus bronchitis (30%) in CF were applied to those &gt;18 years and compared with notified ABPA cases.
p12819
sg4
(lp12820
sg14
(lp12821
(dp12822
g7
I25
sg17
VC0004031
p12823
sg10
I4
sg11
VABPA
p12824
sg13
I1
sa(dp12825
g7
I25
sg17
VC0004031
p12826
sg10
I4
sg11
VABPA
p12827
sg13
I1
sa(dp12828
g7
I77
sg17
VC2919277
p12829
sg10
I22
sg11
VAspergillus bronchitis
p12830
sg13
I2
sasa(dp12831
g2
VAspergillus sensitisation, associated with increased bronchiectasis and reduced FEV1, affects an anticipated 5,506 patients without ABPA or Aspergillus bronchitis.
p12832
sg4
(lp12833
sg14
(lp12834
(dp12835
g7
I140
sg17
VC2919277
p12836
sg10
I22
sg11
VAspergillus bronchitis
p12837
sg13
I2
sa(dp12838
g7
I132
sg17
VC0004031
p12839
sg10
I4
sg11
VABPA
p12840
sg13
I1
sa(dp12841
g7
I53
sg17
VC0006267
p12842
sg10
I14
sg11
Vbronchiectasis
p12843
sg13
I1
sasa(dp12844
g2
VTogether ABPA and Aspergillus bronchitis are estimated to affect 17,989 adults, 47.7% of the adult CF population.
p12845
sg4
(lp12846
sg14
(lp12847
(dp12848
g7
I9
sg17
VC0004031
p12849
sg10
I4
sg11
VABPA
p12850
sg13
I1
sa(dp12851
g7
I18
sg17
VC2919277
p12852
sg10
I22
sg11
VAspergillus bronchitis
p12853
sg13
I2
sasa(dp12854
g2
VItraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects.
p12855
sg4
(lp12856
sg14
(lp12857
(dp12858
g7
I31
sg17
VC0004031
p12859
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p12860
sg13
I3
sa(dp12861
g7
I81
sg17
VC2919277
p12862
sg10
I22
sg11
VAspergillus bronchitis
p12863
sg13
I2
sa(dp12864
g7
I72
sg17
VC0004031
p12865
sg10
I4
sg11
VABPA
p12866
sg13
I1
sasa(dp12867
g2
VWe selected an average of five serum samples from each of the 17 patients with ABPA (13 proven and 4 probable ABPA) and from 3 patients with Aspergillus bronchitis and rhinosinusitis.
p12868
sg4
(lp12869
sg14
(lp12870
(dp12871
g7
I141
sg17
VC2919277
p12872
sg10
I22
sg11
VAspergillus bronchitis
p12873
sg13
I2
sa(dp12874
g7
I79
sg17
VC0004031
p12875
sg10
I4
sg11
VABPA
p12876
sg13
I1
sa(dp12877
g7
I168
sg17
VC0948780
p12878
sg10
I14
sg11
Vrhinosinusitis
p12879
sg13
I1
sa(dp12880
g7
I79
sg17
VC0004031
p12881
sg10
I4
sg11
VABPA
p12882
sg13
I1
sasa(dp12883
g2
VPatients were diagnosed with ABPA and Aspergillus bronchitis related to innate immune defects.
p12884
sg4
(lp12885
sg14
(lp12886
(dp12887
g7
I29
sg17
VC0004031
p12888
sg10
I4
sg11
VABPA
p12889
sg13
I1
sa(dp12890
g7
I38
sg17
VC2919277
p12891
sg10
I22
sg11
VAspergillus bronchitis
p12892
sg13
I2
sasa(dp12893
g2
VYeasts and filamentous fungi are beginning to emerge as significant microbial pathogens in patients with cystic fibrosis (CF), particularly in relation to allergic-type responses, as seen in patients with allergic bronchopulmonary aspergillosis (ABPA), Aspergillus bronchitis and in invasive fungal disease in lung transplant patients.
p12894
sg4
(lp12895
sg14
(lp12896
(dp12897
g7
I246
sg17
VC0004031
p12898
sg10
I4
sg11
VABPA
p12899
sg13
I1
sa(dp12900
g7
I122
sg17
VC0010674
p12901
sg10
I2
sg11
VCF
p12902
sg13
I1
sa(dp12903
g7
I105
sg17
VC0010674
p12904
sg10
I15
sg11
Vcystic fibrosis
p12905
sg13
I2
sa(dp12906
g7
I253
sg17
VC2919277
p12907
sg10
I22
sg11
VAspergillus bronchitis
p12908
sg13
I2
sa(dp12909
g7
I292
sg17
VC0026946
p12910
sg10
I14
sg11
Vfungal disease
p12911
sg13
I2
sa(dp12912
g7
I205
sg17
VC0004031
p12913
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p12914
sg13
I3
sasa(dp12915
g2
VOn the other hand, a widespread positive reaction for CK 5/8, CK 7, CK 19, and negative reaction for CK 10, was a helpful feature in the differentiation of Paget's disease from Bowen's disease and BAK.
p12916
sg4
(lp12917
(dp12918
g7
I54
sg8
VP02533
p12919
sg10
I6
sg11
VCK 5/8
p12920
sg13
I2
sa(dp12921
g7
I62
sg8
VP08729
p12922
sg10
I4
sg11
VCK 7
p12923
sg13
I2
sa(dp12924
g7
I101
sg8
VP13645
p12925
sg10
I5
sg11
VCK 10
p12926
sg13
I2
sasg14
(lp12927
(dp12928
g7
I177
sg17
VC0006079
p12929
sg10
I15
sg11
VBowen's disease
p12930
sg13
I2
sa(dp12931
g7
I156
sg17
VC0029401
p12932
sg10
I15
sg11
VPaget's disease
p12933
sg13
I2
sasa(dp12934
g2
VTo date, the relation between serum leptin levels of dialysis patients and renal osteodystrophy, defined by histomorphometric and histodynamic parameters of bone, has not been studied.
p12935
sg4
(lp12936
(dp12937
g7
I36
sg8
VP41159
p12938
sg10
I6
sg11
Vleptin
p12939
sg13
I1
sasg14
(lp12940
(dp12941
g7
I75
sg17
VC0035086
p12942
sg10
I20
sg11
Vrenal osteodystrophy
p12943
sg13
I2
sasa(dp12944
g2
VFor 100 years, it has been obvious that Salmonella enterica strains sharing the serotype with the formula 1,4,[5],12:b:1,2-now known as Paratyphi B-can cause diseases ranging from serious systemic infections to self-limiting gastroenteritis.
p12945
sg4
(lp12946
sg14
(lp12947
(dp12948
g7
I225
sg17
VC0017160
p12949
sg10
I15
sg11
Vgastroenteritis
p12950
sg13
I1
sa(dp12951
g7
I40
sg17
VC0036117
p12952
sg10
I10
sg11
VSalmonella
p12953
sg13
I1
sa(dp12954
g7
I188
sg17
VC0243026
p12955
sg10
I19
sg11
Vsystemic infections
p12956
sg13
I2
sasa(dp12957
g2
VInterestingly, in the case of breast cancer patients, this phenomenon correlated with high expression level of several molecular chaperones belonging to the HSPA, DNAJB and HSPC families.
p12958
sg4
(lp12959
sg14
(lp12960
(dp12961
g7
I30
sg17
VC0678222
p12962
sg10
I13
sg11
Vbreast cancer
p12963
sg13
I2
sasa(dp12964
g2
VUnexpectedly, conditioning before HSPC infusion was required to protect the mice from lymphoma developing when transplanting small numbers of progenitors.
p12965
sg4
(lp12966
sg14
(lp12967
(dp12968
g7
I86
sg17
VC0024299
p12969
sg10
I8
sg11
Vlymphoma
p12970
sg13
I1
sasa(dp12971
g2
VHere, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and mediate killing of human ovarian cancer spheroids using an in vivo-like model system and mouse xenograft model.
p12972
sg4
(lp12973
(dp12974
g7
I70
sg8
VP28906
p12975
sg10
I11
sg11
Vhuman CD34+
p12976
sg13
I2
sasg14
(lp12977
(dp12978
g7
I173
sg17
VC1140680
p12979
sg10
I14
sg11
Vovarian cancer
p12980
sg13
I2
sa(dp12981
g7
I133
sg17
VC0332448
p12982
sg10
I10
sg11
Vinfiltrate
p12983
sg13
I1
sasa(dp12984
g2
VThese CD56+Perforin+ HSPC-NK cells were generated under stroma-free conditions in the presence of StemRegenin-1, IL-15, and IL-12, and exerted efficient cytolytic activity and IFNGamma production toward ovarian cancer monolayer cultures.
p12985
sg4
(lp12986
(dp12987
g7
I6
sg8
VP14222
p12988
sg10
I22
sg11
VCD56+Perforin+ HSPC-NK
p12989
sg13
I2
sa(dp12990
g7
I113
sg8
VP40933
p12991
sg10
I5
sg11
VIL-15
p12992
sg13
I1
sasg14
(lp12993
(dp12994
g7
I203
sg17
VC1140680
p12995
sg10
I14
sg11
Vovarian cancer
p12996
sg13
I2
sasa(dp12997
g2
VLive-imaging confocal microscopy demonstrated that these HSPC-NK cells actively migrate, infiltrate, and mediate tumor cell killing in a three-dimensional multicellular ovarian cancer spheroid.
p12998
sg4
(lp12999
sg14
(lp13000
(dp13001
g7
I113
sg17
VC0027651
p13002
sg10
I5
sg11
Vtumor
p13003
sg13
I1
sa(dp13004
g7
I89
sg17
VC0332448
p13005
sg10
I10
sg11
Vinfiltrate
p13006
sg13
I1
sa(dp13007
g7
I169
sg17
VC1140680
p13008
sg10
I14
sg11
Vovarian cancer
p13009
sg13
I2
sasa(dp13010
g2
VFurthermore, intraperitoneal HSPC-NK cell infusions in NOD/SCID-IL2RGammanull (NSG) mice bearing ovarian carcinoma significantly reduced tumor progression.
p13011
sg4
(lp13012
(dp13013
g7
I59
sg8
VP31785
p13014
sg10
I18
sg11
VSCID-IL2RGammanull
p13015
sg13
I1
sa(dp13016
g7
I55
sg8
VP54259
p13017
sg10
I3
sg11
VNOD
p13018
sg13
I1
sasg14
(lp13019
(dp13020
g7
I97
sg17
VC0029925
p13021
sg10
I17
sg11
Vovarian carcinoma
p13022
sg13
I2
sa(dp13023
g7
I55
sg17
VC0751781
p13024
sg10
I3
sg11
VNOD
p13025
sg13
I1
sa(dp13026
g7
I59
sg17
VC0085110
p13027
sg10
I4
sg11
VSCID
p13028
sg13
I1
sa(dp13029
g7
I137
sg17
VC0178874
p13030
sg10
I17
sg11
Vtumor progression
p13031
sg13
I2
sasa(dp13032
g2
VThese findings demonstrate that highly functional HSPC-NK cells efficiently destruct ovarian carcinoma spheroids in vitro and kill intraperitoneal ovarian tumors in vivo, providing great promise for effective immunotherapy through intraperitoneal HSPC-NK cell adoptive transfer in ovarian carcinoma patients.
p13033
sg4
(lp13034
sg14
(lp13035
(dp13036
g7
I85
sg17
VC0029925
p13037
sg10
I17
sg11
Vovarian carcinoma
p13038
sg13
I2
sa(dp13039
g7
I147
sg17
VC0919267
p13040
sg10
I14
sg11
Vovarian tumors
p13041
sg13
I2
sa(dp13042
g7
I85
sg17
VC0029925
p13043
sg10
I17
sg11
Vovarian carcinoma
p13044
sg13
I2
sasa(dp13045
g2
VTreatment with vitamin C, a co-factor of Fe2+ and Alfa-KG-dependent dioxygenases, mimics TET2 restoration by enhancing 5-hydroxymethylcytosine formation in Tet2-deficient mouse HSPCs and suppresses human leukemic colony formation and leukemia progression of primary human leukemia PDXs.
p13046
sg4
(lp13047
(dp13048
g7
I156
sg8
g24
sg10
I26
sg11
VTet2-deficient mouse HSPCs
p13049
sg13
I3
sa(dp13050
g7
I89
sg8
g24
sg10
I4
sg11
VTET2
p13051
sg13
I1
sasg14
(lp13052
(dp13053
g7
I234
sg17
VC0023418
p13054
sg10
I8
sg11
Vleukemia
p13055
sg13
I1
sa(dp13056
g7
I234
sg17
VC0023418
p13057
sg10
I8
sg11
Vleukemia
p13058
sg13
I1
sasa(dp13059
g2
VWe quantified extracellular IL-16 protein (ELISA) and intracellular IL-16 in NK cells, T-cells, B-cells, and monocytes (flow cytometry) in blood samples from long-term tobacco smokers with and without chronic obstructive pulmonary disease (COPD) and in never-smokers.
p13060
sg4
(lp13061
(dp13062
g7
I14
sg8
g24
sg10
I27
sg11
Vextracellular IL-16 protein
p13063
sg13
I3
sa(dp13064
g7
I28
sg8
g24
sg10
I5
sg11
VIL-16
p13065
sg13
I1
sasg14
(lp13066
(dp13067
g7
I240
sg17
VC0024117
p13068
sg10
I4
sg11
VCOPD
p13069
sg13
I1
sa(dp13070
g7
I201
sg17
VC0024117
p13071
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p13072
sg13
I4
sasa(dp13073
g2
VIn asthmatic children with positive ETC, monocyte hemotactic protein-1 (MCP-1) and IL-16 adjusted to pre-EBC forced expiratory volume in 1 s (FEV1) were significantly higher compared to children with negative ETC (p = 0.022 and p = 0.017 respectively).
p13074
sg4
(lp13075
(dp13076
g7
I83
sg8
g24
sg10
I5
sg11
VIL-16
p13077
sg13
I1
sa(dp13078
g7
I72
sg8
VP41597
p13079
sg10
I5
sg11
VMCP-1
p13080
sg13
I1
sa(dp13081
g7
I36
sg8
VP17980
p13082
sg10
I34
sg11
VETC, monocyte hemotactic protein-1
p13083
sg13
I4
sasg14
(lp13084
(dp13085
g7
I3
sg17
VC0004096
p13086
sg10
I9
sg11
Vasthmatic
p13087
sg13
I1
sasa(dp13088
g2
VCompared with the control group, silica dust exposed group, the observation group of objects, the pneumosilicosis patients of IL-16 in induced sputum IL-16 (21.40 +/- 9.24) decreased, the content of PDGF [(5.96 +/- 0.51) ng/L], MMP-2 [(447.86 +/- 27.10) ng/L], MMP-9 [(223.91 +/- 12.28) ng/L], MCP-1 [(122.87 +/- 6.08) ng/L] increased, the differences are statistically significant (P &lt; 0.05).
p13089
sg4
(lp13090
(dp13091
g7
I294
sg8
VP41597
p13092
sg10
I5
sg11
VMCP-1
p13093
sg13
I1
sa(dp13094
g7
I126
sg8
g24
sg10
I5
sg11
VIL-16
p13095
sg13
I1
sa(dp13096
g7
I228
sg8
VP08253
p13097
sg10
I5
sg11
VMMP-2
p13098
sg13
I1
sa(dp13099
g7
I261
sg8
VP14780
p13100
sg10
I5
sg11
VMMP-9
p13101
sg13
I1
sa(dp13102
g7
I199
sg8
VP04085
p13103
sg10
I4
sg11
VPDGF
p13104
sg13
I1
sa(dp13105
g7
I143
sg8
g24
sg10
I12
sg11
Vsputum IL-16
p13106
sg13
I2
sasg14
(lp13107
sa(dp13108
g2
VAs silicosis biomarkers, TNF-alpha, TGF-beta, IL-16, PDGF, MMP-2, MMP-9 and MCP-1 have certain significance, further suggesting that early detection rate of patients with silicosis can be improved by employing the multiple indexes discriminate equation.
p13109
sg4
(lp13110
(dp13111
g7
I66
sg8
VP14780
p13112
sg10
I5
sg11
VMMP-9
p13113
sg13
I1
sa(dp13114
g7
I53
sg8
VP04085
p13115
sg10
I4
sg11
VPDGF
p13116
sg13
I1
sa(dp13117
g7
I46
sg8
g24
sg10
I5
sg11
VIL-16
p13118
sg13
I1
sa(dp13119
g7
I25
sg8
VP01375
p13120
sg10
I9
sg11
VTNF-alpha
p13121
sg13
I1
sa(dp13122
g7
I59
sg8
VP08253
p13123
sg10
I5
sg11
VMMP-2
p13124
sg13
I1
sa(dp13125
g7
I76
sg8
VP41597
p13126
sg10
I5
sg11
VMCP-1
p13127
sg13
I1
sa(dp13128
g7
I36
sg8
VP18075
p13129
sg10
I8
sg11
VTGF-beta
p13130
sg13
I1
sasg14
(lp13131
(dp13132
g7
I3
sg17
VC0037116
p13133
sg10
I9
sg11
Vsilicosis
p13134
sg13
I1
sa(dp13135
g7
I3
sg17
VC0037116
p13136
sg10
I9
sg11
Vsilicosis
p13137
sg13
I1
sasa(dp13138
g2
VBy contrast, compared to eosinophil-normal asthma (eosinophils&lt;=0.3%), eosinophil-high asthma (eosinophils&gt;0.3%) had higher levels of IL-5, IL-13, IL-16, and PDGF-bb, but same neutrophil percentage, IL-8, and FEV1.
p13139
sg4
(lp13140
(dp13141
g7
I146
sg8
VP35225
p13142
sg10
I5
sg11
VIL-13
p13143
sg13
I1
sa(dp13144
g7
I164
sg8
VP04085
p13145
sg10
I7
sg11
VPDGF-bb
p13146
sg13
I1
sa(dp13147
g7
I153
sg8
g24
sg10
I5
sg11
VIL-16
p13148
sg13
I1
sa(dp13149
g7
I140
sg8
VP05113
p13150
sg10
I4
sg11
VIL-5
p13151
sg13
I1
sasg14
(lp13152
(dp13153
g7
I43
sg17
VC0004096
p13154
sg10
I6
sg11
Vasthma
p13155
sg13
I1
sa(dp13156
g7
I43
sg17
VC0004096
p13157
sg10
I6
sg11
Vasthma
p13158
sg13
I1
sasa(dp13159
g2
VHere, we demonstrate that DRG1 is elevated in lung adenocarcinomas while weakly expressed in adjacent lung tissues.
p13160
sg4
(lp13161
(dp13162
g7
I26
sg8
VP55039
p13163
sg10
I4
sg11
VDRG1
p13164
sg13
I1
sasg14
(lp13165
(dp13166
g7
I51
sg17
VC0001418
p13167
sg10
I15
sg11
Vadenocarcinomas
p13168
sg13
I1
sasa(dp13169
g2
VTo this end, we describe the identification of developmentally regulated GTP-binding protein 1 (DRG-1) as a melanoma-associated antigen recognized by HLA-DR11-restricted CD4(+) Th1 cells.
p13170
sg4
(lp13171
(dp13172
g7
I96
sg8
g24
sg10
I5
sg11
VDRG-1
p13173
sg13
I1
sa(dp13174
g7
I150
sg8
VP30486
p13175
sg10
I8
sg11
VHLA-DR11
p13176
sg13
I1
sa(dp13177
g7
I108
sg8
VP08962
p13178
sg10
I27
sg11
Vmelanoma-associated antigen
p13179
sg13
I2
sa(dp13180
g7
I47
sg8
g24
sg10
I47
sg11
Vdevelopmentally regulated GTP-binding protein 1
p13181
sg13
I5
sa(dp13182
g7
I170
sg8
VP01730
p13183
sg10
I3
sg11
VCD4
p13184
sg13
I1
sasg14
(lp13185
(dp13186
g7
I108
sg17
VC0025202
p13187
sg10
I8
sg11
Vmelanoma
p13188
sg13
I1
sasa(dp13189
g2
VReverse transcription-polymerase chain reaction revealed that DRG-1 was highly expressed in melanoma cell lines but not in normal tissues.
p13190
sg4
(lp13191
(dp13192
g7
I62
sg8
g24
sg10
I5
sg11
VDRG-1
p13193
sg13
I1
sasg14
(lp13194
(dp13195
g7
I92
sg17
VC0025202
p13196
sg10
I8
sg11
Vmelanoma
p13197
sg13
I1
sasa(dp13198
g2
VDRG-1 knockdown by lentiviral-based shRNA suppressed melanoma cell proliferation and soft agar colony formation.
p13199
sg4
(lp13200
sg14
(lp13201
(dp13202
g7
I67
sg17
VC0334094
p13203
sg10
I13
sg11
Vproliferation
p13204
sg13
I1
sa(dp13205
g7
I53
sg17
VC0025202
p13206
sg10
I8
sg11
Vmelanoma
p13207
sg13
I1
sasa(dp13208
g2
VTaken together, these data suggest that DRG-1 plays an important role in melanoma cell growth and transformation, indicating that DRG1 may represent a novel target for CD4(+) T cell-mediated immunotherapy in melanoma.
p13209
sg4
(lp13210
(dp13211
g7
I168
sg8
VP01730
p13212
sg10
I3
sg11
VCD4
p13213
sg13
I1
sa(dp13214
g7
I40
sg8
g24
sg10
I5
sg11
VDRG-1
p13215
sg13
I1
sa(dp13216
g7
I130
sg8
VP55039
p13217
sg10
I4
sg11
VDRG1
p13218
sg13
I1
sasg14
(lp13219
(dp13220
g7
I98
sg17
VC1510411
p13221
sg10
I14
sg11
Vtransformation
p13222
sg13
I1
sa(dp13223
g7
I73
sg17
VC0025202
p13224
sg10
I8
sg11
Vmelanoma
p13225
sg13
I1
sa(dp13226
g7
I73
sg17
VC0025202
p13227
sg10
I8
sg11
Vmelanoma
p13228
sg13
I1
sasa(dp13229
g2
VFBXW7 mRNA was identified as a direct target of miR-155 in glioma.
p13230
sg4
(lp13231
(dp13232
g7
I0
sg8
g24
sg10
I10
sg11
VFBXW7 mRNA
p13233
sg13
I2
sasg14
(lp13234
(dp13235
g7
I59
sg17
VC0017638
p13236
sg10
I6
sg11
Vglioma
p13237
sg13
I1
sasa(dp13238
g2
VFinally, we found that MALAT1 positively regulated FBXW7 expression, which was responsible for glioma progression mediated by MALAT1-miR-155 pathway.
p13239
sg4
(lp13240
(dp13241
g7
I51
sg8
g24
sg10
I5
sg11
VFBXW7
p13242
sg13
I1
sa(dp13243
g7
I23
sg8
g24
sg10
I6
sg11
VMALAT1
p13244
sg13
I1
sa(dp13245
g7
I126
sg8
g24
sg10
I10
sg11
VMALAT1-miR
p13246
sg13
I1
sasg14
(lp13247
(dp13248
g7
I95
sg17
VC0017638
p13249
sg10
I6
sg11
Vglioma
p13250
sg13
I1
sasa(dp13251
g2
VBesides those, Fbxw7 activity is controlled at different levels, resulting in specific and tunable regulation of the abundance and activity of its substrates in a variety of human solid tumor types, including glioma malignancy, nasopharyngeal carcinoma, osteosarcoma, melanoma as well as colorectal, lung, breast, gastric, liver, pancreatic, renal, prostate, endometrial, and esophageal cancers.
p13252
sg4
(lp13253
(dp13254
g7
I15
sg8
g24
sg10
I5
sg11
VFbxw7
p13255
sg13
I1
sasg14
(lp13256
(dp13257
g7
I376
sg17
VC0546837
p13258
sg10
I18
sg11
Vesophageal cancers
p13259
sg13
I2
sa(dp13260
g7
I216
sg17
VC0006826
p13261
sg10
I10
sg11
Vmalignancy
p13262
sg13
I1
sa(dp13263
g7
I228
sg17
VC2931822
p13264
sg10
I24
sg11
Vnasopharyngeal carcinoma
p13265
sg13
I2
sa(dp13266
g7
I209
sg17
VC0017638
p13267
sg10
I6
sg11
Vglioma
p13268
sg13
I1
sa(dp13269
g7
I268
sg17
VC0025202
p13270
sg10
I8
sg11
Vmelanoma
p13271
sg13
I1
sa(dp13272
g7
I254
sg17
VC0029463
p13273
sg10
I12
sg11
Vosteosarcoma
p13274
sg13
I1
sa(dp13275
g7
I180
sg17
VC0280100
p13276
sg10
I11
sg11
Vsolid tumor
p13277
sg13
I2
sasa(dp13278
g2
VSubsequently, miR-15/16 activities are reduced and many of their direct targets are de-repressed, including ubiquitin ligase FBXW7 that destabilizes Cyclin E. Conversely, GBM cells expressing low p21 level, or after p21 knock-down, exhibit weaker or no E2F1 response to miR-10b inhibition.
p13279
sg4
(lp13280
(dp13281
g7
I270
sg8
g24
sg10
I7
sg11
VmiR-10b
p13282
sg13
I1
sa(dp13283
g7
I14
sg8
g24
sg10
I9
sg11
VmiR-15/16
p13284
sg13
I1
sa(dp13285
g7
I108
sg8
g24
sg10
I22
sg11
Vubiquitin ligase FBXW7
p13286
sg13
I3
sa(dp13287
g7
I196
sg8
VP42857
p13288
sg10
I3
sg11
Vp21
p13289
sg13
I1
sa(dp13290
g7
I253
sg8
g24
sg10
I4
sg11
VE2F1
p13291
sg13
I1
sa(dp13292
g7
I216
sg8
VP42857
p13293
sg10
I9
sg11
Vp21 knock
p13294
sg13
I2
sa(dp13295
g7
I149
sg8
VP24864
p13296
sg10
I8
sg11
VCyclin E
p13297
sg13
I2
sasg14
(lp13298
(dp13299
g7
I171
sg17
VC0017636
p13300
sg10
I3
sg11
VGBM
p13301
sg13
I1
sasa(dp13302
g2
VNotch pathway genes are overexpressed in ependymomas and gliomas along with FBXW7 downregulation.
p13303
sg4
(lp13304
(dp13305
g7
I0
sg8
VP01893
p13306
sg10
I19
sg11
VNotch pathway genes
p13307
sg13
I3
sa(dp13308
g7
I76
sg8
g24
sg10
I5
sg11
VFBXW7
p13309
sg13
I1
sasg14
(lp13310
(dp13311
g7
I41
sg17
VC0014474
p13312
sg10
I11
sg11
Vependymomas
p13313
sg13
I1
sa(dp13314
g7
I57
sg17
VC0017638
p13315
sg10
I7
sg11
Vgliomas
p13316
sg13
I1
sasa(dp13317
g2
VWe propose that p53 mutations contribute to gliomagenesis by both allowing the overexpression of c-Myc through downregulation of Fbxw7 and by protecting against c-Myc-induced apoptosis.
p13318
sg4
(lp13319
(dp13320
g7
I16
sg8
VP42771
p13321
sg10
I13
sg11
Vp53 mutations
p13322
sg13
I2
sa(dp13323
g7
I97
sg8
VP12524
p13324
sg10
I5
sg11
Vc-Myc
p13325
sg13
I1
sa(dp13326
g7
I129
sg8
g24
sg10
I5
sg11
VFbxw7
p13327
sg13
I1
sa(dp13328
g7
I97
sg8
VP12524
p13329
sg10
I5
sg11
Vc-Myc
p13330
sg13
I1
sasg14
(lp13331
sa(dp13332
g2
VPMD is located adjacent and medial to the nucleus prepositus hypoglossi (PH) in the dorsal medulla and is distinguished by the pattern of immunoreactivity of cells and fibers to several markers including calcium-binding proteins, a synthetic enzyme for nitric oxide (neuronal nitric oxide synthase, nNOS) and a nonphosphorylated neurofilament protein (antibody SMI-32).
p13333
sg4
(lp13334
(dp13335
g7
I42
sg8
VP61457
p13336
sg10
I29
sg11
Vnucleus prepositus hypoglossi
p13337
sg13
I3
sa(dp13338
g7
I299
sg8
VP29475
p13339
sg10
I4
sg11
VnNOS
p13340
sg13
I1
sasg14
(lp13341
(dp13342
g7
I0
sg17
VC1832661
p13343
sg10
I3
sg11
VPMD
p13344
sg13
I1
sasa(dp13345
g2
VCells in PMD are also immunoreactive to nNOS, and immunoreactivity to a neurofilament protein shows many labeled cells and fibers.
p13346
sg4
(lp13347
(dp13348
g7
I40
sg8
VP29475
p13349
sg10
I4
sg11
VnNOS
p13350
sg13
I1
sasg14
(lp13351
(dp13352
g7
I9
sg17
VC1832661
p13353
sg10
I3
sg11
VPMD
p13354
sg13
I1
sasa(dp13355
g2
VRegardless of the type of surgery (PRE-OP, POS-OP1, POS-OP2), the prevalence of periodontitis proved to be high (81.45%).
p13356
sg4
(lp13357
(dp13358
g7
I43
sg8
VP18075
p13359
sg10
I7
sg11
VPOS-OP1
p13360
sg13
I1
sa(dp13361
g7
I52
sg8
VP34820
p13362
sg10
I7
sg11
VPOS-OP2
p13363
sg13
I1
sasg14
(lp13364
(dp13365
g7
I80
sg17
VC0031099
p13366
sg10
I13
sg11
Vperiodontitis
p13367
sg13
I1
sasa(dp13368
g2
VThere was a statistically significant difference in the prevalence of periodontitis among the PRE-OP, POS-OP1, and POS-OP2 groups (P = 0.040).
p13369
sg4
(lp13370
(dp13371
g7
I94
sg8
VP58743
p13372
sg10
I6
sg11
VPRE-OP
p13373
sg13
I1
sa(dp13374
g7
I102
sg8
VP18075
p13375
sg10
I7
sg11
VPOS-OP1
p13376
sg13
I1
sasg14
(lp13377
(dp13378
g7
I70
sg17
VC0031099
p13379
sg10
I13
sg11
Vperiodontitis
p13380
sg13
I1
sasa(dp13381
g2
VLong-term studies with gamma-irradiated 0.5 and 2.5mg hOP-1 per gram of xenogeneic bovine collagenous matrix induce the restitutio ad integrum of the periodontal tissues in furcation defects exposed by chronic periodontitis in P. ursinus.
p13382
sg4
(lp13383
sg14
(lp13384
(dp13385
g7
I173
sg17
VC0206306
p13386
sg10
I17
sg11
Vfurcation defects
p13387
sg13
I2
sa(dp13388
g7
I202
sg17
VC0266929
p13389
sg10
I21
sg11
Vchronic periodontitis
p13390
sg13
I2
sasa(dp13391
g2
VBone morphogenetic protein-7 (BMP 7) induces cementogenesis in periodontitis-associated periodontal ligament (PDL) defects.
p13392
sg4
(lp13393
(dp13394
g7
I0
sg8
VP18075
p13395
sg10
I28
sg11
VBone morphogenetic protein-7
p13396
sg13
I3
sa(dp13397
g7
I30
sg8
VP18075
p13398
sg10
I5
sg11
VBMP 7
p13399
sg13
I2
sasg14
(lp13400
(dp13401
g7
I63
sg17
VC0031099
p13402
sg10
I13
sg11
Vperiodontitis
p13403
sg13
I1
sasa(dp13404
g2
VBoth KRT19 and ANXA8 mRNA may be useful markers for detecting lymph node metastases in OSCC patients.
p13405
sg4
(lp13406
(dp13407
g7
I15
sg8
VP13928
p13408
sg10
I10
sg11
VANXA8 mRNA
p13409
sg13
I2
sasg14
(lp13410
(dp13411
g7
I62
sg17
VC0686619
p13412
sg10
I21
sg11
Vlymph node metastases
p13413
sg13
I3
sasa(dp13414
g2
VNone of the NF1 glioblastomas harbored isocitrate dehydrogenase 1 (IDH1) gene mutation, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation, and telomerase reverse transcriptase (TERT) gene promoter mutation.
p13415
sg4
(lp13416
(dp13417
g7
I161
sg8
g24
sg10
I32
sg11
Vtelomerase reverse transcriptase
p13418
sg13
I3
sa(dp13419
g7
I39
sg8
VP48735
p13420
sg10
I26
sg11
Visocitrate dehydrogenase 1
p13421
sg13
I3
sa(dp13422
g7
I136
sg8
VP15056
p13423
sg10
I4
sg11
VBRAF
p13424
sg13
I1
sa(dp13425
g7
I67
sg8
g24
sg10
I4
sg11
VIDH1
p13426
sg13
I1
sa(dp13427
g7
I195
sg8
g24
sg10
I4
sg11
VTERT
p13428
sg13
I1
sa(dp13429
g7
I12
sg8
VP21359
p13430
sg10
I17
sg11
VNF1 glioblastomas
p13431
sg13
I2
sa(dp13432
g7
I88
sg8
VP15056
p13433
sg10
I46
sg11
Vv-RAF murine sarcoma viral oncogene homolog B1
p13434
sg13
I7
sasg14
(lp13435
(dp13436
g7
I101
sg17
VC1261473
p13437
sg10
I7
sg11
Vsarcoma
p13438
sg13
I1
sa(dp13439
g7
I12
sg17
VC0027831
p13440
sg10
I3
sg11
VNF1
p13441
sg13
I1
sa(dp13442
g7
I16
sg17
VC0017636
p13443
sg10
I13
sg11
Vglioblastomas
p13444
sg13
I1
sasa(dp13445
g2
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p13446
sg4
(lp13447
(dp13448
g7
I55
sg8
VP15056
p13449
sg10
I4
sg11
VBRAF
p13450
sg13
I1
sa(dp13451
g7
I0
sg8
VP04049
p13452
sg10
I53
sg11
VSomatic v-Raf murine sarcoma viral oncogene homolog B
p13453
sg13
I8
sasg14
(lp13454
(dp13455
g7
I21
sg17
VC1261473
p13456
sg10
I7
sg11
Vsarcoma
p13457
sg13
I1
sa(dp13458
g7
I133
sg17
VC0948380
p13459
sg10
I4
sg11
VmCRC
p13460
sg13
I1
sa(dp13461
g7
I103
sg17
VC0948380
p13462
sg10
I28
sg11
Vmetastatic colorectal cancer
p13463
sg13
I3
sasa(dp13464
g2
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p13465
sg4
(lp13466
(dp13467
g7
I42
sg8
VP15056
p13468
sg10
I4
sg11
VBRAF
p13469
sg13
I1
sasg14
(lp13470
(dp13471
g7
I4
sg17
VC1527249
p13472
sg10
I17
sg11
Vcolorectal cancer
p13473
sg13
I2
sasa(dp13474
g2
VWe highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins.
p13475
sg4
(lp13476
(dp13477
g7
I333
sg8
VP15056
p13478
sg10
I4
sg11
VBRAF
p13479
sg13
I1
sa(dp13480
g7
I241
sg8
VP29401
p13481
sg10
I44
sg11
VROS1 proto-oncogene receptor tyrosine kinase
p13482
sg13
I5
sa(dp13483
g7
I200
sg8
VP01133
p13484
sg10
I4
sg11
VEGFR
p13485
sg13
I1
sa(dp13486
g7
I241
sg8
VP08922
p13487
sg10
I4
sg11
VROS1
p13488
sg13
I1
sa(dp13489
g7
I166
sg8
VP01133
p13490
sg10
I32
sg11
Vepidermal growth factor receptor
p13491
sg13
I4
sa(dp13492
g7
I294
sg8
VP15056
p13493
sg10
I37
sg11
Vserine/threonine-protein kinase b-raf
p13494
sg13
I3
sa(dp13495
g7
I235
sg8
g24
sg10
I3
sg11
VALK
p13496
sg13
I1
sa(dp13497
g7
I207
sg8
g24
sg10
I26
sg11
Vanaplastic lymphoma kinase
p13498
sg13
I3
sasg14
(lp13499
(dp13500
g7
I207
sg17
VC1321546
p13501
sg10
I19
sg11
Vanaplastic lymphoma
p13502
sg13
I2
sa(dp13503
g7
I104
sg17
VC0007131
p13504
sg10
I5
sg11
VNSCLC
p13505
sg13
I1
sasa(dp13506
g2
VHere, we investigated the response of normal human keratinocytes to the MEK inhibitors trametinib and cobimetinib, alone and in combination with the v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors dabrafenib and vemurafenib, in terms of signal transduction and de novo gene expression.
p13507
sg4
(lp13508
(dp13509
g7
I196
sg8
VP15056
p13510
sg10
I4
sg11
VBRAF
p13511
sg13
I1
sa(dp13512
g7
I149
sg8
VP04049
p13513
sg10
I45
sg11
Vv-Raf murine sarcoma viral oncogene homolog B
p13514
sg13
I7
sa(dp13515
g7
I72
sg8
VP45985
p13516
sg10
I3
sg11
VMEK
p13517
sg13
I1
sasg14
(lp13518
(dp13519
g7
I162
sg17
VC1261473
p13520
sg10
I7
sg11
Vsarcoma
p13521
sg13
I1
sasa(dp13522
g2
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p13523
sg4
(lp13524
(dp13525
g7
I45
sg8
VP15056
p13526
sg10
I92
sg11
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p13527
sg13
I13
sasg14
(lp13528
(dp13529
g7
I132
sg17
VC0948380
p13530
sg10
I4
sg11
VmCRC
p13531
sg13
I1
sa(dp13532
g7
I102
sg17
VC0948380
p13533
sg10
I28
sg11
Vmetastatic colorectal cancer
p13534
sg13
I3
sa(dp13535
g7
I58
sg17
VC1261473
p13536
sg10
I7
sg11
Vsarcoma
p13537
sg13
I1
sasa(dp13538
g2
VKirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and BRAF mutational status was assayed using direct sequencing.
p13539
sg4
(lp13540
(dp13541
g7
I104
sg8
VP15056
p13542
sg10
I4
sg11
VBRAF
p13543
sg13
I1
sa(dp13544
g7
I51
sg8
VP01116
p13545
sg10
I40
sg11
Vneuroblastoma RAS viral oncogene homolog
p13546
sg13
I5
sa(dp13547
g7
I0
sg8
VP35125
p13548
sg10
I42
sg11
VKirsten rat sarcoma viral oncogene homolog
p13549
sg13
I6
sa(dp13550
g7
I93
sg8
VP01111
p13551
sg10
I4
sg11
VNRAS
p13552
sg13
I1
sa(dp13553
g7
I44
sg8
VP01116
p13554
sg10
I4
sg11
VKRAS
p13555
sg13
I1
sasg14
(lp13556
(dp13557
g7
I51
sg17
VC0027819
p13558
sg10
I13
sg11
Vneuroblastoma
p13559
sg13
I1
sa(dp13560
g7
I8
sg17
VC1882848
p13561
sg10
I11
sg11
Vrat sarcoma
p13562
sg13
I2
sasa(dp13563
g2
VWe performed an unbiased CRISPR-Cas9 knockout screen on melanoma cells that were both resistant and addicted to inhibition of the serine/threonine-protein kinase BRAF, in order to functionally mine their genome for 'addiction genes'.
p13564
sg4
(lp13565
(dp13566
g7
I130
sg8
g24
sg10
I31
sg11
Vserine/threonine-protein kinase
p13567
sg13
I2
sa(dp13568
g7
I162
sg8
VP15056
p13569
sg10
I4
sg11
VBRAF
p13570
sg13
I1
sasg14
(lp13571
(dp13572
g7
I56
sg17
VC0025202
p13573
sg10
I8
sg11
Vmelanoma
p13574
sg13
I1
sa(dp13575
g7
I215
sg17
VC0085281
p13576
sg10
I10
sg11
V'addiction
p13577
sg13
I1
sasa(dp13578
g2
VIn patients with melanoma that had progressed during treatment with a BRAF inhibitor, treatment cessation was followed by increased expression of the receptor tyrosine kinase AXL, which is associated with the phenotype switch.
p13579
sg4
(lp13580
(dp13581
g7
I150
sg8
VP29401
p13582
sg10
I24
sg11
Vreceptor tyrosine kinase
p13583
sg13
I3
sa(dp13584
g7
I70
sg8
VP15056
p13585
sg10
I4
sg11
VBRAF
p13586
sg13
I1
sa(dp13587
g7
I175
sg8
VP30530
p13588
sg10
I3
sg11
VAXL
p13589
sg13
I1
sasg14
(lp13590
(dp13591
g7
I17
sg17
VC0025202
p13592
sg10
I8
sg11
Vmelanoma
p13593
sg13
I1
sasa(dp13594
g2
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant anaplastic xanthoastrocytomas and gangliogliomas may benefit from BRAF and mitogen-activated protein kinase inhibitors.
p13595
sg4
(lp13596
(dp13597
g7
I0
sg8
VP15056
p13598
sg10
I46
sg11
Vv-raf murine sarcoma viral oncogene homolog B1
p13599
sg13
I7
sa(dp13600
g7
I48
sg8
VP15056
p13601
sg10
I4
sg11
VBRAF
p13602
sg13
I1
sa(dp13603
g7
I48
sg8
VP15056
p13604
sg10
I4
sg11
VBRAF
p13605
sg13
I1
sa(dp13606
g7
I136
sg8
VP53779
p13607
sg10
I32
sg11
Vmitogen-activated protein kinase
p13608
sg13
I3
sasg14
(lp13609
(dp13610
g7
I13
sg17
VC1261473
p13611
sg10
I7
sg11
Vsarcoma
p13612
sg13
I1
sa(dp13613
g7
I54
sg17
VC0596988
p13614
sg10
I6
sg11
Vmutant
p13615
sg13
I1
sa(dp13616
g7
I95
sg17
VC0206716
p13617
sg10
I14
sg11
Vgangliogliomas
p13618
sg13
I1
sasa(dp13619
g2
VMutations in the proto-oncogene B-raf (BRAF) occur in approximately 3% of NSCLC cases.
p13620
sg4
(lp13621
(dp13622
g7
I39
sg8
VP15056
p13623
sg10
I4
sg11
VBRAF
p13624
sg13
I1
sa(dp13625
g7
I17
sg8
VP15056
p13626
sg10
I20
sg11
Vproto-oncogene B-raf
p13627
sg13
I2
sasg14
(lp13628
(dp13629
g7
I74
sg17
VC0007131
p13630
sg10
I5
sg11
VNSCLC
p13631
sg13
I1
sasa(dp13632
g2
VTo our knowledge, this is only the second well-documented case of gastrointestinal metastasis from BRAF-mutated lung cancer.
p13633
sg4
(lp13634
sg14
(lp13635
(dp13636
g7
I83
sg17
VC0027627
p13637
sg10
I10
sg11
Vmetastasis
p13638
sg13
I1
sa(dp13639
g7
I112
sg17
VC0684249
p13640
sg10
I11
sg11
Vlung cancer
p13641
sg13
I2
sasa(dp13642
g2
VChanges in the epidermal growth factor receptor (EGFR) gene, Kirsten rat sarcoma viral oncogene (KRAS), v-Raf murine sarcoma viral oncogene homolog B (BRAF), gene encoding neurofibromin (NF1), anaplastic lymphoma kinase (ALK) and ROS1 are the main genes that suffer alterations in the tumors of patients with ADC.
p13643
sg4
(lp13644
(dp13645
g7
I187
sg8
VP21359
p13646
sg10
I3
sg11
VNF1
p13647
sg13
I1
sa(dp13648
g7
I104
sg8
VP04049
p13649
sg10
I45
sg11
Vv-Raf murine sarcoma viral oncogene homolog B
p13650
sg13
I7
sa(dp13651
g7
I230
sg8
VP08922
p13652
sg10
I4
sg11
VROS1
p13653
sg13
I1
sa(dp13654
g7
I97
sg8
VP01116
p13655
sg10
I4
sg11
VKRAS
p13656
sg13
I1
sa(dp13657
g7
I61
sg8
VP35125
p13658
sg10
I34
sg11
VKirsten rat sarcoma viral oncogene
p13659
sg13
I5
sa(dp13660
g7
I172
sg8
VP21359
p13661
sg10
I13
sg11
Vneurofibromin
p13662
sg13
I1
sa(dp13663
g7
I49
sg8
VP01133
p13664
sg10
I4
sg11
VEGFR
p13665
sg13
I1
sa(dp13666
g7
I151
sg8
VP15056
p13667
sg10
I4
sg11
VBRAF
p13668
sg13
I1
sa(dp13669
g7
I15
sg8
VP01133
p13670
sg10
I32
sg11
Vepidermal growth factor receptor
p13671
sg13
I4
sasg14
(lp13672
(dp13673
g7
I187
sg17
VC0027831
p13674
sg10
I3
sg11
VNF1
p13675
sg13
I1
sa(dp13676
g7
I69
sg17
VC1882848
p13677
sg10
I11
sg11
Vrat sarcoma
p13678
sg13
I2
sa(dp13679
g7
I73
sg17
VC1261473
p13680
sg10
I7
sg11
Vsarcoma
p13681
sg13
I1
sa(dp13682
g7
I259
sg17
VC0683278
p13683
sg10
I6
sg11
Vsuffer
p13684
sg13
I1
sa(dp13685
g7
I285
sg17
VC0027651
p13686
sg10
I6
sg11
Vtumors
p13687
sg13
I1
sa(dp13688
g7
I193
sg17
VC1321546
p13689
sg10
I19
sg11
Vanaplastic lymphoma
p13690
sg13
I2
sasa(dp13691
g2
VFor example, "Mongolism" was changed to Down's syndrome; "Australia" antigen to HBsAg; "Mexican" Swine flu to H1N1; "GRID" (Gay Related Immune Deficiency) and 4H-Disease (Haitians, Homosexuals, Haemophiliacs and Heroin Users Disease) to AIDS.
p13692
sg4
(lp13693
sg14
(lp13694
(dp13695
g7
I40
sg17
VC0013080
p13696
sg10
I15
sg11
VDown's syndrome
p13697
sg13
I2
sa(dp13698
g7
I14
sg17
VC0013080
p13699
sg10
I9
sg11
VMongolism
p13700
sg13
I1
sa(dp13701
g7
I97
sg17
VC2076600
p13702
sg10
I9
sg11
VSwine flu
p13703
sg13
I2
sa(dp13704
g7
I136
sg17
VC0850497
p13705
sg10
I17
sg11
VImmune Deficiency
p13706
sg13
I2
sasa(dp13707
g2
VWHEN IT WAS CALLED 'GRID': One year ago today, I told my colleagues that I was dying of AIDS.
p13708
sg4
(lp13709
sg14
(lp13710
sa(dp13711
g2
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and comedication with proton-pump inhibitors.
p13712
sg4
(lp13713
(dp13714
g7
I0
sg8
VP10276
p13715
sg10
I3
sg11
VAPL
p13716
sg13
I1
sasg14
(lp13717
(dp13718
g7
I53
sg17
VC0010674
p13719
sg10
I15
sg11
Vcystic fibrosis
p13720
sg13
I2
sa(dp13721
g7
I0
sg17
VC0023487
p13722
sg10
I3
sg11
VAPL
p13723
sg13
I1
sasa(dp13724
g2
VDMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.
p13725
sg4
(lp13726
(dp13727
g7
I12
sg8
g24
sg10
I4
sg11
VMEN1
p13728
sg13
I1
sasg14
(lp13729
(dp13730
g7
I47
sg17
VC0206754
p13731
sg10
I20
sg11
Vneuroendocrine tumor
p13732
sg13
I2
sa(dp13733
g7
I85
sg17
VC1337011
p13734
sg10
I31
sg11
Vpancreatic neuroendocrine tumor
p13735
sg13
I3
sa(dp13736
g7
I12
sg17
VC0025267
p13737
sg10
I4
sg11
VMEN1
p13738
sg13
I1
sa(dp13739
g7
I180
sg17
VC0025267
p13740
sg10
I35
sg11
Vmultiple endocrine neoplasia type 1
p13741
sg13
I5
sa(dp13742
g7
I47
sg17
VC0206754
p13743
sg10
I20
sg11
Vneuroendocrine tumor
p13744
sg13
I2
sa(dp13745
g7
I47
sg17
VC0206754
p13746
sg10
I20
sg11
Vneuroendocrine tumor
p13747
sg13
I2
sasa(dp13748
g2
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and co-medication with proton-pump inhibitors.
p13749
sg4
(lp13750
(dp13751
g7
I0
sg8
VP10276
p13752
sg10
I3
sg11
VAPL
p13753
sg13
I1
sasg14
(lp13754
(dp13755
g7
I53
sg17
VC0010674
p13756
sg10
I15
sg11
Vcystic fibrosis
p13757
sg13
I2
sa(dp13758
g7
I0
sg17
VC0023487
p13759
sg10
I3
sg11
VAPL
p13760
sg13
I1
sasa(dp13761
g2
VIn both cases, the diagnosis of multiple endocrine neoplasia type 1 was made after proton pump therapy was discontinued.
p13762
sg4
(lp13763
sg14
(lp13764
(dp13765
g7
I32
sg17
VC0025267
p13766
sg10
I35
sg11
Vmultiple endocrine neoplasia type 1
p13767
sg13
I5
sasa(dp13768
g2
VClinical assessment for features of multiple endocrine neoplasia type 1 (eg, serum calcium levels, personal and family history of hypercalcemia, pituitary or pancreatic tumors) could identify patients with higher risk for a tumoral source of hypergastrinemia where imaging studies can help support the diagnosis without the potential side effects of abrupt discontinuation of proton pump inhibitor therapy.
p13769
sg4
(lp13770
sg14
(lp13771
(dp13772
g7
I36
sg17
VC0025267
p13773
sg10
I35
sg11
Vmultiple endocrine neoplasia type 1
p13774
sg13
I5
sa(dp13775
g7
I130
sg17
VC0020437
p13776
sg10
I13
sg11
Vhypercalcemia
p13777
sg13
I1
sa(dp13778
g7
I158
sg17
VC0030297
p13779
sg10
I17
sg11
Vpancreatic tumors
p13780
sg13
I2
sasa(dp13781
g2
VNo correlation was detected between Ki-67 values of HGPs in CLD patients and the presence of portal hypertension, infection with Helicobacter pylori, or proton pump inhibitor use.
p13782
sg4
(lp13783
sg14
(lp13784
(dp13785
g7
I93
sg17
VC0020541
p13786
sg10
I19
sg11
Vportal hypertension
p13787
sg13
I2
sa(dp13788
g7
I52
sg17
VC0033300
p13789
sg10
I4
sg11
VHGPs
p13790
sg13
I1
sa(dp13791
g7
I114
sg17
VC0009450
p13792
sg10
I9
sg11
Vinfection
p13793
sg13
I1
sa(dp13794
g7
I60
sg17
VC0746102
p13795
sg10
I3
sg11
VCLD
p13796
sg13
I1
sasa(dp13797
g2
VMutation screening and phenotypic profiling of 2 amyotrophic lateral sclerosis-(ALS) and frontotemporal dementia-(FTD) associated genes, CHCHD10 and TUBA4A, were performed in a Belgian cohort of 459 FTD, 28 FTD-ALS, and 429 ALS patients.
p13798
sg4
(lp13799
(dp13800
g7
I137
sg8
g24
sg10
I7
sg11
VCHCHD10
p13801
sg13
I1
sa(dp13802
g7
I149
sg8
VP68366
p13803
sg10
I6
sg11
VTUBA4A
p13804
sg13
I1
sasg14
(lp13805
(dp13806
g7
I207
sg17
VC1862937
p13807
sg10
I7
sg11
VFTD-ALS
p13808
sg13
I1
sa(dp13809
g7
I114
sg17
VC0338451
p13810
sg10
I3
sg11
VFTD
p13811
sg13
I1
sa(dp13812
g7
I49
sg17
VC0002736
p13813
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p13814
sg13
I3
sa(dp13815
g7
I80
sg17
VC0002736
p13816
sg10
I3
sg11
VALS
p13817
sg13
I1
sa(dp13818
g7
I80
sg17
VC0002736
p13819
sg10
I3
sg11
VALS
p13820
sg13
I1
sa(dp13821
g7
I89
sg17
VC0338451
p13822
sg10
I23
sg11
Vfrontotemporal dementia
p13823
sg13
I2
sa(dp13824
g7
I114
sg17
VC0338451
p13825
sg10
I3
sg11
VFTD
p13826
sg13
I1
sasa(dp13827
g2
VIn TUBA4A, we detected a novel frameshift mutation (p.Arg64Glyfs*90) leading to a truncated protein in 1 FTD patient (1/459 of 0.22%) with family history of Parkinson's disease and cognitive impairment, and a novel missense mutation (p.Thr381Met) in 2 sibs with familial ALS and memory problems (1 index patient/429, 0.23%) in whom we previously identified a pathogenic Chromosome 9 open reading frame 72 repeat expansion mutation.
p13828
sg4
(lp13829
(dp13830
g7
I3
sg8
VP68366
p13831
sg10
I6
sg11
VTUBA4A
p13832
sg13
I1
sasg14
(lp13833
(dp13834
g7
I105
sg17
VC0338451
p13835
sg10
I3
sg11
VFTD
p13836
sg13
I1
sa(dp13837
g7
I31
sg17
VC0079380
p13838
sg10
I19
sg11
Vframeshift mutation
p13839
sg13
I2
sa(dp13840
g7
I181
sg17
VC0338656
p13841
sg10
I20
sg11
Vcognitive impairment
p13842
sg13
I2
sa(dp13843
g7
I279
sg17
VC0233794
p13844
sg10
I15
sg11
Vmemory problems
p13845
sg13
I2
sa(dp13846
g7
I271
sg17
VC0002736
p13847
sg10
I3
sg11
VALS
p13848
sg13
I1
sa(dp13849
g7
I157
sg17
VC0030567
p13850
sg10
I19
sg11
VParkinson's disease
p13851
sg13
I2
sasa(dp13852
g2
VThe present study confirms the role of CHCHD10 and TUBA4A in the FTD-ALS spectrum, although genetic variations in these 2 genes are extremely rare in the Belgian population and often associated with symptomatology of related neurodegenerative diseases including Parkinson's disease and Alzheimer's disease.
p13853
sg4
(lp13854
(dp13855
g7
I51
sg8
VP68366
p13856
sg10
I6
sg11
VTUBA4A
p13857
sg13
I1
sa(dp13858
g7
I39
sg8
g24
sg10
I7
sg11
VCHCHD10
p13859
sg13
I1
sasg14
(lp13860
(dp13861
g7
I225
sg17
VC0524851
p13862
sg10
I26
sg11
Vneurodegenerative diseases
p13863
sg13
I2
sa(dp13864
g7
I262
sg17
VC0030567
p13865
sg10
I19
sg11
VParkinson's disease
p13866
sg13
I2
sa(dp13867
g7
I65
sg17
VC1862937
p13868
sg10
I7
sg11
VFTD-ALS
p13869
sg13
I1
sa(dp13870
g7
I286
sg17
VC1521724
p13871
sg10
I19
sg11
VAlzheimer's disease
p13872
sg13
I2
sasa(dp13873
g2
VThe tubulin alpha 4a (TUBA4A) gene has been recently associated with amyotrophic lateral sclerosis.
p13874
sg4
(lp13875
(dp13876
g7
I22
sg8
VP68366
p13877
sg10
I6
sg11
VTUBA4A
p13878
sg13
I1
sa(dp13879
g7
I4
sg8
VP68366
p13880
sg10
I16
sg11
Vtubulin alpha 4a
p13881
sg13
I3
sasg14
(lp13882
(dp13883
g7
I69
sg17
VC0002736
p13884
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p13885
sg13
I3
sasa(dp13886
g2
VTUBA4A gene has recently been identified as a potential candidate amyotrophic lateral sclerosis(ALS)-associated gene using exome-wide rare variant burden analysis.
p13887
sg4
(lp13888
(dp13889
g7
I0
sg8
VP68366
p13890
sg10
I11
sg11
VTUBA4A gene
p13891
sg13
I2
sasg14
(lp13892
(dp13893
g7
I66
sg17
VC0002736
p13894
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p13895
sg13
I3
sa(dp13896
g7
I96
sg17
VC0002736
p13897
sg10
I3
sg11
VALS
p13898
sg13
I1
sasa(dp13899
g2
VHere we studied the physiological function of CLAC-P/collagen XXV, a transmembrane-type collagen originally identified as a component of senile plaque amyloid of Alzheimer's disease brains, by means of generating Col25a1-deficient (KO) mice.
p13900
sg4
(lp13901
(dp13902
g7
I46
sg8
g24
sg10
I6
sg11
VCLAC-P
p13903
sg13
I1
sa(dp13904
g7
I213
sg8
g24
sg10
I7
sg11
VCol25a1
p13905
sg13
I1
sasg14
(lp13906
(dp13907
g7
I151
sg17
VC0011560
p13908
sg10
I7
sg11
Vamyloid
p13909
sg13
I1
sa(dp13910
g7
I137
sg17
VC0333463
p13911
sg10
I13
sg11
Vsenile plaque
p13912
sg13
I2
sa(dp13913
g7
I162
sg17
VC1521724
p13914
sg10
I19
sg11
VAlzheimer's disease
p13915
sg13
I2
sasa(dp13916
g2
VCollagen XXV alpha 1 (COL25A1) is a collagenous type II transmembrane protein purified from senile plaques of Alzheimer's disease (AD) brains.
p13917
sg4
(lp13918
(dp13919
g7
I0
sg8
VP25100
p13920
sg10
I20
sg11
VCollagen XXV alpha 1
p13921
sg13
I4
sa(dp13922
g7
I36
sg8
VP27037
p13923
sg10
I41
sg11
Vcollagenous type II transmembrane protein
p13924
sg13
I5
sa(dp13925
g7
I22
sg8
g24
sg10
I7
sg11
VCOL25A1
p13926
sg13
I1
sasg14
(lp13927
(dp13928
g7
I131
sg17
VC1521724
p13929
sg10
I2
sg11
VAD
p13930
sg13
I1
sa(dp13931
g7
I92
sg17
VC0333463
p13932
sg10
I14
sg11
Vsenile plaques
p13933
sg13
I2
sa(dp13934
g7
I110
sg17
VC1521724
p13935
sg10
I19
sg11
VAlzheimer's disease
p13936
sg13
I2
sasa(dp13937
g2
VThe COL25A1 gene, located in 4q25, encodes the CLAC protein, which has been implicated in Alzheimer's disease (AD) pathogenesis.
p13938
sg4
(lp13939
(dp13940
g7
I47
sg8
g24
sg10
I12
sg11
VCLAC protein
p13941
sg13
I2
sa(dp13942
g7
I4
sg8
g24
sg10
I12
sg11
VCOL25A1 gene
p13943
sg13
I2
sasg14
(lp13944
(dp13945
g7
I115
sg17
VC0699748
p13946
sg10
I12
sg11
Vpathogenesis
p13947
sg13
I1
sa(dp13948
g7
I111
sg17
VC1521724
p13949
sg10
I2
sg11
VAD
p13950
sg13
I1
sa(dp13951
g7
I90
sg17
VC1521724
p13952
sg10
I19
sg11
VAlzheimer's disease
p13953
sg13
I2
sasa(dp13954
g2
VThus, in addition to the biochemical data, there is now genetic evidence of association between COL25A1 and risk for Alzheimer's disease.
p13955
sg4
(lp13956
(dp13957
g7
I96
sg8
g24
sg10
I7
sg11
VCOL25A1
p13958
sg13
I1
sasg14
(lp13959
(dp13960
g7
I117
sg17
VC1521724
p13961
sg10
I19
sg11
VAlzheimer's disease
p13962
sg13
I2
sasa(dp13963
g2
VRecently, a novel plaque-associated protein, collagenous Alzheimer amyloid plaque component (CLAC), was identified in brains from patients with Alzheimer's disease.
p13964
sg4
(lp13965
sg14
(lp13966
(dp13967
g7
I67
sg17
VC0333463
p13968
sg10
I14
sg11
Vamyloid plaque
p13969
sg13
I2
sa(dp13970
g7
I18
sg17
VC0011389
p13971
sg10
I6
sg11
Vplaque
p13972
sg13
I1
sa(dp13973
g7
I144
sg17
VC1521724
p13974
sg10
I19
sg11
VAlzheimer's disease
p13975
sg13
I2
sasa(dp13976
g2
VThe biological function and the contribution of CLAC to the pathogenesis of Alzheimer's disease and plaque formation are unknown.
p13977
sg4
(lp13978
sg14
(lp13979
(dp13980
g7
I76
sg17
VC1521724
p13981
sg10
I19
sg11
VAlzheimer's disease
p13982
sg13
I2
sa(dp13983
g7
I100
sg17
VC0011389
p13984
sg10
I6
sg11
Vplaque
p13985
sg13
I1
sa(dp13986
g7
I60
sg17
VC0699748
p13987
sg10
I12
sg11
Vpathogenesis
p13988
sg13
I1
sasa(dp13989
g2
VCLAC (collagenous Alzheimer amyloid plaque component) is a proteolytic fragment derived from a novel membrane-bound collagen, CLAC-P/collagen type XXV, that deposits in senile plaques associated with amyloid beta peptides (Abeta) in the brains of patients with Alzheimer's disease.
p13990
sg4
(lp13991
(dp13992
g7
I200
sg8
g24
sg10
I21
sg11
Vamyloid beta peptides
p13993
sg13
I3
sa(dp13994
g7
I126
sg8
g24
sg10
I6
sg11
VCLAC-P
p13995
sg13
I1
sa(dp13996
g7
I223
sg8
g24
sg10
I5
sg11
VAbeta
p13997
sg13
I1
sasg14
(lp13998
(dp13999
g7
I28
sg17
VC0333463
p14000
sg10
I14
sg11
Vamyloid plaque
p14001
sg13
I2
sa(dp14002
g7
I169
sg17
VC0333463
p14003
sg10
I14
sg11
Vsenile plaques
p14004
sg13
I2
sa(dp14005
g7
I28
sg17
VC0011560
p14006
sg10
I7
sg11
Vamyloid
p14007
sg13
I1
sa(dp14008
g7
I261
sg17
VC1521724
p14009
sg10
I19
sg11
VAlzheimer's disease
p14010
sg13
I2
sasa(dp14011
g2
VThese results suggest the anti-amyloidogenic roles of CLAC in the pathophysiology of Alzheimer's disease.
p14012
sg4
(lp14013
(dp14014
g7
I54
sg8
g24
sg10
I4
sg11
VCLAC
p14015
sg13
I1
sasg14
(lp14016
(dp14017
g7
I85
sg17
VC1521724
p14018
sg10
I19
sg11
VAlzheimer's disease
p14019
sg13
I2
sasa(dp14020
g2
VThe analysis of breast cancer and pancreatic cancer data further shows iSPCA's satisfactory performance.
p14021
sg4
(lp14022
sg14
(lp14023
(dp14024
g7
I16
sg17
VC0678222
p14025
sg10
I13
sg11
Vbreast cancer
p14026
sg13
I2
sa(dp14027
g7
I34
sg17
VC0235974
p14028
sg10
I17
sg11
Vpancreatic cancer
p14029
sg13
I2
sasa(dp14030
g2
VTissue factor (TF) is a transmembrane receptor for coagulation factor VII/VIIa and is frequently overexpressed by cancer cells.
p14031
sg4
(lp14032
(dp14033
g7
I51
sg8
VP08709
p14034
sg10
I22
sg11
Vcoagulation factor VII
p14035
sg13
I3
sasg14
(lp14036
(dp14037
g7
I114
sg17
VC0006826
p14038
sg10
I6
sg11
Vcancer
p14039
sg13
I1
sasa(dp14040
g2
VTo identify the location of missed significant prostate cancer (sPCa) lesions by transrectal ultrasound-guided biopsy (TRUSbx) and multiparametric magnetic resonance imaging-guided biopsy (mpMRIbx) in men undergoing repeat biopsies.
p14041
sg4
(lp14042
sg14
(lp14043
(dp14044
g7
I47
sg17
VC0600139
p14045
sg10
I15
sg11
Vprostate cancer
p14046
sg13
I2
sasa(dp14047
g2
VOf the 289 patients, prostate cancer was detected in 128 (44%) with 88 (30%) having sPCa.
p14048
sg4
(lp14049
(dp14050
g7
I84
sg8
VP08709
p14051
sg10
I4
sg11
VsPCa
p14052
sg13
I1
sasg14
(lp14053
(dp14054
g7
I21
sg17
VC0600139
p14055
sg10
I15
sg11
Vprostate cancer
p14056
sg13
I2
sasa(dp14057
g2
VOverall, 165 separate prostate cancer lesions were detected with 100 being sPCa.
p14058
sg4
(lp14059
sg14
(lp14060
(dp14061
g7
I22
sg17
VC0600139
p14062
sg10
I15
sg11
Vprostate cancer
p14063
sg13
I2
sasa(dp14064
g2
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p14065
sg4
(lp14066
(dp14067
g7
I0
sg8
VP08709
p14068
sg10
I37
sg11
VFactor VII (FVII) activating protease
p14069
sg13
I5
sa(dp14070
g7
I39
sg8
g24
sg10
I4
sg11
VFSAP
p14071
sg13
I1
sa(dp14072
g7
I62
sg8
VP57727
p14073
sg10
I15
sg11
Vserine protease
p14074
sg13
I2
sasg14
(lp14075
(dp14076
g7
I150
sg17
VC0038454
p14077
sg10
I6
sg11
Vstroke
p14078
sg13
I1
sa(dp14079
g7
I158
sg17
VC0004153
p14080
sg10
I15
sg11
Vatherosclerosis
p14081
sg13
I1
sa(dp14082
g7
I175
sg17
VC0239946
p14083
sg10
I14
sg11
Vliver fibrosis
p14084
sg13
I2
sa(dp14085
g7
I206
sg17
VC0006826
p14086
sg10
I6
sg11
Vcancer
p14087
sg13
I1
sa(dp14088
g7
I191
sg17
VC0040053
p14089
sg10
I10
sg11
Vthrombosis
p14090
sg13
I1
sasa(dp14091
g2
VIn the absence of factor VII in platelet-free plasma, thrombin generation in solid pancreatic cancer cell lines was significantly reduced unlike in haematological cell lines.
p14092
sg4
(lp14093
(dp14094
g7
I54
sg8
VP00734
p14095
sg10
I8
sg11
Vthrombin
p14096
sg13
I1
sasg14
(lp14097
(dp14098
g7
I83
sg17
VC0235974
p14099
sg10
I17
sg11
Vpancreatic cancer
p14100
sg13
I2
sasa(dp14101
g2
VSPCA gene expression is significantly elevated in breast cancer subtypes that are associated with microcalcifications.
p14102
sg4
(lp14103
(dp14104
g7
I0
sg8
VP08709
p14105
sg10
I9
sg11
VSPCA gene
p14106
sg13
I2
sasg14
(lp14107
(dp14108
g7
I50
sg17
VC0678222
p14109
sg10
I13
sg11
Vbreast cancer
p14110
sg13
I2
sa(dp14111
g7
I98
sg17
VC0521174
p14112
sg10
I19
sg11
Vmicrocalcifications
p14113
sg13
I1
sasa(dp14114
g2
VClinically significant cancer (SPCa) was defined as Gleason score &gt;=3 + 4.
p14115
sg4
(lp14116
sg14
(lp14117
(dp14118
g7
I23
sg17
VC0006826
p14119
sg10
I6
sg11
Vcancer
p14120
sg13
I1
sasa(dp14121
g2
VHeritable disorders of connective tissue (marfan syndrome, Ehlers-Danlos syndrome, adult polycystic kidney disease, floppy mitral valve/mitral valve prolapse); congenital heart disease (bicuspid aortic valve); inflammatory/immunologic disorders (rheumatic fever, AIDS, Kawasaki disease, syphilis, seronegative spondyloarthropathies, systemic lupus erythematosus, antiphospholipid syndrome); endocardial disorders (nonbacteremic thrombotic endocarditis, infective endocarditis, endomyocardial fibroelastosis); myocardial dysfunction (ischemic heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy); diseases and disorders of other organs (chronic renal failure, carcinoid heart disease); aging (calcific aortic stenosis, mitral annular calcification); postinterventional valvular disease; drugs and physical agents are all clinical entities associated with VHD.
p14122
sg4
(lp14123
sg14
(lp14124
(dp14125
g7
I136
sg17
VC0026267
p14126
sg10
I21
sg11
Vmitral valve prolapse
p14127
sg13
I3
sa(dp14128
g7
I533
sg17
VC0151744
p14129
sg10
I22
sg11
Vischemic heart disease
p14130
sg13
I3
sa(dp14131
g7
I116
sg17
VC0026267
p14132
sg10
I19
sg11
Vfloppy mitral valve
p14133
sg13
I3
sa(dp14134
g7
I160
sg17
VC0152021
p14135
sg10
I24
sg11
Vcongenital heart disease
p14136
sg13
I3
sa(dp14137
g7
I565
sg17
VC0878544
p14138
sg10
I14
sg11
Vcardiomyopathy
p14139
sg13
I1
sa(dp14140
g7
I186
sg17
VC0149630
p14141
sg10
I21
sg11
Vbicuspid aortic valve
p14142
sg13
I3
sa(dp14143
g7
I223
sg17
VC0021053
p14144
sg10
I21
sg11
Vimmunologic disorders
p14145
sg13
I2
sa(dp14146
g7
I611
sg17
VC0012634
p14147
sg10
I22
sg11
Vdiseases and disorders
p14148
sg13
I3
sa(dp14149
g7
I477
sg17
VC0014117
p14150
sg10
I29
sg11
Vendomyocardial fibroelastosis
p14151
sg13
I2
sa(dp14152
g7
I333
sg17
VC0024141
p14153
sg10
I28
sg11
Vsystemic lupus erythematosus
p14154
sg13
I3
sa(dp14155
g7
I674
sg17
VC0007093
p14156
sg10
I23
sg11
Vcarcinoid heart disease
p14157
sg13
I3
sa(dp14158
g7
I565
sg17
VC0007194
p14159
sg10
I28
sg11
Vcardiomyopathy, hypertrophic
p14160
sg13
I2
sa(dp14161
g7
I723
sg17
VC0026269
p14162
sg10
I16
sg11
Vstenosis, mitral
p14163
sg13
I2
sa(dp14164
g7
I439
sg17
VC1541923
p14165
sg10
I23
sg11
Vendocarditis, infective
p14166
sg13
I2
sa(dp14167
g7
I310
sg17
VC0949691
p14168
sg10
I21
sg11
Vspondyloarthropathies
p14169
sg13
I1
sa(dp14170
g7
I246
sg17
VC0035436
p14171
sg10
I15
sg11
Vrheumatic fever
p14172
sg13
I2
sa(dp14173
g7
I439
sg17
VC0014118
p14174
sg10
I12
sg11
Vendocarditis
p14175
sg13
I1
sa(dp14176
g7
I49
sg17
VC0013720
p14177
sg10
I23
sg11
Vsyndrome, Ehlers-Danlos
p14178
sg13
I2
sa(dp14179
g7
I509
sg17
VC0340515
p14180
sg10
I22
sg11
Vmyocardial dysfunction
p14181
sg13
I2
sa(dp14182
g7
I269
sg17
VC0026691
p14183
sg10
I16
sg11
VKawasaki disease
p14184
sg13
I2
sa(dp14185
g7
I83
sg17
VC0085413
p14186
sg10
I31
sg11
Vadult polycystic kidney disease
p14187
sg13
I4
sa(dp14188
g7
I651
sg17
VC0022661
p14189
sg10
I21
sg11
Vchronic renal failure
p14190
sg13
I3
sa(dp14191
g7
I49
sg17
VC0039082
p14192
sg10
I8
sg11
Vsyndrome
p14193
sg13
I1
sa(dp14194
g7
I363
sg17
VC0085278
p14195
sg10
I25
sg11
Vantiphospholipid syndrome
p14196
sg13
I2
sa(dp14197
g7
I287
sg17
VC0039128
p14198
sg10
I8
sg11
Vsyphilis
p14199
sg13
I1
sasa(dp14200
g2
VDescribed here is an autopsy case of a 61-year-old man with polycystic kidney disease who had P. multocida bacteremia and acute infective endocarditis with multiple bacterial clumps involving bicuspid aortic valve.
p14201
sg4
(lp14202
sg14
(lp14203
(dp14204
g7
I192
sg17
VC0149630
p14205
sg10
I21
sg11
Vbicuspid aortic valve
p14206
sg13
I3
sa(dp14207
g7
I107
sg17
VC0004610
p14208
sg10
I10
sg11
Vbacteremia
p14209
sg13
I1
sa(dp14210
g7
I122
sg17
VC0155685
p14211
sg10
I28
sg11
Vacute infective endocarditis
p14212
sg13
I3
sa(dp14213
g7
I60
sg17
VC0022680
p14214
sg10
I25
sg11
Vpolycystic kidney disease
p14215
sg13
I3
sasa(dp14216
g2
VTwenty-five people with COPD + PC (mean (standard deviation (SD)) age 73 (11) years, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II-IV), 25 people with COPD (70 (8) years, GOLD stage II-IV) and 25 controls (70 (7) years) wore the SenseWear Pro3 Armband for 7 days.
p14217
sg4
(lp14218
sg14
(lp14219
(dp14220
g7
I24
sg17
VC0024117
p14221
sg10
I4
sg11
VCOPD
p14222
sg13
I1
sa(dp14223
g7
I141
sg17
VC0024117
p14224
sg10
I4
sg11
VGOLD
p14225
sg13
I1
sa(dp14226
g7
I141
sg17
VC0024117
p14227
sg10
I4
sg11
VGOLD
p14228
sg13
I1
sa(dp14229
g7
I85
sg17
VC0024117
p14230
sg10
I54
sg11
VGlobal Initiative for Chronic Obstructive Lung Disease
p14231
sg13
I7
sa(dp14232
g7
I24
sg17
VC0024117
p14233
sg10
I4
sg11
VCOPD
p14234
sg13
I1
sasa(dp14235
g2
VPatients with severe atopic dermatitis had a decreased CD4+CD29+: CD4+CD45RA+ ratio (p &lt; 0.01).
p14236
sg4
(lp14237
(dp14238
g7
I66
sg8
VP01730
p14239
sg10
I11
sg11
VCD4+CD45RA+
p14240
sg13
I1
sa(dp14241
g7
I55
sg8
VP01730
p14242
sg10
I9
sg11
VCD4+CD29+
p14243
sg13
I1
sasg14
(lp14244
(dp14245
g7
I21
sg17
VC0011615
p14246
sg10
I17
sg11
Vatopic dermatitis
p14247
sg13
I2
sasa(dp14248
g2
VNo significant changes in the CD4+CD29+: CD4+CD45RA+ ratio were found in the peripheral blood of patients with clinically mild or moderate atopic dermatitis.
p14249
sg4
(lp14250
(dp14251
g7
I30
sg8
VP01730
p14252
sg10
I9
sg11
VCD4+CD29+
p14253
sg13
I1
sa(dp14254
g7
I41
sg8
VP01730
p14255
sg10
I11
sg11
VCD4+CD45RA+
p14256
sg13
I1
sasg14
(lp14257
(dp14258
g7
I139
sg17
VC0011615
p14259
sg10
I17
sg11
Vatopic dermatitis
p14260
sg13
I2
sasa(dp14261
g2
VTissue sections from the skin of patients with atopic dermatitis were investigated by means of hematoxylin-eosin staining, the avidin-biotin-peroxidase complex method, and double-labeling immunofluorescence using monoclonal antibodies to cell-surface antigens, including CD45R and CD29.
p14262
sg4
(lp14263
(dp14264
g7
I271
sg8
VP08575
p14265
sg10
I5
sg11
VCD45R
p14266
sg13
I1
sa(dp14267
g7
I141
sg8
VP05164
p14268
sg10
I10
sg11
Vperoxidase
p14269
sg13
I1
sasg14
(lp14270
(dp14271
g7
I47
sg17
VC0011615
p14272
sg10
I17
sg11
Vatopic dermatitis
p14273
sg13
I2
sasa(dp14274
g2
VThese novel data demonstrate the role of HDAC2-mediated epigenetic mechanisms in anxiety and alcoholism.
p14275
sg4
(lp14276
(dp14277
g7
I41
sg8
g24
sg10
I5
sg11
VHDAC2
p14278
sg13
I1
sasg14
(lp14279
(dp14280
g7
I93
sg17
VC0001973
p14281
sg10
I10
sg11
Valcoholism
p14282
sg13
I1
sasa(dp14283
g2
VThe mRNA levels of cholesterol transport regulators ABCA1 and ABCG1 were markedly downregulated by UVB, parallel to the lamellar ichthyosis related glucosylceramide transporter ABCA12 and the suspected sphingosine-1-phosphate and cholesterol sulfate transporter ABCC1.
p14284
sg4
(lp14285
(dp14286
g7
I230
sg8
VP50443
p14287
sg10
I37
sg11
Vcholesterol sulfate transporter ABCC1
p14288
sg13
I4
sasg14
(lp14289
(dp14290
g7
I120
sg17
VC0020758
p14291
sg10
I19
sg11
Vlamellar ichthyosis
p14292
sg13
I2
sasa(dp14293
g2
VTo investigate the potential tumour suppressor functions of glutathione peroxidase 7 (GPX7) and examine the interplay between epigenetic and genetic events in regulating its expression in oesophageal adenocarcinomas (OAC).
p14294
sg4
(lp14295
(dp14296
g7
I86
sg8
g24
sg10
I4
sg11
VGPX7
p14297
sg13
I1
sa(dp14298
g7
I60
sg8
g24
sg10
I24
sg11
Vglutathione peroxidase 7
p14299
sg13
I3
sasg14
(lp14300
(dp14301
g7
I200
sg17
VC0001418
p14302
sg10
I15
sg11
Vadenocarcinomas
p14303
sg13
I1
sa(dp14304
g7
I29
sg17
VC0027651
p14305
sg10
I6
sg11
Vtumour
p14306
sg13
I1
sasa(dp14307
g2
VThe goal of this study was to investigate the expression and secretion levels in vitro and in vivo of kallikrein 10 in uterine serous papillary carcinoma, a highly aggressive variant of endometrial tumor.
p14308
sg4
(lp14309
(dp14310
g7
I102
sg8
g24
sg10
I13
sg11
Vkallikrein 10
p14311
sg13
I2
sasg14
(lp14312
(dp14313
g7
I134
sg17
VC0007133
p14314
sg10
I19
sg11
Vpapillary carcinoma
p14315
sg13
I2
sa(dp14316
g7
I164
sg17
VC0001807
p14317
sg10
I10
sg11
Vaggressive
p14318
sg13
I1
sa(dp14319
g7
I186
sg17
VC0014170
p14320
sg10
I17
sg11
Vendometrial tumor
p14321
sg13
I2
sasa(dp14322
g2
VHuman kallikrein 10 gene expression levels were evaluated in 11 snap-frozen uterine serous papillary carcinoma biopsies and 6 normal endometrial cell biopsies by real-time polymerase chain reaction.
p14323
sg4
(lp14324
(dp14325
g7
I0
sg8
g24
sg10
I24
sg11
VHuman kallikrein 10 gene
p14326
sg13
I4
sasg14
(lp14327
(dp14328
g7
I91
sg17
VC0007133
p14329
sg10
I19
sg11
Vpapillary carcinoma
p14330
sg13
I2
sasa(dp14331
g2
VSecretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA.
p14332
sg4
(lp14333
(dp14334
g7
I13
sg8
g24
sg10
I21
sg11
Vkallikrein 10 protein
p14335
sg13
I3
sasg14
(lp14336
(dp14337
g7
I171
sg17
VC0027651
p14338
sg10
I6
sg11
Vtumors
p14339
sg13
I1
sa(dp14340
g7
I91
sg17
VC0007133
p14341
sg10
I20
sg11
Vpapillary carcinomas
p14342
sg13
I2
sa(dp14343
g7
I41
sg17
VC0677930
p14344
sg10
I13
sg11
Vprimary tumor
p14345
sg13
I2
sa(dp14346
g7
I115
sg17
VC0206687
p14347
sg10
I23
sg11
Vendometrioid carcinomas
p14348
sg13
I2
sasa(dp14349
g2
VFinally, kallikrein 10 concentration in 75 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 21 women with endometrioid carcinomas, and 12 uterine serous papillary carcinoma patients was studied.
p14350
sg4
(lp14351
(dp14352
g7
I9
sg8
g24
sg10
I13
sg11
Vkallikrein 10
p14353
sg13
I2
sasg14
(lp14354
(dp14355
g7
I183
sg17
VC0007133
p14356
sg10
I19
sg11
Vpapillary carcinoma
p14357
sg13
I2
sa(dp14358
g7
I136
sg17
VC0206687
p14359
sg10
I23
sg11
Vendometrioid carcinomas
p14360
sg13
I2
sasa(dp14361
g2
VKallikrein 10 gene expression levels were significantly higher in uterine serous papillary carcinoma when compared with normal endometrial cell biopsies (mean copy number by real time polymerase chain reaction = 743 versus 1.4; uterine serous papillary carcinoma versus endometrioid carcinoma: P &lt; .02).
p14362
sg4
(lp14363
(dp14364
g7
I0
sg8
g24
sg10
I18
sg11
VKallikrein 10 gene
p14365
sg13
I3
sasg14
(lp14366
(dp14367
g7
I81
sg17
VC0007133
p14368
sg10
I19
sg11
Vpapillary carcinoma
p14369
sg13
I2
sa(dp14370
g7
I81
sg17
VC0007133
p14371
sg10
I19
sg11
Vpapillary carcinoma
p14372
sg13
I2
sa(dp14373
g7
I270
sg17
VC0206687
p14374
sg10
I22
sg11
Vendometrioid carcinoma
p14375
sg13
I2
sasa(dp14376
g2
VIn vitro kallikrein 10 secretion was detected in all primary uterine serous papillary carcinoma cell lines tested (mean = 2.7 microg/L), and the secretion levels were not significantly different to those found in primary ovarian serous papillary tumor cultures (mean 4.2 microg/L).
p14377
sg4
(lp14378
(dp14379
g7
I9
sg8
g24
sg10
I13
sg11
Vkallikrein 10
p14380
sg13
I2
sasg14
(lp14381
(dp14382
g7
I76
sg17
VC0007133
p14383
sg10
I19
sg11
Vpapillary carcinoma
p14384
sg13
I2
sa(dp14385
g7
I236
sg17
VC0476073
p14386
sg10
I15
sg11
Vpapillary tumor
p14387
sg13
I2
sasa(dp14388
g2
VIn contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005).
p14389
sg4
(lp14390
(dp14391
g7
I23
sg8
VP03952
p14392
sg10
I17
sg11
Vplasma kallikrein
p14393
sg13
I2
sasg14
(lp14394
(dp14395
g7
I160
sg17
VC0006826
p14396
sg10
I6
sg11
Vcancer
p14397
sg13
I1
sa(dp14398
g7
I69
sg17
VC0007133
p14399
sg10
I19
sg11
Vpapillary carcinoma
p14400
sg13
I2
sa(dp14401
g7
I214
sg17
VC0206687
p14402
sg10
I22
sg11
Vendometrioid carcinoma
p14403
sg13
I2
sasa(dp14404
g2
VKallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients.
p14405
sg4
(lp14406
(dp14407
g7
I0
sg8
VP06870
p14408
sg10
I10
sg11
VKallikrein
p14409
sg13
I1
sasg14
(lp14410
(dp14411
g7
I52
sg17
VC0007133
p14412
sg10
I19
sg11
Vpapillary carcinoma
p14413
sg13
I2
sa(dp14414
g7
I52
sg17
VC0007133
p14415
sg10
I19
sg11
Vpapillary carcinoma
p14416
sg13
I2
sasa(dp14417
g2
VKallikrein 10 may represent a novel biomarker for uterine serous papillary carcinoma.
p14418
sg4
(lp14419
(dp14420
g7
I0
sg8
VP06870
p14421
sg10
I10
sg11
VKallikrein
p14422
sg13
I1
sasg14
(lp14423
(dp14424
g7
I65
sg17
VC0007133
p14425
sg10
I19
sg11
Vpapillary carcinoma
p14426
sg13
I2
sasa(dp14427
g2
VThe present investigation was designed to clarify the role of the subcommissural organ (SCO) in the pathogenesis of hydrocephalus occurring in the HTx rat.
p14428
sg4
(lp14429
sg14
(lp14430
(dp14431
g7
I116
sg17
VC0020255
p14432
sg10
I13
sg11
Vhydrocephalus
p14433
sg13
I1
sa(dp14434
g7
I100
sg17
VC0699748
p14435
sg10
I12
sg11
Vpathogenesis
p14436
sg13
I1
sasa(dp14437
g2
VAt the same time, it functions as a transcriptional regulator of particular genes and as a cytokine: HMGB-1 released from a defective cell has been reported to induce damage to the adjacent cells.With a view to examine the relationship between neuronal damage caused by hydrocephalus and HMGB-1, we analyzed the expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus of 1-day-old congenitally hydrocephalic H-Tx rats.As opposed to nonhydrocephalic H-Tx rats, the hydrocephalic H-Tx rats were observed to show stronger expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus.
p14438
sg4
(lp14439
(dp14440
g7
I101
sg8
VP09429
p14441
sg10
I6
sg11
VHMGB-1
p14442
sg13
I1
sa(dp14443
g7
I101
sg8
VP09429
p14444
sg10
I6
sg11
VHMGB-1
p14445
sg13
I1
sa(dp14446
g7
I101
sg8
VP09429
p14447
sg10
I6
sg11
VHMGB-1
p14448
sg13
I1
sa(dp14449
g7
I101
sg8
VP09429
p14450
sg10
I6
sg11
VHMGB-1
p14451
sg13
I1
sasg14
(lp14452
(dp14453
g7
I270
sg17
VC0020255
p14454
sg10
I13
sg11
Vhydrocephalus
p14455
sg13
I1
sasa(dp14456
g2
VAll studies utilized an animal model such as AQP4-knockout mice, H-Tx rats, and kaolin and L-Alfa-lysophosphatidylcholine (LPC) stearoyl injection models of hydrocephalus.
p14457
sg4
(lp14458
(dp14459
g7
I45
sg8
VP55087
p14460
sg10
I4
sg11
VAQP4
p14461
sg13
I1
sasg14
(lp14462
(dp14463
g7
I157
sg17
VC0020255
p14464
sg10
I13
sg11
Vhydrocephalus
p14465
sg13
I1
sasa(dp14466
g2
VThe purpose of this study was to determine the efficacy of minocycline, an antibiotic known for its anti-inflammatory properties, to reduce gliosis in the H-Tx rat model of congenital hydrocephalus.
p14467
sg4
(lp14468
sg14
(lp14469
(dp14470
g7
I173
sg17
VC0020256
p14471
sg10
I24
sg11
Vcongenital hydrocephalus
p14472
sg13
I2
sa(dp14473
g7
I140
sg17
VC0017639
p14474
sg10
I7
sg11
Vgliosis
p14475
sg13
I1
sasa(dp14476
g2
VIt has been well documented that up to 70% of H-Tx rats' offspring suffer from severe hydrocephalus, which can be fatal if it remains untreated.
p14477
sg4
(lp14478
sg14
(lp14479
(dp14480
g7
I86
sg17
VC0020255
p14481
sg10
I13
sg11
Vhydrocephalus
p14482
sg13
I1
sa(dp14483
g7
I67
sg17
VC0683278
p14484
sg10
I6
sg11
Vsuffer
p14485
sg13
I1
sasa(dp14486
g2
VAside from the well-documented hydrocephalus, H-Tx rats may develop other intracranial malformations that have not yet been documented in the literature.
p14487
sg4
(lp14488
sg14
(lp14489
(dp14490
g7
I31
sg17
VC0020255
p14491
sg10
I13
sg11
Vhydrocephalus
p14492
sg13
I1
sa(dp14493
g7
I87
sg17
VC0000768
p14494
sg10
I13
sg11
Vmalformations
p14495
sg13
I1
sasa(dp14496
g2
VWe investigated the effect of vascular endothelial growth factor (VEGF)-C on lymphangiogenesis, inflammation, and fibrosis in the mouse kidney using the unilateral ureteral obstruction (UUO) model.
p14497
sg4
(lp14498
(dp14499
g7
I30
sg8
g24
sg10
I34
sg11
Vvascular endothelial growth factor
p14500
sg13
I4
sa(dp14501
g7
I66
sg8
g24
sg10
I4
sg11
VVEGF
p14502
sg13
I1
sasg14
(lp14503
(dp14504
g7
I164
sg17
VC0041956
p14505
sg10
I20
sg11
Vureteral obstruction
p14506
sg13
I2
sa(dp14507
g7
I114
sg17
VC0016059
p14508
sg10
I8
sg11
Vfibrosis
p14509
sg13
I1
sa(dp14510
g7
I96
sg17
VC0021368
p14511
sg10
I12
sg11
Vinflammation
p14512
sg13
I1
sa(dp14513
g7
I186
sg17
VC0041956
p14514
sg10
I3
sg11
VUUO
p14515
sg13
I1
sasa(dp14516
g2
VRenal fibrosis was consequently attenuated in the UUO+VEGF-C group.
p14517
sg4
(lp14518
(dp14519
g7
I50
sg8
VP49767
p14520
sg10
I10
sg11
VUUO+VEGF-C
p14521
sg13
I1
sasg14
(lp14522
(dp14523
g7
I0
sg17
VC0151650
p14524
sg10
I14
sg11
VRenal fibrosis
p14525
sg13
I2
sasa(dp14526
g2
VEnhancement of the VEGF-C signaling pathway in LECs may be a therapeutic strategy for renal fibrosis.Laboratory Investigation advance online publication, 30 October 2017; doi:10.1038/labinvest.2017.77.
p14527
sg4
(lp14528
(dp14529
g7
I19
sg8
VP49767
p14530
sg10
I6
sg11
VVEGF-C
p14531
sg13
I1
sasg14
(lp14532
(dp14533
g7
I86
sg17
VC0151650
p14534
sg10
I14
sg11
Vrenal fibrosis
p14535
sg13
I2
sasa(dp14536
g2
VHowever, the relevance of urinary and circulating VEGF-A165b levels in chronic kidney disease patients remains unclear.
p14537
sg4
(lp14538
sg14
(lp14539
(dp14540
g7
I71
sg17
VC1561643
p14541
sg10
I22
sg11
Vchronic kidney disease
p14542
sg13
I3
sasa(dp14543
g2
VTherefore, the present study aimed to investigate the urinary and circulating VEGF-A165b levels in patients with chronic kidney disease.
p14544
sg4
(lp14545
sg14
(lp14546
(dp14547
g7
I113
sg17
VC1561643
p14548
sg10
I22
sg11
Vchronic kidney disease
p14549
sg13
I3
sasa(dp14550
g2
VA low urinary VEGF-A165b level reflects renal dysfunction in the chronic kidney disease stage, while a high circulating VEGF-A165b level cannot be attributed to decreased renal clearance.
p14551
sg4
(lp14552
sg14
(lp14553
(dp14554
g7
I65
sg17
VC1561643
p14555
sg10
I22
sg11
Vchronic kidney disease
p14556
sg13
I3
sasa(dp14557
g2
VBy using a novel, advanced, multicolor fluorescence in situ hybridization approach, we enumerated copy numbers of six genes previously identified by array comparative genomic hybridization to be involved in aggressive prostate cancer [TBL1XR1, CTTNBP2, MYC (alias c-myc), PTEN, MEN1, and PDGFB] in six nonrecurrent and seven recurrent radical prostatectomy cases.
p14558
sg4
(lp14559
(dp14560
g7
I264
sg8
VP12524
p14561
sg10
I5
sg11
Vc-myc
p14562
sg13
I1
sa(dp14563
g7
I253
sg8
VP12524
p14564
sg10
I3
sg11
VMYC
p14565
sg13
I1
sa(dp14566
g7
I244
sg8
g24
sg10
I7
sg11
VCTTNBP2
p14567
sg13
I1
sa(dp14568
g7
I235
sg8
g24
sg10
I7
sg11
VTBL1XR1
p14569
sg13
I1
sa(dp14570
g7
I272
sg8
VP60484
p14571
sg10
I4
sg11
VPTEN
p14572
sg13
I1
sa(dp14573
g7
I278
sg8
g24
sg10
I4
sg11
VMEN1
p14574
sg13
I1
sasg14
(lp14575
(dp14576
g7
I278
sg17
VC0025267
p14577
sg10
I4
sg11
VMEN1
p14578
sg13
I1
sa(dp14579
g7
I218
sg17
VC0600139
p14580
sg10
I15
sg11
Vprostate cancer
p14581
sg13
I2
sa(dp14582
g7
I207
sg17
VC0001807
p14583
sg10
I10
sg11
Vaggressive
p14584
sg13
I1
sasa(dp14585
g2
VThe identification of higher NIHSS scores, higher HAMD scores, lower dopamine level, lower 5-hydroxytryptamine level, higher tumor necrosis factor-Alfa level, and lower nerve growth factor level might be useful for clinicians in recognizing and treating depression in patients after a stroke.
p14586
sg4
(lp14587
(dp14588
g7
I125
sg8
VP01375
p14589
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p14590
sg13
I3
sa(dp14591
g7
I169
sg8
VP01138
p14592
sg10
I19
sg11
Vnerve growth factor
p14593
sg13
I3
sasg14
(lp14594
(dp14595
g7
I254
sg17
VC0011581
p14596
sg10
I10
sg11
Vdepression
p14597
sg13
I1
sa(dp14598
g7
I125
sg17
VC0333516
p14599
sg10
I14
sg11
Vtumor necrosis
p14600
sg13
I2
sa(dp14601
g7
I285
sg17
VC0038454
p14602
sg10
I6
sg11
Vstroke
p14603
sg13
I1
sasa(dp14604
g2
VOther effects include a reduction in the platelet levels of adenosine triphosphate (ATP), serotonin (5-hydroxytryptamine), platelet factor 3 (PF3), PF4 and Beta-thromboglobulin (BTG), decreased platelet adhesiveness in platelets from healthy volunteers and from atherosclerotic patients and an improvement in red blood cell deformability in patients with occlusive vascular disease.
p14605
sg4
(lp14606
(dp14607
g7
I148
sg8
VP02776
p14608
sg10
I3
sg11
VPF4
p14609
sg13
I1
sa(dp14610
g7
I178
sg8
VP02775
p14611
sg10
I3
sg11
VBTG
p14612
sg13
I1
sa(dp14613
g7
I123
sg8
VP14770
p14614
sg10
I17
sg11
Vplatelet factor 3
p14615
sg13
I3
sa(dp14616
g7
I142
sg8
VP14770
p14617
sg10
I3
sg11
VPF3
p14618
sg13
I1
sa(dp14619
g7
I156
sg8
VP02775
p14620
sg10
I20
sg11
VBeta-thromboglobulin
p14621
sg13
I1
sasg14
(lp14622
(dp14623
g7
I355
sg17
VC0750145
p14624
sg10
I26
sg11
Vocclusive vascular disease
p14625
sg13
I3
sasa(dp14626
g2
VObjective: To explore the effect of trimetazidine pre-treatments on serum 5-hydroxytryptamine (5-HT) and serotonin transporter (SERT), platelet 5-HT and SERT in the Sprague Dawley rats with myocardial infarction(MI), depression, and myocardial infarction co-exist with depression (MI+ depression) and in sham operated rats.
p14627
sg4
(lp14628
(dp14629
g7
I128
sg8
VP31645
p14630
sg10
I4
sg11
VSERT
p14631
sg13
I1
sa(dp14632
g7
I105
sg8
VP31645
p14633
sg10
I21
sg11
Vserotonin transporter
p14634
sg13
I2
sa(dp14635
g7
I128
sg8
VP31645
p14636
sg10
I4
sg11
VSERT
p14637
sg13
I1
sasg14
(lp14638
(dp14639
g7
I217
sg17
VC0011581
p14640
sg10
I10
sg11
Vdepression
p14641
sg13
I1
sa(dp14642
g7
I217
sg17
VC0011581
p14643
sg10
I10
sg11
Vdepression
p14644
sg13
I1
sa(dp14645
g7
I217
sg17
VC0011581
p14646
sg10
I10
sg11
Vdepression
p14647
sg13
I1
sa(dp14648
g7
I190
sg17
VC0027051
p14649
sg10
I21
sg11
Vmyocardial infarction
p14650
sg13
I2
sa(dp14651
g7
I190
sg17
VC0027051
p14652
sg10
I21
sg11
Vmyocardial infarction
p14653
sg13
I2
sasa(dp14654
g2
VThe role of histone deacetylase-3 (HDAC3) in allergic skin inflammation was reported.
p14655
sg4
(lp14656
(dp14657
g7
I35
sg8
g24
sg10
I5
sg11
VHDAC3
p14658
sg13
I1
sa(dp14659
g7
I12
sg8
VP56524
p14660
sg10
I21
sg11
Vhistone deacetylase-3
p14661
sg13
I2
sasg14
(lp14662
(dp14663
g7
I54
sg17
VC0011603
p14664
sg10
I17
sg11
Vskin inflammation
p14665
sg13
I2
sasa(dp14666
g2
VIn this study, we investigated SERPINA3 expression in glioma tissue samples and its significance in predicting the prognosis of glioma patients.
p14667
sg4
(lp14668
sg14
(lp14669
(dp14670
g7
I54
sg17
VC0017638
p14671
sg10
I6
sg11
Vglioma
p14672
sg13
I1
sa(dp14673
g7
I54
sg17
VC0017638
p14674
sg10
I6
sg11
Vglioma
p14675
sg13
I1
sasa(dp14676
g2
VWe found that SERPINA3 was upregulated in glioma tissue at both mRNA and protein levels, compared with noncancerous brain tissues.
p14677
sg4
(lp14678
sg14
(lp14679
(dp14680
g7
I42
sg17
VC0017638
p14681
sg10
I6
sg11
Vglioma
p14682
sg13
I1
sasa(dp14683
g2
VWe also found that high SERPINA3 expression in glioma tissues correlated significantly with advanced World Health Organization grade.
p14684
sg4
(lp14685
sg14
(lp14686
(dp14687
g7
I47
sg17
VC0017638
p14688
sg10
I6
sg11
Vglioma
p14689
sg13
I1
sasa(dp14690
g2
VUnivariate and multivariate analyses revealed that high SERPINA3 expression was an independent prognostic factor for poor overall survival of glioma patients.
p14691
sg4
(lp14692
sg14
(lp14693
(dp14694
g7
I142
sg17
VC0017638
p14695
sg10
I6
sg11
Vglioma
p14696
sg13
I1
sasa(dp14697
g2
VTaken together, our results suggest that SERPINA3 plays an oncogenic role in glioma progression and provide an insight into the application of SERPINA3 as a novel predictor of clinical outcomes and a potential biomarker of glioma.
p14698
sg4
(lp14699
sg14
(lp14700
(dp14701
g7
I77
sg17
VC0017638
p14702
sg10
I6
sg11
Vglioma
p14703
sg13
I1
sa(dp14704
g7
I77
sg17
VC0017638
p14705
sg10
I6
sg11
Vglioma
p14706
sg13
I1
sasa(dp14707
g2
VTo investigate the expression and prognostic value of Alfa1-ACT (Alpha1-antichymotrypsin) in patients with HCC (hepatocellular carcinoma) and identify the mechanism by which Alfa1-ACT inhibits proliferation and promotes apoptosis of HCC.
p14708
sg4
(lp14709
(dp14710
g7
I54
sg8
VP63267
p14711
sg10
I9
sg11
VAlfa1-ACT
p14712
sg13
I1
sa(dp14713
g7
I54
sg8
VP63267
p14714
sg10
I9
sg11
VAlfa1-ACT
p14715
sg13
I1
sa(dp14716
g7
I72
sg8
VP05154
p14717
sg10
I16
sg11
Vantichymotrypsin
p14718
sg13
I1
sasg14
(lp14719
(dp14720
g7
I112
sg17
VC2239176
p14721
sg10
I24
sg11
Vhepatocellular carcinoma
p14722
sg13
I2
sa(dp14723
g7
I107
sg17
VC2239176
p14724
sg10
I3
sg11
VHCC
p14725
sg13
I1
sa(dp14726
g7
I193
sg17
VC0334094
p14727
sg10
I13
sg11
Vproliferation
p14728
sg13
I1
sa(dp14729
g7
I107
sg17
VC2239176
p14730
sg10
I3
sg11
VHCC
p14731
sg13
I1
sasa(dp14732
g2
VDeletions were found in LEC1 (9.5% versus 14.3%), LEC2 (4.8% versus 14.3%), cagT (33.3% versus 28.6%), cagE (28.6% versus 28.6%) and the promoter region of the cagA (19.0% versus 42.9%) of gastritis and PUD strains, respectively.
p14733
sg4
(lp14734
(dp14735
g7
I103
sg8
g24
sg10
I4
sg11
VcagE
p14736
sg13
I1
sa(dp14737
g7
I50
sg8
g24
sg10
I4
sg11
VLEC2
p14738
sg13
I1
sa(dp14739
g7
I24
sg8
g24
sg10
I4
sg11
VLEC1
p14740
sg13
I1
sa(dp14741
g7
I160
sg8
VP05109
p14742
sg10
I4
sg11
VcagA
p14743
sg13
I1
sasg14
(lp14744
(dp14745
g7
I203
sg17
VC0030920
p14746
sg10
I3
sg11
VPUD
p14747
sg13
I1
sa(dp14748
g7
I189
sg17
VC0017152
p14749
sg10
I9
sg11
Vgastritis
p14750
sg13
I1
sasa(dp14751
g2
VIn the seven women, increased FDG uptake was due to physiological endometrial uptake (n=2), leiomyoma (n=1), corpus luteum cyst (n=1), physiological ovarian uptake (n=1), urinary leak (n=1), and nonspecific colitis (n=1).
p14752
sg4
(lp14753
sg14
(lp14754
(dp14755
g7
I207
sg17
VC0009319
p14756
sg10
I7
sg11
Vcolitis
p14757
sg13
I1
sa(dp14758
g7
I92
sg17
VC0023267
p14759
sg10
I9
sg11
Vleiomyoma
p14760
sg13
I1
sa(dp14761
g7
I109
sg17
VC0010093
p14762
sg10
I18
sg11
Vcorpus luteum cyst
p14763
sg13
I3
sasa(dp14764
g2
VThe most significant quantitative trait locus, Hsm1 (hereditary spherocytosis modifier 1), localizes to mouse Chromosome 12 and is dominant.
p14765
sg4
(lp14766
(dp14767
g7
I53
sg8
g24
sg10
I35
sg11
Vhereditary spherocytosis modifier 1
p14768
sg13
I4
sa(dp14769
g7
I47
sg8
g24
sg10
I4
sg11
VHsm1
p14770
sg13
I1
sasg14
(lp14771
(dp14772
g7
I53
sg17
VC0037889
p14773
sg10
I24
sg11
Vhereditary spherocytosis
p14774
sg13
I2
sasa(dp14775
g2
VRates of noninfective synovitis and effusion ranged from 0.2% in the LARS ACL group to 27.6% in the Gore-Tex ACL group.
p14776
sg4
(lp14777
sg14
(lp14778
(dp14779
g7
I22
sg17
VC0039103
p14780
sg10
I9
sg11
Vsynovitis
p14781
sg13
I1
sa(dp14782
g7
I36
sg17
VC0013687
p14783
sg10
I8
sg11
Veffusion
p14784
sg13
I1
sasa(dp14785
g2
VPreliminary results for newer-generation devices, specifically the LARS, show lower reported rates of failure, revision, and sterile effusion/synovitis when compared with older devices.
p14786
sg4
(lp14787
sg14
(lp14788
(dp14789
g7
I142
sg17
VC0039103
p14790
sg10
I9
sg11
Vsynovitis
p14791
sg13
I1
sa(dp14792
g7
I133
sg17
VC0013687
p14793
sg10
I8
sg11
Veffusion
p14794
sg13
I1
sa(dp14795
g7
I125
sg17
VC0678108
p14796
sg10
I7
sg11
Vsterile
p14797
sg13
I1
sasa(dp14798
g2
VThe Ligament Augmentation and Reconstruction System (LARS) is a third generation of synthetic ligament, designed to overcome the issues of graft failure and synovitis which led previous generations of synthetic ligaments to fall out of favour.
p14799
sg4
(lp14800
sg14
(lp14801
(dp14802
g7
I139
sg17
VC1262018
p14803
sg10
I13
sg11
Vgraft failure
p14804
sg13
I2
sa(dp14805
g7
I157
sg17
VC0039103
p14806
sg10
I9
sg11
Vsynovitis
p14807
sg13
I1
sasa(dp14808
g2
VUsher syndrome type III (USH3), characterized by progressive deafness, variable balance disorder and blindness, is caused by destabilizing mutations in the gene encoding the clarin-1 (CLRN1) protein.
p14809
sg4
(lp14810
(dp14811
g7
I25
sg8
VP58418
p14812
sg10
I4
sg11
VUSH3
p14813
sg13
I1
sa(dp14814
g7
I184
sg8
VP58418
p14815
sg10
I5
sg11
VCLRN1
p14816
sg13
I1
sa(dp14817
g7
I174
sg8
VP58418
p14818
sg10
I8
sg11
Vclarin-1
p14819
sg13
I1
sasg14
(lp14820
(dp14821
g7
I25
sg17
VC1568248
p14822
sg10
I4
sg11
VUSH3
p14823
sg13
I1
sa(dp14824
g7
I61
sg17
VC0011053
p14825
sg10
I8
sg11
Vdeafness
p14826
sg13
I1
sa(dp14827
g7
I101
sg17
VC0456909
p14828
sg10
I9
sg11
Vblindness
p14829
sg13
I1
sa(dp14830
g7
I0
sg17
VC0271097
p14831
sg10
I14
sg11
VUsher syndrome
p14832
sg13
I2
sa(dp14833
g7
I80
sg17
VC0575090
p14834
sg10
I16
sg11
Vbalance disorder
p14835
sg13
I2
sasa(dp14836
g2
VMutations in the CLRN1 gene cause Usher syndrome type 3 (USH3), a human disease characterized by progressive blindness and deafness.
p14837
sg4
(lp14838
(dp14839
g7
I57
sg8
VP58418
p14840
sg10
I4
sg11
VUSH3
p14841
sg13
I1
sa(dp14842
g7
I17
sg8
VP58418
p14843
sg10
I10
sg11
VCLRN1 gene
p14844
sg13
I2
sa(dp14845
g7
I34
sg8
VP58418
p14846
sg10
I21
sg11
VUsher syndrome type 3
p14847
sg13
I4
sasg14
(lp14848
(dp14849
g7
I109
sg17
VC0456909
p14850
sg10
I9
sg11
Vblindness
p14851
sg13
I1
sa(dp14852
g7
I34
sg17
VC1568248
p14853
sg10
I21
sg11
VUsher syndrome type 3
p14854
sg13
I4
sa(dp14855
g7
I57
sg17
VC1568248
p14856
sg10
I4
sg11
VUSH3
p14857
sg13
I1
sa(dp14858
g7
I123
sg17
VC0011053
p14859
sg10
I8
sg11
Vdeafness
p14860
sg13
I1
sasa(dp14861
g2
VTaken together, CD47 might be a novel target to enhance anti-PD-1 and CLTA-4 efficacy in esophageal squamous cell cancer.
p14862
sg4
(lp14863
(dp14864
g7
I16
sg8
g24
sg10
I4
sg11
VCD47
p14865
sg13
I1
sa(dp14866
g7
I70
sg8
VP09496
p14867
sg10
I6
sg11
VCLTA-4
p14868
sg13
I1
sa(dp14869
g7
I56
sg8
VP18621
p14870
sg10
I9
sg11
Vanti-PD-1
p14871
sg13
I1
sasg14
(lp14872
(dp14873
g7
I100
sg17
VC0007137
p14874
sg10
I20
sg11
Vsquamous cell cancer
p14875
sg13
I3
sasa(dp14876
g2
VIpilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma.
p14877
sg4
(lp14878
(dp14879
g7
I24
sg8
VP09496
p14880
sg10
I15
sg11
VCLTA-4 antibody
p14881
sg13
I2
sasg14
(lp14882
(dp14883
g7
I91
sg17
VC0025202
p14884
sg10
I8
sg11
Vmelanoma
p14885
sg13
I1
sasa(dp14886
g2
VThe most prominent example of this shift is the management of metastatic melanoma, where BRAF and MEK inhibition and CLTA-4 blockade have established an entirely new standard of care in the last 3 years.
p14887
sg4
(lp14888
(dp14889
g7
I89
sg8
VP15056
p14890
sg10
I4
sg11
VBRAF
p14891
sg13
I1
sa(dp14892
g7
I117
sg8
VP09496
p14893
sg10
I6
sg11
VCLTA-4
p14894
sg13
I1
sa(dp14895
g7
I98
sg8
VP45985
p14896
sg10
I3
sg11
VMEK
p14897
sg13
I1
sasg14
(lp14898
(dp14899
g7
I62
sg17
VC0278883
p14900
sg10
I19
sg11
Vmetastatic melanoma
p14901
sg13
I2
sasa(dp14902
g2
VThis was associated with the decreased protein expression of Notch1, Notch2, Notch3 and Hey1, and the increased expression of the tumor suppressor microRNA (miR or miRNA)-200 family members (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) that are typically downregulated in colon cancer.
p14903
sg4
(lp14904
(dp14905
g7
I211
sg8
g24
sg10
I8
sg11
VmiR-200c
p14906
sg13
I1
sa(dp14907
g7
I88
sg8
g24
sg10
I4
sg11
VHey1
p14908
sg13
I1
sa(dp14909
g7
I233
sg8
g24
sg10
I7
sg11
VmiR-429
p14910
sg13
I1
sa(dp14911
g7
I221
sg8
g24
sg10
I7
sg11
VmiR-141
p14912
sg13
I1
sa(dp14913
g7
I201
sg8
g24
sg10
I8
sg11
VmiR-200b
p14914
sg13
I1
sa(dp14915
g7
I77
sg8
g24
sg10
I6
sg11
VNotch3
p14916
sg13
I1
sa(dp14917
g7
I61
sg8
VP46531
p14918
sg10
I6
sg11
VNotch1
p14919
sg13
I1
sa(dp14920
g7
I191
sg8
g24
sg10
I8
sg11
VmiR-200a
p14921
sg13
I1
sa(dp14922
g7
I69
sg8
g24
sg10
I6
sg11
VNotch2
p14923
sg13
I1
sasg14
(lp14924
(dp14925
g7
I130
sg17
VC0027651
p14926
sg10
I5
sg11
Vtumor
p14927
sg13
I1
sa(dp14928
g7
I278
sg17
VC0699790
p14929
sg10
I12
sg11
Vcolon cancer
p14930
sg13
I2
sasa(dp14931
g2
VPhosphorylated IGF-IR/IR (P-IGF-IR/IR) and its downstream signaling partner phospho-S6 (P-S6) were evaluated immunohistochemically in tumor tissue microarrays representing 438 cases of invasive breast cancer.
p14932
sg4
(lp14933
(dp14934
g7
I15
sg8
VP06213
p14935
sg10
I6
sg11
VIGF-IR
p14936
sg13
I1
sa(dp14937
g7
I19
sg8
VP06213
p14938
sg10
I2
sg11
VIR
p14939
sg13
I1
sa(dp14940
g7
I26
sg8
VP06213
p14941
sg10
I8
sg11
VP-IGF-IR
p14942
sg13
I1
sa(dp14943
g7
I19
sg8
VP06213
p14944
sg10
I2
sg11
VIR
p14945
sg13
I1
sasg14
(lp14946
(dp14947
g7
I185
sg17
VC0853879
p14948
sg10
I22
sg11
Vinvasive breast cancer
p14949
sg13
I3
sa(dp14950
g7
I134
sg17
VC0027651
p14951
sg10
I5
sg11
Vtumor
p14952
sg13
I1
sasa(dp14953
g2
VImportantly, P-IGF-IR/IR was detected in all breast cancer subtypes (luminal, 48.1%; triple negative, 41.9%; and HER2, 64.3%).
p14954
sg4
(lp14955
(dp14956
g7
I13
sg8
VP06213
p14957
sg10
I8
sg11
VP-IGF-IR
p14958
sg13
I1
sa(dp14959
g7
I19
sg8
VP06213
p14960
sg10
I2
sg11
VIR
p14961
sg13
I1
sasg14
(lp14962
(dp14963
g7
I45
sg17
VC0678222
p14964
sg10
I13
sg11
Vbreast cancer
p14965
sg13
I2
sasa(dp14966
g2
VThus, we can determine which patients have the activated receptor and provide evidence that P-IGF-IR/IR is a prognostic factor for breast cancer.
p14967
sg4
(lp14968
(dp14969
g7
I92
sg8
VP06213
p14970
sg10
I8
sg11
VP-IGF-IR
p14971
sg13
I1
sa(dp14972
g7
I98
sg8
VP06213
p14973
sg10
I2
sg11
VIR
p14974
sg13
I1
sasg14
(lp14975
(dp14976
g7
I131
sg17
VC0678222
p14977
sg10
I13
sg11
Vbreast cancer
p14978
sg13
I2
sasa(dp14979
g2
VBeyond this, P-IGF-IR/IR could be a predictive marker for response to IGF-IR and/or IR-targeted therapies, as these inhibitors may be of benefit in all breast cancer subtypes including those with acquired resistance to tamoxifen.
p14980
sg4
(lp14981
(dp14982
g7
I13
sg8
VP06213
p14983
sg10
I8
sg11
VP-IGF-IR
p14984
sg13
I1
sa(dp14985
g7
I15
sg8
VP06213
p14986
sg10
I6
sg11
VIGF-IR
p14987
sg13
I1
sa(dp14988
g7
I19
sg8
VP06213
p14989
sg10
I2
sg11
VIR
p14990
sg13
I1
sasg14
(lp14991
(dp14992
g7
I152
sg17
VC0678222
p14993
sg10
I13
sg11
Vbreast cancer
p14994
sg13
I2
sasa(dp14995
g2
VThe genes plo, fimA, fimC, fimE, fimG, nanH, nanP, and cbpA were investigated in 71 T. pyogenes strains recovered from cattle, sheep, goats, dogs, equines, and a pig, recovered from mastitis (n = 35), and non-mastitis (n = 36) cases (abscesses, reproductive tract diseases, pneumonia, lymphadenitis, encephalitis).
p14996
sg4
(lp14997
(dp14998
g7
I39
sg8
g24
sg10
I4
sg11
VnanH
p14999
sg13
I1
sa(dp15000
g7
I45
sg8
g24
sg10
I4
sg11
VnanP
p15001
sg13
I1
sasg14
(lp15002
(dp15003
g7
I182
sg17
VC3251795
p15004
sg10
I8
sg11
Vmastitis
p15005
sg13
I1
sa(dp15006
g7
I285
sg17
VC0024205
p15007
sg10
I13
sg11
Vlymphadenitis
p15008
sg13
I1
sa(dp15009
g7
I27
sg17
VC0917800
p15010
sg10
I4
sg11
VfimE
p15011
sg13
I1
sa(dp15012
g7
I274
sg17
VC0032285
p15013
sg10
I9
sg11
Vpneumonia
p15014
sg13
I1
sa(dp15015
g7
I234
sg17
VC0000833
p15016
sg10
I9
sg11
Vabscesses
p15017
sg13
I1
sa(dp15018
g7
I182
sg17
VC3251795
p15019
sg10
I8
sg11
Vmastitis
p15020
sg13
I1
sa(dp15021
g7
I300
sg17
VC0014038
p15022
sg10
I12
sg11
Vencephalitis
p15023
sg13
I1
sasa(dp15024
g2
VThe aim was to assess the prevalence of anaemia among quranic schoolchildren in khalawi Wad EL Magboul village, rural Rufaa, Gezira State, central Sudan.
p15025
sg4
(lp15026
sg14
(lp15027
(dp15028
g7
I40
sg17
VC0002871
p15029
sg10
I7
sg11
Vanaemia
p15030
sg13
I1
sasa(dp15031
g2
VThrombophilia was present in 294/482 (60.9%) patients: 189/350 LC (54.0%), 31/47 (66.0%) HCC, 29/39 (74.4%) MPN, 35/38 AD (92.1%), and 10/10 (100%) WAD, and 54/150 (36.0%) in HC.
p15032
sg4
(lp15033
sg14
(lp15034
(dp15035
g7
I0
sg17
VC2827470
p15036
sg10
I13
sg11
VThrombophilia
p15037
sg13
I1
sa(dp15038
g7
I89
sg17
VC2239176
p15039
sg10
I3
sg11
VHCC
p15040
sg13
I1
sasa(dp15041
g2
VA cross-sectional study was conducted to investigate the prevalence of anaemia, iron, zinc and copper deficiencies among pregnant women in Wad Medani hospital, central Sudan and to examine the relationship of these micronutrients with haemoglobin (Hb) levels.
p15042
sg4
(lp15043
(dp15044
g7
I235
sg8
g24
sg10
I11
sg11
Vhaemoglobin
p15045
sg13
I1
sa(dp15046
g7
I248
sg8
g24
sg10
I2
sg11
VHb
p15047
sg13
I1
sasg14
(lp15048
(dp15049
g7
I71
sg17
VC0002871
p15050
sg10
I7
sg11
Vanaemia
p15051
sg13
I1
sasa(dp15052
g2
VIn the orbivirinae this would result in 2 genera of cyanovirus (bluetongue, epizootic hemorrhagic disease, Eubenangee and Palyam sub-genera) and Kemerovovirus (Chenunda, Great Island, Kemerovo and Wad Medani sub-genera) and a number of ungrouped sub-genera (African horsesickness, Changuinola, Corriparta, equine encephalosis, Wallal and Warrego sub-genera and the remaining ungrouped viruses).
p15053
sg4
(lp15054
sg14
(lp15055
(dp15056
g7
I86
sg17
VC0019087
p15057
sg10
I19
sg11
Vhemorrhagic disease
p15058
sg13
I2
sa(dp15059
g7
I258
sg17
VC0001748
p15060
sg10
I21
sg11
VAfrican horsesickness
p15061
sg13
I2
sa(dp15062
g7
I64
sg17
VC0005866
p15063
sg10
I10
sg11
Vbluetongue
p15064
sg13
I1
sasa(dp15065
g2
VWe examined the expression of CT-1, leukemia inhibitory factor (LIF), and gp130 by competitive RT-PCR and Western blotting in Dahl salt-sensitive (DS) rats with a high-salt diet, which showed a distinct transition from left ventricular hypertrophy (LVH) to congestive heart failure (CHF).
p15066
sg4
(lp15067
(dp15068
g7
I36
sg8
VP15018
p15069
sg10
I26
sg11
Vleukemia inhibitory factor
p15070
sg13
I3
sa(dp15071
g7
I64
sg8
VP15018
p15072
sg10
I3
sg11
VLIF
p15073
sg13
I1
sa(dp15074
g7
I74
sg8
VP40189
p15075
sg10
I5
sg11
Vgp130
p15076
sg13
I1
sa(dp15077
g7
I30
sg8
g24
sg10
I4
sg11
VCT-1
p15078
sg13
I1
sasg14
(lp15079
(dp15080
g7
I249
sg17
VC0149721
p15081
sg10
I3
sg11
VLVH
p15082
sg13
I1
sa(dp15083
g7
I36
sg17
VC0023418
p15084
sg10
I8
sg11
Vleukemia
p15085
sg13
I1
sa(dp15086
g7
I257
sg17
VC0018802
p15087
sg10
I24
sg11
Vcongestive heart failure
p15088
sg13
I3
sa(dp15089
g7
I203
sg17
VC0599156
p15090
sg10
I10
sg11
Vtransition
p15091
sg13
I1
sa(dp15092
g7
I219
sg17
VC0149721
p15093
sg10
I28
sg11
Vleft ventricular hypertrophy
p15094
sg13
I3
sa(dp15095
g7
I283
sg17
VC0018802
p15096
sg10
I3
sg11
VCHF
p15097
sg13
I1
sasa(dp15098
g2
VNew factors signaling independently of the leukemia inhibitory-factor receptor pathway may sustain cardiomyocyte cell proliferation and thus be a future target for gene therapy of cardiomyopathies and cell therapy of the myocardium.
p15099
sg4
(lp15100
(dp15101
g7
I43
sg8
g24
sg10
I35
sg11
Vleukemia inhibitory-factor receptor
p15102
sg13
I3
sasg14
(lp15103
(dp15104
g7
I118
sg17
VC0334094
p15105
sg10
I13
sg11
Vproliferation
p15106
sg13
I1
sa(dp15107
g7
I180
sg17
VC0878544
p15108
sg10
I16
sg11
Vcardiomyopathies
p15109
sg13
I1
sa(dp15110
g7
I43
sg17
VC0023418
p15111
sg10
I8
sg11
Vleukemia
p15112
sg13
I1
sasa(dp15113
g2
VWe propose a model in which P-Rex1 acts as a crucial node for the integration of upstream inputs from HER/ErbB receptors and CXCR4 in luminal breast cancer cells.
p15114
sg4
(lp15115
(dp15116
g7
I125
sg8
VP61073
p15117
sg10
I5
sg11
VCXCR4
p15118
sg13
I1
sa(dp15119
g7
I28
sg8
g24
sg10
I6
sg11
VP-Rex1
p15120
sg13
I1
sa(dp15121
g7
I106
sg8
g24
sg10
I14
sg11
VErbB receptors
p15122
sg13
I2
sasg14
(lp15123
(dp15124
g7
I142
sg17
VC0678222
p15125
sg10
I13
sg11
Vbreast cancer
p15126
sg13
I2
sasa(dp15127
g2
VNotably, there is a significant association in the expression of P-Rex1 and MMP10 in human luminal breast cancer, and their co-expression is indicative of poor prognosis.
p15128
sg4
(lp15129
(dp15130
g7
I76
sg8
VP09238
p15131
sg10
I5
sg11
VMMP10
p15132
sg13
I1
sa(dp15133
g7
I65
sg8
g24
sg10
I6
sg11
VP-Rex1
p15134
sg13
I1
sasg14
(lp15135
(dp15136
g7
I99
sg17
VC0678222
p15137
sg10
I13
sg11
Vbreast cancer
p15138
sg13
I2
sasa(dp15139
g2
VTreatment of normal MCF-10A or basal-like cancer cells, MDA-MB-231 with the demethylating agent 5-aza-2'-deoxycitidine in combination with the histone deacetylase inhibitor trichostatin A restores P-REX1 levels to those observed in luminal breast cancer cell lines, suggesting that aberrant expression of P-REX1 in luminal breast cancer is a consequence of PREX1 promoter demethylation.
p15140
sg4
(lp15141
(dp15142
g7
I197
sg8
g24
sg10
I6
sg11
VP-REX1
p15143
sg13
I1
sa(dp15144
g7
I197
sg8
g24
sg10
I6
sg11
VP-REX1
p15145
sg13
I1
sa(dp15146
g7
I163
sg8
VP32119
p15147
sg10
I24
sg11
Vinhibitor trichostatin A
p15148
sg13
I3
sa(dp15149
g7
I143
sg8
VP56524
p15150
sg10
I19
sg11
Vhistone deacetylase
p15151
sg13
I2
sasg14
(lp15152
(dp15153
g7
I240
sg17
VC0678222
p15154
sg10
I13
sg11
Vbreast cancer
p15155
sg13
I2
sa(dp15156
g7
I42
sg17
VC0006826
p15157
sg10
I6
sg11
Vcancer
p15158
sg13
I1
sa(dp15159
g7
I240
sg17
VC0678222
p15160
sg10
I13
sg11
Vbreast cancer
p15161
sg13
I2
sasa(dp15162
g2
VWe identify 112 candidate ciliogenesis and ciliopathy genes, including 44 components of the ubiquitin-proteasome system, 12 G-protein-coupled receptors, and 3 pre-mRNA processing factors (PRPF6, PRPF8 and PRPF31) mutated in autosomal dominant retinitis pigmentosa.
p15163
sg4
(lp15164
(dp15165
g7
I195
sg8
g24
sg10
I5
sg11
VPRPF8
p15166
sg13
I1
sa(dp15167
g7
I121
sg8
g24
sg10
I30
sg11
V12 G-protein-coupled receptors
p15168
sg13
I3
sa(dp15169
g7
I205
sg8
g24
sg10
I6
sg11
VPRPF31
p15170
sg13
I1
sa(dp15171
g7
I188
sg8
g24
sg10
I5
sg11
VPRPF6
p15172
sg13
I1
sa(dp15173
g7
I92
sg8
VP62979
p15174
sg10
I9
sg11
Vubiquitin
p15175
sg13
I1
sasg14
(lp15176
(dp15177
g7
I224
sg17
VC0339525
p15178
sg10
I39
sg11
Vautosomal dominant retinitis pigmentosa
p15179
sg13
I4
sasa(dp15180
g2
VMutations in six spliceosomal proteins, PRPF3, PRPF4, PRPF6, PRPF8, PRPF31 and SNRNP200, cause retinitis pigmentosa (RP), a disease characterized by progressive photoreceptor degeneration.
p15181
sg4
(lp15182
(dp15183
g7
I47
sg8
g24
sg10
I5
sg11
VPRPF4
p15184
sg13
I1
sa(dp15185
g7
I68
sg8
g24
sg10
I6
sg11
VPRPF31
p15186
sg13
I1
sa(dp15187
g7
I79
sg8
g24
sg10
I8
sg11
VSNRNP200
p15188
sg13
I1
sa(dp15189
g7
I54
sg8
g24
sg10
I5
sg11
VPRPF6
p15190
sg13
I1
sa(dp15191
g7
I61
sg8
g24
sg10
I5
sg11
VPRPF8
p15192
sg13
I1
sa(dp15193
g7
I40
sg8
g24
sg10
I5
sg11
VPRPF3
p15194
sg13
I1
sasg14
(lp15195
(dp15196
g7
I41
sg17
VC0035334
p15197
sg10
I2
sg11
VRP
p15198
sg13
I1
sa(dp15199
g7
I95
sg17
VC0035334
p15200
sg10
I20
sg11
Vretinitis pigmentosa
p15201
sg13
I2
sa(dp15202
g7
I161
sg17
VC1998028
p15203
sg10
I26
sg11
Vphotoreceptor degeneration
p15204
sg13
I2
sasa(dp15205
g2
VIn addition, a pAsn477Ser change in the neighboring gene PRPF6, a gene previously found to be associated with retinitis pigmentosa, segregated with the ADKD phenotype.
p15206
sg4
(lp15207
(dp15208
g7
I52
sg8
g24
sg10
I10
sg11
Vgene PRPF6
p15209
sg13
I2
sasg14
(lp15210
(dp15211
g7
I110
sg17
VC0035334
p15212
sg10
I20
sg11
Vretinitis pigmentosa
p15213
sg13
I2
sasa(dp15214
g2
VYeast two-hybrid analyses suggest a link between retinitis pigmentosa and an aberrant hPrp31-hPrp6 interaction that blocks U4/U6-U5 tri-snRNP formation.
p15215
sg4
(lp15216
(dp15217
g7
I93
sg8
g24
sg10
I5
sg11
VhPrp6
p15218
sg13
I1
sa(dp15219
g7
I86
sg8
g24
sg10
I6
sg11
VhPrp31
p15220
sg13
I1
sasg14
(lp15221
(dp15222
g7
I49
sg17
VC0035334
p15223
sg10
I20
sg11
Vretinitis pigmentosa
p15224
sg13
I2
sasa(dp15225
g2
VIn humans and in mice, mutations in the Ostm1 gene cause the most severe form of osteopetrosis, a major bone disease, and neuronal degeneration, both of which are associated with early death.
p15226
sg4
(lp15227
(dp15228
g7
I40
sg8
g24
sg10
I10
sg11
VOstm1 gene
p15229
sg13
I2
sasg14
(lp15230
(dp15231
g7
I81
sg17
VC0029454
p15232
sg10
I13
sg11
Vosteopetrosis
p15233
sg13
I1
sa(dp15234
g7
I131
sg17
VC0011164
p15235
sg10
I12
sg11
Vdegeneration
p15236
sg13
I1
sa(dp15237
g7
I104
sg17
VC0005940
p15238
sg10
I12
sg11
Vbone disease
p15239
sg13
I2
sasa(dp15240
g2
VGenetic defects in OSTM1 (osteopetrosis-associated transmembrane protein 1) cause autosomal recessive osteopetrosis in humans.
p15241
sg4
(lp15242
sg14
(lp15243
(dp15244
g7
I26
sg17
VC0029454
p15245
sg10
I13
sg11
Vosteopetrosis
p15246
sg13
I1
sa(dp15247
g7
I26
sg17
VC0029454
p15248
sg10
I13
sg11
Vosteopetrosis
p15249
sg13
I1
sasa(dp15250
g2
VThus, these findings suggest that autosomal recessive osteopetrosis patients with an OSTM1 gene mutation lacking the transmembrane domain produce a secreted form of truncated OSTM1 that inhibits osteoclastogenesis.
p15251
sg4
(lp15252
(dp15253
g7
I85
sg8
g24
sg10
I10
sg11
VOSTM1 gene
p15254
sg13
I2
sasg14
(lp15255
(dp15256
g7
I54
sg17
VC0029454
p15257
sg10
I13
sg11
Vosteopetrosis
p15258
sg13
I1
sasa(dp15259
g2
VLoss of the lysosomal ClC-7/Ostm1 2Cl(-)/H(+) exchanger causes lysosomal storage disease and osteopetrosis in humans and additionally changes fur colour in mice.
p15260
sg4
(lp15261
(dp15262
g7
I12
sg8
VP51798
p15263
sg10
I15
sg11
Vlysosomal ClC-7
p15264
sg13
I2
sa(dp15265
g7
I28
sg8
g24
sg10
I5
sg11
VOstm1
p15266
sg13
I1
sasg14
(lp15267
(dp15268
g7
I63
sg17
VC0085078
p15269
sg10
I25
sg11
Vlysosomal storage disease
p15270
sg13
I3
sa(dp15271
g7
I93
sg17
VC0029454
p15272
sg10
I13
sg11
Vosteopetrosis
p15273
sg13
I1
sasa(dp15274
g2
VLoss of Ostm1 leads to the most severe form of osteopetrosis in mice and humans.
p15275
sg4
(lp15276
(dp15277
g7
I8
sg8
g24
sg10
I5
sg11
VOstm1
p15278
sg13
I1
sasg14
(lp15279
(dp15280
g7
I47
sg17
VC0029454
p15281
sg10
I13
sg11
Vosteopetrosis
p15282
sg13
I1
sasa(dp15283
g2
VMice lacking either ClC-7 or Ostm1 develop a lysosomal storage disease and mutations in either protein have been found to underlie osteopetrosis in mice and humans.
p15284
sg4
(lp15285
(dp15286
g7
I20
sg8
VP51798
p15287
sg10
I5
sg11
VClC-7
p15288
sg13
I1
sa(dp15289
g7
I29
sg8
g24
sg10
I5
sg11
VOstm1
p15290
sg13
I1
sasg14
(lp15291
(dp15292
g7
I45
sg17
VC0085078
p15293
sg10
I25
sg11
Vlysosomal storage disease
p15294
sg13
I3
sa(dp15295
g7
I131
sg17
VC0029454
p15296
sg10
I13
sg11
Vosteopetrosis
p15297
sg13
I1
sasa(dp15298
g2
VMice or humans lacking ClC-7 or Ostm1 display osteopetrosis and lysosomal storage disease.
p15299
sg4
(lp15300
(dp15301
g7
I32
sg8
g24
sg10
I5
sg11
VOstm1
p15302
sg13
I1
sa(dp15303
g7
I23
sg8
VP51798
p15304
sg10
I5
sg11
VClC-7
p15305
sg13
I1
sasg14
(lp15306
(dp15307
g7
I64
sg17
VC0085078
p15308
sg10
I25
sg11
Vlysosomal storage disease
p15309
sg13
I3
sa(dp15310
g7
I46
sg17
VC0029454
p15311
sg10
I13
sg11
Vosteopetrosis
p15312
sg13
I1
sasa(dp15313
g2
VHere we describe for the first time homozygous microdeletions of different sizes affecting the OSTM1 gene in two unrelated consanguineous families with children suffering from neuronopathic infantile malignant osteopetrosis.
p15314
sg4
(lp15315
(dp15316
g7
I95
sg8
g24
sg10
I10
sg11
VOSTM1 gene
p15317
sg13
I2
sasg14
(lp15318
(dp15319
g7
I161
sg17
VC0683278
p15320
sg10
I9
sg11
Vsuffering
p15321
sg13
I1
sa(dp15322
g7
I190
sg17
VC1318518
p15323
sg10
I33
sg11
Vinfantile malignant osteopetrosis
p15324
sg13
I3
sasa(dp15325
g2
VOur findings are summarized as follows: i) BPY2 (testis basic protein on Y, 2), DAZ1 (deleted in azoospermia 1), TTY4 (testis transcript Y 4) mRNAs and 23 ESTs were found; ii) Eighteen of 23 ESTs were transcripts of the DAZ gene(s), one EST was a transcript of TTY4 gene, and the remaining 4 probably corresponded to 4 different pseudogenes; iii) DAZ gene(s) were expressed not only in testis, but also in lung carcinoma cells, stomach and Ewing's sarcoma cells; iv) beta-satellite clusters were present around and within the BPY2 and TTY4 gene region; v) In this study, TTY4, BPY2 and DAZ1 genes were mapped precisely to the AC010088 region.
p15326
sg4
(lp15327
(dp15328
g7
I80
sg8
g24
sg10
I4
sg11
VDAZ1
p15329
sg13
I1
sa(dp15330
g7
I49
sg8
VP15735
p15331
sg10
I20
sg11
Vtestis basic protein
p15332
sg13
I3
sa(dp15333
g7
I43
sg8
g24
sg10
I4
sg11
VBPY2
p15334
sg13
I1
sa(dp15335
g7
I220
sg8
g24
sg10
I8
sg11
VDAZ gene
p15336
sg13
I2
sa(dp15337
g7
I220
sg8
g24
sg10
I11
sg11
VDAZ gene(s)
p15338
sg13
I2
sa(dp15339
g7
I43
sg8
g24
sg10
I4
sg11
VBPY2
p15340
sg13
I1
sa(dp15341
g7
I586
sg8
g24
sg10
I10
sg11
VDAZ1 genes
p15342
sg13
I2
sa(dp15343
g7
I43
sg8
g24
sg10
I4
sg11
VBPY2
p15344
sg13
I1
sa(dp15345
g7
I86
sg8
g24
sg10
I24
sg11
Vdeleted in azoospermia 1
p15346
sg13
I4
sasg14
(lp15347
(dp15348
g7
I406
sg17
VC0684249
p15349
sg10
I14
sg11
Vlung carcinoma
p15350
sg13
I2
sa(dp15351
g7
I440
sg17
VC0553580
p15352
sg10
I15
sg11
VEwing's sarcoma
p15353
sg13
I2
sa(dp15354
g7
I97
sg17
VC1321542
p15355
sg10
I11
sg11
Vazoospermia
p15356
sg13
I1
sasa(dp15357
g2
VLowered POMC and heightened TRPV3 expressions in the HN and mNTS are involved in development of hyperphagia and obesity in OP rats.
p15358
sg4
(lp15359
(dp15360
g7
I8
sg8
VP01189
p15361
sg10
I4
sg11
VPOMC
p15362
sg13
I1
sa(dp15363
g7
I28
sg8
g24
sg10
I5
sg11
VTRPV3
p15364
sg13
I1
sasg14
(lp15365
(dp15366
g7
I112
sg17
VC0028754
p15367
sg10
I7
sg11
Vobesity
p15368
sg13
I1
sa(dp15369
g7
I96
sg17
VC0020505
p15370
sg10
I11
sg11
Vhyperphagia
p15371
sg13
I1
sasa(dp15372
g2
VHere, we have shown that it is applicable to 10 human colorectal carcinoma cell lines with a direct correlation between viral toxicity and CPG2 production.
p15373
sg4
(lp15374
sg14
(lp15375
(dp15376
g7
I54
sg17
VC0009402
p15377
sg10
I20
sg11
Vcolorectal carcinoma
p15378
sg13
I2
sasa(dp15379
g2
VTen patients with colorectal carcinoma expressing carcinoembryonic antigen received antibody-directed enzyme prodrug therapy with A5B7 F(ab')2 antibody to carcinoembryonic antigen conjugated to carboxypeptidase G2 (CPG2).
p15380
sg4
(lp15381
(dp15382
g7
I194
sg8
VP10619
p15383
sg10
I19
sg11
Vcarboxypeptidase G2
p15384
sg13
I2
sa(dp15385
g7
I50
sg8
VP40198
p15386
sg10
I24
sg11
Vcarcinoembryonic antigen
p15387
sg13
I2
sa(dp15388
g7
I215
sg8
VP10619
p15389
sg10
I4
sg11
VCPG2
p15390
sg13
I1
sasg14
(lp15391
(dp15392
g7
I18
sg17
VC0009402
p15393
sg10
I20
sg11
Vcolorectal carcinoma
p15394
sg13
I2
sasa(dp15395
g2
VHuman tumor cell lines A2780, SK-OV-3 (ovarian adenocarcinomas), LS174T, and WiDr (colon carcinomas) were engineered to express constitutively either CPG2 or bacterial beta-galactosidase.
p15396
sg4
(lp15397
(dp15398
g7
I158
sg8
VP16278
p15399
sg10
I28
sg11
Vbacterial beta-galactosidase
p15400
sg13
I2
sasg14
(lp15401
(dp15402
g7
I6
sg17
VC0027651
p15403
sg10
I5
sg11
Vtumor
p15404
sg13
I1
sa(dp15405
g7
I47
sg17
VC0001418
p15406
sg10
I15
sg11
Vadenocarcinomas
p15407
sg13
I1
sa(dp15408
g7
I52
sg17
VC0007097
p15409
sg10
I10
sg11
Vcarcinomas
p15410
sg13
I1
sasa(dp15411
g2
VThey have been used to treat mouse models of connective tissue disease such as lumican-null (Lum) and mucopolysaccharidosis (Gusb) mice.
p15412
sg4
(lp15413
(dp15414
g7
I93
sg8
VP51884
p15415
sg10
I3
sg11
VLum
p15416
sg13
I1
sa(dp15417
g7
I79
sg8
VP51884
p15418
sg10
I12
sg11
Vlumican-null
p15419
sg13
I1
sasg14
(lp15420
(dp15421
g7
I45
sg17
VC0009782
p15422
sg10
I25
sg11
Vconnective tissue disease
p15423
sg13
I3
sa(dp15424
g7
I102
sg17
VC0026703
p15425
sg10
I21
sg11
Vmucopolysaccharidosis
p15426
sg13
I1
sasa(dp15427
g2
VExpression of fibromodulin was significantly higher in plaques obtained from patients with diabetes and a high fibromodulin expression was associated with a higher incidence of post-operative cerebrovascular events, whereas no such associations were seen for lumican.
p15428
sg4
(lp15429
(dp15430
g7
I14
sg8
g24
sg10
I12
sg11
Vfibromodulin
p15431
sg13
I1
sa(dp15432
g7
I259
sg8
VP51884
p15433
sg10
I7
sg11
Vlumican
p15434
sg13
I1
sa(dp15435
g7
I14
sg8
g24
sg10
I12
sg11
Vfibromodulin
p15436
sg13
I1
sasg14
(lp15437
(dp15438
g7
I55
sg17
VC0333463
p15439
sg10
I7
sg11
Vplaques
p15440
sg13
I1
sa(dp15441
g7
I91
sg17
VC0011849
p15442
sg10
I8
sg11
Vdiabetes
p15443
sg13
I1
sasa(dp15444
g2
VThis study aimed to identify which myometrial ECM components are affected by diabetes, including fibril-forming collagen types I, III and V, as well as proteoglycans, decorin, lumican, fibromodulin and biglycan.
p15445
sg4
(lp15446
(dp15447
g7
I185
sg8
g24
sg10
I12
sg11
Vfibromodulin
p15448
sg13
I1
sa(dp15449
g7
I176
sg8
VP51884
p15450
sg10
I7
sg11
Vlumican
p15451
sg13
I1
sa(dp15452
g7
I35
sg8
g24
sg10
I25
sg11
Vmyometrial ECM components
p15453
sg13
I3
sa(dp15454
g7
I167
sg8
VP07585
p15455
sg10
I7
sg11
Vdecorin
p15456
sg13
I1
sasg14
(lp15457
(dp15458
g7
I77
sg17
VC0011849
p15459
sg10
I8
sg11
Vdiabetes
p15460
sg13
I1
sasa(dp15461
g2
VUsing the polymicrobial model of murine sepsis, we investigated the role of C5a receptors in septic lymphopenia.
p15462
sg4
(lp15463
(dp15464
g7
I76
sg8
VP21730
p15465
sg10
I13
sg11
VC5a receptors
p15466
sg13
I2
sasg14
(lp15467
(dp15468
g7
I40
sg17
VC0243026
p15469
sg10
I6
sg11
Vsepsis
p15470
sg13
I1
sa(dp15471
g7
I100
sg17
VC0024312
p15472
sg10
I11
sg11
Vlymphopenia
p15473
sg13
I1
sasa(dp15474
g2
VIn wild-type mice, cecal ligation and puncture resulted in splenocyte apoptosis and significant lymphopenia after 3 d, which was not observed in C5aR1(-/-) or C5aR2(-/-) mice.
p15475
sg4
(lp15476
(dp15477
g7
I145
sg8
VP21730
p15478
sg10
I5
sg11
VC5aR1
p15479
sg13
I1
sasg14
(lp15480
(dp15481
g7
I96
sg17
VC0024312
p15482
sg10
I11
sg11
Vlymphopenia
p15483
sg13
I1
sasa(dp15484
g2
VNDT 9513727 effectively inhibited C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo.
p15485
sg4
(lp15486
(dp15487
g7
I34
sg8
VP21730
p15488
sg10
I3
sg11
VC5a
p15489
sg13
I1
sasg14
(lp15490
sa(dp15491
g2
VNonetheless, topical application of C5aR antagonists produced circulating levels of the drugs that antagonized the LPS-induced systemic responses of neutropenia and hypotension.
p15492
sg4
(lp15493
(dp15494
g7
I36
sg8
VP21730
p15495
sg10
I4
sg11
VC5aR
p15496
sg13
I1
sasg14
(lp15497
(dp15498
g7
I115
sg17
VC0175697
p15499
sg10
I3
sg11
VLPS
p15500
sg13
I1
sasa(dp15501
g2
VSeveral of these antigens (CD2, CD25, CD35, CD88, CD203c) appear to be upregulated on MCs in patients with systemic mastocytosis and therefore are used as diagnostic markers.
p15502
sg4
(lp15503
(dp15504
g7
I27
sg8
VP06729
p15505
sg10
I3
sg11
VCD2
p15506
sg13
I1
sa(dp15507
g7
I50
sg8
g24
sg10
I6
sg11
VCD203c
p15508
sg13
I1
sa(dp15509
g7
I32
sg8
VP01589
p15510
sg10
I4
sg11
VCD25
p15511
sg13
I1
sa(dp15512
g7
I44
sg8
VP21730
p15513
sg10
I4
sg11
VCD88
p15514
sg13
I1
sa(dp15515
g7
I38
sg8
VP11274
p15516
sg10
I4
sg11
VCD35
p15517
sg13
I1
sasg14
(lp15518
(dp15519
g7
I86
sg17
VC0036221
p15520
sg10
I3
sg11
VMCs
p15521
sg13
I1
sa(dp15522
g7
I107
sg17
VC0221013
p15523
sg10
I21
sg11
Vsystemic mastocytosis
p15524
sg13
I2
sasa(dp15525
g2
VThis study analysed the expression of various complement-related cell surface antigens (CD11b/CR3, CD11c/CR4, CD35/CR1, CD55/DAF, CD59/MIRL, CD88/C5aR) on bone marrow mast cells (BMMC) in patients suffering from systemic mastocytosis (SM), other haematological diseases and non-haematological disorders (control groups).
p15526
sg4
(lp15527
(dp15528
g7
I125
sg8
VP08174
p15529
sg10
I3
sg11
VDAF
p15530
sg13
I1
sa(dp15531
g7
I146
sg8
VP21730
p15532
sg10
I4
sg11
VC5aR
p15533
sg13
I1
sa(dp15534
g7
I46
sg8
g24
sg10
I40
sg11
Vcomplement-related cell surface antigens
p15535
sg13
I4
sa(dp15536
g7
I130
sg8
VP13987
p15537
sg10
I4
sg11
VCD59
p15538
sg13
I1
sa(dp15539
g7
I115
sg8
VP17927
p15540
sg10
I3
sg11
VCR1
p15541
sg13
I1
sa(dp15542
g7
I105
sg8
VP20702
p15543
sg10
I3
sg11
VCR4
p15544
sg13
I1
sa(dp15545
g7
I88
sg8
VP11215
p15546
sg10
I5
sg11
VCD11b
p15547
sg13
I1
sa(dp15548
g7
I110
sg8
VP11274
p15549
sg10
I4
sg11
VCD35
p15550
sg13
I1
sa(dp15551
g7
I120
sg8
VP08174
p15552
sg10
I4
sg11
VCD55
p15553
sg13
I1
sa(dp15554
g7
I94
sg8
VP51864
p15555
sg10
I3
sg11
VCR3
p15556
sg13
I1
sa(dp15557
g7
I135
sg8
VP13987
p15558
sg10
I4
sg11
VMIRL
p15559
sg13
I1
sa(dp15560
g7
I99
sg8
VP20702
p15561
sg10
I5
sg11
VCD11c
p15562
sg13
I1
sa(dp15563
g7
I141
sg8
VP21730
p15564
sg10
I4
sg11
VCD88
p15565
sg13
I1
sasg14
(lp15566
(dp15567
g7
I278
sg17
VC0018939
p15568
sg10
I24
sg11
Vhaematological disorders
p15569
sg13
I2
sa(dp15570
g7
I197
sg17
VC0683278
p15571
sg10
I9
sg11
Vsuffering
p15572
sg13
I1
sa(dp15573
g7
I235
sg17
VC0221013
p15574
sg10
I2
sg11
VSM
p15575
sg13
I1
sa(dp15576
g7
I212
sg17
VC0221013
p15577
sg10
I21
sg11
Vsystemic mastocytosis
p15578
sg13
I2
sasa(dp15579
g2
VA cyclic peptide, Phe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] (F-[OPdChaWR]), was recently shown in vitro to antagonise the binding of C5a to its receptor (CD88) on human polymorphonuclear leukocytes (PMNs) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide (LPS) in rats.
p15580
sg4
(lp15581
(dp15582
g7
I154
sg8
VP21730
p15583
sg10
I4
sg11
VCD88
p15584
sg13
I1
sa(dp15585
g7
I133
sg8
VP21730
p15586
sg10
I3
sg11
VC5a
p15587
sg13
I1
sasg14
(lp15588
(dp15589
g7
I260
sg17
VC0036983
p15590
sg10
I12
sg11
Vseptic shock
p15591
sg13
I2
sa(dp15592
g7
I304
sg17
VC0175697
p15593
sg10
I3
sg11
VLPS
p15594
sg13
I1
sa(dp15595
g7
I284
sg17
VC0175697
p15596
sg10
I18
sg11
Vlipopolysaccharide
p15597
sg13
I1
sasa(dp15598
g2
VSome in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs).
p15599
sg4
(lp15600
(dp15601
g7
I31
sg8
g24
sg10
I14
sg11
Vcomplement C5a
p15602
sg13
I2
sasg14
(lp15603
sa(dp15604
g2
VThe abnormal C5aR expression on eosinophils and neutrophils became normal after spontaneous resolution of symptoms and blood eosinophilia.
p15605
sg4
(lp15606
(dp15607
g7
I13
sg8
VP21730
p15608
sg10
I4
sg11
VC5aR
p15609
sg13
I1
sasg14
(lp15610
(dp15611
g7
I125
sg17
VC0014457
p15612
sg10
I12
sg11
Veosinophilia
p15613
sg13
I1
sasa(dp15614
g2
VThe therapeutic potential of DPPSC was tested in a wound healing mouse model and in two genetic mouse models of muscular dystrophy (Scid/mdx and Sgcb-null Rag2-null Gammac-null).
p15615
sg4
(lp15616
(dp15617
g7
I145
sg8
VP55895
p15618
sg10
I31
sg11
VSgcb-null Rag2-null Gammac-null
p15619
sg13
I3
sasg14
(lp15620
(dp15621
g7
I112
sg17
VC0026850
p15622
sg10
I18
sg11
Vmuscular dystrophy
p15623
sg13
I2
sa(dp15624
g7
I137
sg17
VC1839839
p15625
sg10
I3
sg11
Vmdx
p15626
sg13
I1
sa(dp15627
g7
I132
sg17
VC0085110
p15628
sg10
I4
sg11
VScid
p15629
sg13
I1
sasa(dp15630
g2
VMutations in the RAG1/RAG2 genes are associated with a broad spectrum of clinical phenotypes, ranging from severe combined immunodeficiency to various autoimmune diseases.
p15631
sg4
(lp15632
(dp15633
g7
I22
sg8
VP55895
p15634
sg10
I4
sg11
VRAG2
p15635
sg13
I1
sa(dp15636
g7
I17
sg8
VP15918
p15637
sg10
I4
sg11
VRAG1
p15638
sg13
I1
sasg14
(lp15639
(dp15640
g7
I107
sg17
VC0085110
p15641
sg10
I32
sg11
Vsevere combined immunodeficiency
p15642
sg13
I3
sa(dp15643
g7
I151
sg17
VC0004364
p15644
sg10
I19
sg11
Vautoimmune diseases
p15645
sg13
I2
sasa(dp15646
g2
VIn this review, the molecular pathology of diseases caused by RAG1/RAG2 mutations, in particular Omenn syndrome, will be discussed.
p15647
sg4
(lp15648
(dp15649
g7
I62
sg8
VP15918
p15650
sg10
I4
sg11
VRAG1
p15651
sg13
I1
sa(dp15652
g7
I67
sg8
VP55895
p15653
sg10
I4
sg11
VRAG2
p15654
sg13
I1
sasg14
(lp15655
(dp15656
g7
I30
sg17
VC0677042
p15657
sg10
I9
sg11
Vpathology
p15658
sg13
I1
sa(dp15659
g7
I97
sg17
VC1801959
p15660
sg10
I14
sg11
VOmenn syndrome
p15661
sg13
I2
sasa(dp15662
g2
VSevere combined immunodeficiency (SCID) is a potentially fatal primary immunodeficiency (PID) that is caused by mutations in genes such as IL2RG, JAK3, IL7RA, RAG1, RAG2, and ADA.
p15663
sg4
(lp15664
(dp15665
g7
I159
sg8
VP15918
p15666
sg10
I4
sg11
VRAG1
p15667
sg13
I1
sa(dp15668
g7
I139
sg8
VP31785
p15669
sg10
I5
sg11
VIL2RG
p15670
sg13
I1
sa(dp15671
g7
I175
sg8
VP00813
p15672
sg10
I3
sg11
VADA
p15673
sg13
I1
sa(dp15674
g7
I165
sg8
VP55895
p15675
sg10
I4
sg11
VRAG2
p15676
sg13
I1
sa(dp15677
g7
I146
sg8
VP52333
p15678
sg10
I4
sg11
VJAK3
p15679
sg13
I1
sasg14
(lp15680
(dp15681
g7
I34
sg17
VC0085110
p15682
sg10
I4
sg11
VSCID
p15683
sg13
I1
sa(dp15684
g7
I63
sg17
VC0398686
p15685
sg10
I24
sg11
Vprimary immunodeficiency
p15686
sg13
I2
sa(dp15687
g7
I0
sg17
VC0085110
p15688
sg10
I32
sg11
VSevere combined immunodeficiency
p15689
sg13
I3
sa(dp15690
g7
I89
sg17
VC0242172
p15691
sg10
I3
sg11
VPID
p15692
sg13
I1
sasa(dp15693
g2
VSevere combined immunodeficiency can be caused by loss-of-function mutations in genes involved in the DNA recombination machinery, such as recombination-activating gene 1 (RAG1), RAG2, or DNA cross-link repair 1C (DCLRE1C).
p15694
sg4
(lp15695
(dp15696
g7
I139
sg8
VP15918
p15697
sg10
I31
sg11
Vrecombination-activating gene 1
p15698
sg13
I3
sa(dp15699
g7
I179
sg8
VP55895
p15700
sg10
I4
sg11
VRAG2
p15701
sg13
I1
sa(dp15702
g7
I172
sg8
VP15918
p15703
sg10
I4
sg11
VRAG1
p15704
sg13
I1
sasg14
(lp15705
(dp15706
g7
I0
sg17
VC0085110
p15707
sg10
I32
sg11
VSevere combined immunodeficiency
p15708
sg13
I3
sasa(dp15709
g2
VSeven of the 98 cases (7%) of carcinomas showed TLE-1 expression, including 1 each of prostate adenocarcinoma (ADCA), esophageal ADCA, basal cell carcinoma, adrenocortical carcinoma, endometrial ADCA, ovarian serous carcinoma, and small cell carcinoma.
p15710
sg4
(lp15711
sg14
(lp15712
(dp15713
g7
I86
sg17
VC0007112
p15714
sg10
I23
sg11
Vprostate adenocarcinoma
p15715
sg13
I2
sa(dp15716
g7
I231
sg17
VC0262584
p15717
sg10
I20
sg11
Vsmall cell carcinoma
p15718
sg13
I3
sa(dp15719
g7
I111
sg17
VC0007112
p15720
sg10
I4
sg11
VADCA
p15721
sg13
I1
sa(dp15722
g7
I111
sg17
VC0007112
p15723
sg10
I4
sg11
VADCA
p15724
sg13
I1
sa(dp15725
g7
I48
sg17
VC0014556
p15726
sg10
I3
sg11
VTLE
p15727
sg13
I1
sa(dp15728
g7
I146
sg17
VC0206686
p15729
sg10
I25
sg11
Vcarcinoma, adrenocortical
p15730
sg13
I2
sa(dp15731
g7
I30
sg17
VC0007097
p15732
sg10
I10
sg11
Vcarcinomas
p15733
sg13
I1
sa(dp15734
g7
I111
sg17
VC0007112
p15735
sg10
I4
sg11
VADCA
p15736
sg13
I1
sa(dp15737
g7
I172
sg17
VC0476089
p15738
sg10
I22
sg11
Vcarcinoma, endometrial
p15739
sg13
I2
sa(dp15740
g7
I201
sg17
VC1335177
p15741
sg10
I24
sg11
Vovarian serous carcinoma
p15742
sg13
I3
sasa(dp15743
g2
VHere, we evaluated the effects of 15d-PGJ2 alone and in combination with the tyrosine kinas inhibitor (TKI) dasatinib in uterine sarcoma cell lines (MES-SA, MES-SA/DX5 and SKN).
p15744
sg4
(lp15745
(dp15746
g7
I149
sg8
VP31947
p15747
sg10
I6
sg11
VMES-SA
p15748
sg13
I1
sa(dp15749
g7
I77
sg8
VP14679
p15750
sg10
I24
sg11
Vtyrosine kinas inhibitor
p15751
sg13
I3
sa(dp15752
g7
I103
sg8
VP14679
p15753
sg10
I3
sg11
VTKI
p15754
sg13
I1
sa(dp15755
g7
I172
sg8
g24
sg10
I3
sg11
VSKN
p15756
sg13
I1
sasg14
(lp15757
(dp15758
g7
I149
sg17
VC0265215
p15759
sg10
I3
sg11
VMES
p15760
sg13
I1
sa(dp15761
g7
I121
sg17
VC0338113
p15762
sg10
I15
sg11
Vuterine sarcoma
p15763
sg13
I2
sa(dp15764
g7
I149
sg17
VC0265215
p15765
sg10
I3
sg11
VMES
p15766
sg13
I1
sasa(dp15767
g2
VPrevious studies have shown that N(1),N(12)-bis(all-trans-retinoyl)spermine (RASP), a retinoid analog, inhibits RNase P activity and angiogenesis in the chicken embryo chorioallantoic membrane, demonstrates anti-tumor activity on prostate cancer cells, and acts as anti-inflammatory agent, being more effective and less toxic than all-trans retinoic acid.
p15768
sg4
(lp15769
(dp15770
g7
I112
sg8
VP07998
p15771
sg10
I7
sg11
VRNase P
p15772
sg13
I2
sasg14
(lp15773
(dp15774
g7
I212
sg17
VC0027651
p15775
sg10
I5
sg11
Vtumor
p15776
sg13
I1
sa(dp15777
g7
I230
sg17
VC0600139
p15778
sg10
I15
sg11
Vprostate cancer
p15779
sg13
I2
sasa(dp15780
g2
VThese results suggest RASP, as a promising lead compound for the treatment of several dermatological disorders and certain cancer types, has apparently minimal toxic side-effects as revealed in this two-generation reproduction study in rats.
p15781
sg4
(lp15782
(dp15783
g7
I22
sg8
g24
sg10
I4
sg11
VRASP
p15784
sg13
I1
sasg14
(lp15785
(dp15786
g7
I86
sg17
VC0037274
p15787
sg10
I24
sg11
Vdermatological disorders
p15788
sg13
I2
sa(dp15789
g7
I123
sg17
VC0006826
p15790
sg10
I6
sg11
Vcancer
p15791
sg13
I1
sasa(dp15792
g2
VTo determine the functional significance of Hhat expression in breast cancer, we used a panel of breast cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen resistant cells.
p15793
sg4
(lp15794
(dp15795
g7
I155
sg8
VP03372
p15796
sg10
I2
sg11
VER
p15797
sg13
I1
sa(dp15798
g7
I169
sg8
VP04626
p15799
sg10
I4
sg11
VHER2
p15800
sg13
I1
sa(dp15801
g7
I136
sg8
VP03372
p15802
sg10
I17
sg11
Vestrogen receptor
p15803
sg13
I2
sasg14
(lp15804
(dp15805
g7
I63
sg17
VC0678222
p15806
sg10
I13
sg11
Vbreast cancer
p15807
sg13
I2
sa(dp15808
g7
I63
sg17
VC0678222
p15809
sg10
I13
sg11
Vbreast cancer
p15810
sg13
I2
sasa(dp15811
g2
VDepletion of Hhat decreased anchorage-dependent and anchorage-independent proliferation of ER positive, but not triple negative, breast cancer cells.
p15812
sg4
(lp15813
sg14
(lp15814
(dp15815
g7
I129
sg17
VC0678222
p15816
sg10
I13
sg11
Vbreast cancer
p15817
sg13
I2
sa(dp15818
g7
I74
sg17
VC0334094
p15819
sg10
I13
sg11
Vproliferation
p15820
sg13
I1
sasa(dp15821
g2
VThese data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic benefit in breast cancer.
p15822
sg4
(lp15823
(dp15824
g7
I67
sg8
VP04626
p15825
sg10
I4
sg11
VHER2
p15826
sg13
I1
sasg14
(lp15827
(dp15828
g7
I105
sg17
VC0678222
p15829
sg10
I13
sg11
Vbreast cancer
p15830
sg13
I2
sa(dp15831
g7
I119
sg17
VC0334094
p15832
sg10
I13
sg11
Vproliferation
p15833
sg13
I1
sa(dp15834
g7
I105
sg17
VC0678222
p15835
sg10
I13
sg11
Vbreast cancer
p15836
sg13
I2
sasa(dp15837
g2
VHedgehog acyltransferase (HHAT) is the enzyme in the endoplasmic reticulum that palmitoylates Hedgehog proteins, is a member of a small subfamily of membrane-bound O-acyltransferase proteins that acylate secreted proteins, and is an important drug target in cancer.
p15838
sg4
(lp15839
(dp15840
g7
I26
sg8
g24
sg10
I4
sg11
VHHAT
p15841
sg13
I1
sa(dp15842
g7
I164
sg8
VP02649
p15843
sg10
I26
sg11
VO-acyltransferase proteins
p15844
sg13
I2
sa(dp15845
g7
I0
sg8
g24
sg10
I24
sg11
VHedgehog acyltransferase
p15846
sg13
I2
sasg14
(lp15847
(dp15848
g7
I258
sg17
VC0006826
p15849
sg10
I6
sg11
Vcancer
p15850
sg13
I1
sasa(dp15851
g2
VThe STARD3 gene belongs to the minimal amplicon in HER2-positive breast cancers and encodes a cholesterol-binding membrane protein.
p15852
sg4
(lp15853
(dp15854
g7
I51
sg8
VP04626
p15855
sg10
I4
sg11
VHER2
p15856
sg13
I1
sa(dp15857
g7
I4
sg8
g24
sg10
I11
sg11
VSTARD3 gene
p15858
sg13
I2
sa(dp15859
g7
I94
sg8
VP63244
p15860
sg10
I36
sg11
Vcholesterol-binding membrane protein
p15861
sg13
I3
sasg14
(lp15862
(dp15863
g7
I65
sg17
VC0006142
p15864
sg10
I14
sg11
Vbreast cancers
p15865
sg13
I2
sasa(dp15866
g2
VTo study how elevated StAR-related lipid transfer protein 3 (StARD3) expression affects breast cancer cells, we generated MCF-7 cells stably overexpressing StARD3-green fluorescent protein.
p15867
sg4
(lp15868
(dp15869
g7
I156
sg8
g24
sg10
I32
sg11
VStARD3-green fluorescent protein
p15870
sg13
I3
sa(dp15871
g7
I22
sg8
g24
sg10
I37
sg11
VStAR-related lipid transfer protein 3
p15872
sg13
I5
sa(dp15873
g7
I61
sg8
g24
sg10
I6
sg11
VStARD3
p15874
sg13
I1
sasg14
(lp15875
(dp15876
g7
I88
sg17
VC0678222
p15877
sg10
I13
sg11
Vbreast cancer
p15878
sg13
I2
sa(dp15879
g7
I22
sg17
VC2678045
p15880
sg10
I4
sg11
VStAR
p15881
sg13
I1
sasa(dp15882
g2
VIn two Finnish nationwide patient cohorts, approximately 10% (212/2220) breast cancers exhibited high StARD3 protein levels, which was strongly associated with HER2 amplification; several factors related to poor disease outcome and poor breast cancer-specific survival.
p15883
sg4
(lp15884
(dp15885
g7
I160
sg8
VP04626
p15886
sg10
I4
sg11
VHER2
p15887
sg13
I1
sa(dp15888
g7
I102
sg8
g24
sg10
I14
sg11
VStARD3 protein
p15889
sg13
I2
sasg14
(lp15890
(dp15891
g7
I165
sg17
VC1705759
p15892
sg10
I13
sg11
Vamplification
p15893
sg13
I1
sa(dp15894
g7
I72
sg17
VC0006142
p15895
sg10
I14
sg11
Vbreast cancers
p15896
sg13
I2
sa(dp15897
g7
I72
sg17
VC0006142
p15898
sg10
I13
sg11
Vbreast cancer
p15899
sg13
I2
sasa(dp15900
g2
VIn addition, high StARD3 levels in breast cancers were associated with elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and anti-Src-Tyr416 immunoreactivity.
p15901
sg4
(lp15902
(dp15903
g7
I80
sg8
VP04035
p15904
sg10
I52
sg11
V3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA
p15905
sg13
I4
sa(dp15906
g7
I144
sg8
VP12931
p15907
sg10
I8
sg11
Vanti-Src
p15908
sg13
I1
sa(dp15909
g7
I18
sg8
g24
sg10
I6
sg11
VStARD3
p15910
sg13
I1
sasg14
(lp15911
(dp15912
g7
I35
sg17
VC0006142
p15913
sg10
I14
sg11
Vbreast cancers
p15914
sg13
I2
sasa(dp15915
g2
VThese results provide evidence that StARD3 overexpression results in increased cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and enhancing oncogenic signaling.
p15916
sg4
(lp15917
(dp15918
g7
I36
sg8
g24
sg10
I6
sg11
VStARD3
p15919
sg13
I1
sa(dp15920
g7
I108
sg8
VP12931
p15921
sg10
I10
sg11
VSrc kinase
p15922
sg13
I2
sa(dp15923
g7
I36
sg8
g24
sg10
I6
sg11
VStARD3
p15924
sg13
I1
sasg14
(lp15925
(dp15926
g7
I227
sg17
VC0001807
p15927
sg10
I14
sg11
Vaggressiveness
p15928
sg13
I1
sa(dp15929
g7
I131
sg17
VC0678222
p15930
sg10
I13
sg11
Vbreast cancer
p15931
sg13
I2
sa(dp15932
g7
I131
sg17
VC0678222
p15933
sg10
I13
sg11
Vbreast cancer
p15934
sg13
I2
sasa(dp15935
g2
VIn addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer.
p15936
sg4
(lp15937
(dp15938
g7
I124
sg8
g24
sg10
I4
sg11
VMED1
p15939
sg13
I1
sa(dp15940
g7
I138
sg8
g24
sg10
I4
sg11
VGRB7
p15941
sg13
I1
sa(dp15942
g7
I144
sg8
VP10827
p15943
sg10
I4
sg11
VTHRA
p15944
sg13
I1
sa(dp15945
g7
I187
sg8
VP01350
p15946
sg10
I4
sg11
VGAST
p15947
sg13
I1
sa(dp15948
g7
I130
sg8
g24
sg10
I6
sg11
VSTARD3
p15949
sg13
I1
sa(dp15950
g7
I164
sg8
VP32248
p15951
sg10
I4
sg11
VCCR7
p15952
sg13
I1
sa(dp15953
g7
I150
sg8
VP10276
p15954
sg10
I4
sg11
VRARA
p15955
sg13
I1
sa(dp15956
g7
I170
sg8
VP35900
p15957
sg10
I5
sg11
VKRT20
p15958
sg13
I1
sasg14
(lp15959
(dp15960
g7
I196
sg17
VC0678222
p15961
sg10
I13
sg11
Vbreast cancer
p15962
sg13
I2
sa(dp15963
g7
I76
sg17
VC1705759
p15964
sg10
I13
sg11
Vamplification
p15965
sg13
I1
sasa(dp15966
g2
VUsing a quantitative polymerase chain reaction method and DNA extracted from frozen tumor specimens, 11 genes (MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20, KRT19 and GAS), which are localized within Chr17q12-q21 and have a putative role in breast cancer development, were quantified.
p15967
sg4
(lp15968
(dp15969
g7
I156
sg8
VP22692
p15970
sg10
I6
sg11
VIGFBP4
p15971
sg13
I1
sa(dp15972
g7
I131
sg8
g24
sg10
I4
sg11
VGRB7
p15973
sg13
I1
sa(dp15974
g7
I111
sg8
g24
sg10
I4
sg11
VMED1
p15975
sg13
I1
sa(dp15976
g7
I117
sg8
g24
sg10
I6
sg11
VSTARD3
p15977
sg13
I1
sa(dp15978
g7
I170
sg8
VP35900
p15979
sg10
I5
sg11
VKRT20
p15980
sg13
I1
sa(dp15981
g7
I149
sg8
g24
sg10
I5
sg11
VTOP2A
p15982
sg13
I1
sa(dp15983
g7
I164
sg8
VP32248
p15984
sg10
I4
sg11
VCCR7
p15985
sg13
I1
sa(dp15986
g7
I125
sg8
VP04626
p15987
sg10
I4
sg11
VHER2
p15988
sg13
I1
sa(dp15989
g7
I137
sg8
VP10827
p15990
sg10
I4
sg11
VTHRA
p15991
sg13
I1
sa(dp15992
g7
I187
sg8
VP01350
p15993
sg10
I3
sg11
VGAS
p15994
sg13
I1
sa(dp15995
g7
I143
sg8
VP10276
p15996
sg10
I4
sg11
VRARA
p15997
sg13
I1
sasg14
(lp15998
(dp15999
g7
I261
sg17
VC0678222
p16000
sg10
I13
sg11
Vbreast cancer
p16001
sg13
I2
sa(dp16002
g7
I84
sg17
VC0027651
p16003
sg10
I5
sg11
Vtumor
p16004
sg13
I1
sasa(dp16005
g2
VThe metastatic lymph node 64 (MLN64) gene was initially identified as highly expressed in the metastatic lymph node from breast cancer.
p16006
sg4
(lp16007
(dp16008
g7
I30
sg8
g24
sg10
I5
sg11
VMLN64
p16009
sg13
I1
sa(dp16010
g7
I4
sg8
g24
sg10
I24
sg11
Vmetastatic lymph node 64
p16011
sg13
I4
sasg14
(lp16012
(dp16013
g7
I121
sg17
VC0678222
p16014
sg10
I13
sg11
Vbreast cancer
p16015
sg13
I2
sasa(dp16016
g2
VHowever, the role played by MLN64 in breast cancer remains unclear.
p16017
sg4
(lp16018
(dp16019
g7
I28
sg8
g24
sg10
I5
sg11
VMLN64
p16020
sg13
I1
sasg14
(lp16021
(dp16022
g7
I37
sg17
VC0678222
p16023
sg10
I13
sg11
Vbreast cancer
p16024
sg13
I2
sasa(dp16025
g2
VIn the present study, the expression of MLN64 was examined in a breast cancer cohort using quantitative real-time PCR and immunohistochemical staining.
p16026
sg4
(lp16027
(dp16028
g7
I40
sg8
g24
sg10
I5
sg11
VMLN64
p16029
sg13
I1
sasg14
(lp16030
(dp16031
g7
I64
sg17
VC0678222
p16032
sg10
I13
sg11
Vbreast cancer
p16033
sg13
I2
sasa(dp16034
g2
VA panel of breast cancer cell sublines was subsequently developed by knockdown of MLN64 expression.
p16035
sg4
(lp16036
(dp16037
g7
I82
sg8
g24
sg10
I5
sg11
VMLN64
p16038
sg13
I1
sasg14
(lp16039
(dp16040
g7
I11
sg17
VC0678222
p16041
sg10
I13
sg11
Vbreast cancer
p16042
sg13
I2
sasa(dp16043
g2
VIn conclusion, MLN64 is overexpressed in breast cancer, and its level correlates with poor prognosis and patient survival.
p16044
sg4
(lp16045
(dp16046
g7
I15
sg8
g24
sg10
I5
sg11
VMLN64
p16047
sg13
I1
sasg14
(lp16048
(dp16049
g7
I41
sg17
VC0678222
p16050
sg10
I13
sg11
Vbreast cancer
p16051
sg13
I2
sasa(dp16052
g2
VMLN64 contributes to the development and progression of breast cancer through the regulation of cell proliferation and adhesive capacity.
p16053
sg4
(lp16054
(dp16055
g7
I0
sg8
g24
sg10
I5
sg11
VMLN64
p16056
sg13
I1
sasg14
(lp16057
(dp16058
g7
I101
sg17
VC0334094
p16059
sg10
I13
sg11
Vproliferation
p16060
sg13
I1
sa(dp16061
g7
I56
sg17
VC0678222
p16062
sg10
I13
sg11
Vbreast cancer
p16063
sg13
I2
sasa(dp16064
g2
VSTARD3 and RARA also hold clinical relevance, the former having been shown to function in steroidogenesis and therefore implicated in hormone-receptor-positive breast cancer.
p16065
sg4
(lp16066
(dp16067
g7
I0
sg8
g24
sg10
I6
sg11
VSTARD3
p16068
sg13
I1
sa(dp16069
g7
I11
sg8
VP10276
p16070
sg10
I4
sg11
VRARA
p16071
sg13
I1
sasg14
(lp16072
(dp16073
g7
I160
sg17
VC0678222
p16074
sg10
I13
sg11
Vbreast cancer
p16075
sg13
I2
sasa(dp16076
g2
VWe used a genetic association study design to determine if common genetic variation (frequency&gt;or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk.
p16077
sg4
(lp16078
(dp16079
g7
I169
sg8
g24
sg10
I4
sg11
VCRK7
p16080
sg13
I1
sa(dp16081
g7
I175
sg8
g24
sg10
I7
sg11
VNEUROD2
p16082
sg13
I1
sa(dp16083
g7
I207
sg8
VP11086
p16084
sg10
I4
sg11
VPNMT
p16085
sg13
I1
sa(dp16086
g7
I226
sg8
g24
sg10
I8
sg11
VC17ORF37
p16087
sg13
I1
sa(dp16088
g7
I184
sg8
g24
sg10
I7
sg11
VPPP1R1B
p16089
sg13
I1
sa(dp16090
g7
I236
sg8
g24
sg10
I4
sg11
VGRB7
p16091
sg13
I1
sa(dp16092
g7
I161
sg8
g24
sg10
I6
sg11
VPPARBP
p16093
sg13
I1
sa(dp16094
g7
I213
sg8
g24
sg10
I4
sg11
VCAB2
p16095
sg13
I1
sa(dp16096
g7
I245
sg8
g24
sg10
I13
sg11
VZNFN1A3 genes
p16097
sg13
I2
sa(dp16098
g7
I193
sg8
g24
sg10
I6
sg11
VSTARD3
p16099
sg13
I1
sa(dp16100
g7
I136
sg8
VP04626
p16101
sg10
I5
sg11
VERBB2
p16102
sg13
I1
sa(dp16103
g7
I136
sg8
VP04626
p16104
sg10
I5
sg11
VERBB2
p16105
sg13
I1
sa(dp16106
g7
I201
sg8
g24
sg10
I4
sg11
VTCAP
p16107
sg13
I1
sasg14
(lp16108
(dp16109
g7
I280
sg17
VC0678222
p16110
sg10
I13
sg11
Vbreast cancer
p16111
sg13
I2
sasa(dp16112
g2
VThe applicability of salivary Beta -hexosaminidase (Beta-HEX A%, percentage of Beta-HEX A isoenzyme to total Beta-HEX) and Beta-HEX B% (Beta-HEX B/Beta-HEX) indexes was investigated as a possible marker of periodontitis.
p16113
sg4
(lp16114
(dp16115
g7
I21
sg8
VP04745
p16116
sg10
I29
sg11
Vsalivary Beta -hexosaminidase
p16117
sg13
I3
sa(dp16118
g7
I52
sg8
g24
sg10
I8
sg11
VBeta-HEX
p16119
sg13
I1
sa(dp16120
g7
I52
sg8
g24
sg10
I8
sg11
VBeta-HEX
p16121
sg13
I1
sa(dp16122
g7
I123
sg8
g24
sg10
I11
sg11
VBeta-HEX B%
p16123
sg13
I2
sa(dp16124
g7
I123
sg8
g24
sg10
I10
sg11
VBeta-HEX B
p16125
sg13
I2
sa(dp16126
g7
I52
sg8
g24
sg10
I10
sg11
VBeta-HEX A
p16127
sg13
I2
sasg14
(lp16128
(dp16129
g7
I206
sg17
VC0031099
p16130
sg10
I13
sg11
Vperiodontitis
p16131
sg13
I1
sasa(dp16132
g2
VSalivary Beta-HEX A% is a promising excellent marker for the diagnosis of periodontitis.
p16133
sg4
(lp16134
sg14
(lp16135
(dp16136
g7
I74
sg17
VC0031099
p16137
sg10
I13
sg11
Vperiodontitis
p16138
sg13
I1
sasa(dp16139
g2
VTo evaluate the prognostic impact of gene expression levels (ELs) of two tumor suppressor genes, sprouty 4 (SPRY4, located on 5q) and lysine methyltransferase 2C (KMT2C, located on 7q) in correlation with clinical characteristics and genetic abnormalities assessed at initial diagnosis in acute myeloid leukemia (AML).
p16140
sg4
(lp16141
(dp16142
g7
I163
sg8
g24
sg10
I5
sg11
VKMT2C
p16143
sg13
I1
sa(dp16144
g7
I134
sg8
g24
sg10
I27
sg11
Vlysine methyltransferase 2C
p16145
sg13
I3
sa(dp16146
g7
I97
sg8
g24
sg10
I9
sg11
Vsprouty 4
p16147
sg13
I2
sa(dp16148
g7
I108
sg8
g24
sg10
I5
sg11
VSPRY4
p16149
sg13
I1
sasg14
(lp16150
(dp16151
g7
I73
sg17
VC0027651
p16152
sg10
I5
sg11
Vtumor
p16153
sg13
I1
sa(dp16154
g7
I313
sg17
VC0023467
p16155
sg10
I3
sg11
VAML
p16156
sg13
I1
sa(dp16157
g7
I289
sg17
VC0023467
p16158
sg10
I22
sg11
Vacute myeloid leukemia
p16159
sg13
I3
sasa(dp16160
g2
VAs a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
p16161
sg4
(lp16162
(dp16163
g7
I50
sg8
VP29323
p16164
sg10
I3
sg11
VERK
p16165
sg13
I1
sa(dp16166
g7
I46
sg8
VP01116
p16167
sg10
I3
sg11
VRAS
p16168
sg13
I1
sasg14
(lp16169
(dp16170
g7
I143
sg17
VC0006826
p16171
sg10
I7
sg11
Vcancers
p16172
sg13
I1
sa(dp16173
g7
I158
sg17
VC0024623
p16174
sg10
I14
sg11
Vgastric cancer
p16175
sg13
I2
sasa(dp16176
g2
VSprouty proteins are modulators of mitogeninduced signal transduction processes and therefore can influence the process of cancerogenesis.
p16177
sg4
(lp16178
sg14
(lp16179
sa(dp16180
g2
VThe encoded protein of Sprouty homolog 4 (SPRY4) is associated with various human cancers.
p16181
sg4
(lp16182
(dp16183
g7
I23
sg8
g24
sg10
I17
sg11
VSprouty homolog 4
p16184
sg13
I3
sa(dp16185
g7
I42
sg8
g24
sg10
I5
sg11
VSPRY4
p16186
sg13
I1
sasg14
(lp16187
(dp16188
g7
I82
sg17
VC0006826
p16189
sg10
I7
sg11
Vcancers
p16190
sg13
I1
sasa(dp16191
g2
VWe show that these retained super-enhancers are essential for rhabdoid tumor survival, including some that are shared by all subtypes, such as SPRY1, and other lineage-specific super-enhancers, such as SOX2 in brain-derived rhabdoid tumors.
p16192
sg4
(lp16193
(dp16194
g7
I202
sg8
VP48431
p16195
sg10
I4
sg11
VSOX2
p16196
sg13
I1
sa(dp16197
g7
I143
sg8
g24
sg10
I5
sg11
VSPRY1
p16198
sg13
I1
sasg14
(lp16199
(dp16200
g7
I224
sg17
VC0206743
p16201
sg10
I15
sg11
Vrhabdoid tumors
p16202
sg13
I2
sa(dp16203
g7
I62
sg17
VC0206743
p16204
sg10
I14
sg11
Vrhabdoid tumor
p16205
sg13
I2
sasa(dp16206
g2
VAs a member of the Sprouty family, Sprouty4 has been previously shown to function as a tumour suppressor in lung and breast cancer.
p16207
sg4
(lp16208
sg14
(lp16209
(dp16210
g7
I117
sg17
VC0678222
p16211
sg10
I13
sg11
Vbreast cancer
p16212
sg13
I2
sa(dp16213
g7
I87
sg17
VC0027651
p16214
sg10
I6
sg11
Vtumour
p16215
sg13
I1
sasa(dp16216
g2
VIn this issue of Blood, Dietrich et al make the first observation of the presence of deleterious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).
p16217
sg4
(lp16218
(dp16219
g7
I97
sg8
VP46527
p16220
sg10
I15
sg11
VCDKN1B mutation
p16221
sg13
I2
sasg14
(lp16222
(dp16223
g7
I137
sg17
VC0023443
p16224
sg10
I19
sg11
Vhairy cell leukemia
p16225
sg13
I3
sa(dp16226
g7
I158
sg17
VC0023443
p16227
sg10
I3
sg11
VHCL
p16228
sg13
I1
sasa(dp16229
g2
VWe previously found that global CypD knockout mice (KO) are protected from diet-induced glucose intolerance; however, the tissue-specific function of CypD and mPTP, particularly in the control of glucose homeostasis, has not been ascertained.
p16230
sg4
(lp16231
(dp16232
g7
I32
sg8
g24
sg10
I4
sg11
VCypD
p16233
sg13
I1
sasg14
(lp16234
(dp16235
g7
I88
sg17
VC0271650
p16236
sg10
I19
sg11
Vglucose intolerance
p16237
sg13
I2
sasa(dp16238
g2
VMice lacking CypD were protected from high fat diet-induced glucose intolerance due to increased glucose uptake in skeletal muscle.
p16239
sg4
(lp16240
(dp16241
g7
I13
sg8
g24
sg10
I4
sg11
VCypD
p16242
sg13
I1
sasg14
(lp16243
(dp16244
g7
I60
sg17
VC0271650
p16245
sg10
I19
sg11
Vglucose intolerance
p16246
sg13
I2
sasa(dp16247
g2
VAdult CypD(-/-) developed hyperglycemia, insulin resistance and glucose intolerance albeit resistant to DIO.
p16248
sg4
(lp16249
(dp16250
g7
I6
sg8
g24
sg10
I4
sg11
VCypD
p16251
sg13
I1
sa(dp16252
g7
I41
sg8
VP01308
p16253
sg10
I7
sg11
Vinsulin
p16254
sg13
I1
sasg14
(lp16255
(dp16256
g7
I64
sg17
VC0271650
p16257
sg10
I19
sg11
Vglucose intolerance
p16258
sg13
I2
sa(dp16259
g7
I26
sg17
VC0020456
p16260
sg10
I13
sg11
Vhyperglycemia
p16261
sg13
I1
sa(dp16262
g7
I41
sg17
VC0021655
p16263
sg10
I18
sg11
Vinsulin resistance
p16264
sg13
I2
sasa(dp16265
g2
Vvon Willebrand factor (VWF) is an independent risk factor for adverse events in patients with non-valvular atrial fibrillation (NVAF).
p16266
sg4
(lp16267
(dp16268
g7
I23
sg8
VP04275
p16269
sg10
I3
sg11
VVWF
p16270
sg13
I1
sa(dp16271
g7
I0
sg8
VP04275
p16272
sg10
I21
sg11
Vvon Willebrand factor
p16273
sg13
I3
sasg14
(lp16274
(dp16275
g7
I107
sg17
VC0004238
p16276
sg10
I19
sg11
Vatrial fibrillation
p16277
sg13
I2
sasa(dp16278
g2
VHigher VWF level correlated with higher CHADS2 scores and with progressing intensity of blood stasis in the left atrium and thrombus formation in all three time periods of atrial fibrillation duration.
p16279
sg4
(lp16280
sg14
(lp16281
(dp16282
g7
I172
sg17
VC0004238
p16283
sg10
I19
sg11
Vatrial fibrillation
p16284
sg13
I2
sa(dp16285
g7
I94
sg17
VC0333138
p16286
sg10
I6
sg11
Vstasis
p16287
sg13
I1
sa(dp16288
g7
I124
sg17
VC0302148
p16289
sg10
I8
sg11
Vthrombus
p16290
sg13
I1
sasa(dp16291
g2
VPatients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 levels.
p16292
sg4
(lp16293
(dp16294
g7
I61
sg8
VP04275
p16295
sg10
I3
sg11
VvWF
p16296
sg13
I1
sasg14
(lp16297
(dp16298
g7
I35
sg17
VC0004238
p16299
sg10
I2
sg11
VAF
p16300
sg13
I1
sa(dp16301
g7
I14
sg17
VC0004238
p16302
sg10
I19
sg11
Vatrial fibrillation
p16303
sg13
I2
sasa(dp16304
g2
VIn a multicenter case-control association study, we studied the SNPs rs11136000 (clusterin, CLU), rs541458 (phosphatidylinositol binding clatrin assembly protein, PICALM), and rs1554948 (transcription factor A, and tyrosine kinase, non-receptor, 1, TNK1) according to the three age groups 50-65 years (group 1), 66-80 years (group 2), and 80+ years (group 3) in 569 older subjects without cognitive impairment (NoCI) and 520 Alzheimer's disease (AD) patients.
p16305
sg4
(lp16306
(dp16307
g7
I215
sg8
VP29401
p16308
sg10
I15
sg11
Vtyrosine kinase
p16309
sg13
I2
sa(dp16310
g7
I108
sg8
VP63244
p16311
sg10
I36
sg11
Vphosphatidylinositol binding clatrin
p16312
sg13
I3
sa(dp16313
g7
I232
sg8
g24
sg10
I15
sg11
Vnon-receptor, 1
p16314
sg13
I2
sa(dp16315
g7
I249
sg8
g24
sg10
I4
sg11
VTNK1
p16316
sg13
I1
sasg14
(lp16317
(dp16318
g7
I446
sg17
VC1521724
p16319
sg10
I2
sg11
VAD
p16320
sg13
I1
sa(dp16321
g7
I389
sg17
VC0338656
p16322
sg10
I20
sg11
Vcognitive impairment
p16323
sg13
I2
sa(dp16324
g7
I425
sg17
VC1521724
p16325
sg10
I19
sg11
VAlzheimer's disease
p16326
sg13
I2
sasa(dp16327
g2
VTo study the association of apolipoprotein E (APOE), Clusterin (CLU) and phosphatidylinositol binding clathrin assembly protein (PICALM) polymorphisms in Alzheimer's disease (AD) subjects compared to cognitively normal control subjects in an Indian population.
p16328
sg4
(lp16329
(dp16330
g7
I64
sg8
VP10909
p16331
sg10
I3
sg11
VCLU
p16332
sg13
I1
sa(dp16333
g7
I46
sg8
VP02649
p16334
sg10
I4
sg11
VAPOE
p16335
sg13
I1
sa(dp16336
g7
I28
sg8
VP02649
p16337
sg10
I16
sg11
Vapolipoprotein E
p16338
sg13
I2
sa(dp16339
g7
I73
sg8
VP63244
p16340
sg10
I37
sg11
Vphosphatidylinositol binding clathrin
p16341
sg13
I3
sa(dp16342
g7
I53
sg8
VP10909
p16343
sg10
I9
sg11
VClusterin
p16344
sg13
I1
sasg14
(lp16345
(dp16346
g7
I175
sg17
VC1521724
p16347
sg10
I2
sg11
VAD
p16348
sg13
I1
sa(dp16349
g7
I154
sg17
VC1521724
p16350
sg10
I19
sg11
VAlzheimer's disease
p16351
sg13
I2
sasa(dp16352
g2
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p16353
sg4
(lp16354
(dp16355
g7
I292
sg8
g24
sg10
I6
sg11
VPICALM
p16356
sg13
I1
sa(dp16357
g7
I176
sg8
g24
sg10
I5
sg11
VCD2AP
p16358
sg13
I1
sa(dp16359
g7
I270
sg8
g24
sg10
I6
sg11
VMS4A4E
p16360
sg13
I1
sa(dp16361
g7
I255
sg8
g24
sg10
I5
sg11
VMEF2C
p16362
sg13
I1
sa(dp16363
g7
I227
sg8
VP30486
p16364
sg10
I3
sg11
VHLA
p16365
sg13
I1
sa(dp16366
g7
I206
sg8
g24
sg10
I4
sg11
VDSG2
p16367
sg13
I1
sa(dp16368
g7
I189
sg8
g24
sg10
I5
sg11
VCELF1
p16369
sg13
I1
sa(dp16370
g7
I157
sg8
VP02649
p16371
sg10
I4
sg11
VAPOE
p16372
sg13
I1
sa(dp16373
g7
I150
sg8
g24
sg10
I5
sg11
VABCA7
p16374
sg13
I1
sa(dp16375
g7
I313
sg8
g24
sg10
I4
sg11
VRIN3
p16376
sg13
I1
sa(dp16377
g7
I328
sg8
g24
sg10
I5
sg11
VSORL1
p16378
sg13
I1
sa(dp16379
g7
I319
sg8
g24
sg10
I7
sg11
VSLC24A4
p16380
sg13
I1
sa(dp16381
g7
I247
sg8
g24
sg10
I6
sg11
VINPP5D
p16382
sg13
I1
sa(dp16383
g7
I262
sg8
g24
sg10
I6
sg11
VMS4A4A
p16384
sg13
I1
sa(dp16385
g7
I183
sg8
VP20138
p16386
sg10
I4
sg11
VCD33
p16387
sg13
I1
sa(dp16388
g7
I300
sg8
g24
sg10
I4
sg11
VPLD3
p16389
sg13
I1
sa(dp16390
g7
I219
sg8
g24
sg10
I6
sg11
VFERMT2
p16391
sg13
I1
sa(dp16392
g7
I169
sg8
g24
sg10
I5
sg11
VCASS4
p16393
sg13
I1
sa(dp16394
g7
I196
sg8
VP10909
p16395
sg10
I3
sg11
VCLU
p16396
sg13
I1
sa(dp16397
g7
I306
sg8
g24
sg10
I5
sg11
VPTK2B
p16398
sg13
I1
sa(dp16399
g7
I212
sg8
VP21709
p16400
sg10
I5
sg11
VEPHA1
p16401
sg13
I1
sa(dp16402
g7
I278
sg8
g24
sg10
I6
sg11
VMS4A6E
p16403
sg13
I1
sa(dp16404
g7
I227
sg8
VP30486
p16405
sg10
I3
sg11
VHLA
p16406
sg13
I1
sa(dp16407
g7
I201
sg8
VP17927
p16408
sg10
I3
sg11
VCR1
p16409
sg13
I1
sa(dp16410
g7
I339
sg8
g24
sg10
I12
sg11
VZCWPW1 genes
p16411
sg13
I2
sa(dp16412
g7
I286
sg8
g24
sg10
I4
sg11
VNME8
p16413
sg13
I1
sa(dp16414
g7
I231
sg8
g24
sg10
I4
sg11
VDRB1
p16415
sg13
I1
sasg14
(lp16416
(dp16417
g7
I95
sg17
VC0002395
p16418
sg10
I20
sg11
VAlzheimer's diseases
p16419
sg13
I2
sa(dp16420
g7
I117
sg17
VC0002395
p16421
sg10
I2
sg11
VAD
p16422
sg13
I1
sasa(dp16423
g2
VThe PICALM rs541458 T allele has been recognized as a risk factor for late-onset Alzheimer's disease, and age might modulate the effects that genetic factors have on cognitive functions and brain.
p16424
sg4
(lp16425
(dp16426
g7
I4
sg8
g24
sg10
I24
sg11
VPICALM rs541458 T allele
p16427
sg13
I4
sasg14
(lp16428
(dp16429
g7
I81
sg17
VC1521724
p16430
sg10
I19
sg11
VAlzheimer's disease
p16431
sg13
I2
sasa(dp16432
g2
VThe association of variants in CLU, CR1, PICALM, BIN1, ABCA7, and CD33 genes with late-onset Alzheimer's disease (LOAD) was evaluated and confirmed through genome-wide association study.
p16433
sg4
(lp16434
(dp16435
g7
I31
sg8
VP10909
p16436
sg10
I3
sg11
VCLU
p16437
sg13
I1
sa(dp16438
g7
I41
sg8
g24
sg10
I6
sg11
VPICALM
p16439
sg13
I1
sa(dp16440
g7
I55
sg8
g24
sg10
I5
sg11
VABCA7
p16441
sg13
I1
sa(dp16442
g7
I66
sg8
VP20138
p16443
sg10
I10
sg11
VCD33 genes
p16444
sg13
I2
sa(dp16445
g7
I36
sg8
VP17927
p16446
sg10
I3
sg11
VCR1
p16447
sg13
I1
sasg14
(lp16448
(dp16449
g7
I93
sg17
VC1521724
p16450
sg10
I19
sg11
VAlzheimer's disease
p16451
sg13
I2
sasa(dp16452
g2
VIn vivo, depletion of GDF-15 in Ras-driven tumor xenografts and in an orthotopic model of pancreatic cancer delayed tumor development.
p16453
sg4
(lp16454
(dp16455
g7
I22
sg8
g24
sg10
I6
sg11
VGDF-15
p16456
sg13
I1
sa(dp16457
g7
I32
sg8
VP01116
p16458
sg10
I3
sg11
VRas
p16459
sg13
I1
sasg14
(lp16460
(dp16461
g7
I43
sg17
VC0027651
p16462
sg10
I5
sg11
Vtumor
p16463
sg13
I1
sa(dp16464
g7
I90
sg17
VC0235974
p16465
sg10
I17
sg11
Vpancreatic cancer
p16466
sg13
I2
sa(dp16467
g7
I43
sg17
VC0027651
p16468
sg10
I5
sg11
Vtumor
p16469
sg13
I1
sasa(dp16470
g2
VFurther, production of GDF-15 is directly regulated by NF-KB, and the colocalization of activated NF-KB and GDF-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of this observation.
p16471
sg4
(lp16472
(dp16473
g7
I23
sg8
g24
sg10
I6
sg11
VGDF-15
p16474
sg13
I1
sa(dp16475
g7
I23
sg8
g24
sg10
I6
sg11
VGDF-15
p16476
sg13
I1
sasg14
(lp16477
(dp16478
g7
I144
sg17
VC0281361
p16479
sg10
I25
sg11
Vpancreatic adenocarcinoma
p16480
sg13
I2
sasa(dp16481
g2
VThe present study investigated the association between cancer-associated weight loss and plasma GDF-15 concentration, as well as other biomarkers, in patients with metastatic lung or exocrine pancreatic cancer.
p16482
sg4
(lp16483
(dp16484
g7
I89
sg8
g24
sg10
I13
sg11
Vplasma GDF-15
p16485
sg13
I2
sasg14
(lp16486
(dp16487
g7
I183
sg17
VC0346648
p16488
sg10
I26
sg11
Vexocrine pancreatic cancer
p16489
sg13
I3
sa(dp16490
g7
I55
sg17
VC0006826
p16491
sg10
I6
sg11
Vcancer
p16492
sg13
I1
sasa(dp16493
g2
VIn pancreatic cancer patients, no association between GDF-15 levels and weight loss was identified.
p16494
sg4
(lp16495
(dp16496
g7
I54
sg8
g24
sg10
I6
sg11
VGDF-15
p16497
sg13
I1
sasg14
(lp16498
(dp16499
g7
I3
sg17
VC0235974
p16500
sg10
I17
sg11
Vpancreatic cancer
p16501
sg13
I2
sasa(dp16502
g2
VThe aim of the present case-control study was to compare the diagnostic value of ULBP2, MIC-1 and carbohydrate antigen 19-9 (CA19-9) in 359 serum samples, consisting of 152 cases of PC, 20 cases of pre-pancreatic cancer, 91 cases of chronic pancreatitis (CP) and 96 normal controls (NC).
p16503
sg4
(lp16504
(dp16505
g7
I125
sg8
VP14209
p16506
sg10
I6
sg11
VCA19-9
p16507
sg13
I1
sa(dp16508
g7
I88
sg8
g24
sg10
I5
sg11
VMIC-1
p16509
sg13
I1
sa(dp16510
g7
I81
sg8
g24
sg10
I5
sg11
VULBP2
p16511
sg13
I1
sa(dp16512
g7
I98
sg8
VP14209
p16513
sg10
I25
sg11
Vcarbohydrate antigen 19-9
p16514
sg13
I3
sasg14
(lp16515
(dp16516
g7
I202
sg17
VC0235974
p16517
sg10
I17
sg11
Vpancreatic cancer
p16518
sg13
I2
sa(dp16519
g7
I255
sg17
VC0149521
p16520
sg10
I2
sg11
VCP
p16521
sg13
I1
sa(dp16522
g7
I233
sg17
VC0149521
p16523
sg10
I20
sg11
Vchronic pancreatitis
p16524
sg13
I2
sasa(dp16525
g2
VMacrophage inhibitory cytokine 1 (MIC-1/GDF15) has been identified as a potential novel biomarker for detection of pancreatic cancer (PCa).
p16526
sg4
(lp16527
(dp16528
g7
I34
sg8
g24
sg10
I5
sg11
VMIC-1
p16529
sg13
I1
sa(dp16530
g7
I0
sg8
g24
sg10
I32
sg11
VMacrophage inhibitory cytokine 1
p16531
sg13
I4
sa(dp16532
g7
I40
sg8
g24
sg10
I5
sg11
VGDF15
p16533
sg13
I1
sasg14
(lp16534
(dp16535
g7
I115
sg17
VC0235974
p16536
sg10
I17
sg11
Vpancreatic cancer
p16537
sg13
I2
sa(dp16538
g7
I134
sg17
VC0268398
p16539
sg10
I3
sg11
VPCa
p16540
sg13
I1
sasa(dp16541
g2
VHowever, the diagnostic value of serum MIC-1 for pancreatic ductal adenocarcinoma (PDAC), particularly for those at the early stage, and the value for treatment response monitoring have not yet been investigated.
p16542
sg4
(lp16543
(dp16544
g7
I33
sg8
g24
sg10
I11
sg11
Vserum MIC-1
p16545
sg13
I2
sasg14
(lp16546
(dp16547
g7
I83
sg17
VC1335302
p16548
sg10
I4
sg11
VPDAC
p16549
sg13
I1
sa(dp16550
g7
I49
sg17
VC1335302
p16551
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p16552
sg13
I3
sasa(dp16553
g2
VCD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer.
p16554
sg4
(lp16555
(dp16556
g7
I43
sg8
VP21781
p16557
sg10
I5
sg11
VKGF-2
p16558
sg13
I1
sa(dp16559
g7
I107
sg8
VP21583
p16560
sg10
I3
sg11
VSCF
p16561
sg13
I1
sa(dp16562
g7
I98
sg8
VP13725
p16563
sg10
I3
sg11
VOSM
p16564
sg13
I1
sa(dp16565
g7
I20
sg8
g24
sg10
I14
sg11
Vchordin-like 2
p16566
sg13
I2
sa(dp16567
g7
I50
sg8
g24
sg10
I29
sg11
Vgrowth/differentiation factor
p16568
sg13
I2
sa(dp16569
g7
I0
sg8
VP32971
p16570
sg10
I11
sg11
VCD30 ligand
p16571
sg13
I2
sa(dp16572
g7
I90
sg8
g24
sg10
I6
sg11
VCXCL11
p16573
sg13
I1
sa(dp16574
g7
I12
sg8
VP32971
p16575
sg10
I6
sg11
VTNFSF8
p16576
sg13
I1
sasg14
(lp16577
(dp16578
g7
I208
sg17
VC0235974
p16579
sg10
I17
sg11
Vpancreatic cancer
p16580
sg13
I2
sasa(dp16581
g2
VRadiologists evaluated following CT findings: maximum tumor diameter, percentage of solid component (%solid), air bronchogram, spiculation, adjacency of bullae or interstitial pneumonia (IP) around the tumor, notch, and pleural indent.
p16582
sg4
(lp16583
sg14
(lp16584
(dp16585
g7
I54
sg17
VC0027651
p16586
sg10
I5
sg11
Vtumor
p16587
sg13
I1
sa(dp16588
g7
I54
sg17
VC0027651
p16589
sg10
I5
sg11
Vtumor
p16590
sg13
I1
sa(dp16591
g7
I163
sg17
VC0206061
p16592
sg10
I22
sg11
Vinterstitial pneumonia
p16593
sg13
I2
sa(dp16594
g7
I153
sg17
VC0005758
p16595
sg10
I6
sg11
Vbullae
p16596
sg13
I1
sa(dp16597
g7
I187
sg17
VC0206061
p16598
sg10
I2
sg11
VIP
p16599
sg13
I1
sasa(dp16600
g2
VThe results strongly suggest that electronic self-auscultation at a single location (suprasternal notch) can support diagnosis of pneumonia in patients with COPD.
p16601
sg4
(lp16602
sg14
(lp16603
(dp16604
g7
I130
sg17
VC0032285
p16605
sg10
I9
sg11
Vpneumonia
p16606
sg13
I1
sa(dp16607
g7
I157
sg17
VC0024117
p16608
sg10
I4
sg11
VCOPD
p16609
sg13
I1
sasa(dp16610
g2
VWe compared patients who underwent PAO for the treatment of Charcot-Marie-Tooth disease hip dysplasia (CMTHD group) with patients who underwent PAO for treatment of hip dysplasia secondary to DDH in terms of (1) modified Harris Hip scores; (2) radiographic correction of acetabular dysplasia; and (3) the rate of complications.
p16611
sg4
(lp16612
(dp16613
g7
I192
sg8
g24
sg10
I3
sg11
VDDH
p16614
sg13
I1
sasg14
(lp16615
(dp16616
g7
I271
sg17
VC1306065
p16617
sg10
I20
sg11
Vacetabular dysplasia
p16618
sg13
I2
sa(dp16619
g7
I88
sg17
VC1328407
p16620
sg10
I13
sg11
Vhip dysplasia
p16621
sg13
I2
sa(dp16622
g7
I60
sg17
VC0007959
p16623
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p16624
sg13
I2
sa(dp16625
g7
I88
sg17
VC1328407
p16626
sg10
I13
sg11
Vhip dysplasia
p16627
sg13
I2
sasa(dp16628
g2
VTwenty-seven subjects with Charcot-Marie-Tooth disease who underwent a PAO between January 1991 and December 2010 were matched to 54 subjects with DDH on the basis of sex, age, date of surgery, and body mass index.
p16629
sg4
(lp16630
(dp16631
g7
I147
sg8
g24
sg10
I3
sg11
VDDH
p16632
sg13
I1
sasg14
(lp16633
(dp16634
g7
I27
sg17
VC0007959
p16635
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p16636
sg13
I2
sasa(dp16637
g2
VThe purpose of this study is to evaluate the use of the Dega osteotomy in the treatment of hip pathology resulting from both developmental dysplasia (DDH) and neuromuscular disease (NM).
p16638
sg4
(lp16639
sg14
(lp16640
(dp16641
g7
I95
sg17
VC0677042
p16642
sg10
I9
sg11
Vpathology
p16643
sg13
I1
sa(dp16644
g7
I182
sg17
VC0027868
p16645
sg10
I2
sg11
VNM
p16646
sg13
I1
sa(dp16647
g7
I139
sg17
VC0334044
p16648
sg10
I9
sg11
Vdysplasia
p16649
sg13
I1
sa(dp16650
g7
I159
sg17
VC0027868
p16651
sg10
I21
sg11
Vneuromuscular disease
p16652
sg13
I2
sasa(dp16653
g2
VNeuromuscular dysplasia of the hip (NDH) is a sequel of neuromuscular disease, and generally presents later in childhood than DDH.
p16654
sg4
(lp16655
sg14
(lp16656
(dp16657
g7
I56
sg17
VC0027868
p16658
sg10
I21
sg11
Vneuromuscular disease
p16659
sg13
I2
sa(dp16660
g7
I14
sg17
VC0334044
p16661
sg10
I9
sg11
Vdysplasia
p16662
sg13
I1
sasa(dp16663
g2
VTo explore this suggestion we ascertained the presence of neuromuscular disease within a cohort of DDH patients, and asked whether the neuromuscular condition is the initial etiology of the dysplasia or a coincidental finding.
p16664
sg4
(lp16665
sg14
(lp16666
(dp16667
g7
I190
sg17
VC0334044
p16668
sg10
I9
sg11
Vdysplasia
p16669
sg13
I1
sa(dp16670
g7
I149
sg17
VC0012634
p16671
sg10
I9
sg11
Vcondition
p16672
sg13
I1
sa(dp16673
g7
I58
sg17
VC0027868
p16674
sg10
I21
sg11
Vneuromuscular disease
p16675
sg13
I2
sasa(dp16676
g2
VWe examined 45 infants with nondevelopmental dysplasia of the hip (non-DDH), including congenital deficiency of the femur (CDF) (20 infants), neuromuscular syndrome (five infants), skeletal dysplasia (15 infants), and infection (five infants), and present the sonographic findings.
p16677
sg4
(lp16678
sg14
(lp16679
(dp16680
g7
I87
sg17
VC0333006
p16681
sg10
I21
sg11
Vcongenital deficiency
p16682
sg13
I2
sa(dp16683
g7
I218
sg17
VC0009450
p16684
sg10
I9
sg11
Vinfection
p16685
sg13
I1
sa(dp16686
g7
I156
sg17
VC0039082
p16687
sg10
I8
sg11
Vsyndrome
p16688
sg13
I1
sa(dp16689
g7
I181
sg17
VC0410528
p16690
sg10
I18
sg11
Vskeletal dysplasia
p16691
sg13
I2
sa(dp16692
g7
I45
sg17
VC0334044
p16693
sg10
I9
sg11
Vdysplasia
p16694
sg13
I1
sasa(dp16695
g2
VIn previous studies, we demonstrated that human RHBDD2 is over-expressed in the advanced stages of breast and colorectal cancers, suggesting a favorable role in cell proliferation.
p16696
sg4
(lp16697
sg14
(lp16698
(dp16699
g7
I166
sg17
VC0334094
p16700
sg10
I13
sg11
Vproliferation
p16701
sg13
I1
sa(dp16702
g7
I110
sg17
VC1527249
p16703
sg10
I18
sg11
Vcolorectal cancers
p16704
sg13
I2
sasa(dp16705
g2
VSo far little is known about the expression of RHBDD2 in other tissues and other species, and because of similarities between cancer and embryonic cells, this study focused on the evaluation of Rhbdd2 expression in embryonic and adult rat tissues.
p16706
sg4
(lp16707
(dp16708
g7
I47
sg8
g24
sg10
I6
sg11
VRHBDD2
p16709
sg13
I1
sa(dp16710
g7
I194
sg8
g24
sg10
I6
sg11
VRhbdd2
p16711
sg13
I1
sasg14
(lp16712
(dp16713
g7
I126
sg17
VC0006826
p16714
sg10
I6
sg11
Vcancer
p16715
sg13
I1
sasa(dp16716
g2
VQuantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis showed a significant RHBDD2 mRNA overexpression in advanced breast cancer compared with normal tissue samples (p = 0.012).
p16717
sg4
(lp16718
(dp16719
g7
I100
sg8
g24
sg10
I11
sg11
VRHBDD2 mRNA
p16720
sg13
I2
sasg14
(lp16721
(dp16722
g7
I139
sg17
VC0678222
p16723
sg10
I13
sg11
Vbreast cancer
p16724
sg13
I2
sasa(dp16725
g2
VImmunohistochemistry analysis showed a significant increase of RHBDD2 protein expression in association with breast cancer samples negative for progesterone receptor (p = 0.015).
p16726
sg4
(lp16727
(dp16728
g7
I63
sg8
g24
sg10
I14
sg11
VRHBDD2 protein
p16729
sg13
I2
sa(dp16730
g7
I144
sg8
VP06401
p16731
sg10
I21
sg11
Vprogesterone receptor
p16732
sg13
I2
sasg14
(lp16733
(dp16734
g7
I109
sg17
VC0678222
p16735
sg10
I13
sg11
Vbreast cancer
p16736
sg13
I2
sasa(dp16737
g2
VRhomboid domain containing 2 (RHBDD2) was previously observed overexpressed and amplified in breast cancer samples.
p16738
sg4
(lp16739
(dp16740
g7
I0
sg8
g24
sg10
I28
sg11
VRhomboid domain containing 2
p16741
sg13
I4
sa(dp16742
g7
I30
sg8
g24
sg10
I6
sg11
VRHBDD2
p16743
sg13
I1
sasg14
(lp16744
(dp16745
g7
I93
sg17
VC0678222
p16746
sg10
I13
sg11
Vbreast cancer
p16747
sg13
I2
sasa(dp16748
g2
VIn order to identify biological pathways modulated by RHBDD2, gene expression profiles of RHBDD2 silenced breast cancer cells were analyzed using whole genome human microarray.
p16749
sg4
(lp16750
(dp16751
g7
I54
sg8
g24
sg10
I6
sg11
VRHBDD2
p16752
sg13
I1
sa(dp16753
g7
I54
sg8
g24
sg10
I6
sg11
VRHBDD2
p16754
sg13
I1
sasg14
(lp16755
(dp16756
g7
I106
sg17
VC0678222
p16757
sg10
I13
sg11
Vbreast cancer
p16758
sg13
I2
sasa(dp16759
g2
VWe used a lentivirus-based approach for stable silencing of RHBDD2 mRNA in the T47D breast cancer cell line, and we examined the transcriptional consequences on UPR genes as well as the phenotypic effects on migration and proliferation processes.
p16760
sg4
(lp16761
(dp16762
g7
I60
sg8
g24
sg10
I11
sg11
VRHBDD2 mRNA
p16763
sg13
I2
sasg14
(lp16764
(dp16765
g7
I84
sg17
VC0678222
p16766
sg10
I13
sg11
Vbreast cancer
p16767
sg13
I2
sa(dp16768
g7
I222
sg17
VC0334094
p16769
sg10
I13
sg11
Vproliferation
p16770
sg13
I1
sasa(dp16771
g2
VBased on these studies, we hypothesize that RHBDD2 overexpression in breast cancer could represent an adaptive phenotype to the stressful tumor microenvironment by modulating the ER stress response.
p16772
sg4
(lp16773
(dp16774
g7
I44
sg8
g24
sg10
I6
sg11
VRHBDD2
p16775
sg13
I1
sasg14
(lp16776
(dp16777
g7
I69
sg17
VC0678222
p16778
sg10
I13
sg11
Vbreast cancer
p16779
sg13
I2
sa(dp16780
g7
I138
sg17
VC0027651
p16781
sg10
I5
sg11
Vtumor
p16782
sg13
I1
sasa(dp16783
g2
VIn previous studies, we identified rhomboid domain containing 2 (RHBDD2) gene to be markedly overexpressed in breast cancer patients that developed recurrence of the disease.
p16784
sg4
(lp16785
(dp16786
g7
I65
sg8
g24
sg10
I6
sg11
VRHBDD2
p16787
sg13
I1
sa(dp16788
g7
I35
sg8
g24
sg10
I28
sg11
Vrhomboid domain containing 2
p16789
sg13
I4
sasg14
(lp16790
(dp16791
g7
I148
sg17
VC1458156
p16792
sg10
I10
sg11
Vrecurrence
p16793
sg13
I1
sa(dp16794
g7
I110
sg17
VC0678222
p16795
sg10
I13
sg11
Vbreast cancer
p16796
sg13
I2
sasa(dp16797
g2
VIn this study, we evaluated for the first time RHBDD2 gene expression in colorectal cancer (CRC).
p16798
sg4
(lp16799
(dp16800
g7
I42
sg8
g24
sg10
I16
sg11
Vtime RHBDD2 gene
p16801
sg13
I3
sasg14
(lp16802
(dp16803
g7
I92
sg17
VC1527249
p16804
sg10
I3
sg11
VCRC
p16805
sg13
I1
sa(dp16806
g7
I73
sg17
VC1527249
p16807
sg10
I17
sg11
Vcolorectal cancer
p16808
sg13
I2
sasa(dp16809
g2
VOverall, these results showed that RHBDD2 overexpression might play a role in colorectal cancer progression.
p16810
sg4
(lp16811
(dp16812
g7
I35
sg8
g24
sg10
I6
sg11
VRHBDD2
p16813
sg13
I1
sasg14
(lp16814
(dp16815
g7
I89
sg17
VC0178874
p16816
sg10
I18
sg11
Vcancer progression
p16817
sg13
I2
sasa(dp16818
g2
VIn the course of breast cancer global gene expression studies, we identified an uncharacterized gene known as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients with recurrent disease.
p16819
sg4
(lp16820
(dp16821
g7
I118
sg8
g24
sg10
I28
sg11
VRhomboid domain containing 2
p16822
sg13
I4
sa(dp16823
g7
I110
sg8
g24
sg10
I6
sg11
VRHBDD2
p16824
sg13
I1
sasg14
(lp16825
(dp16826
g7
I181
sg17
VC0677930
p16827
sg10
I14
sg11
Vprimary tumors
p16828
sg13
I2
sa(dp16829
g7
I17
sg17
VC0678222
p16830
sg10
I13
sg11
Vbreast cancer
p16831
sg13
I2
sa(dp16832
g7
I215
sg17
VC0277556
p16833
sg10
I17
sg11
Vrecurrent disease
p16834
sg13
I2
sasa.